PUBLIC_ID	MMTX_TYPE	MMTX_TYPE_STD	MMTX_ISTHISLINEOFT_1	MMTX_ISTHISLINEOFT_STD	MMTX_THERAPY	MMTX_THERAPY_STD	MMTX_ENTERCLINICAL	MMTX_ONGOING_1	MMTX_REASONFORTREA	MMTX_REASONFORTREA_STD	MMTX_DOSE_1	MMTX_UNITS	MMTX_UNITS_STD	MMTX_FREQUENCY_1	MMTX_FREQUENCY_STD	MMTX_ROUTE	MMTX_ROUTE_STD	VJ_INTERVAL	MMTX_ISTHISLINEOFT	MMTX_SPECIFY6	MMTX_ONGOING	MMTX_DOSE	MMTX_FREQUENCY	MMTX_SPECIFY3	MMTX_SPECIFY	MMTX_SPECIFY4	MMTX_SPECIFY2	MMTX_SPECIFY5	startday	stopday	enr
MMRF_1014	First line of therapy	First Line Therapy	PLATEAUED	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	Q week	Q week	IV	IV	Log Forms	Other	PLATEAUED		2.6	Q week	Q week					540	752	1
MMRF_1014	First line of therapy	First Line Therapy	HIGH DOSE CHEMO PRE TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	UNKNOW	Other	IV	IV	Log Forms	Other	HIGH DOSE CHEMO PRE TRANSPLANT		200	Other	UNKNOW					814	815	1
MMRF_1014	First line of therapy	First Line Therapy	PLATEAUED	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	Q WEEK	Other	IV	IV	Log Forms	Other	PLATEAUED		500	Other	Q WEEK					540	752	1
MMRF_1014	First line of therapy	First Line Therapy	Maintenance	Maintenance	Thalidomide	Thalidomide		1			100	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	100	Q day	Q day					977		1
MMRF_1014	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	39	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		39	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					449	535	1
MMRF_1014	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Lack of response	Lack of response	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IVB	IVB	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	166	1
MMRF_1014	First line of therapy	First Line Therapy			Vincristine	Vincristine			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	Q28 DAYS	Other	IV	IV	Log Forms				2	Other	Q28 DAYS					381	407	1
MMRF_1014	First line of therapy	First Line Therapy			Liposomal doxorubicin	Liposomal doxorubicin			Adverse Event or co-morbidity	Adverse Event or co-morbidity	75	mg	mg	Q28 DAYS	Other	IV	IV	Log Forms				75	Other	Q28 DAYS					381	407	1
MMRF_1014	First line of therapy	First Line Therapy			Thalidomide	Thalidomide			PLATEAUED RESPONSE	Other	100	mg	mg	Q day	Q day	PO	PO	Log Forms				100	Q day	Q day					186	365	1
MMRF_1014	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAILY ON DAYS 1-4 (ALL CYCLES) AND 9-12 (CYCLE 1 AND 2)	Other	PO	PO	Log Forms				40	Other	DAILY ON DAYS 1-4 (ALL CYCLES) AND 9-12 (CYCLE 1 AND 2)					1	819	1
MMRF_1014	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	INJECTION	Other	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1014	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					66	106	1
MMRF_1017	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DEATH	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	508	1
MMRF_1017	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			DEATH	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					9	508	1
MMRF_1024	First line of therapy	First Line Therapy			Melphalan	Melphalan			Lack of response	Lack of response	6	mg	mg	DAILY FOR 7 DAYS EACH MONTH; THEN DAILY FOR 5 DAYS EACH MONTH	Other	PO	PO	Log Forms				6	Other	DAILY FOR 7 DAYS EACH MONTH; THEN DAILY FOR 5 DAYS EACH MONTH					1	149	1
MMRF_1024	First line of therapy	First Line Therapy			Prednisone	Prednisone			Lack of response	Lack of response	60	mg	mg	DAILY FOR 7 DAYS EACH MONTH	Other	PO	PO	Log Forms				60	Other	DAILY FOR 7 DAYS EACH MONTH					1	149	1
MMRF_1024	First line of therapy	First Line Therapy			Thalidomide	Thalidomide			Lack of response	Lack of response	100	mg	mg	DAILY	Other	PO	PO	Log Forms				100	Other	DAILY					1	149	1
MMRF_1024	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					295	582	1
MMRF_1024	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD DAYS 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms				40	Other	QD DAYS 1,2,4,5,8,9,11,12					295	582	1
MMRF_1024	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					162	240	1
MMRF_1024	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					162	240	1
MMRF_1024	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					659	1352	1
MMRF_1024	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			2.5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	2.5	QD (D1-21)	QD (D1-21)					1353		1
MMRF_1038	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DEATH	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	1735	1
MMRF_1038	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			DEATH	Other	15	mg	mg	DAILY	Other	PO	PO	Log Forms				15	Other	DAILY					9	1738	1
MMRF_1033	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	123	1
MMRF_1033	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	123	1
MMRF_1033	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					2713	2825	1
MMRF_1033	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	2.4	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.4	Q week	Q week					2713	2818	1
MMRF_1033	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	D1, 8, & 15 OF EVERY 28-DAY CYCLE	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	D1, 8, & 15 OF EVERY 28-DAY CYCLE					2713	2825	1
MMRF_1007	First line of therapy	First Line Therapy			Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	8	mg	mg	QD (D1-7)	QD (D1-7)	PO	PO	Log Forms				8	QD (D1-7)	QD (D1-7)					1	85	1
MMRF_1007	First line of therapy	First Line Therapy			Prednisone	Prednisone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	80	mg	mg	QD (D1-28)	Other	PO	PO	Log Forms				80	Other	QD (D1-28)					1	85	1
MMRF_1007	First line of therapy	First Line Therapy			Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	50	mg	mg	QD (D1-7)	QD (D1-7)	PO	PO	Log Forms				50	QD (D1-7)	QD (D1-7)					1	85	1
MMRF_1007	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	ONCE A DAY, 3 WEEKS ON, 1 WEEK OFF	Other	PO	PO	Log Forms				10	Other	ONCE A DAY, 3 WEEKS ON, 1 WEEK OFF					92	145	1
MMRF_1007	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					92	145	1
MMRF_1007	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms				2	Q week	Q week					155	208	1
MMRF_1007	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		10	Q week	Q week					155	208	1
MMRF_1052	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.8	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					174	273	1
MMRF_1052	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	ODD CYCLES: D1-4, 9-12 AND 17-20; EVEN CYCLES: D1-4	Other	PO	PO	Log Forms				40	Other	ODD CYCLES: D1-4, 9-12 AND 17-20; EVEN CYCLES: D1-4					119	162	1
MMRF_1052	First line of therapy	First Line Therapy			Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	200	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				200	QD (D1-14)	QD (D1-14)					119	160	1
MMRF_1052	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QWK	QWK	PO	PO	Log Forms				20	QWK	QWK					1	51	1
MMRF_1052	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	1 TABLET DAILY FOR 28 DAYS	Other	PO	PO	Log Forms				15	Other	1 TABLET DAILY FOR 28 DAYS					1	29	1
MMRF_1082	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	NEW LINE	Other	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	NEW LINE		4	QD (D1-21)	QD (D1-21)					588	680	1
MMRF_1082	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	ETOPOSIDE	Other			Completed regimen	Completed regimen	75	mg	mg	QD (D1-4)	QD (D1-4)	CIV	Other	Log Forms	Consolidation	Consolidation		75	QD (D1-4)	QD (D1-4)					661	750	1
MMRF_1082	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	CISPLATIN	Other			Completed regimen	Completed regimen	75	mg	mg	QD (D1-4)	QD (D1-4)	CIV	Other	Log Forms	Consolidation	Consolidation		75	QD (D1-4)	QD (D1-4)					661	750	1
MMRF_1082	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					661	750	1
MMRF_1082	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	750	mg	mg	QD (D1-4)	QD (D1-4)	CIV	Other	Log Forms	Other	SALVAGE		750	QD (D1-4)	QD (D1-4)					661	750	1
MMRF_1082	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QWK	QWK	IVB	IVB	Log Forms				40	QWK	QWK					1	274	1
MMRF_1082	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	274	1
MMRF_1082	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					500	582	1
MMRF_1082	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	BID	BID	IV	IV	Log Forms	Unknown	Unknown		100	BID	BID					371	372	1
MMRF_1082	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	D1, 8,15, 22	Other	PO	PO	Log Forms				40	Other	D1, 8,15, 22					288	326	1
MMRF_1082	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					288	326	1
MMRF_1082	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					288	326	1
MMRF_1082	First line of therapy	First Line Therapy			Thalidomide	Thalidomide			Investigator decision for other reasons	Investigator decision for other reasons	50	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				50	QD (D1-21)	QD (D1-21)					1	274	1
MMRF_1094	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	95	1
MMRF_1094	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	154	mg	mg	Q day	Q day	IV	IV	Log Forms				154	Q day	Q day					142	143	1
MMRF_1094	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	ACP-196	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	100	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		100	BID	BID					1327	1454	1
MMRF_1094	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1094	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	95	1
MMRF_1094	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	PEMBROLIZUMAB	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg/m^2	mg/m^2	EVERY DAY 1	Other	IV	IV	Log Forms	Induction	Induction		2	Other	EVERY DAY 1					1327	1454	1
MMRF_1094	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Investigator decision for other reasons	Investigator decision for other reasons	900	mg	mg	C1-2D1,8,15,22; C3-6D1,15; C7+D1	Other	IV	IV	Log Forms	Induction	Induction		900	Other	C1-2D1,8,15,22; C3-6D1,15; C7+D1					1830	2033	1
MMRF_1094	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	D1,8,15,22	Other	IV	IV	Log Forms	Induction	Induction		20	Other	D1,8,15,22					1830	2033	1
MMRF_1094	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1829	2061	1
MMRF_1094	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	900	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		900	QWK	QWK					2361	2521	1
MMRF_1094	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2565	2573	1
MMRF_1094	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	STRO-001	Other	NCT03424603	0	Disease progression/Relapse	Disease progression/Relapse	0.91	mg/kg	mg/kg	D1 & D15 Q 28 DAYS	Other	IV	IV	Log Forms	Unknown	Unknown		0.91	Other	D1 & D15 Q 28 DAYS					2683	2698	1
MMRF_1093	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	154	1
MMRF_1093	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	185	1
MMRF_1129	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DEATH	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					256	610	1
MMRF_1129	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAILY ON DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms				40	Other	DAILY ON DAYS 1, 8, 15, 22					1	249	1
MMRF_1129	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	248	1
MMRF_1130	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	351	1
MMRF_1130	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	351	1
MMRF_1130	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	351	1
MMRF_1130	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-14)	QD (D1-14)					361	541	1
MMRF_1130	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	PROGRESSION OF MYELOMA	Other	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	PROGRESSION OF MYELOMA		25	QD (D1-21)	QD (D1-21)					879	1243	1
MMRF_1130	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	PROGRESSIVE MULTIPLE MYELOMA	Other	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	QD ( D1, D8, D15 AND D22)	Other	PO	PO	Log Forms	Other	PROGRESSIVE MULTIPLE MYELOMA		40	Other	QD ( D1, D8, D15 AND D22)					879	1243	1
MMRF_1130	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		4	Q day	Q day					1373	2004	1
MMRF_1130	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Maintenance	Maintenance	Checked	16	Q week	Q week					2087		1
MMRF_1137	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					337	501	1
MMRF_1137	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		100	Q day	Q day					223	224	1
MMRF_1137	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					5	178	1
MMRF_1137	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	195	1
MMRF_1137	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Lack of response	Lack of response	5	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	EVERY OTHER DAY					632	675	1
MMRF_1137	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD ( D1, D4, D8, D11, D21)	Other	IV	IV	Log Forms	Unknown	Unknown		1.3	Other	QD ( D1, D4, D8, D11, D21)					722	764	1
MMRF_1137	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD ( D1, D4, D8, D11, D21)	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD ( D1, D4, D8, D11, D21)					722	764	1
MMRF_1137	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					785	1090	1
MMRF_1137	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD ( D1, D2, D8, D9, D16, D22, D23)	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD ( D1, D2, D8, D9, D16, D22, D23)					785	1090	1
MMRF_1137	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Lack of response	Lack of response	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					675	722	1
MMRF_1132	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DEATH	Other	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					103	238	1
MMRF_1132	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DEATH	Other	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					103	238	1
MMRF_1132	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					5	85	1
MMRF_1132	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	92	1
MMRF_1178	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1870	1988	1
MMRF_1178	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Maintenance	Maintenance		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1870	1988	1
MMRF_1178	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			PROCEEDING WITH AUTOLOGOUS STEM CELL TRANSPLANT	Other	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	150	1
MMRF_1178	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAY 1-4, 9-12	Other	PO	PO	Log Forms				40	Other	DAY 1-4, 9-12					1	150	1
MMRF_1178	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	QD (D1-3)	QD (D1-3)	IV	IV	Log Forms				100	QD (D1-3)	QD (D1-3)					130	162	1
MMRF_1178	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1870	1975	1
MMRF_1178	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	D1 & D15	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Other	D1 & D15					2712		1
MMRF_1178	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					2712		1
MMRF_1178	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	D1 & D15	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	20	Other	D1 & D15					2712		1
MMRF_1193	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	DAY 1, 8, 15, 22 OF EACH 28 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAY 1, 8, 15, 22 OF EACH 28 DAY CYCLE					1379	1437	1
MMRF_1193	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	DAY 1, 8, 15, 22	Other	IV	IV	Log Forms	Induction	Induction		8	Other	DAY 1, 8, 15, 22					1381	1437	1
MMRF_1193	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1381	1437	1
MMRF_1193	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	647	mg	mg	DAY 1, 8, 15, 22  (28 DAY CYCLE)	Other	IV	IV	Log Forms	Induction	Induction		647	Other	DAY 1, 8, 15, 22  (28 DAY CYCLE)					1381	1437	1
MMRF_1193	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	PROGRESSIVE DISEASE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	PROGRESSIVE DISEASE		40	Q week	Q week					896	1321	1
MMRF_1193	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	PROGRESIVE DISEASE	Other	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	PROGRESIVE DISEASE		25	QD (D1-21)	QD (D1-21)					896	1321	1
MMRF_1193	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			PARTIAL RESPONSE.	Other	1.3	mg	mg	DAY 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1, 8, 15					596	682	1
MMRF_1193	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			PARTIAL RESPONSE.	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					596	682	1
MMRF_1193	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	144	1
MMRF_1193	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms				2.6	QWK	QWK					1	144	1
MMRF_1229	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	173	1
MMRF_1229	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	173	1
MMRF_1229	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Liposomal doxorubicin	Liposomal doxorubicin			Lack of response	Lack of response	67	mg	mg	EVERY 21 DAYS	Other	IV	IV	Log Forms	Induction	Induction		67	Other	EVERY 21 DAYS					183	270	1
MMRF_1229	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					311	395	1
MMRF_1229	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					183	277	1
MMRF_1229	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					426	427	1
MMRF_1229	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1538	1602	1
MMRF_1229	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1538	1619	1
MMRF_1229	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					1538	1619	1
MMRF_1229	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	172	1
MMRF_1229	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q 4 WEEKS	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Other	Q 4 WEEKS					2202		1
MMRF_1256	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms				2.5	QWK	QWK					1	172	1
MMRF_1256	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1-4, 9-12	Other	PO	PO	Log Forms				40	Other	DAYS 1-4, 9-12					1	172	1
MMRF_1256	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.5	mg	mg	DAYS 1 AND 8	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.5	Other	DAYS 1 AND 8					206	488	1
MMRF_1256	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					206	488	1
MMRF_1256	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	DAYS 2 AND 9	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 2 AND 9					206	488	1
MMRF_1256	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					506		1
MMRF_1277	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					46	77	1
MMRF_1277	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					1	77	1
MMRF_1277	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_1285	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.5	Q week	Q week					1	204	1
MMRF_1285	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	550	mg	mg	DAYS 1, 8, 15, 22 OF EACH CYCLE	Other	PO	PO	Log Forms				550	Other	DAYS 1, 8, 15, 22 OF EACH CYCLE					1	204	1
MMRF_1285	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	204	1
MMRF_1285	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.5	mg	mg	Q21DAYS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.5	Other	Q21DAYS					303	877	1
MMRF_1285	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	AFTER PROGRESSION	Other	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.5	mg	mg	WEEKLY ( Q D1, D8,D15) 1 WEEK OFF	Other	IV	IV	Log Forms	Other	AFTER PROGRESSION		2.5	Other	WEEKLY ( Q D1, D8,D15) 1 WEEK OFF					898	1051	1
MMRF_1285	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	NEW LINE DUE TO PROGRESSION	Other	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	NEW LINE DUE TO PROGRESSION		15	QD (D1-21)	QD (D1-21)					898	1051	1
MMRF_1285	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	NEW LINE DUE TO PROGRESSION	Other	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	NEW LINE DUE TO PROGRESSION		20	QWK	QWK					898	1051	1
MMRF_1285	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					1093	1205	1
MMRF_1285	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					1209	1823	1
MMRF_1285	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Ixazomib	Ixazomib		0	DEATH	Other	4	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		4	QWK	QWK					1851	2018	1
MMRF_1285	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	DEATH	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1851	2018	1
MMRF_1285	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	DEATH	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1851	2018	1
MMRF_1359	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		40	Q day	Q day					1123	1162	1
MMRF_1359	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1123	1162	1
MMRF_1359	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	36	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IVB	IVB	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1123	1162	1
MMRF_1359	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					882	1106	1
MMRF_1359	First line of therapy	First Line Therapy	MOBILATION PRIOR TO HARVESTED AOUTOLOGOUS STEM CELL TRANPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILATION PRIOR TO HARVESTED AOUTOLOGOUS STEM CELL TRANPLANT		200	Q day	Q day					168	169	1
MMRF_1359	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					694	876	1
MMRF_1359	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3	mg	mg	QD ( D1, D8,D15,D22)	Other	SUB - Q	Other	Log Forms	Induction	Induction		3	Other	QD ( D1, D8,D15,D22)					694	862	1
MMRF_1359	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	QD ( D1, D8, D15, D22)	Other	PO	PO	Log Forms	Induction	Induction		500	Other	QD ( D1, D8, D15, D22)					694	876	1
MMRF_1359	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			TO PROCEED WITH TRANSPLANT	Other	40	mg	mg	D1-4, D 9-12	Other	PO	PO	Log Forms				40	Other	D1-4, D 9-12					1	116	1
MMRF_1359	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			TO PROCEED WITH TRANSPLANT	Other	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	116	1
MMRF_1395	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	108	1
MMRF_1395	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q 1, 2, 4, 5, 8, 9, 11, 12 OF EACH 21-DAY CYCLE	Other	PO	PO	Log Forms				20	Other	Q 1, 2, 4, 5, 8, 9, 11, 12 OF EACH 21-DAY CYCLE					1	126	1
MMRF_1395	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	126	1
MMRF_1395	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		100	Q day	Q day					189	190	1
MMRF_1395	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1156	1492	1
MMRF_1395	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					1493		1
MMRF_1401	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					430	500	1
MMRF_1401	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					430	500	1
MMRF_1401	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD	Other	PO	PO	Log Forms	Maintenance	Maintenance		15	Other	QD					261	427	1
MMRF_1401	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Lack of response	Lack of response	15	mg	mg	QD	Other	PO	PO	Log Forms	Consolidation	Consolidation		15	Other	QD					91	260	1
MMRF_1401	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Lack of response	Lack of response	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					91	247	1
MMRF_1401	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	542	1
MMRF_1401	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	75	1
MMRF_1401	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	75	1
MMRF_1410	First line of therapy	First Line Therapy	Consolidation	Consolidation	RANDOMIZED MILS TRIAL, J1343 (NO MILS ARM)	Other			Completed regimen	Completed regimen	200	UNKNOWN	Other	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					187	187	1
MMRF_1410	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					245		1
MMRF_1410	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	164	1
MMRF_1410	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	164	1
MMRF_1410	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	164	1
MMRF_1410	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	UNK	UNK	Other	DAY -2 AND -1	Other	IV	IV	Log Forms	Other	TRANSPLANT			Other	DAY -2 AND -1					175	176	1
MMRF_1598	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	45	1
MMRF_1598	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			DEATH	Other	100	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		100	Q day	Q day					1	45	1
MMRF_1670	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PLAN FOR STEM CELL RESCUE WHEN IN REMISSION	Other	3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1670	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			PLAN FOR STEM CELL RESCUE WHEN IN REMISSION.	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_1670	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PLAN FOR STEM CELL RESCUE WHEN IN REMISSION.	Other	40	mg	mg	ONCE WEEKLY	Other	PO	PO	Log Forms	Induction	Induction		40	Other	ONCE WEEKLY					1	74	1
MMRF_1670	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	DUE TO PROGRESSION	Other	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	D1,D8,D15	Other	IV	IV	Log Forms	Other	DUE TO PROGRESSION		20	Other	D1,D8,D15					484	612	1
MMRF_1670	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Unknown	Unknown		16	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1283	1416	1
MMRF_1670	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1283	1429	1
MMRF_1670	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q 2 WKS	Other	IV	IV	Log Forms	Unknown	Unknown		20	Other	Q 2 WKS					1283	1416	1
MMRF_1670	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab		0	Disease progression/Relapse	Disease progression/Relapse	10	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		10	QWK	QWK					1443	1462	1
MMRF_1670	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1436	1473	1
MMRF_1670	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	750	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Maintenance	Maintenance		750	QD (D1-4)	QD (D1-4)					1478	1502	1
MMRF_1670	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	210	mg	mg	QD ON DAYS -2 AND -1 PRE TRANSPLANT	Other	IV	IV	Log Forms	Induction	Induction		210	Other	QD ON DAYS -2 AND -1 PRE TRANSPLANT					127	128	1
MMRF_1670	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	QD					278	477	1
MMRF_1670	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	ACP-196	Other			Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		100	BID	BID					683	773	1
MMRF_1670	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	PEMBROLIZUMAB	Other			Disease progression/Relapse	Disease progression/Relapse	2	mg/kg	mg/kg	DAY 1	Other	IV	IV	Log Forms	Induction	Induction		2	Other	DAY 1					683	773	1
MMRF_1670	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	600	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		600	Other	DAYS 1, 8, 15, 22					943	1111	1
MMRF_1670	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg/m^2	mg/m^2	DAYS 1, 8, 15, 22	Other	IV	IV	Log Forms	Induction	Induction		1.5	Other	DAYS 1, 8, 15, 22					943	1111	1
MMRF_1670	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Maintenance	Maintenance	CISPLATIN	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Maintenance	Maintenance		25	QD (D1-4)	QD (D1-4)					1478	1502	1
MMRF_1670	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Maintenance	Maintenance	ETOPOSIDE	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	75	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Maintenance	Maintenance		75	QD (D1-4)	QD (D1-4)					1478	1502	1
MMRF_1670	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg/kg	mg/kg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Maintenance	Maintenance		16	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1562	1646	1
MMRF_1670	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1562	1656	1
MMRF_1670	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Maintenance	Maintenance	MESNA	Other		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	750	mg	mg	QD (D1-4)	QD (D1-4)	CONTINUOUS IV INFUSION	Other	Log Forms	Maintenance	Maintenance		750	QD (D1-4)	QD (D1-4)					1478	1502	1
MMRF_1670	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Maintenance	Maintenance		40	QD (D1-4)	QD (D1-4)					1478	1502	1
MMRF_1670	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	D1, 8, & 15	Other	IV	IV	Log Forms	Maintenance	Maintenance		20	Other	D1, 8, & 15					1562	1646	1
MMRF_1670	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Unknown	Unknown	Ixazomib	Ixazomib		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	D1, 8, & 15	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	D1, 8, & 15					1804	1877	1
MMRF_1670	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-14)	QD (D1-14)					1804	1877	1
MMRF_1670	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1804	1877	1
MMRF_1695	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					471		1
MMRF_1695	First line of therapy	First Line Therapy	MOBILIZATION	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	70	mg/kg	mg/kg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		70	Q day	Q day					198	198	1
MMRF_1695	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	214	1
MMRF_1695	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DUE TO TRANSPLANT , MOBILIZATION	Other	15	mg	mg	EVERY OTHER DAY DAYS 1-14	Other	PO	PO	Log Forms	Induction	Induction		15	Other	EVERY OTHER DAY DAYS 1-14					1	144	1
MMRF_1695	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DUE TO TRANSPLANT , MOBILIZATION	Other	2.6	mg	mg	QD (D1, D4, D8, D11)	Other	IV	IV	Log Forms	Induction	Induction		2.6	Other	QD (D1, D4, D8, D11)					1	144	1
MMRF_1838	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1-4, 9-12, 17-20	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1-4, 9-12, 17-20					78	155	1
MMRF_1838	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	DAYS 1, 8, 15, 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Other	DAYS 1, 8, 15, 22					78	155	1
MMRF_1838	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	50	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		50	Other	DAYS 1, 8, 15, 22					1	71	1
MMRF_1838	First line of therapy	First Line Therapy	NOT SUFFICIENT RESPONSE TO PREVIOUS TREATMENT.	Other	Lenalidomide	Lenalidomide			AUTOLOGOUS TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Other	NOT SUFFICIENT RESPONSE TO PREVIOUS TREATMENT.		25	QD (D1-14)	QD (D1-14)					78	155	1
MMRF_1838	First line of therapy	First Line Therapy	PRE TRANSPLANT TREAMENT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	70	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	PRE TRANSPLANT TREAMENT		70	Q day	Q day					209	210	1
MMRF_1838	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					316	615	1
MMRF_1838	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			DEATH	Other	48	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		48	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					630	1005	1
MMRF_1838	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					630	1005	1
MMRF_1866	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV SubQ	IV SubQ	Log Forms	Other	PRE-TRANSPLANT		1.3	QD (D1-4)	QD (D1-4)					1173	1182	1
MMRF_1866	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	D1-4 & D7	Other	PO	PO	Log Forms	Other	PRE-TRANSPLANT		20	Other	D1-4 & D7					1173	1183	1
MMRF_1866	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	Thalidomide	Thalidomide		0	Completed regimen	Completed regimen	100	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Other	PRE-TRANSPLANT		100	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1173	1183	1
MMRF_1866	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	CISPLATIN	Other		0	Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	CONTINUOUS IV INFUSION	Other	Log Forms	Other	PRE-TRANSPLANT		100	QD (D1-4)	QD (D1-4)					1173	1179	1
MMRF_1866	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	Doxorubicin	Doxorubicin		0	Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	CONTINUOUS IV INFUSION	Other	Log Forms	Other	PRE-TRANSPLANT		10	QD (D1-4)	QD (D1-4)					1173	1179	1
MMRF_1866	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	400	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	CONTINUOUS IV INFUSION	Other	Log Forms	Other	PRE-TRANSPLANT		400	QD (D1-4)	QD (D1-4)					1173	1179	1
MMRF_1866	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	ETOPOSIDE	Other		0	Completed regimen	Completed regimen	40	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	CONTINUOUS IV INFUSION	Other	Log Forms	Other	PRE-TRANSPLANT		40	QD (D1-4)	QD (D1-4)					1173	1179	1
MMRF_1866	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			COMPLETED CYCLE	Other	20	mg	mg	QD(D1, D2,D4,D5,D8,D9,D11) OF EACH 21-DAY CYCLE.	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD(D1, D2,D4,D5,D8,D9,D11) OF EACH 21-DAY CYCLE.					1	13	1
MMRF_1866	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			COMPLETED CYCLE 2	Other	20	mg	mg	QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-DAY CYCLE					22	33	1
MMRF_1866	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			COMPLETED CYCLE 3	Other	20	mg	mg	QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-DAY CYCLE					43	57	1
MMRF_1866	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			COMPLETED CYCLE 4	Other	20	mg	mg	QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-DAY CYCLE					65	78	1
MMRF_1866	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			COMPLETED CYCLE 5	Other	20	mg	mg	QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-DAY CYCLE					85	96	1
MMRF_1866	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Patient decision	Patient decision	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					107	192	1
MMRF_1866	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			UNKNOWN	Other	12	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		12	QWK	QWK					105	918	1
MMRF_1866	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IVB	IVB	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1866	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance	Checked	16	QWK	QWK					1296		1
MMRF_1866	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	4	QD (D1-21)	QD (D1-21)					1348		1
MMRF_1866	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1597		1
MMRF_1866	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	192	1
MMRF_1950	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3	mg	mg	Q D1, 8, 15, 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3	Other	Q D1, 8, 15, 22					1	289	1
MMRF_1950	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	Q 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		300	Other	Q 1, 8, 15, 22					1	107	1
MMRF_1950	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	107	1
MMRF_1950	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1,D2) Q 2 WEEKS	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (D1,D2) Q 2 WEEKS					114	289	1
MMRF_1950	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Investigator decision for other reasons	Investigator decision for other reasons	1100	mg	mg	Q week	Q week	IVB	IVB	Log Forms	Maintenance	Maintenance		1100	Q week	Q week					1152	1310	1
MMRF_1950	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Investigator decision for other reasons	Investigator decision for other reasons	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1152	1236	1
MMRF_1950	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	D1, 2, 8, 15	Other	IV	IV	Log Forms	Maintenance	Maintenance		20	Other	D1, 2, 8, 15					1152	1310	1
MMRF_1997	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		0	Investigator decision for other reasons	Investigator decision for other reasons	3	mg	mg	D1, 8, & 15	Other	PO	PO	Log Forms	Maintenance	Maintenance		3	Other	D1, 8, & 15					1604	1660	1
MMRF_1997	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1604	1660	1
MMRF_1997	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1604	1660	1
MMRF_1997	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					7	93	1
MMRF_1997	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Patient decision	Patient decision	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	787	1
MMRF_1997	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					94	241	1
MMRF_1997	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	DAYS 1, 8, 15, 22	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	DAYS 1, 8, 15, 22					473	557	1
MMRF_1997	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	DAY 1, 15	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	DAY 1, 15					564	621	1
MMRF_2214	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	Q3 WEEKS ON AND ONE WEEK OFF	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	Q3 WEEKS ON AND ONE WEEK OFF					44	433	1
MMRF_2214	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		4	QWK	QWK					1	433	1
MMRF_2214	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	DAY 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		300	Other	DAY 1, 8, 15, 22					1	426	1
MMRF_2214	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.1	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3.1	Q week	Q week					9	36	1
MMRF_2230	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	DAY 1-4. 9-12, 17-20	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAY 1-4. 9-12, 17-20					1	124	1
MMRF_2230	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.7	mg	mg	DAY 1. 8, 15 AND 22	Other	IV	IV	Log Forms	Induction	Induction		2.7	Other	DAY 1. 8, 15 AND 22					1	64	1
MMRF_2230	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	DAYS 1, 8, 15 AND 22	Other	PO	PO	Log Forms	Induction	Induction		500	Other	DAYS 1, 8, 15 AND 22					1	64	1
MMRF_2258	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	112	1
MMRF_2258	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	112	1
MMRF_2442	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	190	1
MMRF_2442	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	190	1
MMRF_2442	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	D1, 8, & 15	Other	IV	IV	Log Forms	Induction	Induction		20	Other	D1, 8, & 15					1106	1254	1
MMRF_2442	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					779	1040	1
MMRF_2442	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	D1, 8, & 15	Other	IV	IV	Log Forms	Induction	Induction		16	Other	D1, 8, & 15					1106	1254	1
MMRF_2442	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1274	1543	1
MMRF_2442	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	DAY 1-2, 4-5, 8-9, 11-12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY 1-2, 4-5, 8-9, 11-12					1	36	1
MMRF_2442	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAY 1-2, 4-5, 8-9, 11-12	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAY 1-2, 4-5, 8-9, 11-12					36	190	1
MMRF_2442	First line of therapy	First Line Therapy	Unknown	Unknown	Melphalan	Melphalan			Completed regimen	Completed regimen	177	mg	mg	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		177	Q day	Q day					224	225	1
MMRF_2442	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					406	767	1
MMRF_2442	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1106	1263	1
MMRF_2442	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q 4WKS	Other	IV	IV	Log Forms	Maintenance	Maintenance		16	Other	Q 4WKS					1274	1543	1
MMRF_2442	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q 4 WKS	Other	IV	IV	Log Forms	Maintenance	Maintenance		20	Other	Q 4 WKS					1274	1543	1
MMRF_2442	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1-21)	QD (D1-21)			Log Forms	Maintenance	Maintenance		3	QD (D1-21)	QD (D1-21)					1555	1732	1
MMRF_2442	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q 4 WKS	Other	IV	IV	Log Forms	Maintenance	Maintenance		16	Other	Q 4 WKS					1555	1702	1
MMRF_2442	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	D1-2, D15-16	Other	IV	IV	Log Forms	Maintenance	Maintenance		27	Other	D1-2, D15-16					1555	1717	1
MMRF_2442	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q 4 WKS	Other	IV	IV	Log Forms	Maintenance	Maintenance		20	Other	Q 4 WKS					1555	1702	1
MMRF_2456	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib		1						D1, D8, D15	Other	IV	IV	Log Forms	Consolidation	Consolidation	Checked		Other	D1, D8, D15					1788		1
MMRF_2456	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation	Checked	10	Q day	Q day					1788		1
MMRF_2456	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation	Checked	20	Q week	Q week					1788		1
MMRF_2456	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	D1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1, 8, 15, 22					153	469	1
MMRF_2456	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					918	1788	1
MMRF_2456	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					596	918	1
MMRF_2456	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					153	472	1
MMRF_2456	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	54	mg	mg	Q WEEKLY D1,D8,D15	Other	IV	IV	Log Forms	Induction	Induction		54	Other	Q WEEKLY D1,D8,D15					153	469	1
MMRF_2456	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		40	BID	BID					1	110	1
MMRF_2456	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	3	mg	mg	DAY 1, 8, 15, 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3	Other	DAY 1, 8, 15, 22					5	124	1
MMRF_2456	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	600	mg	mg	DAY 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		600	Other	DAY 1, 8, 15, 22					5	110	1
MMRF_2456	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan		0	Completed regimen	Completed regimen	UNK	UNK	Other	DAY -2 & DAY -1	Other	IV	IV	Log Forms	Induction	Induction			Other	DAY -2 & DAY -1					509	510	1
MMRF_2471	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	231	1
MMRF_2471	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8, 15, 22					4	597	1
MMRF_2471	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					154	231	1
MMRF_2471	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	5	mg	mg	BID	BID	PO	PO	Log Forms	Maintenance	Maintenance		5	BID	BID					232	597	1
MMRF_2471	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1136	1184	1
MMRF_2471	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	50	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IVB	IVB	Log Forms	Induction	Induction		50	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1148	1184	1
MMRF_2471	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1148		1
MMRF_2471	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1148	1207	1
MMRF_2475	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	131	1
MMRF_2475	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	222	1
MMRF_2475	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAYS 1,2,4,5,8,9,11,12 OF EACH 21 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1,2,4,5,8,9,11,12 OF EACH 21 DAY CYCLE					1	222	1
MMRF_2475	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					423		1
MMRF_2546	First line of therapy	First Line Therapy	Unknown	Unknown	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.8	mg	mg	Q 28 D ( D1,8,15)	Other	IV	IV	Log Forms	Unknown	Unknown		2.8	Other	Q 28 D ( D1,8,15)					197	366	1
MMRF_2546	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	136	1
MMRF_2546	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	117	1
MMRF_2579	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	101	1
MMRF_2579	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	73	1
MMRF_2579	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D4-5, D8-9, D11-12)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D4-5, D8-9, D11-12)					1	105	1
MMRF_2579	First line of therapy	First Line Therapy	INDUCTION	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	INDUCTION		100	Q day	Q day					140	141	1
MMRF_1021	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					84	84	1
MMRF_1021	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			TOXICITY	Other	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	29	1
MMRF_1021	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	29	1
MMRF_1021	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			TOXICITY	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	29	1
MMRF_1021	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	EVIDENCE OF DISEASE PROGRESION	Other	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	EVIDENCE OF DISEASE PROGRESION		25	QD (D1-21)	QD (D1-21)					630	825	1
MMRF_1021	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	EVIDENCE OF DISEASE PROGRESSION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Other	EVIDENCE OF DISEASE PROGRESSION		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					630	825	1
MMRF_1021	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV SubQ	IV SubQ	Log Forms	Other	CONDITIONING		1.6	QD (D1-4)	QD (D1-4)					845	848	1
MMRF_1021	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING	Other	FLUDARABINE	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		30	Q day	Q day					844	847	1
MMRF_1021	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONSOLIDATION	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONSOLIDATION		140	Q day	Q day					847	847	1
MMRF_1021	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING	Other	THYMOGLOBULIN	Other			Completed regimen	Completed regimen	2	MG/KG	Other	QD (D1-3)	QD (D1-3)	IV	IV	Log Forms	Other	CONDITIONING		2	QD (D1-3)	QD (D1-3)					847	848	1
MMRF_1021	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/m^2	mg/m^2	MONTHLY	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Other	MONTHLY					2363		1
MMRF_1021	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					2363		1
MMRF_1021	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	DAYS 1, 8, 15					2363		1
MMRF_1030	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			PATIENT WENT TO TRANSPLANT	Other	1	mg	mg	QWK	QWK	IV	IV	Log Forms				1	QWK	QWK					1	106	1
MMRF_1030	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms				200	Q day	Q day					140	140	1
MMRF_1030	First line of therapy	First Line Therapy			Thalidomide	Thalidomide			Completed regimen	Completed regimen	1000	mg	mg	Q day	Q day	PO	PO	Log Forms				1000	Q day	Q day					280	283	1
MMRF_1030	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms				1.6	Q day	Q day					281	283	1
MMRF_1030	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms				200	Q day	Q day					282	282	1
MMRF_1030	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1984	2205	1
MMRF_1030	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1984	2205	1
MMRF_1030	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1984	2205	1
MMRF_1030	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					2373	2459	1
MMRF_1030	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	DAYS 1, 8, AND 15	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	DAYS 1, 8, AND 15					2373	2459	1
MMRF_1030	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					2373	2459	1
MMRF_1030	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	DAYS 1, 2, 8, 9, 15, 16	Other	IV	IV	Log Forms	Other	SALVAGE		27	Other	DAYS 1, 2, 8, 9, 15, 16					2465	2493	1
MMRF_1030	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					2465	2493	1
MMRF_1030	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1, 2, 8, 9, 15, 16	Other	IV	IV	Log Forms	Other	SALVAGE		20	Other	DAYS 1, 2, 8, 9, 15, 16					2465	2493	1
MMRF_1030	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV	IV	Log Forms	Other	SALVAGE		300	Other	DAYS 1, 8, 15					2493	2677	1
MMRF_1030	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	DAYS 1, 2, 8, 9, 15, 16	Other	IV	IV	Log Forms	Other	SALVAGE		27	Other	DAYS 1, 2, 8, 9, 15, 16					2493	2677	1
MMRF_1030	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					2493	2677	1
MMRF_1030	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1, 2, 8, 9, 15, 16	Other	IV	IV	Log Forms	Other	SALVAGE		20	Other	DAYS 1, 2, 8, 9, 15, 16					2493	2677	1
MMRF_1030	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			PATIENT WENT TO TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	106	1
MMRF_1030	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			PATIENT WENT TO TRANSPLANT	Other	20	mg	mg	QWK	QWK	IV	IV	Log Forms				20	QWK	QWK					1	106	1
MMRF_1030	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			PATIENT GOING TO TRANSPLANT	Other	3	GRAMS	Other	Q day	Q day	IV	IV	Log Forms				3	Q day	Q day					116	116	1
MMRF_1030	First line of therapy	First Line Therapy			ETOPOSIDE	Other			PATIENT GOING TO TRANSPLANT	Other	300	mg	mg	Q day	Q day	IV	IV	Log Forms				300	Q day	Q day					116	116	1
MMRF_1030	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			PATIENT GOING TO TRANSPLANT	Other	40	mg	mg	Q day	Q day	IV	IV	Log Forms				40	Q day	Q day					116	116	1
MMRF_1032	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			DIED	Other	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		12	Q week	Q week					726	934	1
MMRF_1032	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			DIED	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					612	934	1
MMRF_1032	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					439	725	1
MMRF_1032	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					439	578	1
MMRF_1032	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	42	1
MMRF_1032	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	1050	mg	mg	Q week	Q week	IV	IV	Log Forms				1050	Q week	Q week					1	39	1
MMRF_1032	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	52	1
MMRF_1072	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Carfilzomib	Carfilzomib		0	Investigator decision for other reasons	Investigator decision for other reasons	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2117	2292	1
MMRF_1072	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Carfilzomib	Carfilzomib		0	Investigator decision for other reasons	Investigator decision for other reasons	56	mg/m^2	mg/m^2	QD (D1-2, D15-16)	Other	IV	IV	Log Forms				56	Other	QD (D1-2, D15-16)					2305	2445	1
MMRF_1072	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			PT GOING TO TRANSPLANT	Other	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_1072	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	14	1
MMRF_1072	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			GOING TO TRANSPLANT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_1072	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3.1	G	Other	Q day	Q day	PO	PO	Log Forms	Other	MOBILIZATION		3.1	Q day	Q day					60	60	1
MMRF_1072	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	310	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		310	Q day	Q day					60	60	1
MMRF_1072	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					60	60	1
MMRF_1072	First line of therapy	First Line Therapy	CONDITIONIG	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	312	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONIG		312	Q day	Q day					86	86	1
MMRF_1072	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)			Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	QD (D1, D8, D15)	Other	IV	IV	Log Forms			Checked	16	Other	QD (D1, D8, D15)					3033		1
MMRF_1072	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)			Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms			Checked	4	QD (D1-21)	QD (D1-21)					3033		1
MMRF_1072	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)			Dexamethasone	Dexamethasone		0			20	mg	mg	QD (D1, D8, D15)	Other	IV	IV	Log Forms				20	Other	QD (D1, D8, D15)					3033		1
MMRF_1072	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2117	2292	1
MMRF_1072	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1-2, D15-16)	Other	IV	IV	Log Forms				20	Other	QD (D1-2, D15-16)					2305	2445	1
MMRF_1079	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.4	mg	mg	QD(D1,D5,D15,D19)	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.4	Other	QD(D1,D5,D15,D19)					1999	2074	1
MMRF_1079	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Panobinostat	Panobinostat			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1, D3, D5, D15, D17, D19)	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD (D1, D3, D5, D15, D17, D19)					1999	2074	1
MMRF_1079	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	ON DAYS OF VELCADE	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	ON DAYS OF VELCADE					1999	2074	1
MMRF_1079	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Bortezomib	Bortezomib			DEATH	Other	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2081	2126	1
MMRF_1079	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	NELFINAVIR (VIRACEPT)	Other			DEATH	Other	625	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		625	Q day	Q day					2081	2126	1
MMRF_1079	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2081	2126	1
MMRF_1079	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	DAYS 1,8,15 & 22 OF A 28 DAYS FOR C1&2/DAYS A AND 15 C3TO C6/DAYS 1 CYCLE 7	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	DAYS 1,8,15 & 22 OF A 28 DAYS FOR C1&2/DAYS A AND 15 C3TO C6/DAYS 1 CYCLE 7					1887	1971	1
MMRF_1079	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1887	1971	1
MMRF_1079	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	WITH EACH DARATUMUMAB INFUSION	Other	IV	IV	Log Forms	Unknown	Unknown		40	Other	WITH EACH DARATUMUMAB INFUSION					1887	1971	1
MMRF_1079	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SECOND LINE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1331	1752	1
MMRF_1079	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SECOND LINE		25	QD (D1-21)	QD (D1-21)					1331	1752	1
MMRF_1079	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SECOND LINE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1331	1752	1
MMRF_1079	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	THIRD LINE	Other	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	500	mg/m^2	mg/m^2	D1, 8	Other	IV	IV	Log Forms	Other	THIRD LINE		500	Other	D1, 8					1597	1752	1
MMRF_1079	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					226	226	1
MMRF_1079	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					99	99	1
MMRF_1079	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					75	75	1
MMRF_1079	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		10	Q day	Q day					75	75	1
MMRF_1079	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		2000	Q day	Q day					75	75	1
MMRF_1079	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			PROCEED TO TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	43	1
MMRF_1079	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PROCEED TO TRANSPLANT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	40	1
MMRF_1079	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			MOVE TO TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	40	1
MMRF_1098	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	89	1
MMRF_1098	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	89	1
MMRF_1098	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	92	1
MMRF_1098	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					105	329	1
MMRF_1099	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Induction	Induction		25	Other	EVERY OTHER DAY					144	285	1
MMRF_1099	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					333	588	1
MMRF_1099	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Pomalidomide	Pomalidomide			Patient decision	Patient decision	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				4	QD (D1-21)	QD (D1-21)					333	588	1
MMRF_1099	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	285	1
MMRF_1099	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	136	1
MMRF_1099	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	4	1
MMRF_1139	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1139	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	35	1
MMRF_1139	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1139	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M^2	Other	Q day	Q day	IV	IV	Log Forms				2	Q day	Q day					74	74	1
MMRF_1139	First line of therapy	First Line Therapy			ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms				200	Q day	Q day					74	74	1
MMRF_1139	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms				10	Q day	Q day					74	74	1
MMRF_1139	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					99	99	1
MMRF_1139	First line of therapy	First Line Therapy	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	CONDITIONING		1.3	QD (D1-4)	QD (D1-4)					274	277	1
MMRF_1139	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					276	276	1
MMRF_1159	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				3.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	92	1
MMRF_1159	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	92	1
MMRF_1159	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4.7	G	Other	ONCE	Other	IV	IV	Log Forms				4.7	Other	ONCE					122	122	1
MMRF_1159	First line of therapy	First Line Therapy			ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms				200	Other	ONCE					122	122	1
MMRF_1159	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	ONCE	Other	IV	IV	Log Forms				10	Other	ONCE					122	122	1
MMRF_1159	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms				200	Other	ONCE					170	170	1
MMRF_1177	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			DEATH	Other	890	mg	mg	QD (D1, D8)	Other	IV	IV	Log Forms	Other	SALVAGE		890	Other	QD (D1, D8)					711	819	1
MMRF_1177	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Bortezomib	Bortezomib			DEATH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					711	819	1
MMRF_1177	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Other	SALVAGE		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					711	819	1
MMRF_1177	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			INTOLERANCE TO THERAPY	Other	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	242	1
MMRF_1177	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			INTOLERANCE TO THERAPY	Other	500	mg/m^2	mg/m^2	QD (D1, D8)	Other	IV	IV	Log Forms				500	Other	QD (D1, D8)					1	242	1
MMRF_1177	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	242	1
MMRF_1208	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					8	66	1
MMRF_1208	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	QD 1-8	Other	IV	IV	Log Forms				500	Other	QD 1-8					1	63	1
MMRF_1208	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	63	1
MMRF_1208	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					170	170	1
MMRF_1208	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE THERAPY	Other	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	SECOND LINE THERAPY		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					711	722	1
MMRF_1208	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE THERAPY	Other	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Other	SECOND LINE THERAPY		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					711	742	1
MMRF_1208	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SECOND LINE		15	QD (D1-21)	QD (D1-21)					732	905	1
MMRF_1208	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	32	mg	mg	QD (DAY1-DAY2; DAY15-DAY16)	Other	IV	IV	Log Forms	Consolidation	Consolidation		32	Other	QD (DAY1-DAY2; DAY15-DAY16)					1137	1320	1
MMRF_1208	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Thalidomide	Thalidomide			Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		100	QD (D1-21)	QD (D1-21)					1074	1114	1
MMRF_1208	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	DAYS 1 & 15	Other	IV	IV	Log Forms	Consolidation	Consolidation		300	Other	DAYS 1 & 15					1074	1102	1
MMRF_1208	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	DAYS 1, 8, 15	Other	IV	IV	Log Forms	Consolidation	Consolidation		40	Other	DAYS 1, 8, 15					1074	1114	1
MMRF_1208	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1137	1320	1
MMRF_1194	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	90	1
MMRF_1194	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					181	181	1
MMRF_1194	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QID	QID	IV	IV	Log Forms	Other	MOBILIZATION		10	QID	QID					142	142	1
MMRF_1194	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	QID	QID	IV	IV	Log Forms	Other	MOBILIZATION		200	QID	QID					142	142	1
MMRF_1194	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	QID	QID	IV	IV	Log Forms	Other	MOBILIZATION		2000	QID	QID					142	142	1
MMRF_1194	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					91	136	1
MMRF_1194	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					91	136	1
MMRF_1194	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					91	100	1
MMRF_1194	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	90	1
MMRF_1205	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	N/A	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	N/A		12	Q week	Q week					667	685	1
MMRF_1205	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	N/A	Other	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QOD (D1-21)	Other	PO	PO	Log Forms	Other	N/A		4	Other	QOD (D1-21)					667	685	1
MMRF_1205	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					618	666	1
MMRF_1205	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					618	666	1
MMRF_1205	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		140	Q day	Q day					187	187	1
MMRF_1205	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Induction	Induction		500	QWK	QWK					135	135	1
MMRF_1205	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					114	127	1
MMRF_1205	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_1205	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	300	mg/m^2	mg/m^2	QD (D1, D8)	Other	IV	IV	Log Forms				300	Other	QD (D1, D8)					1	85	1
MMRF_1205	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_1211			CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					127	127	1
MMRF_1211	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					101	101	1
MMRF_1211	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		40	Q day	Q day					101	101	1
MMRF_1211	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD1, 8, 15	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD1, 8, 15					64	78	1
MMRF_1211	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.6	mg/m^2	mg/m^2	QD1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.6	Other	QD1, 8, 15					64	78	1
MMRF_1211	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		2000	Q day	Q day					101	101	1
MMRF_1211	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1211	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1221	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					947	1067	1
MMRF_1221	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					852	922	1
MMRF_1221	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	500	mg/m^2	mg/m^2	D1 AND D8	Other	IV	IV	Log Forms	Unknown	Unknown		500	Other	D1 AND D8					851	914	1
MMRF_1221	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					851	922	1
MMRF_1221	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	REINDUCTION	Other	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	REINDUCTION		40	QWK	QWK					711	760	1
MMRF_1221	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	REINDUCTION	Other	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	REINDUCTION		25	QD (D1-21)	QD (D1-21)					711	760	1
MMRF_1221	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					128	128	1
MMRF_1221	First line of therapy	First Line Therapy	Induction	Induction	TH1 CELL INFUSION	Other			Completed regimen	Completed regimen	0	N/A. INFUSION	Other	ONCE	Other	IV	IV	Log Forms	Induction	Induction		0	Other	ONCE					352	352	1
MMRF_1221	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					297	297	1
MMRF_1221	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAY 1 AND 4	Other	IV	IV	Log Forms	Other	MOBILIZATION		20	Other	DAY 1 AND 4					295	298	1
MMRF_1221	First line of therapy	First Line Therapy	MOBILIZATION	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	DAY 1 AND 4	Other	IV	IV	Log Forms	Other	MOBILIZATION		1.6	Other	DAY 1 AND 4					295	298	1
MMRF_1221	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					96	96	1
MMRF_1221	First line of therapy	First Line Therapy	MOBLOZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBLOZATION		2000	Q day	Q day					96	96	1
MMRF_1221	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					96	96	1
MMRF_1221	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_1221	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	64	1
MMRF_1221	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_1221	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			ADMITTED	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Maintenance	Maintenance		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1093	1164	1
MMRF_1221	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			ADMISSION	Other	4	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-14)	QD (D1-14)					1093	1164	1
MMRF_1221	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Bortezomib	Bortezomib			ADMITTED	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1093	1164	1
MMRF_1221	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	PANOBINOSTAT	Other			ADMITTED	Other	20	mg	mg	THREE TIMES WEEKLY (MONDAY-WEDNESDAY-FRIDAY)	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	THREE TIMES WEEKLY (MONDAY-WEDNESDAY-FRIDAY)					1093	1164	1
MMRF_1221	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					947	1080	1
MMRF_1221	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					947	1079	1
MMRF_1230	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms				200	Q day	Q day					168	168	1
MMRF_1230	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	8	mg	mg	Q day	Q day	PO	PO	Log Forms				8	Q day	Q day					169	169	1
MMRF_1230	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	8	mg	mg	BID	BID	PO	PO	Log Forms				8	BID	BID					170	170	1
MMRF_1230	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	Q day	Q day	PO	PO	Log Forms				12	Q day	Q day					168	168	1
MMRF_1230	First line of therapy	First Line Therapy			ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms				200	Q day	Q day					136	136	1
MMRF_1230	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms				10	Q day	Q day					136	136	1
MMRF_1230	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M^2	Other	Q day	Q day	IV	IV	Log Forms				2	Q day	Q day					136	136	1
MMRF_1230	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	500	mg/m^2	mg/m^2	QD D1 AND D8	Other	IV	IV	Log Forms				500	Other	QD D1 AND D8					22	102	1
MMRF_1230	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_1230	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	107	1
MMRF_1230	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_1257	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	52	1
MMRF_1257	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1248	1418	1
MMRF_1257	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1248	1418	1
MMRF_1257	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1, D8 & D15)	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1, D8 & D15)					1248	1418	1
MMRF_1257	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					905	1214	1
MMRF_1257	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	500	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		500	QD (D1-4)	QD (D1-4)					905	1207	1
MMRF_1257	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					905	1214	1
MMRF_1257	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					99	99	1
MMRF_1257	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	52	1
MMRF_1257	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	QD DAY 1-8	Other	IV	IV	Log Forms				500	Other	QD DAY 1-8					1	29	1
MMRF_1257	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1428	1443	1
MMRF_1257	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1428	1443	1
MMRF_1257	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1428	1448	1
MMRF_1257	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	WEEKLY FOR WEEKS 1-8, EVERY OTHER WEEK 9-24, MONTHLY WEEK 25 ONWARDS	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	WEEKLY FOR WEEKS 1-8, EVERY OTHER WEEK 9-24, MONTHLY WEEK 25 ONWARDS					1449	1578	1
MMRF_1257	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Thalidomide	Thalidomide			Investigator decision for other reasons	Investigator decision for other reasons	200	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		200	Q day	Q day					1449	1554	1
MMRF_1257	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		4	Q week	Q week					1449	1578	1
MMRF_1257	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	DAYS 1 AND 2 FOLLOWING DARA DOSING	Other	PO	PO	Log Forms	Unknown	Unknown		25	Other	DAYS 1 AND 2 FOLLOWING DARA DOSING					1452	1578	1
MMRF_1257	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	ANTI CANCER REGIMEN	Other	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	D 1,8 &15	Other	IV	IV	Log Forms	Other	ANTI CANCER REGIMEN		300	Other	D 1,8 &15					1536	1578	1
MMRF_1257	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1564	1578	1
MMRF_1257	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		56	Q day	Q day					1589	1590	1
MMRF_1257	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Bendamustine	Bendamustine			Completed regimen	Completed regimen	110	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		110	Q day	Q day					1589	1590	1
MMRF_1257	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		40	Q day	Q day					1589	1590	1
MMRF_1257	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	PEMBROLIZUMAB	Other			DEATH	Other	100	mg	mg	EVERY TWO WEEKS	Other	IV	IV	Log Forms	Unknown	Unknown		100	Other	EVERY TWO WEEKS					1617	1666	1
MMRF_1257	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			DEATH	Other	4	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-4)	QD (D1-4)					1610	1666	1
MMRF_1257	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1617	1666	1
MMRF_1257	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1248	1418	1
MMRF_1274	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1274	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	QD (D1-7)	QD (D1-7)	IV	IV	Log Forms				500	QD (D1-7)	QD (D1-7)					1	50	1
MMRF_1274	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1274	First line of therapy	First Line Therapy			FLUDARABINE	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms				30	Q day	Q day					288	291	1
MMRF_1274	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M^2	Other	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION		2	Other	ONCE					92	92	1
MMRF_1274	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION		200	Other	ONCE					92	92	1
MMRF_1274	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION		10	Other	ONCE					92	92	1
MMRF_1274	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					117	117	1
MMRF_1274	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		140	Q day	Q day					291	291	1
MMRF_1274	First line of therapy	First Line Therapy	MOBILIZATION	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	MOBILIZATION		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					289	292	1
MMRF_1286	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	40	1
MMRF_1286	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	47	1
MMRF_1286	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	40	1
MMRF_1286	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M^2	Other	ONCE	Other	IV	IV	Log Forms				2	Other	ONCE					74	74	1
MMRF_1286	First line of therapy	First Line Therapy			ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms				200	Other	ONCE					74	74	1
MMRF_1286	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					74	74	1
MMRF_1286	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		140	Q day	Q day					100	100	1
MMRF_1286	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					268	920	1
MMRF_1286	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					268	1018	1
MMRF_1286	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	THIRD LINE	Other	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	THIRD LINE		4	QD (D1-21)	QD (D1-21)					941	1107	1
MMRF_1286	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	FOURTH LINE (VELCADE POMALIDOMIDE DEXAMETHASONE)	Other	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, 8, 15)	Other	IV SubQ	IV SubQ	Log Forms	Other	FOURTH LINE (VELCADE POMALIDOMIDE DEXAMETHASONE)		1.3	Other	QD (D1, 8, 15)					1032	1101	1
MMRF_1286	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	FOURTH LINE (VELCADE POMALIDOMIDE DEXAMETHASONE)	Other	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, 8, 15)	Other	PO	PO	Log Forms	Other	FOURTH LINE (VELCADE POMALIDOMIDE DEXAMETHASONE)		20	Other	QD (D1, 8, 15)					1032	1101	1
MMRF_1286	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	FOURTH LINE (IXAZOMIB, POMALIDOMIDE, DEXAMETHASONE)	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	FOURTH LINE (IXAZOMIB, POMALIDOMIDE, DEXAMETHASONE)		20	Q week	Q week					1129	1206	1
MMRF_1286	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	FOURTH LINE (IXAZOMIB, POMALIDOMIDE, DEXAMETHASONE)	Other	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QWK (D1, 8, 15)	Other	PO	PO	Log Forms	Other	FOURTH LINE (IXAZOMIB, POMALIDOMIDE, DEXAMETHASONE)		4	Other	QWK (D1, 8, 15)					1129	1199	1
MMRF_1286	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	FOURTH LINE (IXAZOMIB, POM, DEX)	Other	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	FOURTH LINE (IXAZOMIB, POM, DEX)		4	QD (D1-21)	QD (D1-21)					1129	1205	1
MMRF_1286	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	FIFTH LINE	Other	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	FIFTH LINE		16	Q week	Q week					1227	2017	1
MMRF_1286	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	FIFTH LINE	Other	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	FIFTH LINE		4	QD (D1-21)	QD (D1-21)					1227	2017	1
MMRF_1286	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	FIFTH LINE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Other	FIFTH LINE		40	Q week	Q week					1227	2017	1
MMRF_1286	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	FIFTH LINE	Other	Prednisone	Prednisone		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	EVERY FRIDAY AND SATURDAY AFTER DARATUMUMAB ADMINISTRATION	Other	PO	PO	Log Forms	Other	FIFTH LINE		25	Other	EVERY FRIDAY AND SATURDAY AFTER DARATUMUMAB ADMINISTRATION					1229	2017	1
MMRF_1286	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	1.6	mg/m^2	mg/m^2	QD (1,8,15)	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1.6	Other	QD (1,8,15)					2083	2139	1
MMRF_1286	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	VENETOCLAX	Other		0	Disease progression/Relapse	Disease progression/Relapse	400	mg	mg	DAYS 1-8	Other	PO	PO	Log Forms	Other	SALVAGE		400	Other	DAYS 1-8					2083	2139	1
MMRF_1286	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					2083	2139	1
MMRF_1286	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	Panobinostat	Panobinostat		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	DAYS 1,3,5; 15,17,19	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	DAYS 1,3,5; 15,17,19					2146	2153	1
MMRF_1286	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.6	mg/m^2	mg/m^2	DAYS 1,8,15	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1.6	Other	DAYS 1,8,15					2146	2153	1
MMRF_1286	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	DAYS 1,8,15	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	DAYS 1,8,15					2146	2153	1
MMRF_1325	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	Q day	Q day	PO	PO	Log Forms				15	Q day	Q day					1	80	1
MMRF_1325	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	78	1
MMRF_1325	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					39	78	1
MMRF_1325	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	QID	QID	IV	IV	Log Forms	Other	MOBILIZATION		2000	QID	QID					123	123	1
MMRF_1325	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QID	QID	IV	IV	Log Forms	Other	MOBILIZATION		10	QID	QID					123	123	1
MMRF_1325	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	QID	QID	IV	IV	Log Forms	Other	MOBILIZATION		200	QID	QID					123	123	1
MMRF_1325	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					148	148	1
MMRF_1394	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		1			33	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE	Checked	33	Q week	Q week					2136		1
MMRF_1394	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)			Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	D1, D8, D15	Other	IV	IV	Log Forms				300	Other	D1, D8, D15					2192	2206	1
MMRF_1394	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1394	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	74	1
MMRF_1394	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	77	1
MMRF_1394	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M^2	Other	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION		2	Other	ONCE					87	87	1
MMRF_1394	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION		10	Other	ONCE					87	87	1
MMRF_1394	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION		200	Other	ONCE					87	87	1
MMRF_1394	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					112	112	1
MMRF_1394	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Ixazomib	Ixazomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1,8,15)	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1,8,15)					1366	1400	1
MMRF_1394	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1366	1414	1
MMRF_1394	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1366	1400	1
MMRF_1394	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	WEEKLY FOR WEEKS 1-8, QOW 9-24, MONTHLY 25 ONWARD	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Other	WEEKLY FOR WEEKS 1-8, QOW 9-24, MONTHLY 25 ONWARD					1821		1
MMRF_1394	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Bortezomib	Bortezomib			PATIENT HAS DEBILITATING NEUROPATHY	Other	1.3	mg/m^2	mg/m^2	D1, D8, D15	Other	IV	IV	Log Forms	Other	SALVAGE		1.3	Other	D1, D8, D15					1821	1961	1
MMRF_1394	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			40	mg	mg	DAY OF AND DAY AFTER DARA	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	40	Other	DAY OF AND DAY AFTER DARA					1821		1
MMRF_1408	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1408	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	101	1
MMRF_1408	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1408	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2.9	GM	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		2.9	Q day	Q day					121	121	1
MMRF_1408	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	290	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		290	Q day	Q day					121	121	1
MMRF_1408	First line of therapy	First Line Therapy	MOILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOILIZATION		10	Q day	Q day					121	121	1
MMRF_1408	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	296	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		296	Q day	Q day					272	272	1
MMRF_1408	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Ixazomib	Ixazomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1, D8, D15, D22)	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1, D8, D15, D22)					1624	1722	1
MMRF_1408	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1624	1722	1
MMRF_1408	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					1624	1722	1
MMRF_1408	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab		1			10	mg/kg	mg/kg	WEEKLY 1-8, QOW 9 ONWARD	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	10	Other	WEEKLY 1-8, QOW 9 ONWARD					1748		1
MMRF_1408	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			28	mg	mg	3-24 HOURS PRIOR TO ELO	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	28	Other	3-24 HOURS PRIOR TO ELO					1748		1
MMRF_1408	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					1748		1
MMRF_1413	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1413	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	QD (D1, D8)	Other	IV	IV	Log Forms	Induction	Induction		500	Other	QD (D1, D8)					1	78	1
MMRF_1413	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1413	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					127	127	1
MMRF_1413	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M^2	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					101	101	1
MMRF_1413	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	MOBILIZATION		10	Q day	Q day					101	101	1
MMRF_1413	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		0			20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1-21)	QD (D1-21)					1571	1612	1
MMRF_1413	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0			8	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		8	Q week	Q week					1570	1612	1
MMRF_1413	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab		0			10	mg/kg	mg/kg	WEEKLY FOR WEEKS 1-8, QOW WEEKS 9 ONWARD	Other	IV	IV	Log Forms	Unknown	Unknown		10	Other	WEEKLY FOR WEEKS 1-8, QOW WEEKS 9 ONWARD					1591	1612	1
MMRF_1413	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		1			70	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	70	Other	DAYS 1, 8, 15					1661		1
MMRF_1413	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			16	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	16	Other	DAYS 1, 8, 15					1661		1
MMRF_1413	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					101	101	1
MMRF_1418	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1418	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1418	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	57	1
MMRF_1418	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	QID	QID	IV	IV	Log Forms	Other	MOBILIZATION		2000	QID	QID					80	80	1
MMRF_1418	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QID	QID	IV	IV	Log Forms	Other	MOBILIZATION		10	QID	QID					80	80	1
MMRF_1418	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	QID	QID	IV	IV	Log Forms	Other	MOBILIZATION		200	QID	QID					80	80	1
MMRF_1418	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	QID	QID	IV	IV	Log Forms	Consolidation	Consolidation		200	QID	QID					108	108	1
MMRF_1418	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	QOD	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.6	Other	QOD					284	286	1
MMRF_1418	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					286	286	1
MMRF_1418	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		1			27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1185		1
MMRF_1418	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					1185		1
MMRF_1418	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1185		1
MMRF_1423	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	28	1
MMRF_1423	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	28	1
MMRF_1423	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	28	1
MMRF_1423	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					99	99	1
MMRF_1426	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	59	1
MMRF_1426	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	62	1
MMRF_1426	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	59	1
MMRF_1426	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M^2	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					122	122	1
MMRF_1426	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	MOBILIZATION		10	Q day	Q day					122	122	1
MMRF_1426	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					122	122	1
MMRF_1426	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					71	91	1
MMRF_1426	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					71	92	1
MMRF_1426	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					147	147	1
MMRF_1433	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1433	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	68	1
MMRF_1433	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				40	QD (D1-14)	QD (D1-14)					1	68	1
MMRF_1433	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M2	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					95	95	1
MMRF_1433	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					95	95	1
MMRF_1433	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					95	95	1
MMRF_1433	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					120	120	1
MMRF_1433	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	Q day	Q day	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.6	Q day	Q day					256	256	1
MMRF_1433	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					257	257	1
MMRF_1433	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	70	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		70	Q week	Q week					883	1082	1
MMRF_1433	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					883	1082	1
MMRF_1433	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					883	1082	1
MMRF_1433	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1-21)					1100	1332	1
MMRF_1433	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		40	Q week	Q week					1100	1332	1
MMRF_1433	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	PEMBROLIZUMAB	Other			Disease progression/Relapse	Disease progression/Relapse	200	mg	mg	Q2W	Other	IV	IV	Log Forms	Unknown	Unknown		200	Other	Q2W					1359	1472	1
MMRF_1433	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD 91-21)	Other	PO	PO	Log Forms	Unknown	Unknown		25	Other	QD 91-21)					1359	1472	1
MMRF_1433	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1359	1472	1
MMRF_1433	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	IDASANUTLIN	Other			Disease progression/Relapse	Disease progression/Relapse	200	mg	mg	QD (D1-5) OF A 28 DAYS CYCLE	Other	PO	PO	Log Forms	Unknown	Unknown		200	Other	QD (D1-5) OF A 28 DAYS CYCLE					1523	1607	1
MMRF_1433	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1,8,15) OF A28 DAYS CYCLE	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1,8,15) OF A28 DAYS CYCLE					1523	1607	1
MMRF_1433	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1,D8,D15,D22) OF A 28 DAYS CYCLE	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	QD (D1,D8,D15,D22) OF A 28 DAYS CYCLE					1523	1607	1
MMRF_1433	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	PATIENT EXPIRED	Other	1778	mg	mg	WEEKLY FOR CYCLES 1-3, Q3 WEEKS 4-8, MONTHLY 9 ONWARD	Other	IV	IV	Log Forms	Unknown	Unknown		1778	Other	WEEKLY FOR CYCLES 1-3, Q3 WEEKS 4-8, MONTHLY 9 ONWARD					1646	2158	1
MMRF_1433	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Bortezomib	Bortezomib		0	PATIENT EXPIRED	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1646	2158	1
MMRF_1433	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	PATIENT EXPIRED	Other	20	mg	mg	DAYS 1,2,4,5,8,9,11,12	Other	IV	IV	Log Forms	Unknown	Unknown		20	Other	DAYS 1,2,4,5,8,9,11,12					1646	2158	1
MMRF_1434	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1434	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_1434	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1434	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M^2	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					88	88	1
MMRF_1434	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					88	88	1
MMRF_1434	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					88	88	1
MMRF_1434	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					113	113	1
MMRF_1434	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					1677		1
MMRF_1434	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	DIARRHEA AND WORSENING FATIGUE	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1677	2271	1
MMRF_1452	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	86	1
MMRF_1452	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	D1 & D8	Other	IV	IV	Log Forms				500	Other	D1 & D8					1	83	1
MMRF_1452	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	86	1
MMRF_1452	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M^2	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					107	107	1
MMRF_1452	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					107	107	1
MMRF_1452	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					107	107	1
MMRF_1452	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					133	133	1
MMRF_1452	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					177	272	1
MMRF_1452	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					177	272	1
MMRF_1452	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					177	272	1
MMRF_1452	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	Q day	Q day	IV SubQ	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Q day	Q day					289	292	1
MMRF_1452	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONSOLIDATION	Other	FLUDARABINE	Other			Completed regimen	Completed regimen	49	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONSOLIDATION		49	Q day	Q day					288	291	1
MMRF_1452	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	MAINTENANCE	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MAINTENANCE		140	Q day	Q day					291	291	1
MMRF_1461	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1461	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_1461	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1461	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	QID	QID	IV	IV	Log Forms	Consolidation	Consolidation		200	QID	QID					107	107	1
MMRF_1461	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					508	815	1
MMRF_1461	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					508	815	1
MMRF_1461	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Patient decision	Patient decision	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					823	831	1
MMRF_1461	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					823	831	1
MMRF_1461	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	44	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		44	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					850	865	1
MMRF_1461	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					850	865	1
MMRF_1461	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	500	mg/m^2	mg/m^2	QD (D1 AND D8)	Other	IV	IV	Log Forms	Unknown	Unknown		500	Other	QD (D1 AND D8)					850	865	1
MMRF_1461	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					878	962	1
MMRF_1461	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Panobinostat	Panobinostat			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	D1 ,3,5,15,17,19	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	D1 ,3,5,15,17,19					878	962	1
MMRF_1461	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					878	962	1
MMRF_1461	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					969	1003	1
MMRF_1461	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					969	1003	1
MMRF_1461	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Panobinostat	Panobinostat			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	D1, 3,5,15,17,19	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	D1, 3,5,15,17,19					969	1003	1
MMRF_1461	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					969	1003	1
MMRF_1466	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1466	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1466	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					3	57	1
MMRF_1466	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M^2	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					88	88	1
MMRF_1466	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					88	88	1
MMRF_1466	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					88	88	1
MMRF_1466	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					115	115	1
MMRF_1466	First line of therapy	First Line Therapy	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Other	CONDITIONING		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					113	116	1
MMRF_1466	First line of therapy	First Line Therapy	CONDITIONING	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		10	Q day	Q day					113	113	1
MMRF_1466	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	NOT APPLICABLE	Other	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	NOT APPLICABLE		25	QD (D1-21)	QD (D1-21)					745	942	1
MMRF_1466	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	NOT APPLICABLE	Other	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	NOT APPLICABLE		20	Q week	Q week					745	943	1
MMRF_1466	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	THIRD LINE	Other	Carfilzomib	Carfilzomib		1			36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	THIRD LINE	Checked	36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1327		1
MMRF_1466	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	THIRD LINE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	THIRD LINE	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1327		1
MMRF_1466	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	THIRD LINE	Other	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	THIRD LINE	Checked	15	QD (D1-21)	QD (D1-21)					1327		1
MMRF_1478	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	73	1
MMRF_1478	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	73	1
MMRF_1478	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		500	Q day	Q day					7	7	1
MMRF_1478	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					21	76	1
MMRF_1478	First line of therapy	First Line Therapy	MOBILIZATION	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	MOBILIZATION		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					91	94	1
MMRF_1478	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Other	MOBILIZATION		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					91	94	1
MMRF_1478	First line of therapy	First Line Therapy	MOBILIZATION	Other	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	MOBILIZATION		25	QD (D1-4)	QD (D1-4)					91	94	1
MMRF_1478	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	40	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	MOBILIZATION		40	QD (D1-4)	QD (D1-4)					91	94	1
MMRF_1478	First line of therapy	First Line Therapy	MOBILIZATION	Other	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	MOBILIZATION		10	QD (D1-4)	QD (D1-4)					91	94	1
MMRF_1478	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	MOBILIZATION		500	QD (D1-4)	QD (D1-4)					91	94	1
MMRF_1478	First line of therapy	First Line Therapy	MOBILIZATION	Other	CISPLATIN	Other			Completed regimen	Completed regimen	15	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	MOBILIZATION		15	QD (D1-4)	QD (D1-4)					91	94	1
MMRF_1478	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					118	118	1
MMRF_1478	First line of therapy	First Line Therapy	CONDITIONING	Other	FLUDARABINE	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		30	Q day	Q day					305	308	1
MMRF_1478	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		140	Q day	Q day					675	675	1
MMRF_1485	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	15	1
MMRF_1485	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	15	1
MMRF_1497	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	21	1
MMRF_1497	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					35	119	1
MMRF_1497	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	22	1
MMRF_1497	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					35	119	1
MMRF_1497	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					35	119	1
MMRF_1497	First line of therapy	First Line Therapy	DEBULKING/MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M^2	Other	Q day	Q day	IV	IV	Log Forms	Other	DEBULKING/MOBILIZATION		2	Q day	Q day					172	172	1
MMRF_1497	First line of therapy	First Line Therapy	DEBULKING/MOBOLIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	DEBULKING/MOBOLIZATION		200	Q day	Q day					182	182	1
MMRF_1497	First line of therapy	First Line Therapy	DEBULKING/MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	DEBULKING/MOBILIZATION		10	Q day	Q day					182	182	1
MMRF_1497	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	360	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		360	Q day	Q day					208	208	1
MMRF_1489	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	107	1
MMRF_1489	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					357	357	1
MMRF_1489	First line of therapy	First Line Therapy	MOBILIZATION	Other	PLERIXAFOR	Other			Completed regimen	Completed regimen	18	mg	mg	QD FIRST 3 DAYS; QOD WEEK 2	Other	IV SubQ	IV SubQ	Log Forms	Other	MOBILIZATION		18	Other	QD FIRST 3 DAYS; QOD WEEK 2					334	343	1
MMRF_1489	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	107	1
MMRF_1489	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	107	1
MMRF_1491	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, 8, 15, 22)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1, 8, 15, 22)					1	179	1
MMRF_1491	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	179	1
MMRF_1491	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					193	193	1
MMRF_1491	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	360	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		360	Q day	Q day					193	193	1
MMRF_1491	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					193	193	1
MMRF_1491	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE REGIMEN	Other	Bortezomib	Bortezomib			PATIENT DECEASED	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE REGIMEN		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					390	397	1
MMRF_1491	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE REGIMEN	Other	Cyclophosphamide	Cyclophosphamide			PATIENT DECEASED	Other	500	mg	mg	DAY 1 AND  8	Other	IV	IV	Log Forms	Other	SALVAGE REGIMEN		500	Other	DAY 1 AND  8					390	397	1
MMRF_1491	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE REGIMEN	Other	Dexamethasone	Dexamethasone			PATIENT DECEASED	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Other	SALVAGE REGIMEN		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					390	397	1
MMRF_1491	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					234	234	1
MMRF_1494	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	34	1
MMRF_1494	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	34	1
MMRF_1494	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	35	1
MMRF_1494	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		2000	Q day	Q day					65	65	1
MMRF_1494	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					65	65	1
MMRF_1494	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					65	65	1
MMRF_1494	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					90	90	1
MMRF_1494	First line of therapy	First Line Therapy	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	DAYS -4 AND -1	Other	IV SubQ	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Other	DAYS -4 AND -1					264	272	1
MMRF_1494	First line of therapy	First Line Therapy	CONSOLIDATION	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONSOLIDATION		200	Q day	Q day					266	266	1
MMRF_1500	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1500	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1500	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	46	1
MMRF_1500	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					122	122	1
MMRF_1500	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M^2	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					102	102	1
MMRF_1500	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	MOBILIZATION		10	Q day	Q day					102	102	1
MMRF_1500	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					102	102	1
MMRF_1500	First line of therapy	First Line Therapy	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	DAYS -4 AND -1	Other	IV SubQ	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Other	DAYS -4 AND -1					260	263	1
MMRF_1500	First line of therapy	First Line Therapy	CONSOLIDATION	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONSOLIDATION		200	Q day	Q day					262	262	1
MMRF_1500	First line of therapy	First Line Therapy	CONSOLIDATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONSOLIDATION		10	Q day	Q day					260	263	1
MMRF_1500	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			PATIENT GOIN OT ASTC	Other	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					947	1198	1
MMRF_1500	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					947	974	1
MMRF_1500	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			PATIENT GOING TO ASCT	Other	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					947	1198	1
MMRF_1500	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					1214	1214	1
MMRF_1500	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					1214	1214	1
MMRF_1500	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	NIVOLUMAB	Other		0	Completed regimen	Completed regimen	3	mg/kg	mg/kg	WEEKS 1,4,7,10,12,14,16,18,22,24,& 26	Other	IV	IV	Log Forms	Maintenance	Maintenance		3	Other	WEEKS 1,4,7,10,12,14,16,18,22,24,& 26					1243	1419	1
MMRF_1500	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	IPILIMIMAB	Other		0	Completed regimen	Completed regimen	1	mg/kg	mg/kg	WEEKS 1,4,7,10,16 & 22	Other	IV	IV	Log Forms	Maintenance	Maintenance		1	Other	WEEKS 1,4,7,10,16 & 22					1243	1419	1
MMRF_1500	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Prednisone	Prednisone			REDUCE DOSAGE PER SUB-INVESTIGATOR	Other	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		5	Q day	Q day					1636	1670	1
MMRF_1500	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Prednisone	Prednisone		0	Completed regimen	Completed regimen	2.5	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		2.5	Q day	Q day					1670	1670	1
MMRF_1500	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Completed regimen	Completed regimen	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					2053	2101	1
MMRF_1500	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Completed regimen	Completed regimen	16	mg/kg	mg/kg	QD (D1, D15)	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	QD (D1, D15)					2108	2206	1
MMRF_1500	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	QD (D1)	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Other	QD (D1)					2220		1
MMRF_1500	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					2053		1
MMRF_1500	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1)	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	20	Other	QD (D1)					2053		1
MMRF_1500	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D8, D15)	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	20	Other	QD (D8, D15)					2053		1
MMRF_1523	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	25	QD (D1-21)	QD (D1-21)					2344		1
MMRF_1523	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	41	1
MMRF_1523	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	44	1
MMRF_1523	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	41	1
MMRF_1523	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	QID	QID	IV	IV	Log Forms	Other	MOBILIZATION		2000	QID	QID					79	79	1
MMRF_1523	First line of therapy	First Line Therapy	MOBOLIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg	mg	QID	QID	IV	IV	Log Forms	Other	MOBOLIZATION		200	QID	QID					79	79	1
MMRF_1523	First line of therapy	First Line Therapy	MOBOLIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QID	QID	IV	IV	Log Forms	Other	MOBOLIZATION		10	QID	QID					79	79	1
MMRF_1523	First line of therapy	First Line Therapy	CONDITINING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITINING		200	Q day	Q day					103	103	1
MMRF_1523	First line of therapy	First Line Therapy	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	DAYS -7 AND -1 PRE-PBSCT	Other	IV SubQ	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Other	DAYS -7 AND -1 PRE-PBSCT					250	259	1
MMRF_1523	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	DAY -2 OF PBSCT	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	DAY -2 OF PBSCT					258	258	1
MMRF_1537	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	52	1
MMRF_1537	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	52	1
MMRF_1537	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	52	1
MMRF_1565	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	104	1
MMRF_1565	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	104	1
MMRF_1565	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					20	104	1
MMRF_1565	First line of therapy	First Line Therapy	MOBOLIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBOLIZATION		200	Q day	Q day					129	129	1
MMRF_1565	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	315	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		315	Q day	Q day					129	129	1
MMRF_1565	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					129	129	1
MMRF_1565	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	314	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		314	Q day	Q day					162	162	1
MMRF_1565	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		1			27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1183		1
MMRF_1565	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					1183		1
MMRF_1565	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Unknown	Unknown	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1183		1
MMRF_1573	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	88	1
MMRF_1573	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	111	1
MMRF_1573	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	88	1
MMRF_1573	First line of therapy	First Line Therapy	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	DAYS -4 AND -1 PRE-SCT	Other	IV SubQ	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Other	DAYS -4 AND -1 PRE-SCT					193	196	1
MMRF_1573	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		140	Q day	Q day					195	195	1
MMRF_1583	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1583	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	QD1, 8	Other	IV	IV	Log Forms	Induction	Induction		500	Other	QD1, 8					1	29	1
MMRF_1583	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1583	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	370	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		370	Q day	Q day					67	67	1
MMRF_1583	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3.7	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		3.7	Q day	Q day					67	67	1
MMRF_1583	First line of therapy	First Line Therapy	MOBOLIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBOLIZATION		10	Q day	Q day					67	67	1
MMRF_1583	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	364	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		364	Q day	Q day					119	119	1
MMRF_1583	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	370	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		370	Q day	Q day					261	261	1
MMRF_1583	First line of therapy	First Line Therapy	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	DAYS -7 TO -1	Other	IV SubQ	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Other	DAYS -7 TO -1					259	262	1
MMRF_1583	First line of therapy	First Line Therapy	CONDITION	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITION		200	Q day	Q day					262	262	1
MMRF_1583	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan		0			200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					2481	2481	1
MMRF_1625	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	40	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		40	Q day	Q day					30	34	1
MMRF_1625	First line of therapy	First Line Therapy	MOBILIZATION	Other	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					30	34	1
MMRF_1625	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		500	Q day	Q day					30	34	1
MMRF_1625	First line of therapy	First Line Therapy	MOBILIZATION	Other	CISPLATIN	Other			Completed regimen	Completed regimen	15	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		15	Q day	Q day					30	34	1
MMRF_1625	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					111	111	1
MMRF_1625	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					245	245	1
MMRF_1625	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	QD D-4, D-1	Other	IV SubQ	IV SubQ	Log Forms	Other	CONDITIONING		1.6	Other	QD D-4, D-1					243	246	1
MMRF_1625	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	D1 & D8	Other	IV	IV	Log Forms	Induction	Induction		500	Other	D1 & D8					1	12	1
MMRF_1625	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	12	1
MMRF_1625	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	12	1
MMRF_1625	First line of therapy	First Line Therapy	MOBILIZATION	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	MOBILIZATION		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					29	32	1
MMRF_1625	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Other	MOBILIZATION		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					29	32	1
MMRF_1625	First line of therapy	First Line Therapy	MOBILIZATION	Other	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	MOBILIZATION		25	Q day	Q day					30	34	1
MMRF_1640	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_1640	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	34	1
MMRF_1640	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_1640	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					136	136	1
MMRF_1683	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1683	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	84	1
MMRF_1683	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1683	First line of therapy	First Line Therapy	CONSOLIDATION	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONSOLIDATION		200	Q day	Q day					135	135	1
MMRF_1683	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					1363	1640	1
MMRF_1683	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		20	Q week	Q week					1363	1640	1
MMRF_1683	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	SOLUMEDROL	Other		0	Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	PRIOR TO EACH DOSE OF DARATUMUMAB	Other	IV	IV	Log Forms	Unknown	Unknown		100	Other	PRIOR TO EACH DOSE OF DARATUMUMAB					1220	1640	1
MMRF_1683	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					1363	1640	1
MMRF_1683	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		1			70	mg/m^2	mg/m^2	QD (1,8,15)	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	70	Other	QD (1,8,15)					2186		1
MMRF_1683	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (1,8,15)	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	QD (1,8,15)					2186		1
MMRF_1683	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1653	2178	1
MMRF_1683	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1653	2178	1
MMRF_1683	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1653	2178	1
MMRF_1714	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	50	1
MMRF_1714	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	53	1
MMRF_1714	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	50	1
MMRF_1714	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4.4	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		4.4	Q day	Q day					74	74	1
MMRF_1714	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					74	74	1
MMRF_1714	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	440	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		440	Q day	Q day					74	74	1
MMRF_1714	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					100	100	1
MMRF_1731	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	D1, D8, D15	Other	IV	IV	Log Forms	Induction	Induction	Checked	16	Other	D1, D8, D15					2148		1
MMRF_1731	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	35	1
MMRF_1731	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	QD (D1, 8)	Other	IV	IV	Log Forms	Induction	Induction		500	Other	QD (D1, 8)					1	9	1
MMRF_1731	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	35	1
MMRF_1731	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					24	37	1
MMRF_1731	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3.1	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		3.1	Q day	Q day					59	59	1
MMRF_1731	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	310	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		310	Q day	Q day					69	69	1
MMRF_1731	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					59	59	1
MMRF_1731	First line of therapy	First Line Therapy	CONSOLIDATION	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONSOLIDATION		200	Q day	Q day					84	84	1
MMRF_1731	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					755	1616	1
MMRF_1731	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					755		1
MMRF_1731	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction	Checked	40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					755		1
MMRF_1730	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	33	1
MMRF_1730	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	36	1
MMRF_1730	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	33	1
MMRF_1730	First line of therapy	First Line Therapy	MOBOLIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4.2	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBOLIZATION		4.2	Q day	Q day					92	92	1
MMRF_1730	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					92	92	1
MMRF_1730	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	420	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		420	Q day	Q day					92	92	1
MMRF_1730	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	428	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		428	Q day	Q day					117	117	1
MMRF_1730	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-4)	QD (D1-4)					706	802	1
MMRF_1730	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					705	802	1
MMRF_1730	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan		0	Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		140	Other	ONCE					852	852	1
MMRF_1730	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	FLUDARABINE	Other		0	Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	DAYS -6 THRU -3	Other	IV	IV	Log Forms	Consolidation	Consolidation		30	Other	DAYS -6 THRU -3					848	851	1
MMRF_1730	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	RATG	Other		0	Completed regimen	Completed regimen	4	mg/kg	mg/kg	DAYS -3 THRU -1	Other	IV	IV	Log Forms	Consolidation	Consolidation		4	Other	DAYS -3 THRU -1					851	853	1
MMRF_1730	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					1824		1
MMRF_1730	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Q week	Q week					1824		1
MMRF_1730	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					1824		1
MMRF_1730	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown	Checked	20	QWK	QWK					1824		1
MMRF_1759	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	507	1
MMRF_1759	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	500	mg/m^2	mg/m^2	QD (D1, 8)	Other	IV	IV	Log Forms	Induction	Induction		500	Other	QD (D1, 8)					1	507	1
MMRF_1759	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	507	1
MMRF_1759	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.4	mg	mg	EVERY TWO TO THREE WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.4	Other	EVERY TWO TO THREE WEEKS					507	714	1
MMRF_1759	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	EVERY TWO TO THREE WEEKS WITH BORTEZOMIB DOSING	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	EVERY TWO TO THREE WEEKS WITH BORTEZOMIB DOSING					507	714	1
MMRF_1759	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		1			37	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown	Checked	37	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					741		1
MMRF_1759	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			0	MG (DOSE UNKNOWN)	Other	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	0	QD (D1-21)	QD (D1-21)					741		1
MMRF_1759	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			5	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown	Checked	5	QWK	QWK					741		1
MMRF_1758	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1758	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	QD (D1, 8)	Other	IV	IV	Log Forms	Induction	Induction		500	Other	QD (D1, 8)					1	62	1
MMRF_1758	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1758	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					111	111	1
MMRF_1758	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		1	Adverse Event or co-morbidity	Adverse Event or co-morbidity	44	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown	Checked	44	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1300	1589	1
MMRF_1758	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1	Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown	Checked	12	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1300	1589	1
MMRF_1781	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1781	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1781	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	60	1
MMRF_1781	First line of therapy	First Line Therapy	MOBILIZATION	Other	MOZOBIL	Other			Completed regimen	Completed regimen	12	mg	mg	Q day	Q day	IV SubQ	IV SubQ	Log Forms	Other	MOBILIZATION		12	Q day	Q day					85	87	1
MMRF_1781	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					106	106	1
MMRF_1781	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	PRE-TRANSPLANT		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					295	298	1
MMRF_1781	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	PRE-TRANSPLANT		200	Q day	Q day					297	297	1
MMRF_1781	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	DAYS 1,8,15,22 CYCLE 1-2. DAYS 1-5 CYCLES 3-6 DAY 1 C7 AND BEYOND	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Other	DAYS 1,8,15,22 CYCLE 1-2. DAYS 1-5 CYCLES 3-6 DAY 1 C7 AND BEYOND					1990		1
MMRF_1781	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					1990		1
MMRF_1781	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	D 1,8,15	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	D 1,8,15					1990		1
MMRF_1787	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1787	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1787	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_1787	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4.3	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		4.3	Q day	Q day					82	82	1
MMRF_1787	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					82	82	1
MMRF_1787	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	430	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		430	Q day	Q day					82	82	1
MMRF_1787	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	412	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		412	Q day	Q day					106	106	1
MMRF_1802	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1802	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1802	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	57	1
MMRF_1802	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	360	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		360	Q day	Q day					85	85	1
MMRF_1802	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3.6	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		3.6	Q day	Q day					85	85	1
MMRF_1802	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					85	85	1
MMRF_1802	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	352	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		352	Q day	Q day					111	111	1
MMRF_1802	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		1.6	Other	ONCE					232	232	1
MMRF_1802	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		1.6	Other	ONCE					235	235	1
MMRF_1802	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					234	234	1
MMRF_1801	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1801	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	87	1
MMRF_1801	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1801	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		2000	Q day	Q day					102	102	1
MMRF_1801	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		10	Q day	Q day					102	102	1
MMRF_1801	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					102	102	1
MMRF_1801	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					127	127	1
MMRF_1801	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	PRE-TRANSPLANT		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					295	298	1
MMRF_1801	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	PRE-TRANSPLANT		200	Q day	Q day					297	297	1
MMRF_1807	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	82	1
MMRF_1807	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	76	1
MMRF_1807	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	82	1
MMRF_1807	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					122	122	1
MMRF_1819	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	35	1
MMRF_1819	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	35	1
MMRF_1819	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	35	1
MMRF_1850	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			MOVE TO TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					9	68	1
MMRF_1850	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			MOVE TO TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	71	1
MMRF_1850	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			MOVE TO TRANSPLANT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					9	68	1
MMRF_1850	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		2000	Q day	Q day					95	95	1
MMRF_1850	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		10	Q day	Q day					95	95	1
MMRF_1850	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					95	95	1
MMRF_1850	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					121	121	1
MMRF_1850	First line of therapy	First Line Therapy	MOBILIZATION	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Other	MOBILIZATION		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					274	277	1
MMRF_1850	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					276	276	1
MMRF_1850	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					529		1
MMRF_1860	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	75	1
MMRF_1860	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	75	1
MMRF_1860	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	75	1
MMRF_1860	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1090	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		1090	Q day	Q day					95	98	1
MMRF_1860	First line of therapy	First Line Therapy	MOBILIZATION	Other	CISPLATIN	Other			Completed regimen	Completed regimen	25	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		25	Q day	Q day					95	98	1
MMRF_1860	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	75	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		75	Q day	Q day					95	98	1
MMRF_1860	First line of therapy	First Line Therapy	MOBILIZATION	Other	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	22	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		22	Q day	Q day					95	98	1
MMRF_1860	First line of therapy	First Line Therapy	MOBILIZATION	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q day	Q day	IV SubQ	IV SubQ	Log Forms	Other	MOBILIZATION		1.3	Q day	Q day					95	95	1
MMRF_1860	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	428	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		428	Q day	Q day					123	123	1
MMRF_1860	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	438	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		438	Q day	Q day					256	256	1
MMRF_1860	First line of therapy	First Line Therapy	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.5	mg	mg	D1 TO D4	Other	IV SubQ	IV SubQ	Log Forms	Other	CONDITIONING		3.5	Other	D1 TO D4					254	257	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	30	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	33	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	30	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			MOVE TO TRANSPLANT	Other	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					47	118	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			MOVE TO TRANSPLANT	Other	300	mg/m^2	mg/m^2	QD1, 8, 15	Other	IV	IV	Log Forms	Induction	Induction		300	Other	QD1, 8, 15					47	117	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			MOVE TO TRANSPLANT	Other	40	mg	mg	QWEEK D1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QWEEK D1, 8, 15, 22					47	124	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		2000	Q day	Q day					141	141	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		10	Q day	Q day					141	141	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					141	141	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					167	167	1
MMRF_1865	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	465	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION		465	Other	ONCE					141	141	1
MMRF_1865	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION		40	Other	ONCE					141	141	1
MMRF_1865	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION		200	Other	ONCE					141	141	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	ONCE	Other	IV	IV	Log Forms	Induction	Induction		10	Other	ONCE					167	167	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	D-4 AND -1 TRANSPLANT	Other	IV	IV	Log Forms	Induction	Induction		1.6	Other	D-4 AND -1 TRANSPLANT					325	328	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	FLUDARABINE	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	QD (D1-3)	QD (D1-3)	IV	IV	Log Forms	Induction	Induction		30	QD (D1-3)	QD (D1-3)					324	326	1
MMRF_1865	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	214	mg	mg	ONCE	Other	IV	IV	Log Forms	Induction	Induction		214	Other	ONCE					327	327	1
MMRF_1895	First line of therapy	First Line Therapy	MOBILIZATION	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Other	MOBILIZATION		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					287	290	1
MMRF_1895	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					289	289	1
MMRF_1895	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			MOVING TO TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	98	1
MMRF_1895	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			MOVING TO TRANSPLANT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1895	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		2000	Q day	Q day					122	122	1
MMRF_1895	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		10	Q day	Q day					122	122	1
MMRF_1895	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					122	122	1
MMRF_1895	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					148	148	1
MMRF_1895	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			MOVING TO TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1936	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1936	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	57	1
MMRF_1936	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Melphalan	Melphalan			Completed regimen	Completed regimen	120	mg	mg	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		120	Q day	Q day					578	578	1
MMRF_1936	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1345	mg	mg	QD (D1-14)	QD (D1-14)	IV	IV	Log Forms	Unknown	Unknown		1345	QD (D1-14)	QD (D1-14)					604	625	1
MMRF_1936	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	TWO DAYS AFTER DARATUMUMAB	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	TWO DAYS AFTER DARATUMUMAB					604	625	1
MMRF_1936	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q day	Q day	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q day	Q day					97	97	1
MMRF_1936	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1936	First line of therapy	First Line Therapy	MOBILIZATION	Other	CISPLATIN	Other			Completed regimen	Completed regimen	25	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		25	Q day	Q day					97	99	1
MMRF_1936	First line of therapy	First Line Therapy	MOBOLIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1065	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBOLIZATION		1065	Q day	Q day					97	99	1
MMRF_1936	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	75	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		75	Q day	Q day					97	99	1
MMRF_1936	First line of therapy	First Line Therapy	MOBILIZATION	Other	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	20	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		20	Q day	Q day					97	99	1
MMRF_1936	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	FIRST RELAPSE	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	FIRST RELAPSE		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					155	242	1
MMRF_1936	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	FISRT RELAPSE	Other	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	4	mg	mg	QD FROM DAY 1 - 14, OFF FOR 7 DAYS IN A 21 DAY CYCLE	Other	PO	PO	Log Forms	Other	FISRT RELAPSE		4	Other	QD FROM DAY 1 - 14, OFF FOR 7 DAYS IN A 21 DAY CYCLE					155	256	1
MMRF_1936	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	FIRST RELAPSE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Other	FIRST RELAPSE		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					155	242	1
MMRF_1936	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	426	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		426	Q day	Q day					294	294	1
MMRF_1936	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4.2	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		4.2	Q day	Q day					270	270	1
MMRF_1936	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	420	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		420	Q day	Q day					270	270	1
MMRF_1936	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					270	270	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	FIRST RELAPSE	Other	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	41	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	FIRST RELAPSE		41	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					457	457	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	RELAPSE	Other	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	RELAPSE		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					457	457	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	RELAPSE	Other	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	1020	mg	mg	DAYS 1 AND 8 OF 21 DAYS CYCLE	Other	IV	IV	Log Forms	Other	RELAPSE		1020	Other	DAYS 1 AND 8 OF 21 DAYS CYCLE					457	526	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Lack of response	Lack of response	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Unknown	Unknown		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					465	529	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					465	529	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-4)	QD (D1-4)					465	524	1
MMRF_1936	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	PANIBINOSTAT	Other			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1,3,5,8,10 &12)	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD (D1,3,5,8,10 &12)					550	556	1
MMRF_1936	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					557	568	1
MMRF_1936	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					557	568	1
MMRF_1936	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	PANOBINOSTAT	Other			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1,D3,D5,D8,D10,D12)	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD (D1,D3,D5,D8,D10,D12)					557	568	1
MMRF_1936	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	CARMUSTINE	Other			Completed regimen	Completed regimen	120	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		120	Q day	Q day					578	578	1
MMRF_1936	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		40	Q day	Q day					578	578	1
MMRF_1941	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			MOVE TO TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1941	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1941	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			MOVE TO TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	98	1
MMRF_1941	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			MOVE TO TRANSPLANT	Other	12	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		12	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					85	95	1
MMRF_1941	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		2000	Q day	Q day					130	130	1
MMRF_1941	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		10	Q day	Q day					130	130	1
MMRF_1941	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					130	130	1
MMRF_1941	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	OTHER	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	OTHER					191	191	1
MMRF_1947	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1947	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_1947	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_1947	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M^2	Other	Q day	Q day	IV	IV	Log Forms	Induction	Induction		2	Q day	Q day					80	80	1
MMRF_1947	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					80	80	1
MMRF_1947	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					80	80	1
MMRF_1947	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					105	105	1
MMRF_1947	First line of therapy	First Line Therapy	MOBILIZATION	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Other	MOBILIZATION		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					287	290	1
MMRF_1947	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					289	289	1
MMRF_1947	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	16 MG/K (WEEKLY 1-8, QOW 9-24, MONTHLY 25 ONWARD)	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	16 MG/K (WEEKLY 1-8, QOW 9-24, MONTHLY 25 ONWARD)					1218	2136	1
MMRF_1947	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0			20	mg	mg	EACH DARATUMUMAB DOSE	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	EACH DARATUMUMAB DOSE					1218	2136	1
MMRF_1947	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		0			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1218	2136	1
MMRF_1947	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		1			56	mg/m^2	mg/m^2	20 MG/M2 ON DAYS 1, AND THEN 56MG/M2 ON ALL SUBSEQUENT DAYS	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	56	Other	20 MG/M2 ON DAYS 1, AND THEN 56MG/M2 ON ALL SUBSEQUENT DAYS					2178		1
MMRF_1947	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					2178		1
MMRF_1947	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	QD 1, 8, 15	Other	IV ON DAY 1 AND 20 MG ORALLY ON DAYS 8 AND 15.	Other	Log Forms	Other	SALVAGE	Checked	20	Other	QD 1, 8, 15					2178		1
MMRF_1951	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QOW	Other	IV	IV	Log Forms	Other	SALVAGE		16	Other	QOW					1475	1538	1
MMRF_1951	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1475	1538	1
MMRF_1951	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	SOLUMEDROL	Other		0	Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	QOW	Other	IV	IV	Log Forms	Other	SALVAGE		100	Other	QOW					1475	1538	1
MMRF_1951	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	ONCE WEEKLY ON THE WEEKS OFF OF DARA	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	ONCE WEEKLY ON THE WEEKS OFF OF DARA					1475	1538	1
MMRF_1951	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	56	mg/kg	mg/kg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1579	2027	1
MMRF_1951	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1, 8 AND 15	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	DAYS 1, 8 AND 15					1579	2027	1
MMRF_1951	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	607	1
MMRF_1951	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	607	1
MMRF_1951	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					614	617	1
MMRF_1951	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					614	617	1
MMRF_1951	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1, D8, D15, D20)	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1, D8, D15, D20)					656	918	1
MMRF_1951	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					656	918	1
MMRF_1951	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	695	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		695	Q week	Q week					930	972	1
MMRF_1951	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					930	972	1
MMRF_1951	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	28	mg	mg	3-24H PRIOR ELOTUZUMAB DOSING	Other	PO	PO	Log Forms	Unknown	Unknown		28	Other	3-24H PRIOR ELOTUZUMAB DOSING					930	972	1
MMRF_1951	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	PRIOR TO ELO	Other	PO	PO	Log Forms	Unknown	Unknown		8	Other	PRIOR TO ELO					899	972	1
MMRF_1951	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					986	1097	1
MMRF_1951	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					986	1097	1
MMRF_1951	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	1131	mg	mg	WEEKLY FOR WEEKS 1-8, QOW WEEKS 9-25, MONTHLY WEEK 25 ONWARD	Other	IV	IV	Log Forms	Unknown	Unknown		1131	Other	WEEKLY FOR WEEKS 1-8, QOW WEEKS 9-25, MONTHLY WEEK 25 ONWARD					1104	1468	1
MMRF_1951	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1104	1468	1
MMRF_1951	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Prednisone	Prednisone		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	DAYS 1,2 FOLLOWING EACH DARA DOSE	Other	PO	PO	Log Forms	Unknown	Unknown		25	Other	DAYS 1,2 FOLLOWING EACH DARA DOSE					1107	1468	1
MMRF_1951	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	SOLUMEDROL	Other		0	Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	PRIOR TO EACH DOSE OF DARA	Other	IV	IV	Log Forms	Unknown	Unknown		100	Other	PRIOR TO EACH DOSE OF DARA					1077	1468	1
MMRF_1967	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-14)	QD (D1-14)					1		1
MMRF_1967	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction	Checked	20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1967	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1967	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					166	166	1
MMRF_1965	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1965	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					6	60	1
MMRF_1965	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_1965	First line of therapy	First Line Therapy	Induction	Induction	CISPLATIN	Other			Completed regimen	Completed regimen	15	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		15	QD (D1-4)	QD (D1-4)					81	84	1
MMRF_1965	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		500	QD (D1-4)	QD (D1-4)					81	84	1
MMRF_1965	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	40	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					81	84	1
MMRF_1965	First line of therapy	First Line Therapy	Induction	Induction	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					81	84	1
MMRF_1965	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-4)	QD (D1-4)					81	84	1
MMRF_1965	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD1 & 4	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD1 & 4					81	84	1
MMRF_1965	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					81	84	1
MMRF_1965	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					111	111	1
MMRF_1965	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	PRE-TRANSPLANT		1.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					262	265	1
MMRF_1965	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	FLUDARABINE	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	D -5, D -2	Other	IV	IV	Log Forms	Other	PRE-TRANSPLANT		30	Other	D -5, D -2					261	264	1
MMRF_1965	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	PRE-TRANSPLANT		140	Q day	Q day					264	264	1
MMRF_1965	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SECOND LINE		4	QD (D1-21)	QD (D1-21)					855	938	1
MMRF_1965	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Prednisone	Prednisone			Investigator decision for other reasons	Investigator decision for other reasons	16	mg	mg	48MG IN QAM, 32MG QHS	Other	PO	PO	Log Forms	Other	SECOND LINE		16	Other	48MG IN QAM, 32MG QHS					855	903	1
MMRF_1965	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Prednisone	Prednisone			Investigator decision for other reasons	Investigator decision for other reasons	32	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SECOND LINE		32	Q day	Q day					904	910	1
MMRF_1965	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Prednisone	Prednisone			Investigator decision for other reasons	Investigator decision for other reasons	16	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SECOND LINE		16	Q day	Q day					911	924	1
MMRF_1965	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Prednisone	Prednisone			Investigator decision for other reasons	Investigator decision for other reasons	8	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SECOND LINE		8	Q day	Q day					925	945	1
MMRF_1965	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Prednisone	Prednisone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	8MG QOD, 4MG QOD	Other	PO	PO	Log Forms	Other	SECOND LINE		4	Other	8MG QOD, 4MG QOD					946	1086	1
MMRF_1965	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SECOND LINE		3	QD (D1-21)	QD (D1-21)					946	1086	1
MMRF_1981	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Ixazomib	Ixazomib		1			3	mg	mg	QD (D1,8,15)	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	3	Other	QD (D1,8,15)					1484		1
MMRF_1981	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TOXICITY (NEUROPATHY)	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	39	1
MMRF_1981	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		15	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	76	1
MMRF_1981	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	76	1
MMRF_1981	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					126	126	1
MMRF_1981	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4100	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		4100	Q day	Q day					101	101	1
MMRF_1981	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					101	101	1
MMRF_1981	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	410	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		410	Q day	Q day					101	101	1
MMRF_1981	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D 1, 8, 15)	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD (D 1, 8, 15)					1022	1418	1
MMRF_1981	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	650	mg	mg	QD (D 1, 8, 15)	Other	PO	PO	Log Forms	Unknown	Unknown		650	Other	QD (D 1, 8, 15)					1022	1418	1
MMRF_1981	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1022	1418	1
MMRF_1981	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	WEEKS 1-8, QOW 9-24, MONTHLY 25 ONWARD	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Other	WEEKS 1-8, QOW 9-24, MONTHLY 25 ONWARD					1429		1
MMRF_1981	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Ixazomib	Ixazomib		0	DOSE REDUCED	Other	4	mg	mg	DAYS 1,8,15	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	DAYS 1,8,15					1429	1483	1
MMRF_1981	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	THE DAY OF AND DAY AFTER DARA	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	THE DAY OF AND DAY AFTER DARA					1429		1
MMRF_1988	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	82	1
MMRF_1988	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	85	1
MMRF_1988	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	82	1
MMRF_1988	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					115	115	1
MMRF_1988	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		1			25	mg	mg	EVERY OTHER DAY (D1-D21)	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	25	Other	EVERY OTHER DAY (D1-D21)					1573		1
MMRF_1988	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	QD (D1, D8, D15)					1573		1
MMRF_2059	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			MOVE TO TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	43	1
MMRF_2059	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			MOVE TO TRANSPLANT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	43	1
MMRF_2059	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			MOVE TO TRANSPLANT	Other	500	mg/m^2	mg/m^2	DAY 1 AND 8 OF 21-DAY CYCLE	Other	IV	IV	Log Forms	Induction	Induction		500	Other	DAY 1 AND 8 OF 21-DAY CYCLE					1	43	1
MMRF_2059	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			MOVE TO TRANSPLANT	Other	5	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-14)	QD (D1-14)					1	46	1
MMRF_2059	First line of therapy	First Line Therapy	Induction	Induction	MOZOBIL	Other			Completed regimen	Completed regimen	18.6	mg	mg	Q day	Q day	IV SubQ	IV SubQ	Log Forms	Induction	Induction		18.6	Q day	Q day					74	76	1
MMRF_2059	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		140	Q day	Q day					105	105	1
MMRF_2059	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Carfilzomib	Carfilzomib		1			27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SECOND LINE	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					839		1
MMRF_2059	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SECOND LINE	Checked	40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					839		1
MMRF_2059	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SECOND LINE	Checked	4	QD (D1-21)	QD (D1-21)					839		1
MMRF_2061	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	44	1
MMRF_2061	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	DAY 1 & 8 OF 28 DAYS CYCLE	Other	IV	IV	Log Forms	Induction	Induction		500	Other	DAY 1 & 8 OF 28 DAYS CYCLE					1	44	1
MMRF_2061	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	47	1
MMRF_2061	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	44	1
MMRF_2061	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	402	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		402	Q day	Q day					85	85	1
MMRF_2076	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TOXICITY; PERIPHERAL NEUROPATHY	Other	1.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	42	1
MMRF_2076	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	42	1
MMRF_2076	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	42	1
MMRF_2076	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					124	124	1
MMRF_2076	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg/kg	mg/kg	D A,8,15 AND 22 OF A 28D CYCLE FOR C1-C2/D 1 & 15 FOR CYCLE 3-6/ D1 C7 AND	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	D A,8,15 AND 22 OF A 28D CYCLE FOR C1-C2/D 1 & 15 FOR CYCLE 3-6/ D1 C7 AND					943	1363	1
MMRF_2076	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					943	1363	1
MMRF_2076	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	WITH EACH DARATUMUMAB INFUSION	Other	IV	IV	Log Forms	Unknown	Unknown		20	Other	WITH EACH DARATUMUMAB INFUSION					943	1363	1
MMRF_2076	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					1846		1
MMRF_2076	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Prednisone	Prednisone		1			60	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	60	Other	DAYS 1, 8, 15					1846		1
MMRF_2129	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					151	151	1
MMRF_2129	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	330	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		330	Q day	Q day					151	151	1
MMRF_2129	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					175	175	1
MMRF_2129	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3.3	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		3.3	Q day	Q day					151	151	1
MMRF_2129	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			MOVE TO TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_2129	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			MOVE TO TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	125	1
MMRF_2129	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			MOVE TO TRANSPLANT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_2129	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			MOVE TO TRANSPLANT	Other	500	mg/m^2	mg/m^2	QD1, 8 OF EACH CYCLE	Other	IV	IV	Log Forms	Induction	Induction		500	Other	QD1, 8 OF EACH CYCLE					49	119	1
MMRF_1755	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	105	1
MMRF_1755	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	21	1
MMRF_1755	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					205	205	1
MMRF_1755	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	105	1
MMRF_2152	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2152	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction	Checked	40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2152	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide		1			500	mg/m^2	mg/m^2	DAY 1 AND 8	Other	IV	IV	Log Forms	Induction	Induction	Checked	500	Other	DAY 1 AND 8					1		1
MMRF_2172	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			MOVE TO TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_2172	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			MOVE TO TRANSPLANT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_2172	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			MOVE TO TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_2172	First line of therapy	First Line Therapy	MOBILIZATION	Other	MOBOZIL	Other			Completed regimen	Completed regimen	22	mg	mg	TWICE (5/JAN/15 AND 13/JAN/15)	Other	IV SubQ	IV SubQ	Log Forms	Other	MOBILIZATION		22	Other	TWICE (5/JAN/15 AND 13/JAN/15)					103	111	1
MMRF_2172	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					126	126	1
MMRF_2172	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SECOND LINE		25	QD (D1-21)	QD (D1-21)					345	431	1
MMRF_2172	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Dexamethasone	Dexamethasone			SWITCH ROUTE WITH CARFILZOMIB ADDITION	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SECOND LINE		40	QWK	QWK					349	364	1
MMRF_2172	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SECOND LINE		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					365	555	1
MMRF_2172	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SECOND LINE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					365	461	1
MMRF_2172	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	PULSE D1-4 THEN QWK	Other	PO	PO	Log Forms	Other	SECOND LINE		40	Other	PULSE D1-4 THEN QWK					345	348	1
MMRF_2172	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SECOND LINE		4	QD (D1-21)	QD (D1-21)					446	522	1
MMRF_2172	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	60	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SECOND LINE		60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					474	513	1
MMRF_2172	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	300	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV	IV	Log Forms	Other	SECOND LINE		300	Other	DAYS 1, 8, 15					474	554	1
MMRF_2172	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SECOND LINE		25	QD (D1-21)	QD (D1-21)					540	560	1
MMRF_2172	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SECOND LINE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					540	555	1
MMRF_2231	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					130	130	1
MMRF_2231	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					232	232	1
MMRF_2231	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_2231	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_2231	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	64	1
MMRF_2231	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	325	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		325	Q day	Q day					130	130	1
MMRF_2231	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3.2	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		3.2	Q day	Q day					130	130	1
MMRF_2231	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Ixazomib	Ixazomib		1			4	mg	mg	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	4	Other	QD (D1, D8, D15)					1781		1
MMRF_2231	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					1781		1
MMRF_2231	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1, D8, D15)	Other	PO	PO	Log Forms			Checked	20	Other	QD (D1, D8, D15)					1781		1
MMRF_2267	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1300	1331	1
MMRF_2267	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1300	1331	1
MMRF_2267	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		1			20/56	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE	Checked		QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1419		1
MMRF_2267	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE	Checked	10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1419		1
MMRF_2267	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	58	1
MMRF_2267	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	23	1
MMRF_2267	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_2267	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD(1-2,8-9 & 15-16)	Other	IV	IV	Log Forms	Induction	Induction		20	Other	QD(1-2,8-9 & 15-16)					62	142	1
MMRF_2267	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QD(1-2,8-9 & 15-16)	Other	PO	PO	Log Forms	Induction	Induction		4	Other	QD(1-2,8-9 & 15-16)					72	142	1
MMRF_2267	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					155	155	1
MMRF_2291	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2291	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-14)	QD (D1-14)					1		1
MMRF_2291	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction	Checked	20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2310	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1384	mg	mg	QID	QID	IV	IV	Log Forms	Unknown	Unknown		1384	QID	QID					815	815	1
MMRF_2310	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2310	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	QD1, D8	Other	IV	IV	Log Forms	Induction	Induction		500	Other	QD1, D8					1	8	1
MMRF_2310	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2310	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					119	119	1
MMRF_2310	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2	G/M2	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		2	Q day	Q day					95	95	1
MMRF_2310	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		200	Q day	Q day					95	95	1
MMRF_2310	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					95	95	1
MMRF_2310	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	10	mg/kg	mg/kg	QD (1,8,15,22)	Other	IV	IV	Log Forms	Unknown	Unknown		10	Other	QD (1,8,15,22)					605	648	1
MMRF_2310	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	QD (1,8,15,22)	Other	IV	IV	Log Forms	Unknown	Unknown		8	Other	QD (1,8,15,22)					605	648	1
MMRF_2310	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					605	655	1
MMRF_2310	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	27	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					666	759	1
MMRF_2310	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					666	815	1
MMRF_2310	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (1,8,15,22)	Other	IV	IV	Log Forms	Unknown	Unknown		40	Other	QD (1,8,15,22)					666	815	1
MMRF_2310	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					22	43	1
MMRF_2316	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	D 1, 8, 15, 22	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Other	D 1, 8, 15, 22					1849		1
MMRF_2316	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					1849		1
MMRF_2316	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	D 1, 8, 15, 22	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	20	Other	D 1, 8, 15, 22					1849		1
MMRF_2316	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1080	mg	mg	QD (D1-7)	QD (D1-7)	IV	IV	Log Forms	Induction	Induction		1080	QD (D1-7)	QD (D1-7)					1	102	1
MMRF_2316	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_2316	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_2330	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PROCEED TO TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2330	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PROCEED TO TRANSPLANT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2330	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			PROCEED TO TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	77	1
MMRF_2330	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		2000	Q day	Q day					88	88	1
MMRF_2330	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		10	Q day	Q day					88	88	1
MMRF_2330	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					88	88	1
MMRF_2330	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					122	122	1
MMRF_2330	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		1.3	Q day	Q day					235	235	1
MMRF_2330	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					234	234	1
MMRF_2330	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab			Lack of response	Lack of response	10	mg/kg	mg/kg	D1, 8, 15, 22	Other	IV	IV	Log Forms	Unknown	Unknown		10	Other	D1, 8, 15, 22					607	677	1
MMRF_2330	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					607	683	1
MMRF_2330	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	QWK 1 DAY BEFORE ELOTUZUMAB	Other	IV	IV	Log Forms	Unknown	Unknown		40	Other	QWK 1 DAY BEFORE ELOTUZUMAB					607	684	1
MMRF_2330	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SECOND LINE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					694	857	1
MMRF_2330	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Lenalidomide	Lenalidomide			TOOK LENALIDOMIDE UNTIL POMALIDOMIDE DELIVERED	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SECOND LINE		25	QD (D1-21)	QD (D1-21)					694	695	1
MMRF_2330	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SECOND LINE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					694	857	1
MMRF_2330	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE	Other	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SECOND LINE		4	QD (D1-21)	QD (D1-21)					696	857	1
MMRF_2330	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		100	Q day	Q day					874	874	1
MMRF_2330	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING	Other	FLUDARABINE	Other			Completed regimen	Completed regimen	77	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		77	Q day	Q day					875	875	1
MMRF_2330	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Q week	Q week					1186		1
MMRF_2330	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					1186		1
MMRF_2330	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	METHYLPREDNISONE	Other		1			125	mg	mg	WITH DARA ADMINISTRATION	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	125	Other	WITH DARA ADMINISTRATION					1186		1
MMRF_2331	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Elotuzumab	Elotuzumab		1			10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE	Checked	10	Q week	Q week					1510		1
MMRF_2331	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	25	QD (D1-21)	QD (D1-21)					1510		1
MMRF_2331	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Q week	Q week					1510		1
MMRF_2331	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_2331	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_2331	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	64	1
MMRF_2331	First line of therapy	First Line Therapy	CONSOLIDATION	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONSOLIDATION		200	Q day	Q day					122	122	1
MMRF_2378	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_2378	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	44	1
MMRF_2378	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	25	1
MMRF_2378	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					86	86	1
MMRF_2407	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PROCEED TO TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	33	1
MMRF_2407	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			SWITCHED TO LENALIDOMIDE AFTER ONE CYCLE	Other	500	mg/m^2	mg/m^2	D1 AND D8	Other	IV	IV	Log Forms	Induction	Induction		500	Other	D1 AND D8					1	8	1
MMRF_2407	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PROCEED TO TRANSPLANT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	33	1
MMRF_2407	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			PROCEED TO TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					22	36	1
MMRF_2407	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		2000	Q day	Q day					64	64	1
MMRF_2407	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		10	Q day	Q day					64	64	1
MMRF_2407	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					64	64	1
MMRF_2407	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					89	89	1
MMRF_2407	First line of therapy	First Line Therapy	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	D-4 AND D-1	Other	IV	IV	Log Forms	Other	CONDITIONING		1.6	Other	D-4 AND D-1					207	210	1
MMRF_2407	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					209	209	1
MMRF_2407	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/m^2	mg/m^2	DAYS 1,8,15,22; THEN DAYS 1 AND 15 FOR CYCLES 3-6; THEN DAY 1 FOR CYCLE 7 AND BEYOND	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Other	DAYS 1,8,15,22; THEN DAYS 1 AND 15 FOR CYCLES 3-6; THEN DAY 1 FOR CYCLE 7 AND BEYOND					1800		1
MMRF_2407	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	25	QD (D1-21)	QD (D1-21)					1800		1
MMRF_2407	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0			20	mg	mg	DAY OF AND AFTER DARA FOR FIRST WEEK, THEN 40 MG ON DAY OF DARA THEREAFTER	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	DAY OF AND AFTER DARA FOR FIRST WEEK, THEN 40 MG ON DAY OF DARA THEREAFTER					1800		1
MMRF_2422	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_2422	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_2422	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		4200	Q day	Q day					237	237	1
MMRF_2422	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	424	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		424	Q day	Q day					254	254	1
MMRF_2437	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2437	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	QD (D1 AND D8)	Other	IV	IV	Log Forms	Induction	Induction		500	Other	QD (D1 AND D8)					1	8	1
MMRF_2437	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2437	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	57	1
MMRF_2437	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	278	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		278	Q day	Q day					106	106	1
MMRF_2437	First line of therapy	First Line Therapy	CONDITIONING	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	CONDITIONING		12	Q day	Q day					106	106	1
MMRF_2437	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/m^2	mg/m^2	DAY 1	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Other	DAY 1					1499		1
MMRF_2437	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		1			20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	20	QD (D1-21)	QD (D1-21)					1499		1
MMRF_2437	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	DAYS 1, 8, 15					1499		1
MMRF_2489	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	CYLE 1 DAYS 1,8,15,22. C2 DAYS 1,15,	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Other	CYLE 1 DAYS 1,8,15,22. C2 DAYS 1,15,					1383		1
MMRF_2489	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	25	QD (D1-21)	QD (D1-21)					1383		1
MMRF_2489	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	ON DAYS OF AND AFTER DARATUMUMAB	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	ON DAYS OF AND AFTER DARATUMUMAB					1383		1
MMRF_2489	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2489	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2489	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_2489	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	400	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		400	Q day	Q day					73	73	1
MMRF_2489	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		4	Q day	Q day					73	73	1
MMRF_2489	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					73	73	1
MMRF_2489	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	390	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		390	Q day	Q day					98	98	1
MMRF_2489	First line of therapy	First Line Therapy	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	DAYS -4 AND -1	Other	IV	IV	Log Forms	Other	CONDITIONING		1.6	Other	DAYS -4 AND -1					273	276	1
MMRF_2489	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					275	275	1
MMRF_2499	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					28	86	1
MMRF_2499	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	58	1
MMRF_2499	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					28	115	1
MMRF_2499	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1045	mg	mg	QD (D1, D8)	Other	IV	IV	Log Forms	Induction	Induction		1045	Other	QD (D1, D8)					58	115	1
MMRF_2499	First line of therapy	First Line Therapy	Consolidation	Consolidation	ETOPOSIDE	Other			Completed regimen	Completed regimen	420	mg	mg	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		420	Other	ONCE					115	115	1
MMRF_2499	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	412	mg	mg	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		412	Other	ONCE					871	871	1
MMRF_2499	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Ixazomib	Ixazomib		1			4	mg	mg	QD (1,8,15)	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	4	Other	QD (1,8,15)					1561		1
MMRF_2499	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		1			300	mg/m^2	mg/m^2	QD (1,8,15)	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	300	Other	QD (1,8,15)					1561		1
MMRF_2499	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (1,8,15)	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	QD (1,8,15)					1561		1
MMRF_2506	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			MD TEMPORARILY GIVING PATIENT BREAK FROM TREATMENT	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	370	1
MMRF_2506	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			MD TEMPORARILY GIVING PATIENT BREAK FROM TREATMENT	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	369	1
MMRF_2548	First line of therapy	First Line Therapy	CONDITIONING	Other	FLUDARABINE	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		30	Q day	Q day					247	249	1
MMRF_2548	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		140	Q day	Q day					250	250	1
MMRF_2548	First line of therapy	First Line Therapy	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	QD-4, D-1	Other	IV	IV	Log Forms	Other	CONDITIONING		1.6	Other	QD-4, D-1					248	251	1
MMRF_2548	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	500	mg/m^2	mg/m^2	QD (D1, D8)	Other	IV	IV	Log Forms	Induction	Induction		500	Other	QD (D1, D8)					1	1	1
MMRF_2548	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PROCEED TO TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_2548	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PROCEED TO TRANSPLANT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_2548	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			PROCEED TO TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					8	57	1
MMRF_2548	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		2000	Q day	Q day					79	79	1
MMRF_2548	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		10	Q day	Q day					79	79	1
MMRF_2548	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					79	79	1
MMRF_2548	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					103	103	1
MMRF_2554	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_2554	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	102	1
MMRF_2554	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_2554	First line of therapy	First Line Therapy	MOBOLIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3.3	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBOLIZATION		3.3	Q day	Q day					126	126	1
MMRF_2554	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	330	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		330	Q day	Q day					126	126	1
MMRF_2554	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					126	126	1
MMRF_2554	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	320	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		320	Q day	Q day					161	161	1
MMRF_2574	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	1,2,8,9,15,16	Other	IV	IV	Log Forms	Unknown	Unknown		40	Other	1,2,8,9,15,16					445	446	1
MMRF_2574	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					89	89	1
MMRF_2574	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_2574	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	54	1
MMRF_2574	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_2574	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	DAYS 1,2,8,9,15,16	Other	IV	IV	Log Forms	Unknown	Unknown		40	Other	DAYS 1,2,8,9,15,16					445	446	1
MMRF_2593	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PROCEED TO TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	50	1
MMRF_2593	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	15	1
MMRF_2593	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PROCEED TO TRANSPLANT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	50	1
MMRF_2593	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		2000	Q day	Q day					64	64	1
MMRF_2593	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		10	Q day	Q day					64	64	1
MMRF_2593	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					64	64	1
MMRF_2593	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					90	90	1
MMRF_2593	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					1079		1
MMRF_2593	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Ixazomib	Ixazomib		1			4	mg	mg	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	4	Other	QD (D1, D8, D15)					1079		1
MMRF_2593	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown	Checked	40	Q week	Q week					1079		1
MMRF_2596	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_2596	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	11	1
MMRF_2596	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_2596	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	392	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		392	Q day	Q day					78	78	1
MMRF_2605	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	850	mg	mg	DAYS 1,8,15,22	Other	IV	IV	Log Forms	Unknown	Unknown		850	Other	DAYS 1,8,15,22					901	971	1
MMRF_2605	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	DAYS OF AND AFTER DARATUMMUMAB	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	DAYS OF AND AFTER DARATUMMUMAB					901	971	1
MMRF_2605	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					901	971	1
MMRF_2605	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	IDASINUTLIN	Other			Disease progression/Relapse	Disease progression/Relapse	200	mg	mg	QD (D 1-5)	Other	PO	PO	Log Forms	Other	SALVAGE		200	Other	QD (D 1-5)					1016	1020	1
MMRF_2605	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D 1, 8, 15 OUT OF 28 DAYS CYCLE)	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	QD (D 1, 8, 15 OUT OF 28 DAYS CYCLE)					1016	1030	1
MMRF_2605	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		40	QWK	QWK					1016	1030	1
MMRF_2605	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	459	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	SALVAGE		459	Q day	Q day					1113	1115	1
MMRF_2605	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	FLUDARABINE	Other			Completed regimen	Completed regimen	28	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	SALVAGE		28	Q day	Q day					1113	1115	1
MMRF_2605	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	CAR T CELLS	Other			Completed regimen	Completed regimen	150	X10^6 CAR T CELLS.	Other	ONCE	Other	IV	IV	Log Forms	Other	SALVAGE		150	Other	ONCE					1118	1118	1
MMRF_2605	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	37	1
MMRF_2605	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	37	1
MMRF_2605	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	37	1
MMRF_2605	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	310	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		310	Q day	Q day					65	65	1
MMRF_2605	First line of therapy	First Line Therapy	MOBIIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3.1	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBIIZATION		3.1	Q day	Q day					65	65	1
MMRF_2605	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					65	65	1
MMRF_2605	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	302	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		302	Q day	Q day					90	90	1
MMRF_2605	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					603	884	1
MMRF_2605	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					603	884	1
MMRF_2605	First line of therapy	First Line Therapy	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		2.5	Q day	Q day					257	260	1
MMRF_2605	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	310	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		310	Q day	Q day					259	259	1
MMRF_2605	First line of therapy	First Line Therapy	CONDITIONING	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		10	Q day	Q day					257	260	1
MMRF_2605	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					603	884	1
MMRF_2619	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					444	457	1
MMRF_2619	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					444	457	1
MMRF_2619	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					444	457	1
MMRF_2619	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					28	35	1
MMRF_2619	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	300	mg/m^2	mg/m^2	PHYSICIAN DISCRETION	Other	IV	IV	Log Forms	Induction	Induction		300	Other	PHYSICIAN DISCRETION					1	35	1
MMRF_2619	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					472	500	1
MMRF_2619	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					472	500	1
MMRF_2619	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4.6	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		4.6	Q day	Q day					510	510	1
MMRF_2619	First line of therapy	First Line Therapy	MOBILIZATION	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	4.6	G	Other	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		4.6	Q day	Q day					510	510	1
MMRF_2619	First line of therapy	First Line Therapy	MOBILIZATION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		10	Q day	Q day					510	510	1
MMRF_2619	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		200	Q day	Q day					536	536	1
MMRF_2619	First line of therapy	First Line Therapy	SALVAGE	Other	Daratumumab	Daratumumab		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Other	SALVAGE		16	QWK	QWK					1500	1662	1
MMRF_2619	First line of therapy	First Line Therapy	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	QD 1-21	Other	PO	PO	Log Forms	Other	SALVAGE		3	Other	QD 1-21					1500	1662	1
MMRF_2619	First line of therapy	First Line Therapy	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWEEK FOR 9 DOSES	Other	PO	PO	Log Forms	Other	SALVAGE		40	Other	QWEEK FOR 9 DOSES					1500	1662	1
MMRF_1222	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					170	354	1
MMRF_1222	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					170	354	1
MMRF_1222	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				4	QD (D1-21)	QD (D1-21)					170	359	1
MMRF_1222	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					407	407	1
MMRF_1222	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		140	Q day	Q day					532	532	1
MMRF_1222	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bendamustine	Bendamustine			Adverse Event or co-morbidity	Adverse Event or co-morbidity	120	mg/m^2	mg/m^2	UNKNOWN	Other	IV	IV	Log Forms	Induction	Induction		120	Other	UNKNOWN					513	513	1
MMRF_1222	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					513	520	1
MMRF_1222	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		20	Q week	Q week					513	520	1
MMRF_1222	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					597	611	1
MMRF_1222	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			DOSE TO BE ESCALATED PER STANDARD TREATMENT REGIMEN	Other	20	mg/m^2	mg/m^2	QD1, D2	Other	IV	IV	Log Forms	Induction	Induction		20	Other	QD1, D2					618	619	1
MMRF_1222	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			DOSE TO BE ESCALATED PER STANDARD TREATMENT REGIMEN	Other	27	mg/m^2	mg/m^2	QD (D8-9, D15-16)	Other	IV	IV	Log Forms	Induction	Induction		27	Other	QD (D8-9, D15-16)					625	633	1
MMRF_1222	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			STOPPED SO PATIENT COULD RECEIVE XRT TO ORBITAL PLASMACYTOMA	Other	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					646	660	1
MMRF_1222	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			NO LONGER INDICATED	Other	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1107		1
MMRF_1222	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBQ	Other	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	160	1
MMRF_1222	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					1	160	1
MMRF_1264	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	372	1
MMRF_1264	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					1	15	1
MMRF_1264	First line of therapy	First Line Therapy			Melphalan	Melphalan			Investigator decision for other reasons	Investigator decision for other reasons	2	mg	mg	6 TABS DAILY FOR 5 DAYS Q6 WEEKS	Other	PO	PO	Log Forms				2	Other	6 TABS DAILY FOR 5 DAYS Q6 WEEKS					86	302	1
MMRF_1264	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-14)	QD (D1-14)					45	58	1
MMRF_1264	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		3	QD (D1-21)	QD (D1-21)					388	1210	1
MMRF_1264	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			DOSE DECREASED	Other	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		3	QD (D1-21)	QD (D1-21)					1239	1550	1
MMRF_1264	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		2	Q day	Q day					1551	1610	1
MMRF_1547	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			SUBJECT TO BE WORKED UP FOR TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					1	148	1
MMRF_1547	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			SUBJECT TO BE WORKED UP FOR TRANSPLANT	Other	10	mg	mg	QD (D1-2)	Other	PO	PO	Log Forms	Induction	Induction		10	Other	QD (D1-2)					1	148	1
MMRF_1547	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			SUBJECT TO BE WORKED UP FOR TRANSPLANT	Other	300	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	148	1
MMRF_1547	First line of therapy	First Line Therapy	2 DAYS HIGH DOSE MELPHALAN PRIOR TO TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	QD -1,-2	Other	IV	IV	Log Forms	Other	2 DAYS HIGH DOSE MELPHALAN PRIOR TO TRANSPLANT		200	Other	QD -1,-2					192	193	1
MMRF_1547	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			PATIENT STARTED TO HAVE DIFFICULTIES TOLERATING THERAPY	Other	1.3	mg/m^2	mg/m^2	Q (D1, D8)	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	Q (D1, D8)					642	865	1
MMRF_1547	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					892	1222	1
MMRF_1570	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Patient decision	Patient decision	2.3	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	SUBQ INJECTION	Other	Log Forms	Induction	Induction		2.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	29	1
MMRF_1570	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	DAY 1 AND DAY 2	Other	PO	PO	Log Forms	Induction	Induction		10	Other	DAY 1 AND DAY 2					1	110	1
MMRF_1570	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	150	mg	mg	DAY 1 AND DAY 2	Other	PO	PO	Log Forms	Induction	Induction		150	Other	DAY 1 AND DAY 2					1	110	1
MMRF_1570	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.3	mg	mg	QD (D1-3)	QD (D1-3)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.3	QD (D1-3)	QD (D1-3)					29	110	1
MMRF_1570	First line of therapy	First Line Therapy	HIGH DOSE MELPHALAN GIVEN 1 DAY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	HIGH DOSE MELPHALAN GIVEN 1 DAY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT		200	Q day	Q day					155	155	1
MMRF_1570	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	Q2W	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	Q2W					386	546	1
MMRF_1570	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Patient decision	Patient decision	10	mg	mg	MONDAY & TUESDAY FOR 3 WEEKS THEN 1 WEEK OFF	Other	PO	PO	Log Forms	Unknown	Unknown		10	Other	MONDAY & TUESDAY FOR 3 WEEKS THEN 1 WEEK OFF					546	546	1
MMRF_1570	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Patient decision	Patient decision	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					546	546	1
MMRF_1586	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			CHANGED FREQUENCY	Other	2.04	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	SUBQ	Other	Log Forms	Induction	Induction		2.04	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	128	1
MMRF_1586	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			10	mg	mg	QD 1-2, 8-9, 22-23, 29-30	Other	PO	PO	Log Forms	Induction	Induction	Checked	10	Other	QD 1-2, 8-9, 22-23, 29-30					1		1
MMRF_1586	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	Q EVERY 2 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	Q EVERY 2 WEEKS					128		1
MMRF_2038	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	2	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2	Q week	Q week					1	92	1
MMRF_2038	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	10	mg	mg	QD (D1-D2)	Other	PO	PO	Log Forms	Induction	Induction		10	Other	QD (D1-D2)					1	94	1
MMRF_2038	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	34	1
MMRF_2038	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		5	Q day	Q day					35	94	1
MMRF_2038	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	DAYS 1,4,8	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAYS 1,4,8					121	128	1
MMRF_2038	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Completed regimen	Completed regimen	200	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		200	BID	BID					124	127	1
MMRF_2038	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1-4 AND DAY 8	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1-4 AND DAY 8					121	128	1
MMRF_2038	First line of therapy	First Line Therapy	Induction	Induction	ADRIAMYCIN	Other			Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					121	124	1
MMRF_2038	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		300	QD (D1-4)	QD (D1-4)					121	124	1
MMRF_2038	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			Completed regimen	Completed regimen	40	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					121	124	1
MMRF_2038	First line of therapy	First Line Therapy	Unknown	Unknown	Melphalan	Melphalan			Completed regimen	Completed regimen	50	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		50	Q day	Q day					158	158	1
MMRF_2038	First line of therapy	First Line Therapy	Unknown	Unknown	Melphalan	Melphalan			Completed regimen	Completed regimen	50	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		50	Q day	Q day					164	164	1
MMRF_2038	First line of therapy	First Line Therapy	Unknown	Unknown	Melphalan	Melphalan			Completed regimen	Completed regimen	75	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		75	Q day	Q day					168	168	1
MMRF_2038	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		20	Q day	Q day					158	158	1
MMRF_2038	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		20	Q day	Q day					164	164	1
MMRF_2038	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		20	Q day	Q day					168	168	1
MMRF_2038	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					275	666	1
MMRF_2038	First line of therapy	First Line Therapy	Maintenance	Maintenance	Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	50	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		50	Q day	Q day					275	409	1
MMRF_2038	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		12	Q week	Q week					539	632	1
MMRF_2038	First line of therapy	First Line Therapy	Maintenance	Maintenance	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	1	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		1	QD (D1-21)	QD (D1-21)					698	719	1
MMRF_2038	First line of therapy	First Line Therapy	Maintenance	Maintenance	Pomalidomide	Pomalidomide		0	OUTSIDE PROVIDER DECIDED PATIENT DOING WELL OFF TREATMENT AND IN SCR	Other	1	mg	mg	EVERY OTHER DAY FOR 28 DAY CYCLES WITH NO BREAK	Other	PO	PO	Log Forms	Maintenance	Maintenance		1	Other	EVERY OTHER DAY FOR 28 DAY CYCLES WITH NO BREAK					732	1675	1
MMRF_2168	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	281	1
MMRF_2168	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-2, D8-9, D22-23, D29-30)	Other	PO	PO	Log Forms	Induction	Induction		10	Other	QD (D1-2, D8-9, D22-23, D29-30)					1	322	1
MMRF_2168	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					135	276	1
MMRF_2168	First line of therapy	First Line Therapy	CONDITIONING FOR BONE MARROW TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING FOR BONE MARROW TRANSPLANT		200	Q day	Q day					308	308	1
MMRF_2168	First line of therapy	First Line Therapy	HIGH-DOSE PRIMING PRIOR TO STEM CELL COLLECTION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	HIGH-DOSE PRIMING PRIOR TO STEM CELL COLLECTION		3000	Q day	Q day					288	288	1
MMRF_2168	First line of therapy	First Line Therapy	Consolidation	Consolidation	Ixazomib	Ixazomib			Completed regimen	Completed regimen	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		4	Q week	Q week					430	542	1
MMRF_2168	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					430	542	1
MMRF_2168	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					430	542	1
MMRF_2168	First line of therapy	First Line Therapy	Induction	Induction	Daratumumab	Daratumumab			Completed regimen	Completed regimen	16	mg/m^2	mg/m^2	Q2 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		16	Other	Q2 WEEKS					626	891	1
MMRF_2168	First line of therapy	First Line Therapy	Induction	Induction	Daratumumab	Daratumumab		1			16	mg/m^2	mg/m^2	Q4 WEEKS	Other	IV	IV	Log Forms	Induction	Induction	Checked	16	Other	Q4 WEEKS					919		1
MMRF_2215	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2215	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-2, D4-5, D8-9, D11-12)	Other	PO	PO	Log Forms	Induction	Induction		10	Other	QD (D1-2, D4-5, D8-9, D11-12)					1	94	1
MMRF_2215	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		140	Q day	Q day					128	128	1
MMRF_2215	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					242	423	1
MMRF_2215	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			CHANGED DOSING FREQUENCY	Other	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					428	1090	1
MMRF_2215	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			PATIENT TOLERATES THE 21/28 DAY REGIMEN BETTER	Other	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					1098	1388	1
MMRF_2215	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					1388		1
MMRF_1011	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			GRADE 2 NEUROPATHY	Other	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1011	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1, D2, D3, D4,D9,D10, D11, D12	Other	PO	PO	Log Forms				40	Other	D1, D2, D3, D4,D9,D10, D11, D12					1	67	1
MMRF_1011	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAY 1 AND DAY 8	Other	PO	PO	Log Forms				40	Other	DAY 1 AND DAY 8					67	156	1
MMRF_1011	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			DOSE CHANGE	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					253	451	1
MMRF_1011	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			PATIENT DIAGNOSED WITH COLON CANCER	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					452	925	1
MMRF_1011	First line of therapy	First Line Therapy	MOBILIZATION FOR BONE MARROW TRANSPLANT	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3720	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION FOR BONE MARROW TRANSPLANT		3720	Other	ONCE					131	131	1
MMRF_1011	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	370	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		370	Other	ONCE					153	153	1
MMRF_1011	First line of therapy	First Line Therapy	CONDITIONING	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3720	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		3720	Other	ONCE					131	131	1
MMRF_1011	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1726	1908	1
MMRF_1011	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1726	1909	1
MMRF_1011	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		1			1	mg/dL	mg/dL	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	1	Q day	Q day					1933		1
MMRF_1034	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DOSEAGE AND ROUTE CHANGED DUE TO NEUROPATHY	Other	2	mg	mg	QWK	QWK	IV	IV	Log Forms				2	QWK	QWK					5	60	1
MMRF_1034	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DOSEAGE CHANGED	Other	10	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms				10	QD (D1-4)	QD (D1-4)					1	60	1
MMRF_1034	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			PATIENT DEVELOPED HYPERCALCEMIA	Other	1	mg/dL	mg/dL	QWK	QWK	IV SubQ	IV SubQ	Log Forms				1	QWK	QWK					60	115	1
MMRF_1034	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DOSEAGE AND FREQUENCY CHANGED	Other	20	mg	mg	QWK	QWK	PO	PO	Log Forms				20	QWK	QWK					60	110	1
MMRF_1034	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			BEGINNING STEM CELL MOBILIZATION FOR AUTOLOGOUS STEM CELL TRANSPLANT	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					115	249	1
MMRF_1034	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			BEGINNING STEM CELL MOBLIZATION FOR AUTOLOGOUS STEM CELL TRANSPLANT	Other	40	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms				40	Other	DAYS 1, 8, 15, 22					115	249	1
MMRF_1034	First line of therapy	First Line Therapy	STEM CELL MOBILIZATION	Other	PLERIXAFOR	Other			Completed regimen	Completed regimen	24	mg	mg	Q day	Q day	SUBQ	Other	Log Forms	Other	STEM CELL MOBILIZATION		24	Q day	Q day					254	255	1
MMRF_1034	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	300	mg	mg	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		300	Q day	Q day					258	258	1
MMRF_1029	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			GRADE 2 PERIPHERAL NEUROPATHY AND GOOD RESPONSE	Other	3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1029	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					22	560	1
MMRF_1029	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	DAYS 1, 2, 8, 9, 15, 16, 22, 23	Other	PO	PO	Log Forms				20	Other	DAYS 1, 2, 8, 9, 15, 16, 22, 23					1	84	1
MMRF_1029	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					85	530	1
MMRF_1029	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	Q day	Q day	PO	PO	Log Forms				15	Q day	Q day					561	883	1
MMRF_1029	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms			Checked	20	Q week	Q week					561		1
MMRF_1029	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					913		1
MMRF_1042	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			PATIENT'S RESPONSE REACHED A PLATEAU	Other	2.4	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms				2.4	QWK	QWK					1	148	1
MMRF_1042	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DOSEAGE REDUCED	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	148	1
MMRF_1042	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			LOWERED DOSAGE	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					581	882	1
MMRF_1042	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					581	644	1
MMRF_1042	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					644	700	1
MMRF_1042	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					882		1
MMRF_1042	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	8	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		8	QWK	QWK					1429	1764	1
MMRF_1039	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms				2.6	QWK	QWK					1	105	1
MMRF_1039	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1-4, 9-12	Other	PO	PO	Log Forms				40	Other	DAYS 1-4, 9-12					1	246	1
MMRF_1039	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					102	210	1
MMRF_1039	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					998	1149	1
MMRF_1039	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1150	1358	1
MMRF_1039	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1038	1358	1
MMRF_1039	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	385	mg	mg	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		385	Other	ONCE					243	243	1
MMRF_1039	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.5	Q week	Q week					105	210	1
MMRF_1039	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2	Q week	Q week					210	221	1
MMRF_1039	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	2	QD (D1-21)	QD (D1-21)					1403		1
MMRF_1039	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					1373		1
MMRF_1055	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	MG	Other	Q week	Q week	IV SubQ	IV SubQ	Log Forms				2.5	Q week	Q week					1	142	1
MMRF_1055	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	142	1
MMRF_1055	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					296	392	1
MMRF_1055	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					414	444	1
MMRF_1055	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	385	mg	mg	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		385	Other	ONCE					165	165	1
MMRF_1124	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DISCHARGED FROM HOSPITAL TO FOLLOW-UP CARE IN OKLAHOMA	Other	20	mg	mg	ONE TIME DOSING	Other	PO	PO	Log Forms				20	Other	ONE TIME DOSING					1	1	1
MMRF_1124	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Patient decision	Patient decision	2.1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					18	379	1
MMRF_1124	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	DAY 1-4 AND DAY 9-12	Other	PO	PO	Log Forms				20	Other	DAY 1-4 AND DAY 9-12					15	60	1
MMRF_1124	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					60	379	1
MMRF_1166	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_1166	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	D1-2, D4-5, D8-9, D11-12	Other	PO	PO	Log Forms				20	Other	D1-2, D4-5, D8-9, D11-12					1	106	1
MMRF_1166	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	106	1
MMRF_1209	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DEATH	Other	2.1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	320	1
MMRF_1209	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			DEATH	Other	750	mg	mg	D1, D8, D11	Other	PO	PO	Log Forms				750	Other	D1, D8, D11					1	320	1
MMRF_1209	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	D1, D8, D15	Other	PO	PO	Log Forms				20	Other	D1, D8, D15					1	320	1
MMRF_1333	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms				1.3	Q week	Q week					1	176	1
MMRF_1333	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	750	mg/m^2	mg/m^2	Q28D (D1)	Other	IV	IV	Log Forms				750	Other	Q28D (D1)					1	176	1
MMRF_1333	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	IV	IV	Log Forms				40	Q week	Q week					1	176	1
MMRF_1342	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	747	1
MMRF_1342	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Patient decision	Patient decision	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				15	QD (D1-14)	QD (D1-14)					1	747	1
MMRF_1342	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			PATIENT WAS EXPERIENCING ANXIETY	Other	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	498	1
MMRF_1342	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	12	mg	mg	TWICE A WEEK	Other	PO	PO	Log Forms	Induction	Induction		12	Other	TWICE A WEEK					498	672	1
MMRF_1342	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	16	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		16	Q week	Q week					672	778	1
MMRF_1383	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.3	Q week	Q week					1	135	1
MMRF_1383	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms				300	Q week	Q week					1	135	1
MMRF_1383	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	DAYS 1-4, 9-12, 17-20	Other	PO	PO	Log Forms				20	Other	DAYS 1-4, 9-12, 17-20					1	56	1
MMRF_1383	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					57	135	1
MMRF_1383	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.3	mg/m^2	mg/m^2	Q2WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.3	Other	Q2WEEKS					276	1009	1
MMRF_1383	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	240	mg	mg	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		240	Other	ONCE					167	167	1
MMRF_1550	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	23	1
MMRF_1550	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	204	1
MMRF_1550	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	142	1
MMRF_1550	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Q week	Q week					30	51	1
MMRF_1550	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	.7	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		0.7	Q week	Q week					58	142	1
MMRF_1550	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Lack of response	Lack of response	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					709	827	1
MMRF_1550	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg/dL	mg/dL	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					310	708	1
MMRF_1550	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab			Lack of response	Lack of response	16	mg/kg	mg/kg	Q2WK	Other	IV	IV	Log Forms	Induction	Induction		16	Other	Q2WK					838	1232	1
MMRF_1550	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	3	QD (D1-21)	QD (D1-21)					1332		1
MMRF_1550	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			4	mg	mg	10 Q.W.	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	4	Other	10 Q.W.					1328		1
MMRF_1568	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	22	1
MMRF_1568	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	50	1
MMRF_1568	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	22	1
MMRF_1568	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Q week	Q week					29	113	1
MMRF_1568	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	100	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		100	Q week	Q week					55	113	1
MMRF_1568	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					29	113	1
MMRF_1568	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					285	441	1
MMRF_1568	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	300	mg	mg	ONCE	Other	IV	IV	Log Forms	Induction	Induction		300	Other	ONCE					171	171	1
MMRF_1568	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		1			8	mg/kg	mg/kg	CYCLE 1 - D1, D2, D8, D15, D22, CYCLE 2 AND BEYOND - D1, D8, D15, D22	Other	IV	IV	Log Forms	Induction	Induction	Checked	8	Other	CYCLE 1 - D1, D2, D8, D15, D22, CYCLE 2 AND BEYOND - D1, D8, D15, D22					1275		1
MMRF_1568	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib		1			2.4	mg/m^2	mg/m^2	D1, D8	Other	INJECTION	Other	Log Forms	Induction	Induction	Checked	2.4	Other	D1, D8					1275		1
MMRF_1568	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction	Checked	40	QWK	QWK					1275		1
MMRF_1721	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	120	1
MMRF_1721	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	120	1
MMRF_1721	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TROUBLE SLEEPING	Other	40	mg	mg	D1-4. D9-12, D17-20	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1-4. D9-12, D17-20					1	120	1
MMRF_1721	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					57	120	1
MMRF_1834	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	69	1
MMRF_1834	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	69	1
MMRF_1834	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1-2, 4-5, 8-9, 11-12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1-2, 4-5, 8-9, 11-12					1	69	1
MMRF_1834	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	300	mg	mg	ONCE	Other	IV	IV	Log Forms	Induction	Induction		300	Other	ONCE					145	145	1
MMRF_1834	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	D1, D8D, D15	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	D1, D8D, D15					222	940	1
MMRF_1834	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					222	940	1
MMRF_1970	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	176	1
MMRF_1970	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	DAYS 1,8,15,22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1,8,15,22					1	148	1
MMRF_2057	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_2057	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	DAYS. 1,8,15,22	Other	PO	PO	Log Forms	Induction	Induction	Checked	20	Other	DAYS. 1,8,15,22					1		1
MMRF_2454	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		25	BID	BID					1	74	1
MMRF_2454	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		40	Q week	Q week					1	74	1
MMRF_2480	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DEATH	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	141	1
MMRF_2480	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					14	141	1
MMRF_2560	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_2560	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DOSE ADJUSTMENT	Other	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_2560	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	20 MG DAILY ON D1, D2, D4, D5, D8, D9, D11, D12 AND D21.	Other	PO	PO	Log Forms	Induction	Induction		20	Other	20 MG DAILY ON D1, D2, D4, D5, D8, D9, D11, D12 AND D21.					1	74	1
MMRF_2560	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	74	1
MMRF_1031	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	61	1
MMRF_1031	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	61	1
MMRF_1031	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1, D4, D11, D18	Other	PO	PO	Log Forms				20	Other	D1, D4, D11, D18					1	61	1
MMRF_1031	First line of therapy	First Line Therapy			MAGE VACCINE	Other			Disease progression/Relapse	Disease progression/Relapse	300	MCG	Other	Q3 WEEKS APPROXIMATELY	Other	IV	IV	Log Forms				300	Other	Q3 WEEKS APPROXIMATELY					185	1339	1
MMRF_1031	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		25	Q day	Q day					1339	1581	1
MMRF_1031	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					1339	1581	1
MMRF_1031	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1581	1670	1
MMRF_1031	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1581	1670	1
MMRF_1018	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	160	1
MMRF_1018	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms				20	QWK	QWK					1	160	1
MMRF_1018	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	D1,8,15	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	D1,8,15					44	105	1
MMRF_1018	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms			Checked	10	QD (D1-21)	QD (D1-21)					218		1
MMRF_1018	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms			Checked	20	Q week	Q week					218		1
MMRF_1041	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	18	1
MMRF_1041	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IVB	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	18	1
MMRF_1041	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	250	mg/m^2	mg/m^2	DAYS 4, 11	Other	IV	IV	Log Forms				250	Other	DAYS 4, 11					1	18	1
MMRF_1041	First line of therapy	First Line Therapy			Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	50	mg	mg	DAYS 1 - 28	Other	PO	PO	Log Forms				50	Other	DAYS 1 - 28					18	260	1
MMRF_1041	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					18	432	1
MMRF_1041	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					18	211	1
MMRF_1041	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	250	mg/m^2	mg/m^2	DAYS 1, 8	Other	IV	IV	Log Forms				250	Other	DAYS 1, 8					18	159	1
MMRF_1041	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	EVERY OTHER DAY FOR 21 DAYS	Other	PO	PO	Log Forms	Consolidation	Consolidation		15	Other	EVERY OTHER DAY FOR 21 DAYS					260	406	1
MMRF_1041	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					432	953	1
MMRF_1041	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Consolidation	Consolidation		300	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					432	953	1
MMRF_1041	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					981	1084	1
MMRF_1041	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	QD D1 AND D15	Other	IV	IV	Log Forms	Consolidation	Consolidation		300	Other	QD D1 AND D15					1061	1095	1
MMRF_1041	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		40	Q day	Q day					953	1226	1
MMRF_1016	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	DAYS 1, 4, 11, 18	Other	PO	PO	Log Forms				40	Other	DAYS 1, 4, 11, 18					1	43	1
MMRF_1016	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	DAYS 1, 4, 11, 18	Other	IVP ON DAYS 1, 4 AND SUBQ ON 11 AND 18	Other	Log Forms				1.3	Other	DAYS 1, 4, 11, 18					1	43	1
MMRF_1016	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	250	mg/m^2	mg/m^2	DAYS 1, 11	Other	IVB	IVB	Log Forms				250	Other	DAYS 1, 11					1	43	1
MMRF_1016	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					43	113	1
MMRF_1016	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	DAYS 1, 4, 11, 18	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	DAYS 1, 4, 11, 18					43	113	1
MMRF_1016	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	DAYS 1, 4, 11, 18	Other	PO	PO	Log Forms				40	Other	DAYS 1, 4, 11, 18					43	113	1
MMRF_1016	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	DAYS 1, 4, 11, 18	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	DAYS 1, 4, 11, 18					113	158	1
MMRF_1016	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	250	mg/m^2	mg/m^2	DAYS 1, 11	Other	IV	IV	Log Forms				250	Other	DAYS 1, 11					113	158	1
MMRF_1016	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	DAYS 1, 4, 11, 18	Other	PO	PO	Log Forms				40	Other	DAYS 1, 4, 11, 18					113	158	1
MMRF_1016	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	DAYS 1, 8, 15					234	535	1
MMRF_1016	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms				40	Other	DAYS 1, 8, 15					234	673	1
MMRF_1016	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					234	458	1
MMRF_1016	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					547	673	1
MMRF_1016	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	300	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Consolidation	Consolidation		300	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					547	673	1
MMRF_1054	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QWK	QWK	PO	PO	Log Forms				20	QWK	QWK					1	21	1
MMRF_1054	First line of therapy	First Line Therapy			Prednisone	Prednisone			Investigator decision for other reasons	Investigator decision for other reasons	50	mg	mg	3 X PER WEEK: M, W, F	Other	PO	PO	Log Forms				50	Other	3 X PER WEEK: M, W, F					29	112	1
MMRF_1054	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	112	1
MMRF_1054	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	DAYS 1, 4, 11, 18	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	DAYS 1, 4, 11, 18					112	568	1
MMRF_1054	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	DAYS 1, 8	Other	IV	IV	Log Forms				300	Other	DAYS 1, 8					112	162	1
MMRF_1054	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	DAYS 1, 4, 11, 18	Other	PO	PO	Log Forms				40	Other	DAYS 1, 4, 11, 18					112	169	1
MMRF_1054	First line of therapy	First Line Therapy			Prednisone	Prednisone			Investigator decision for other reasons	Investigator decision for other reasons	50	mg	mg	3 X PER WEEK: M, W, F	Other	PO	PO	Log Forms				50	Other	3 X PER WEEK: M, W, F					169	568	1
MMRF_1054	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg/dL	mg/dL	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					167	568	1
MMRF_1054	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	30	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Induction	Induction		30	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					568	757	1
MMRF_1054	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					568	2862	1
MMRF_1049	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QID	QID	PO	PO	Log Forms	Maintenance	Maintenance		25	QID	QID					1084	1224	1
MMRF_1049	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					1084	1224	1
MMRF_1049	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	ATEZOLIZUMAB	Other		0	Disease progression/Relapse	Disease progression/Relapse	1200	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		1200	QWK	QWK					1291	2818	1
MMRF_1049	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	1016	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		1016	QWK	QWK					1392	2113	1
MMRF_1049	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QID	QID	PO	PO	Log Forms	Maintenance	Maintenance		2	QID	QID					1414	2078	1
MMRF_1049	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		20	QWK	QWK					1392	2085	1
MMRF_1049	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					2144	2207	1
MMRF_1049	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	510	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		510	QD (D1-4)	QD (D1-4)					2144	2177	1
MMRF_1049	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Induction	Induction	ETOPOSIDE	Other		0	Completed regimen	Completed regimen	52	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		52	QD (D1-4)	QD (D1-4)					2144	2177	1
MMRF_1049	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Induction	Induction	CISPLATIN	Other		0	Completed regimen	Completed regimen	13	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		13	QD (D1-4)	QD (D1-4)					2144	2177	1
MMRF_1049	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab		0	Disease progression/Relapse	Disease progression/Relapse	655	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		655	QWK	QWK					2395	2416	1
MMRF_1049	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		3	QD (D1-21)	QD (D1-21)					2415	2431	1
MMRF_1049	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		20	QWK	QWK					2395	2416	1
MMRF_1049	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Maintenance	Maintenance	GSK2857916	Other		0	Disease progression/Relapse	Disease progression/Relapse	219	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		219	QWK	QWK					2452	2493	1
MMRF_1049	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Maintenance	Maintenance	CC-220	Other		0	Disease progression/Relapse	Disease progression/Relapse	0.2	mg	mg	QID	QID	PO	PO	Log Forms	Maintenance	Maintenance		0.2	QID	QID					2731	2807	1
MMRF_1049	Tenth Line of Therapy (following 9th relapse)	Tenth Line of Therapy (following 9th relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	89.6	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		89.6	QWK	QWK					2873	2887	1
MMRF_1049	Tenth Line of Therapy (following 9th relapse)	Tenth Line of Therapy (following 9th relapse)	Maintenance	Maintenance	SELINEXOR	Other		0	Disease progression/Relapse	Disease progression/Relapse	80	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		80	QWK	QWK					2870	2922	1
MMRF_1049	Tenth Line of Therapy (following 9th relapse)	Tenth Line of Therapy (following 9th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		8	QWK	QWK					2873	2939	1
MMRF_1049	Eleventh Line of Therapy (following 10th relapse)	Eleventh Line of Therapy (following 10th relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	900	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		900	QWK	QWK					2991	3012	1
MMRF_1049	Eleventh Line of Therapy (following 10th relapse)	Eleventh Line of Therapy (following 10th relapse)	Maintenance	Maintenance	VENETOCLAX	Other		0	Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	QID	QID	PO	PO	Log Forms	Maintenance	Maintenance		100	QID	QID					2978	3012	1
MMRF_1049	Eleventh Line of Therapy (following 10th relapse)	Eleventh Line of Therapy (following 10th relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	1.55	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.55	QWK	QWK					2991	3019	1
MMRF_1049	Eleventh Line of Therapy (following 10th relapse)	Eleventh Line of Therapy (following 10th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	12	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		12	QWK	QWK					2991	3021	1
MMRF_1049	Twelfth Line of Therapy (following 11th relapse)	Twelfth Line of Therapy (following 11th relapse)	Maintenance	Maintenance	METRO28	Other		1										Log Forms	Maintenance	Maintenance	Checked								3019		1
MMRF_1049	Twelfth Line of Therapy (following 11th relapse)	Twelfth Line of Therapy (following 11th relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	DEATH	Other	920	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		920	QWK	QWK					3030	3037	1
MMRF_1049	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	22	1
MMRF_1049	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_1049	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		300	Other	ONCE					22	183	1
MMRF_1049	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					218	711	1
MMRF_1049	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	15	mg	mg	ONCE	Other	PO	PO	Log Forms	Induction	Induction		15	Other	ONCE						189	1
MMRF_1049	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	15	mg	mg	ONCE	Other	PO	PO	Log Forms	Maintenance	Maintenance		15	Other	ONCE						1079	1
MMRF_1049	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)	PO	PO	Log Forms	Maintenance	Maintenance		40	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)					218	1079	1
MMRF_1049	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Panobinostat	Panobinostat		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	ON DAYS 1,3,5,15,17, AND 19 AS DIRECTED PER STUDY PROTOCOL.	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	ON DAYS 1,3,5,15,17, AND 19 AS DIRECTED PER STUDY PROTOCOL.					1084	1224	1
MMRF_1064	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	692	1
MMRF_1064	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Completed regimen	Completed regimen	16	mg/kg	mg/kg	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	EVERY OTHER WEEK					2740	3016	1
MMRF_1064	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	70	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		70	QWK	QWK					2740	3016	1
MMRF_1064	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Completed regimen	Completed regimen	2	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		2	QD (D1-4)	QD (D1-4)					2740	3016	1
MMRF_1064	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		40	QWK	QWK					2740	3025	1
MMRF_1064	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	92	1
MMRF_1064	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			REORDER	Other	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms				20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	373	1
MMRF_1064	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		20	QWK	QWK					374	762	1
MMRF_1064	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	DAY 1, 8, 15	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	DAY 1, 8, 15					1511	1543	1
MMRF_1064	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		25	Q day	Q day					1511	1543	1
MMRF_1064	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Consolidation	Consolidation		4	Other	DAYS 1, 8, 15					1511	1543	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	DAYS 1 AND 2	Other	IV	IV	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1 AND 2					1543	1602	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	DAYS 8, 9, 15, 16	Other	IV	IV	Log Forms	Consolidation	Consolidation		36	Other	DAYS 8, 9, 15, 16					1543	1592	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1543	1568	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					1616	1616	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab		0	Completed regimen	Completed regimen	10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Maintenance	Maintenance		10	Q week	Q week					1769	2806	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					1769	2806	1
MMRF_1064	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					1769	2740	1
MMRF_1071	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	7	1
MMRF_1071	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1071	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1071	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAYS 1, 8	Other	IV	IV	Log Forms				300	Other	DAYS 1, 8					102	137	1
MMRF_1071	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms				40	Other	DAYS 1, 8, 15					102	137	1
MMRF_1071	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	DAYS 1, 8, 15					102	137	1
MMRF_1071	First line of therapy	First Line Therapy	Induction	Induction	MAGE- A3 VACCINE	Other			Completed regimen	Completed regimen	300	MCG	Other	GIVEN Q3WKS THEN 3 MONTH INTERVALS.	Other	IM	Other	Log Forms	Induction	Induction		300	Other	GIVEN Q3WKS THEN 3 MONTH INTERVALS.					158	197	1
MMRF_1071	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					973	1757	1
MMRF_1071	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					973	1904	1
MMRF_1071	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1757	2219	1
MMRF_1084	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms				1.3	QWK	QWK					1	93	1
MMRF_1084	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	93	1
MMRF_1084	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QWK	QWK	PO	PO	Log Forms				20	QWK	QWK					1	93	1
MMRF_1084	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	QWK	QWK	PO	PO	Log Forms				12	QWK	QWK					200	313	1
MMRF_1084	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					200	313	1
MMRF_1084	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					631	996	1
MMRF_1084	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	D1,D8	Other	IV	IV	Log Forms	Consolidation	Consolidation		300	Other	D1,D8					631	996	1
MMRF_1084	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					631	984	1
MMRF_1084	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD  (D1-28)	Other	PO	PO	Log Forms	Consolidation	Consolidation		2	Other	QD  (D1-28)					996	1142	1
MMRF_1084	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		10	QWK	QWK					996	1142	1
MMRF_1084	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QWK	QWK					1102	1142	1
MMRF_1084	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		40	Q day	Q day					1166	1338	1
MMRF_1084	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Doxorubicin	Doxorubicin			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-21)	QD (D1-21)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-21)	QD (D1-21)					1166	1338	1
MMRF_1084	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	400	mg/m^2	mg/m^2	QD (D1-21)	QD (D1-21)	IV	IV	Log Forms	Consolidation	Consolidation		400	QD (D1-21)	QD (D1-21)					1166	1338	1
MMRF_1084	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	CISPLATIN	Other			Disease progression/Relapse	Disease progression/Relapse	15	mg/m^2	mg/m^2	QD (D1-21)	QD (D1-21)	IV	IV	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					1166	1338	1
MMRF_1084	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	ETOPOSIDE	Other			Disease progression/Relapse	Disease progression/Relapse	40	mg/m^2	mg/m^2	QD (D1-21)	QD (D1-21)	IV	IV	Log Forms	Consolidation	Consolidation		40	QD (D1-21)	QD (D1-21)					1166	1338	1
MMRF_1084	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		16	Q week	Q week					1363	1648	1
MMRF_1084	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	TWICE WEEKLY	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	TWICE WEEKLY					1363	1648	1
MMRF_1100	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	D1,4,11,18	Other	IV	IV	Log Forms				1.3	Other	D1,4,11,18					1	128	1
MMRF_1100	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	D1-28	Other	PO	PO	Log Forms				25	Other	D1-28					1	128	1
MMRF_1100	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1,4,11,18	Other	PO	PO	Log Forms				20	Other	D1,4,11,18					1	128	1
MMRF_1100	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	DAY 1 AND DAY 4	Other	IV	IV	Log Forms				2.5	Other	DAY 1 AND DAY 4					128	155	1
MMRF_1100	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					128	155	1
MMRF_1100	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	580	mg	mg	DAY 1 AND DAY 4	Other	IV	IV	Log Forms				580	Other	DAY 1 AND DAY 4					128	155	1
MMRF_1100	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	D1,4,11,18	Other	IV	IV	Log Forms	Consolidation	Consolidation		1.3	Other	D1,4,11,18					190	606	1
MMRF_1100	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					190	974	1
MMRF_1100	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	D1,4,11,18	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	D1,4,11,18					190	974	1
MMRF_1100	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					859	947	1
MMRF_1100	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	160	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		160	Other	ONCE					975	975	1
MMRF_1100	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Completed regimen	Completed regimen	16	mg/kg	mg/kg	ONCE WKLY	Other	IV	IV	Log Forms	Consolidation	Consolidation		16	Other	ONCE WKLY					1187	1927	1
MMRF_1100	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1384	1800	1
MMRF_1101	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	250	mg/m^2	mg/m^2	BID	BID	PO	PO	Log Forms				250	BID	BID					1	29	1
MMRF_1101	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms				20	Other	DAYS 1, 8, 15					1	422	1
MMRF_1101	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			PET CT NEGATIVE	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					50	534	1
MMRF_1101	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			CR	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					534	562	1
MMRF_1101	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	DAYS 1, 8, 15					1	99	1
MMRF_1111	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	DAYS 1, 5, 8, 12	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	DAYS 1, 5, 8, 12					1	26	1
MMRF_1111	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	DAYS 1, 5, 8, 12	Other	IV	IV	Log Forms				300	Other	DAYS 1, 5, 8, 12					1	26	1
MMRF_1111	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	DAYS 1, 5, 8, 12	Other	PO	PO	Log Forms				40	Other	DAYS 1, 5, 8, 12					1	26	1
MMRF_1111	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	DAYS 1, 4, 8, 15	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	DAYS 1, 4, 8, 15					26	285	1
MMRF_1111	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 4, 8, 15	Other	PO	PO	Log Forms				40	Other	DAYS 1, 4, 8, 15					26	553	1
MMRF_1111	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					26	340	1
MMRF_1111	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					340	2223	1
MMRF_1111	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	DAYS 1, 5, 8, 12	Other	IV	IV	Log Forms	Consolidation	Consolidation		300	Other	DAYS 1, 5, 8, 12					109	124	1
MMRF_1127	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV	IV	Log Forms				1.3	Other	DAYS 1, 8, 15					1	82	1
MMRF_1127	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	82	1
MMRF_1127	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms				40	Other	DAYS 1, 8, 15					2	82	1
MMRF_1127	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					264	264	1
MMRF_1127	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown	Checked	1.3	Q week	Q week					2018		1
MMRF_1127	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			12	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown	Checked	12	Q week	Q week					2018		1
MMRF_1127	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			25	mg/dL	mg/dL	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					2046		1
MMRF_1151	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	37	1
MMRF_1151	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	37	1
MMRF_1151	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAYS 1, 8	Other	IV	IV	Log Forms				300	Other	DAYS 1, 8					1	37	1
MMRF_1151	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DEATH	Other	1.3	MG/MSQ	Other	QWK	QWK	IV SubQ	IV SubQ	Log Forms				1.3	QWK	QWK					70	250	1
MMRF_1151	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DEATH	Other	40	mg	mg	QWK	QWK	IV	IV	Log Forms				40	QWK	QWK					71	250	1
MMRF_1156	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	84	1
MMRF_1156	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			INDUCTION	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	204	1
MMRF_1156	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			INDUCTION	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	204	1
MMRF_1156	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					315	1358	1
MMRF_1156	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					315	1368	1
MMRF_1156	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			INDUCTION	Other	300	mg	mg	DAYS 1 , 8,  15	Other	PO	PO	Log Forms	Induction	Induction		300	Other	DAYS 1 , 8,  15					87	204	1
MMRF_1156	First line of therapy	First Line Therapy	Induction	Induction	ETOPOSIDE	Other			INDUCTION	Other	30	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		30	QD (D1-4)	QD (D1-4)					143	204	1
MMRF_1156	First line of therapy	First Line Therapy	Induction	Induction	CISPLATIN	Other			INDUCTION	Other	15	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		15	QD (D1-4)	QD (D1-4)					143	204	1
MMRF_1156	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Lack of response	Lack of response	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					211	211	1
MMRF_1156	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	ATEZOLIZUMAB	Other			Disease progression/Relapse	Disease progression/Relapse	1200	mg	mg	QWK	QWK	IV	IV	Log Forms	Consolidation	Consolidation		1200	QWK	QWK					1746	1893	1
MMRF_1156	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					1746	1991	1
MMRF_1156	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	3	QD (D1-21)	QD (D1-21)					1982		1
MMRF_1156	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			20	MG/ML	Other	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	20	Other	EVERY OTHER WEEK					1924		1
MMRF_1156	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	4 CYCLES	Other	IV	IV	Log Forms	Induction	Induction		20	Other	4 CYCLES					1642	1829	1
MMRF_1156																		Log Forms													1
MMRF_1157	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Maintenance	Maintenance	GSK2857916	Other		0	Disease progression/Relapse	Disease progression/Relapse	107.4	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		107.4	QWK	QWK					2271	2397	1
MMRF_1157	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Maintenance	Maintenance	ONC 201	Other		0	Disease progression/Relapse	Disease progression/Relapse								Log Forms	Maintenance	Maintenance									2445	2466	1
MMRF_1157	Tenth Line of Therapy (following 9th relapse)	Tenth Line of Therapy (following 9th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		20	QWK	QWK					2508	2634	1
MMRF_1157	Tenth Line of Therapy (following 9th relapse)	Tenth Line of Therapy (following 9th relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	10	mg	mg	QID	QID	PO	PO	Log Forms	Maintenance	Maintenance		10	QID	QID					2511	2619	1
MMRF_1157	Tenth Line of Therapy (following 9th relapse)	Tenth Line of Therapy (following 9th relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Completed regimen	Completed regimen	20	MG/ML	Other	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		20	QWK	QWK					2508	2634	1
MMRF_1157	Eleventh Line of Therapy (following 10th relapse)	Eleventh Line of Therapy (following 10th relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		0	Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	ONCE A WEEK ON DAYS 1, 8 AND 15 OF A 28-DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		3	Other	ONCE A WEEK ON DAYS 1, 8 AND 15 OF A 28-DAY CYCLE					2634	2739	1
MMRF_1157	Eleventh Line of Therapy (following 10th relapse)	Eleventh Line of Therapy (following 10th relapse)	Maintenance	Maintenance	ONC 201	Other		0	Disease progression/Relapse	Disease progression/Relapse								Log Forms	Maintenance	Maintenance									2634	2746	1
MMRF_1157	Eleventh Line of Therapy (following 10th relapse)	Eleventh Line of Therapy (following 10th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	ON DAYS 1, 8, 15 OF A 28 DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	ON DAYS 1, 8, 15 OF A 28 DAY CYCLE					2634	2739	1
MMRF_1157	Twelfth Line of Therapy (following 11th relapse)	Twelfth Line of Therapy (following 11th relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			900	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance	Checked	900	QWK	QWK					2746		1
MMRF_1157	Twelfth Line of Therapy (following 11th relapse)	Twelfth Line of Therapy (following 11th relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		1			2	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	2	QWK	QWK					2746		1
MMRF_1157	Twelfth Line of Therapy (following 11th relapse)	Twelfth Line of Therapy (following 11th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance	Checked	20	QWK	QWK					2746		1
MMRF_1157	Twelfth Line of Therapy (following 11th relapse)	Twelfth Line of Therapy (following 11th relapse)	Maintenance	Maintenance	VENETOCLAX	Other		1			100	mg	mg	QID	QID	PO	PO	Log Forms	Maintenance	Maintenance	Checked	100	QID	QID					2739		1
MMRF_1157	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	240	1
MMRF_1157	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			FURTHER THERAPY	Other	300	mg/m^2	mg/m^2	DAYS 1, 8	Other	IV	IV	Log Forms				300	Other	DAYS 1, 8					1	43	1
MMRF_1157	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			SCH	Other	1.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	156	1
MMRF_1157	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			INCREASED DOSE	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					43	71	1
MMRF_1157	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			INDUCTION	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					71	222	1
MMRF_1157	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					326	442	1
MMRF_1157	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					415	556	1
MMRF_1157	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					415	527	1
MMRF_1157	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		140	Other	ONCE					240	240	1
MMRF_1157	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	33	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		33	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					591	682	1
MMRF_1157	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	IBRUTINIB	Other			Disease progression/Relapse	Disease progression/Relapse	140	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		140	Q day	Q day					598	682	1
MMRF_1157	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					682	921	1
MMRF_1157	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					682	921	1
MMRF_1157	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	D1, 18,15, 22	Other	IV	IV	Log Forms	Consolidation	Consolidation		16	Other	D1, 18,15, 22					960	1578	1
MMRF_1157	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					960	969	1
MMRF_1157	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		3	QD (D1-21)	QD (D1-21)					990	1578	1
MMRF_1157	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	SELINEXOR	Other			Disease progression/Relapse	Disease progression/Relapse	80	mg	mg	DAYS 1, 3, 8, 10, 15, 17, 22 AND 24	Other	PO	PO	Log Forms	Consolidation	Consolidation		80	Other	DAYS 1, 3, 8, 10, 15, 17, 22 AND 24					1626	1836	1
MMRF_1157	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	D1,3,8,10,15,17,22,24	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	D1,3,8,10,15,17,22,24					1626	1836	1
MMRF_1157	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	TAS4464	Other			Disease progression/Relapse	Disease progression/Relapse	40	mg/m^2	mg/m^2	TWICE WEEKLY	Other	IV	IV	Log Forms	Unknown	Unknown		40	Other	TWICE WEEKLY					1870	1927	1
MMRF_1157	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	ONCE WEEKLY	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	ONCE WEEKLY					1944	2097	1
MMRF_1157	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	ONCE WEEKLY	Other	IV	IV	Log Forms	Unknown	Unknown		27	Other	ONCE WEEKLY					1944	2097	1
MMRF_1157	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	ONCE WEEKLY	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	20	Other	ONCE WEEKLY					1944		1
MMRF_1157	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	JNJ-64407564	Other		1			1.5	UG/KG	Other	DAY 1 AND DAY 15 ON 28 DAY CYCLE	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	1.5	Other	DAY 1 AND DAY 15 ON 28 DAY CYCLE					2130		1
MMRF_1179	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.3	Q week	Q week					1	269	1
MMRF_1179	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					1	20	1
MMRF_1179	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					1	715	1
MMRF_1179	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	400	mg	mg	QWK (DAY 1, 8, 15)	Other	PO	PO	Log Forms	Consolidation	Consolidation		400	Other	QWK (DAY 1, 8, 15)					687	715	1
MMRF_1179	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					715	1024	1
MMRF_1179	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Thalidomide	Thalidomide			Completed regimen	Completed regimen	50	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		50	QD (D1-21)	QD (D1-21)					843	1024	1
MMRF_1179	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		16	Q week	Q week					1087	1709	1
MMRF_1179	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Ixazomib	Ixazomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		3	Q week	Q week					1767	1773	1
MMRF_1179	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					1356	1693	1
MMRF_1179	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	VENETOCLAX	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	100	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		100	Q day	Q day					1732	1773	1
MMRF_1212	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	233	1
MMRF_1212	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	D1,D8	Other	IV	IV	Log Forms				300	Other	D1,D8					1	148	1
MMRF_1212	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (1-28)	Other	PO	PO	Log Forms				20	Other	QD (1-28)					1	176	1
MMRF_1212	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					120	127	1
MMRF_1212	First line of therapy	First Line Therapy			Thalidomide	Thalidomide		1			50	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms			Checked	50	QD (D1-21)	QD (D1-21)					176		1
MMRF_1212	First line of therapy	First Line Therapy	Consolidation	Consolidation	Prednisone	Prednisone		1			50	mg	mg	3 X WEEK	Other	PO	PO	Log Forms	Consolidation	Consolidation	Checked	50	Other	3 X WEEK					176		1
MMRF_1212	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			LOST TO FOLLOW UP	Other	50	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		50	BID	BID					148	947	1
MMRF_1212	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Other	EVERY OTHER WEEK					233	657	1
MMRF_1223	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					7	334	1
MMRF_1223	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			FURTHER THERAPY	Other	300	mg/m^2	mg/m^2	DAYS 1, 8	Other	IV SubQ	IV SubQ	Log Forms				300	Other	DAYS 1, 8					7	95	1
MMRF_1223	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms				4	QD (D1-4)	QD (D1-4)					1	508	1
MMRF_1223	First line of therapy	First Line Therapy			Thalidomide	Thalidomide			FURTHER THERAPY	Other	200	mg	mg	Q day	Q day	PO	PO	Log Forms				200	Q day	Q day					7	95	1
MMRF_1223	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					95	606	1
MMRF_1223	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONE TIME ONLY	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONE TIME ONLY					606	606	1
MMRF_1223	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Lack of response	Lack of response	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					742	839	1
MMRF_1223	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Consolidation	Consolidation		16	QWK	QWK					942	1453	1
MMRF_1223	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1, 2, 4, 5, 8, 9, 15	Other	IV	IV	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1, 2, 4, 5, 8, 9, 15					942	1453	1
MMRF_1223	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1476	2010	1
MMRF_1223	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		8	Q week	Q week					1481	2020	1
MMRF_1223	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	MG/KG	Other	TWICE MONTHLY	Other	IV	IV	Log Forms	Consolidation	Consolidation		16	Other	TWICE MONTHLY					1509	2020	1
MMRF_1223	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1593	2020	1
MMRF_1223	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		1			20	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE	Checked	20	Q week	Q week					2042		1
MMRF_1223	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	DAYS 1,2,8,9,15,16,22,23	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	DAYS 1,2,8,9,15,16,22,23					2042		1
MMRF_1223	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	SELINEXOR	Other		0	TREATMENT FAILURE WITH FORMULARY ALTERNATIVE	Other	100	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		100	Q week	Q week					2042	2204	1
MMRF_1223	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	60	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		60	QWK	QWK					2303	2373	1
MMRF_1223	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Maintenance	Maintenance	VENETOCLAX	Other		0	Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	QID	QID	PO	PO	Log Forms	Maintenance	Maintenance		100	QID	QID					2297	2316	1
MMRF_1223	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		4	QWK	QWK					2303	2359	1
MMRF_1223	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab		0	Disease progression/Relapse	Disease progression/Relapse	735	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		735	QWK	QWK					2380	2471	1
MMRF_1223	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	5 TIMES A WEEK	Other	PO	PO	Log Forms	Maintenance	Maintenance		2	Other	5 TIMES A WEEK					2365	2465	1
MMRF_1223	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Maintenance	Maintenance	Panobinostat	Panobinostat		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	EVERY MON, WED, & FRI	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	EVERY MON, WED, & FRI					2364	2464	1
MMRF_1223	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Maintenance	Maintenance	IBRANCE	Other		0	Disease progression/Relapse	Disease progression/Relapse	75	mg	mg	QID	QID	PO	PO	Log Forms	Maintenance	Maintenance		75	QID	QID					2364	2464	1
MMRF_1223	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Induction	Induction	BCNU	BCNU		0	Disease progression/Relapse	Disease progression/Relapse	100	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		100	Other	ONCE					2497	2497	1
MMRF_1223	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Induction	Induction	Melphalan	Melphalan		0	Disease progression/Relapse	Disease progression/Relapse	100	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		100	Other	ONCE					2498	2498	1
MMRF_1223	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Maintenance	Maintenance	SELINEXOR	Other		1			60	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance	Checked	60	QWK	QWK					2597		1
MMRF_1224	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Bendamustine	Bendamustine		0	Disease progression/Relapse	Disease progression/Relapse	135	mg	mg	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		135	QWK	QWK					2234	2237	1
MMRF_1224	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0			40	mg	mg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		40	Q week	Q week					2066	2191	1
MMRF_1224	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			SCH	Other	300	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	PO	PO	Log Forms				300	Other	DAYS 1, 8, 15					1	203	1
MMRF_1224	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			SCH	Other	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	203	1
MMRF_1224	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					226	780	1
MMRF_1224	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					226	666	1
MMRF_1224	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					1056	1057	1
MMRF_1224	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	10	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		10	Q week	Q week					1178	1492	1
MMRF_1224	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					1178	1492	1
MMRF_1224	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					1178	1492	1
MMRF_1224	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1526	1890	1
MMRF_1224	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	50	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		50	BID	BID					1525	1890	1
MMRF_1224	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					1525	1890	1
MMRF_1224	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	8	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		8	Q week	Q week					1967	2142	1
MMRF_1224	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		1.3	Q week	Q week					1967	2142	1
MMRF_1224	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1967	2142	1
MMRF_1224	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Doxorubicin	Doxorubicin			Adverse Event or co-morbidity	Adverse Event or co-morbidity	.5	mg/m^2	mg/m^2	DAY 1-28	Other	IV	IV	Log Forms	Other	SALVAGE		0.5	Other	DAY 1-28					2002	2020	1
MMRF_1224	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Vincristine	Vincristine			Adverse Event or co-morbidity	Adverse Event or co-morbidity	.07	mg	mg	DAY 1-28	Other	IV	IV	Log Forms	Other	SALVAGE		0.07	Other	DAY 1-28					2002	2020	1
MMRF_1224	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	Q24H	Other	IV	IV	Log Forms	Other	SALVAGE		12	Other	Q24H					2002	2020	1
MMRF_1224	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	CISPLATIN	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	DAY 1-28	Other	IV	IV	Log Forms	Other	SALVAGE		1	Other	DAY 1-28					2002	2020	1
MMRF_1224	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	8	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		8	Q week	Q week					2107	2193	1
MMRF_1224	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Bortezomib	Bortezomib		0			1.3	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		1.3	Q week	Q week					2066	2172	1
MMRF_1224	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			SCH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	203	1
MMRF_1224	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	METRO28	Other		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	EVERY 8 HOURS	Other	IV	IV	Log Forms	Unknown	Unknown		500	Other	EVERY 8 HOURS					2206	2331	1
MMRF_1231	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			DEATH	Other	300	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				300	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					8	85	1
MMRF_1231	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DEATH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1231	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1232	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	86	1
MMRF_1232	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	86	1
MMRF_1232	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Induction	Induction		300	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					33	101	1
MMRF_1232	First line of therapy	First Line Therapy	Induction	Induction	RECMAGE VACCINE	Other			Completed regimen	Completed regimen	300	MCG	Other	21, 10, 31,52,73, 94, 180, 194, 270, 284, 360, 374 DAYS POST TRANSPLANT	Other	IM	Other	Log Forms	Induction	Induction		300	Other	21, 10, 31,52,73, 94, 180, 194, 270, 284, 360, 374 DAYS POST TRANSPLANT					109	417	1
MMRF_1232	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					522	560	1
MMRF_1232	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					560	707	1
MMRF_1232	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					560	655	1
MMRF_1232	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					655	707	1
MMRF_1232	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					852	951	1
MMRF_1232	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					852	951	1
MMRF_1232	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		3	QD (D1-21)	QD (D1-21)					847	951	1
MMRF_1232	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1-3)	QD (D1-3)	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QD (D1-3)	QD (D1-3)					783	847	1
MMRF_1232	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		40	Q day	Q day					783	847	1
MMRF_1232	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	CISPLATIN	Other			Completed regimen	Completed regimen	17	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Consolidation	Consolidation		17	QD (D1-4)	QD (D1-4)					783	847	1
MMRF_1232	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	336	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Consolidation	Consolidation		336	QD (D1-4)	QD (D1-4)					783	847	1
MMRF_1232	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	ETOPOSIDE	Other			Completed regimen	Completed regimen	34	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Consolidation	Consolidation		34	QD (D1-4)	QD (D1-4)					783	847	1
MMRF_1244	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			UNKNOWN	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	158	1
MMRF_1244	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			UNKNOWN	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	158	1
MMRF_1244	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			UNKNOWN	Other	300	mg/m^2	mg/m^2	DAYS 1, 8	Other	IV SubQ	IV SubQ	Log Forms				300	Other	DAYS 1, 8					1	158	1
MMRF_1252	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	45	1
MMRF_1252	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	45	1
MMRF_1252	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAYS 1, 8	Other	IV	IV	Log Forms				300	Other	DAYS 1, 8					1	45	1
MMRF_1252	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					45	333	1
MMRF_1252	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					45	333	1
MMRF_1252	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					45	333	1
MMRF_1252	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					338	366	1
MMRF_1252	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					338	366	1
MMRF_1266	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	1632	1
MMRF_1266	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D11, D18)	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	QD (D1, D4, D11, D18)					1	1314	1
MMRF_1266	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D11, D18)	Other	PO	PO	Log Forms				20	Other	QD (D1, D4, D11, D18)					1	408	1
MMRF_1266	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib			Completed regimen	Completed regimen	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					1314	1437	1
MMRF_1267	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	272	mg	mg	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		272	Other	ONCE					368	368	1
MMRF_1267	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					472	665	1
MMRF_1267	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					472	563	1
MMRF_1267	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Maintenance	Maintenance		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					472	1066	1
MMRF_1267	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Bendamustine	Bendamustine			Completed regimen	Completed regimen	90	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		90	Other	ONCE					901	901	1
MMRF_1267	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					901	924	1
MMRF_1267	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		40	Q day	Q day					901	945	1
MMRF_1267	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	BCNU	BCNU			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		300	Other	ONCE					945	963	1
MMRF_1267	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		100	Other	ONCE					960	960	1
MMRF_1267	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					985	1016	1
MMRF_1267	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Consolidation	Consolidation	NIVOLUMAB	Other			Disease progression/Relapse	Disease progression/Relapse	6	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		6	Q week	Q week					1010	1016	1
MMRF_1267	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	D1, D8, D15, D22	Other	IV	IV	Log Forms	Consolidation	Consolidation		16	Other	D1, D8, D15, D22					1036	1066	1
MMRF_1267	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1	mg/m^2	mg/m^2	D1,4,7,10,13,16,19,22,25,28	Other	IV	IV	Log Forms	Consolidation	Consolidation		1	Other	D1,4,7,10,13,16,19,22,25,28					1066	1094	1
MMRF_1267	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	12	mg	mg	D1-4, 7-10, 13-16, 19-22, 25-28	Other	PO	PO	Log Forms	Consolidation	Consolidation		12	Other	D1-4, 7-10, 13-16, 19-22, 25-28					1066	1094	1
MMRF_1267	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Consolidation	Consolidation	Thalidomide	Thalidomide			Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		100	Q day	Q day					1066	1094	1
MMRF_1267	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Consolidation	Consolidation	Doxorubicin	Doxorubicin			Disease progression/Relapse	Disease progression/Relapse	1	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		1	Q day	Q day					1066	1094	1
MMRF_1267	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Consolidation	Consolidation	CISPLATIN	Other			Disease progression/Relapse	Disease progression/Relapse	1	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		1	Q day	Q day					1066	1094	1
MMRF_1267	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	183	1
MMRF_1267	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					2	183	1
MMRF_1267	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	183	1
MMRF_1267	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					191	224	1
MMRF_1267	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					191	224	1
MMRF_1267	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					191	224	1
MMRF_1267	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	540	mg	mg	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		540	Other	ONCE					234	234	1
MMRF_1267	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	.07	mg	mg	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		0.07	Q day	Q day					1066	1094	1
MMRF_1275	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1275	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1275	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	300	mg/m^2	mg/m^2	DAYS 1, 8	Other	IV	IV	Log Forms				300	Other	DAYS 1, 8					1	8	1
MMRF_1275	First line of therapy	First Line Therapy			Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					19	391	1
MMRF_1275	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	8	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms				8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					19	380	1
MMRF_1275	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					19	380	1
MMRF_1275	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					401	401	1
MMRF_1275	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		3	Q week	Q week					557	620	1
MMRF_1275	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					557	663	1
MMRF_1275	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					557	610	1
MMRF_1275	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					638	663	1
MMRF_1275	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					610	663	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					663	695	1
MMRF_1275	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	CISPLATIN	Other			Completed regimen	Completed regimen	67	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Consolidation	Consolidation		67	QD (D1-4)	QD (D1-4)					663	666	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	ETOPOSIDE	Other			Completed regimen	Completed regimen	270	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Consolidation	Consolidation		270	QD (D1-4)	QD (D1-4)					663	667	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2688	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Consolidation	Consolidation		2688	QD (D1-4)	QD (D1-4)					663	667	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		30	Other	ONCE					663	663	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					695	733	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bendamustine	Bendamustine			Disease progression/Relapse	Disease progression/Relapse	90	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		90	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					695	733	1
MMRF_1275	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Disease progression/Relapse	Disease progression/Relapse	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					792	848	1
MMRF_1280	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	351	1
MMRF_1280	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	351	1
MMRF_1280	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	580	mg/dL	mg/dL	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				580	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	37	1
MMRF_1280	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					37	351	1
MMRF_1280	First line of therapy	First Line Therapy	Consolidation	Consolidation	Prednisone	Prednisone			Completed regimen	Completed regimen	60	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		60	Q day	Q day					401	429	1
MMRF_1280	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					350	350	1
MMRF_1280	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Maintenance	Maintenance		1.3	Q week	Q week					589	645	1
MMRF_1280	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	300	mg/m^2	mg/m^2	3 OF 4 WEEKS	Other	IV	IV	Log Forms	Consolidation	Consolidation		300	Other	3 OF 4 WEEKS					997	1193	1
MMRF_1280	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	3 OF 4 WEEKS	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	3 OF 4 WEEKS					997	1193	1
MMRF_1280	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					1024	1193	1
MMRF_1280	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Thalidomide	Thalidomide			Patient decision	Patient decision	50	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		50	Q day	Q day					1130	1130	1
MMRF_1280	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab			Completed regimen	Completed regimen	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		16	QWK	QWK					1235	1900	1
MMRF_1280	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	EVERY 2 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Other	EVERY 2 WEEKS					1522	1935	1
MMRF_1280	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	CISPLATIN	Other			Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		10	QD (D1-4)	QD (D1-4)					2089	2093	1
MMRF_1280	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		300	QD (D1-4)	QD (D1-4)					2089	2093	1
MMRF_1280	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					2089	2093	1
MMRF_1280	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SALVAGE		20	QD (D1-4)	QD (D1-4)					2089	2093	1
MMRF_1308	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	232	1
MMRF_1308	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	232	1
MMRF_1308	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV	IV	Log Forms				300	Other	DAYS 1, 8, 15					1	138	1
MMRF_1308	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					26	102	1
MMRF_1308	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					283	563	1
MMRF_1308	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	50	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		50	QD (D1-21)	QD (D1-21)					354	563	1
MMRF_1308	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Panobinostat	Panobinostat			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					563	1670	1
MMRF_1308	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	D1, D8, D15	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	D1, D8, D15					283	563	1
MMRF_1308	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					563	1670	1
MMRF_1308	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					563	1670	1
MMRF_1308	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		1			27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1328		1
MMRF_1308	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	ISATUXIMAB	Other		1			10	mg/kg	mg/kg	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	10	Other	EVERY OTHER WEEK					1693		1
MMRF_1308	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			10	mg	mg	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	10	Other	EVERY OTHER WEEK					1693		1
MMRF_1307	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1142	1
MMRF_1307	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					11	1724	1
MMRF_1307	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	D1,8,15,22	Other	PO	PO	Log Forms				40	Other	D1,8,15,22					11	1724	1
MMRF_1307	First line of therapy	First Line Therapy	Induction	Induction	Ixazomib	Ixazomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	EVERY OTHER WEEK	Other	PO	PO	Log Forms	Induction	Induction		4	Other	EVERY OTHER WEEK					1142	1724	1
MMRF_1314	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1428	1
MMRF_1314	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	D1, D8	Other	IV	IV	Log Forms				300	Other	D1, D8					1	15	1
MMRF_1314	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1428	1
MMRF_1314	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					15	1428	1
MMRF_1311	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	242	1
MMRF_1311	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	252	1
MMRF_1311	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	242	1
MMRF_1311	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	450	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		450	Q day	Q day					281	281	1
MMRF_1311	First line of therapy	First Line Therapy	CONDITIONING	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.6	mg	mg	Q day	Q day	IV SubQ	IV SubQ	Log Forms	Other	CONDITIONING		3.6	Q day	Q day					441	441	1
MMRF_1311	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	446	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		446	Q day	Q day					443	443	1
MMRF_1324	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					4	424	1
MMRF_1324	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	334	1
MMRF_1324	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			INDUCTION	Other	300	mg/m^2	mg/m^2	ONCE	Other	PO	PO	Log Forms				300	Other	ONCE					1	3	1
MMRF_1324	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			SCH	Other	300	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms				300	Q week	Q week					92	124	1
MMRF_1324	First line of therapy	First Line Therapy	Maintenance	Maintenance	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	50	mg	mg	ONCE	Other	PO	PO	Log Forms	Maintenance	Maintenance		50	Other	ONCE					323	607	1
MMRF_1324	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					774	774	1
MMRF_1324	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					623	680	1
MMRF_1324	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	50	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		50	Q week	Q week					623	730	1
MMRF_1324	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		10	Q week	Q week					623	1310	1
MMRF_1324	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					680	730	1
MMRF_1324	First line of therapy	First Line Therapy	ASCT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	ASCT		200	Other	ONCE					775	775	1
MMRF_1324	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					880	1446	1
MMRF_1324	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QOW	Other	IV	IV	Log Forms	Maintenance	Maintenance		27	Other	QOW					953	1310	1
MMRF_1324	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0			56	mg/m^2	mg/m^2	QOW	Other	IV	IV	Log Forms	Unknown	Unknown		56	Other	QOW					1310	2427	1
MMRF_1324	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0			8	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		8	Q week	Q week					1310	2199	1
MMRF_1324	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	607	1
MMRF_1345	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	218	1
MMRF_1345	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					9	73	1
MMRF_1345	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	218	1
MMRF_1345	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	D1,8	Other	IV	IV	Log Forms	Induction	Induction		300	Other	D1,8					95	218	1
MMRF_1345	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					219	219	1
MMRF_1345	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	250	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		250	Q week	Q week					911	1086	1
MMRF_1345	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					911	1086	1
MMRF_1345	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					911	1598	1
MMRF_1345	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1086	1598	1
MMRF_1345	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					1674	1751	1
MMRF_1345	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		10	QD (D1-21)	QD (D1-21)					1674	1751	1
MMRF_1345	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1674	1751	1
MMRF_1345	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1774	1810	1
MMRF_1345	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1774	1810	1
MMRF_1345	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1774	1810	1
MMRF_1345	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1819	1823	1
MMRF_1345	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		300	QD (D1-4)	QD (D1-4)					1819	1823	1
MMRF_1345	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	ETOPOSIDE	Other			Disease progression/Relapse	Disease progression/Relapse	30	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1819	1823	1
MMRF_1345	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	CISPLATIN	Other			Disease progression/Relapse	Disease progression/Relapse	15	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		15	QD (D1-4)	QD (D1-4)					1819	1823	1
MMRF_1345	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Q week	Q week					1926		1
MMRF_1345	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	NIVOLUMAB	Other		1			240	mg	mg	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	240	Other	EVERY OTHER WEEK					1828		1
MMRF_1345	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	3	QD (D1-21)	QD (D1-21)					1828		1
MMRF_1352	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	WEEKLY X 4 WEEKS	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	WEEKLY X 4 WEEKS					1	218	1
MMRF_1352	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg/dL	mg/dL	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	190	1
MMRF_1352	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	WEEKLY X 4 WEEKS	Other	PO	PO	Log Forms				40	Other	WEEKLY X 4 WEEKS					1	233	1
MMRF_1352	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					267	267	1
MMRF_1352	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	D1 AND 8	Other	IV	IV	Log Forms	Consolidation	Consolidation		300	Other	D1 AND 8					190	218	1
MMRF_1352	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					374	1102	1
MMRF_1352	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	3 WEEKS ON AND 1 WEEK OFF	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	3 WEEKS ON AND 1 WEEK OFF					374	1102	1
MMRF_1352	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	8	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		8	QD (D1-21)	QD (D1-21)					1102	1515	1
MMRF_1352	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1102	1515	1
MMRF_1354	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_1354	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_1354	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			FURTHER THERAPY	Other	520	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				520	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	22	1
MMRF_1354	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					22	389	1
MMRF_1354	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Prednisone	Prednisone			Lack of response	Lack of response	10	mg	mg	3 TIMES A WEEK	Other	PO	PO	Log Forms	Induction	Induction		10	Other	3 TIMES A WEEK					391	1175	1
MMRF_1354	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Elotuzumab	Elotuzumab		1			10	mg/kg	mg/kg	DAY 1 AND 15 OF 21 DAY CYCLE	Other	IV	IV	Log Forms	Induction	Induction	Checked	10	Other	DAY 1 AND 15 OF 21 DAY CYCLE					1089		1
MMRF_1354	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Prednisone	Prednisone		1			100	mg	mg	DAY 1, 8, 15	Other	PO	PO	Log Forms	Consolidation	Consolidation	Checked	100	Other	DAY 1, 8, 15					1175		1
MMRF_1354	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	15	QD (D1-21)	QD (D1-21)					1175		1
MMRF_1089	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	547	1
MMRF_1089	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms				40	Other	DAYS 1, 8, 15					1	547	1
MMRF_1089	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					547		1
MMRF_1387	First line of therapy	First Line Therapy			Bortezomib	Bortezomib		1			1.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms			Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1387	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide		1			300	mg/m^2	mg/m^2	D1, D8	Other	IV	IV	Log Forms			Checked	300	Other	D1, D8					1		1
MMRF_1387	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		1			40	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms			Checked	40	Other	DAYS 1, 8, 15					1		1
MMRF_1389	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	78	1
MMRF_1389	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms				1.3	QWK	QWK					1	78	1
MMRF_1389	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms				40	Other	DAYS 1, 8, 15					1	78	1
MMRF_1389	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					183	183	1
MMRF_1391	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			PT MOVING TO FLORIDA.	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IVP	Other	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	148	1
MMRF_1391	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			PATIENT MOVING TO FLORIDA	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	148	1
MMRF_1391	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			PATIENT MOVING TO FLORIDA	Other	20	mg	mg	DAYS 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms				20	Other	DAYS 1,2,4,5,8,9,11,12					1	148	1
MMRF_1391	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	320	mg/dL	mg/dL	ONCE	Other	IV	IV	Log Forms	Induction	Induction		320	Other	ONCE					161	161	1
MMRF_1391	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg/dL	mg/dL	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1026		1
MMRF_1446	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_1446	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	D4,11	Other	IV	IV	Log Forms				300	Other	D4,11					1	11	1
MMRF_1446	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	346	1
MMRF_1446	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					106	346	1
MMRF_1446	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	D1,D8	Other	IV	IV	Log Forms	Consolidation	Consolidation		300	Other	D1,D8					163	190	1
MMRF_1446	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					345	345	1
MMRF_1446	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Disease progression/Relapse	Disease progression/Relapse	50	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		50	Q week	Q week					190	239	1
MMRF_1446	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					239	346	1
MMRF_1446	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					805	1682	1
MMRF_1446	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					106	162	1
MMRF_1446	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					805	1682	1
MMRF_1446	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	ACY-1215	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	160	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		160	QD (D1-21)	QD (D1-21)					805	1682	1
MMRF_1450	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DEATH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	16	1
MMRF_1450	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	16	1
MMRF_1455	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	140	1
MMRF_1455	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		10	Q week	Q week					1	140	1
MMRF_1455	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	140	1
MMRF_1455	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					146	146	1
MMRF_1455	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					252		1
MMRF_1455	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			10	mg	mg	D1,8,15	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	D1,8,15					247		1
MMRF_1454	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.3	Q week	Q week					1	159	1
MMRF_1454	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					160	160	1
MMRF_1454	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Q week	Q week					337	524	1
MMRF_1454	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	159	1
MMRF_1454	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	159	1
MMRF_1474	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	8	1
MMRF_1474	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	947	1
MMRF_1474	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					389	1030	1
MMRF_1474	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	300	mg	mg	ONCE	Other	IV	IV	Log Forms	Induction	Induction		300	Other	ONCE					205	205	1
MMRF_1474	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					389	1030	1
MMRF_1474	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					526	942	1
MMRF_1474	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	ATEZOLIZUMAB	Other			Patient decision	Patient decision	840	mg	mg	D12,D16 OF CYCLE 1 AND D1,D15 OF CYCLES THEREAFTER	Other	IV	IV	Log Forms	Consolidation	Consolidation		840	Other	D12,D16 OF CYCLE 1 AND D1,D15 OF CYCLES THEREAFTER					1188	1457	1
MMRF_1474	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Patient decision	Patient decision	16	mg/kg	mg/kg	D1,8,15,22	Other	IV	IV	Log Forms	Consolidation	Consolidation		16	Other	D1,8,15,22					1187	1457	1
MMRF_1474	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		1			20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1697		1
MMRF_1474	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	3	QD (D1-21)	QD (D1-21)					1691		1
MMRF_1474	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1697		1
MMRF_1479	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	190	1
MMRF_1479	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	TWICE WEEKLY	Other	PO	PO	Log Forms	Induction	Induction		20	Other	TWICE WEEKLY					1	151	1
MMRF_1479	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					5	190	1
MMRF_1479	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					204	204	1
MMRF_1479	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					314	363	1
MMRF_1479	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					314	647	1
MMRF_1479	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					314	1166	1
MMRF_1479	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		4	Q week	Q week					1185	1254	1
MMRF_1479	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Patient decision	Patient decision	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					1185	1254	1
MMRF_1479	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		8	Q week	Q week					1185	1254	1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation	Checked	16	Q week	Q week					1275		1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib		1			20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1275		1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1275		1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	TRAMETINIB	Other			Completed regimen	Completed regimen	2	mg	mg	TID	TID	PO	PO	Log Forms	Consolidation	Consolidation		2	TID	TID					1272	1612	1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1275	1613	1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1613	1713	1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	4	QD (D1-21)	QD (D1-21)					1713		1
MMRF_1479	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	MEKINIST	Other		1			2	mg	mg	THREE TIMES PER WEEK	Other	PO	PO	Log Forms	Consolidation	Consolidation	Checked	2	Other	THREE TIMES PER WEEK					1713		1
MMRF_1502	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		1			16	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation	Checked	16	Q week	Q week					1346	1403	1
MMRF_1502	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	TRAMETINIB	Other			Patient decision	Patient decision	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					1403	1403	1
MMRF_1502	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab		1	Disease progression/Relapse	Disease progression/Relapse	UNK			Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation	Checked		Q week	Q week					1346	1403	1
MMRF_1502	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Patient decision	Patient decision	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1346	1403	1
MMRF_1502	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	47	1
MMRF_1502	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	D1,8	Other	IV	IV	Log Forms	Induction	Induction		300	Other	D1,8					1	47	1
MMRF_1502	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	47	1
MMRF_1502	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					812	1182	1
MMRF_1502	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	28	mg	mg	D1, D8, D15, D22	Other	PO	PO	Log Forms	Consolidation	Consolidation		28	Other	D1, D8, D15, D22					812	1143	1
MMRF_1502	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					218	218	1
MMRF_1502	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		1.3	QWK	QWK					368	764	1
MMRF_1502	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Elotuzumab	Elotuzumab			Completed regimen	Completed regimen	631	mg	mg	D1, D8, D15, D22	Other	IV	IV	Log Forms	Consolidation	Consolidation		631	Other	D1, D8, D15, D22					829	898	1
MMRF_1502	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/dL	mg/dL	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		16	Q week	Q week					1130	1311	1
MMRF_1502	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1130	1311	1
MMRF_1502	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					1130	1311	1
MMRF_1502	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	UNK	Other	IV	IV	Log Forms	Consolidation	Consolidation		20	Other	UNK					1346	1394	1
MMRF_1510	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	TREATMENT AFTER PD	Other	Daratumumab	Daratumumab		1			1800	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Other	TREATMENT AFTER PD	Checked	1800	QWK	QWK					2556		1
MMRF_1510	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	TREATMENT AFTER PD	Other	Carfilzomib	Carfilzomib		1			20	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Other	TREATMENT AFTER PD	Checked	20	Q week	Q week					2556		1
MMRF_1510	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	TREATMENT AFTER PD	Other	Pomalidomide	Pomalidomide		0	Completed regimen	Completed regimen	2	mg	mg	QD (D1-7)	QD (D1-7)	PO	PO	Log Forms	Other	TREATMENT AFTER PD		2	QD (D1-7)	QD (D1-7)					2551	2557	1
MMRF_1510	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	VENETOCLAX	Other		0	Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	QID	QID	PO	PO	Log Forms	Maintenance	Maintenance		100	QID	QID					2283	2436	1
MMRF_1510	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	240	1
MMRF_1510	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	281	1
MMRF_1510	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	726	1
MMRF_1510	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Patient decision	Patient decision	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					726	1447	1
MMRF_1510	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		12	Q week	Q week					245	281	1
MMRF_1510	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1470	1671	1
MMRF_1510	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	DAY 1,8	Other	IV	IV	Log Forms	Consolidation	Consolidation		300	Other	DAY 1,8					1481	1516	1
MMRF_1510	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1470	1671	1
MMRF_1510	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					1744	1744	1
MMRF_1513	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	889	1
MMRF_1513	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1, 2, 4, 5, 8, 9, 11 AND 12 EVERY 21 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1, 2, 4, 5, 8, 9, 11 AND 12 EVERY 21 DAY CYCLE					1	889	1
MMRF_1513	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.73	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.73	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	889	1
MMRF_1513	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					904	905	1
MMRF_1513	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	ONCE A WEEK	Other	PO	PO	Log Forms	Maintenance	Maintenance		3	Other	ONCE A WEEK					1022	1639	1
MMRF_1513	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Consolidation	Consolidation		16	QWK	QWK					1646	1717	1
MMRF_1513	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	ATEZOLIZUMAB	Other			Disease progression/Relapse	Disease progression/Relapse	840	mg	mg	QWK	QWK	IV	IV	Log Forms	Consolidation	Consolidation		840	QWK	QWK					1646	1717	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1200	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Consolidation	Consolidation		1200	QD (D1-4)	QD (D1-4)					1722	1722	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	ETOPOSIDE	Other			Completed regimen	Completed regimen	120	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Consolidation	Consolidation		120	QD (D1-4)	QD (D1-4)					1722	1722	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	CISPLATIN	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Consolidation	Consolidation		30	QD (D1-4)	QD (D1-4)					1722	1722	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	TAKE 5 TABLETS BY MOUTH ONCE A WEEK. FOR 3 WEEKS, ONE WEEK BREAK	Other	PO	PO	Log Forms	Consolidation	Consolidation		4	Other	TAKE 5 TABLETS BY MOUTH ONCE A WEEK. FOR 3 WEEKS, ONE WEEK BREAK					1722	1722	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1757	1780	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1757	1780	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1780	1816	1
MMRF_1513	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1780	1816	1
MMRF_1516	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_1516	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone		1			30	mg	mg	TIW (MON,WED,FRI)	Other	PO	PO	Log Forms	Induction	Induction	Checked	30	Other	TIW (MON,WED,FRI)					1		1
MMRF_1622	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	638	1
MMRF_1622	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	638	1
MMRF_1622	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	D1,8	Other	IV	IV	Log Forms	Induction	Induction		10	Other	D1,8					1	18	1
MMRF_1622	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					18	638	1
MMRF_1622	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					306	306	1
MMRF_1622	First line of therapy	First Line Therapy	Induction	Induction	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					638		1
MMRF_1622	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					638	990	1
MMRF_1628	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	404	1
MMRF_1628	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	404	1
MMRF_1628	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					430	1027	1
MMRF_1628	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					430	1027	1
MMRF_1628	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	50	mg	mg	BIW	Other	PO	PO	Log Forms	Induction	Induction		50	Other	BIW					430	500	1
MMRF_1628	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					1158	1158	1
MMRF_1628	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					474	1061	1
MMRF_1628	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1560	1715	1
MMRF_1628	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					1560	1714	1
MMRF_1628	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1560	1714	1
MMRF_1628	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	MEKINIST	Other			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	DAYS MONDAY/THURSDAY X 4/4 WEEKS	Other	PO	PO	Log Forms	Other	SALVAGE		2	Other	DAYS MONDAY/THURSDAY X 4/4 WEEKS					1560	1715	1
MMRF_1628	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1560	1665	1
MMRF_1628	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1748	1762	1
MMRF_1628	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					1748	1762	1
MMRF_1628	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	SALVAGE		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1748	1762	1
MMRF_1634	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DEATH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	16	1
MMRF_1634	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DEATH	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	16	1
MMRF_1634	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	16	1
MMRF_1637	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	206	1
MMRF_1637	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	209	1
MMRF_1637	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	209	1
MMRF_1637	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	422	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	TRANSPLANT		422	Other	ONCE					206	206	1
MMRF_1637	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	D1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Other	D1, 8, 15					337	460	1
MMRF_1637	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					337	596	1
MMRF_1637	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	D1, D8, D15	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	D1, D8, D15					337	596	1
MMRF_1637	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Patient decision	Patient decision	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					597	621	1
MMRF_1637	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					597	621	1
MMRF_1637	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					662	719	1
MMRF_1637	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg	mg	WEEKLY X 3 WEEKS ON/1 WEEK OFF	Other	PO	PO	Log Forms	Consolidation	Consolidation		300	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					662	719	1
MMRF_1637	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	WEEKLY X 3 WEEKS ON/1 WEEK OFF	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					662	719	1
MMRF_1637	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	20	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		20	Q week	Q week					721	838	1
MMRF_1637	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	WEEKLY X 3 WEEKS ON/1 WEEK OFF	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					721	1073	1
MMRF_1637	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					838	901	1
MMRF_1637	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	70	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		70	Q week	Q week					906	1073	1
MMRF_1637	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					964	1073	1
MMRF_1637	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	4 DAYS	Other	IV	IV	Log Forms	Consolidation	Consolidation		300	Other	4 DAYS					662	1090	1
MMRF_1637	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	ETOPOSIDE	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	4 DAYS	Other	IV	IV	Log Forms	Consolidation	Consolidation		30	Other	4 DAYS					1073	1073	1
MMRF_1637	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	CISPLATIN	Other			Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	4 DAYS	Other	IV	IV	Log Forms	Consolidation	Consolidation		10	Other	4 DAYS					1073	1073	1
MMRF_1637	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	4 DAYS	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	4 DAYS					1073	1073	1
MMRF_1637	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					1272	1510	1
MMRF_1637	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Consolidation	Consolidation	Panobinostat	Panobinostat			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1, 3, 5, 8, 10, 12 OF 21 DAY CYCLE	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1, 3, 5, 8, 10, 12 OF 21 DAY CYCLE					1272	1510	1
MMRF_1637	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		16	Q week	Q week					1272	1510	1
MMRF_1637	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1433	1510	1
MMRF_1637	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Consolidation	Consolidation	VENETOCLAX	Other			Disease progression/Relapse	Disease progression/Relapse	400	mg	mg	DAY 1-28	Other	PO	PO	Log Forms	Consolidation	Consolidation		400	Other	DAY 1-28					1433	1510	1
MMRF_1637	First line of therapy	First Line Therapy	Consolidation	Consolidation	Panobinostat	Panobinostat			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	DAYS 1, 3, 5, 8, 10, 12	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1, 3, 5, 8, 10, 12					1289	1346	1
MMRF_1637	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		300	QD (D1-4)	QD (D1-4)					1510	1513	1
MMRF_1637	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1510	1513	1
MMRF_1637	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	CISPLATIN	Other			Completed regimen	Completed regimen	7.5	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		7.5	QD (D1-4)	QD (D1-4)					1510	1513	1
MMRF_1637	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	ADRIAMYCIN	Other			Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		10	QD (D1-4)	QD (D1-4)					1510	1513	1
MMRF_1637	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1510	1513	1
MMRF_1637	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1517	1517	1
MMRF_1637	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		300	QD (D1-4)	QD (D1-4)					1517	1517	1
MMRF_1637	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1517	1517	1
MMRF_1637	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	CISPLATIN	Other			Completed regimen	Completed regimen	7.5	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		7.5	QD (D1-4)	QD (D1-4)					1517	1517	1
MMRF_1637	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	ADRIAMYCIN	Other			Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		10	QD (D1-4)	QD (D1-4)					1517	1517	1
MMRF_1637	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	CARMUSTINE	Other			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	SALVAGE		100	Other	ONCE					1566	1566	1
MMRF_1637	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	SALVAGE		100	Other	ONCE					1567	1567	1
MMRF_1637	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	CISPLATIN	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1702	1705	1
MMRF_1637	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1200	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		1200	QD (D1-4)	QD (D1-4)					1702	1706	1
MMRF_1637	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	120	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		120	QD (D1-4)	QD (D1-4)					1702	1706	1
MMRF_1643	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	632	1
MMRF_1643	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	359	1
MMRF_1643	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	479	1
MMRF_1648	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1648	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-14)	QD (D1-14)					1		1
MMRF_1648	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	DAYS 1,2,4,5,8,9,11 AND 12	Other	PO	PO	Log Forms	Induction	Induction	Checked	20	Other	DAYS 1,2,4,5,8,9,11 AND 12					1		1
MMRF_1665	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	309	1
MMRF_1665	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	309	1
MMRF_1665	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					22	121	1
MMRF_1665	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	D1 AND D8	Other	PO	PO	Log Forms	Induction	Induction		300	Other	D1 AND D8					1	22	1
MMRF_1665	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					309	309	1
MMRF_1665	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DECREASING RENAL FUNCTION	Other	5	mg	mg	MWF 3 WKS ON 1 WK OFF	Other	PO	PO	Log Forms	Induction	Induction		5	Other	MWF 3 WKS ON 1 WK OFF					432	831	1
MMRF_1665	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Investigator decision for other reasons	Investigator decision for other reasons	50	mg	mg	MWF QW	Other	PO	PO	Log Forms	Induction	Induction		50	Other	MWF QW					432	831	1
MMRF_1665	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	EVERY OTHER WEEK					436	932	1
MMRF_1665	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib			Completed regimen	Completed regimen	3	mg	mg	ONCE A WEEK	Other	PO	PO	Log Forms	Maintenance	Maintenance		3	Other	ONCE A WEEK					936	1016	1
MMRF_1665	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	70	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		70	QWK	QWK					1648	1674	1
MMRF_1665	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			POOR TOLERANCE	Other	56	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Other	SALVAGE		56	QWK	QWK					1678	1774	1
MMRF_1677	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	218	1
MMRF_1677	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					2	218	1
MMRF_1677	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					7	26	1
MMRF_1677	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					38	218	1
MMRF_1677	First line of therapy	First Line Therapy	Induction	Induction	Liposomal doxorubicin	Liposomal doxorubicin			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					300	300	1
MMRF_1677	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					218	574	1
MMRF_1677	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					218	313	1
MMRF_1677	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					57	313	1
MMRF_1677	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					300	300	1
MMRF_1677	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	X3/4 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		300	Other	X3/4 WEEKS					148	175	1
MMRF_1677	First line of therapy	First Line Therapy	Consolidation	Consolidation	Elotuzumab	Elotuzumab			Completed regimen	Completed regimen								Log Forms	Consolidation	Consolidation									1121	1282	1
MMRF_1677	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	X3/4 WEEKS	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	X3/4 WEEKS					577	1135	1
MMRF_1677	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Q week	Q week					1375	1674	1
MMRF_1677	First line of therapy	First Line Therapy	Maintenance	Maintenance	VENETOCLAX	Other		1			400	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	400	Q day	Q day					1375		1
MMRF_1677	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1375	1674	1
MMRF_1677	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			10	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q week	Q week					1674		1
MMRF_1686	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PATIENT HAD TRANSPLANT.	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	214	1
MMRF_1686	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PATIENT HAD TRANSPLANT.	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	214	1
MMRF_1686	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	214	1
MMRF_1686	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					224	224	1
MMRF_1686	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			ADMITTED FOR C2 FRACTURE, TREATMENT PUT ON HOLD.	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					85	172	1
MMRF_1686	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			9/10 MATCHED UNRELATED DONOR IDENTIFIED.	Other	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					275	380	1
MMRF_1686	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			9/10 MATCHED UNRELATED DONOR IDENTIFIED.	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					275	380	1
MMRF_1710	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	235	1
MMRF_1710	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	235	1
MMRF_1710	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	235	1
MMRF_1710	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	QWK	QWK					253		1
MMRF_1710	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	QWK	QWK					618		1
MMRF_1710	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	25	QD (D1-21)	QD (D1-21)					580		1
MMRF_1698	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	60	1
MMRF_1698	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	54	1
MMRF_1698	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAYS 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1,2,4,5,8,9,11,12					1	54	1
MMRF_1698	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					127	127	1
MMRF_1698	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					204	270	1
MMRF_1698	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					204	270	1
MMRF_1698	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					204	270	1
MMRF_1698	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					268	900	1
MMRF_1746	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					22	1125	1
MMRF_1746	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	153	1
MMRF_1746	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	153	1
MMRF_1746	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					274	1125	1
MMRF_1746	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					160	160	1
MMRF_1744	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	874	1
MMRF_1744	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAY 1 AND DAY 4	Other	IV	IV	Log Forms	Induction	Induction		300	Other	DAY 1 AND DAY 4					1	321	1
MMRF_1744	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	854	1
MMRF_1744	First line of therapy	First Line Therapy	Induction	Induction	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	DAY 4	Other	IV	IV	Log Forms	Induction	Induction		30	Other	DAY 4					43	64	1
MMRF_1744	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	100	mg	mg	D1-28	Other	PO	PO	Log Forms	Induction	Induction		100	Other	D1-28					30	37	1
MMRF_1744	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	MWF	Other	PO	PO	Log Forms	Induction	Induction		10	Other	MWF					120	854	1
MMRF_1744	First line of therapy	First Line Therapy	Induction	Induction	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	10	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Induction	Induction		10	QWK	QWK					727	867	1
MMRF_1744	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Consolidation	Consolidation		16	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					884	1128	1
MMRF_1744	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		8	Q week	Q week					885	947	1
MMRF_1744	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					875	1156	1
MMRF_1744	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	MONTHLY	Other	IV	IV	Log Forms	Consolidation	Consolidation		16	Other	MONTHLY					1161	1525	1
MMRF_1744	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	NELFINAVIR	Other			Disease progression/Relapse	Disease progression/Relapse	625	mg	mg	BID FOR 14 DAYS	Other	PO	PO	Log Forms	Consolidation	Consolidation		625	Other	BID FOR 14 DAYS					1075	1155	1
MMRF_1744	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					1075	1155	1
MMRF_1744	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1161	1532	1
MMRF_1744	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	VENETOCLAX	Other			Disease progression/Relapse	Disease progression/Relapse	400	mg	mg	QD	Other	PO	PO	Log Forms	Unknown	Unknown		400	Other	QD					1155	1433	1
MMRF_1744	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	QD	Other	IV	IV	Log Forms	Unknown	Unknown		100	Other	QD					1550	1550	1
MMRF_1744	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	QD	Other	IV	IV	Log Forms	Unknown	Unknown		100	Other	QD					1551	1551	1
MMRF_1744	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		20	QWK	QWK					1696	1699	1
MMRF_1744	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	477.5	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Maintenance	Maintenance		477.5	QD (D1-4)	QD (D1-4)					1696	1700	1
MMRF_1744	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	ETOPOSIDE	Other		0	Completed regimen	Completed regimen	48	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Maintenance	Maintenance		48	QD (D1-4)	QD (D1-4)					1696	1700	1
MMRF_1744	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	CISPLATIN	Other		0	Completed regimen	Completed regimen	14.5	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Maintenance	Maintenance		14.5	QD (D1-4)	QD (D1-4)					1696	1700	1
MMRF_1744	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	GSK2857916	Other		0	Disease progression/Relapse	Disease progression/Relapse	222.2	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		222.2	QWK	QWK					1724	1870	1
MMRF_1744	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	GPRC5D	Other		0	Disease progression/Relapse	Disease progression/Relapse	20	MCG/KG	Other	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		20	QWK	QWK					1980	2219	1
MMRF_1744	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	SELINEXOR	Other		0	Disease progression/Relapse	Disease progression/Relapse	80	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		80	QWK	QWK					2226	2305	1
MMRF_1744	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	2.4	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.4	QWK	QWK					2232	2239	1
MMRF_1744	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Ixazomib	Ixazomib		0	Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		3	QWK	QWK					2241	2270	1
MMRF_1768	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	148	1
MMRF_1768	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	148	1
MMRF_1768	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	148	1
MMRF_1768	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					148	148	1
MMRF_1808	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1808	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	DAY 1 AND DAY 8	Other	IV	IV	Log Forms	Induction	Induction		300	Other	DAY 1 AND DAY 8					1	15	1
MMRF_1808	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	174	1
MMRF_1808	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					79	174	1
MMRF_1808	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					33	71	1
MMRF_1808	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Induction	Induction		300	QWK	QWK					79	174	1
MMRF_1808	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					174	174	1
MMRF_1808	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					267	396	1
MMRF_1808	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	30	mg	mg	TIW	Other	PO	PO	Log Forms	Induction	Induction		30	Other	TIW					267	367	1
MMRF_1808	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Consolidation	Consolidation		56	QWK	QWK					367	501	1
MMRF_1808	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					367	501	1
MMRF_1830	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	862	1
MMRF_1830	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAY 1 AND DAY 8	Other	IV	IV	Log Forms	Induction	Induction		300	Other	DAY 1 AND DAY 8					1	79	1
MMRF_1830	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1317	1
MMRF_1830	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					123	1317	1
MMRF_1830	First line of therapy	First Line Therapy	Induction	Induction	Ixazomib	Ixazomib			Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					863	1317	1
MMRF_1830	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib			NONE	Other	3	mg	mg	QOW	Other	PO	PO	Log Forms	Maintenance	Maintenance		3	Other	QOW					1317	1467	1
MMRF_1830	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1317		1
MMRF_1830	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			NONE	Other	8	mg	mg	QOW	Other	PO	PO	Log Forms	Maintenance	Maintenance		8	Other	QOW					1317	1467	1
MMRF_1859	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	161	1
MMRF_1859	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	161	1
MMRF_1859	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	161	1
MMRF_1859	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					234	547	1
MMRF_1859	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QW 3WK ON 1WK OFF	Other	IV	IV	Log Forms	Induction	Induction		300	Other	QW 3WK ON 1WK OFF					234	262	1
MMRF_1859	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					262	945	1
MMRF_1871	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1871	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide		1			300	mg/m^2	mg/m^2	DAY 1, 8, 15	Other	IV	IV	Log Forms	Induction	Induction	Checked	300	Other	DAY 1, 8, 15					1		1
MMRF_1871	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			4	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	4	Q day	Q day					3		1
MMRF_1871	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					166	166	1
MMRF_1921	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	419	1
MMRF_1921	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	34	1
MMRF_1921	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	720	1
MMRF_1921	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1 AND D8)	Other	IV	IV	Log Forms	Induction	Induction		300	Other	QD (D1 AND D8)					34	207	1
MMRF_1921	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					221	221	1
MMRF_1921	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	D1, D15	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	D1, D15					419	720	1
MMRF_1921	First line of therapy	First Line Therapy	Induction	Induction	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		3	Q week	Q week					724	1307	1
MMRF_1921	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		1			20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1342		1
MMRF_1921	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	ISATUXIMAB	Other		1			5	mg/kg	mg/kg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Unknown	Unknown	Checked	5	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1342		1
MMRF_1921	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1342		1
MMRF_1963	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	Q week	Q week					1		1
MMRF_1963	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					1		1
MMRF_1963	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_1992	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	113	1
MMRF_1992	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	430	mg	mg	D 1, 8, 15	Other	IV	IV	Log Forms	Induction	Induction		430	Other	D 1, 8, 15					2	19	1
MMRF_1992	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	JNJ-64407564	Other		0	Disease progression/Relapse	Disease progression/Relapse	2.25	MCG/KG	Other	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		2.25	QWK	QWK					1596	1694	1
MMRF_1992	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	110.88	mg	mg	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		110.88	QWK	QWK					1717	1849	1
MMRF_1992	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	SELINEXOR	Other		0	Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	WEEKLY ON DAYS 1, 8, 15 & 22 OF CYCLE	Other	PO	PO	Log Forms	Unknown	Unknown		100	Other	WEEKLY ON DAYS 1, 8, 15 & 22 OF CYCLE					1717	1843	1
MMRF_1992	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	1500	mg	mg	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		1500	QWK	QWK					1848	2001	1
MMRF_1992	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	73.08	mg	mg	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		73.08	QWK	QWK					1849	2002	1
MMRF_1992	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1-7)	QD (D1-7)	PO	PO	Log Forms	Unknown	Unknown		3	QD (D1-7)	QD (D1-7)					1849	2002	1
MMRF_1992	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		8	QWK	QWK					1849	2002	1
MMRF_1992	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Unknown	Unknown	REGN5458	Other		1			5	mg	mg	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown	Checked	5	QWK	QWK					2217		1
MMRF_1992	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1,2,3,5,6	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1,2,3,5,6					1	111	1
MMRF_1992	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					19	113	1
MMRF_1992	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					166	166	1
MMRF_1992	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					467	659	1
MMRF_1992	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	D1,8,15	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	D1,8,15					467	653	1
MMRF_1992	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Panobinostat	Panobinostat			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1, 3, 5, 15, 17, 19.	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1, 3, 5, 15, 17, 19.					467	655	1
MMRF_1992	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Elotuzumab	Elotuzumab			Investigator decision for other reasons	Investigator decision for other reasons	10	mg/m^2	mg/m^2	D1,8,15,22	Other	IV	IV	Log Forms	Consolidation	Consolidation		10	Other	D1,8,15,22					701	786	1
MMRF_1992	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					701	786	1
MMRF_1992	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1800	mg	mg	D1,8,15,22	Other	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1800	Other	D1,8,15,22					811	961	1
MMRF_1992	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	8	mg	mg	D1,8,15,22	Other	IV	IV	Log Forms	Consolidation	Consolidation		8	Other	D1,8,15,22					701	786	1
MMRF_1992	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		16	Q week	Q week					975	1051	1
MMRF_1992	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					975	1051	1
MMRF_1992	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	IBRUTINIB	Other			Disease progression/Relapse	Disease progression/Relapse	840	mg/dL	mg/dL	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		840	Q day	Q day					1205	1498	1
MMRF_1992	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1198	1493	1
MMRF_1992	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1198	1493	1
MMRF_1992	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1506	1569	1
MMRF_1992	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		300	Q week	Q week					1506	1562	1
MMRF_1992	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1506	1569	1
MMRF_1998	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DEATH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	292	1
MMRF_1998	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	121	1
MMRF_1998	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD D1 AND D8	Other	IV	IV	Log Forms	Induction	Induction		300	Other	QD D1 AND D8					1	85	1
MMRF_1998	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		25	Q day	Q day					162	252	1
MMRF_1998	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	8	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		8	Q week	Q week					162	252	1
MMRF_2000	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2000	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	D1, D8	Other	IV	IV	Log Forms	Induction	Induction		300	Other	D1, D8					1	8	1
MMRF_2000	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2000	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					18	93	1
MMRF_2000	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					126	126	1
MMRF_2000	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					287		1
MMRF_2000	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					287	638	1
MMRF_2000	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			12	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance	Checked	12	Q week	Q week					638		1
MMRF_2000	First line of therapy	First Line Therapy	Consolidation	Consolidation	Elotuzumab	Elotuzumab		1			10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation	Checked	10	Q week	Q week					1178		1
MMRF_2002	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	450	1
MMRF_2002	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	D1, D8	Other	IV	IV	Log Forms	Induction	Induction		300	Other	D1, D8					1	80	1
MMRF_2002	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction	Checked	20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2002	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			15	mg	mg	WD (D1, 4, 11, AND 18)	Other	PO	PO	Log Forms	Induction	Induction	Checked	15	Other	WD (D1, 4, 11, AND 18)					80		1
MMRF_2018	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	29	1
MMRF_2018	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	29	1
MMRF_2018	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	29	1
MMRF_2018	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	ONCE A WEEK. X 3  OUT OF 4 WEEKS,	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	ONCE A WEEK. X 3  OUT OF 4 WEEKS,					29	126	1
MMRF_2018	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Completed regimen	Completed regimen	100	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		100	Q day	Q day					29	211	1
MMRF_2018	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	300	mg/m^2	mg/m^2	D1 AND D8	Other	IV	IV	Log Forms	Induction	Induction		300	Other	D1 AND D8					29	126	1
MMRF_2018	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	WEEKLY X 3 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	WEEKLY X 3 WEEKS					80	1113	1
MMRF_2018	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					126	127	1
MMRF_2018	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					133	316	1
MMRF_2018	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					329	728	1
MMRF_2018	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	70	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		70	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					742	1113	1
MMRF_2018	First line of therapy	First Line Therapy	Induction	Induction	Ixazomib	Ixazomib		1			4	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	4	Q week	Q week					1120		1
MMRF_2081	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	100	1
MMRF_2081	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	100	1
MMRF_2081	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					8	100	1
MMRF_2081	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					373	736	1
MMRF_2081	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	180	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		180	Other	ONCE					179	179	1
MMRF_2081	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					373	736	1
MMRF_2081	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					373	736	1
MMRF_2081	First line of therapy	First Line Therapy	Maintenance	Maintenance	Elotuzumab	Elotuzumab		0	Completed regimen	Completed regimen	10	mg/kg	mg/kg	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Maintenance	Maintenance		10	Other	EVERY OTHER WEEK					736	1814	1
MMRF_2081	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					736	1186	1
MMRF_2081	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	10	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		10	Q week	Q week					736	1186	1
MMRF_2081	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			20	MG/ML	Other	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown	Checked	20	QWK	QWK					1731		1
MMRF_2081	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	TWICE WEEKLY	Other	IV	IV	Log Forms	Unknown	Unknown		36	Other	TWICE WEEKLY					1731	2024	1
MMRF_2081	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			2	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown	Checked	2	Q day	Q day					1717		1
MMRF_2082								1			0							Log Forms			Checked	0									1
MMRF_2082	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	EVERY OTHER WEEK	Other	IVPB	Other	Log Forms	Maintenance	Maintenance	Checked	16	Other	EVERY OTHER WEEK					1307		1
MMRF_2082	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	EVERY OTHER WEEK	Other	IVPB	Other	Log Forms	Maintenance	Maintenance	Checked	20	Other	EVERY OTHER WEEK					1307		1
MMRF_2082	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	284	1
MMRF_2082	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					508	508	1
MMRF_2082	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					437	498	1
MMRF_2082	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					437	498	1
MMRF_2082	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					437	498	1
MMRF_2082	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	284	1
MMRF_2082	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	284	1
MMRF_2107	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	295	1
MMRF_2107	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	1161	1
MMRF_2107	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	1100	1
MMRF_2107	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QOW	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QOW					295	375	1
MMRF_2107	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					1161		1
MMRF_2144	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	68	1
MMRF_2144	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	68	1
MMRF_2144	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAYS 1 AND 8 OF EVERY 21 DAY CYCLE	Other	IV	IV	Log Forms	Induction	Induction		300	Other	DAYS 1 AND 8 OF EVERY 21 DAY CYCLE					1	68	1
MMRF_2144	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					253		1
MMRF_2176	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	Q week	Q week					1		1
MMRF_2176	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	1348	1
MMRF_2176	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_2180	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	102	1
MMRF_2180	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	10	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		10	Q week	Q week					1	176	1
MMRF_2180	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	176	1
MMRF_2180	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	50	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		50	Q week	Q week					102	176	1
MMRF_2180	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					176	380	1
MMRF_2180	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	5	mg	mg	TIW	Other	PO	PO	Log Forms	Induction	Induction		5	Other	TIW					176	380	1
MMRF_2180	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	30	mg	mg	TIW	Other	PO	PO	Log Forms	Induction	Induction		30	Other	TIW					176	380	1
MMRF_2180	First line of therapy	First Line Therapy	Consolidation	Consolidation	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	QOW	Other	IV	IV	Log Forms	Consolidation	Consolidation	Checked	16	Other	QOW					1033		1
MMRF_2180	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		1			4	mg	mg	2 DAYS POST DARA INFUSION	Other	PO	PO	Log Forms	Consolidation	Consolidation	Checked	4	Other	2 DAYS POST DARA INFUSION					1033		1
MMRF_2180	First line of therapy	First Line Therapy	Induction	Induction	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		3	QD (D1-21)	QD (D1-21)					1312	1314	1
MMRF_2180	First line of therapy	First Line Therapy	Induction	Induction	Pomalidomide	Pomalidomide		1			1	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	1	QD (D1-21)	QD (D1-21)					1340		1
MMRF_2199	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	237	1
MMRF_2199	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					1		1
MMRF_2199	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	15	QD (D1-21)	QD (D1-21)					13		1
MMRF_2199	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	30	mg	mg	MWF	Other	PO	PO	Log Forms	Induction	Induction		30	Other	MWF					237	461	1
MMRF_2207	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	122	1
MMRF_2207	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	122	1
MMRF_2207	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	122	1
MMRF_2207	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					172	172	1
MMRF_2207	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		36	Q week	Q week					323	802	1
MMRF_2207	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation	Checked	20	Q week	Q week					323		1
MMRF_2207	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	15	QD (D1-21)	QD (D1-21)					323		1
MMRF_2207	First line of therapy	First Line Therapy	Consolidation	Consolidation	Ixazomib	Ixazomib		1			3	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation	Checked	3	Q week	Q week					802		1
MMRF_2240	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	D1, D8, D15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1, D8, D15					1	90	1
MMRF_2240	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	300	mg/m^2	mg/m^2	D1 AND D8	Other	PO	PO	Log Forms	Induction	Induction		300	Other	D1 AND D8					1	68	1
MMRF_2240	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	91	1
MMRF_2240	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	WEEKLY X 3 WEEKS ON/1 WEEK OFF	Other	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					91	202	1
MMRF_2240	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					91	202	1
MMRF_2240	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	WEEKLY X 3 WEEKS ON/1 WEEK OFF	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					91	202	1
MMRF_2240	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					202	672	1
MMRF_2240	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					202	672	1
MMRF_2240	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					202	672	1
MMRF_2240	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					733	733	1
MMRF_2240	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab		0			16	mg/m^2	mg/m^2	ONCE WEEKLY	Other	IV	IV	Log Forms	Consolidation	Consolidation		16	Other	ONCE WEEKLY					849	1083	1
MMRF_2240	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide		0			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					846	1141	1
MMRF_2240	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	VENETOCLAX	Other			Disease progression/Relapse	Disease progression/Relapse	400	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		400	Q day	Q day					1015	1128	1
MMRF_2240	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		20	Other	ONCE					1070	1070	1
MMRF_2240	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1071	1128	1
MMRF_2240	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	CYTOXAN	Other			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		300	QD (D1-4)	QD (D1-4)					1136	1140	1
MMRF_2240	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	ETOPOSIDE	Other			Disease progression/Relapse	Disease progression/Relapse	30	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1136	1140	1
MMRF_2240	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	CISPLATIN	Other			Disease progression/Relapse	Disease progression/Relapse	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		10	QD (D1-4)	QD (D1-4)					1136	1140	1
MMRF_2240	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1136	1140	1
MMRF_2240	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	MEKINIST	Other			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	TIW	Other	PO	PO	Log Forms	Induction	Induction		2	Other	TIW					1037	1128	1
MMRF_2240	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	VENETOCLAX	Other			Completed regimen	Completed regimen	800	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		800	Q day	Q day					1176	1251	1
MMRF_2240	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	X3/4 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	X3/4 WEEKS					1176	1544	1
MMRF_2240	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	VENETOCLAX	Other		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	125	mg	mg	M-F UNTIL MARCH 2018, THEN MWF	Other	PO	PO	Log Forms	Unknown	Unknown		125	Other	M-F UNTIL MARCH 2018, THEN MWF					1176	1544	1
MMRF_2289	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	239	1
MMRF_2289	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	D1-D14	Other	PO	PO	Log Forms	Induction	Induction		25	Other	D1-D14					1	239	1
MMRF_2289	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1, D2, D4, D5, D8, D9, D10, D11	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1, D2, D4, D5, D8, D9, D10, D11					1	239	1
MMRF_2289	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					239	358	1
MMRF_2289	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					359	431	1
MMRF_2289	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Consolidation	Consolidation		300	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					359	431	1
MMRF_2289	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		40	QD (D1-21)	QD (D1-21)					359	431	1
MMRF_2289	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					442	442	1
MMRF_2289	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					550	1033	1
MMRF_2289	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	SAR650984 ISATUXIMAB	Other		1			10	mg/kg	mg/kg	D1, 15	Other	IV	IV	Log Forms	Induction	Induction	Checked	10	Other	D1, 15					1047		1
MMRF_2289	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		1			27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1047		1
MMRF_2289	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	D1, 15	Other	IV	IV	Log Forms	Induction	Induction	Checked	20	Other	D1, 15					1047		1
MMRF_2289	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			4	mg	mg	D2, 8, 9, 16	Other	PO	PO	Log Forms	Induction	Induction	Checked	4	Other	D2, 8, 9, 16					1047		1
MMRF_2341	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	85	1
MMRF_2341	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	85	1
MMRF_2341	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	85	1
MMRF_2344	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_2344	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	300	mg	mg	D1, D8	Other	IV	IV	Log Forms	Induction	Induction		300	Other	D1, D8					1	22	1
MMRF_2344	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	596	1
MMRF_2344	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					219	328	1
MMRF_2344	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					22	175	1
MMRF_2344	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	300	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		300	Q week	Q week					106	267	1
MMRF_2344	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	250	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		250	Q week	Q week					279	328	1
MMRF_2344	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		15	Q day	Q day					279	328	1
MMRF_2344	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Completed regimen	Completed regimen	16	mg/kg	mg/kg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Unknown	Unknown		16	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					338	568	1
MMRF_2344	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					338	568	1
MMRF_2344	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					572	572	1
MMRF_2344	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab		1			10	mg/kg	mg/kg	UNKNOWN	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	10	Other	UNKNOWN					1241		1
MMRF_2344	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	2	QD (D1-21)	QD (D1-21)					1241		1
MMRF_2344	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			4	mg	mg	WEEKLY ON POM WEEKS THAT PATIENT DOES NOT RECEIVE ELOTUZUMAB	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	4	Other	WEEKLY ON POM WEEKS THAT PATIENT DOES NOT RECEIVE ELOTUZUMAB					1241		1
MMRF_2353	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	DAY 1, 8 , 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1, 8 , 15					1	127	1
MMRF_2353	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAY 1, 8, 15	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15					1	127	1
MMRF_2353	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	288	1
MMRF_2353	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					443	443	1
MMRF_2353	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	WEEKLY	Other	PO	PO	Log Forms	Induction	Induction		500	Other	WEEKLY					176	394	1
MMRF_2353	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					176	394	1
MMRF_2353	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	WEEKLY	Other	PO	PO	Log Forms	Induction	Induction		20	Other	WEEKLY					176	394	1
MMRF_2366	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	D 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D 1, 8, 15					1	42	1
MMRF_2366	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	250	mg/m^2	mg/m^2	D 1, 8 15	Other	IV	IV	Log Forms	Induction	Induction		250	Other	D 1, 8 15					1	42	1
MMRF_2366	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	D 1, 8, 15	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D 1, 8, 15					1	42	1
MMRF_2366	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.32	mg/m^2	mg/m^2	D 1,8,15	Other	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.32	Other	D 1,8,15					80	261	1
MMRF_2366	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					80	164	1
MMRF_2366	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAY 1,8,15	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	DAY 1,8,15					80	261	1
MMRF_2366	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Bendamustine	Bendamustine			Disease progression/Relapse	Disease progression/Relapse	70	mg/m^2	mg/m^2	DAYS 1, 4	Other	IV	IV	Log Forms	Unknown	Unknown		70	Other	DAYS 1, 4					261	287	1
MMRF_2366	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	DAY 1, 4	Other	IV	IV	Log Forms	Consolidation	Consolidation		1.3	Other	DAY 1, 4					261	287	1
MMRF_2366	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAY 1, 4	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	DAY 1, 4					261	287	1
MMRF_2366	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib		1			20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					324		1
MMRF_2366	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1, 8, 15	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	D1, 8, 15					324	387	1
MMRF_2366	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	D2, 9, 16	Other	PO	PO	Log Forms	Consolidation	Consolidation		4	Other	D2, 9, 16					324	387	1
MMRF_2366	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		1			4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					387		1
MMRF_2373	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	D 1, 4 , 11, 18	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D 1, 4 , 11, 18					1	146	1
MMRF_2373	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	146	1
MMRF_2373	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	D 1, 4, 11 , 18	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D 1, 4, 11 , 18					1	146	1
MMRF_2373	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					274	351	1
MMRF_2373	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					274	515	1
MMRF_2373	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					274	515	1
MMRF_2373	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					361	515	1
MMRF_2404	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	WEEKLY X 3 WEEKS ON / 1 WEEK OFF	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	WEEKLY X 3 WEEKS ON / 1 WEEK OFF					1	29	1
MMRF_2404	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	DAYS 1 ,8	Other	IV	IV	Log Forms	Induction	Induction		300	Other	DAYS 1 ,8					1	29	1
MMRF_2404	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	WEEKLY X 3 WEEKS ON / 1 WEEK OFF	Other	PO	PO	Log Forms	Induction	Induction		40	Other	WEEKLY X 3 WEEKS ON / 1 WEEK OFF					1	29	1
MMRF_2404	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					103	103	1
MMRF_2404	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		40	Q day	Q day					33	202	1
MMRF_2404	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	400	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Consolidation	Consolidation		400	QD (D1-4)	QD (D1-4)					33	202	1
MMRF_2404	First line of therapy	First Line Therapy	Consolidation	Consolidation	CISPLATIN	Other			Disease progression/Relapse	Disease progression/Relapse	15	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Consolidation	Consolidation		15	QD (D1-4)	QD (D1-4)					33	202	1
MMRF_2404	First line of therapy	First Line Therapy	Consolidation	Consolidation	ETOPOSIDE	Other			Disease progression/Relapse	Disease progression/Relapse	40	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		40	Q day	Q day					33	202	1
MMRF_2404	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		25	Q day	Q day					207	245	1
MMRF_2404	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		27	Q day	Q day					207	245	1
MMRF_2404	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		10	Q day	Q day					207	245	1
MMRF_2410	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2410	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	64	1
MMRF_2410	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_2410	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction	Checked	20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					75		1
MMRF_2445	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.75	mg	mg	2X A WEEK	Other	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		2.75	Other	2X A WEEK					1	361	1
MMRF_2445	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	479	1
MMRF_2445	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					116	479	1
MMRF_2445	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		10	Q week	Q week					585	704	1
MMRF_2445	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-21)	QD (D1-21)					592	691	1
MMRF_2445	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-4)	QD (D1-4)					779	782	1
MMRF_2445	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	CISPLATIN	Other			Completed regimen	Completed regimen	7.5	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Consolidation	Consolidation		7.5	QD (D1-4)	QD (D1-4)					779	782	1
MMRF_2445	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	250	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Consolidation	Consolidation		250	QD (D1-4)	QD (D1-4)					779	782	1
MMRF_2445	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	ETOPOSIDE	Other			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-4)	QD (D1-4)					779	782	1
MMRF_2445	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QOW	Other	IV	IV	Log Forms	Consolidation	Consolidation		16	Other	QOW					802	1110	1
MMRF_2445	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	TRAMETINIB	Other		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	2	QD (D1-21)	QD (D1-21)					1120		1
MMRF_2445	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	DABRAFENIB	Other		1			75	mg	mg	BID	BID	PO	PO	Log Forms	Other	SALVAGE	Checked	75	BID	BID					1120		1
MMRF_2445	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	VENCLEXTA	Other		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	300	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		300	Q day	Q day					1135	1192	1
MMRF_2445	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance	Checked	16	QWK	QWK					1501		1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q24H	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	Q24H					825	828	1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	Q24H	Other	IV	IV	Log Forms	Consolidation	Consolidation		10	Other	Q24H					825	828	1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	CISPLATIN	Other			Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	Q24H	Other	IV	IV	Log Forms	Consolidation	Consolidation		10	Other	Q24H					825	828	1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	ETOPOSIDE	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	Q24H	Other	IV	IV	Log Forms	Consolidation	Consolidation		30	Other	Q24H					825	828	1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		16	Q week	Q week					881	916	1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					881	893	1
MMRF_2457	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Panobinostat	Panobinostat			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	EVERY OTHER DAY.	Other	PO	PO	Log Forms	Consolidation	Consolidation		15	Other	EVERY OTHER DAY.					905	929	1
MMRF_2457	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1051	1058	1
MMRF_2457	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1051	1058	1
MMRF_2457	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1051	1058	1
MMRF_2457	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	WEEKLY X3, 3 WEEKD ON 1/WEEK OFF	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	WEEKLY X3, 3 WEEKD ON 1/WEEK OFF					1	9	1
MMRF_2457	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	331	1
MMRF_2457	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	WEEKLY X 3, 3 WEEKS ON/1 WEEK OFF	Other	PO	PO	Log Forms	Induction	Induction		20	Other	WEEKLY X 3, 3 WEEKS ON/1 WEEK OFF					1	40	1
MMRF_2457	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	1.5	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		1.5	Q week	Q week					40	331	1
MMRF_2457	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	10	mg	mg	THREE TIMES WEEK	Other	PO	PO	Log Forms	Induction	Induction		10	Other	THREE TIMES WEEK					40	162	1
MMRF_2457	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					162	198	1
MMRF_2457	First line of therapy	First Line Therapy	Consolidation	Consolidation	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	THREE TIMES WEEK	Other	PO	PO	Log Forms	Consolidation	Consolidation		10	Other	THREE TIMES WEEK					223	331	1
MMRF_2457	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					369	369	1
MMRF_2457	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	10	mg/m^2	mg/m^2	DAYS 1, 8, 15, 22	Other	IV	IV	Log Forms	Consolidation	Consolidation		10	Other	DAYS 1, 8, 15, 22					587	699	1
MMRF_2457	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg/dL	mg/dL	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					587	699	1
MMRF_2457	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	28	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Consolidation	Consolidation		28	Other	DAYS 1, 8, 15, 22					587	699	1
MMRF_2457	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1800	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1800	Q week	Q week					734	805	1
MMRF_2469	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	235	1
MMRF_2469	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	235	1
MMRF_2469	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					396	396	1
MMRF_2469	First line of therapy	First Line Therapy	Consolidation	Consolidation	Elotuzumab	Elotuzumab			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	DAY 1 OF EVERY 28 DAY CYCLE	Other	IV	IV	Log Forms	Consolidation	Consolidation		20	Other	DAY 1 OF EVERY 28 DAY CYCLE					401	708	1
MMRF_2469	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					736		1
MMRF_2469	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					8	235	1
MMRF_2472	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					1	1086	1
MMRF_2472	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	1	1
MMRF_2472	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction	Checked	40	QWK	QWK					1		1
MMRF_2472	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					36	283	1
MMRF_2472	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	15	QD (D1-21)	QD (D1-21)					283		1
MMRF_2498	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	106	1
MMRF_2498	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	111	1
MMRF_2498	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	111	1
MMRF_2498	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					173	173	1
MMRF_2498	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	TWICE MONTHLY	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	TWICE MONTHLY					288	343	1
MMRF_2498	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	TWICE MONTHLY	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	TWICE MONTHLY					288	343	1
MMRF_2498	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib		0	Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					334	664	1
MMRF_2498	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	MG/ML	Other	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		20	QWK	QWK					1347	1377	1
MMRF_2498	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		2	Q day	Q day					1349	1377	1
MMRF_2498	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QWK	QWK					1410	1878	1
MMRF_2538	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	D1,8,15,22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1,8,15,22					1	727	1
MMRF_2538	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	77	1
MMRF_2538	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	99	1
MMRF_2538	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	30	mg	mg	Q MONDAY, WED, FRIDAY	Other	PO	PO	Log Forms	Induction	Induction		30	Other	Q MONDAY, WED, FRIDAY					162	727	1
MMRF_2538	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	Q 3 WEEKS ON, 1 WEEK OFF	Other	IV	IV	Log Forms	Induction	Induction		300	Other	Q 3 WEEKS ON, 1 WEEK OFF					92	99	1
MMRF_2538	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					162	727	1
MMRF_2538	First line of therapy	First Line Therapy	Induction	Induction	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		10	Q week	Q week					727	977	1
MMRF_2538	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					727	977	1
MMRF_2538	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	MWF	Other	PO	PO	Log Forms	Induction	Induction		10	Other	MWF					727	977	1
MMRF_2538	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0			16	mg/m^2	mg/m^2	D1,8,15,22	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	D1,8,15,22					1075	1326	1
MMRF_2538	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		0			1.3	mg/m^2	mg/m^2	D1,8, 15, 22	Other	IV	IV	Log Forms	Maintenance	Maintenance		1.3	Other	D1,8, 15, 22					1075	1326	1
MMRF_2538	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		16	QWK	QWK					1326	1404	1
MMRF_2538	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		2	QWK	QWK					1326	1404	1
MMRF_2550	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2550	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction	Checked	20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2550	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_2564	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	71	1
MMRF_2564	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		25	Q week	Q week					1	414	1
MMRF_2564	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	71	1
MMRF_2564	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					118	118	1
MMRF_2564	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		16	QWK	QWK					1114	1367	1
MMRF_2564	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD FOR THREE WEEKS, THEN ONE WEEK OFF.	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	QD FOR THREE WEEKS, THEN ONE WEEK OFF.					1110	1367	1
MMRF_2564	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)			Pomalidomide	Pomalidomide		1			3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms			Checked	3	QD (D1-21)	QD (D1-21)					1367		1
MMRF_2564	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)			Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms			Checked	1.3	Q week	Q week					1514		1
MMRF_2564	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)			Daratumumab	Daratumumab		1			16	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms			Checked	16	QWK	QWK					1367		1
MMRF_2577	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0			16	mg/kg	mg/kg	Q ALT WK	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	Q ALT WK					1396	1737	1
MMRF_2577	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	191	1
MMRF_2577	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	200	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		200	Q week	Q week					1	171	1
MMRF_2577	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	792	1
MMRF_2577	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					171	850	1
MMRF_2577	First line of therapy	First Line Therapy	Induction	Induction	Ixazomib	Ixazomib			Completed regimen	Completed regimen	4	mg	mg	D1,8,15	Other	PO	PO	Log Forms	Induction	Induction		4	Other	D1,8,15					185	953	1
MMRF_2577	First line of therapy	First Line Therapy	Induction	Induction	Daratumumab	Daratumumab			Completed regimen	Completed regimen	16	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		16	Q week	Q week					470	703	1
MMRF_2577	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					779	779	1
MMRF_2577	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1151	1375	1
MMRF_2577	First line of therapy	First Line Therapy	Induction	Induction	Ixazomib	Ixazomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	D1,8,15	Other	PO	PO	Log Forms	Induction	Induction		3	Other	D1,8,15					963	1123	1
MMRF_2577	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide		1			747	mg	mg	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown	Checked	747	QWK	QWK					1737		1
MMRF_2577	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			4	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown	Checked	4	QWK	QWK					1737		1
MMRF_2614	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	180	1
MMRF_2614	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	113	1
MMRF_2614	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	155	1
MMRF_2614	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					181	181	1
MMRF_2614	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	50	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		50	QD (D1-21)	QD (D1-21)					142	171	1
MMRF_2614	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	5	mg	mg	M/W/F X 3/4 WEEKS	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	M/W/F X 3/4 WEEKS					300	507	1
MMRF_2614	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	M/W/F X 3/4 WEEKS	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	M/W/F X 3/4 WEEKS					510	1252	1
MMRF_2614	First line of therapy	First Line Therapy	Maintenance	Maintenance	Prednisone	Prednisone			Completed regimen	Completed regimen	30	mg	mg	TIW	Other	PO	PO	Log Forms	Maintenance	Maintenance		30	Other	TIW					35	741	1
MMRF_2614	First line of therapy	First Line Therapy	Maintenance	Maintenance	Prednisone	Prednisone		0	Investigator decision for other reasons	Investigator decision for other reasons	1	mg	mg	TIW	Other	PO	PO	Log Forms	Maintenance	Maintenance		1	Other	TIW					741	1252	1
MMRF_2614	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Elotuzumab	Elotuzumab		0	Investigator decision for other reasons	Investigator decision for other reasons	10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms				10	Q week	Q week					1267	1483	1
MMRF_2614	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RELAPSED	Other	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	RELAPSED		25	QD (D1-21)	QD (D1-21)					1267	1483	1
MMRF_2614	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RELAPSED	Other	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	RELAPSED		20	Q week	Q week					1267	1483	1
MMRF_2614	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)			Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	QOW X 8 DOSES; C7 MONTHLY	Other	IV	IV	Log Forms			Checked	16	Other	QOW X 8 DOSES; C7 MONTHLY					1486		1
MMRF_2614	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)			Pomalidomide	Pomalidomide		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms			Checked	2	QD (D1-21)	QD (D1-21)					1486		1
MMRF_1037	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Patient decision	Patient decision	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					15	88	1
MMRF_1037	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms				40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	88	1
MMRF_1088	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms				40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	13	1
MMRF_1088	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					124	126	1
MMRF_1088	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					109	118	1
MMRF_1088	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IVB	IVB	Log Forms				2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	87	1
MMRF_1102	First line of therapy	First Line Therapy			Thalidomide	Thalidomide			Patient decision	Patient decision	200	mg	mg	Q day	Q day	PO	PO	Log Forms				200	Q day	Q day					28	34	1
MMRF_1102	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					1	13	1
MMRF_1128	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IVB	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	116	1
MMRF_1128	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAY 1 & 8	Other	IV	IV	Log Forms				300	Other	DAY 1 & 8					1	40	1
MMRF_1128	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	DAY 1-2, 4-5, 8-9, 11-12	Other	PO	PO	Log Forms				4	Other	DAY 1-2, 4-5, 8-9, 11-12					1	117	1
MMRF_1128	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Completed regimen	Completed regimen	100	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		100	Q day	Q day					62	147	1
MMRF_1128	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					313	537	1
MMRF_1128	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					537	634	1
MMRF_1128	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Patient decision	Patient decision	5	mg	mg	QOD D1-21	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	QOD D1-21					634	1118	1
MMRF_1128	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					214	215	1
MMRF_1475	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_1735	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/dL	mg/dL	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1735	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	85	1
MMRF_1735	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	85	1
MMRF_1735	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					176	241	1
MMRF_1735	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					241	507	1
MMRF_1735	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					516	1011	1
MMRF_1735	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					516	718	1
MMRF_1735	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					106	107	1
MMRF_1735	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					718	764	1
MMRF_1735	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE	Checked	40	Q week	Q week					1937		1
MMRF_1735	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1940	1953	1
MMRF_1735	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	3.2	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		3.2	Q week	Q week					1955	2074	1
MMRF_1735	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	SWITCHED FREQUENCY TO Q 3 WEEKS	Other	1800	mg	mg	QWK	QWK	IV	IV	Log Forms	Other	SALVAGE		1800	QWK	QWK					1968	2032	1
MMRF_1735	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			1800	mg	mg	W 3 WEEKS	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	1800	Other	W 3 WEEKS					2032		1
MMRF_1735	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	3.3	mg	mg	EVERY 2 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		3.3	Other	EVERY 2 WEEKS					2082	2140	1
MMRF_1061	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			AUTOLOGOUS BONE MARROW TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1061	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			AUTOLOGOUS BONE MARROW TRANSPLANT	Other	20	mg	mg	DAYS 1,2, 4,5, 8, 9, 11, 12	Other	PO	PO	Log Forms				20	Other	DAYS 1,2, 4,5, 8, 9, 11, 12					1	74	1
MMRF_1061	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			AUTOLOGOUS BONE MARROW TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					15	74	1
MMRF_1061	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	240	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		240	Q day	Q day					118	118	1
MMRF_1061	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib		1			43	mg	mg	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Induction	Induction	Checked	43	Other	EVERY OTHER WEEK					2061		1
MMRF_1068	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	78	1
MMRF_1068	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	64	1
MMRF_1068	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms				1.3	QWK	QWK					239	407	1
MMRF_1068	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					239	407	1
MMRF_1068	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QD (D1-7)	QD (D1-7)	PO	PO	Log Forms				4	QD (D1-7)	QD (D1-7)					239	407	1
MMRF_1068	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	DAYS 1 - 7	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAYS 1 - 7					1	78	1
MMRF_1068	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Induction	Induction		20	QWK	QWK					477	535	1
MMRF_1068	First line of therapy	First Line Therapy	MELPHALAN	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MELPHALAN		200	Q day	Q day					127	127	1
MMRF_1065	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1065	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		0		Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	115	1
MMRF_1065	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	DAYS 1,2,3,4,5	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAYS 1,2,3,4,5					1	214	1
MMRF_1065	First line of therapy	First Line Therapy	MALPHALAN	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MALPHALAN		100	Q day	Q day					124	125	1
MMRF_1368	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	282	1
MMRF_1368	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	282	1
MMRF_1368	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	DAYS 1,2,3,4,5	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAYS 1,2,3,4,5					1	282	1
MMRF_1368	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	DAYS 1 - 28	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	DAYS 1 - 28					299		1
MMRF_1368	First line of therapy	First Line Therapy	TRANSPLANT	Other	MOZOBIL	Other			Completed regimen	Completed regimen	26	mg	mg	Q day	Q day	IV SubQ	IV SubQ	Log Forms	Other	TRANSPLANT		26	Q day	Q day					148	150	1
MMRF_1180	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.3	mg	mg	D1, D8, D22	Other	IV	IV	Log Forms				2.3	Other	D1, D8, D22					7	112	1
MMRF_1180	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	50	mg	mg	Q day	Q day	PO	PO	Log Forms				50	Q day	Q day					7	539	1
MMRF_1180	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	PO	PO	Log Forms				40	Q day	Q day					1	125	1
MMRF_1180	First line of therapy	First Line Therapy	TRANSPLANT	Other	ALKERAN	Other			Completed regimen	Completed regimen	215	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	TRANSPLANT		215	Q day	Q day					194	194	1
MMRF_1180	First line of therapy	First Line Therapy	TRANSPLANT	Other	MELPHALAN	Other			Completed regimen	Completed regimen	50	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	TRANSPLANT		50	Q day	Q day					194	194	1
MMRF_1188	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.54	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				2.54	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	800	1
MMRF_1188	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms			Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1		1
MMRF_1188	First line of therapy	First Line Therapy			Bendamustine	Bendamustine			Completed regimen	Completed regimen	156	mg	mg	D1, D2	Other	IV	IV	Log Forms				156	Other	D1, D2					1	234	1
MMRF_1188	First line of therapy	First Line Therapy	Induction	Induction	Elotuzumab	Elotuzumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	778	mg	mg	UNKNOWN	Other	IV	IV	Log Forms	Induction	Induction		778	Other	UNKNOWN					1198	1331	1
MMRF_1188	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					1303	1352	1
MMRF_1188	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	DAYS 1, 8, 15, AND 28/CYCLE	Other	PO	PO	Log Forms	Induction	Induction		3	Other	DAYS 1, 8, 15, AND 28/CYCLE					1479	1647	1
MMRF_1213	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	1638	1
MMRF_1213	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.9	mg	mg	DAYS 1, 4, 8, 22	Other	SUBCUTANEOUS	Other	Log Forms				2.9	Other	DAYS 1, 4, 8, 22					34	217	1
MMRF_1213	First line of therapy	First Line Therapy	Unknown	Unknown	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					210	1251	1
MMRF_1213	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			DEATH	Other	4	mg	mg	DAYS 1,2,3,4,5	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	DAYS 1,2,3,4,5					224	1694	1
MMRF_1213	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	85	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		85	Q day	Q day					1055	1384	1
MMRF_1213	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Elotuzumab	Elotuzumab			LACK OF INSURANCE	Other	993	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		993	QWK	QWK					1271	1450	1
MMRF_1213	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab			DEATH	Other	1364	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		1364	QWK	QWK					1462	1694	1
MMRF_1268	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.7	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms				2.7	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	100	1
MMRF_1268	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	DAYS 1, 2, 8, 15	Other	IV	IV	Log Forms				12	Other	DAYS 1, 2, 8, 15					1	100	1
MMRF_1268	First line of therapy	First Line Therapy			BENDAMUSTINE	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	167	mg	mg	DAYS 1 & 2	Other	IV	IV	Log Forms				167	Other	DAYS 1 & 2					1	87	1
MMRF_1331	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Lack of response	Lack of response	2.8	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUS	Other	Log Forms				2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_1331	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	DAYS 1, 2, 4, 5, 8, 9, 11, AND 12	Other	PO	PO	Log Forms				20	Other	DAYS 1, 2, 4, 5, 8, 9, 11, AND 12					1	99	1
MMRF_1331	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Lack of response	Lack of response	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					1	99	1
MMRF_1331	First line of therapy	First Line Therapy	SECOND LINE OF TREATMENT, PRIOR TO RELAPSE	Other	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SECOND LINE OF TREATMENT, PRIOR TO RELAPSE	Checked	10	QD (D1-21)	QD (D1-21)					102		1
MMRF_1331	First line of therapy	First Line Therapy	SECOND LINE OF TREATMENT, PRIOR TO RELAPSE	Other	Dexamethasone	Dexamethasone		1			4	mg	mg	DAILY 1-10	Other	PO	PO	Log Forms	Other	SECOND LINE OF TREATMENT, PRIOR TO RELAPSE	Checked	4	Other	DAILY 1-10					102		1
MMRF_1487	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	970	1
MMRF_1487	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					1	60	1
MMRF_1487	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	170	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	TRANSPLANT		170	Q day	Q day					184	185	1
MMRF_1487	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	DAYS 1,2,4,5, 8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAYS 1,2,4,5, 8,9,11,12					1	136	1
MMRF_1541	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	36	mg/m^2	mg/m^2	C1-C8: D1, D2, D8, D9, D15, D16, D22	Other	IV	IV	Log Forms	Induction	Induction		36	Other	C1-C8: D1, D2, D8, D9, D15, D16, D22					1	204	1
MMRF_1541																		Log Forms													1
MMRF_1541	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	204	1
MMRF_1541	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	DAY 1, 8, 15, & 22	Other	IV	IV	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15, & 22					1	204	1
MMRF_1541	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		3	QD (D1-21)	QD (D1-21)					379	561	1
MMRF_1541	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	KPT-330	Other			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Maintenance	Maintenance		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					561	645	1
MMRF_1541	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			40	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance	Checked	40	QWK	QWK					889		1
MMRF_1541	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	61	mg	mg	Q day	Q day	IV	IV	Log Forms	Maintenance	Maintenance		61	Q day	Q day					676	860	1
MMRF_1541	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1700	mg	mg	Q day	Q day	IV	IV	Log Forms	Maintenance	Maintenance		1700	Q day	Q day					902	1308	1
MMRF_1541	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1309		1
MMRF_1541	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Induction	Induction	Daratumumab	Daratumumab			Completed regimen	Completed regimen	20	MG/ML	Other	QWK	QWK	IV	IV	Log Forms	Induction	Induction		20	QWK	QWK					1295	1469	1
MMRF_1603	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	280	1
MMRF_1603	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	400	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Induction	Induction		400	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	280	1
MMRF_1603	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1, D8, D15	Other	IV	IV	Log Forms	Induction	Induction		40	Other	D1, D8, D15					1	280	1
MMRF_1603	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					280	403	1
MMRF_1603	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.4	mg	mg	Q day	Q day	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.4	Q day	Q day					731	819	1
MMRF_1603	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			4	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance	Checked	4	Q week	Q week					731		1
MMRF_1664	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	TRANSPLANT		100	Q day	Q day					174	175	1
MMRF_1664	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	5	QD (D1-21)	QD (D1-21)					941		1
MMRF_1664	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			STEM CELL TRANSPLANT	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	116	1
MMRF_1664	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8, 15, 22					17	676	1
MMRF_1664	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	76	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		76	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					17	676	1
MMRF_1664	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					283	940	1
MMRF_1664	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	IV	IV	Log Forms	Consolidation	Consolidation		40	QWK	QWK					283	676	1
MMRF_1664	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	76	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		76	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					283	676	1
MMRF_1719	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					310	419	1
MMRF_1719	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					10	51	1
MMRF_1719	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	DAYS 1,2,4,5, 8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAYS 1,2,4,5, 8,9,11,12					1	197	1
MMRF_1719	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		200	QD (D1-4)	QD (D1-4)					199	203	1
MMRF_1719	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					218	310	1
MMRF_1719	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					218	310	1
MMRF_1719	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					10	197	1
MMRF_1815	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	4	mg	mg	DAYS 1-5	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAYS 1-5					1	117	1
MMRF_1815	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Patient decision	Patient decision	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	117	1
MMRF_1880	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_1880	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	142	1
MMRF_1880	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	DAYS 1,2,3,4,5	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAYS 1,2,3,4,5					1	142	1
MMRF_1880	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	170	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	TRANSPLANT		170	Q day	Q day					188	189	1
MMRF_1949	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	814	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	IV	IV	Log Forms	Induction	Induction		814	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					708	1369	1
MMRF_1949	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					708	1369	1
MMRF_1949	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			1357	mg	mg	C1-C2 (D1, D8, D15, D22), C3-ONGOING (D1, D15)	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	1357	Other	C1-C2 (D1, D8, D15, D22), C3-ONGOING (D1, D15)					1374		1
MMRF_1949	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	68	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		68	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	667	1
MMRF_1949	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					1	400	1
MMRF_1949	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			4	mg	mg	DAYS 1-5	Other	PO	PO	Log Forms	Induction	Induction	Checked	4	Other	DAYS 1-5					1		1
MMRF_1949	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	TRANSPLANT		140	Q day	Q day					184	184	1
MMRF_2216	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAYS 1, 8, 15, 22					1	77	1
MMRF_2216	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					12	385	1
MMRF_2429	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	43	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		43	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	253	1
MMRF_2429	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			40	mg/dL	mg/dL	DAYS 1,8,15	Other	PO	PO	Log Forms	Induction	Induction	Checked	40	Other	DAYS 1,8,15					1		1
MMRF_2429	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	D 1,8,15, 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	40	Other	D 1,8,15, 22					1		1
MMRF_2429	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	77	mg	mg	D 8-9, 15-16	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		77	Other	D 8-9, 15-16					1	625	1
MMRF_2539	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2539	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			4	mg	mg	DAYS 1-10	Other	PO	PO	Log Forms	Induction	Induction	Checked	4	Other	DAYS 1-10					1		1
MMRF_2539	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-14)	QD (D1-14)					1		1
MMRF_2562	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	137	1
MMRF_2562	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	DAYS 1-10	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAYS 1-10					1	137	1
MMRF_2562	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	137	1
MMRF_2562	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			PATIENT RECEIVED ASCT	Other	56	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		56	Q week	Q week					199	396	1
MMRF_2562	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			PATIENT RECEIVED ASCT	Other	20	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		20	QWK	QWK					298	396	1
MMRF_2562	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					199	255	1
MMRF_2562	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			PATIENT UNDERWENT ASCT	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					199	297	1
MMRF_2562	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Maintenance	Maintenance		3	Other	QD (D1, D8, D15)					585	661	1
MMRF_2562	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					704	1004	1
MMRF_2562	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q28D	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	Q28D					704	1004	1
MMRF_2562	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1038	1117	1
MMRF_2562	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	1432	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		1432	Q week	Q week					1039	1117	1
MMRF_2562	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	3	mg/dL	mg/dL	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1038	1117	1
MMRF_2562	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	ASCT PREP	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	ASCT PREP		200	Q day	Q day					437	439	1
MMRF_1020	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	61	1
MMRF_1020	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D9-11)	Other	PO	PO	Log Forms				40	Other	QD (D1-4, D9-11)					1	61	1
MMRF_1020	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					827	1360	1
MMRF_1020	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					827	1360	1
MMRF_1020	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-4, D9-11)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D9-11)					827	1360	1
MMRF_1020	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					132	133	1
MMRF_1020	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					987	988	1
MMRF_1020	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1370	1623	1
MMRF_1020	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	D1, D8, D15	Other	IV	IV	Log Forms	Induction	Induction		300	Other	D1, D8, D15					1370	1623	1
MMRF_1020	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1	PT DEATH	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction	Checked	40	QWK	QWK					1370	2150	1
MMRF_1020	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Daratumumab	Daratumumab		0	PT DEATH	Other	16	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		16	QWK	QWK					1638	2142	1
MMRF_1020	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					6	91	1
MMRF_1045	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			CONTINUE AT A REDUCED DOSE DUE TO BAD TASTE/DECREASED APPETITE	Other	15	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms				15	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	127	1
MMRF_1045	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					1	229	1
MMRF_1045	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					130	322	1
MMRF_1044	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	78	1
MMRF_1044	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	DAY 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms				1	Other	DAY 1, 8, 15					183	1688	1
MMRF_1044	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	24	mg	mg	Q week	Q week	PO	PO	Log Forms				24	Q week	Q week					29	541	1
MMRF_1044	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				15	QD (D1-14)	QD (D1-14)					78	127	1
MMRF_1044	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					127	183	1
MMRF_1044	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-12)	Other	PO	PO	Log Forms			Checked	5	Other	QD (D1-12)					183		1
MMRF_1044	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	DAY 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	DAY 1, 8, 15					155	183	1
MMRF_1044	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		12	QWK	QWK					568	1688	1
MMRF_1044	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	155	1
MMRF_1044	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	29	1
MMRF_1044	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.525	mg	mg	D1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.525	Other	D1, 8, 15					2878		1
MMRF_1044	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					2878		1
MMRF_1046	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			ROUTE SWITCHED FROM IV TO SUBQ	Other	2.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_1046	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					43	102	1
MMRF_1046	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	Other	PO	PO	Log Forms				25	Other	QD (D1-14)					5	105	1
MMRF_1046	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DECREASED DOSE	Other	20	mg	mg	QD (D1-2, 4-5, 8-9, 11-12)	Other	PO	PO	Log Forms				20	Other	QD (D1-2, 4-5, 8-9, 11-12)					1	82	1
MMRF_1046	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1-2, 4-5, 8-9, 11-12)	Other	PO	PO	Log Forms				10	Other	QD (D1-2, 4-5, 8-9, 11-12)					92	103	1
MMRF_1046	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					218	267	1
MMRF_1046	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					218	267	1
MMRF_1046	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, 2, 4, 5, 8, 9, 11, 12)	Other	PO	PO	Log Forms				20	Other	QD (D1, 2, 4, 5, 8, 9, 11, 12)					218	306	1
MMRF_1046	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					267	305	1
MMRF_1046	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				15	QD (D1-14)	QD (D1-14)					267	308	1
MMRF_1046	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms			Checked	10	QD (D1-21)	QD (D1-21)					323		1
MMRF_1046	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	170	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		170	Q day	Q day					134	135	1
MMRF_1059	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	175	1
MMRF_1059	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DOSE REDUCED	Other	20	mg	mg	QD (D1-2, 4-5, 8-9. 11-12)	Other	PO	PO	Log Forms				20	Other	QD (D1-2, 4-5, 8-9. 11-12)					1	115	1
MMRF_1059	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1-2, 4-5, 8-9, 11-12)	Other	PO	PO	Log Forms				10	Other	QD (D1-2, 4-5, 8-9, 11-12)					116	176	1
MMRF_1059	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					74	181	1
MMRF_1059	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					287	390	1
MMRF_1059	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Lack of response	Lack of response	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					390	1236	1
MMRF_1059	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	160	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		160	Q day	Q day					934	935	1
MMRF_1059	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1		Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	25	QD (D1-21)	QD (D1-21)					1243		1
MMRF_1059	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	QWK	QWK					1827		1
MMRF_1059	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			8	mg/kg	mg/kg	MONTHLY	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	8	Other	MONTHLY					2483		1
MMRF_1059	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		1			20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2485		1
MMRF_1059	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	D1-2, 8-9, 15-16, 22	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	D1-2, 8-9, 15-16, 22					2485		1
MMRF_1059	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	3	QD (D1-21)	QD (D1-21)					2611		1
MMRF_1074	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DOSE MODIFIED	Other	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	8	1
MMRF_1074	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	98	1
MMRF_1074	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (1-2, 4-5, 8-9, 11-12)	Other	PO	PO	Log Forms				20	Other	QD (1-2, 4-5, 8-9, 11-12)					1	54	1
MMRF_1074	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D 1-2, 4-5, 8-9, 11-12)	Other	PO	PO	Log Forms				10	Other	QD (D 1-2, 4-5, 8-9, 11-12)					64	96	1
MMRF_1074	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DOSE MODIFIED	Other	.7	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				0.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					8	11	1
MMRF_1074	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	95	1
MMRF_1074	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					204	319	1
MMRF_1074	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					204	225	1
MMRF_1074	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D2, D4, D5, D8, D9, D11, D12)	Other	PO	PO	Log Forms				20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					204	294	1
MMRF_1074	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					225	294	1
MMRF_1074	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1, D2, D4, D5, D8, D9, D11, D12)	Other	PO	PO	Log Forms				10	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					294	319	1
MMRF_1074	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					294	319	1
MMRF_1074	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					294	319	1
MMRF_1074	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					330	415	1
MMRF_1074	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms				300	Other	ONCE					330	386	1
MMRF_1074	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					319	414	1
MMRF_1074	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Carfilzomib	Carfilzomib			Lack of response	Lack of response	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					414	415	1
MMRF_1074	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					414	414	1
MMRF_1074	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	METHOTREXATE	Other			Patient decision	Patient decision	15	mg	mg	X2	Other	INTRATHECAL	Other	Log Forms	Unknown	Unknown		15	Other	X2					414	417	1
MMRF_1074	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	150	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		150	Q day	Q day					126	127	1
MMRF_1150	First line of therapy	First Line Therapy			Bortezomib	Bortezomib		1			2.6	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms			Checked	2.6	Q week	Q week					8		1
MMRF_1150	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms			Checked	25	QD (D1-14)	QD (D1-14)					1		1
MMRF_1150	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms			Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1		1
MMRF_1181	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			PATIENT DIED	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	39	1
MMRF_1181	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			PATIENT DIED	Other	40	mg	mg	DAYS 1, 2,3,4,8,9, 10, 11	Other	PO	PO	Log Forms				40	Other	DAYS 1, 2,3,4,8,9, 10, 11					1	39	1
MMRF_1181	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			DEATH	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					22	39	1
MMRF_1242	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QWK	QWK	PO	PO	Log Forms				300	QWK	QWK					1	72	1
MMRF_1242	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms				1.3	QWK	QWK					1	190	1
MMRF_1242	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	190	1
MMRF_1242	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					141	190	1
MMRF_1242	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					386	540	1
MMRF_1242	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					386	540	1
MMRF_1242	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	Other	QD (D1, D8, D15)					386	540	1
MMRF_1242	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		100	Q day	Q day					232	233	1
MMRF_1242	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	150	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		150	Q day	Q day					302	303	1
MMRF_1258	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	246	1
MMRF_1258	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					11	268	1
MMRF_1281	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	153	1
MMRF_1281	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	560	mg	mg	QWK	QWK	IV	IV	Log Forms				560	QWK	QWK					1	153	1
MMRF_1281	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1, D2, D4, D5, D8, D9, D11)	Other	IV	IV	Log Forms				20	Other	QD (D1, D2, D4, D5, D8, D9, D11)					1	153	1
MMRF_1318	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	204	1
MMRF_1318	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					1	29	1
MMRF_1318	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					29	85	1
MMRF_1318	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					85	155	1
MMRF_1318	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.3	Q week	Q week					29	113	1
MMRF_1318	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					113	368	1
MMRF_1318	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	D1, D8, D15	Other	IV	IV	Log Forms	Consolidation	Consolidation	Checked	1.3	Other	D1, D8, D15					379		1
MMRF_1318	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	10	QD (D1-21)	QD (D1-21)					211		1
MMRF_1318	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					162		1
MMRF_1355	First line of therapy	First Line Therapy			Elotuzumab	Elotuzumab			Investigator decision for other reasons	Investigator decision for other reasons	20	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms				20	Q week	Q week					1	1282	1
MMRF_1355	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	1282	1
MMRF_1355	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	8	mg	mg	Q week	Q week	PO	PO	Log Forms				8	Q week	Q week					1	1282	1
MMRF_1358	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Patient decision	Patient decision	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	121	1
MMRF_1358	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					1	194	1
MMRF_1358	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.6	mg/m^2	mg/m^2	QD (D1, D8, D15, D22)	Other	IV	IV	Log Forms	Induction	Induction		1.6	Other	QD (D1, D8, D15, D22)					194	313	1
MMRF_1358	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					194	327	1
MMRF_1358	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					327		1
MMRF_1361	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			SWITCHED FROM IV TO SUBQ	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	47	1
MMRF_1361	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					47	68	1
MMRF_1361	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, D2, D4, D5, D8, D9, D11, D12)	Other	PO	PO	Log Forms				20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1	68	1
MMRF_1361	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms				300	Q week	Q week					22	68	1
MMRF_1361	First line of therapy	First Line Therapy			Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					68	154	1
MMRF_1361	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					68	138	1
MMRF_1361	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					68	160	1
MMRF_1361	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		300	Q week	Q week					117	153	1
MMRF_1392	First line of therapy	First Line Therapy			Carfilzomib	Carfilzomib			STEM CELL COLLECTION	Other	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	139	1
MMRF_1392	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			STEM CELL COLLECTION	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	139	1
MMRF_1392	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			STEM CELL COLLECTION	Other	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms				40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	139	1
MMRF_1392	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					168	463	1
MMRF_1392	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					168	463	1
MMRF_1392	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (1, 8, 15, 22)					168	463	1
MMRF_1392	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	240	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		240	Q day	Q day					504	505	1
MMRF_1392	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					595	769	1
MMRF_1392	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					595	763	1
MMRF_1392	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	27	mg/m^2	mg/m^2	QD D1-2, D15-16)	Other	IV	IV	Log Forms	Consolidation	Consolidation		27	Other	QD D1-2, D15-16)					595	764	1
MMRF_1393	First line of therapy	First Line Therapy			Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	323	1
MMRF_1393	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	1209	1
MMRF_1393	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (1,2, 8,9, 15,16, 22,23)	Other	PO	PO	Log Forms				20	Other	QD (1,2, 8,9, 15,16, 22,23)					1	490	1
MMRF_1393	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					131	132	1
MMRF_1393	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D15-16)	Other	IV	IV	Log Forms	Maintenance	Maintenance		36	Other	QD (D1-2, D15-16)					323	590	1
MMRF_1393	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (1, 8, 15, 22)					490	590	1
MMRF_1393	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					1210		1
MMRF_1420	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_1420	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	300	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms				300	Q week	Q week					1	64	1
MMRF_1420	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, D2, D4, D5, D8, D9, D11, D12)	Other	PO	PO	Log Forms				20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1	1205	1
MMRF_1420	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					99	134	1
MMRF_1420	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					274	1205	1
MMRF_1520	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	71	1
MMRF_1520	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	106	1
MMRF_1520	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	57	1
MMRF_1520	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					148	149	1
MMRF_1520	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					71	106	1
MMRF_1520	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					225	442	1
MMRF_1520	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D15-16)	Other	IV	IV	Log Forms	Maintenance	Maintenance		27	Other	QD (D1-2, D15-16)					442	607	1
MMRF_1520	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					225	414	1
MMRF_1520	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-21)	QD (D1-21)					414	442	1
MMRF_1520	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-21)	QD (D1-21)					442	980	1
MMRF_1520	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (1, 8, 15, 22)					57	106	1
MMRF_1520	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (1, 8, 15, 22)					225	281	1
MMRF_1520	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Consolidation	Consolidation		12	Other	QD (1, 8, 15, 22)					281	442	1
MMRF_1520	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Maintenance	Maintenance		12	Other	QD (1, 8, 15, 22)					442	607	1
MMRF_1520	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					1204		1
MMRF_1540	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	518	1
MMRF_1540	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	518	1
MMRF_1540	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	518	1
MMRF_1576	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	21	1
MMRF_1576	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	21	1
MMRF_1621	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	106	1
MMRF_1621	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_1621	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (1, 8, 15, 22)					1	225	1
MMRF_1621	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	230	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		230	Q day	Q day					137	138	1
MMRF_1621	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					225	365	1
MMRF_1621	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D15-16)	Other	IV	IV	Log Forms	Maintenance	Maintenance		36	Other	QD (D1-2, D15-16)					365	645	1
MMRF_1621	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (1, 8, 15, 22)					225	645	1
MMRF_1630	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD(D1, D8, D15, D22)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD(D1, D8, D15, D22)					1	133	1
MMRF_1630	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					21	133	1
MMRF_1630	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					21	867	1
MMRF_1630	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					171	172	1
MMRF_1630	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					252	371	1
MMRF_1630	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D15-16)	Other	IV	IV	Log Forms	Maintenance	Maintenance		36	Other	QD (D1-2, D15-16)					371	658	1
MMRF_1630	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (1, 8, 15, 22)					252	658	1
MMRF_1630	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					867		1
MMRF_1652	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	100	1
MMRF_1652	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD(D1, D8, D15, D22)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD(D1, D8, D15, D22)					1	100	1
MMRF_1652	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	100	1
MMRF_1652	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					139	140	1
MMRF_1652	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					246	632	1
MMRF_1652	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					246	632	1
MMRF_1652	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	15	QD (D1-21)	QD (D1-21)					246		1
MMRF_1690	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	107	1
MMRF_1690	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	107	1
MMRF_1690	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D8, D15, D22)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D15, D22)					1	107	1
MMRF_1690	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	180	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		180	Q day	Q day					138	139	1
MMRF_1690	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					226	345	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D15-16)	Other	IV	IV	Log Forms	Maintenance	Maintenance		27	Other	QD (D1-2, D15-16)					345	625	1
MMRF_1690	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					226	254	1
MMRF_1690	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					254	345	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					345	653	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (1-21: 2D ON, 1D OFF)	Other	PO	PO	Log Forms	Maintenance	Maintenance		25	Other	QD (1-21: 2D ON, 1D OFF)					653	734	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					734		1
MMRF_1690	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					226	345	1
MMRF_1690	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D22)	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (D22)					226	345	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					345	401	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D22)	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (D22)					345	401	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QD (D2, D16)	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	QD (D2, D16)					569	625	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	QD (D8, D22)	Other	PO	PO	Log Forms	Maintenance	Maintenance		12	Other	QD (D8, D22)					569	625	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1, D15)	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	QD (D1, D15)					401	569	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	6	mg	mg	QD (D2, D16)	Other	PO	PO	Log Forms	Maintenance	Maintenance		6	Other	QD (D2, D16)					401	457	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg	mg	QD (D8, D22)	Other	PO	PO	Log Forms	Maintenance	Maintenance		16	Other	QD (D8, D22)					401	457	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D2, D16)	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	QD (D2, D16)					457	569	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	14	mg	mg	QD (D8, D22)	Other	PO	PO	Log Forms	Maintenance	Maintenance		14	Other	QD (D8, D22)					457	569	1
MMRF_1690	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	8	mg	mg	QD (D1, D15)	Other	PO	PO	Log Forms	Maintenance	Maintenance		8	Other	QD (D1, D15)					569	625	1
MMRF_1749	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	106	1
MMRF_1749	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	106	1
MMRF_1749	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	IV OR PO	Other	Log Forms	Induction	Induction		40	QWK	QWK					1	106	1
MMRF_1749	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	195	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		195	Q day	Q day					144	145	1
MMRF_1749	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					231	953	1
MMRF_1749	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			DOSE ESCALATION	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					596	617	1
MMRF_1749	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		12	Q week	Q week					231	1274	1
MMRF_1749	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	25	QD (D1-21)	QD (D1-21)					259		1
MMRF_1773	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	191	1
MMRF_1773	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_1773	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (1,2, 4,5, 8,9, 11,12)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (1,2, 4,5, 8,9, 11,12)					1	722	1
MMRF_1773	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	225	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		225	Q day	Q day					116	117	1
MMRF_1773	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	230	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		230	Q day	Q day					217	218	1
MMRF_1773	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					303	710	1
MMRF_1797	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	567	1
MMRF_1797	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	567	1
MMRF_1797	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	567	1
MMRF_1797	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					225	226	1
MMRF_1822	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Patient decision	Patient decision	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	130	1
MMRF_1822	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Patient decision	Patient decision	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	135	1
MMRF_1822	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	136	1
MMRF_1822	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Patient decision	Patient decision	1.3	mg/m^2	mg/m^2	QD (D1, D18, D15, D22)	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1, D18, D15, D22)					185	284	1
MMRF_1822	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Patient decision	Patient decision	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					185	284	1
MMRF_1822	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					185	284	1
MMRF_1822	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib			INSURANCE REASONS	Other	4	mg	mg	ONCE WEEK FOR 3WKS 4TH WK OFF	Other	PO	PO	Log Forms	Induction	Induction		4	Other	ONCE WEEK FOR 3WKS 4TH WK OFF					746	962	1
MMRF_1822	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			LOST TO FOLLOW-UP, NONCOMPLIANCE (UNKNOWN ACTUAL STOP-DATE)	Other	4	mg	mg	QD (D1, D8, D15, D22)	Other	PO	PO	Log Forms	Induction	Induction		4	Other	QD (D1, D8, D15, D22)					962	1021	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.3	mg	mg	EVERY 72 HOURS	Other	INJECTION	Other	Log Forms	Induction	Induction		2.3	Other	EVERY 72 HOURS					1591	1606	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		40	Q day	Q day					1591	1606	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	2	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		2	Q day	Q day					1591	1606	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	12	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	SALVAGE		12	Q day	Q day					1591	1606	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	70	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	SALVAGE		70	Q day	Q day					1591	1606	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1561	1606	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					1613	1688	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1614	1688	1
MMRF_1822	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	TWICE WEEKLY	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	TWICE WEEKLY					1614	1688	1
MMRF_1822	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)			Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1690	1795	1
MMRF_1822	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)			Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1690	1795	1
MMRF_1822	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)			Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV	IV	Log Forms				300	Other	QD (D1, D8, D15)					1690	1795	1
MMRF_2005	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	29	1
MMRF_2005	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	112	1
MMRF_2005	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	112	1
MMRF_2005	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					148	149	1
MMRF_2005	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					239	626	1
MMRF_2005	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			DOSE ESCALATION	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					239	260	1
MMRF_2005	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					239	639	1
MMRF_2005	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	25	QD (D1-21)	QD (D1-21)					267		1
MMRF_2005	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	27	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					29	64	1
MMRF_2005	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					64	113	1
MMRF_2021	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	21	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		21	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	105	1
MMRF_2021	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D8, D22, D22)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D22, D22)					1	105	1
MMRF_2021	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	105	1
MMRF_2021	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	220	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		220	Q day	Q day					144	145	1
MMRF_2021	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					224	336	1
MMRF_2021	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					224	252	1
MMRF_2021	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	36	mg/m^2	mg/m^2	QD (D1-2, D15-16)	Other	IV	IV	Log Forms	Maintenance	Maintenance		36	Other	QD (D1-2, D15-16)					336	449	1
MMRF_2021	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					252	336	1
MMRF_2021	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					336	354	1
MMRF_2021	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-21)	QD (D1-21)					364	434	1
MMRF_2021	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (1-21: 3D ON, 1D OFF)	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (1-21: 3D ON, 1D OFF)					434	450	1
MMRF_2021	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					462	504	1
MMRF_2021	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					504	505	1
MMRF_2021	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					529		1
MMRF_2021	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (1, 8, 15, 22)					224	336	1
MMRF_2021	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (1, 8, 15, 22)					336	687	1
MMRF_2056	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	106	1
MMRF_2056	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D8, D15, D22)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D15, D22)					1	106	1
MMRF_2056	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	1247	1
MMRF_2056	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	175	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		175	Q day	Q day					141	142	1
MMRF_2056	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					232	359	1
MMRF_2056	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D15-16)	Other	IV	IV	Log Forms	Maintenance	Maintenance		36	Other	QD (D1-2, D15-16)					359	1247	1
MMRF_2056	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (1, 8, 15, 22)					232	1247	1
MMRF_2056	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1247	1687	1
MMRF_2056	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	QWK FOR 8 WEEKS, THEN Q2WK FOR 16 WEEKS, THEN QMONTH	Other	IV	IV	Log Forms	Induction	Induction	Checked	16	Other	QWK FOR 8 WEEKS, THEN Q2WK FOR 16 WEEKS, THEN QMONTH					1715		1
MMRF_2056	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					1715		1
MMRF_2056	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib		1			27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1715		1
MMRF_2056	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction	Checked	20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1715		1
MMRF_2091	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1585	1619	1
MMRF_2091	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1585	1619	1
MMRF_2091	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1585	1619	1
MMRF_2091	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	CAR-T	Other	CAR-T	Other		0	Completed regimen	Completed regimen				ONCE	Other	IV	IV	Log Forms	Other	CAR-T			Other	ONCE					1752	1752	1
MMRF_2091	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/dL	mg/dL	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	617	1
MMRF_2091	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D8, D15, D22)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D15, D22)					1	617	1
MMRF_2091	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	1080	1
MMRF_2091	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	230	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		230	Q day	Q day					141	142	1
MMRF_2091	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1149	1562	1
MMRF_2091	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1149	1562	1
MMRF_2091	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1149	1562	1
MMRF_2091	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	SPLIT 1+2, 8, 15, 22	Other	IV	IV	Log Forms	Induction	Induction		16	Other	SPLIT 1+2, 8, 15, 22					1149	1562	1
MMRF_2098	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-21)	QD (D1-21)					1	216	1
MMRF_2098	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-5; D8-12; D15-19)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-5; D8-12; D15-19)					1	216	1
MMRF_2122	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	264	1
MMRF_2122	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	264	1
MMRF_2122	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D4-5, D8-9, D11-12)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D4-5, D8-9, D11-12)					1	264	1
MMRF_2122	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib		1			4	mg	mg	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Induction	Induction	Checked	4	Other	QD (D1, D8, D15)					602		1
MMRF_2122	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			4	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	4	Q week	Q week					615		1
MMRF_2122	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					609		1
MMRF_2238	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					27	118	1
MMRF_2238	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	118	1
MMRF_2238	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		300	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					27	118	1
MMRF_2238	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	245	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		245	Q day	Q day					140	141	1
MMRF_2238	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					230	1722	1
MMRF_2238	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q MONTH (D1)	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Other	Q MONTH (D1)					1777		1
MMRF_2238	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					1777		1
MMRF_2238	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			10	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE	Checked	10	Q week	Q week					1777		1
MMRF_2570	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	101	1
MMRF_2570	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	106	1
MMRF_2570	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	107	1
MMRF_2570	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	150	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		150	Q day	Q day					145	146	1
MMRF_2570	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	QD (1, 8, 15, 22)					225	253	1
MMRF_2570	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (1, 8, 15, 22)	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	QD (1, 8, 15, 22)					253	625	1
MMRF_2570	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-21)	QD (D1-21)					225	623	1
MMRF_2570	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D15-16)	Other	IV	IV	Log Forms	Consolidation	Consolidation		27	Other	QD (D1-2, D15-16)					225	618	1
MMRF_2570	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	QD (D1-21)	QD (D1-21)					631		1
MMRF_1085	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	211	1
MMRF_1085	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	217	1
MMRF_1085	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1, D2, D4, D5, D8, D9, D11, AND D12	Other	PO	PO	Log Forms				20	Other	D1, D2, D4, D5, D8, D9, D11, AND D12					1	212	1
MMRF_1085	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms				10	Q day	Q day					225	308	1
MMRF_1085	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					316	413	1
MMRF_1085	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					449	841	1
MMRF_1085	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					449	841	1
MMRF_1085	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					449	841	1
MMRF_1085	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	SINGLE DOSE IN PREPARATION FOR STEM CELL TRANSPLANT	Other	IV	IV	Log Forms	Unknown	Unknown		140	Other	SINGLE DOSE IN PREPARATION FOR STEM CELL TRANSPLANT					870	870	1
MMRF_1085	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Bendamustine	Bendamustine			Disease progression/Relapse	Disease progression/Relapse	201	mg	mg	DAYS 1 & 2	Other	IV	IV	Log Forms	Consolidation	Consolidation		201	Other	DAYS 1 & 2					1105	1162	1
MMRF_1085	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.4	mg	mg	DAYS 1 & 8	Other	IV	IV	Log Forms	Consolidation	Consolidation		1.4	Other	DAYS 1 & 8					1105	1162	1
MMRF_1085	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			DIFFICULTY TOLERATING THERAPY	Other	20	mg	mg	TWICE PER WEEK	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	TWICE PER WEEK					1182	1217	1
MMRF_1085	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	SELINEXOR	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	80	mg	mg	TWICE PER WEEK	Other	PO	PO	Log Forms	Consolidation	Consolidation		80	Other	TWICE PER WEEK					1182	1217	1
MMRF_1233	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			PATIENT NON-COMPLIANT	Other	500	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms				500	Q week	Q week					2	128	1
MMRF_1233	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.5	Q week	Q week					1	319	1
MMRF_1233	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	266	1
MMRF_1233	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Induction	Induction		15	Other	EVERY OTHER DAY					477	589	1
MMRF_1233	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					589	2684	1
MMRF_1233	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					477	575	1
MMRF_1233	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab		1										Log Forms	Induction	Induction	Checked								2723		1
MMRF_1327	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide		1			300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms			Checked	300	Q week	Q week					1		1
MMRF_1327	First line of therapy	First Line Therapy			Bortezomib	Bortezomib		1			1.5	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms			Checked	1.5	Q week	Q week					1		1
MMRF_1327	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms			Checked	40	Q week	Q week					1		1
MMRF_1700	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			TOXICITY - BONE AND JOINT ARTHRALGIA	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	14	1
MMRF_1700	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	481	1
MMRF_1700	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.6	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	Q week	Q week					19	432	1
MMRF_1700	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		300	Q week	Q week					47	194	1
MMRF_1700	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg/dL	mg/dL	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					194	432	1
MMRF_1700	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Lack of response	Lack of response	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					439	481	1
MMRF_1700	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		2	Q day	Q day					481	559	1
MMRF_1739	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	QWK	QWK	SQ	Other	Log Forms	Induction	Induction		1.5	QWK	QWK					1	253	1
MMRF_1739	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	350	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Induction	Induction		350	QWK	QWK					1	155	1
MMRF_1739	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	253	1
MMRF_1739	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					171	256	1
MMRF_1739	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					525	1878	1
MMRF_1739	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					734	1100	1
MMRF_1739	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					734	1100	1
MMRF_1739	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	44	ML	Other	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		44	Q week	Q week					1101	1195	1
MMRF_1739	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1193	1878	1
MMRF_1739	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1193	1878	1
MMRF_1739	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Other	SALVAGE		20	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1193	1878	1
MMRF_1774	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	214	1
MMRF_1774	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	211	1
MMRF_1774	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1, 2, 4, 5, 8, 9, 11, AND 12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1, 2, 4, 5, 8, 9, 11, AND 12					1	212	1
MMRF_1774	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					213	305	1
MMRF_1774	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					306	954	1
MMRF_1774	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg	mg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		1.3	Q week	Q week					986	1435	1
MMRF_1774	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					986	1435	1
MMRF_1774	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Melphalan	Melphalan			GIVEN IN PREOARATION FOR TRANSPLANT	Other	140	mg/m^2	mg/m^2	ONE TIME	Other	IVB	IVB	Log Forms	Other	SALVAGE		140	Other	ONE TIME					1013	1013	1
MMRF_1774	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1461	1591	1
MMRF_1774	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					1461	1591	1
MMRF_1774	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	154	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		154	QWK	QWK					1660	1958	1
MMRF_1774	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1523	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		1523	QWK	QWK					1628	1660	1
MMRF_1814	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Patient decision	Patient decision	552	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		552	QWK	QWK					1	113	1
MMRF_1814	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Patient decision	Patient decision	1.5	mg/m^2	mg/m^2	QWK	QWK	SQ	Other	Log Forms	Induction	Induction		1.5	QWK	QWK					1	113	1
MMRF_1814	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	113	1
MMRF_1823	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PROCEEDING TO AUTOLOGOUS STEM CELL TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QWK	QWK	SQ	Other	Log Forms	Induction	Induction		1.3	QWK	QWK					1	141	1
MMRF_1823	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			PROCEEDING TO AUTOLOGOUS STEM CELL TRANSPLANT	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	141	1
MMRF_1823	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PROCEEDING TO AUTOLOGOUS STEM CELL TRANSPLANT	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	141	1
MMRF_1823	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					293	743	1
MMRF_1823	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					714	887	1
MMRF_1823	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					714	887	1
MMRF_1823	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IVB	IVB	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					888	1280	1
MMRF_1823	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					888	1345	1
MMRF_1823	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			DOSE REDUCTION PER PROTOCOL REQUIREMENT	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		40	QWK	QWK					888	994	1
MMRF_1823	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		20	QWK	QWK					1001	1280	1
MMRF_1823	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					196	196	1
MMRF_1832	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBQ	Other	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	117	1
MMRF_1832	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	117	1
MMRF_1832	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					141	210	1
MMRF_1832	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	EVERY OTHER WEEK	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	EVERY OTHER WEEK					141	210	1
MMRF_1832	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			DEATH	Other	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Q week	Q week					211	1188	1
MMRF_1832	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			DEATH	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					211	1188	1
MMRF_1841	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	162	1
MMRF_1841	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	113	1
MMRF_1841	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1, 2, 4, 5, 8, 9, 11, 12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1, 2, 4, 5, 8, 9, 11, 12					1	162	1
MMRF_1841	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	DOSE REDUCED	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					288	1211	1
MMRF_1841	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			2.2	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	2.2	Q week	Q week					439		1
MMRF_1841	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					1211		1
MMRF_2080	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					428		1
MMRF_2080	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	212	1
MMRF_2080	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	212	1
MMRF_2080	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D 1, 2, 4, 5, 8, 9, 11, 12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D 1, 2, 4, 5, 8, 9, 11, 12					1	212	1
MMRF_2080	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	DOSE REDUCED DUE TO AE	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					212	428	1
MMRF_2104	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	43	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		43	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	269	1
MMRF_2104	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	269	1
MMRF_2104	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	D 1, 2, 4, 5, 8, 9, 11, 12	Other	PO	PO	Log Forms	Induction	Induction	Checked	20	Other	D 1, 2, 4, 5, 8, 9, 11, 12					1		1
MMRF_2104	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					302		1
MMRF_2190	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1295	1
MMRF_2190	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	1295	1
MMRF_2190	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1, 2, 4, 5, 8, 9, 11, AND 12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1, 2, 4, 5, 8, 9, 11, AND 12					1	1295	1
MMRF_2190	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1042	mg	mg	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		1042	Q week	Q week					1305	1764	1
MMRF_2190	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					1305	1764	1
MMRF_2190	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1305	1764	1
MMRF_2250	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_2250	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	106	1
MMRF_2250	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	D 1, 2, 4, 5, 8, 9, 11, 12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D 1, 2, 4, 5, 8, 9, 11, 12					1	106	1
MMRF_2250	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					106	1066	1
MMRF_2250	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-21)	QD (D1-21)					1072	1278	1
MMRF_2250	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	923	mg	mg	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		923	Q week	Q week					1072	1278	1
MMRF_2250	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					1072	1278	1
MMRF_2250	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0			40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1291	1362	1
MMRF_2250	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1291	1362	1
MMRF_2250	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	UK	mg	mg	Q2WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance			Other	Q2WEEKS					1545	1765	1
MMRF_2250	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	REGN5458	Other	NCT03761108	1			UK	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction	Checked		QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1807		1
MMRF_2333	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.2	mg	mg	QWK	QWK	SUBCUTANEOUS	Other	Log Forms	Maintenance	Maintenance		2.2	QWK	QWK					1	176	1
MMRF_2333	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_2333	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	QWK	QWK					1		1
MMRF_2333	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	EVERY OTHER WEEK					176		1
MMRF_2511	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	308	1
MMRF_2511	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0			10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					1	308	1
MMRF_2511	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0			20	mg	mg	DAYS 1, 2, 4, 5, 8, 9, 11, AND 12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1, 2, 4, 5, 8, 9, 11, AND 12					1	308	1
MMRF_2511	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	ONE TIME DOSE	Other	IV	IV	Log Forms	Consolidation	Consolidation		140	Other	ONE TIME DOSE					391	391	1
MMRF_2511	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	Q OTHER DAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	Q OTHER DAY					484	1566	1
MMRF_2511	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					1639		1
MMRF_2511	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib		1			4	mg	mg	QD1,8,15	Other	PO	PO	Log Forms	Induction	Induction	Checked	4	Other	QD1,8,15					1639		1
MMRF_2511	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction	Checked	16	Q week	Q week					1639		1
MMRF_1056	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	170	mg	mg	DAYS -2, -1	Other	IV	IV	Log Forms	Other	CONDITIONING		170	Other	DAYS -2, -1					106	107	1
MMRF_1056	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	69	1
MMRF_1056	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAY OF AND DAY AFTER BORTEZOMIB	Other	PO	PO	Log Forms				20	Other	DAY OF AND DAY AFTER BORTEZOMIB					1	69	1
MMRF_1056	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	69	1
MMRF_1056	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					215	446	1
MMRF_1056	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	TWICE MONTHLY	Other	IV	IV	Log Forms	Maintenance	Maintenance		1.3	Other	TWICE MONTHLY					446	635	1
MMRF_1056	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					635	691	1
MMRF_1056	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	DAY OF AND DAY AFTER BORTEZOMIB	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER BORTEZOMIB					653	1396	1
MMRF_1056	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					698	1142	1
MMRF_1056	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	10	mg/kg	mg/kg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		10	Q week	Q week					1063	1142	1
MMRF_1056	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	OPROZOMIB	Other			Lack of response	Lack of response	180	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Consolidation	Consolidation		180	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1170	1237	1
MMRF_1056	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					1269	1396	1
MMRF_1056	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	SAR650984	Other			Lack of response	Lack of response	10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		10	Q week	Q week					1269	1396	1
MMRF_1056	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1397	1766	1
MMRF_1056	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		40	QWK	QWK					1397	1766	1
MMRF_1056	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	BIAXIN	Other			Disease progression/Relapse	Disease progression/Relapse	500	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		500	Q day	Q day					1397	1766	1
MMRF_1056	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Lack of response	Lack of response	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1780	1912	1
MMRF_1056	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			DOSE REDUCTION TO IMPROVE BLOOD COUNTS	Other	300	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV	IV	Log Forms	Other	SALVAGE		300	Other	QD (D1, D8, D15)					1780	1842	1
MMRF_1056	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1780	1912	1
MMRF_1056	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	150	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Other	SALVAGE		150	Other	QD (D1, D8, D15)					1843	1912	1
MMRF_1056	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QW(C1-2), Q2W(C3-6), Q4W(C7+)	Other	IV	IV	Log Forms	Other	SALVAGE		16	Other	QW(C1-2), Q2W(C3-6), Q4W(C7+)					1929	2312	1
MMRF_1056	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1929	2312	1
MMRF_1056	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		20	QWK	QWK					1929	2312	1
MMRF_1048	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.2	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1048	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1048	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1048	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					192	953	1
MMRF_1048	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/kg	mg/kg	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1	QWK	QWK					192	953	1
MMRF_1048	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	DAYS -3 -2	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	DAYS -3 -2					81	82	1
MMRF_1048	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Elotuzumab	Elotuzumab		1			10	mg/kg	mg/kg	WEEKLY(C1-2), Q 2 WEEKS(C3+)	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	10	Other	WEEKLY(C1-2), Q 2 WEEKS(C3+)					1832		1
MMRF_1048	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	25	QD (D1-21)	QD (D1-21)					1832		1
MMRF_1048	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE	Checked	40	Q week	Q week					1832		1
MMRF_1057	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			MOVED TO SCT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_1057	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			MOVED TO AUTO SCT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_1057	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			MOVED TO AUTO SCT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					22	103	1
MMRF_1057	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					233	954	1
MMRF_1057	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	DAYS -3 -2	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	DAYS -3 -2					132	133	1
MMRF_1060	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	161	mg	mg	DAYS -2, -1	Other	IV	IV	Log Forms	Other	CONDITIONING		161	Other	DAYS -2, -1					162	163	1
MMRF_1060	First line of therapy	First Line Therapy			Vincristine	Vincristine			Lack of response	Lack of response	.1	mg/dL	mg/dL	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				0.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	54	1
MMRF_1060	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms				40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	138	1
MMRF_1060	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1000	mg	mg	ONCE MONTHLY	Other	IV	IV	Log Forms				1000	Other	ONCE MONTHLY					1	138	1
MMRF_1060	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					54	138	1
MMRF_1060	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-14)	QD (D1-14)					285	425	1
MMRF_1060	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					285	716	1
MMRF_1060	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		40	QWK	QWK					285	716	1
MMRF_1060	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					534	898	1
MMRF_1060	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Ixazomib	Ixazomib			PERIPHERAL NEUROPATHY	Other	4	mg	mg	QD (DAYS 1, 8, 15)	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	QD (DAYS 1, 8, 15)					1990	2088	1
MMRF_1060	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			PERIPHERAL NEUROPATHY	Other	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1990	2088	1
MMRF_1070	First line of therapy	First Line Therapy			Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	EVERY 2 WEEKS---MAINTENANCE THERAPY	Other	IV	IV	Log Forms			Checked	1.3	Other	EVERY 2 WEEKS---MAINTENANCE THERAPY					208		1
MMRF_1070	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_1070	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_1070	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_1086	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			MOVED TO AUTO SCT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_1086	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			MOVED TO AUTO SCT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	142	1
MMRF_1086	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			MOVED TO AUTO SCT	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	142	1
MMRF_1086	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			TRAUMATIC RIGHT LEG FRACTURE- NON-MM	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					257	358	1
MMRF_1086	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					23	114	1
MMRF_1086	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Ixazomib	Ixazomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	QD (D1, D8, D15)					1900	1942	1
MMRF_1086	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1900	2203	1
MMRF_1086	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q 2 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1.3	Other	Q 2 WEEKS					1956	2203	1
MMRF_1086	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			SCHEDULE/DOSE CHANGE DUE TO TRAVELLING COMPLICATION	Other	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2206	2251	1
MMRF_1086	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			SCHEDULE/DOSE CHANGE DUE TO TRAVELLING COMPLICATION	Other	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	SALVAGE		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2206	2251	1
MMRF_1086	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	45	mg/m^2	mg/m^2	DAYS 1,8,15	Other	IV	IV	Log Forms	Other	SALVAGE		45	Other	DAYS 1,8,15					2251	2507	1
MMRF_1086	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	DAYS 1,8,15	Other	PO	PO	Log Forms	Other	SALVAGE		10	Other	DAYS 1,8,15					2251	2507	1
MMRF_1086	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	QW(C1-2), Q2W(C3-6), Q4W(C7+)	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Other	QW(C1-2), Q2W(C3-6), Q4W(C7+)					2648		1
MMRF_1086	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		10	Q day	Q day					2648	2655	1
MMRF_1086	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE	Checked	40	Q week	Q week					2648		1
MMRF_1097	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1097	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	85	1
MMRF_1097	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_1097	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Bortezomib	Bortezomib			DOCTOR DECISION	Other	1.3	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		1.3	Q week	Q week					1196	1492	1
MMRF_1097	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			DOCTOR DECISION	Other	20	mg	mg	QD (D1-2, D4-5, D8-9, D11-12)	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	QD (D1-2, D4-5, D8-9, D11-12)					1196	1492	1
MMRF_1110	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	185	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	CONDITIONING		185	Other	DAYS -3, -2					93	94	1
MMRF_1110	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			MOVED TO AUTO SCT	Other	3.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				3.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_1110	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			MOVED TO AUTO SCT	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	71	1
MMRF_1110	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			MOVED TO AUTO SCT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	71	1
MMRF_1110	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					204	344	1
MMRF_1110	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			HOSPITALIZATION FOR PNEUMONIA	Other	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					371	671	1
MMRF_1110	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					712	876	1
MMRF_1110	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1331	1496	1
MMRF_1110	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			POOR TOLERANCE	Other	300	mg/m^2	mg/m^2	QD: D1, D8, D15	Other	PO	PO	Log Forms	Other	SALVAGE		300	Other	QD: D1, D8, D15					1331	1387	1
MMRF_1110	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1331	1496	1
MMRF_1110	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	250	mg	mg	DAY -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		250	Other	DAY -2					1501	1501	1
MMRF_1110	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		2	Q day	Q day					1635	1822	1
MMRF_1110	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	DAYS 1, 8, 15 OF 28D CYCLE	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	DAYS 1, 8, 15 OF 28D CYCLE					1846	1895	1
MMRF_1110	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		40	QWK	QWK					1846	1895	1
MMRF_1110	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1909	2142	1
MMRF_1110	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		40	QWK	QWK					1909	2142	1
MMRF_1110	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg/kg	mg/kg	WEEKLY(C1-C2); Q 2 WEEKS(C3-C6); MONTHLY(C7+)	Other	IV	IV	Log Forms	Other	SALVAGE		16	Other	WEEKLY(C1-C2); Q 2 WEEKS(C3-C6); MONTHLY(C7+)					1909	2142	1
MMRF_1110	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg/kg	mg/kg	WEEKLY(C1-2); Q2W(C3-6); Q4W(C7+)	Other	IV	IV	Log Forms	Other	SALVAGE		16	Other	WEEKLY(C1-2); Q2W(C3-6); Q4W(C7+)					2304	2350	1
MMRF_1110	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					2304	2350	1
MMRF_1110	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		40	QWK	QWK					2304	2350	1
MMRF_1119	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			MOVED TO AUTO SCT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_1119	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			MOVED TO AUTO SCT	Other	20	mg	mg	DAY OF AND DAY AFTER BORTEZOMIB	Other	PO	PO	Log Forms				20	Other	DAY OF AND DAY AFTER BORTEZOMIB					1	68	1
MMRF_1119	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			MOVED TO AUTO SCT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					22	70	1
MMRF_1119	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					207	225	1
MMRF_1119	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE INCREASED	Other	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					225	379	1
MMRF_1119	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					379	683	1
MMRF_1119	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					683	960	1
MMRF_1119	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					960		1
MMRF_1138	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			MOVED TO SCT	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	60	1
MMRF_1138	First line of therapy	First Line Therapy			Thalidomide	Thalidomide			MOVED TO SCT	Other	0	DOSE UNKNOWN	Other	UNKNOWN	Other	PO	PO	Log Forms				0	Other	UNKNOWN					1	60	1
MMRF_1138	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					258		1
MMRF_1138	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			MOVED TO SCT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	60	1
MMRF_1141	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	175	1
MMRF_1141	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	175	1
MMRF_1141	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	48	1
MMRF_1142	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			MOVED TO SCT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	63	1
MMRF_1142	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			MOVED TO SCT	Other	20	mg	mg	DAY OF AND DAY AFTER BORTEZOMIB	Other	PO	PO	Log Forms				20	Other	DAY OF AND DAY AFTER BORTEZOMIB					1	63	1
MMRF_1142	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			MOVED TO SCT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	63	1
MMRF_1142	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					216	948	1
MMRF_1142	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	185	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		185	Other	DAYS -3, -2					103	104	1
MMRF_1142	First line of therapy	First Line Therapy	TRANSPLANT	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	DAYS -3, -2, -1	Other	IV	IV	Log Forms	Other	TRANSPLANT		10	Other	DAYS -3, -2, -1					103	105	1
MMRF_1143	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			1	mg	mg			PO	PO	Log Forms	Other	SALVAGE	Checked	1							2887		1
MMRF_1143	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg			PO	PO	Log Forms	Other	SALVAGE	Checked	20							2887		1
MMRF_1143	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1								IV	IV	Log Forms	Other	SALVAGE	Checked								2887		1
MMRF_1143	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	187	1
MMRF_1143	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	187	1
MMRF_1143	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					997	1090	1
MMRF_1143	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-14)	QD (D1-14)					997	1090	1
MMRF_1143	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					997	1090	1
MMRF_1143	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					1202	1652	1
MMRF_1155	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		0	FREQUENCY CHANGE TO REDUCE CLINIC VISITS BECAUSE OF COVID-19	Other	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2748	2799	1
MMRF_1155	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	56	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Other	SALVAGE		56	QWK	QWK					2811	2846	1
MMRF_1155	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		1			27	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Other	SALVAGE	Checked	27	QWK	QWK					2867		1
MMRF_1155	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					2748	2867	1
MMRF_1155	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	DAYS 1,2,8,9,15,16,22,23	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	DAYS 1,2,8,9,15,16,22,23					2748		1
MMRF_1155	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			MOVED TO SCT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_1155	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			MOVED TO SCT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_1155	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			TOXICITY	Other	25	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	596	1
MMRF_1155	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1473	1586	1
MMRF_1155	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD: (D1, D8, D15)	Other	PO	PO	Log Forms	Other	SALVAGE		300	Other	QD: (D1, D8, D15)					1473	1586	1
MMRF_1155	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1473	1586	1
MMRF_1155	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	375	mg	mg	DAY -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		375	Other	DAY -2					1591	1591	1
MMRF_1155	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib			DOSE REDUCTION DUE TO FATIGUE	Other	4	mg	mg	DAYS 1, 8, 15 OF 28D CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	DAYS 1, 8, 15 OF 28D CYCLE					1771	1829	1
MMRF_1155	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib			DOSE REDUCTION DUE TO FATIGUE	Other	3	mg	mg	DAYS 1, 8, 15 OF 28D CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		3	Other	DAYS 1, 8, 15 OF 28D CYCLE					1830	1872	1
MMRF_1155	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		0	Disease progression/Relapse	Disease progression/Relapse	2.3	mg	mg	DAYS 1, 8, 15 OF 28D CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		2.3	Other	DAYS 1, 8, 15 OF 28D CYCLE					1873	2468	1
MMRF_1155	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	TAK-079	Other		0	Disease progression/Relapse	Disease progression/Relapse	600	mg	mg	QW(C1-2); Q2W(C3-6); Q4W(C7+)	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		600	Other	QW(C1-2); Q2W(C3-6); Q4W(C7+)					2482	2713	1
MMRF_1155	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	BEFORE TAK-079 INJECTION	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	BEFORE TAK-079 INJECTION					2482	2713	1
MMRF_1155	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	TAKE FOR 2 DAYS FOLLOWING TAK-079 INJECTION	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	TAKE FOR 2 DAYS FOLLOWING TAK-079 INJECTION					2482	2545	1
MMRF_1160	First line of therapy	First Line Therapy			Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms			Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1173	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	126	1
MMRF_1173	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	126	1
MMRF_1173	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	126	1
MMRF_1173	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					248	2155	1
MMRF_1173	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					2188		1
MMRF_1195	First line of therapy	First Line Therapy			Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms			Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1195	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms			Checked	20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1195	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		1			25	mg	mg	QD 1-14	Other	PO	PO	Log Forms			Checked	25	Other	QD 1-14					1		1
MMRF_1195	First line of therapy	First Line Therapy	TRANSPLANT	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	DAYS -3, -2, -1	Other	IV	IV	Log Forms	Other	TRANSPLANT		10	Other	DAYS -3, -2, -1					106	108	1
MMRF_1195	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	185	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		185	Other	DAYS -3, -2					106	107	1
MMRF_1219	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1219	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	25	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1219	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1219	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	72	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		72	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					278	1307	1
MMRF_1219	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Doxorubicin	Doxorubicin			Disease progression/Relapse	Disease progression/Relapse	30	mg/m^2	mg/m^2	DAY 8	Other	IV	IV	Log Forms	Induction	Induction		30	Other	DAY 8					278	1307	1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Elotuzumab	Elotuzumab			Completed regimen	Completed regimen	10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		10	Q week	Q week					1377	1433	1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			DOSE REDUCTION DUE TO DIZZINESS	Other	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1377	1433	1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1377	1797	1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		1			3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	3	QD (D1-21)	QD (D1-21)					1433		1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Elotuzumab	Elotuzumab			Completed regimen	Completed regimen	10	mg/kg	mg/kg	D1, D15	Other	IV	IV	Log Forms	Induction	Induction		10	Other	D1, D15					1433	1545	1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Elotuzumab	Elotuzumab		1			20	mg/kg	mg/kg	D1	Other	IV	IV	Log Forms	Induction	Induction	Checked	20	Other	D1					1545		1
MMRF_1219	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					1797		1
MMRF_1225	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	TAK-079	Other		1			1200	mg	mg	QW(C1-2); Q2W(C3-6); Q4W(C7+)	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE	Checked	1200	Other	QW(C1-2); Q2W(C3-6); Q4W(C7+)					2507		1
MMRF_1225	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	BEFORE TAK-079 INJECTION	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	BEFORE TAK-079 INJECTION					2507		1
MMRF_1225	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			4	mg	mg	FOR 2 DAYS FOLLOWING TAK-079 INJECTION	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	4	Other	FOR 2 DAYS FOLLOWING TAK-079 INJECTION					2507		1
MMRF_1225	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			MOVED TO SCT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	132	1
MMRF_1225	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					267	341	1
MMRF_1225	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-14)	QD (D1-14)					267	344	1
MMRF_1225	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 8, AND 15	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	DAYS 1, 8, AND 15					267	344	1
MMRF_1225	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					358	394	1
MMRF_1225	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		5	Q day	Q day					410	431	1
MMRF_1225	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Patient decision	Patient decision	1.3	mg/m^2	mg/m^2	TWICE A MONTH	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	TWICE A MONTH					431	960	1
MMRF_1225	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			DOSE REDUCTION	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1373	1422	1
MMRF_1225	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1422	1513	1
MMRF_1225	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Ixazomib	Ixazomib		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	DAYS 1, 8, 15					1669	2489	1
MMRF_1225	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1669	2489	1
MMRF_1225	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			MOVED TO SCT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	132	1
MMRF_1225	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			MOVED TO SCT	Other	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms				40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	132	1
MMRF_1226	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	68	1
MMRF_1226	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	68	1
MMRF_1226	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	68	1
MMRF_1226	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			DOCTOR DECISION	Other	2.2	mg	mg	Q2W	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.2	Other	Q2W					218	1212	1
MMRF_1226	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					736		1
MMRF_1226	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib		1			4	mg	mg	QD: DAYS 1, 8, 15	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	4	Other	QD: DAYS 1, 8, 15					1219		1
MMRF_1226	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					1219	1377	1
MMRF_1226	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	160	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		160	Other	DAYS -3, -2					96	97	1
MMRF_1234	First line of therapy	First Line Therapy			Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms			Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1234	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms			Checked	40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1234	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms			Checked	25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1234	First line of therapy	First Line Therapy	TRANSPLANT	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	DAYS -3, -2, -1	Other	IV	IV	Log Forms	Other	TRANSPLANT		10	Other	DAYS -3, -2, -1					80	82	1
MMRF_1234	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	215	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		215	Other	DAYS -3, -2					80	81	1
MMRF_1234	First line of therapy	First Line Therapy	TRANSPLANT	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	DAYS -3, -2, -1	Other	IV	IV	Log Forms	Other	TRANSPLANT		10	Other	DAYS -3, -2, -1					204	206	1
MMRF_1234	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	210	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		210	Other	DAYS -3, -2					204	205	1
MMRF_1269	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_1269	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	103	1
MMRF_1269	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms				20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	103	1
MMRF_1269	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					236	1462	1
MMRF_1269	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1475	1538	1
MMRF_1269	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	IV WEEKS WITH CARFILZOMIB, PO OFF-WEEK	Other	Log Forms	Other	SALVAGE		40	Q week	Q week					1475	1538	1
MMRF_1269	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab			DEATH	Other	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					1544	1590	1
MMRF_1269	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			DEATH	Other	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1544	1590	1
MMRF_1269	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			DEATH	Other	4	mg	mg	DAYS 1, 2 AFTER DARATUMUMAB	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	DAYS 1, 2 AFTER DARATUMUMAB					1544	1590	1
MMRF_1269	First line of therapy	First Line Therapy	PRE-TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	205	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	PRE-TRANSPLANT		205	Other	DAYS -3, -2					135	136	1
MMRF_1270	First line of therapy	First Line Therapy			Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms			Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1270	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms			Checked	40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1270	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms			Checked	25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1289	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			MOVED TO AUTO SCT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	49	1
MMRF_1289	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			MOVED TO AUTO SCT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	49	1
MMRF_1289	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			MOVED TO AUTO SCT	Other	20	mg	mg	DAY OF AND DAY AFTER BORTEZOMIB	Other	PO	PO	Log Forms				20	Other	DAY OF AND DAY AFTER BORTEZOMIB					1	49	1
MMRF_1289	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					219	295	1
MMRF_1289	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	TWICE A MONTH	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	TWICE A MONTH					219	295	1
MMRF_1289	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					330	393	1
MMRF_1289	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					330	393	1
MMRF_1289	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					330	393	1
MMRF_1289	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	DAILY DAYS 1-4	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAILY DAYS 1-4					393	417	1
MMRF_1289	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	400	mg/m^2	mg/m^2	DAILY DAYS 1-4	Other	IV	IV	Log Forms	Induction	Induction		400	Other	DAILY DAYS 1-4					393	417	1
MMRF_1289	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	ETOPOSIDE	Other			Patient decision	Patient decision	40	mg/m^2	mg/m^2	DAILY DAYS 1-4	Other	IV	IV	Log Forms	Induction	Induction		40	Other	DAILY DAYS 1-4					393	417	1
MMRF_1289	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	CISPLATIN	Other			Disease progression/Relapse	Disease progression/Relapse	10	mg/m^2	mg/m^2	DAILY DAYS 1-4	Other	IV	IV	Log Forms	Induction	Induction		10	Other	DAILY DAYS 1-4					393	417	1
MMRF_1289	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Vincristine	Vincristine			PATIENT WENT ON HOSPICE	Other	1.2	mg/m^2	mg/m^2	QID	QID	IV	IV	Log Forms	Unknown	Unknown		1.2	QID	QID					465	477	1
MMRF_1289	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	BCNU	BCNU			PATIENT WENT ON HOSPICE	Other	20	mg/m^2	mg/m^2	QID	QID	IV	IV	Log Forms	Unknown	Unknown		20	QID	QID					465	477	1
MMRF_1289	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Melphalan	Melphalan			PATIENT WENT ON HOSPICE	Other	8	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		8	QD (D1-4)	QD (D1-4)					465	477	1
MMRF_1289	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			PATIENT WENT ON HOSPICE	Other	400	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		400	QD (D1-4)	QD (D1-4)					465	477	1
MMRF_1289	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Prednisone	Prednisone			PATIENT WENT ON HOSPICE	Other	40	mg/m^2	mg/m^2	QD (D1-7)	QD (D1-7)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1-7)	QD (D1-7)					465	477	1
MMRF_1289	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	190	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		190	Other	DAYS -3, -2					88	89	1
MMRF_1356	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	260	1
MMRF_1356	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms				25	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	260	1
MMRF_1356	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms				40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	260	1
MMRF_1356	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					260	464	1
MMRF_1356	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	EVERY 2 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY 2 WEEKS					659	1002	1
MMRF_1356	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	125	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		125	Other	DAYS -3, -2					548	549	1
MMRF_1356	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					1018	1298	1
MMRF_1356	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1018	1298	1
MMRF_1356	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Elotuzumab	Elotuzumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		10	Q week	Q week					1018	1298	1
MMRF_1356	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	57	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		57	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1424	1501	1
MMRF_1356	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		25	Q week	Q week					1424	1501	1
MMRF_1356	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	50	mg	mg	Q week	Q week	10 MG IV; 40 MG PO	Other	Log Forms	Other	SALVAGE		50	Q week	Q week					1424	1501	1
MMRF_1356	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	WEEKLY(C1-2); Q 2 WEEKS(C3-6); MONTHLY(C7+)	Other	IV	IV	Log Forms	Other	SALVAGE		16	Other	WEEKLY(C1-2); Q 2 WEEKS(C3-6); MONTHLY(C7+)					1515	1675	1
MMRF_1356	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		20	Q week	Q week					1515	1675	1
MMRF_1373	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms				20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	71	1
MMRF_1373	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	18	1
MMRF_1373	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	155	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		155	Other	DAYS -3, -2					124	125	1
MMRF_1373	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE REDUCTION DUE TO NEUTROPENIA	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					227	328	1
MMRF_1373	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					328		1
MMRF_1373	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IVB	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_1390	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	47	1
MMRF_1390	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms				40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	26	1
MMRF_1441	First line of therapy	First Line Therapy			Bortezomib	Bortezomib		1			2.16	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms			Checked	2.16	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1441	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		1			10	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms			Checked	10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1441	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms			Checked	15	QD (D1-21)	QD (D1-21)					1		1
MMRF_1445	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	37	1
MMRF_1445	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.08	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.08	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	86	1
MMRF_1445	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	86	1
MMRF_1445	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			4	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	4	Q week	Q week					133		1
MMRF_1445	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.08	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Induction	Induction	Checked	2.08	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					133		1
MMRF_1496	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	121	1
MMRF_1496	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					5	60	1
MMRF_1496	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					47	121	1
MMRF_1496	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					226	293	1
MMRF_1496	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					320	342	1
MMRF_1496	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		4	Q day	Q day					289	453	1
MMRF_1496	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	50	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		50	QWK	QWK					320	370	1
MMRF_1496	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					342	423	1
MMRF_1496	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					383	423	1
MMRF_1496	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	180	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		180	Other	DAYS -3, -2					121	122	1
MMRF_1496	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TRANSPLANT	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4200	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		4200	Other	DAYS -3, -2					423	424	1
MMRF_1511	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	1	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		1	Q week	Q week					1749	2241	1
MMRF_1511	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			MOVED TO SCT	Other	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	63	1
MMRF_1511	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			MOVED TO SCT	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	63	1
MMRF_1511	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	8	1
MMRF_1511	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			INCREASING NEUROPATHY	Other	1	mg/m^2	mg/m^2	TWICE A MONTH	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1	Other	TWICE A MONTH					192	777	1
MMRF_1511	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD: DAYS 1, 2, 15, 16	Other	IV	IV	Log Forms	Maintenance	Maintenance		36	Other	QD: DAYS 1, 2, 15, 16					777	973	1
MMRF_1511	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		4	Q week	Q week					1215	1496	1
MMRF_1511	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		2	Q week	Q week					1215	1496	1
MMRF_1511	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Patient decision	Patient decision	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Other	SALVAGE		16	QWK	QWK					1518	1600	1
MMRF_1511	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			DOSE REDUCTION	Other	2	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		2	QWK	QWK					1518	1748	1
MMRF_1511	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	Q 2 DAYS (DAYS 1-21 OF 28D)	Other	PO	PO	Log Forms	Other	SALVAGE		2	Other	Q 2 DAYS (DAYS 1-21 OF 28D)					1518	2241	1
MMRF_1511	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2252		1
MMRF_1511	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Elotuzumab	Elotuzumab		1			10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE	Checked	10	Q week	Q week					2252		1
MMRF_1511	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	DAYS 2,4,5,9,11,12 Q 21D	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	DAYS 2,4,5,9,11,12 Q 21D					2252		1
MMRF_1584	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-14)	QD (D1-14)					32		1
MMRF_1584	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction	Checked	2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					32		1
MMRF_1584	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					32		1
MMRF_1584	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			CHANGED DOSE	Other	16	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		16	Q day	Q day					1	11	1
MMRF_1584	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			CHNAGED DOSE	Other	4	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		4	Q day	Q day					11	32	1
MMRF_1624	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	142	1
MMRF_1624	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	142	1
MMRF_1624	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	142	1
MMRF_1624	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					292	1440	1
MMRF_1624	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QW(C1-2); Q2W(C3-6)	Other	IV	IV	Log Forms	Other	SALVAGE		16	Other	QW(C1-2); Q2W(C3-6)					1449	1582	1
MMRF_1624	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1449	1469	1
MMRF_1624	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg/dL	mg/dL	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		4	Q day	Q day					1449	1469	1
MMRF_1624	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1616	1861	1
MMRF_1624	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1616	1840	1
MMRF_1624	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1616	1861	1
MMRF_1624	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	300	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		300	QWK	QWK					1840	1861	1
MMRF_1624	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	TRANSPLANT	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	TRANSPLANT		140	Other	ONCE					1922	1922	1
MMRF_1624	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	140	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	TRANSPLANT		140	Q day	Q day					181	182	1
MMRF_1667	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			MOVED TO SCT	Other	20	mg	mg	DAY OF AND DAY AFTER VELCADE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER VELCADE					1	107	1
MMRF_1667	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			MOVED TO SCT	Other	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	106	1
MMRF_1667	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			MOVED TO SCT	Other	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	106	1
MMRF_1667	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					259	474	1
MMRF_1667	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					475	536	1
MMRF_1668	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	650	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Induction	Induction		650	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					8	142	1
MMRF_1668	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					2	142	1
MMRF_1668	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	3.2	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		3.2	Q week	Q week					1	142	1
MMRF_1668	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					142	202	1
MMRF_1668	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		40	QWK	QWK					143	202	1
MMRF_1668	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					142	202	1
MMRF_1668	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					209	251	1
MMRF_1668	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					209	251	1
MMRF_1668	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					209	251	1
MMRF_1760	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					135	197	1
MMRF_1760	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1	Q week	Q week					211	848	1
MMRF_1760	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			DOCTOR DECISION	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					211	673	1
MMRF_1760	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			FREQUENCY CHANGE DUE TO PERIPHERAL NEUROPATHY	Other	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					953	1057	1
MMRF_1760	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					953	1113	1
MMRF_1760	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	Q 2 DAYS (DAYS 1-21)	Other	PO	PO	Log Forms	Other	SALVAGE		2	Other	Q 2 DAYS (DAYS 1-21)					1058	1113	1
MMRF_1760	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg/kg	mg/kg	WEEKLY(C1-2); Q 2 WEEKS(C3-6); MONTHY (C7+)	Other	IV	IV	Log Forms	Other	SALVAGE		16	Other	WEEKLY(C1-2); Q 2 WEEKS(C3-6); MONTHY (C7+)					1211	2052	1
MMRF_1760	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	8	mg	mg	WEEKLY(C1-2); Q 2 WEEKS(C3-6); MONTHY (C7+)	Other	PO	PO	Log Forms	Other	SALVAGE		8	Other	WEEKLY(C1-2); Q 2 WEEKS(C3-6); MONTHY (C7+)					1211	2052	1
MMRF_1760	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					22	134	1
MMRF_1760	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	134	1
MMRF_1760	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Disease progression/Relapse	Disease progression/Relapse	16	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					135	197	1
MMRF_1783	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	156	1
MMRF_1783	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3.71	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		3.71	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1783	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	156	1
MMRF_1783	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					192	380	1
MMRF_1783	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					192	380	1
MMRF_1783	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					380	481	1
MMRF_1783	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		300	QWK	QWK					380	481	1
MMRF_1783	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					380	481	1
MMRF_1783	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide			DEATH	Other	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-21)	QD (D1-21)					632	718	1
MMRF_1783	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	470	mg	mg	DAY -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		470	Other	DAY -2					493	493	1
MMRF_1784	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			MOVED TO SCT	Other	40	mg	mg	DAY OF AND AFTER BORTEZOIB	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAY OF AND AFTER BORTEZOIB					1	75	1
MMRF_1784	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			MOVED TO AUTO SCT	Other	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1784	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			MOVED TO SCT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					22	77	1
MMRF_1784	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					204	1688	1
MMRF_1784	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Elotuzumab	Elotuzumab		0	Completed regimen	Completed regimen	10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		10	Q week	Q week					1702	1814	1
MMRF_1784	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		1			20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2110		1
MMRF_1784	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide		1			300	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV	IV	Log Forms	Induction	Induction	Checked	300	Other	QD (D1, D8, D15)					2110		1
MMRF_1784	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2110		1
MMRF_1784	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1702	1814	1
MMRF_1784	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	36	mg	mg	Q week	Q week	28MG(PO); 8MG(IV)	Other	Log Forms	Other	SALVAGE		36	Q week	Q week					1702	1814	1
MMRF_1784	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TRANSPLANT	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	350	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	TRANSPLANT		350	Other	ONCE					1820	1820	1
MMRF_1784	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Elotuzumab	Elotuzumab		0	Disease progression/Relapse	Disease progression/Relapse	10	mg/kg	mg/kg	Q 2 WEEKS	Other	IV	IV	Log Forms	Consolidation	Consolidation		10	Other	Q 2 WEEKS					1929	2108	1
MMRF_1784	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					1929	2108	1
MMRF_1784	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	Q 2 WEEKS	Other	PO	PO	Log Forms	Consolidation	Consolidation		8	Other	Q 2 WEEKS					1929	2108	1
MMRF_1839	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	170	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	TRANSPLANT		170	Q day	Q day					113	114	1
MMRF_1839	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					7	102	1
MMRF_1839	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	102	1
MMRF_1839	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	102	1
MMRF_1839	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					240	1123	1
MMRF_1839	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	TWICE A MONTH	Other	IV	IV	Log Forms	Maintenance	Maintenance		1.3	Other	TWICE A MONTH					240	898	1
MMRF_1851	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	4	1
MMRF_1851	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			PATIENT WENT ON HOSPICE	Other	20	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-14)	QD (D1-14)					13	25	1
MMRF_1851	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PATIENT WENT ON HOSPICE	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					12	25	1
MMRF_1851	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PATIENT WENT ON HOSPICE	Other	20	mg	mg	DAY OF AND DAY AFTER BORTEZOMIB	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER BORTEZOMIB					12	25	1
MMRF_1876	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1876	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QWK	QWK	PO	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	85	1
MMRF_1876	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD 1-4, 9-12, 17-20 OF 28	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD 1-4, 9-12, 17-20 OF 28					1	85	1
MMRF_1876	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Lack of response	Lack of response	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Other	SALVAGE		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					490	564	1
MMRF_1876	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Other	SALVAGE		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					490	564	1
MMRF_1876	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	150	mg/m^2	mg/m^2	BID (D1-5)	Other	PO	PO	Log Forms	Other	SALVAGE		150	Other	BID (D1-5)					490	564	1
MMRF_1876	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					239	490	1
MMRF_1889	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	38	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		38	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	106	1
MMRF_1889	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	106	1
MMRF_1889	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	106	1
MMRF_1889	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		25	Q day	Q day					266	421	1
MMRF_1889	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.5	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1.5	QWK	QWK					421	519	1
MMRF_1889	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		300	QWK	QWK					421	519	1
MMRF_1889	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		40	Q day	Q day					421	519	1
MMRF_1889	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Lack of response	Lack of response	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					519	554	1
MMRF_1889	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Thalidomide	Thalidomide			Lack of response	Lack of response	200	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		200	Q day	Q day					519	554	1
MMRF_1889	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					687	800	1
MMRF_1889	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					519	638	1
MMRF_1889	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Bendamustine	Bendamustine			Disease progression/Relapse	Disease progression/Relapse	80	mg/m^2	mg/m^2	D1, D2	Other	IVB	IVB	Log Forms	Other	SALVAGE		80	Other	D1, D2					557	638	1
MMRF_1889	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			DOSE REDUCTION DUE TO ADVERSE EVENT	Other	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					659	687	1
MMRF_1889	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					659	800	1
MMRF_1889	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	60	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		60	Q week	Q week					659	800	1
MMRF_1889	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	160	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		160	Other	DAYS -3, -2					139	140	1
MMRF_1891	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_1891	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	103	1
MMRF_1891	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAY OF AND DAY AFTER BORTEZOMIB	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER BORTEZOMIB					1	103	1
MMRF_1891	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					204	599	1
MMRF_1891	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	ABBV-838	Other			NEUROPATHY	Other	.6	mg/kg	mg/kg	Q 21 DAYS	Other	IV	IV	Log Forms	Other	SALVAGE		0.6	Other	Q 21 DAYS					645	1037	1
MMRF_1891	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Elotuzumab	Elotuzumab		1			10	mg/kg	mg/kg	WEEKLY(C1-2); Q 2 WEEKS(C3+)	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	10	Other	WEEKLY(C1-2); Q 2 WEEKS(C3+)					1058		1
MMRF_1891	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	25	QD (D1-21)	QD (D1-21)					1058		1
MMRF_1891	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			28	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE	Checked	28	Q week	Q week					1058		1
MMRF_1893	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					4	73	1
MMRF_1893	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	73	1
MMRF_1893	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAY OF AND DAY AFTER BORTEZOMIB	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER BORTEZOMIB					4	73	1
MMRF_1893	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			SWITCHED REGIMEN	Other	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	3	1
MMRF_1893	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			PATIENT FORGETFULLNESS AND INABILITY/RELUCTANCE TO MEET DEDUCTIBLE	Other	20	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		20	Q day	Q day					232	802	1
MMRF_1893	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	180	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	TRANSPLANT		180	Q day	Q day					117	118	1
MMRF_1900	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-14)	QD (D1-14)					405	539	1
MMRF_1900	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	TWICE WEEKLY	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	TWICE WEEKLY					405	539	1
MMRF_1900	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOCTOR DECISION	Other	5	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-14)	QD (D1-14)					614	708	1
MMRF_1900	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			DOCTOR DECISION	Other	20	mg	mg	B.I. WEEKLY	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	B.I. WEEKLY					614	708	1
MMRF_1900	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			DEATH	Other	5	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Other	SALVAGE		5	QD (D1-14)	QD (D1-14)					925	1282	1
MMRF_1900	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			DEATH	Other	4	mg	mg	3X WEEKLY	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	3X WEEKLY					925	1282	1
MMRF_1900	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	DAY 1, DAY 8 & DAY 15, OF 28	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1, DAY 8 & DAY 15, OF 28					1	253	1
MMRF_1900	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	253	1
MMRF_1900	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAY 1, DAY 8 & DAY 15, OF 28	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY 1, DAY 8 & DAY 15, OF 28					1	253	1
MMRF_1900	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					253	344	1
MMRF_1911	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	91	1
MMRF_1911	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	91	1
MMRF_1911	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	91	1
MMRF_1911	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					213	317	1
MMRF_1911	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					213	317	1
MMRF_1911	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					213	317	1
MMRF_1911	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					360		1
MMRF_1953	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1953	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	65	1
MMRF_1953	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	65	1
MMRF_1953	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOCTOR DECISION	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					248	640	1
MMRF_1953	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					752		1
MMRF_1953	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	175	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	TRANSPLANT		175	Q day	Q day					124	125	1
MMRF_1955	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			SWITCHED TO WEEKLY DEX	Other	40	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		40	Q day	Q day					1	4	1
MMRF_1955	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	162	1
MMRF_1955	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	DAY OF AND DAY AFTER BORTEZOMIB	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER BORTEZOMIB					10	162	1
MMRF_1974	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1974	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			CHANGED FREQUENCY	Other	40	mg	mg	DAYS 1-4, 9-12, 17-20	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1-4, 9-12, 17-20					1	22	1
MMRF_1974	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAYS 1 AND 8	Other	IV	IV	Log Forms	Induction	Induction		300	Other	DAYS 1 AND 8					4	96	1
MMRF_1974	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAY OF AND DAY AFTER BORTEZOMIB	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER BORTEZOMIB					23	96	1
MMRF_1974	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					188	363	1
MMRF_1974	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					188	363	1
MMRF_1974	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					188	363	1
MMRF_1974	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					371	398	1
MMRF_1974	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	DAYS 1,8,15,22	Other	PO	PO	Log Forms	Other	SALVAGE		40	Other	DAYS 1,8,15,22					371	398	1
MMRF_1974	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	CLARITHROMYCIN (BIAXIN)	Other			Disease progression/Relapse	Disease progression/Relapse	250	mg	mg	BID	BID	PO	PO	Log Forms	Other	SALVAGE		250	BID	BID					371	398	1
MMRF_1974	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Bendamustine	Bendamustine			Disease progression/Relapse	Disease progression/Relapse	75	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Other	SALVAGE		75	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					408	419	1
MMRF_1974	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	50	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Other	SALVAGE		50	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					408	419	1
MMRF_1974	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					429	545	1
MMRF_1974	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	400	mg/m^2	mg/m^2	CONTINUOUS INFUSION DAYS 1-4	Other	IV	IV	Log Forms	Other	SALVAGE		400	Other	CONTINUOUS INFUSION DAYS 1-4					429	545	1
MMRF_1974	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	ETOPOSIDE (VEPESID)	Other			Investigator decision for other reasons	Investigator decision for other reasons	40	mg/m^2	mg/m^2	CONTINUOUS INFUSION DAYS 1-4	Other	IV	IV	Log Forms	Other	SALVAGE		40	Other	CONTINUOUS INFUSION DAYS 1-4					429	545	1
MMRF_1974	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	CISPLATIN (PLATINOL)	Other			Investigator decision for other reasons	Investigator decision for other reasons	15	mg/m^2	mg/m^2	CONTINUOUS INFUSION DAYS 1-4	Other	IV	IV	Log Forms	Other	SALVAGE		15	Other	CONTINUOUS INFUSION DAYS 1-4					429	545	1
MMRF_1974	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					573	713	1
MMRF_1974	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	2.5	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		2.5	Q day	Q day					573	636	1
MMRF_1974	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					573	636	1
MMRF_1974	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					671	713	1
MMRF_1974	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	400	mg/m^2	mg/m^2	CONTINUOUS INFUSION DAYS 1-4	Other	IV	IV	Log Forms	Other	SALVAGE		400	Other	CONTINUOUS INFUSION DAYS 1-4					721	842	1
MMRF_1974	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					721	842	1
MMRF_1974	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	ETOPOSIDE (VEPESID)	Other			Disease progression/Relapse	Disease progression/Relapse	40	mg/m^2	mg/m^2	CONTINUOUS INFUSION DAYS 1-4	Other	IV	IV	Log Forms	Other	SALVAGE		40	Other	CONTINUOUS INFUSION DAYS 1-4					721	842	1
MMRF_1974	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	CISPLATIN (PLATINOL)	Other			Disease progression/Relapse	Disease progression/Relapse	15	mg/m^2	mg/m^2	CONTINUOUS INFUSION DAYS 1-4	Other	IV	IV	Log Forms	Other	SALVAGE		15	Other	CONTINUOUS INFUSION DAYS 1-4					721	842	1
MMRF_1974	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	NIVOLUMAB	Other			DEATH	Other	3	mg/kg	mg/kg	QD (D1, D15)	Other	IV	IV	Log Forms	Other	SALVAGE		3	Other	QD (D1, D15)					863	892	1
MMRF_1974	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			DEATH	Other	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					863	892	1
MMRF_1974	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			DEATH	Other	40	mg	mg	QD (D8, D22)	Other	PO	PO	Log Forms	Other	SALVAGE		40	Other	QD (D8, D22)					863	892	1
MMRF_1974	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	185	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		185	Other	DAYS -3, -2					103	104	1
MMRF_1982	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	91	1
MMRF_1982	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	91	1
MMRF_1982	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAY OF AND DAY AFTER VELCADE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND DAY AFTER VELCADE					1	91	1
MMRF_1982	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		4	Q day	Q day					91	165	1
MMRF_1986	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			SWITCHED TO PO DEX	Other	40	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		40	Q day	Q day					1	2	1
MMRF_1986	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			SWITCHED TO WEEKLY DEX	Other	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		40	Q day	Q day					3	4	1
MMRF_1986	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					6	125	1
MMRF_1986	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DISCONTINUED DUE TO GRADE 2 TRANSAMINITIS	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					6	398	1
MMRF_1986	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DISCONTINUED DUE TO GRADE 2 TRANSAMINITIS	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					13	398	1
MMRF_1999	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			SWITCHED TO WEEKLY	Other	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	4	1
MMRF_1999	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					14	56	1
MMRF_1999	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					10	56	1
MMRF_1999	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					10	56	1
MMRF_1999	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	145	mg	mg	DAYS -3, -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		145	Other	DAYS -3, -2					118	119	1
MMRF_2014	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		1	PATIENT DECEASED	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	10	QD (D1-21)	QD (D1-21)					2042	2094	1
MMRF_2014	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1	PATIENT DECEASED	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE	Checked	40	Q week	Q week					2042	2094	1
MMRF_2014	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2014	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	93	1
MMRF_2014	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	93	1
MMRF_2014	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					212	1010	1
MMRF_2014	First line of therapy	First Line Therapy	Maintenance	Maintenance	Prednisone	Prednisone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		40	Q day	Q day					458	711	1
MMRF_2014	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Elotuzumab	Elotuzumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		10	Q week	Q week					1066	1320	1
MMRF_2014	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			SHOULDER SURGERY	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		15	QD (D1-21)	QD (D1-21)					1066	1320	1
MMRF_2014	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	28	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		28	Q week	Q week					1066	1320	1
MMRF_2043	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_2043	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	81	1
MMRF_2043	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	81	1
MMRF_2043	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Patient decision	Patient decision	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					202	254	1
MMRF_2063	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PATIENT EXPIRED	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	46	1
MMRF_2063	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			PATIENT EXPIRED	Other	450	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		450	Q week	Q week					1	46	1
MMRF_2101	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		4	QWK	QWK					1	89	1
MMRF_2101	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	89	1
MMRF_2101	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					20	62	1
MMRF_2101	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE REDUCTION	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					224	567	1
MMRF_2101	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					567		1
MMRF_2124	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					280	679	1
MMRF_2124	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					280	679	1
MMRF_2124	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					280	679	1
MMRF_2124	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE REDUCTION DUE TO GRADE 2 NEUTROPENIA	Other	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					679	762	1
MMRF_2124	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	2.5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		2.5	Q day	Q day					763	1218	1
MMRF_2124	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Elotuzumab	Elotuzumab			Completed regimen	Completed regimen	10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		10	Q week	Q week					1258	1370	1
MMRF_2124	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1258	1370	1
MMRF_2124	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1258	1370	1
MMRF_2124	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1386	1475	1
MMRF_2124	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Completed regimen	Completed regimen	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		16	Q week	Q week					1386	1475	1
MMRF_2124	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1386	1475	1
MMRF_2124	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	20	1
MMRF_2124	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.2	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		2.2	Q week	Q week					1	20	1
MMRF_2124	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					21	159	1
MMRF_2124	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					21	159	1
MMRF_2124	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					21	159	1
MMRF_2124	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	TRANSPLANT CONDITIONING	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	300	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	TRANSPLANT CONDITIONING		300	Other	ONCE					1497	1497	1
MMRF_2124	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	TRANSPLANT CONDITIONING	Other	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	TRANSPLANT CONDITIONING		10	Q day	Q day					1497	1499	1
MMRF_2124	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		1			3	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance	Checked	3	Q week	Q week					1624		1
MMRF_2198	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	29	1
MMRF_2198	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TOXICITY	Other	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	99	1
MMRF_2198	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TOXICITY	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_2198	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			TOXICITY	Other	50	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		50	Q day	Q day					29	99	1
MMRF_2198	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					141	225	1
MMRF_2198	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		10	Q day	Q day					141	225	1
MMRF_2198	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			FATIGUE	Other	1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					365	743	1
MMRF_2198	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	QD (D1, D8, D15)					743	897	1
MMRF_2198	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	WEEKLY(C1-2), Q 2WEEKS(C3-6), MONTHLY(C7+)	Other	IV	IV	Log Forms	Other	SALVAGE		16	Other	WEEKLY(C1-2), Q 2WEEKS(C3-6), MONTHLY(C7+)					943	1170	1
MMRF_2198	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	DURVALUMAB	Other			Disease progression/Relapse	Disease progression/Relapse	1500	mg	mg	DAY 1 (28D CYCLE)	Other	IV	IV	Log Forms	Other	SALVAGE		1500	Other	DAY 1 (28D CYCLE)					943	1170	1
MMRF_2198	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		20	QWK	QWK					943	1170	1
MMRF_2198	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1188	1527	1
MMRF_2198	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			DOSE REDUCTION	Other	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					1188	1274	1
MMRF_2198	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1188	1527	1
MMRF_2198	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1275	1527	1
MMRF_2198	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					1558	1611	1
MMRF_2198	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		0	DOSE REDUCTION	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					1558	1582	1
MMRF_2198	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		15	QD (D1-21)	QD (D1-21)					1583	1611	1
MMRF_2198	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					1558	1611	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	DOSE REDUCTION	Other	400	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		400	QD (D1-4)	QD (D1-4)					1635	1639	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	CISPLATIN	Other		0	DOSE REDUCTION	Other	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		10	QD (D1-4)	QD (D1-4)					1635	1639	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	ETOPOSIDE	Other		0	DOSE REDUCTION	Other	40	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1635	1639	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	DOSE REDUCTION	Other	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1635	1639	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		300	QD (D1-4)	QD (D1-4)					1671	1711	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	CISPLATIN	Other		0	Completed regimen	Completed regimen	7.5	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		7.5	QD (D1-4)	QD (D1-4)					1671	1711	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	ETOPOSIDE	Other		0	Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		30	QD (D1-4)	QD (D1-4)					1671	1711	1
MMRF_2198	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SALVAGE		20	QD (D1-4)	QD (D1-4)					1671	1711	1
MMRF_2198	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	DAY 1 Q 28D	Other	IV	IV	Log Forms	Other	SALVAGE		2000	Other	DAY 1 Q 28D					1940	1940	1
MMRF_2198	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		1			1500	mg/m^2	mg/m^2	DAY 1 Q 28D	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	1500	Other	DAY 1 Q 28D					1981		1
MMRF_2198	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			10	mg	mg	DAY 1 Q 28D	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	10	Other	DAY 1 Q 28D					1940		1
MMRF_2198	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			8	mg	mg	DAY 1,2, POST CYCLOPHOSPHAMIDE ADMINSTRATION	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	8	Other	DAY 1,2, POST CYCLOPHOSPHAMIDE ADMINSTRATION					1941		1
MMRF_2226	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2226	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction	Checked	15	QD (D1-14)	QD (D1-14)					1		1
MMRF_2226	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1		1
MMRF_2270	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_2270	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	99	1
MMRF_2270	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	99	1
MMRF_2270	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	DAYS -3, -2	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	DAYS -3, -2					110	111	1
MMRF_2270	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	DOSE REDUCTION	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					226	957	1
MMRF_2270	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					957	1991	1
MMRF_2271	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	154	1
MMRF_2271	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	12	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		12	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	154	1
MMRF_2272	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	17	1
MMRF_2272	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	17	1
MMRF_2449	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2449	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	10	mg/kg	mg/kg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		10	Q week	Q week					1	74	1
MMRF_2449	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		20	Q day	Q day					1	74	1
MMRF_2449	First line of therapy	First Line Therapy	PRE-ASCT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	315	mg	mg	Q day	Q day	IVB	IVB	Log Forms	Other	PRE-ASCT		315	Q day	Q day					114	114	1
MMRF_2449	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	EVERY 2 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	EVERY 2 WEEKS					215		1
MMRF_2449	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					215		1
MMRF_2446	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	304	mg	mg	DAYS -2	Other	PO	PO	Log Forms	Other	CONDITIONING		304	Other	DAYS -2					118	118	1
MMRF_2446	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2446	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	93	1
MMRF_2446	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					1	93	1
MMRF_2446	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.6	mg/m^2	mg/m^2	TWICE A MONTH	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	1.6	Other	TWICE A MONTH					232		1
MMRF_2446	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					260		1
MMRF_2514	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					1	23	1
MMRF_2514	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	24	1
MMRF_2514	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					105	196	1
MMRF_2514	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					105	210	1
MMRF_2514	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					105	210	1
MMRF_2514	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	D1, D8, D15	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	D1, D8, D15					287	389	1
MMRF_2514	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	23	1
MMRF_2514	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					287	389	1
MMRF_2514	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	330	mg	mg	DAY -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		330	Other	DAY -2					418	418	1
MMRF_2514	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					555		1
MMRF_2531	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_2531	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_2531	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	85	1
MMRF_2531	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					239	413	1
MMRF_2531	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					423	480	1
MMRF_2531	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV	IV	Log Forms	Other	SALVAGE		300	Other	QD (D1, D8, D15)					423	480	1
MMRF_2531	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					423	480	1
MMRF_2531	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab			DEATH	Other	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					484	546	1
MMRF_2531	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			DEATH	Other	4	mg	mg	QD: D1, D2 AFTER DARATUMUMAB INFUSION	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	QD: D1, D2 AFTER DARATUMUMAB INFUSION					484	546	1
MMRF_2531	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					484	505	1
MMRF_2531	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	298	mg	mg	DAY -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		298	Other	DAY -2					119	119	1
MMRF_2541	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2541	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	500	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Induction	Induction		500	QWK	QWK					1	93	1
MMRF_2541	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	158	1
MMRF_2541	First line of therapy	First Line Therapy	SALVAGE	Other	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					106	158	1
MMRF_2541	First line of therapy	First Line Therapy	SALVAGE	Other	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					106	158	1
MMRF_2541	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib			Completed regimen	Completed regimen	3	mg	mg	QD: D1, D8, D15	Other	PO	PO	Log Forms	Maintenance	Maintenance		3	Other	QD: D1, D8, D15					329	385	1
MMRF_2541	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					329	561	1
MMRF_2541	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	CISPLATIN	Other			Disease progression/Relapse	Disease progression/Relapse	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		10	QD (D1-4)	QD (D1-4)					926	953	1
MMRF_2541	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Melphalan	Melphalan			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-4)	QD (D1-4)					968	1029	1
MMRF_2541	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	5 TIMES A DAY FOR DAYS 1-7, TAPER BY 10 MG FOR DAYS 8-11	Other	PO	PO	Log Forms	Other	SALVAGE		10	Other	5 TIMES A DAY FOR DAYS 1-7, TAPER BY 10 MG FOR DAYS 8-11					968	1029	1
MMRF_2541	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Vincristine	Vincristine			Disease progression/Relapse	Disease progression/Relapse	1.28	mg	mg	DAY 1	Other	IV	IV	Log Forms	Other	SALVAGE		1.28	Other	DAY 1					968	1029	1
MMRF_2541	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	425	mg	mg	DAY 1	Other	IV	IV	Log Forms	Other	SALVAGE		425	Other	DAY 1					968	1029	1
MMRF_2541	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	BCNU	BCNU			Disease progression/Relapse	Disease progression/Relapse	16	mg	mg	DAY 1	Other	IV	IV	Log Forms	Other	SALVAGE		16	Other	DAY 1					968	1029	1
MMRF_2541	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	DAYS 1,4,15,18	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1.3	Other	DAYS 1,4,15,18					1043	1064	1
MMRF_2541	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Panobinostat	Panobinostat			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	M, W, F: Q 2 WEEKS	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	M, W, F: Q 2 WEEKS					1043	1064	1
MMRF_2541	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1,2,4,5,15,16,18,19	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	DAYS 1,2,4,5,15,16,18,19					1043	1064	1
MMRF_2541	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			DEATH	Other	2100	mg	mg	DAY 1	Other	IV	IV	Log Forms	Other	SALVAGE		2100	Other	DAY 1					1068	1079	1
MMRF_2541	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	278	mg	mg	DAY -2	Other	IV	IV	Log Forms	Other	TRANSPLANT		278	Other	DAY -2					161	161	1
MMRF_2541	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	400	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		400	QD (D1-4)	QD (D1-4)					926	953	1
MMRF_2541	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	ETOPOSIDE	Other			Disease progression/Relapse	Disease progression/Relapse	40	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					926	953	1
MMRF_2541	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					621	701	1
MMRF_2541	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			FREQUENCY CHANGE DUE TO SHORTNESS OF BREATH	Other	36	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					666	701	1
MMRF_2541	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					666	760	1
MMRF_2541	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	36	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV	IV	Log Forms	Other	SALVAGE		36	Other	QD (D1, D8, D15)					701	760	1
MMRF_2541	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					792	803	1
MMRF_2541	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Other	SALVAGE		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					792	803	1
MMRF_2541	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	VIRACEPT	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2500	mg	mg	BID (D1-14)	Other	PO	PO	Log Forms	Other	SALVAGE		2500	Other	BID (D1-14)					792	803	1
MMRF_2541	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Bendamustine	Bendamustine			Disease progression/Relapse	Disease progression/Relapse	70	mg/m^2	mg/m^2	QD (D 1-2)	Other	IV	IV	Log Forms	Other	SALVAGE		70	Other	QD (D 1-2)					819	834	1
MMRF_2541	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	50	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SALVAGE		50	QD (D1-4)	QD (D1-4)					819	834	1
MMRF_2541	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Other	SALVAGE		16	QWK	QWK					847	903	1
MMRF_2541	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					847	903	1
MMRF_2541	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		20	QWK	QWK					847	903	1
MMRF_2541	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					926	953	1
MMRF_2541	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD: D1, D8, D15	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	QD: D1, D8, D15					273	385	1
MMRF_2541	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Lack of response	Lack of response	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					571	662	1
MMRF_2541	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			DOSE/FREQUENCY CHANGE	Other	4	mg	mg	Q 2 DAYS	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	Q 2 DAYS					571	620	1
MMRF_2541	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Lack of response	Lack of response	4	mg	mg	DAY 1, 2 AFTER DARATUMUMAB INFUSION	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	DAY 1, 2 AFTER DARATUMUMAB INFUSION					571	662	1
MMRF_2541	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD: D1, D8, D15	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	QD: D1, D8, D15					273	328	1
MMRF_2541	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					273	328	1
MMRF_2592	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					1	125	1
MMRF_2592	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Induction	Induction		300	QWK	QWK					1	125	1
MMRF_2592	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	125	1
MMRF_2592	First line of therapy	First Line Therapy	Consolidation	Consolidation	Ixazomib	Ixazomib			Completed regimen	Completed regimen	4	mg	mg	QD: D1, D8, D15	Other	PO	PO	Log Forms	Consolidation	Consolidation		4	Other	QD: D1, D8, D15					282	394	1
MMRF_2592	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					282	394	1
MMRF_2592	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD: D1, D8, D15	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	QD: D1, D8, D15					282	394	1
MMRF_2592	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					415	468	1
MMRF_2592	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					482		1
MMRF_2611	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	105	1
MMRF_2611	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	105	1
MMRF_2611	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	105	1
MMRF_2611	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					246	358	1
MMRF_2611	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					246	358	1
MMRF_2611	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib			Completed regimen	Completed regimen	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					246	358	1
MMRF_2611	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					379	1502	1
MMRF_2611	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Elotuzumab	Elotuzumab		1			10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE	Checked	10	Q week	Q week					1597		1
MMRF_2611	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					1597		1
MMRF_2611	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			28	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE	Checked	28	Q week	Q week					1597		1
MMRF_2621	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	133	1
MMRF_2621	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	133	1
MMRF_2621	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	133	1
MMRF_1013	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg/m^2	mg/m^2	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	47	1
MMRF_1013	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1013	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1013	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms				200	Q day	Q day					135	136	1
MMRF_1013	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				5	QD (D1-21)	QD (D1-21)					212	1865	1
MMRF_1013	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Unknown	Unknown		3	Other	QD(D1,D8,D15)					1655	1865	1
MMRF_1013	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		20	QWK	QWK					1657	1865	1
MMRF_1013	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	10	mg/kg	mg/kg	QD(D1,D8,D15,D22)	Other	IV	IV	Log Forms	Unknown	Unknown		10	Other	QD(D1,D8,D15,D22)					1896	1957	1
MMRF_1013	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					1896	1957	1
MMRF_1013	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	28	mg	mg	QD(D1,D8,D15,D22)	Other	PO	PO	Log Forms	Unknown	Unknown		28	Other	QD(D1,D8,D15,D22)					1896	1957	1
MMRF_1013	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	Q day	Q day	SUBCUTAN INJECTION	Other	Log Forms	Unknown	Unknown		2	Q day	Q day					2098	2098	1
MMRF_1013	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		40	Q day	Q day					2098	2100	1
MMRF_1013	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	ETOPOSIDE	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	30	mg	mg	Q day	Q day	IVB	IVB	Log Forms	Unknown	Unknown		30	Q day	Q day					2098	2100	1
MMRF_1013	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	460	mg	mg	Q day	Q day	IVB	IVB	Log Forms	Unknown	Unknown		460	Q day	Q day					2098	2100	1
MMRF_1013	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	CISPLATIN	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	8	mg	mg	Q day	Q day	IVB	IVB	Log Forms	Unknown	Unknown		8	Q day	Q day					2098	2100	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					2038	2079	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	QD(D1,D4)	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2	Other	QD(D1,D4)					1986	1989	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	620	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Unknown	Unknown		620	QD (D1-4)	QD (D1-4)					1986	1989	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	CISPLATIN	Other			Completed regimen	Completed regimen	8	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Unknown	Unknown		8	QD (D1-4)	QD (D1-4)					1986	1989	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					1986	1989	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	ETOPOSIDE	Other			Completed regimen	Completed regimen	46	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Unknown	Unknown		46	QD (D1-4)	QD (D1-4)					1986	1989	1
MMRF_1013	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Melphalan	Melphalan			Completed regimen	Completed regimen	50	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		50	Q day	Q day					2126	2126	1
MMRF_1013	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					2038	2088	1
MMRF_1073	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg/m^2	mg/m^2	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	92	1
MMRF_1073	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.9	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	92	1
MMRF_1073	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	92	1
MMRF_1073	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	1X	Other	IV	IV	Log Forms				200	Other	1X					139	139	1
MMRF_1073	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		1			10	mg/dL	mg/dL	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms			Checked	10	QD (D1-21)	QD (D1-21)					265		1
MMRF_1076	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					77	108	1
MMRF_1076	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg/m^2	mg/m^2	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	77	1
MMRF_1076	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	75	1
MMRF_1076	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				12	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_1076	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	Q TWICE A WEEK	Other	PO	PO	Log Forms	Maintenance	Maintenance		8	Other	Q TWICE A WEEK					479	884	1
MMRF_1076	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					434	884	1
MMRF_1076	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	8	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Unknown	Unknown		8	Other	EVERY OTHER DAY					927	1022	1
MMRF_1076	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		500	Q week	Q week					927	1030	1
MMRF_1095	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg/m^2	mg/m^2	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_1095	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1095	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1095	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			PLANNED FOR 2 CYCLES, STEM CELL MOBILIZATION, THEN CONTINUE 2 MORE CYCLES	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					113	142	1
MMRF_1095	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			PLANNED FOR 2 CYCLES, STEM CELL MOBILIZATION, THEN CONTINUE 2 MORE CYCLES	Other	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					113	142	1
MMRF_1095	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	1X	Other	IV	IV	Log Forms				140	Other	1X					286	286	1
MMRF_1095	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					449	478	1
MMRF_1095	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					479	899	1
MMRF_1092	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	83	1
MMRF_1092	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	83	1
MMRF_1092	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	83	1
MMRF_1092	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				15	QD (D1-14)	QD (D1-14)					96	161	1
MMRF_1092	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	1, 8	Other	IV SubQ	IV SubQ	Log Forms				1	Other	1, 8					96	161	1
MMRF_1092	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	1, 8	Other	PO	PO	Log Forms				20	Other	1, 8					96	161	1
MMRF_1092	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					191	1539	1
MMRF_1092	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					191	1539	1
MMRF_1092	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Unknown	Unknown		140	Other	ONCE					1549	1549	1
MMRF_1092	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		1			3	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	3	Other	QD(D1,D8,D15)					1683		1
MMRF_1092	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					1683		1
MMRF_1115	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	1X	Other	IV	IV	Log Forms				200	Other	1X					119	119	1
MMRF_1115	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_1115	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg/m^2	mg/m^2	D1, D8, D15	Other	IV SubQ	IV SubQ	Log Forms				2.5	Other	D1, D8, D15					1	85	1
MMRF_1115	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1, D8, D15 OF 21 DAY CYCLE	Other	PO	PO	Log Forms				40	Other	D1, D8, D15 OF 21 DAY CYCLE					1	85	1
MMRF_1134	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	56	1
MMRF_1134	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg/m^2	mg/m^2	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_1134	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	56	1
MMRF_1134	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	1X	Other	IV	IV	Log Forms				200	Other	1X					134	134	1
MMRF_1134	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					531	757	1
MMRF_1134	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					972	1047	1
MMRF_1134	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					1047		1
MMRF_1153	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	102	1
MMRF_1153	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_1153	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_1153	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	1X	Other	IV	IV	Log Forms				200	Other	1X					183	183	1
MMRF_1153	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					339	875	1
MMRF_1153	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD(Q1,Q15,Q29,Q430	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	QD(Q1,Q15,Q29,Q430					974	1240	1
MMRF_1153	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		4	Q week	Q week					1317	1380	1
MMRF_1153	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					1317	1362	1
MMRF_1153	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1317	1362	1
MMRF_1153	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	QD(D1,D8,D15,D22)	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Other	QD(D1,D8,D15,D22)					1389		1
MMRF_1153	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	15	QD (D1-21)	QD (D1-21)					1389		1
MMRF_1153	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Prednisone	Prednisone		1			20	mg	mg	TWO DOSES POST DARA INFUSION	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	20	Other	TWO DOSES POST DARA INFUSION					1389		1
MMRF_1168	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg/dL	mg/dL	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	156	1
MMRF_1168	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	156	1
MMRF_1168	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					1	156	1
MMRF_1168	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					187		1
MMRF_1171	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	89	1
MMRF_1171	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	89	1
MMRF_1171	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	89	1
MMRF_1171	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	1X	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	1X					155	155	1
MMRF_1171	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	10	Q day	Q day					278		1
MMRF_1185	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					1	81	1
MMRF_1185	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg	mg	Q week	Q week	IV	IV	Log Forms				1.3	Q week	Q week					1	81	1
MMRF_1185	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					1	81	1
MMRF_1185	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	1X	Other	IV	IV	Log Forms				200	Other	1X					117	117	1
MMRF_1185	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				5	QD (D1-21)	QD (D1-21)					256	1211	1
MMRF_1196	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	259	1
MMRF_1196	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	259	1
MMRF_1196	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms				4	Other	1,2,4,5,8,9,11,12					1	259	1
MMRF_1196	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					327	327	1
MMRF_1196	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					370	616	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					617	660	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					617	660	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		2	QD (D1-21)	QD (D1-21)					617	660	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE CYCLE 1	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	QD(D1,D4)	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE CYCLE 1		2.7	Other	QD(D1,D4)					702	706	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					702	705	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE CYCLE 1	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	820	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Other	SALVAGE CYCLE 1		820	QD (D1-4)	QD (D1-4)					702	705	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE CYCLE 1	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Other	SALVAGE CYCLE 1		40	QD (D1-4)	QD (D1-4)					702	705	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE CYCLE 1	Other	CISPLATIN	Other			Completed regimen	Completed regimen	10	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Other	SALVAGE CYCLE 1		10	QD (D1-4)	QD (D1-4)					702	705	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE CYCLE 2	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QD(D1,D4)	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE CYCLE 2		2.6	Other	QD(D1,D4)					740	745	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE CYCLE 2	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD(D4,D5)	Other	PO	PO	Log Forms	Other	SALVAGE CYCLE 2		40	Other	QD(D4,D5)					740	745	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE CYCLE 2	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	800	mg	mg	QD(D4,D5)	Other	IVB	IVB	Log Forms	Other	SALVAGE CYCLE 2		800	Other	QD(D4,D5)					740	745	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALGAVE CYCLE2	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	40	mg	mg	QD(D4,D5)	Other	IVB	IVB	Log Forms	Other	SALGAVE CYCLE2		40	Other	QD(D4,D5)					740	745	1
MMRF_1196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE CYCLE 2	Other	CISPLATIN	Other			Completed regimen	Completed regimen	10	mg	mg	QD(D4,D5)	Other	IVB	IVB	Log Forms	Other	SALVAGE CYCLE 2		10	Other	QD(D4,D5)					740	745	1
MMRF_1235	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING	Other	FLUDARABINE/MELPHALAN	Other	N/A	0	Completed regimen	Completed regimen	UNK	UNKNOWN	Other	QD (1-6)	Other	IV	IV	Log Forms	Other	CONDITIONING			Other	QD (1-6)					2426	2431	1
MMRF_1235	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	72	1
MMRF_1235	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	72	1
MMRF_1235	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	1-2, 4-5, 8-9, 11-12	Other	PO	PO	Log Forms				20	Other	1-2, 4-5, 8-9, 11-12					1	72	1
MMRF_1235	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	1X	Other	IV	IV	Log Forms				200	Other	1X					105	105	1
MMRF_1235	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Patient decision	Patient decision	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					254	2303	1
MMRF_1251	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide	CRB-402	0	Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		300	QD (D1-4)	QD (D1-4)					2781	2786	1
MMRF_1251	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_1251	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1251	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1251	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	1X	Other	IV	IV	Log Forms				200	Other	1X					112	112	1
MMRF_1251	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Consolidation	Consolidation		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					183	213	1
MMRF_1251	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	5	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Consolidation	Consolidation		5	QD (D1-14)	QD (D1-14)					183	213	1
MMRF_1251	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					183	213	1
MMRF_1251	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.9	mg	mg	Q WEEK FOR 3 WEEKS ON A 28 DAY CYCLE	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.9	Other	Q WEEK FOR 3 WEEKS ON A 28 DAY CYCLE					232	1142	1
MMRF_1251	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					834	2165	1
MMRF_1251	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					288	1142	1
MMRF_1251	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Ixazomib	Ixazomib		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD(D1,D8D15)	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD(D1,D8D15)					1156	2165	1
MMRF_1251	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QD (DAYS 1,8,15,&22)	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	QD (DAYS 1,8,15,&22)					2165	2486	1
MMRF_1251	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1, D8, D15, & D22)	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD (D1, D8, D15, & D22)					2165	2486	1
MMRF_1251	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	56	mg/m^2	mg/m^2	QD (D1, D8, & D15	Other	IV	IV	Log Forms	Unknown	Unknown		56	Other	QD (D1, D8, & D15					2488	2739	1
MMRF_1251	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	QD (D1, D8, & D15	Other	PO	PO	Log Forms	Unknown	Unknown		300	Other	QD (D1, D8, & D15					2488	2739	1
MMRF_1251	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	10-12	mg	mg	QD (D1, D8, & D15	Other	PO	PO	Log Forms	Unknown	Unknown			Other	QD (D1, D8, & D15					2488	2739	1
MMRF_1251	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					2165	2486	1
MMRF_1290	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	2X A WK (SATURDAYS AND SUNDAYS)	Other	PO	PO	Log Forms				40	Other	2X A WK (SATURDAYS AND SUNDAYS)					1	86	1
MMRF_1290	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					3	86	1
MMRF_1290	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					7	86	1
MMRF_1290	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	1X	Other	IV	IV	Log Forms				200	Other	1X					130	130	1
MMRF_1290	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO (MONTH AND YEAR FOR START DATE ARE CORRECT, THE EXACT DAY IS UNKNOWN)	Other	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					206		1
MMRF_1284	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			PLANNED FOR 3 CYCLES, VDCEP, THEN STEM CELL MOBILIZATION	Other	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	43	1
MMRF_1284	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			PLANNED FOR 3 CYCLES, VDCEP, THEN STEM CELL MOBILIZATION	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	43	1
MMRF_1284	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			PLANNED FOR 3 CYCLES, VDCEP, THEN STEM CELL MOBILIZATION	Other	20	mg	mg	1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms				20	Other	1,2,4,5,8,9,11,12					1	43	1
MMRF_1284	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	Q72H, 2 DOSES	Other	IV SubQ	IV SubQ	Log Forms				2.5	Other	Q72H, 2 DOSES					71	74	1
MMRF_1284	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					71	74	1
MMRF_1284	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	760	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms				760	QD (D1-4)	QD (D1-4)					71	74	1
MMRF_1284	First line of therapy	First Line Therapy			ETOPOSIDE	Other			Completed regimen	Completed regimen	76	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms				76	QD (D1-4)	QD (D1-4)					71	74	1
MMRF_1284	First line of therapy	First Line Therapy			CISPLATIN	Other			Completed regimen	Completed regimen	19	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms				19	QD (D1-4)	QD (D1-4)					71	74	1
MMRF_1284	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	2	QD (D1-21)	QD (D1-21)					240		1
MMRF_1284	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IVB	IVB	Log Forms	Induction	Induction		200	Q day	Q day					107	107	1
MMRF_1304	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	78	1
MMRF_1304	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms				2.7	Q week	Q week					1	78	1
MMRF_1304	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms				20	Other	1,2,4,5,8,9,11,12					1	78	1
MMRF_1304	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	1X	Other	IV	IV	Log Forms				200	Other	1X					122	122	1
MMRF_1304	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					288	401	1
MMRF_1304	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-14)	QD (D1-14)					429	1038	1
MMRF_1304	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					1038		1
MMRF_1323	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_1323	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					20	77	1
MMRF_1323	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_1323	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			GIVEN FOR ASCT	Other	150	mg/kg	mg/kg	FOR ASCT COLLECTION	Other	IV	IV	Log Forms	Induction	Induction		150	Other	FOR ASCT COLLECTION					117	117	1
MMRF_1323	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					230		1
MMRF_1328	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg/dL	mg/dL	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	215	1
MMRF_1328	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	215	1
MMRF_1328	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms				20	Other	1,2,4,5,8,9,11,12					1	215	1
MMRF_1328	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	UNKNOWN	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	UNKNOWN					216	544	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1334	1371	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Lack of response	Lack of response	56	mg/m^2	mg/m^2	QD(D1,D8,D15)	Other	IV	IV	Log Forms	Unknown	Unknown		56	Other	QD(D1,D8,D15)					1357	1371	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Panobinostat	Panobinostat			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD(TUES/THURS/SAT WEEKS 1 AND 3)	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD(TUES/THURS/SAT WEEKS 1 AND 3)					1357	1367	1
MMRF_1328	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	Q72HR	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.7	Other	Q72HR					1385	1389	1
MMRF_1328	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					1385	1389	1
MMRF_1328	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	820	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Unknown	Unknown		820	QD (D1-4)	QD (D1-4)					1385	1389	1
MMRF_1328	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	CISPLATIN	Other			Completed regimen	Completed regimen	20	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Unknown	Unknown		20	QD (D1-4)	QD (D1-4)					1385	1389	1
MMRF_1328	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	ETOPOSIDE	Other			Completed regimen	Completed regimen	82	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Unknown	Unknown		82	QD (D1-4)	QD (D1-4)					1385	1389	1
MMRF_1328	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	NIVOLUMAB	Other			Disease progression/Relapse	Disease progression/Relapse	3	mg/kg	mg/kg	QD(D1,D15)	Other	IV	IV	Log Forms	Unknown	Unknown		3	Other	QD(D1,D15)					1406	1448	1
MMRF_1328	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	10	mg/kg	mg/kg	QD(D1,D8,D15,D22)	Other	IV	IV	Log Forms	Unknown	Unknown		10	Other	QD(D1,D8,D15,D22)					1406	1455	1
MMRF_1328	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1406	1449	1
MMRF_1328	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	28	mg	mg	QD(D1,D8,D15,D22) DURING C1&C2, QD(D1,D15) DURING C3 AND BEYOND	Other	PO	PO	Log Forms	Unknown	Unknown		28	Other	QD(D1,D8,D15,D22) DURING C1&C2, QD(D1,D15) DURING C3 AND BEYOND					1406	1449	1
MMRF_1328	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		300	QWK	QWK					1441	1455	1
MMRF_1328	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD(D1,D7,D14)	Other	IV	IV	Log Forms	Maintenance	Maintenance		56	Other	QD(D1,D7,D14)					741	838	1
MMRF_1328	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	56	mg/m^2	mg/m^2	QD(D1,D8,D15)	Other	IV	IV	Log Forms	Maintenance	Maintenance		56	Other	QD(D1,D8,D15)					768	838	1
MMRF_1328	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	QD(D1,D8,D15)					741	838	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	CYCLE 1	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	Q72HR	Other	IV SubQ	IV SubQ	Log Forms	Other	CYCLE 1		2	Other	Q72HR					856	859	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	CYCLE 1	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	CYCLE 1		40	QD (D1-4)	QD (D1-4)					856	859	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	CYCLE 1	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	800	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Other	CYCLE 1		800	QD (D1-4)	QD (D1-4)					856	859	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	CYCLE 1	Other	CISPLATIN	Other			Completed regimen	Completed regimen	20	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Other	CYCLE 1		20	QD (D1-4)	QD (D1-4)					856	859	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	CYCLE 1	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	80	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Other	CYCLE 1		80	QD (D1-4)	QD (D1-4)					856	859	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Thalidomide	Thalidomide			Completed regimen	Completed regimen	100	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		100	Q day	Q day					862	897	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	CYCLE 2	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	QD(EVERY 72 HRS)	Other	IV SubQ	IV SubQ	Log Forms	Other	CYCLE 2		2.7	Other	QD(EVERY 72 HRS)					881	885	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	CYCLE 2	Other	CISPLATIN	Other			Completed regimen	Completed regimen	21	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Other	CYCLE 2		21	QD (D1-4)	QD (D1-4)					881	885	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	CYCLE 2 VDCEP	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	830	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Other	CYCLE 2 VDCEP		830	QD (D1-4)	QD (D1-4)					881	885	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	CYCLE 2 VDCEP	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	83	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Other	CYCLE 2 VDCEP		83	QD (D1-4)	QD (D1-4)					881	885	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	CYCLE 2 VDCEP	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	CYCLE 2 VDCEP		40	QD (D1-4)	QD (D1-4)					880	885	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					916	974	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	ONCE A WEEK ON MONDAY	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	ONCE A WEEK ON MONDAY					916	974	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	Q(D1,D5)	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.7	Other	Q(D1,D5)					996	1001	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	824	mg	mg	QD(D1,D3,D4,D5)	Other	IVPB	Other	Log Forms	Unknown	Unknown		824	Other	QD(D1,D3,D4,D5)					996	1001	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	ETOPOSIDE	Other			Completed regimen	Completed regimen	82	mg	mg	QD(D1,D3,D4,D5)	Other	IVPB	Other	Log Forms	Unknown	Unknown		82	Other	QD(D1,D3,D4,D5)					996	1001	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	CISPLATIN	Other			Completed regimen	Completed regimen	21	mg	mg	QD(D1,D3,D4,D5)	Other	IVPB	Other	Log Forms	Unknown	Unknown		21	Other	QD(D1,D3,D4,D5)					996	1001	1
MMRF_1328	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	QD(D1,D8,D15)					684	699	1
MMRF_1328	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	40	mg	mg	QD, DAY 1 AND 2 OF CYCLE 1	Other	IV	IV	Log Forms	Maintenance	Maintenance		40	Other	QD, DAY 1 AND 2 OF CYCLE 1					684	685	1
MMRF_1328	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	54	mg	mg	QD DAYS 8,9,15,16 OF CYCLE 1	Other	IV	IV	Log Forms	Maintenance	Maintenance		54	Other	QD DAYS 8,9,15,16 OF CYCLE 1					691	699	1
MMRF_1328	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	53	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		53	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					713	728	1
MMRF_1328	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	400	mg	mg	Q day	Q day	IVB	IVB	Log Forms	Induction	Induction		400	Q day	Q day					593	593	1
MMRF_1328	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	QD(D1,D8,D15)					713	728	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	40	mg	mg	QD(D1,D2,D3,D5)	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	QD(D1,D2,D3,D5)					996	1001	1
MMRF_1328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QD(D1,D8,D15,D22)	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,D8,D15,D22)					1038	1252	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1038	1252	1
MMRF_1328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		4	Q week	Q week					1038	1252	1
MMRF_1328	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	NIVOLUMAB	Other			Disease progression/Relapse	Disease progression/Relapse	3	mg/kg	mg/kg	QD(D1,D15))	Other	IV	IV	Log Forms	Unknown	Unknown		3	Other	QD(D1,D15))					1182	1252	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					1268	1271	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	QD(D1,D5)	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.7	Other	QD(D1,D5)					1268	1272	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	CISPLATIN	Other			Completed regimen	Completed regimen	21	mg	mg	QD(D1,D2,D3,D5)	Other	IV	IV	Log Forms	Unknown	Unknown		21	Other	QD(D1,D2,D3,D5)					1268	1272	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	830	mg	mg	QD(D1,D2,D3,D5)	Other	IV	IV	Log Forms	Unknown	Unknown		830	Other	QD(D1,D2,D3,D5)					1268	1272	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	ETOPOSIDE	Other			Completed regimen	Completed regimen	83	mg	mg	QD(D1,D2,D3,D5)	Other	IV	IV	Log Forms	Unknown	Unknown		83	Other	QD(D1,D2,D3,D5)					1268	1272	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	D1 & D4	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.7	Other	D1 & D4					1293	1296	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					1293	1296	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	CISPLATIN	Other			Completed regimen	Completed regimen	21	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Unknown	Unknown		21	QD (D1-4)	QD (D1-4)					1293	1296	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	ETOPOSIDE	Other			Completed regimen	Completed regimen	82	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Unknown	Unknown		82	QD (D1-4)	QD (D1-4)					1293	1296	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	825	mg	mg	QD (D1-4)	QD (D1-4)	IVB	IVB	Log Forms	Unknown	Unknown		825	QD (D1-4)	QD (D1-4)					1293	1296	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	41	mg/m^2	mg/m^2	D1	Other	IV	IV	Log Forms	Unknown	Unknown		41	Other	D1					1334	1334	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD(D8,D15)	Other	IV	IV	Log Forms	Unknown	Unknown		56	Other	QD(D8,D15)					1336	1343	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD(D1,D8,D15)					1334	1371	1
MMRF_1328	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg	mg	QD(D1,D8,D15)	Other	IV	IV	Log Forms	Unknown	Unknown		300	Other	QD(D1,D8,D15)					1334	1371	1
MMRF_1328	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					684	838	1
MMRF_1374	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.6	mg/m^2	mg/m^2	QD: DAY 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.6	Other	QD: DAY 1, 8, 15					144	183	1
MMRF_1374	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					144	183	1
MMRF_1374	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD: DAY 1, 8, 15	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	QD: DAY 1, 8, 15					144	183	1
MMRF_1374	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.6	mg/m^2	mg/m^2	QD 1,8,15	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.6	Other	QD 1,8,15					319	340	1
MMRF_1374	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					319	340	1
MMRF_1374	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD 1,8,15	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	QD 1,8,15					319	340	1
MMRF_1374	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					58	58	1
MMRF_1374	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	UNK	Other	IV	IV	Log Forms				2.7	Other	UNK					1	23	1
MMRF_1374	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	UNK	Other	PO	PO	Log Forms				40	Other	UNK					1	23	1
MMRF_1374	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	825	mg	mg	UNK	Other	IV	IV	Log Forms				825	Other	UNK					1	23	1
MMRF_1374	First line of therapy	First Line Therapy			ETOPOSIDE	Other			Completed regimen	Completed regimen	82	mg	mg	UNK	Other	IV	IV	Log Forms				82	Other	UNK					1	23	1
MMRF_1374	First line of therapy	First Line Therapy			CISPLATIN	Other			Completed regimen	Completed regimen	21	mg	mg	UNK	Other	IV	IV	Log Forms				21	Other	UNK					1	23	1
MMRF_1415	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				15	QD (D1-14)	QD (D1-14)					1	84	1
MMRF_1415	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1415	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1415	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Lack of response	Lack of response	10	mg	mg	QD ON A 28 DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	QD ON A 28 DAY CYCLE					220	310	1
MMRF_1415	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	QD	Other	IV	IV	Log Forms	Induction	Induction		200	Other	QD					115	115	1
MMRF_1415	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD ON 28 DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		25	Other	QD ON 28 DAY CYCLE					310	371	1
MMRF_1415	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	UNKNOWN	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		3	Other	UNKNOWN					310	371	1
MMRF_1415	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					320	371	1
MMRF_1415	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE THERAPY	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	0	UNKNOWN	Other	UNKNOWN	Other	UNKNOWN	Other	Log Forms	Other	SALVAGE THERAPY		0	Other	UNKNOWN					378	381	1
MMRF_1415	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE THERAPY	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	0	UNKNOWN	Other	UNKNOWN	Other	UNKNOWN	Other	Log Forms	Other	SALVAGE THERAPY		0	Other	UNKNOWN					378	381	1
MMRF_1415	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	CISPLATIN	Other			Completed regimen	Completed regimen	0	UNKNOWN	Other	UNKNOWN	Other	UNKNOWN	Other	Log Forms	Other	SALVAGE		0	Other	UNKNOWN					378	381	1
MMRF_1415	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE THERAPY	Other	PREDNISONE	Other			Completed regimen	Completed regimen	0	UNKNOWN	Other	UNKNOWN	Other	UNKNOWN	Other	Log Forms	Other	SALVAGE THERAPY		0	Other	UNKNOWN					378	381	1
MMRF_1415	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE THERAPY	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	0	UNKNOWN	Other	UNKNOWN	Other	UNKNOWN	Other	Log Forms	Other	SALVAGE THERAPY		0	Other	UNKNOWN					378	381	1
MMRF_1415	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Lack of response	Lack of response	58	mg	mg	UNKNOWN	Other	IV	IV	Log Forms	Induction	Induction		58	Other	UNKNOWN					402	463	1
MMRF_1415	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Lack of response	Lack of response	4	mg	mg	UNKNOWN	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	UNKNOWN					402	463	1
MMRF_1415	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	UNKNOWN	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	UNKNOWN					402	463	1
MMRF_1430	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.8	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	119	1
MMRF_1430	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib			DEATH	Other	1.6	mg/m^2	mg/m^2	QD(D1,D8,D15)	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.6	Other	QD(D1,D8,D15)					1453	1574	1
MMRF_1430	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	QD(D2,D9,D16)	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD(D2,D9,D16)					1453	1574	1
MMRF_1430	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			DEATH	Other	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1533	1574	1
MMRF_1430	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DOSE REDUCTION	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	3	1
MMRF_1430	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	119	1
MMRF_1430	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Completed regimen	Completed regimen	100	mg	mg	UNKNOWN	Other	PO	PO	Log Forms	Induction	Induction		100	Other	UNKNOWN					42	119	1
MMRF_1430	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		140	Q day	Q day					192	192	1
MMRF_1430	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					316	665	1
MMRF_1430	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab			DEATH	Other	16	mg/kg	mg/kg	QD(D1,D8,D15,D22)	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,D8,D15,D22)					1453	1574	1
MMRF_1447	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1447	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms				20	Other	1,2,4,5,8,9,11,12					1	81	1
MMRF_1447	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	UNKNOWN	Other	UNKNOWN	Other	Log Forms	Induction	Induction		200	Other	UNKNOWN					125	125	1
MMRF_1447	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					259		1
MMRF_1447	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	81	1
MMRF_1506	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.2	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_1506	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_1506	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	77	1
MMRF_1506	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IVB	IVB	Log Forms	Induction	Induction		200	Q day	Q day					105	105	1
MMRF_1522	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.3	mg	mg	QD (D1, D3, D6, D9)	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.3	Other	QD (D1, D3, D6, D9)					1	105	1
MMRF_1522	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1, D3, D6, D9)	Other	PO	PO	Log Forms	Induction	Induction		25	Other	QD (D1, D3, D6, D9)					1	105	1
MMRF_1522	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD D1, D2, D6, D7	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD D1, D2, D6, D7					1	105	1
MMRF_1522	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD 1,8,15	Other	IV	IV	Log Forms	Maintenance	Maintenance		1.3	Other	QD 1,8,15					205	1291	1
MMRF_1522	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					205	1291	1
MMRF_1522	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD DAYS 1,2,8,9,15,16	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	QD DAYS 1,2,8,9,15,16					205	1291	1
MMRF_1522	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					113	113	1
MMRF_1522	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD(D1,D8,D15)					1322	1565	1
MMRF_1522	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1322	1565	1
MMRF_1522	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			16	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown	Checked	16	Q week	Q week					1597		1
MMRF_1522	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	2	QD (D1-21)	QD (D1-21)					1597		1
MMRF_1522	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	1X EVERY 2 WEEKS	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Other	1X EVERY 2 WEEKS					1597		1
MMRF_1534	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QOD FOR 14 DAYS	Other	PO	PO	Log Forms	Induction	Induction		15	Other	QOD FOR 14 DAYS					1	30	1
MMRF_1534	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD DAYS 1,8,15	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD DAYS 1,8,15					1	80	1
MMRF_1534	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	80	1
MMRF_1534	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					30	80	1
MMRF_1534	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					107	161	1
MMRF_1534	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD 1,8,15,21	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD 1,8,15,21					107	161	1
MMRF_1534	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	UNKNOWN	Other	UNKNOWN	Other	Log Forms	Consolidation	Consolidation		200	Other	UNKNOWN					161	163	1
MMRF_1534	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					238	947	1
MMRF_1534	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					947	1101	1
MMRF_1534	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	VENETOCLAX	Other			Disease progression/Relapse	Disease progression/Relapse	800	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		800	QD (D1-21)	QD (D1-21)					1122	1290	1
MMRF_1534	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD(D1,D81,D15)	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	QD(D1,D81,D15)					1122	1290	1
MMRF_1534	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1800	mg	mg	QD(D1,D2,D3,D4,D8,D15,D22)	Other	SUBCUTANEOUS	Other	Log Forms	Unknown	Unknown		1800	Other	QD(D1,D2,D3,D4,D8,D15,D22)					1331	1485	1
MMRF_1534	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	WEEKLYX8WEEKS,EVERY 2WEEKSX8 WEEKS,THEN MONTHLY	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	WEEKLYX8WEEKS,EVERY 2WEEKSX8 WEEKS,THEN MONTHLY					1526	2149	1
MMRF_1534	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1526	2149	1
MMRF_1534	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	NIGHT BEFORE DARA INFUSION	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	NIGHT BEFORE DARA INFUSION					1526	2149	1
MMRF_1539	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					45	175	1
MMRF_1539	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	175	1
MMRF_1539	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD D1,D2,D4,D5,D8,D9, D11,D12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD D1,D2,D4,D5,D8,D9, D11,D12					1	175	1
MMRF_1539	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					327	1181	1
MMRF_1539	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Q week	Q week					605	878	1
MMRF_1539	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		140	Q day	Q day					227	227	1
MMRF_1539	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD(D1,8,15)	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD(D1,8,15)					878	1181	1
MMRF_1539	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD(D1,8,15)	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD(D1,8,15)					878	1181	1
MMRF_1539	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		16	QWK	QWK					1181	1361	1
MMRF_1539	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1181	1361	1
MMRF_1539	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	VENETOCLAX	Other		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	400	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		400	QD (D1-21)	QD (D1-21)					1398	1998	1
MMRF_1539	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1398		1
MMRF_1543	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	109	1
MMRF_1543	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	QD 1,8,15,22	Other	IV	IV	Log Forms	Induction	Induction		2	Other	QD 1,8,15,22					1	109	1
MMRF_1543	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QD 1,8,15,22	Other	PO	PO	Log Forms	Induction	Induction		4	Other	QD 1,8,15,22					1	109	1
MMRF_1543	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					143	143	1
MMRF_1546	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1546	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1546	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1546	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					140	237	1
MMRF_1546	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		10	QWK	QWK					140	596	1
MMRF_1546	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-21)	QD (D1-21)					238	386	1
MMRF_1546	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	5	QD (D1-21)	QD (D1-21)					534		1
MMRF_1546	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					386	414	1
MMRF_1546	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					414	534	1
MMRF_1546	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TO ALLOW OPTIMAL MUSCLE STRENGTHENING	Other	8	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		8	Q week	Q week					596	680	1
MMRF_1572	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q D1, D2, D4, D5, D8, D9, D11, D12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	Q D1, D2, D4, D5, D8, D9, D11, D12					1	124	1
MMRF_1572	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	124	1
MMRF_1572	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	124	1
MMRF_1572	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					268	270	1
MMRF_1572	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IVB	IVB	Log Forms	Induction	Induction		200	Q day	Q day					149	149	1
MMRF_1595	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1,D8,D15)	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	QD (D1,D8,D15)					1	107	1
MMRF_1595	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	107	1
MMRF_1595	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD 1,8,15,22	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 1,8,15,22					1	107	1
MMRF_1595	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					107	162	1
MMRF_1595	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					179	227	1
MMRF_1602	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	UNKNOWN	Other	QWK	QWK	IV	IV	Log Forms	Induction	Induction		2.6	QWK	QWK					1	83	1
MMRF_1602	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	83	1
MMRF_1602	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	83	1
MMRF_1602	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					116	116	1
MMRF_1602	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					265	704	1
MMRF_1602	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1041		1
MMRF_1656	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	79	1
MMRF_1656	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	22	1
MMRF_1656	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QD 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		4	Other	QD 1,2,4,5,8,9,11,12					1	79	1
MMRF_1656	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QOD DAYS 1-14	Other	PO	PO	Log Forms	Induction	Induction		25	Other	QOD DAYS 1-14					22	79	1
MMRF_1656	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3	G/M2	Other	UNKNOWN	Other	IV	IV	Log Forms	Other	MOBILIZATION		3	Other	UNKNOWN					99	110	1
MMRF_1656	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	UNKNOWN	Other	IV	IV	Log Forms	Other	CONDITIONING		140	Other	UNKNOWN					131	133	1
MMRF_1656	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					229	260	1
MMRF_1656	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					229	260	1
MMRF_1656	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1,8,15,22	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	DAYS 1,8,15,22					229	260	1
MMRF_1656	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					444	505	1
MMRF_1656	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					444	505	1
MMRF_1656	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD(D1,D8,D15,D22)	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	QD(D1,D8,D15,D22)					444	505	1
MMRF_1656	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.1	mg	mg	QD(D1,D4)	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.1	Other	QD(D1,D4)					512	515	1
MMRF_1656	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1-14)	QD (D1-14)					512	515	1
MMRF_1656	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	660	mg	mg	QD(D1,D4)	Other	IVPB	Other	Log Forms	Unknown	Unknown		660	Other	QD(D1,D4)					512	515	1
MMRF_1656	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	ETOPOSIDE	Other			Completed regimen	Completed regimen	66	mg	mg	QD(D1,D4)	Other	IVPB	Other	Log Forms	Unknown	Unknown		66	Other	QD(D1,D4)					512	515	1
MMRF_1656	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	CISPLATIN	Other			Completed regimen	Completed regimen	16.5	mg	mg	QD(D1,D4)	Other	IVPB	Other	Log Forms	Unknown	Unknown		16.5	Other	QD(D1,D4)					512	515	1
MMRF_1674	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.1	mg	mg	QD 1,3,7,10	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.1	Other	QD 1,3,7,10					1	104	1
MMRF_1674	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	104	1
MMRF_1674	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD 1,3,7,10	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 1,3,7,10					1	63	1
MMRF_1674	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD 2,5,9,12	Other	PO	PO	Log Forms	Induction	Induction		10	Other	QD 2,5,9,12					64	104	1
MMRF_1674	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					138	138	1
MMRF_1674	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			MRD NEGATIVE	Other	1.3	mg/m^2	mg/m^2	QD 1,8,15	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	QD 1,8,15					235	912	1
MMRF_1694	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	20	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-14)	QD (D1-14)					1	123	1
MMRF_1694	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_1694	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	123	1
MMRF_1694	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					168	168	1
MMRF_1694	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					394	935	1
MMRF_1694	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD(D1,D8,D15) EVERY 28 DAYS	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD(D1,D8,D15) EVERY 28 DAYS					935	1509	1
MMRF_1694	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					935	1509	1
MMRF_1694	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		20	QWK	QWK					935	1509	1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	CISPLATIN	Other			Completed regimen	Completed regimen	24	mg	mg	QD(D1,D2,D3,D4)	Other	IVB	IVB	Log Forms	Unknown	Unknown		24	Other	QD(D1,D2,D3,D4)					1514	1517	1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	970	mg	mg	QD(D1,D2,D3,D4)	Other	IVB	IVB	Log Forms	Unknown	Unknown		970	Other	QD(D1,D2,D3,D4)					1514	1517	1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	ETOPOSIDE	Other			Completed regimen	Completed regimen	97	mg	mg	QD(D1,D2,D3,D4)	Other	IVB	IVB	Log Forms	Unknown	Unknown		97	Other	QD(D1,D2,D3,D4)					1514	1517	1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD(D1,D2,D3,D4)	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	QD(D1,D2,D3,D4)					1514	1517	1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.1	mg	mg	Q72HRS	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		3.1	Other	Q72HRS					1514	1517	1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Q week	Q week					1551		1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1551		1
MMRF_1694	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	2	QD (D1-21)	QD (D1-21)					1642		1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVEGE	Other	CISPLATIN	Other		0	Completed regimen	Completed regimen	11	mg	mg	Q24H	Other	IV	IV	Log Forms	Other	SALVEGE		11	Other	Q24H					1721	1724	1
MMRF_1711	Eleventh Line of Therapy (following 10th relapse)	Eleventh Line of Therapy (following 10th relapse)	SALVEGE	Other	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	630	mg	mg	Q24H	Other	IV	IV	Log Forms	Other	SALVEGE		630	Other	Q24H					1721	1724	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVEGE	Other	ETOPOSIDE	Other		0	Completed regimen	Completed regimen	42	mg	mg	Q24H	Other	IV	IV	Log Forms	Other	SALVEGE		42	Other	Q24H					1721	1724	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	Q24H	Other	PO	PO	Log Forms	Other	SALVAGE		40	Other	Q24H					1721	1724	1
MMRF_1711	Twelfth Line of Therapy (following 11th relapse)	Twelfth Line of Therapy (following 11th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	840	mg	mg	Q24H	Other	IV	IV	Log Forms	Other	SALVAGE		840	Other	Q24H					1998	2001	1
MMRF_1711	Twelfth Line of Therapy (following 11th relapse)	Twelfth Line of Therapy (following 11th relapse)	SALVAGE	Other	CISPLATIN	Other		0	Completed regimen	Completed regimen	21	mg	mg	Q24H	Other	IV	IV	Log Forms	Other	SALVAGE		21	Other	Q24H					1998	2001	1
MMRF_1711	Twelfth Line of Therapy (following 11th relapse)	Twelfth Line of Therapy (following 11th relapse)	SALVAGE	Other	ETOPOSIDE	Other		0	Completed regimen	Completed regimen	84	mg	mg	Q24H	Other	IV	IV	Log Forms	Other	SALVAGE		84	Other	Q24H					1998	2001	1
MMRF_1711	Twelfth Line of Therapy (following 11th relapse)	Twelfth Line of Therapy (following 11th relapse)	SALVAE	Other	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	Q24H	Other	PO	PO	Log Forms	Other	SALVAE		40	Other	Q24H					1999	2001	1
MMRF_1711	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.8	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1711	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	11	1
MMRF_1711	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	11	1
MMRF_1711	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					29	82	1
MMRF_1711	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					29	82	1
MMRF_1711	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					29	82	1
MMRF_1711	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	UNKNOWN	Other	Log Forms	Consolidation	Consolidation		200	Q day	Q day					122	122	1
MMRF_1711	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					240	1017	1
MMRF_1711	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1020	1080	1
MMRF_1711	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD(D1,D8,D15,D22)	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD(D1,D8,D15,D22)					1020	1080	1
MMRF_1711	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1020	1080	1
MMRF_1711	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QD(D1,D8,D15,D22)	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,D8,D15,D22)					1095	1150	1
MMRF_1711	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1095	1150	1
MMRF_1711	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD(D1,D8,D15,D22)	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD(D1,D8,D15,D22)					1095	1150	1
MMRF_1711	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	D22	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	D22					1157	1584	1
MMRF_1711	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	600	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Unknown	Unknown		600	Other	QD(D1,D8,D15)					1157	1290	1
MMRF_1711	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	41	mg	mg	QD(D1,D2)	Other	IV	IV	Log Forms	Unknown	Unknown		41	Other	QD(D1,D2)					1157	1584	1
MMRF_1711	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	56	mg	mg	QD(D8,D9,D15,D16)	Other	IV	IV	Log Forms	Unknown	Unknown		56	Other	QD(D8,D9,D15,D16)					1157	1584	1
MMRF_1711	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Prednisone	Prednisone		0	Disease progression/Relapse	Disease progression/Relapse	60	mg	mg	QD(D2,D9,D16)	Other	PO	PO	Log Forms	Unknown	Unknown		60	Other	QD(D2,D9,D16)					1304	1584	1
MMRF_1711	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab		0	Disease progression/Relapse	Disease progression/Relapse	812	mg	mg	QD (D1, D8, D15, & D22)	Other	IV	IV	Log Forms	Unknown	Unknown		812	Other	QD (D1, D8, D15, & D22)					1640	1696	1
MMRF_1711	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1640	1696	1
MMRF_1711	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	28	mg	mg	QD (D1, D8, D15, & D22)	Other	IV	IV	Log Forms	Unknown	Unknown		28	Other	QD (D1, D8, D15, & D22)					1640	1696	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	LEUKAPHERESIS	Other	CART BB2121	0	Completed regimen	Completed regimen								Log Forms	Unknown	Unknown									1704	1704	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	56	mg/m^2	mg/m^2	QD (D1, D8, D15, D22)	Other	IV	IV	Log Forms	Unknown	Unknown		56	Other	QD (D1, D8, D15, D22)					2071	2083	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)			Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QD (D1, D8, D15, D22)	Other	IV	IV	Log Forms				16	Other	QD (D1, D8, D15, D22)					1706	1718	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)			Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1, D8, D15, D22)	Other	IV	IV	Log Forms				20	Other	QD (D1, D8, D15, D22)					1706	1718	1
MMRF_1711	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	2.7	mg	mg	Q72H	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		2.7	Other	Q72H					1721	1724	1
MMRF_1711	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	600	mg	mg	QD (D-5, D-4, D-3)	Other	IV	IV	Log Forms	Unknown	Unknown		600	Other	QD (D-5, D-4, D-3)					1753	1755	1
MMRF_1711	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Unknown	Unknown	FLUDARABINE	Other		0	Completed regimen	Completed regimen	36.5	mg	mg	QD (D-5, D-4, D-3)	Other	IV	IV	Log Forms	Unknown	Unknown		36.5	Other	QD (D-5, D-4, D-3)					1753	1755	1
MMRF_1711	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Unknown	Unknown	B2121	Other		0	Completed regimen	Completed regimen	450	10^6 CELLS	Other	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		450	Q day	Q day					1758	1758	1
MMRF_1711	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	600	mg	mg	QD (D-5, D-4, D-3)	Other	IV	IV	Log Forms	Unknown	Unknown		600	Other	QD (D-5, D-4, D-3)					1831	1833	1
MMRF_1711	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Unknown	Unknown	FLUDARABINE	Other		0	Completed regimen	Completed regimen	50	mg	mg	QD (D-5, D-4, D-3)	Other	IV	IV	Log Forms	Unknown	Unknown		50	Other	QD (D-5, D-4, D-3)					1831	1833	1
MMRF_1711	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	2.7	mg	mg	ONCE	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		2.7	Other	ONCE					1593	1593	1
MMRF_1711	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	ONCE	Other	PO	PO	Log Forms	Other	SALVAGE		40	Other	ONCE					1593	1593	1
MMRF_1711	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	840	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	SALVAGE		840	Other	ONCE					1593	1593	1
MMRF_1711	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	ETOPOSIDE	Other		0	Completed regimen	Completed regimen	84	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	SALVAGE		84	Other	ONCE					1593	1593	1
MMRF_1711	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	CISPLATIN	Other		0	Completed regimen	Completed regimen	20	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	SALVAGE		20	Other	ONCE					1593	1593	1
MMRF_1711	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	2.6	mg	mg	ONCE	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		2.6	Other	ONCE					1615	1615	1
MMRF_1711	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	ONCE	Other	PO	PO	Log Forms	Other	SALVAGE		40	Other	ONCE					1615	1615	1
MMRF_1711	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	800	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	SALVAGE		800	Other	ONCE					1615	1615	1
MMRF_1711	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	ETOPOSIDE	Other		0	Completed regimen	Completed regimen	80	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	SALVAGE		80	Other	ONCE					1615	1615	1
MMRF_1711	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	CISPLATIN	Other		0	Completed regimen	Completed regimen	20	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	SALVAGE		20	Other	ONCE					1615	1615	1
MMRF_1711	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Unknown	Unknown	BB2121	Other		0	Completed regimen	Completed regimen	450	10^6 CELLS	Other	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		450	Q day	Q day					1836	1836	1
MMRF_1711	Tenth Line of Therapy (following 9th relapse)	Tenth Line of Therapy (following 9th relapse)	Unknown	Unknown	NIVOLUMAB	Other		0	Disease progression/Relapse	Disease progression/Relapse	240	mg	mg	QD (D1 & D15)	Other	IV	IV	Log Forms	Unknown	Unknown		240	Other	QD (D1 & D15)					1873	1941	1
MMRF_1711	Tenth Line of Therapy (following 9th relapse)	Tenth Line of Therapy (following 9th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1873	1941	1
MMRF_1711	Eleventh Line of Therapy (following 10th relapse)	Eleventh Line of Therapy (following 10th relapse)	Unknown	Unknown	TAK-573-1501	Other	TAK-573-1501	0	Disease progression/Relapse	Disease progression/Relapse	33	mg	mg	QD (D1)	Other	IV	IV	Log Forms	Unknown	Unknown		33	Other	QD (D1)					1976	1998	1
MMRF_1711	Twelfth Line of Therapy (following 11th relapse)	Twelfth Line of Therapy (following 11th relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	2.7	mg	mg	Q72H	Other	IV	IV	Log Forms	Other	SALVAGE		2.7	Other	Q72H					1998	2001	1
MMRF_1713	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	83	1
MMRF_1713	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	126	1
MMRF_1713	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD 1-14 ON 21 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		15	Other	QD 1-14 ON 21 DAY CYCLE					21	28	1
MMRF_1713	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q WEEKLY (4 ON AND 2 OFF)	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	Q WEEKLY (4 ON AND 2 OFF)					84	126	1
MMRF_1713	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					281	350	1
MMRF_1713	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					170	170	1
MMRF_1713	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Patient decision	Patient decision	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					350	448	1
MMRF_1713	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		5	QD (D1-21)	QD (D1-21)					1053	1148	1
MMRF_1713	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					1148	1233	1
MMRF_1713	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	5	QD (D1-21)	QD (D1-21)					1233		1
MMRF_1722	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_1722	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	71	1
MMRF_1722	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	71	1
MMRF_1722	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		140	Q day	Q day					139	139	1
MMRF_1722	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					408		1
MMRF_1736	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	34	1
MMRF_1736	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	DAY AFTER EACH DOSE OF VELCADE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY AFTER EACH DOSE OF VELCADE					1	34	1
MMRF_1736	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					1	34	1
MMRF_1736	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	QD(D1,D8,D15,D22)	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Other	QD(D1,D8,D15,D22)					1219		1
MMRF_1736	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			4	mg	mg	4MG TWO DAYS AFTER DARA INFUSION	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	4	Other	4MG TWO DAYS AFTER DARA INFUSION					1219		1
MMRF_1817	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	92	1
MMRF_1817	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	93	1
MMRF_1817	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	DAYS 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1,2,4,5,8,9,11,12					1	25	1
MMRF_1817	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	QD 1,2	Other	PO	PO	Log Forms	Induction	Induction		12	Other	QD 1,2					26	29	1
MMRF_1817	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	16	mg	mg	QD 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		16	Other	QD 1,2,4,5,8,9,11,12					30	93	1
MMRF_1817	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IVB	IVB	Log Forms	Induction	Induction		200	Q day	Q day					169	169	1
MMRF_1817	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Patient decision	Patient decision	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					401	432	1
MMRF_1817	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					550	774	1
MMRF_1817	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					947	1251	1
MMRF_1817	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	VENETACLEX	Other			Disease progression/Relapse	Disease progression/Relapse	400	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		400	Q day	Q day					1293	1404	1
MMRF_1817	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					1404	1551	1
MMRF_1817	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg/kg	mg/kg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1404	1488	1
MMRF_1817	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	3	mg/kg	mg/kg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1488	1551	1
MMRF_1817	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1404	1551	1
MMRF_1817	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QD(D1, D4)	Other	IVB	IVB	Log Forms	Other	SALVAGE		2.6	Other	QD(D1, D4)					1551	1554	1
MMRF_1817	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD(D1,D2,D3,D4)	Other	PO	PO	Log Forms	Other	SALVAGE		40	Other	QD(D1,D2,D3,D4)					1551	1554	1
MMRF_1817	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	ETOPOSIDE	Other			Completed regimen	Completed regimen	80	mg	mg	QD(D1,D2,D3,D4)	Other	IVB	IVB	Log Forms	Other	SALVAGE		80	Other	QD(D1,D2,D3,D4)					1551	1554	1
MMRF_1817	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	800	mg	mg	QD(D1,D2,D3,D4)	Other	IVB	IVB	Log Forms	Other	SALVAGE		800	Other	QD(D1,D2,D3,D4)					1551	1554	1
MMRF_1817	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	CISPLATIN	Other			Completed regimen	Completed regimen	20	mg	mg	QD(D1,D2,D3,D4)	Other	IVB	IVB	Log Forms	Other	SALVAGE		20	Other	QD(D1,D2,D3,D4)					1551	1554	1
MMRF_1837	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.29	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.29	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	76	1
MMRF_1837	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	76	1
MMRF_1837	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	76	1
MMRF_1837	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	UNKNOWN	Other	UNKNOWN	Other	Log Forms	Other	CONDITIONING		200	Other	UNKNOWN					123	124	1
MMRF_1837	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Patient decision	Patient decision	1.3	mg/m^2	mg/m^2	QD (D1,D8,D15)	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	QD (D1,D8,D15)					216	700	1
MMRF_1837	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					216	1248	1
MMRF_1837	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	QD(D1,D8,D15)					216	1248	1
MMRF_1837	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	QD(D1,D8,D15)					693	776	1
MMRF_1837	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		3	Q week	Q week					776	1248	1
MMRF_1837	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1267		1
MMRF_1837	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	VENETOCLEX	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	800	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		800	Q day	Q day					1267	1323	1
MMRF_1837	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	VENETOCLAX	Other		1			400	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown	Checked	400	Q day	Q day					1323		1
MMRF_1854	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1854	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_1854	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1854	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					211	1282	1
MMRF_1854	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1,D8,D15)	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	QD (D1,D8,D15)					211	1282	1
MMRF_1854	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1,D2,D8,D9,D15,D16)	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (D1,D2,D8,D9,D15,D16)					211	1282	1
MMRF_1854	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					118	118	1
MMRF_1854	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1282		1
MMRF_1906	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					8	167	1
MMRF_1906	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg	mg	QD DAYS 1,8 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		300	Other	QD DAYS 1,8 OF 28 DAY CYCLE					1	28	1
MMRF_1906	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD DAYS 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD DAYS 1,2,4,5,8,9,11,12					8	206	1
MMRF_1906	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					168	206	1
MMRF_1906	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	DAYS 15 AND 22 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		500	Other	DAYS 15 AND 22 OF 28 DAY CYCLE					28	206	1
MMRF_1906	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	QD (D1,D8)	Other	PO	PO	Log Forms	Induction	Induction		500	Other	QD (D1,D8)					63	206	1
MMRF_1906	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					344	772	1
MMRF_1906	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					344	772	1
MMRF_1906	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD(D1,D2)	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		20	Other	QD(D1,D2)					421	422	1
MMRF_1906	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD(D8,D9,D15,D16)	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		27	Other	QD(D8,D9,D15,D16)					421	772	1
MMRF_1906	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg/kg	mg/kg	QD(D1,8,15,22)	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,8,15,22)					792	876	1
MMRF_1906	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	8	mg	mg	QD(D15,22)	Other	PO	PO	Log Forms	Unknown	Unknown		8	Other	QD(D15,22)					792	813	1
MMRF_1906	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	8	mg	mg	QD(D1,D8,D15,D22)	Other	PO	PO	Log Forms	Unknown	Unknown		8	Other	QD(D1,D8,D15,D22)					792	876	1
MMRF_1906	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					792	876	1
MMRF_1906	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-14)	QD (D1-14)					238	313	1
MMRF_1940	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1940	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD 2,5,9,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 2,5,9,12					1	81	1
MMRF_1940	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	18	1
MMRF_1940	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD(D1,D15,D29,D43)	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	QD(D1,D15,D29,D43)					291	1481	1
MMRF_1940	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					160	160	1
MMRF_1940	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib		1			4	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance	Checked	4	Q week	Q week					1481		1
MMRF_1957	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	144	1
MMRF_1957	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	144	1
MMRF_1957	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					324	1077	1
MMRF_1957	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	270	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		270	Q day	Q day					194	194	1
MMRF_1957	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	VENETOCLAX	Other		1			800	mg	mg	QD(D1-D28)	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	800	Other	QD(D1-D28)					1226		1
MMRF_2001	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_2001	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	103	1
MMRF_2001	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	103	1
MMRF_2001	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					169	169	1
MMRF_2001	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					404	549	1
MMRF_2001	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			16	mg/m^2	mg/m^2	WEEKLY X 2 MONTHS, THEN EVERY OTHER WEEK FOR MONTH 3 -6, THEN MONTHLY	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Other	WEEKLY X 2 MONTHS, THEN EVERY OTHER WEEK FOR MONTH 3 -6, THEN MONTHLY					1428		1
MMRF_2001	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					1428		1
MMRF_2001	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg/dL	mg/dL	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1063		1
MMRF_2090	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_2090	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					14	95	1
MMRF_2090	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	95	1
MMRF_2090	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					139	139	1
MMRF_2090	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					263	477	1
MMRF_2090	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					513		1
MMRF_2111	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	93	1
MMRF_2111	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	93	1
MMRF_2111	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	93	1
MMRF_2111	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IVB	IVB	Log Forms	Induction	Induction		200	Q day	Q day					153	153	1
MMRF_2111	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					327	1564	1
MMRF_2111	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			1300	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance	Checked	1300	QWK	QWK					1659		1
MMRF_2111	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					1659		1
MMRF_2111	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		1			4	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	4	Q day	Q day					1659		1
MMRF_2128	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_2128	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD 1-14 OF 21 DAYS	Other	PO	PO	Log Forms	Induction	Induction		25	Other	QD 1-14 OF 21 DAYS					1	106	1
MMRF_2128	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	106	1
MMRF_2128	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		140	Q day	Q day					161	161	1
MMRF_2128	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					323	343	1
MMRF_2137	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD 1,4,8,11,15,18	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	QD 1,4,8,11,15,18					1	107	1
MMRF_2137	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	107	1
MMRF_2137	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD 1,8,15,22	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 1,8,15,22					1	107	1
MMRF_2137	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					112	112	1
MMRF_2137	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					467		1
MMRF_2140	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					95	200	1
MMRF_2140	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					95	200	1
MMRF_2140	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD 1,8,15	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD 1,8,15					95	200	1
MMRF_2140	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	451	1
MMRF_2140	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					451		1
MMRF_2211	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2211	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1,2,4,5,8,9,11,12					1	36	1
MMRF_2211	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					43	74	1
MMRF_2211	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD(D1,D2,D4,D5,D8,D9,D11,D12)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD(D1,D2,D4,D5,D8,D9,D11,D12)					43	74	1
MMRF_2211	First line of therapy	First Line Therapy	ASCT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	ASCT		200	Q day	Q day					120	120	1
MMRF_2211	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					249	396	1
MMRF_2211	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					396	1054	1
MMRF_2211	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1075	1715	1
MMRF_2211	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Prednisone	Prednisone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAILY X 2 ON QD(D2,D9,D16,D23)	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	DAILY X 2 ON QD(D2,D9,D16,D23)					1075	1715	1
MMRF_2211	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QD(D1,D8,D15,D22)	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,D8,D15,D22)					1075	1715	1
MMRF_2211	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Ixazomib	Ixazomib		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		4	Q week	Q week					1722	1796	1
MMRF_2211	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1722	1796	1
MMRF_2211	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1722	1796	1
MMRF_2211	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		1			36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown	Checked	36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1838		1
MMRF_2211	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)			Cyclophosphamide	Cyclophosphamide		1			300	mg/m^2	mg/m^2	QD (D1, D8, & D15)	Other	PO	PO	Log Forms			Checked	300	Other	QD (D1, D8, & D15)					1838		1
MMRF_2211	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)			Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1, D8, & D15)	Other	PO	PO	Log Forms			Checked	40	Other	QD (D1, D8, & D15)					1838		1
MMRF_2209	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	8	1
MMRF_2209	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	8	1
MMRF_2209	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	8	1
MMRF_2209	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	Q WK X3 (DAYS 1,2,8,9,15,16) WITH 12 SAY REST Q 28 DAYS X	Other	IV	IV	Log Forms	Induction	Induction		20	Other	Q WK X3 (DAYS 1,2,8,9,15,16) WITH 12 SAY REST Q 28 DAYS X					22	125	1
MMRF_2209	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD 1,8,15,22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD 1,8,15,22					22	125	1
MMRF_2209	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IVB	IVB	Log Forms	Induction	Induction		140	Q day	Q day					173	173	1
MMRF_2239	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	32	1
MMRF_2239	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_2239	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD1 2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD1 2,4,5,8,9,11,12					1	74	1
MMRF_2239	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					236		1
MMRF_2239	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					43	74	1
MMRF_2239	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg	mg	Q day	Q day	IVB	IVB	Log Forms	Induction	Induction		140	Q day	Q day					126	126	1
MMRF_2284	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-21)	QD (D1-21)					239	771	1
MMRF_2284	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					133	133	1
MMRF_2284	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 1,2,4,5,8,9,11,12					1	64	1
MMRF_2284	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	94	1
MMRF_2284	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2284	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	MLN9708	Other		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD D1, 8, 15	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	QD D1, 8, 15					1317	1400	1
MMRF_2284	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD D1, 8, 15, 22	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	QD D1, 8, 15, 22					1317	1400	1
MMRF_2284	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	2.4	mg	mg	Q72H	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		2.4	Other	Q72H					1377	1381	1
MMRF_2284	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	Q24H	Other	PO	PO	Log Forms	Other	SALVAGE		40	Other	Q24H					1377	1381	1
MMRF_2284	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	740	mg	mg	Q24H	Other	IV	IV	Log Forms	Other	SALVAGE		740	Other	Q24H					1377	1381	1
MMRF_2284	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	ETOPOSIDE	Other		0	Completed regimen	Completed regimen	74	mg	mg	Q24H	Other	IV	IV	Log Forms	Other	SALVAGE		74	Other	Q24H					1377	1381	1
MMRF_2284	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	DEATH	Other	1300	mg	mg	D1, 8,15,22	Other	IV	IV	Log Forms	Other	SALVAGE		1300	Other	D1, 8,15,22					1415	1487	1
MMRF_2284	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	DEATH	Other	2	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		2	Q day	Q day					1415	1487	1
MMRF_2284	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	DEATH	Other	20	mg	mg	D1, 8,15, 22	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	D1, 8,15, 22					1415	1487	1
MMRF_2397	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2397	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	53	1
MMRF_2397	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD(1,2,4,5,8,9,11,12)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD(1,2,4,5,8,9,11,12)					1	53	1
MMRF_2397	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	400	mg	mg	Q day	Q day	IVB	IVB	Log Forms	Induction	Induction		400	Q day	Q day					99	99	1
MMRF_2397	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					183	218	1
MMRF_2397	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					183	218	1
MMRF_2397	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-14)	QD (D1-14)					183	218	1
MMRF_2397	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD(D1,D8,D15)	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	QD(D1,D8,D15)					284	343	1
MMRF_2397	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	QD(D1,D8,D15)					343	876	1
MMRF_2397	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib		1			3	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	3	Other	QD(D1,D8,D15)					876		1
MMRF_2383	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2383	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD(D1,D8,D15)					1	74	1
MMRF_2383	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_2383	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IVB	IVB	Log Forms	Induction	Induction		200	Q day	Q day					126	126	1
MMRF_2383	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					235		1
MMRF_2388	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	85	1
MMRF_2388	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1,8,15)	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1,8,15)					1	616	1
MMRF_2388	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD(D1,D8,D15)					1	1242	1
MMRF_2388	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					150	175	1
MMRF_2388	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-21)	QD (D1-21)					175	616	1
MMRF_2388	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD(D1-D7),(D15-D21)	Other	PO	PO	Log Forms	Unknown	Unknown		10	Other	QD(D1-D7),(D15-D21)					633	1088	1
MMRF_2388	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QD(D1,D8,D15,D22)	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,D8,D15,D22)					633	1088	1
MMRF_2388	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Ixazomib	Ixazomib		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1,D8,D15)	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD (D1,D8,D15)					1102	1767	1
MMRF_2388	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1102	1767	1
MMRF_2388	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		12	Q week	Q week					1242	1557	1
MMRF_2388	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		1			56	mg/m^2	mg/m^2	QD (D1, D8, & D15)	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	56	Other	QD (D1, D8, & D15)					1774		1
MMRF_2388	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide		1			300	mg/m^2	mg/m^2	QD (D1, D8, & D15)	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	300	Other	QD (D1, D8, & D15)					1774		1
MMRF_2388	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			4	mg	mg	QD (D1, D8, & D15)	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	4	Other	QD (D1, D8, & D15)					1774		1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	CISPLATIN	Other		0	Completed regimen	Completed regimen	19	mg	mg	Q24H	Other	IV	IV	Log Forms	Other	SALVAGE		19	Other	Q24H					1578	1581	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	ETOPOSIDE	Other		0	Completed regimen	Completed regimen	75	mg	mg	Q24H	Other	IV	IV	Log Forms	Other	SALVAGE		75	Other	Q24H					1578	1581	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)			Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	750	mg	mg	Q24H	Other	IV	IV	Log Forms				750	Other	Q24H					1578	1581	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)			Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	Q24H	Other	PO	PO	Log Forms				40	Other	Q24H					1578	1581	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	CISPLATIN	Other		0	Completed regimen	Completed regimen	19	mg	mg	Q24H	Other	IV	IV	Log Forms	Other	SALVAGE		19	Other	Q24H					1599	1602	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)			ETOPOSIDE	Other		0	Completed regimen	Completed regimen	76	mg	mg	Q24H	Other	IV	IV	Log Forms				76	Other	Q24H					1599	1602	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)			Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	750	mg	mg	Q24H	Other	IV	IV	Log Forms				750	Other	Q24H					1599	1602	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)			Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	Q24H	Other	PO	PO	Log Forms				40	Other	Q24H					1599	1602	1
MMRF_2411	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	FLUDARABINE	Other	JARC125	1			30	mg/m^2	mg/m^2	DAYS -5, -4, & -3	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	30	Other	DAYS -5, -4, & -3					1801		1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	2.4	mg	mg	Q72H	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		2.4	Other	Q72H					1578	1581	1
MMRF_2411	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	2.4	mg	mg	Q72H	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		2.4	Other	Q72H					1599	1602	1
MMRF_2411	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1618	1737	1
MMRF_2411	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab		0	Disease progression/Relapse	Disease progression/Relapse	700	mg	mg	QD (D1, D8, D15, & D22)	Other	IV	IV	Log Forms	Unknown	Unknown		700	Other	QD (D1, D8, D15, & D22)					1618	1737	1
MMRF_2411	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1, D8, D15, & D22)	Other	IV	IV	Log Forms	Unknown	Unknown		40	Other	QD (D1, D8, D15, & D22)					1618	1737	1
MMRF_2411	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide	JCAR125	1			300	mg/m^2	mg/m^2	DAYS -5, -4, & -3	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	300	Other	DAYS -5, -4, & -3					1801		1
MMRF_2411	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_2411	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2411	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2411	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IVB	IVB	Log Forms	Induction	Induction		200	Q day	Q day					129	129	1
MMRF_2411	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					246	914	1
MMRF_2411	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QD(D1,D8,D15,D22)	Other	IV	IV	Log Forms	Unknown	Unknown		16	Other	QD(D1,D8,D15,D22)					926	1023	1
MMRF_2411	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					926	1023	1
MMRF_2411	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAILY X 2 DAYS BEGINNING THE DAY AFTER EACH DARA INFUSION	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	DAILY X 2 DAYS BEGINNING THE DAY AFTER EACH DARA INFUSION					928	1023	1
MMRF_2411	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1058	1446	1
MMRF_2411	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	600	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Unknown	Unknown		600	Other	QD(D1,D8,D15)					1058	1446	1
MMRF_2411	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1058	1446	1
MMRF_2459	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	82	1
MMRF_2459	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	82	1
MMRF_2459	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD(D1,D2,D4,D5,D8,D9,D11,D12)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD(D1,D2,D4,D5,D8,D9,D11,D12)					1	82	1
MMRF_2459	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					136	136	1
MMRF_2459	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					224	606	1
MMRF_2459	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-14)	QD (D1-14)					606		1
MMRF_2516	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	9	1
MMRF_2516	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					1	4	1
MMRF_2516	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	74	1
MMRF_2516	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					22	77	1
MMRF_2516	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD 2,5,9,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD 2,5,9,12					22	74	1
MMRF_2516	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		140	Q day	Q day					119	119	1
MMRF_2516	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					245	259	1
MMRF_2516	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	QD(D1, D8, D15, D22)	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Other	QD(D1, D8, D15, D22)					1589		1
MMRF_2516	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown	Checked	40	Q week	Q week					1589		1
MMRF_2532	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_2532	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					1	81	1
MMRF_2532	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD(D1,D2,D4,D5,D8,D9,D11,D12)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD(D1,D2,D4,D5,D8,D9,D11,D12)					1	81	1
MMRF_2532	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	.7	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		0.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					71	81	1
MMRF_2532	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		140	Q day	Q day					133	133	1
MMRF_2532	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Patient decision	Patient decision	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					239	605	1
MMRF_2559	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2559	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2559	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_2559	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	QID	QID	IVB	IVB	Log Forms	Induction	Induction		200	QID	QID					131	131	1
MMRF_2559	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					275	410	1
MMRF_2559	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-14)	QD (D1-14)					410		1
MMRF_1121	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_1121	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1121	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms				20	Other	D1,2,4,5,8,9,11,12					1	74	1
MMRF_1121	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			LOST INSURANCE FOR ONE MONTH	Other	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					541	660	1
MMRF_1121	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					660		1
MMRF_1121	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	MG/M2	Other	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					494	494	1
MMRF_1121	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE REDUCED DUE TO PERIPHERAL NEUROPATHY	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					345	375	1
MMRF_1121	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			GOING ON VACATION TO CHINA	Other	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					375	464	1
MMRF_1149	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		40	Q day	Q day					844	845	1
MMRF_1149	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	300	mg/m^2	mg/m^2	QD(D1,D8,D15)	Other	IV	IV	Log Forms	Unknown	Unknown		300	Other	QD(D1,D8,D15)					844	852	1
MMRF_1149	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD(D1,D2)	Other	IV	IV	Log Forms	Unknown	Unknown		20	Other	QD(D1,D2)					844	846	1
MMRF_1149	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	27	mg/m^2	mg/m^2	QD(D8,D9,D15,D16)	Other	IV	IV	Log Forms	Unknown	Unknown		27	Other	QD(D8,D9,D15,D16)					851	852	1
MMRF_1149	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					701	760	1
MMRF_1149	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Thalidomide	Thalidomide			Disease progression/Relapse	Disease progression/Relapse	50	mg	mg	QD 1-28	Other	PO	PO	Log Forms	Other	SALVAGE		50	Other	QD 1-28					701	760	1
MMRF_1149	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	VORINOSTAT	Other			Disease progression/Relapse	Disease progression/Relapse	400	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Other	SALVAGE		400	QD (D1-14)	QD (D1-14)					701	730	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QD 1 AND 4	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.6	Other	QD 1 AND 4					772	776	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD 1,2,4,5	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD 1,2,4,5					772	776	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Thalidomide	Thalidomide			Completed regimen	Completed regimen	50	mg	mg	QD 1,2,3,4	Other	PO	PO	Log Forms	Unknown	Unknown		50	Other	QD 1,2,3,4					772	776	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	CISPLATIN	Other			Completed regimen	Completed regimen	20	mg	mg	QD 1,2,3,4	Other	IV	IV	Log Forms	Unknown	Unknown		20	Other	QD 1,2,3,4					772	776	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	20	mg	mg	QD 1,2,3,4	Other	IV	IV	Log Forms	Unknown	Unknown		20	Other	QD 1,2,3,4					772	776	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	800	mg	mg	QD 1,2,3,4	Other	IV	IV	Log Forms	Unknown	Unknown		800	Other	QD 1,2,3,4					772	776	1
MMRF_1149	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	ETOPOSIDE	Other			Completed regimen	Completed regimen	80	mg	mg	QD 1,2,3,4	Other	IV	IV	Log Forms	Unknown	Unknown		80	Other	QD 1,2,3,4					772	776	1
MMRF_1149	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	28	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Unknown	Unknown		28	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					809	837	1
MMRF_1149	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	ELOTUZUMAB	Other			Disease progression/Relapse	Disease progression/Relapse	795	mg	mg	QD(D1,D8,D15,D22)	Other	IV	IV	Log Forms	Unknown	Unknown		795	Other	QD(D1,D8,D15,D22)					809	837	1
MMRF_1149	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					809	837	1
MMRF_1149	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					809	837	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	D 1,8, 15, 21	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	D 1,8, 15, 21					458	564	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QD FOR FOUR DAYS (OFF FOR 24 DAYS)	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.6	Other	QD FOR FOUR DAYS (OFF FOR 24 DAYS)					564	595	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD FOR FOUR DAYS (OFF FOR 24 DAYS)	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	QD FOR FOUR DAYS (OFF FOR 24 DAYS)					564	595	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	800	mg	mg	QD FOR FOUR DAYS (OFF FOR 24 DAYS)	Other	IV	IV	Log Forms	Unknown	Unknown		800	Other	QD FOR FOUR DAYS (OFF FOR 24 DAYS)					564	595	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	ETOPOSIDE	Other			Completed regimen	Completed regimen	80	mg	mg	QD FOR 4 DAYS (OFF FOR 24 DAYS)	Other	IV	IV	Log Forms	Unknown	Unknown		80	Other	QD FOR 4 DAYS (OFF FOR 24 DAYS)					564	595	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	CISPLATIN	Other			Completed regimen	Completed regimen	20	mg	mg	QD FOR 4 DAYS (OFF FOR 24 DAYS)	Other	IV	IV	Log Forms	Unknown	Unknown		20	Other	QD FOR 4 DAYS (OFF FOR 24 DAYS)					564	595	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.6	mg/m^2	mg/m^2	QD 1,8,15	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1.6	Other	QD 1,8,15					620	645	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					620	645	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					620	645	1
MMRF_1149	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					701	760	1
MMRF_1149	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	600	mg	mg	QD 1,8,15,22	Other	PO	PO	Log Forms	Other	SALVAGE		600	Other	QD 1,8,15,22					701	760	1
MMRF_1149	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			REFERRED FOR BONE MARROW TRANSPLANT	Other	20	mg	mg	D1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms				20	Other	D1,2,4,5,8,9,11,12					1	85	1
MMRF_1149	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	TOTAL DOSE	Other	IV	IV	Log Forms				200	Other	TOTAL DOSE					158	204	1
MMRF_1149	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	DAILY DAYS 1 - 21 OF A 28 DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	DAILY DAYS 1 - 21 OF A 28 DAY CYCLE					330	457	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	DAY 2,9,16 OF EACH 28 DAY CYCLE	Other	IV	IV	Log Forms	Unknown	Unknown		4	Other	DAY 2,9,16 OF EACH 28 DAY CYCLE					458	563	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					458	564	1
MMRF_1149	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					458	564	1
MMRF_1149	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			REFERRED FOR BONE MARROW TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1149	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			REFERRED FOR BONE MARROW TRANSPLANT	Other	25	MG	Other	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	85	1
MMRF_1080	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	D1 Q21 DAYS	Other	IV	IV	Log Forms				1.3	Other	D1 Q21 DAYS					1	144	1
MMRF_1080	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg/dL	mg/dL	D1 & D8 Q21 DAYS	Other	IV	IV	Log Forms				25	Other	D1 & D8 Q21 DAYS					1	144	1
MMRF_1080	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	144	1
MMRF_1080	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms			Checked	10	Q day	Q day					295		1
MMRF_1198	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	309	1
MMRF_1198	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	309	1
MMRF_1198	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg/dL	mg/dL	D1 Q21 DAYS	Other	IV	IV	Log Forms				25	Other	D1 Q21 DAYS					1	309	1
MMRF_1198	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					316	434	1
MMRF_1198	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QAD	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	QAD					434		1
MMRF_1255	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					4	179	1
MMRF_1255	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				20	QD (D1-14)	QD (D1-14)					1	179	1
MMRF_1255	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q21 DAYS	Other	IV	IV	Log Forms				1.3	Other	Q21 DAYS					1	179	1
MMRF_1255	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	10	Q day	Q day					179		1
MMRF_1339	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	24	1
MMRF_1339	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	24	1
MMRF_1236	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	190	1
MMRF_1236	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	190	1
MMRF_1236	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	190	1
MMRF_1236	First line of therapy	First Line Therapy	Maintenance	Maintenance	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-21)	QD (D1-21)					313	342	1
MMRF_1236	First line of therapy	First Line Therapy	Maintenance	Maintenance	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-14)	QD (D1-14)					343	1397	1
MMRF_1236	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	DAYS 1,2,8,9,15,16 OF 21 DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1,2,8,9,15,16 OF 21 DAY CYCLE					1028	1069	1
MMRF_1236	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1069	1173	1
MMRF_1236	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1,4,8,11,15,19	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1,4,8,11,15,19					1174	1397	1
MMRF_1236	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	WEEKLY X8, BI-WEEKLY TO 6 MONTHS,THEN MONTHLY	Other	IV	IV	Log Forms	Induction	Induction		16	Other	WEEKLY X8, BI-WEEKLY TO 6 MONTHS,THEN MONTHLY					1407	1673	1
MMRF_1236	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-14)	QD (D1-14)					1407	1700	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	DAYS 1,2,8,9,15,16,22,23 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1,2,8,9,15,16,22,23 OF 28 DAY CYCLE					1701	1814	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg/m^2	mg/m^2	DAYS 1,2,8,9,15,16,22,23 OF 28 DAY CYCLE	Other	IV	IV	Log Forms	Induction	Induction		20	Other	DAYS 1,2,8,9,15,16,22,23 OF 28 DAY CYCLE					1701	1897	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide		0	Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	DAY 1, 8, 15	Other	PO	PO	Log Forms	Consolidation	Consolidation		300	Other	DAY 1, 8, 15					1792	1821	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	70	mg/m^2	mg/m^2	WEEKS 1,3 OF 28 DAY CYCLE	Other	IV	IV	Log Forms	Induction	Induction		70	Other	WEEKS 1,3 OF 28 DAY CYCLE					1957	2086	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	WEEKS 1,3 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	WEEKS 1,3 OF 28 DAY CYCLE					1957	2086	1
MMRF_1236	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan		0	Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	DAYS -2, -1 PRE-TRANSPLANT	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	DAYS -2, -1 PRE-TRANSPLANT					200	201	1
MMRF_1236	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Bendamustine	Bendamustine		0	Completed regimen	Completed regimen	125	mg	mg	ONCE	Other	IV	IV	Log Forms	Induction	Induction		125	Other	ONCE					2154	2154	1
MMRF_1236	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			25	mg	mg	DAILY X 21 DAYS THEN OFF X 7 DAYS	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	25	Other	DAILY X 21 DAYS THEN OFF X 7 DAYS					2301		1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Melphalan	Melphalan	01054196	0	Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	DAYS -2, -1 PRE-TRANSPLANT	Other	IV	IV	Log Forms	Consolidation	Consolidation		100	Other	DAYS -2, -1 PRE-TRANSPLANT					2188	2188	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide	01054196	0	Completed regimen	Completed regimen	UNK	mg	mg	DAYS -5,-4,-3,-2,-1 PRE-TRANSPLANT	Other	PO	PO	Log Forms	Consolidation	Consolidation			Other	DAYS -5,-4,-3,-2,-1 PRE-TRANSPLANT					2185	2190	1
MMRF_1236	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					1407	1700	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	WEEKLY X3, 1 WEEK OFF	Other	IV	IV	Log Forms	Induction	Induction		500	Other	WEEKLY X3, 1 WEEK OFF					1835	1897	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	12	mg	mg	DAYS 1,2,8,9,15,16 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		12	Other	DAYS 1,2,8,9,15,16 OF 28 DAY CYCLE					1821	1957	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg/m^2	mg/m^2	DAYS 1,2,15,16 OF 28 DAY CYCLE	Other	IV	IV	Log Forms	Induction	Induction		20	Other	DAYS 1,2,15,16 OF 28 DAY CYCLE					1897	1957	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	DAYS 1,15 OF 28 DAY CYCLE	Other	IV	IV	Log Forms	Induction	Induction		500	Other	DAYS 1,15 OF 28 DAY CYCLE					1897	2048	1
MMRF_1236	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	500	mg	mg	WEEK 3 OF 4 WEEK CYCLE	Other	IV	IV	Log Forms	Induction	Induction		500	Other	WEEK 3 OF 4 WEEK CYCLE					2048	2079	1
MMRF_1236	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	2.3	mg	mg	ONCE	Other	SUB-Q	Other	Log Forms	Induction	Induction		2.3	Other	ONCE					2154	2154	1
MMRF_1918	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			REFERRED FOR AUTOLOGOUS TRANSPLANT	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	270	1
MMRF_1918	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			REFERRED FOR AUTOLOGOUS TRANSPLANT	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	270	1
MMRF_1918	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			REFERRED FOR AUTOLOGOUS TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	273	1
MMRF_1918	First line of therapy	First Line Therapy	STEM CELL MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	573	mg	mg	Q week	Q week	IV	IV	Log Forms	Other	STEM CELL MOBILIZATION		573	Q week	Q week					92	99	1
MMRF_1918	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					286	287	1
MMRF_1918	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	DAYS 1-21 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Consolidation	Consolidation		25	Other	DAYS 1-21 OF 28 DAY CYCLE					456	631	1
MMRF_1918	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	20	mg/m^2	mg/m^2	DAYS 1,2,8,9,15,16 OF 28 DAY CYCLE	Other	IV	IV	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1,2,8,9,15,16 OF 28 DAY CYCLE					456	471	1
MMRF_1918	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	27	mg/m^2	mg/m^2	DAYS 1,2, 8,9,15,16 OF 21 DAY CYCLE	Other	IV	IV	Log Forms	Consolidation	Consolidation		27	Other	DAYS 1,2, 8,9,15,16 OF 21 DAY CYCLE					484	527	1
MMRF_1918	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	DAYS 1,2,8,9,15,16 OF 21 DAY CYCLE	Other	IV	IV	Log Forms	Consolidation	Consolidation		36	Other	DAYS 1,2,8,9,15,16 OF 21 DAY CYCLE					547	625	1
MMRF_1918	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					659	1627	1
MMRF_1918	First line of therapy	First Line Therapy	Consolidation	Consolidation	Elotuzumab	Elotuzumab			Completed regimen	Completed regimen	4	mg	mg	DAYS 1,8,15  OF 28 DAY CYCLE	Other	IV	IV	Log Forms	Consolidation	Consolidation		4	Other	DAYS 1,8,15  OF 28 DAY CYCLE					659	1627	1
MMRF_1918	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1,8,15 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	DAYS 1,8,15 OF 28 DAY CYCLE					659	1627	1
MMRF_1918	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1634	2080	1
MMRF_1918	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	28	mg	mg	D1, D8, D22	Other	PO	PO	Log Forms	Maintenance	Maintenance		28	Other	D1, D8, D22					1634	2080	1
MMRF_1918	First line of therapy	First Line Therapy	Maintenance	Maintenance	Elotuzumab	Elotuzumab		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg/kg	mg/kg	MONTHLY	Other	IV	IV	Log Forms	Maintenance	Maintenance		10	Other	MONTHLY					1634	2080	1
MMRF_2329	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE ESCALATION	Other	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					358	501	1
MMRF_2329	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			WHIPPLE PROCEDURE AND COMPLICATIONS; DOSE HELD; PANCREATIC CANCER TREATMENT	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					502	724	1
MMRF_2329	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		0	DIAGNOSED WITH RECURRENT METASTATIC CHOLANGIOCARCINOMA	Other	16	mg/m^2	mg/m^2	D1, D8, D15, D22	Other	IV	IV	Log Forms	Induction	Induction		16	Other	D1, D8, D15, D22					1172	1710	1
MMRF_2329	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	DIAGNOSED WITH RECURRENT METASTATIC CHOLANGIOCARCINOMA	Other	20	mg	mg	DAY 1, DAY 8, DAY 15, DAY 22	Other	IV	IV	Log Forms	Induction	Induction		20	Other	DAY 1, DAY 8, DAY 15, DAY 22					1172	1710	1
MMRF_2329	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	DIAGNOSED WITH RECURRENT METASTATIC CHOLANGIOCARCINOMA	Other	20	mg	mg	D2, D 9, D 16, D 23	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D2, D 9, D 16, D 23					1172	1710	1
MMRF_2329	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	DIAGNOSED WITH RECURRENT METASTATIC CHOLANGIOCARCINOMA	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1172	1716	1
MMRF_2329	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1016	1171	1
MMRF_2329	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	176	1
MMRF_2329	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	155	1
MMRF_2329	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	176	1
MMRF_1067	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	112	1
MMRF_1067	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms				300	Q week	Q week					1	15	1
MMRF_1067	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	DAYS 1, 2, 4, 5, 8, 9, 11, 12	Other	PO	PO	Log Forms				40	Other	DAYS 1, 2, 4, 5, 8, 9, 11, 12					1	12	1
MMRF_1067	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					53	113	1
MMRF_1067	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4380	mg	mg	ONCE	Other	IV	IV	Log Forms				4380	Other	ONCE					148	148	1
MMRF_1067	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	ONCE	Other	PO	PO	Log Forms				12	Other	ONCE					148	148	1
MMRF_1067	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	250	mg	mg	ONCE	Other	IV	IV	Log Forms				250	Other	ONCE					161	161	1
MMRF_1067	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUS	Other	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					348	421	1
MMRF_1067	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAYS 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms				20	Other	DAYS 1,2,4,5,8,9,11,12					348	419	1
MMRF_1067	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				15	QD (D1-14)	QD (D1-14)					348	417	1
MMRF_1067	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1595	1805	1
MMRF_1067	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab		1			806	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown	Checked	806	Q week	Q week					2430		1
MMRF_1067	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	2	QD (D1-21)	QD (D1-21)					1835		1
MMRF_1067	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1835		1
MMRF_1067	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					718	865	1
MMRF_1067	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	1216	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		1216	Q week	Q week					1294	1343	1
MMRF_1067	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1427	1817	1
MMRF_1067	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					1369	1569	1
MMRF_1067	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					545	718	1
MMRF_1131	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	1, 2, 4, 5	Other	PO	PO	Log Forms				40	Other	1, 2, 4, 5					1	57	1
MMRF_1131	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	8, 9, 11 AND 12	Other	PO	PO	Log Forms				20	Other	8, 9, 11 AND 12					8	12	1
MMRF_1131	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					22	345	1
MMRF_1131	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	Q week	Q week	SUBCUTANEOUS	Other	Log Forms				1	Q week	Q week					100	114	1
MMRF_1131	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	DQ (D1, D7, D14)	Other	SUBCUTANEOUS	Other	Log Forms				1.3	Other	DQ (D1, D7, D14)					186	256	1
MMRF_1131	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					100	175	1
MMRF_1131	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					179	269	1
MMRF_1131	First line of therapy	First Line Therapy			Prednisone	Prednisone			Completed regimen	Completed regimen	20	mg	mg	1, 2, 4, 5, 8, 9, 11, 12	Other	PO	PO	Log Forms				20	Other	1, 2, 4, 5, 8, 9, 11, 12					22	269	1
MMRF_1131	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Prednisone	Prednisone			Patient decision	Patient decision	50	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		50	Q week	Q week					312	333	1
MMRF_1131	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Patient decision	Patient decision	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					312	333	1
MMRF_1131	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUSLY	Other	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	256	1
MMRF_1245	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	QD (D1, D8, D15, D22)	Other	SUBCUTANEOUS	Other	Log Forms				1.5	Other	QD (D1, D8, D15, D22)					1	239	1
MMRF_1245	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD ( D1, D8, D15, D22)	Other	PO	PO	Log Forms				20	Other	QD ( D1, D8, D15, D22)					1	239	1
MMRF_1245	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			MOVED TO OHIO	Other	1.5	mg/m^2	mg/m^2	ONCE EVERY 2 WEEKS	Other	SUBCUTANEOUS	Other	Log Forms	Maintenance	Maintenance		1.5	Other	ONCE EVERY 2 WEEKS					250	295	1
MMRF_1412	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUS	Other	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1412	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	99	1
MMRF_1412	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	99	1
MMRF_1412	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	5176	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION		5176	Other	ONCE					134	134	1
MMRF_1412	First line of therapy	First Line Therapy	CONDITIONING REGIMEN	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	410	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING REGIMEN		410	Other	ONCE					147	147	1
MMRF_1412	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					323		1
MMRF_1412	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					294	323	1
MMRF_1680	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	D1, D8, D15	Other	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1.5	Other	D1, D8, D15					1	104	1
MMRF_1680	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	27	1
MMRF_1680	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	132	1
MMRF_1680	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					28	132	1
MMRF_1680	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	6250	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION		6250	Other	ONCE					133	133	1
MMRF_1680	First line of therapy	First Line Therapy	CONDITIONING REGIMEN	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	505	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING REGIMEN		505	Other	ONCE					145	145	1
MMRF_1680	First line of therapy	First Line Therapy	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SALVAGE		40	QD (D1-4)	QD (D1-4)					1376	1422	1
MMRF_1680	First line of therapy	First Line Therapy	SALVAGE	Other	CISPLATIN (PLATINOL)	Other			Completed regimen	Completed regimen	24	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		24	QD (D1-4)	QD (D1-4)					1376	1422	1
MMRF_1680	First line of therapy	First Line Therapy	SALVAGE	Other	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	24.2	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		24.2	QD (D1-4)	QD (D1-4)					1376	1422	1
MMRF_1680	First line of therapy	First Line Therapy	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	968	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		968	QD (D1-4)	QD (D1-4)					1376	1422	1
MMRF_1680	First line of therapy	First Line Therapy	SALVAGE	Other	ETOPOSIDE (VERSED)	Other			Completed regimen	Completed regimen	96	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		96	QD (D1-4)	QD (D1-4)					1376	1422	1
MMRF_2119	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			STRIGENT COMPLETE RESPONSE	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	165	1
MMRF_2119	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			STRIGENT COMPLETE RESPONSE	Other	1.5	mg/m^2	mg/m^2	DAY 1, 8, 15	Other	SUBCUTANE	Other	Log Forms	Induction	Induction		1.5	Other	DAY 1, 8, 15					1	165	1
MMRF_2119	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			STRIGENT COMPLETE RESPONSE	Other	40	mg	mg	DAY 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15, 22					1	165	1
MMRF_2119	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q MONDAY AND TUESDAY	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	Q MONDAY AND TUESDAY					191	530	1
MMRF_2119	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					191	530	1
MMRF_2119	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					533	654	1
MMRF_2119	First line of therapy	First Line Therapy	Unknown	Unknown	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.5	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		1.5	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					422	530	1
MMRF_2119	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					422	530	1
MMRF_2119	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					533	652	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	50	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Unknown	Unknown		50	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					653	716	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Unknown	Unknown		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					653	716	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					653	716	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					736	785	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1-21)	QD (D1-21)					736	770	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					771	925	1
MMRF_2119	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					771	857	1
MMRF_2213	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAYS 1, 8, 15, 22	Other	IV	IV	Log Forms	Induction	Induction		300	Other	DAYS 1, 8, 15, 22					1	99	1
MMRF_2213	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	DAYS 1, 8, 15, 22	Other	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1.5	Other	DAYS 1, 8, 15, 22					1	99	1
MMRF_2213	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	99	1
MMRF_2213	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		5	Q day	Q day					312	356	1
MMRF_2213	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	1.78	mg	mg	QOW	Other	IV	IV	Log Forms	Maintenance	Maintenance		1.78	Other	QOW					356	1778	1
MMRF_2213	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Melphalan	Melphalan		0	Completed regimen	Completed regimen	210	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		210	Q day	Q day					1918	1918	1
MMRF_2213	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD 1,8,15,22	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD 1,8,15,22					1785	1840	1
MMRF_2213	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1785	1840	1
MMRF_2213	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	29.6	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		29.6	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1785	1840	1
MMRF_2213	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD 1,8,15	Other	IV	IV	Log Forms	Unknown	Unknown		300	Other	QD 1,8,15					1841	1898	1
MMRF_2213	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1841	1898	1
MMRF_2213	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QD 1,8,15,22	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD 1,8,15,22					1841	1898	1
MMRF_2476	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			10	mg	mg	Q WEDNESDAY AND THURSDAY WITH BREAKFAST	Other	PO	PO	Log Forms	Induction	Induction	Checked	10	Other	Q WEDNESDAY AND THURSDAY WITH BREAKFAST					1		1
MMRF_2476	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					29		1
MMRF_2549	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	600	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		600	Q week	Q week					292	453	1
MMRF_2549	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	3.6	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		3.6	Q week	Q week					292	453	1
MMRF_2549	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					292	453	1
MMRF_2549	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		15	Q day	Q day					467	985	1
MMRF_2549	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	MONDAY AND TUESDAY WEEKLY	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	MONDAY AND TUESDAY WEEKLY					545	985	1
MMRF_2549	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab		0	Disease progression/Relapse	Disease progression/Relapse	1271	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		1271	Q week	Q week					880	985	1
MMRF_2549	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Patient decision	Patient decision	10	mg	mg	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		10	QWK	QWK					1020	1101	1
MMRF_2549	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Patient decision	Patient decision	4	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		4	Q day	Q day					1020	1101	1
MMRF_2549	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Patient decision	Patient decision	10	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		10	Q week	Q week					1020	1101	1
MMRF_2549	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		20	Q day	Q day					1	6	1
MMRF_2549	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					7	39	1
MMRF_2549	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	TWICE A WEEK	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	TWICE A WEEK					39	285	1
MMRF_2549	First line of therapy	First Line Therapy	Unknown	Unknown	Bortezomib	Bortezomib		0	Investigator decision for other reasons	Investigator decision for other reasons	3.08	mg	mg	BI-WEEKLY	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		3.08	Other	BI-WEEKLY					40	285	1
MMRF_1309	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms				10	Q day	Q day					1	3	1
MMRF_1309	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.6	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms				2.6	QWK	QWK					34	97	1
MMRF_1309	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.5	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.5	Q week	Q week					1663	1768	1
MMRF_1431	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	Q day	Q day	PO	PO	Log Forms				25	Q day	Q day					1	1230	1
MMRF_1431	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					1	1230	1
MMRF_1431	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.6	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.6	Q week	Q week					33	837	1
MMRF_2308	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	12	1
MMRF_2308	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction	Checked	20	QWK	QWK					1		1
MMRF_2308	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QOD	Other	PO	PO	Log Forms	Induction	Induction		25	Other	QOD					13	42	1
MMRF_2308	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	5	QD (D1-21)	QD (D1-21)					94		1
MMRF_2308	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.8	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.8	Q week	Q week					127		1
MMRF_1077	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			CYCLE ENDED	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IVB	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1077	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			CYCLE ENDED	Other	10	MG	Other	DAILY	Other	PO	PO	Log Forms				10	Other	DAILY					22	31	1
MMRF_1077	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			CYCLE ENDED	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1077	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			CYCLE ENDED	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IVB	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	32	1
MMRF_1077	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			CYCLE ENDED	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	32	1
MMRF_1077	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			CYCLE ENDED	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IVB	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					43	71	1
MMRF_1077	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			CYCLE ENDED	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					43	71	1
MMRF_1077	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	BID	BID	PO	PO	Log Forms	Maintenance	Maintenance		4	BID	BID					1429	1540	1
MMRF_1077	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3510	mg	mg	Q day	Q day	IV	IV	Log Forms				3510	Q day	Q day					205	205	1
MMRF_1077	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		3	Q week	Q week					245	259	1
MMRF_1077	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Lack of response	Lack of response	10	MG	Other	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					43	1903	1
MMRF_1078	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	2000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms				2000	Q day	Q day					142	142	1
MMRF_1078	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Prednisone	Prednisone		0	Lack of response	Lack of response	20	mg	mg	QID	QID	PO	PO	Log Forms				20	QID	QID					2290	2301	1
MMRF_1078	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D8-11)	Other	PO	PO	Log Forms				40	Other	QD (D1-4, D8-11)					2301	2311	1
MMRF_1078	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	44	mg	mg	Q day	Q day	IV	IV	Log Forms				44	Q day	Q day					2367	2367	1
MMRF_1078	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms				40	Other	QD(D1,D8,D15)					2367	2394	1
MMRF_1078	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	60	mg	mg	RECEIVED INFUSIONS 10/3, 10/11, 10/12	Other	IV	IV	Log Forms				60	Other	RECEIVED INFUSIONS 10/3, 10/11, 10/12					2373	2382	1
MMRF_1078	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	60	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2395	2396	1
MMRF_1078	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	4	mg	mg	ONCE	Other	PO	PO	Log Forms				4	Other	ONCE					2396	2396	1
MMRF_1078	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	4	mg	mg	ONCE	Other	PO	PO	Log Forms				4	Other	ONCE					2403	2403	1
MMRF_1078	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	4	mg	mg	ONCE	Other	PO	PO	Log Forms				4	Other	ONCE					2431	2431	1
MMRF_1078	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	4	mg	mg	ONCE	Other	PO	PO	Log Forms				4	Other	ONCE					2438	2438	1
MMRF_1078	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	4	mg	mg	ONCE	Other	PO	PO	Log Forms				4	Other	ONCE					2445	2445	1
MMRF_1078	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	4	mg	mg	ONCE	Other	PO	PO	Log Forms				4	Other	ONCE					2466	2466	1
MMRF_1078	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	4	mg	mg	ONCE	Other	PO	PO	Log Forms				4	Other	ONCE					2473	2473	1
MMRF_1078	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1078	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	MG	Other	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	77	1
MMRF_1078	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1-2, D4-5, D8-9, D11-12	Other	PO	PO	Log Forms				20	Other	D1-2, D4-5, D8-9, D11-12					1	75	1
MMRF_1078	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	406	mg	mg	Q day	Q day	IV	IV	Log Forms				406	Q day	Q day					174	174	1
MMRF_1105	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	302	1
MMRF_1105	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	339	1
MMRF_1105	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	MG	Other	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	295	1
MMRF_1105	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	875	mg	mg	DAYS 1, 8	Other	IV	IV	Log Forms				875	Other	DAYS 1, 8					169	302	1
MMRF_1105	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	EVERYDAY/NO BREAKS	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	EVERYDAY/NO BREAKS					618		1
MMRF_1136	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	85	1
MMRF_1136	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	D1-4, D8-11	Other	PO	PO	Log Forms				20	Other	D1-4, D8-11					1	23	1
MMRF_1136	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	MG	Other	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					1	77	1
MMRF_1136	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					23	64	1
MMRF_1136	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	D1-4, D8-11	Other	PO	PO	Log Forms				20	Other	D1-4, D8-11					64	85	1
MMRF_1136	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					85	95	1
MMRF_1136	First line of therapy	First Line Therapy			CISPLATIN	Other			Completed regimen	Completed regimen	10	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms				10	QD (D1-4)	QD (D1-4)					96	100	1
MMRF_1136	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	414	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms				414	QD (D1-4)	QD (D1-4)					96	100	1
MMRF_1136	First line of therapy	First Line Therapy			ETOPOSIDE	Other			Completed regimen	Completed regimen	41	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms				41	QD (D1-4)	QD (D1-4)					96	100	1
MMRF_1136	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					96	100	1
MMRF_1136	First line of therapy	First Line Therapy			CISPLATIN	Other			Completed regimen	Completed regimen	8	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms				8	QD (D1-4)	QD (D1-4)					127	131	1
MMRF_1136	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	610	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms				610	QD (D1-4)	QD (D1-4)					127	131	1
MMRF_1136	First line of therapy	First Line Therapy			ETOPOSIDE	Other			Completed regimen	Completed regimen	60	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms				60	QD (D1-4)	QD (D1-4)					127	131	1
MMRF_1136	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms				40	QD (D1-4)	QD (D1-4)					127	130	1
MMRF_1136	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	6120	mg	mg	Q day	Q day	IV	IV	Log Forms				6120	Q day	Q day					170	170	1
MMRF_1136	First line of therapy	First Line Therapy			Melphalan	Melphalan			Completed regimen	Completed regimen	284	mg	mg	Q day	Q day	IV	IV	Log Forms				284	Q day	Q day					205	205	1
MMRF_1136	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	15	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		15	Q week	Q week					309	309	1
MMRF_1136	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	50	mg	mg	Q day	Q day	PO	PO	Log Forms				50	Q day	Q day					366	372	1
MMRF_1136	First line of therapy	First Line Therapy	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	1	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		1	Q day	Q day					342	360	1
MMRF_1136	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-7)	QD (D1-7)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-7)	QD (D1-7)					342	360	1
MMRF_1148	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			PATIENT DIED	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IVB	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	270	1
MMRF_1148	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			PATIENT DIED	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					6	270	1
MMRF_1148	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Lack of response	Lack of response	10	MG	Other	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				10	QD (D1-14)	QD (D1-14)					6	227	1
MMRF_1148	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			PATIENT DIED	Other	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					227	270	1
MMRF_1189	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IVB	IVB	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1189	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					1	4	1
MMRF_1189	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D8, D11)	Other	PO	PO	Log Forms				20	Other	QD (D8, D11)					8	11	1
MMRF_1189	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1500	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		1500	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1600	1667	1
MMRF_1189	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	ONCE WEEKLY	Other	IV	IV	Log Forms				20	Other	ONCE WEEKLY					1600	1670	1
MMRF_1189	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.75	mg	mg	D1, D4, D8, AND D11	Other	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		2.75	Other	D1, D4, D8, AND D11					1600	1670	1
MMRF_1189	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			PRIOR TO TRANSPLANT	Other	170	mg	mg	EVERY 30MIN @1068 ML/HR OVER 30MIN	Other	IV	IV	Log Forms	Induction	Induction		170	Other	EVERY 30MIN @1068 ML/HR OVER 30MIN					225	225	1
MMRF_1189	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	ONCE	Other	IV	IV	Log Forms	Induction	Induction		8	Other	ONCE					1675	1675	1
MMRF_1189	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					697	1271	1
MMRF_1214	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	151	1
MMRF_1214	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Lack of response	Lack of response	5	mg	mg	QD (D1, D3, D5, D8, D10, D12)	Other	PO	PO	Log Forms				5	Other	QD (D1, D3, D5, D8, D10, D12)					11	18	1
MMRF_1214	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-4, D9-12, D17-20)	Other	PO	PO	Log Forms				20	Other	QD (D1-4, D9-12, D17-20)					87	162	1
MMRF_1214	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					39	303	1
MMRF_1335	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3740	mg	mg	Q day	Q day	IV	IV	Log Forms	Maintenance	Maintenance		3740	Q day	Q day					781	1311	1
MMRF_1335	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	100.5	mg	mg	ONCE	Other	IV	IV	Log Forms	Unknown	Unknown		100.5	Other	ONCE					1202	1202	1
MMRF_1335	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide			DONE IN ATTEMPT TO PROLONG PATIENT SURVIVAL	Other	3740	mg	mg	Q day	Q day	IV	IV	Log Forms	Maintenance	Maintenance		3740	Q day	Q day					1311	1311	1
MMRF_1335	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1335	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms				20	Other	D1,2,4,5,8,9,11,12					1	352	1
MMRF_1335	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					22	71	1
MMRF_1335	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3420	mg	mg	ONCE	Other	IV	IV	Log Forms	Induction	Induction		3420	Other	ONCE					354	354	1
MMRF_1402	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	PO	PO	Log Forms				40	Q day	Q day					1	247	1
MMRF_1402	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	Q day	Q day	PO	PO	Log Forms				25	Q day	Q day					1	246	1
MMRF_1402	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					143	243	1
MMRF_1402	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	ONCE	Other	UNKNOWN	Other	Log Forms	Induction	Induction		1.5	Other	ONCE					282	282	1
MMRF_1402	First line of therapy	First Line Therapy			Melphalan	Melphalan		0	Completed regimen	Completed regimen	318	mg	mg	Q day	Q day	IV	IV	Log Forms				318	Q day	Q day					310	310	1
MMRF_1402	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					558	1152	1
MMRF_1560	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					436		1
MMRF_1560	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3.1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		3.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	25	1
MMRF_1560	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Patient decision	Patient decision	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	5	1
MMRF_1560	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	22	1
MMRF_1560	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					44	114	1
MMRF_1560	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					3	5	1
MMRF_1560	First line of therapy	First Line Therapy	RE-INDUCTION	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	RE-INDUCTION		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					186	264	1
MMRF_1560	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3000	mg/m^2	mg/m^2	ONCE	Other	UNKNOWN	Other	Log Forms	Other	MOBILIZATION		3000	Other	ONCE					291	291	1
MMRF_1560	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					325	325	1
MMRF_1560	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	114	1
MMRF_1579	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					17	60	1
MMRF_1579	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			UNKNOWN	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					17	91	1
MMRF_1579	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					1	105	1
MMRF_1579	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QOD (1-21)	Other	PO	PO	Log Forms	Induction	Induction		5	Other	QOD (1-21)					105	123	1
MMRF_1579	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	DAY 1, DAY 2	Other	IV	IV	Log Forms	Consolidation	Consolidation		40	Other	DAY 1, DAY 2					997	1823	1
MMRF_1579	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	600	mg	mg	DAY 1, DAY 15	Other	PO	PO	Log Forms	Induction	Induction		600	Other	DAY 1, DAY 15					631	1444	1
MMRF_1579	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAY 1, DAY, DAY 28	Other	IV	IV	Log Forms	Consolidation	Consolidation		300	Other	DAY 1, DAY, DAY 28					1401	1444	1
MMRF_1579	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	DAY 1, DAY 8, DAY 15, DAY 22	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	DAY 1, DAY 8, DAY 15, DAY 22					989	993	1
MMRF_1579	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		1			4	mg	mg	DAY 2, DAY 9 AND DAY 16	Other	PO	PO	Log Forms	Consolidation	Consolidation	Checked	4	Other	DAY 2, DAY 9 AND DAY 16					990		1
MMRF_1613	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			RISK FOR RELAPSE.DOES NOT WANT TRANSPLANT, PURSUING MAINTENANCE- REV ONLY.	Other	2.86	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IVB	IVB	Log Forms	Induction	Induction		2.86	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	118	1
MMRF_1613	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PER TREATING PHYSICIAN  GUIDANCE	Other	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	7	1
MMRF_1613	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			Lack of response	Lack of response	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		5	QD (D1-21)	QD (D1-21)					396	467	1
MMRF_1613	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					492	522	1
MMRF_1613	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Patient decision	Patient decision	1500	mg	mg	Q WK EXCEPT WHEN HELD	Other	IV	IV	Log Forms	Unknown	Unknown		1500	Other	Q WK EXCEPT WHEN HELD					799	1254	1
MMRF_1613	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		40	Q day	Q day					878	882	1
MMRF_1613	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		20	QWK	QWK					883	1004	1
MMRF_1613	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Patient decision	Patient decision	12	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		12	QWK	QWK					1008	1129	1
MMRF_1613	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Patient decision	Patient decision	28	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		28	QWK	QWK					1226	1283	1
MMRF_1613	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Lack of response	Lack of response	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-21)	QD (D1-21)					468	694	1
MMRF_1613	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Lack of response	Lack of response	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					695	799	1
MMRF_1613	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab			Patient decision	Patient decision	800	mg	mg	EVERY 2 WEEKS	Other	IV	IV	Log Forms	Unknown	Unknown		800	Other	EVERY 2 WEEKS					1261	1282	1
MMRF_1613	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		20	QWK	QWK					520	539	1
MMRF_1613	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Patient decision	Patient decision	10	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		10	Q week	Q week					684	695	1
MMRF_1613	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		20	QWK	QWK					695	799	1
MMRF_1613	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Patient decision	Patient decision	4	mg	mg	TWICE WEEKLY	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	TWICE WEEKLY					800	1008	1
MMRF_1613	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PER TREATING PHYSICIAN GUIDANCE	Other	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					8	43	1
MMRF_1613	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	TWICE WEEKLY	Other	PO	PO	Log Forms	Induction	Induction		20	Other	TWICE WEEKLY					44	118	1
MMRF_1761	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	990	1
MMRF_1761	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QID	QID	PO	PO	Log Forms	Unknown	Unknown		15	QID	QID					231	568	1
MMRF_1761	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	BID	BID	IV	IV	Log Forms	Maintenance	Maintenance		20	BID	BID					231	260	1
MMRF_1761	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Ixazomib	Ixazomib		1			4	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown	Checked	4	Q week	Q week					1155		1
MMRF_1761	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		15	Q day	Q day					1184	1205	1
MMRF_1761	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					1450	1822	1
MMRF_1761	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		0	Patient decision	Patient decision	5	mg	mg	THREE TIMES WEEKLY	Other	PO	PO	Log Forms	Unknown	Unknown		5	Other	THREE TIMES WEEKLY					1822	1840	1
MMRF_1890	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	100	1
MMRF_1890	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	EVERY DAY EXCEPT FOR A BREAK FROM 8.24-8.27.2014	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	EVERY DAY EXCEPT FOR A BREAK FROM 8.24-8.27.2014					119	133	1
MMRF_1890	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	5880	mg	mg	ONCE	Other	IV	IV	Log Forms	Unknown	Unknown		5880	Other	ONCE					121	121	1
MMRF_1890	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	MESNA	Other			Completed regimen	Completed regimen	1176	mg	mg	BID	BID	IV	IV	Log Forms	Unknown	Unknown		1176	BID	BID					121	122	1
MMRF_2183	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					2	103	1
MMRF_2183	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		20	Q day	Q day					1	103	1
MMRF_2183	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Patient decision	Patient decision	5	mg	mg	21/28D	Other	PO	PO	Log Forms	Induction	Induction		5	Other	21/28D					121	336	1
MMRF_2246	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			UNKNOWN	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	158	1
MMRF_2246	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			UNKNOWN	Other	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					23	219	1
MMRF_2246	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		0	Patient decision	Patient decision	4	mg	mg	Q week	Q week	PO	PO	Log Forms				4	Q week	Q week					141	262	1
MMRF_2246	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	15	mg	mg	Q day	Q day	PO	PO	Log Forms				15	Q day	Q day					183	231	1
MMRF_2246	First line of therapy	First Line Therapy	Unknown	Unknown	Prednisone	Prednisone		0	Patient decision	Patient decision	20	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		20	Q day	Q day					345	478	1
MMRF_2246	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	8	mg	mg	ONCE	Other	PO	PO	Log Forms				8	Other	ONCE					1866	1866	1
MMRF_2246					Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	8	mg	mg	ONCE	Other	PO	PO	Log Forms				8	Other	ONCE					1900	1900	1
MMRF_2246					Bortezomib	Bortezomib		1										Log Forms			Checked								1866		1
MMRF_2246					Daratumumab	Daratumumab		1										Log Forms			Checked								2006		1
MMRF_2477	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	71	1
MMRF_2477	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					8	71	1
MMRF_2477	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		25	Q day	Q day					40	57	1
MMRF_2477	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	D1, 8, 15 OF 28 D CYCLE	Other	PO	PO	Log Forms	Induction	Induction		3	Other	D1, 8, 15 OF 28 D CYCLE					382	483	1
MMRF_1163	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	136	1
MMRF_1163	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					3	136	1
MMRF_1163	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD X 14 DAYS EVERY 21 DAYS	Other	PO	PO	Log Forms				25	Other	QD X 14 DAYS EVERY 21 DAYS					1	136	1
MMRF_1163	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Carfilzomib	Carfilzomib		1			40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms			Checked	40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					150		1
MMRF_1182	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Patient decision	Patient decision	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					433	644	1
MMRF_1182	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			CHANGE IN DOSAGE	Other	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1182	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	234	1
MMRF_1182	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					25	234	1
MMRF_1182	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1,D2, D4, D5, D8, D9, D11, D12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1,D2, D4, D5, D8, D9, D11, D12					1	234	1
MMRF_1182	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					264	433	1
MMRF_1186	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	234	1
MMRF_1186	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, 9-12, 17-20)	Other	PO	PO	Log Forms				40	Other	QD (D1-4, 9-12, 17-20)					1	215	1
MMRF_1186	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			PATIENT DEATH	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		10	Q day	Q day					1264	1850	1
MMRF_1186	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					312	979	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	BRIDGING	Other	Dexamethasone	Dexamethasone		0	AWAITING CLINICAL TRIAL SLOT	Other	16	mg	mg	QD X3-4 (PATIENT TOOK AT HOME, UNSURE IF TOOK FOR 3 OR 4 DAYS TOTAL)	Other	PO	PO	Log Forms	Other	BRIDGING		16	Other	QD X3-4 (PATIENT TOOK AT HOME, UNSURE IF TOOK FOR 3 OR 4 DAYS TOTAL)					2128	2131	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	BRIDGING	Other	Daratumumab	Daratumumab		0	Completed regimen	Completed regimen	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Other	BRIDGING		16	QWK	QWK					2233	2252	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	BRIDGING	Other	Pomalidomide	Pomalidomide		0	Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	BRIDGING		4	QD (D1-21)	QD (D1-21)					2233	2252	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	BRIDGING	Other	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	BRIDGING		20	Q week	Q week					2233	2252	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	CAR-T	Other	FLUDARABINE	Other		0	Completed regimen	Completed regimen	24	mg/m^2	mg/m^2	QD X3	Other	IV	IV	Log Forms	Other	CAR-T		24	Other	QD X3					2275	2277	1
MMRF_1201	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Other	SALVAGE		16	QWK	QWK					2410	2472	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	BRIDGING	Other	Bendamustine	Bendamustine		0	AWAITING CLINICAL TRIAL SLOT	Other	80	mg/m^2	mg/m^2	QD X2	Other	IV	IV	Log Forms	Other	BRIDGING		80	Other	QD X2					2128	2129	1
MMRF_1201	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-21)	QD (D1-21)					2410	2472	1
MMRF_1201	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	ON DAY 2 AND 3 AFTER EACH DARA	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	ON DAY 2 AND 3 AFTER EACH DARA					2410	2472	1
MMRF_1201	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	BRIDGING	Other	Cyclophosphamide	Cyclophosphamide		0	STARTING CLINICAL TRIAL	Other	300	mg	mg	Q WEEK	Other	PO	PO	Log Forms	Other	BRIDGING		300	Other	Q WEEK					2486	2500	1
MMRF_1201	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	BRIDGING	Other	Carfilzomib	Carfilzomib		0	STARTING CLINICAL TRIAL	Other	20	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Other	BRIDGING		20	Q week	Q week					2486	2500	1
MMRF_1201	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	BRIDGING	Other	Dexamethasone	Dexamethasone		0	STARTING CLINICAL TRIAL	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	BRIDGING		20	Q week	Q week					2486	2500	1
MMRF_1201	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	CAR-T	Other	CYCLOPHOSPHAMIDE	Other		0	Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD X3	Other	IV	IV	Log Forms	Other	CAR-T		300	Other	QD X3					2549	2551	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Bendamustine	Bendamustine		0	Disease progression/Relapse	Disease progression/Relapse	80	mg/m^2	mg/m^2	DAY 1, 2	Other	IV	IV	Log Forms	Other	SALVAGE		80	Other	DAY 1, 2					1848	2128	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1848	2128	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAY 1, 8, 15, 22	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	DAY 1, 8, 15, 22					1848	2128	1
MMRF_1201	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	CAR-T	Other	CYTOXAN	Other		0	Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD X3	Other	IV	IV	Log Forms	Other	CAR-T		300	Other	QD X3					2275	2277	1
MMRF_1201	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	CAR-T	Other	FLUDARABINE	Other		0	Completed regimen	Completed regimen	75	mg/m^2	mg/m^2	QD X3	Other	IV	IV	Log Forms	Other	CAR-T		75	Other	QD X3					2549	2551	1
MMRF_1201	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					436	513	1
MMRF_1201	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					643	789	1
MMRF_1201	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Lack of response	Lack of response	2.1	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		2.1	Q week	Q week					790	923	1
MMRF_1201	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		40	Q week	Q week					790	923	1
MMRF_1201	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	450	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		450	Q week	Q week					790	923	1
MMRF_1201	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	CB-5083	Other			Lack of response	Lack of response	200	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Other	SALVAGE		200	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1007	1034	1
MMRF_1201	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Panobinostat	Panobinostat			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1, 3, 5, 8, 10, 12, 15, 17, 19	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	DAYS 1, 3, 5, 8, 10, 12, 15, 17, 19					1034	1356	1
MMRF_1201	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	59	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		59	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1034	1356	1
MMRF_1201	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	CC-90002	Other			Lack of response	Lack of response	116	mg	mg	D 1, 15	Other	IV	IV	Log Forms	Other	SALVAGE		116	Other	D 1, 15					1392	1422	1
MMRF_1201	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					1430	1728	1
MMRF_1201	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		15	QD (D1-21)	QD (D1-21)					1430	1729	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1.3	Q week	Q week					1731	1773	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		20	Q week	Q week					1731	1773	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	VENETOCLAX	Other			Lack of response	Lack of response	600	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		600	Q day	Q day					1731	1773	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Lack of response	Lack of response	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1783	1835	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Lack of response	Lack of response	400	mg	mg	D 1-2	Other	PO	PO	Log Forms	Other	SALVAGE		400	Other	D 1-2					1783	1835	1
MMRF_1201	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Lack of response	Lack of response	20	mg	mg	D 1, 8, 15, 22	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	D 1, 8, 15, 22					1783	1835	1
MMRF_1201	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			INVESTIGATOR CHANGE IN FREQUENCY	Other	2	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	63	1
MMRF_1201	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			INVESTIGATOR CHANGE IN FREQUENCY	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	63	1
MMRF_1201	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			INVESTIGATOR CHANGED DOSAGE	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	31	1
MMRF_1201	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2	Q week	Q week					71	148	1
MMRF_1201	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			INVESTIGATOR CHANGE IN FREQUENCY	Other	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					50	54	1
MMRF_1201	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					71	196	1
MMRF_1201	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DOSAGE CHANGED, SUBJECT ON MAINTENANCE REV	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					71	148	1
MMRF_1202	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	227	1
MMRF_1202	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	227	1
MMRF_1202	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					152	227	1
MMRF_1202	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					697	810	1
MMRF_1202	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					697	810	1
MMRF_1202	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	TWICE WEEKLY	Other	PO	PO	Log Forms	Induction	Induction		20	Other	TWICE WEEKLY					697	810	1
MMRF_1202	First line of therapy	First Line Therapy	ASCT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	0	UNK	Other	UNK	Other	UNK	Other	Log Forms	Other	ASCT		0	Other	UNK					312	312	1
MMRF_1202	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Lack of response	Lack of response	60	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					872	890	1
MMRF_1202	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					872	890	1
MMRF_1210	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			STARTING ASCT	Other	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1503	1681	1
MMRF_1210	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.9	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.9	Q week	Q week					1	156	1
MMRF_1210	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	123	1
MMRF_1210	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	156	1
MMRF_1210	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.9	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		2.9	QWK	QWK					171	292	1
MMRF_1210	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			STARTING ASCT	Other	20	mg/m^2	mg/m^2	QD (D1-21)	QD (D1-21)	IV	IV	Log Forms	Other	SALVAGE		20	QD (D1-21)	QD (D1-21)					1503	1681	1
MMRF_1210	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					503	1495	1
MMRF_1210	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					503	1495	1
MMRF_1210	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		12	Q week	Q week					1055	1495	1
MMRF_1210	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					171	292	1
MMRF_1210	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		1			27	mg/m^2	mg/m^2	DAYS 1, 2, 15, 16	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	27	Other	DAYS 1, 2, 15, 16					1819		1
MMRF_1210	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1819		1
MMRF_1210	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			10	mg	mg	DAYS 1, 2, 15, 16	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	DAYS 1, 2, 15, 16					1819		1
MMRF_1210	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	STARTING ASCT	Other	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	SALVAGE		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1503	1681	1
MMRF_1293	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	BIAXIN	Other		0	Lack of response	Lack of response	250	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		250	Q day	Q day					1100	1163	1
MMRF_1293	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		0	Lack of response	Lack of response	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1184	1226	1
MMRF_1293	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Lack of response	Lack of response	8	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	SALVAGE		8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1184	1226	1
MMRF_1293	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	400	mg	mg	WEEKLY, 3/4 WEEKS	Other	PO	PO	Log Forms	Other	SALVAGE		400	Other	WEEKLY, 3/4 WEEKS					1245	2383	1
MMRF_1293	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	SALVAGE		8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1245	1288	1
MMRF_1293	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		12	Q week	Q week					1100	1163	1
MMRF_1293	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Other	SALVAGE		16	QWK	QWK					1450	2451	1
MMRF_1293	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1450	2451	1
MMRF_1293	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	CAR-T	Other	CYTOXAN	Other	NCT03601078	0	Completed regimen	Completed regimen	600	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CAR-T		600	Q day	Q day					2527	2529	1
MMRF_1293	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	CAR-T	Other	FLUDARABINE	Other	NCT03601078	0	Completed regimen	Completed regimen	60	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CAR-T		60	Q day	Q day					2527	2529	1
MMRF_1293	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3	Q week	Q week					1	432	1
MMRF_1293	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	432	1
MMRF_1293	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			INVESTIGATOR CHANGED DOSAGE	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	21	1
MMRF_1293	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					32	432	1
MMRF_1293	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			Lack of response	Lack of response	10	mg	mg	QID	QID	PO	PO	Log Forms	Other	SALVAGE		10	QID	QID					916	1163	1
MMRF_1293	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Lack of response	Lack of response	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE		12	Q week	Q week					916	1163	1
MMRF_1293	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Other	SALVAGE		25	QD (D1-14)	QD (D1-14)					1320	1398	1
MMRF_1293	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	ATEZOLIZUMAB	Other		0	Disease progression/Relapse	Disease progression/Relapse	1200	mg	mg	ONCE EVERY 3 WEEKS	Other	IV	IV	Log Forms	Other	SALVAGE		1200	Other	ONCE EVERY 3 WEEKS					1320	1398	1
MMRF_1320	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		2.6	Q week	Q week					2	46	1
MMRF_1320	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1-3, 8-11, 15-18	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1-3, 8-11, 15-18					1	46	1
MMRF_1320	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	700	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		700	QD (D1-4)	QD (D1-4)					2	46	1
MMRF_1320	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Maintenance	Maintenance		3	Other	EVERY OTHER WEEK					337	1073	1
MMRF_1320	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					337	1073	1
MMRF_1320	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	27	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1149	2123	1
MMRF_1320	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	WEEKLY, 3 OUT OF  4 WEEKS	Other	IV	IV	Log Forms	Other	SALVAGE		300	Other	WEEKLY, 3 OUT OF  4 WEEKS					1149	2123	1
MMRF_1320	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1149	2123	1
MMRF_1320	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	1000	mg	mg	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Other	SALVAGE		1000	Other	EVERY OTHER WEEK					2123	2675	1
MMRF_1320	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		3	QD (D1-21)	QD (D1-21)					2123	2698	1
MMRF_1320	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	EVERY OTHER WEEK (AS DARA PRE-MED)	Other	PO	PO	Log Forms	Other	SALVAGE		2	Other	EVERY OTHER WEEK (AS DARA PRE-MED)					2123	2724	1
MMRF_1320	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					46	337	1
MMRF_1320	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	WEEKLY, 3/4 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Other	WEEKLY, 3/4 WEEKS					46	337	1
MMRF_1320	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	WEEKLY, 3/4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	WEEKLY, 3/4 WEEKS					46	337	1
MMRF_1320	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	FOR46	Other	NCT03650491	1			2.2	mg/kg	mg/kg	EVERY 21 DAYS	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	2.2	Other	EVERY 21 DAYS					2724		1
MMRF_1320	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			10	mg	mg	EVERY 21 DAYS AS PREMED TO FOR46	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	10	Other	EVERY 21 DAYS AS PREMED TO FOR46					2724		1
MMRF_1300	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	BIAXIN	Other		0	Completed regimen	Completed regimen	500	mg	mg	Q12H	Other	PO	PO	Log Forms	Other	SALVAGE		500	Other	Q12H					490	727	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1.3	QWK	QWK					1063	1097	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Investigator decision for other reasons	Investigator decision for other reasons	200	mg	mg	QWK	QWK	IV	IV	Log Forms	Other	SALVAGE		200	QWK	QWK					1063	1097	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		20	QWK	QWK					1063	1097	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (DAYS 1, 8, AND 15)	Other	IV	IV	Log Forms	Other	SALVAGE		1.3	Other	QD (DAYS 1, 8, AND 15)					1141	1484	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	BIAXIN	Other		0	Disease progression/Relapse	Disease progression/Relapse	500	mg	mg	BID	BID	PO	PO	Log Forms	Other	SALVAGE		500	BID	BID					1141	1484	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		15	QD (D1-21)	QD (D1-21)					1141	1484	1
MMRF_1300	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE		20	QWK	QWK					1141	1484	1
MMRF_1300	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		1			350	mg/m^2	mg/m^2	Q12H ON DAYS 1-3	Other	IV	IV	Log Forms	Other	SALVAGE	Checked	350	Other	Q12H ON DAYS 1-3					2582		1
MMRF_1300	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			40	mg	mg	DAYS 1-4, 8-11, AND 15-18	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	40	Other	DAYS 1-4, 8-11, AND 15-18					2582		1
MMRF_1300	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	154	1
MMRF_1300	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-21)	QD (D1-21)					1	154	1
MMRF_1300	First line of therapy	First Line Therapy	Induction	Induction	BIAXIN (BIRD REGIMEN FOR A FEW MONTHS THEN RVD ONLY)	Other			Completed regimen	Completed regimen	500	mg	mg	QID	QID	PO	PO	Log Forms	Induction	Induction		500	QID	QID					1	154	1
MMRF_1300	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	SQ WK	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	SQ WK					154	207	1
MMRF_1300	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	SQ WK	Other	IV	IV	Log Forms	Maintenance	Maintenance		1.3	Other	SQ WK					207	490	1
MMRF_1300	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	SQ WK	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	SQ WK					207	490	1
MMRF_1300	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	EVERY 7 (SEVEN) DAYS. 3 OUT OF 4 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1.3	Other	EVERY 7 (SEVEN) DAYS. 3 OUT OF 4 WEEKS					490	727	1
MMRF_1300	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					490	727	1
MMRF_1300	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	EVERY 7 (SEVEN) DAYS. 3 OUT OF 4 WEEKS	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	EVERY 7 (SEVEN) DAYS. 3 OUT OF 4 WEEKS					490	727	1
MMRF_1300	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			Lack of response	Lack of response	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		15	QD (D1-21)	QD (D1-21)					910	1479	1
MMRF_1300	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, 8 & 15)	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		1.3	Other	QD (D1, 8 & 15)					910	1479	1
MMRF_1300	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	QD (D1, 8 & 15)	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	QD (D1, 8 & 15)					910	1479	1
MMRF_1300	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	3.5	mg	mg	ONCE EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		3.5	Other	ONCE EVERY OTHER WEEK					1484	1801	1
MMRF_1300	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	400	mg	mg	DAY 1, 8, 15	Other	PO	PO	Log Forms	Other	SALVAGE		400	Other	DAY 1, 8, 15					1801	2386	1
MMRF_1300	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1801	2386	1
MMRF_1300	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Other	SALVAGE		20	Other	DAYS 1, 8, 15					1801	2386	1
MMRF_1300	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV	IV	Log Forms	Other	SALVAGE		20	Other	DAYS 1, 8, 15					2386	2569	1
MMRF_1300	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Other	SALVAGE		10	Other	DAYS 1, 8, 15					2386	2569	1
MMRF_1300	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	800	mg	mg	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Other	SALVAGE		800	Other	EVERY OTHER WEEK					1484	1801	1
MMRF_1338	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			ALLERGIC REACTION, RASH CHANGED TO QOD INSTEAD	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					15	22	1
MMRF_1338	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QOD NO BREAK 14/28 DAYS	Other	PO	PO	Log Forms				25	Other	QOD NO BREAK 14/28 DAYS					22	852	1
MMRF_1338	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.3	Q week	Q week					15	852	1
MMRF_1338	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			MD ORDER	Other	40	mg	mg	Q day	Q day	PO	PO	Log Forms				40	Q day	Q day					1	4	1
MMRF_1338	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			MD ORDER	Other	40	mg	mg	Q day	Q day	PO	PO	Log Forms				40	Q day	Q day					9	12	1
MMRF_1338	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					15	852	1
MMRF_1375	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.8	mg/kg	mg/kg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.8	Q week	Q week					21	181	1
MMRF_1375	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		40	BID	BID					1	181	1
MMRF_1375	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					41	181	1
MMRF_1375	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					360	1218	1
MMRF_1490	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	483	1
MMRF_1490	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.6	QWK	QWK					1	325	1
MMRF_1490	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	7	1
MMRF_1490	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					15	1331	1
MMRF_1490	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	4	QD (D1-21)	QD (D1-21)					514		1
MMRF_1490	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SALVAGE	Checked	20	QWK	QWK					2003		1
MMRF_1518	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	74	1
MMRF_1518	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.7	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1518	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DOSE CHANGE	Other	20	mg	mg	D1,2, 4,5, 8,9, 11,12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1,2, 4,5, 8,9, 11,12					1	98	1
MMRF_1518	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	730	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		730	Q day	Q day					98	135	1
MMRF_1518	First line of therapy	First Line Therapy	Induction	Induction	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	20	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		20	Q day	Q day					98	135	1
MMRF_1518	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			CHANGE IN DOSE	Other	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		40	Q day	Q day					98	135	1
MMRF_1518	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	340	mg	mg	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		340	Q day	Q day					155	158	1
MMRF_1518	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			PATIENT DEATH	Other	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					221	240	1
MMRF_1518	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			PATIENT DEATH	Other	20	mg	mg	QD 1 AND 2 AND THEN 27MG /M2	Other	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		20	Other	QD 1 AND 2 AND THEN 27MG /M2					221	240	1
MMRF_1518	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			PATIENT DEATH	Other	20	mg	mg	ON DAYS OF CARFILZOMIB	Other	PO	PO	Log Forms	Induction	Induction		20	Other	ON DAYS OF CARFILZOMIB					221	240	1
MMRF_1772	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	2	QD (D1-21)	QD (D1-21)					1256		1
MMRF_1772	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Q week	Q week					1256		1
MMRF_1772	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	65	1
MMRF_1772	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	65	1
MMRF_1772	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	1157	1
MMRF_1772	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	43	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance		43	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					73	1157	1
MMRF_1772	First line of therapy	First Line Therapy	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	650	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		650	Q day	Q day					73	1157	1
MMRF_1772	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Ixazomib	Ixazomib		1			4	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE	Checked	4	Q week	Q week					1256		1
MMRF_1952	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Patient decision	Patient decision	2.7	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	Q week	Q week					1	309	1
MMRF_1952	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Patient decision	Patient decision	540	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		540	Q week	Q week					1	309	1
MMRF_1952	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	309	1
MMRF_1952	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Induction	Induction		25	Other	EVERY OTHER DAY					320	1580	1
MMRF_1952	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	D 1, 7, 14	Other	PO	PO	Log Forms	Induction	Induction		8	Other	D 1, 7, 14					320	1600	1
MMRF_1952	First line of therapy	First Line Therapy	Induction	Induction	BIAXIN	Other		0	Lack of response	Lack of response	250	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		250	Q day	Q day					1188	1244	1
MMRF_1952	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Q week	Q week					1593		1
MMRF_1952	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		1			3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	3	QD (D1-21)	QD (D1-21)					1600		1
MMRF_1952	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			4	mg	mg	TWICE A WEEK	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	4	Other	TWICE A WEEK					1600		1
MMRF_1983	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	316	1
MMRF_1983	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	316	1
MMRF_1983	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	WEEKLY X8, THEN Q 2 WEEKS X8, THEN Q 4 WEEKS	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Other	WEEKLY X8, THEN Q 2 WEEKS X8, THEN Q 4 WEEKS					1230		1
MMRF_1983	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1230		1
MMRF_1983	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			25	mg	mg	DAILY, DAYS 1-21/28	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	25	Other	DAILY, DAYS 1-21/28					1230		1
MMRF_1991	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		25	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	20	1
MMRF_1991	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	9	1
MMRF_1991	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-21)	QD (D1-21)					1	9	1
MMRF_1991	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					516	822	1
MMRF_1991	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					516	822	1
MMRF_1991	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	SALVAGE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					516	822	1
MMRF_1991	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	350	mg/m^2	mg/m^2	D 1-4	Other	IV	IV	Log Forms	Other	SALVAGE		350	Other	D 1-4					828	871	1
MMRF_1991	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	MESNA	Other			Disease progression/Relapse	Disease progression/Relapse	700	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	SALVAGE		700	QD (D1-4)	QD (D1-4)					828	871	1
MMRF_1991	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D 1-4, 15-18	Other	PO	PO	Log Forms	Other	SALVAGE		40	Other	D 1-4, 15-18					828	871	1
MMRF_1991	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					828	871	1
MMRF_1991	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SALVAGE		4	Q day	Q day					876	1457	1
MMRF_1991	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Q week	Q week					876		1
MMRF_1991	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	WEEKLY FOR 3/4 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	WEEKLY FOR 3/4 WEEKS					260	507	1
MMRF_1991	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	12-20	mg	mg	WEEKLY, 3/4 WEEKS (ON DAYS OF VELCADE)	Other	PO/IV	Other	Log Forms	Maintenance	Maintenance			Other	WEEKLY, 3/4 WEEKS (ON DAYS OF VELCADE)					260	507	1
MMRF_2097	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	600	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		600	Q week	Q week					1	162	1
MMRF_2097	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.6	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	Q week	Q week					7	311	1
MMRF_2097	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					7		1
MMRF_2097	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					162	1373	1
MMRF_2097	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					1360	1360	1
MMRF_2367	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3	mg	mg	WEEKLY 3 OUT OF 4 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3	Other	WEEKLY 3 OUT OF 4 WEEKS					1	612	1
MMRF_2367	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	800	mg	mg	WEEKLY 3 OUT OF 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		800	Other	WEEKLY 3 OUT OF 4 WEEKS					1	246	1
MMRF_2367	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	WEEKLY 3 OUT OF 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		20	Other	WEEKLY 3 OUT OF 4 WEEKS					1	581	1
MMRF_2367	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			8	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE	Checked	8	Q week	Q week					1109		1
MMRF_2367	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Carfilzomib	Carfilzomib		1			20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	SALVAGE	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1109		1
MMRF_2412	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Patient decision	Patient decision	1.3	mg/m^2	mg/m^2	TWICE PER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	TWICE PER WEEK					1	130	1
MMRF_2412	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Patient decision	Patient decision	400	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		400	Q week	Q week					1	130	1
MMRF_2412	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	130	1
MMRF_2412	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	TURMERIC	Other			Patient decision	Patient decision	8	GMS	Other	QID	QID	PO	PO	Log Forms	Unknown	Unknown		8	QID	QID					164	1004	1
MMRF_2412	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab		0	Patient decision	Patient decision	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE		16	Q week	Q week					727	1261	1
MMRF_2433	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	STARTING SCT	Other	2.9	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.9	Q week	Q week					1	209	1
MMRF_2433	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	760	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		760	Q week	Q week					1	153	1
MMRF_2433	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	STARTING SCT	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	215	1
MMRF_2433	First line of therapy	First Line Therapy	AUTOLOGOUS HCT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	AUTOLOGOUS HCT		200	Other	ONCE					248	248	1
MMRF_2433	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	STARTING SCT	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					167	215	1
MMRF_2433	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					342		1
MMRF_2458	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			20	mg	mg	20 MG WEEK 1, THEN 4 MG ON DAYS 2 + 3 WEEK 2-3	Other	PO	PO	Log Forms	Other	SALVAGE	Checked	20	Other	20 MG WEEK 1, THEN 4 MG ON DAYS 2 + 3 WEEK 2-3					1968		1
MMRF_2458	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					141	169	1
MMRF_2458	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					141	169	1
MMRF_2458	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	12	mg	mg	TAKEN ON DAYS OF AND AFTER VELCADE	Other	PO	PO	Log Forms	Induction	Induction		12	Other	TAKEN ON DAYS OF AND AFTER VELCADE					138	169	1
MMRF_2458	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	TWICE A WEEK EVERY OTHER WEEK	Other	IV	IV	Log Forms	Consolidation	Consolidation		27	Other	TWICE A WEEK EVERY OTHER WEEK					351	436	1
MMRF_2458	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					351	436	1
MMRF_2458	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					351	436	1
MMRF_2458	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0			15	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					436	1793	1
MMRF_2458	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1	Disease progression/Relapse	Disease progression/Relapse	1800	mg/kg	mg/kg	QWEEK X1 MONTH, THEN QOW FOR 8 DOSES, THEN EVERY 4 WEEKS ONGOING.	Other	IV SubQ	IV SubQ	Log Forms	Other	SALVAGE	Checked	1800	Other	QWEEK X1 MONTH, THEN QOW FOR 8 DOSES, THEN EVERY 4 WEEKS ONGOING.					1968		1
MMRF_2458	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE	Checked	15	QD (D1-21)	QD (D1-21)					1968		1
MMRF_2458	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	120	1
MMRF_2458	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	Investigator decision for other reasons	Investigator decision for other reasons	1.5	mg/m^2	mg/m^2	D 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Other	D 1, 8, 15					1	120	1
MMRF_2458	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	120	1
MMRF_1112	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					2	190	1
MMRF_1112	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.3	Q week	Q week					1	190	1
MMRF_1112	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	190	1
MMRF_1112	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					489		1
MMRF_1112	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					489	685	1
MMRF_1112	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	REL/REFR	Other	ACP-196	Other			Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	BID	BID	PO	PO	Log Forms	Other	REL/REFR		100	BID	BID					1316	1379	1
MMRF_1112	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	REL/REFR	Other	PEMBROLIZUMAB	Other			Disease progression/Relapse	Disease progression/Relapse	2	mg/kg	mg/kg	Q3WK	Other	IV	IV	Log Forms	Other	REL/REFR		2	Other	Q3WK					1316	1358	1
MMRF_1112	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	REL/REFR	Other	Carfilzomib	Carfilzomib		0	Investigator decision for other reasons	Investigator decision for other reasons	92	mg	mg	Q week	Q week	IV	IV	Log Forms	Other	REL/REFR		92	Q week	Q week					1385	1695	1
MMRF_1152	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	DAY 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	DAY 1, 8, 15					1	192	1
MMRF_1152	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAY 1, 8, 15, 22	Other	PO	PO	Log Forms				40	Other	DAY 1, 8, 15, 22					1	192	1
MMRF_1152	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					108	192	1
MMRF_1152	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-14)	QD (D1-14)					304	2685	1
MMRF_1283	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms			Checked	10	QD (D1-21)	QD (D1-21)					1		1
MMRF_1283	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			4	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	4	Q day	Q day					1		1
MMRF_1360	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					1	389	1
MMRF_1360	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			COMPLETED THIS PIECE, ON MAINTENANCE DEX/LENOLIDAMIDE	Other	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	176	1
MMRF_1360	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	399	1
MMRF_1484	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction	Checked	1.3	Q week	Q week					1		1
MMRF_1484	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					1		1
MMRF_1601	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.9	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.9	Q week	Q week					1	16	1
MMRF_1601	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	16	1
MMRF_1641	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.2	mg	mg	D1, D8, D15 Q28D	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	Other	D1, D8, D15 Q28D					1	146	1
MMRF_1641	First line of therapy	First Line Therapy	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	D1 D8 Q4WK CYCLE	Other	IV	IV	Log Forms	Unknown	Unknown		500	Other	D1 D8 Q4WK CYCLE					34	145	1
MMRF_1641	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	70	mg/m^2	mg/m^2	D1,8,15 Q28D	Other	IV	IV	Log Forms	Unknown	Unknown		70	Other	D1,8,15 Q28D					211	470	1
MMRF_1641	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1,8, 15 Q28D	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	D1,8, 15 Q28D					20	506	1
MMRF_2083	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	321	1
MMRF_2083	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	321	1
MMRF_2083	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	321	1
MMRF_2083	First line of therapy	First Line Therapy	REL/REF	Other	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	105	mg	mg	D1, D8, D15 - Q4W	Other	IV	IV	Log Forms	Other	REL/REF		105	Other	D1, D8, D15 - Q4W					476	630	1
MMRF_2083	First line of therapy	First Line Therapy	REL/REFR	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	D1, D8, D15, D22 - Q4WK	Other	PO	PO	Log Forms	Other	REL/REFR		40	Other	D1, D8, D15, D22 - Q4WK					476	630	1
MMRF_2083	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	REL/REF	Other	Daratumumab	Daratumumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1600	mg	mg	EVERY 2 WEEKS	Other	IV	IV	Log Forms	Other	REL/REF		1600	Other	EVERY 2 WEEKS					659	667	1
MMRF_2083	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	REL/REF	Other	METHYLPREDNISOLONE	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	100	mg	mg	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Other	REL/REF		100	Other	EVERY OTHER WEEK					659	667	1
MMRF_2083	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	REL/REF	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	REL/REF		40	QD (D1-4)	QD (D1-4)					682	683	1
MMRF_2083	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	REL/REF	Other	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	820	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	REL/REF		820	QD (D1-4)	QD (D1-4)					682	722	1
MMRF_2083	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	REL/REF	Other	ETOPOSIDE	Other			Disease progression/Relapse	Disease progression/Relapse	82	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	REL/REF		82	QD (D1-4)	QD (D1-4)					682	722	1
MMRF_2083	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	REL/REF	Other	CISPLATIN	Other			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	REL/REF		20	QD (D1-4)	QD (D1-4)					682	722	1
MMRF_2083	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	REL/REF	Other	Doxorubicin	Doxorubicin			Disease progression/Relapse	Disease progression/Relapse	82	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	REL/REF		82	QD (D1-4)	QD (D1-4)					682	722	1
MMRF_2083	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	REL/REF	Other	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	REL/REF		20	Q week	Q week					804	869	1
MMRF_2083	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	REL/REF	Other	Elotuzumab	Elotuzumab			Patient decision	Patient decision	900	mg	mg	QD (D1, D8, D15, D22)	Other	IV	IV	Log Forms	Other	REL/REF		900	Other	QD (D1, D8, D15, D22)					804	869	1
MMRF_2400	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_2400	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			10	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction	Checked	10	QWK	QWK					1		1
MMRF_2400	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			NOT SPECIFIED IF CONTINUING AS PART OF REGIMEN AT THIS TIME	Other	1.3	mg/m^2	mg/m^2	Q day	Q day	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q day	Q day					14	14	1
MMRF_2473	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	15	QD (D1-21)	QD (D1-21)					1		1
MMRF_2473	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	10	Q day	Q day					1		1
MMRF_1310	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg	mg	QWK	QWK	IV	IV	Log Forms				300	QWK	QWK					1	148	1
MMRF_1310	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms				1.5	QWK	QWK					1	148	1
MMRF_1310	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	IV	IV	Log Forms				20	QWK	QWK					1	148	1
MMRF_1310	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			DECREASED DOSE	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	182	1
MMRF_1310	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					183	211	1
MMRF_1310	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					225	1751	1
MMRF_1407	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	78	1
MMRF_1407	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1-2, 4-5, 8-9 AND 11-12	Other	PO	PO	Log Forms				20	Other	D1-2, 4-5, 8-9 AND 11-12					1	78	1
MMRF_1407	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					7	78	1
MMRF_1407	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.8	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		2.8	QWK	QWK					201	271	1
MMRF_1407	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					201	271	1
MMRF_1407	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-21)	QD (D1-21)					201	277	1
MMRF_1407	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					286	1021	1
MMRF_1424	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1424	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	95	1
MMRF_1424	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	109	1
MMRF_1424	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.5	Q week	Q week					150	192	1
MMRF_1424	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					150	192	1
MMRF_1424	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		3000	Q day	Q day					214	214	1
MMRF_1424	First line of therapy	First Line Therapy	CONIDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONIDITIONING		100	Q day	Q day					247	248	1
MMRF_1424	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					361	473	1
MMRF_1424	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE CHANGED FROM 10MG QOD TO 5MG QD	Other	10	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	EVERY OTHER DAY					586	676	1
MMRF_1424	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					677	926	1
MMRF_1424	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Q week	Q week					981	1278	1
MMRF_1424	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		3	QD (D1-21)	QD (D1-21)					1376	1495	1
MMRF_1424	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1376	1377	1
MMRF_1424	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	56	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		56	Q week	Q week					1383	1495	1
MMRF_1424	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	D1, D8, D15 & D22 Q 28 DAYS X 7 CYCLES	Other	IVPB	Other	Log Forms	Unknown	Unknown		16	Other	D1, D8, D15 & D22 Q 28 DAYS X 7 CYCLES					1516	1600	1
MMRF_1424	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					1516	1600	1
MMRF_1424	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	D1, D8, D15 & D22 Q 28 DAYS	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	D1, D8, D15 & D22 Q 28 DAYS					1516	1600	1
MMRF_1424	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			ADDITIONAL STEROID TO PREVENT INFUSION REACTION. NO LONGER REQUIRED.	Other	20	mg	mg	D1, D8, D15 & D22 Q CYCLE	Other	IV	IV	Log Forms	Unknown	Unknown		20	Other	D1, D8, D15 & D22 Q CYCLE					1516	1517	1
MMRF_1424	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	TREATMENT UNTIL DISEASE PROGRESSION	Other	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	TREATMENT UNTIL DISEASE PROGRESSION		3	QD (D1-21)	QD (D1-21)					1614	1719	1
MMRF_1424	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	TREATMENT UNTIL DISEASE PROGRESSION	Other	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	800	mg	mg	QWK	QWK	IVB	IVB	Log Forms	Other	TREATMENT UNTIL DISEASE PROGRESSION		800	QWK	QWK					1614	1712	1
MMRF_1424	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	TREATMENT UNTIL DISEASE PROGRESSION	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	28	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	TREATMENT UNTIL DISEASE PROGRESSION		28	QWK	QWK					1614	1719	1
MMRF_1424	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	TREATMENT UNTIL DISEASE PROGRESSION	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	QWK	QWK	IVB	IVB	Log Forms	Other	TREATMENT UNTIL DISEASE PROGRESSION		8	QWK	QWK					1614	1712	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	CONDITIONING	Other	BUSULFAN	Other			Completed regimen	Completed regimen	204	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		204	Q day	Q day					1759	1760	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	130	mg/dL	mg/dL	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		130	Q day	Q day					1760	1761	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib			DOSE REDUCED	Other	4	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		4	QWK	QWK					1919	1941	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		1			3	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance	Checked	3	QWK	QWK					1955	2032	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide			DOSE REDUCTION	Other	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		3	QD (D1-21)	QD (D1-21)					1919	1941	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		0	INSURANCE TERMED	Other	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-21)	QD (D1-21)					1955	2102	1
MMRF_1424	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	DEATH	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1919	2144	1
MMRF_1556	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		1.5	Q week	Q week					1	113	1
MMRF_1556	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		300	Q week	Q week					1	113	1
MMRF_1556	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		20	Q week	Q week					1	113	1
MMRF_1556	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Lack of response	Lack of response	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.5	Q week	Q week					1212	1337	1
MMRF_1556	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	300	mg/m^2	mg/m^2	D1, D8 & D15 Q28	Other	IVB	IVB	Log Forms	Consolidation	Consolidation		300	Other	D1, D8 & D15 Q28					1212	1335	1
MMRF_1556	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	WKLY	Other	IV	IV	Log Forms	Consolidation	Consolidation		20	Other	WKLY					1212	1335	1
MMRF_1617	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	101	1
MMRF_1617	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					2	108	1
MMRF_1617	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					2	101	1
MMRF_1617	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	120	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		120	Q day	Q day					146	147	1
MMRF_1617	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					251		1
MMRF_1723	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	267	1
MMRF_1723	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	267	1
MMRF_1723	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	121	1
MMRF_1723	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		500	QWK	QWK					128	267	1
MMRF_1723	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					272		1
MMRF_1723	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	D1, 8, 15 Q28DAYS	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	D1, 8, 15 Q28DAYS					272		1
MMRF_1984	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	QWK	QWK					1	84	1
MMRF_1984	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	84	1
MMRF_1984	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	84	1
MMRF_1984	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					257		1
MMRF_1107	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				12	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	94	1
MMRF_1107	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms				1.3	Q week	Q week					1	15	1
MMRF_1107	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms				1	Q week	Q week					15	93	1
MMRF_1227	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms				1.3	Q week	Q week					1	127	1
MMRF_1227	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			CHANGE IN FREQUENCY	Other	12	mg	mg	Q week	Q week	IV	IV	Log Forms				12	Q week	Q week					1	64	1
MMRF_1227	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	12	mg	mg	TWICE A WEEK	Other	IV	IV	Log Forms				12	Other	TWICE A WEEK					65	206	1
MMRF_1227	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	3 WEEKS ON, 1 WEEK OFF	Other	PO	PO	Log Forms				25	Other	3 WEEKS ON, 1 WEEK OFF					73	206	1
MMRF_1227	First line of therapy	First Line Therapy			Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	Q day	Q day	PO	PO	Log Forms				4	Q day	Q day					207	257	1
MMRF_1227	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	PO	PO	Log Forms				20	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					207	413	1
MMRF_1227	First line of therapy	First Line Therapy	Unknown	Unknown	Pomalidomide	Pomalidomide			Patient decision	Patient decision	2	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		2	Q day	Q day					258	413	1
MMRF_1271	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	269	1
MMRF_1271	First line of therapy	First Line Therapy			Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	18	mg	mg	Q day	Q day	PO	PO	Log Forms				18	Q day	Q day					1	22	1
MMRF_1271	First line of therapy	First Line Therapy	Induction	Induction	Daratumumab	Daratumumab			Completed regimen	Completed regimen	1270	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		1270	QWK	QWK					1262	1320	1
MMRF_1271	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		500	QWK	QWK					39	269	1
MMRF_1271	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					12	306	1
MMRF_1271	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QOD	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	QOD					292	354	1
MMRF_1271	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	Q 3 WEKS	Other	IV	IV	Log Forms	Maintenance	Maintenance		2.5	Other	Q 3 WEKS					383	1058	1
MMRF_1271	First line of therapy	First Line Therapy	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	1450	mg	mg	Q3 WKS	Other	IV	IV	Log Forms	Maintenance	Maintenance		1450	Other	Q3 WKS					471	542	1
MMRF_1271	First line of therapy	First Line Therapy	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide			LOWERING DOSE TO AVOID LONG TERM PROBLEMS W BONE MARROW ON ALKALATING AGENT	Other	1200	mg	mg	Q3 WKS	Other	IV	IV	Log Forms	Maintenance	Maintenance		1200	Other	Q3 WKS					569	980	1
MMRF_1271	First line of therapy	First Line Therapy	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	Q 6WEEKS	Other	IV	IV	Log Forms	Maintenance	Maintenance		500	Other	Q 6WEEKS					981	1058	1
MMRF_1271	First line of therapy	First Line Therapy	Maintenance	Maintenance	Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	8	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Maintenance	Maintenance		8	QD (D1-4)	QD (D1-4)					1142	1206	1
MMRF_1271	First line of therapy	First Line Therapy	Maintenance	Maintenance	Prednisone	Prednisone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	50	mg	mg	DAYS 1-2	Other	PO	PO	Log Forms	Maintenance	Maintenance		50	Other	DAYS 1-2					1142	1204	1
MMRF_1271	First line of therapy	First Line Therapy	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	500	mg	mg	Q3 WKS	Other	IV	IV	Log Forms	Maintenance	Maintenance		500	Other	Q3 WKS					383	450	1
MMRF_1271	First line of therapy	First Line Therapy			Prednisone	Prednisone			BLOOD SUGAR BECOME QUITE HIGH (SIDE EFFECT)	Other	100	mg	mg	Q day	Q day	PO	PO	Log Forms				100	Q day	Q day					1	12	1
MMRF_1440	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q21DAYS  -OFF 7DAYS Q28DAYS	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	Q21DAYS  -OFF 7DAYS Q28DAYS					192		1
MMRF_1440	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.2	mg	mg	Q week	Q week	IVB	IVB	Log Forms	Maintenance	Maintenance		2.2	Q week	Q week					568	799	1
MMRF_1440	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q week	Q week	IVB	IVB	Log Forms	Induction	Induction		10	Q week	Q week					568	680	1
MMRF_1440	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		12	Q week	Q week					708	1226	1
MMRF_1440	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	149	1
MMRF_1440	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	149	1
MMRF_1687	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		15	Q day	Q day					1	114	1
MMRF_1687	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	114	1
MMRF_1687	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PT BECAME TO ILL	Other	2.1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					146	177	1
MMRF_1929	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	450	mg	mg	DAY 1, 8, 15 AND 22	Other	PO	PO	Log Forms	Induction	Induction		450	Other	DAY 1, 8, 15 AND 22					1	85	1
MMRF_1929	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.2	mg	mg	DAYS 1,8,15 AND 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	Other	DAYS 1,8,15 AND 22					1	85	1
MMRF_1929	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1-4, 9-12 AND 17-20	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1-4, 9-12 AND 17-20					1	85	1
MMRF_1929	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOES REDUCTION	Other	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					238	1005	1
MMRF_1929	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		140	Other	ONCE					111	111	1
MMRF_1929	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		1			3	mg	mg	D1, D5, D15	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	3	Other	D1, D5, D15					1329		1
MMRF_1929	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			2.5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	2.5	QD (D1-21)	QD (D1-21)					1006		1
MMRF_1929	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	D1, D8, D15	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	D1, D8, D15					1329		1
MMRF_2132	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PT IN REHAB	Other	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	134	1
MMRF_2132	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PT IN REHAB	Other	40	mg	mg	1-4,9-12	Other	PO	PO	Log Forms	Induction	Induction		40	Other	1-4,9-12					1	134	1
MMRF_2455	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DEATH	Other	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	257	1
MMRF_2455	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	255	1
MMRF_2455	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	255	1
MMRF_1388	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Patient decision	Patient decision	2.1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUB - Q	Other	Log Forms				2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	383	1
MMRF_2598	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	DEATH	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	1690	1
MMRF_2598	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					10	42	1
MMRF_2598	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Patient decision	Patient decision	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					100	1304	1
MMRF_1170	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Patient decision	Patient decision	2.6	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms				2.6	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	169	1
MMRF_1170	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	BID	BID	PO	PO	Log Forms				40	BID	BID					1	161	1
MMRF_1346	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.9	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms				1.9	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	62	1
MMRF_1439	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			PATIENT DID NOT SHOW TO THE CLINIC. LOST TO FOLLOW UP	Other	2.6	mg	mg	QD (D1-21)	QD (D1-21)	IV	IV	Log Forms				2.6	QD (D1-21)	QD (D1-21)					1	51	1
MMRF_1108	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	MG	Other	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					4	40	1
MMRF_1108	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	D1,D8,D15,D22	Other	PO	PO	Log Forms				40	Other	D1,D8,D15,D22					1	44	1
MMRF_1108	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				10	QD (D1-21)	QD (D1-21)					4	40	1
MMRF_1108	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			PARTIAL RESPONSE	Other	10	mg	mg	DAY 1, AND D 15	Other	IV	IV	Log Forms				10	Other	DAY 1, AND D 15					4	40	1
MMRF_1108	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			PARTIAL RESPONSE	Other	1.6	mg	mg	D1, AND D8	Other	IV SubQ	IV SubQ	Log Forms				1.6	Other	D1, AND D8					40	194	1
MMRF_1108	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	POST INDUCTION	Other	Bortezomib	Bortezomib			SWITCHED TO A HIGHER DOSE	Other	1.6	mg	mg	C1, D8	Other	SUB-Q	Other	Log Forms	Other	POST INDUCTION		1.6	Other	C1, D8					306	1034	1
MMRF_1108	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	POST INDUCTION	Other	Bortezomib	Bortezomib			BIOCHEMICAL PROGRESSION	Other	2.2	mg	mg	D1, D8 AND D21	Other	SUB Q	Other	Log Forms	Other	POST INDUCTION		2.2	Other	D1, D8 AND D21					1048	1174	1
MMRF_1108	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	POST INDUCTION	Other	Dexamethasone	Dexamethasone			SWITCHED TO A HIGHER DOSE	Other	10	mg	mg	D1, D15 EVERY 21 DAYS	Other	IV	IV	Log Forms	Other	POST INDUCTION		10	Other	D1, D15 EVERY 21 DAYS					306	1034	1
MMRF_1108	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	POST INDUCTION	Other	Dexamethasone	Dexamethasone			BIOCHEMICAL PROGRESSION	Other	20	mg	mg	D1, D8 EVERY 21 DAYS	Other	IV	IV	Log Forms	Other	POST INDUCTION		20	Other	D1, D8 EVERY 21 DAYS					1048	1174	1
MMRF_1108	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	POST INDUCTION	Other	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.2	mg	mg	EVERY 21 DAYS C1, D15	Other	SUB-Q	Other	Log Forms	Other	POST INDUCTION		2.2	Other	EVERY 21 DAYS C1, D15					1188	1314	1
MMRF_1108	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	POST INDUCTION	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	EVERY 21 DAYS D1 , D15	Other	IV	IV	Log Forms	Other	POST INDUCTION		20	Other	EVERY 21 DAYS D1 , D15					1188	1314	1
MMRF_1108	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	POST INDUCTION	Other	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	2	mg	mg	DAYS 21 AND 28	Other	PO	PO	Log Forms	Other	POST INDUCTION		2	Other	DAYS 21 AND 28					1083	1230	1
MMRF_1108	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	PROGRESSIVE DISEASE	Other	Ixazomib	Ixazomib			UNTIL NEXT TREATMENT	Other	3	mg	mg	EVERY ONE PO EVERY WEDNESDAY FOR 3 WEEKS	Other	PO	PO	Log Forms	Other	PROGRESSIVE DISEASE		3	Other	EVERY ONE PO EVERY WEDNESDAY FOR 3 WEEKS					1433	1433	1
MMRF_1108	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	POST INDUCTION	Other	Dexamethasone	Dexamethasone			UNTIL NEXT TREATMENT	Other	12	mg	mg	ONCE A WEEK WITH ORAL CHEMO	Other	PO	PO	Log Forms	Other	POST INDUCTION		12	Other	ONCE A WEEK WITH ORAL CHEMO					1433	1433	1
MMRF_1113	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				25	QD (D1-14)	QD (D1-14)					1	48	1
MMRF_1113	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	IV	IV	Log Forms				20	Q week	Q week					8	101	1
MMRF_1113	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.3	MG	Other	D1 AND D8 ONOF 21 D CYCLE	Other	IV SubQ	IV SubQ	Log Forms				2.3	Other	D1 AND D8 ONOF 21 D CYCLE					8	101	1
MMRF_1113	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.2	mg	mg	DAYS 1 AND 15	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.2	Other	DAYS 1 AND 15					444	598	1
MMRF_1113	First line of therapy	First Line Therapy	Unknown	Unknown	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	35	mg	mg	WEEKLY 2 DAYS A WEEK	Other	IV	IV	Log Forms	Unknown	Unknown		35	Other	WEEKLY 2 DAYS A WEEK					114	121	1
MMRF_1113	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Lack of response	Lack of response	1.4	mg	mg	QD (D1-14)	QD (D1-14)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.4	QD (D1-14)	QD (D1-14)					997	1137	1
MMRF_1113	First line of therapy	First Line Therapy	Maintenance	Maintenance	Thalidomide	Thalidomide			Investigator decision for other reasons	Investigator decision for other reasons	100	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		100	Q day	Q day					66	111	1
MMRF_1113	First line of therapy	First Line Therapy	Maintenance	Maintenance	Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	200	mg	mg	BID	BID	PO	PO	Log Forms	Maintenance	Maintenance		200	BID	BID					126	174	1
MMRF_1113	First line of therapy	First Line Therapy	Maintenance	Maintenance	Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	200	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		200	Other	EVERY OTHER DAY					174	197	1
MMRF_1113	First line of therapy	First Line Therapy	Maintenance	Maintenance	Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	100	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		100	Q day	Q day					412	441	1
MMRF_1113	First line of therapy	First Line Therapy	Maintenance	Maintenance	Thalidomide	Thalidomide			Disease progression/Relapse	Disease progression/Relapse	50	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		50	Q day	Q day					441	604	1
MMRF_1113	First line of therapy	First Line Therapy	Maintenance	Maintenance	Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	50	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		50	Q day	Q day					678	926	1
MMRF_1113	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					55	62	1
MMRF_1164	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	Q day	Q day	PO	PO	Log Forms				25	Q day	Q day					1	280	1
MMRF_1164	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DEATH	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	372	1
MMRF_1164	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			DEATH	Other	24	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		24	QWK	QWK					280	372	1
MMRF_1169	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	121	1
MMRF_1169	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DISEASE PROGRESSION	Other	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms				40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	139	1
MMRF_1169	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DISEASE PROGRESSION	Other	2.1	mg	mg	EVERY 21 DAYS	Other	IV SubQ	IV SubQ	Log Forms				2.1	Other	EVERY 21 DAYS					121	139	1
MMRF_1312	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			PREPARATION FOR TRANSPLANT	Other	2.8	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	150	1
MMRF_1312	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			PREPARATION FOR TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-14)	QD (D1-14)					1	150	1
MMRF_1312	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			PREPERATION FOR TRANSPLANT	Other	40	mg	mg	DAY 1, 8, 15, AND 22	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	DAY 1, 8, 15, AND 22					1	150	1
MMRF_1312	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					341	739	1
MMRF_1312								0										Log Forms													1
MMRF_1312	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		20	Q day	Q day					1569	1844	1
MMRF_1312	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg/m^2	mg/m^2	QWK	QWK	IVB	IVB	Log Forms	Induction	Induction		20	QWK	QWK					1579	1586	1
MMRF_1312	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	27	mg/m^2	mg/m^2	Q week	Q week	IVB	IVB	Log Forms	Induction	Induction		27	Q week	Q week					1586	2178	1
MMRF_1312	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		1			4	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	4	Q day	Q day					1870		1
MMRF_1312	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		1			10	mg	mg	D1,2,8,9,15,16,22,23,28	Other	PO	PO	Log Forms	Consolidation	Consolidation	Checked	10	Other	D1,2,8,9,15,16,22,23,28					1870		1
MMRF_1312	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	4	QD (D1-21)	QD (D1-21)					2199		1
MMRF_1796	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			NOT TOLERATING TREATMENT OF VELCADE + DEX	Other	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	63	1
MMRF_1796	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		10	QWK	QWK					1	63	1
MMRF_1796	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					66	177	1
MMRF_1796	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone		0			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					66	231	1
MMRF_1796	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					317	1192	1
MMRF_1796	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1206		1
MMRF_2186	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					37	1694	1
MMRF_2186	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.9	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		2.9	QWK	QWK					1560	1679	1
MMRF_2186								0										Log Forms													1
MMRF_2186								0										Log Forms													1
MMRF_2186								0										Log Forms													1
MMRF_2186	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	TREATMENT ON HOLD FOR HIP SURGERY	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	244	1
MMRF_2186	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	37	1
MMRF_2186	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QID	QID	PO	PO	Log Forms	Induction	Induction		10	QID	QID					41	447	1
MMRF_2545	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	PATIENT EXPIRED 23DEC2019.	Other	10	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1681	1
MMRF_2545	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_2545	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	55	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IVB	IVB	Log Forms	Induction	Induction		55	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1122	1402	1
MMRF_2545	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					213	241	1
MMRF_2545	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					255	1088	1
MMRF_2545	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	45	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IVB	IVB	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1402	1508	1
MMRF_2545	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Daratumumab	Daratumumab		0	PATIENT EXPIRED 23DEC2019	Other	16	mg/kg	mg/kg	QD (D1-7)	QD (D1-7)	IVB	IVB	Log Forms	Induction	Induction		16	QD (D1-7)	QD (D1-7)					1572	1671	1
MMRF_2545	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	PATIENT EXPIRED 23DEC2019.	Other	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1572	1681	1
MMRF_1239	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	742	1
MMRF_1239	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					12	176	1
MMRF_1436	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	Q day	Q day	PO	PO	Log Forms				25	Q day	Q day					1	323	1
MMRF_1436	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		1			40	mg	mg	Q day	Q day	PO	PO	Log Forms			Checked	40	Q day	Q day					1		1
MMRF_1436	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					323		1
MMRF_2595	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	92	1
MMRF_2595	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	75	1
MMRF_2595	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	20 MG BY MOUTH ON DAY OF AND DAY AFTER VELCADE THERAPY	Other	PO	PO	Log Forms	Induction	Induction		20	Other	20 MG BY MOUTH ON DAY OF AND DAY AFTER VELCADE THERAPY					1	92	1
MMRF_2595	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	SQ	Other	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					260	344	1
MMRF_2595	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					360	451	1
MMRF_2595	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					498	1072	1
MMRF_2595	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					505	1072	1
MMRF_2595	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg/kg	mg/kg	QW(FOR WEEKS 1-8); Q2W(FOR WEEKS 9-24); Q4W(THERE AFTER UNTIL PROGRESSION)	Other	IV	IV	Log Forms	Induction	Induction		16	Other	QW(FOR WEEKS 1-8); Q2W(FOR WEEKS 9-24); Q4W(THERE AFTER UNTIL PROGRESSION)					501	788	1
MMRF_2595	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		16	Q week	Q week					1009	1072	1
MMRF_2595	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1079	1151	1
MMRF_2595	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					1079	1151	1
MMRF_2595	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1079	1151	1
MMRF_2595	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Bendamustine	Bendamustine		0	DEATH	Other	163	mg	mg	Q 4 WEEKS	Other	IV	IV	Log Forms	Maintenance	Maintenance		163	Other	Q 4 WEEKS					1169	1169	1
MMRF_2595	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	BONE MARROW TRANSPLANT	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other			Log Forms	Other	BONE MARROW TRANSPLANT		200	Other	ONCE					114	114	1
MMRF_1273	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DEATH	Other	2.9	mg	mg	Q week	Q week	SQ	Other	Log Forms				2.9	Q week	Q week					1	113	1
MMRF_1273	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			DEATH	Other	600	mg	mg	Q week	Q week	PO	PO	Log Forms				600	Q week	Q week					1	113	1
MMRF_1109	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DEATH	Other	8	mg	mg	8MG PO, ONCE A WEEK ON MONDAY, BEFORE TREATMENT	Other	PO	PO	Log Forms				8	Other	8MG PO, ONCE A WEEK ON MONDAY, BEFORE TREATMENT					1	117	1
MMRF_1109	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DEATH	Other	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	117	1
MMRF_1117	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	74	1
MMRF_1117	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAY 1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms				40	Other	DAY 1,2,4,5,8,9,11,12					1	106	1
MMRF_1117	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Lack of response	Lack of response	5	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms				5	QD (D1-14)	QD (D1-14)					321	340	1
MMRF_1117	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					395	736	1
MMRF_1117	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					85	95	1
MMRF_1117	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			PER MD KAPPA LIGHT CHAINS CONTINUE TO SHOW INCREASE SLOWLY	Other	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					341	394	1
MMRF_1117	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-4)	QD (D1-4)					737	924	1
MMRF_1117	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					925	1193	1
MMRF_1117	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	21 DAYS ON 7 DAYS OFF	Other	PO	PO	Log Forms	Induction	Induction		4	Other	21 DAYS ON 7 DAYS OFF					1062	1312	1
MMRF_1146	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	167	1
MMRF_1146	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	10 TABS A WEEK	Other	PO	PO	Log Forms				4	Other	10 TABS A WEEK					9	184	1
MMRF_1146	First line of therapy	First Line Therapy			Melphalan	Melphalan			PREPARATIVE REGIMEN FOR TRANSPLANT	Other	214	mg	mg	Q day	Q day	IV	IV	Log Forms				214	Q day	Q day					198	199	1
MMRF_1146	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					319	1194	1
MMRF_1146	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib		1			3.3	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	3.3	Q week	Q week					1201		1
MMRF_1184	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	161	1
MMRF_1184	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1,8,15,22	Other	PO	PO	Log Forms				40	Other	DAYS 1,8,15,22					1	199	1
MMRF_1184	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					295	546	1
MMRF_1184	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					547		1
MMRF_1250	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	33	1
MMRF_1250	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1,8,15 & 22	Other	PO	PO	Log Forms				40	Other	DAYS 1,8,15 & 22					1	298	1
MMRF_1250	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				15	QD (D1-21)	QD (D1-21)					33	298	1
MMRF_1250	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					337		1
MMRF_1261	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg	mg	Q week	Q week	PO	PO	Log Forms				300	Q week	Q week					1	106	1
MMRF_1261	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.5	Q week	Q week					1	232	1
MMRF_1261	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms				40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	202	1
MMRF_1261	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.5	mg	mg	Q14DAYS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.5	Other	Q14DAYS					364	615	1
MMRF_1261	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					351	615	1
MMRF_1261	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	33	mg	mg	DAYS 1, 8, 15	Other	IV	IV	Log Forms	Induction	Induction		33	Other	DAYS 1, 8, 15					638	757	1
MMRF_1261	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	INVESTIGATIONAL PRODUCT	Other			Disease progression/Relapse	Disease progression/Relapse	45	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		45	BID	BID					793	909	1
MMRF_1261	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		4	Q day	Q day					932	1060	1
MMRF_1261	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	INVESTIGATIONAL PRODUCT	Other			Disease progression/Relapse	Disease progression/Relapse	1	TABLET	Other	DAYS 1-2, 8-9, 15-16, 22-23	Other	PO	PO	Log Forms	Induction	Induction		1	Other	DAYS 1-2, 8-9, 15-16, 22-23					932	1060	1
MMRF_1261	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1-2, 8-9, 15-16, 22-23	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1-2, 8-9, 15-16, 22-23					932	1060	1
MMRF_1261	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	INVESTIGATIONAL PRODUCT	Other			Disease progression/Relapse	Disease progression/Relapse	110	mg	mg	Q21D	Other	IV	IV	Log Forms	Induction	Induction		110	Other	Q21D					1077	1098	1
MMRF_1261	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	INVESTIGATIONAL PRODUCT	Other			Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		100	BID	BID					1077	1098	1
MMRF_1260	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	Q week	Q week	IV	IV	Log Forms				2.5	Q week	Q week					1	106	1
MMRF_1260	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAYS 1,8,15,22	Other	PO	PO	Log Forms				300	Other	DAYS 1,8,15,22					1	106	1
MMRF_1260	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1-4,9-12,17-20 ON CYCLES 1 &2	Other	PO	PO	Log Forms				40	Other	DAYS 1-4,9-12,17-20 ON CYCLES 1 &2					1	106	1
MMRF_1260	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.5	mg	mg	Q2WEEKS	Other	SUB-Q	Other	Log Forms	Maintenance	Maintenance		2.5	Other	Q2WEEKS					142	1038	1
MMRF_1260	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	DAYS 1, 8, 15, 22					142	226	1
MMRF_1295	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.3	Q week	Q week					2	381	1
MMRF_1295	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms				20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	282	1
MMRF_1295	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	500	mg	mg	DAY 1, DAY 8, DAY 15 AND DAY 22	Other	PO	PO	Log Forms				500	Other	DAY 1, DAY 8, DAY 15 AND DAY 22					37	282	1
MMRF_1295	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.5	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	QWK	QWK					23	262	1
MMRF_1295	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			UNKNOWN AT THIS TIME	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					418	1376	1
MMRF_1295	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	EVERY MONDAY	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	EVERY MONDAY					418		1
MMRF_1344	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DOSE CHANGED DUE TO GRADE 1 NEUROPATHY	Other	1.5	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms				1.5	QWK	QWK					1	100	1
MMRF_1344	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QWK	QWK	PO	PO	Log Forms				300	QWK	QWK					1	106	1
MMRF_1344	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	106	1
MMRF_1344	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	QWK	QWK					106	106	1
MMRF_1344	First line of therapy	First Line Therapy	MOBILIZATION FOR STEM CELL TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION FOR STEM CELL TRANSPLANT		200	Other	ONCE					169	169	1
MMRF_1344	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	QWK	QWK					361		1
MMRF_1344	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					361		1
MMRF_1453	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	700	mg	mg	DAYS 1,8,15,22	Other	PO	PO	Log Forms				700	Other	DAYS 1,8,15,22					1	106	1
MMRF_1453	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.5	Q week	Q week					1	106	1
MMRF_1453	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1-4, 9-12, 17-20	Other	PO	PO	Log Forms				40	Other	DAYS 1-4, 9-12, 17-20					1	106	1
MMRF_1453	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					236		1
MMRF_1538	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			REVIEW OF BONE MARROW BIOPSY SHOWED NO EVIDENCE OF DISEASE	Other	3.1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	944	1
MMRF_1538	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	134	1
MMRF_1538	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1, D2, D4, D5, D8, D9, D11, D12)	Other	PO	PO	Log Forms	Induction	Induction	Checked	20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1		1
MMRF_1588	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			PREP FOR BONE MARROW TRANSPLANT	Other	700	mg	mg	QD (D1, D8, D15, D22)	Other	PO	PO	Log Forms	Induction	Induction		700	Other	QD (D1, D8, D15, D22)					1	161	1
MMRF_1588	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PREP FOR BONE MARROW TRANSPLANT	Other	3.5	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3.5	Q week	Q week					1	161	1
MMRF_1588	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PREP FOR BONE MARROW TRANSPLANT	Other	40	mg	mg	QD (D1-4, D9-12, D17-20)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D9-12, D17-20)					1	161	1
MMRF_1588	First line of therapy	First Line Therapy	TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	TRANSPLANT		200	Other	ONCE					205	205	1
MMRF_1588	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab		1			1100	mg	mg	Q4W	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	1100	Other	Q4W					1463		1
MMRF_1588	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	25	QD (D1-21)	QD (D1-21)					1458		1
MMRF_1596	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	186	1
MMRF_1596	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	QWK	QWK					1	8	1
MMRF_1596	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	186	1
MMRF_1596	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					15	186	1
MMRF_1596	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	400	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		400	QWK	QWK					200	249	1
MMRF_1596	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	ETOPOSIDE	Other			Lack of response	Lack of response	40	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					284	310	1
MMRF_1596	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.5	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	QWK	QWK					200	249	1
MMRF_1596	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					200	249	1
MMRF_1596	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	CISPLATIN	Other			Lack of response	Lack of response	10	mg/m^2	mg/m^2	QD (D1-14)	QD (D1-14)	IV	IV	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					284	310	1
MMRF_1596	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	1000	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		1000	QD (D1-4)	QD (D1-4)					284	310	1
MMRF_1596	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Doxorubicin	Doxorubicin			Lack of response	Lack of response	9	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					284	310	1
MMRF_1596	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					284	310	1
MMRF_1596	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					327	343	1
MMRF_1596	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					356	364	1
MMRF_1596	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					327	364	1
MMRF_1596	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					327	364	1
MMRF_1740	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	25	Q day	Q day					1		1
MMRF_1740	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			12	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction	Checked	12	QWK	QWK					9		1
MMRF_1740	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					715		1
MMRF_1794	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	240	mg/m^2	mg/m^2	QWK	QWK	PO	PO	Log Forms	Induction	Induction		240	QWK	QWK					1	239	1
MMRF_1794	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	239	1
MMRF_1794	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	QWK	QWK					1	239	1
MMRF_1794	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Completed regimen	Completed regimen	960	mg	mg	Q4W	Other	IV	IV	Log Forms	Maintenance	Maintenance		960	Other	Q4W					1059	1640	1
MMRF_1794	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab		1			1100	mg	mg	Q2W	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	1100	Other	Q2W					1378		1
MMRF_1794	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	QD (D1-21)	QD (D1-21)					1379		1
MMRF_1794	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	D1, 8, 15, 22	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	D1, 8, 15, 22					1744		1
MMRF_1932	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			PREP FOR BONE MARROW TRANSPLANT	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	164	1
MMRF_1932	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PREP FOR BONE MARROW TRANSPLANT	Other	10	mg	mg	DAYS 1,8,15 AND 22	Other	PO	PO	Log Forms	Induction	Induction		10	Other	DAYS 1,8,15 AND 22					1	164	1
MMRF_1932	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					325		1
MMRF_1932	First line of therapy	First Line Therapy	PREPARATION	Other	Melphalan	Melphalan			STEM CELL	Other	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	PREPARATION		200	Other	ONCE					184	184	1
MMRF_1980	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			INCREASE IN KAPPA LIGHT CHAIN	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	742	1
MMRF_1980	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			10	mg	mg	D1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction	Checked	10	Other	D1, 8, 15, 22					1		1
MMRF_1980	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			1030	mg	mg	Q4W	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	1030	Other	Q4W					1195		1
MMRF_1980	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		1			2.2	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	2.2	Q week	Q week					1020		1
MMRF_2173	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			25	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	25	Q day	Q day					42		1
MMRF_2173	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			UNKNOWN	Other	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	355	1
MMRF_2173	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2	mg	mg	D1, 8, 15 , 22	Other	IV	IV	Log Forms	Induction	Induction	Checked	2	Other	D1, 8, 15 , 22					15		1
MMRF_2173	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	400	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		400	Other	DAYS 1, 8, 15, 22					15	380	1
MMRF_2220	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	Patient decision	Patient decision	2.8	mg	mg	D1, 8, 15, 22	Other	SUBQ	Other	Log Forms	Induction	Induction		2.8	Other	D1, 8, 15, 22					1	1614	1
MMRF_2220	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	106	1
MMRF_2220	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	D1-4, 9-12, 17-20	Other	PO	PO	Log Forms	Induction	Induction	Checked	40	Other	D1-4, 9-12, 17-20					1		1
MMRF_2220	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		1			32	mg	mg	D1, 8, 15	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	32	Other	D1, 8, 15					1668		1
MMRF_2587	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	5000	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		5000	Other	DAYS 1, 8, 15, 22					1	104	1
MMRF_2587	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.5	mg	mg	DAYS 1, 8, 15, 22	Other	SUB Q	Other	Log Forms	Induction	Induction	Checked	2.5	Other	DAYS 1, 8, 15, 22					1		1
MMRF_2587	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	1-4, 9-12, 17-20	Other	PO	PO	Log Forms	Induction	Induction	Checked	40	Other	1-4, 9-12, 17-20					1		1
MMRF_2587	First line of therapy	First Line Therapy	HIGH DOSE FOLLOWED BY STEM CELL TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	HIGH DOSE FOLLOWED BY STEM CELL TRANSPLANT		200	Q day	Q day					134	138	1
MMRF_1216	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	116	1
MMRF_1216	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DIFFERENT FREQUENCY	Other	40	mg	mg	DAY 1-4 THEN DAYS 9-12	Other	PO	PO	Log Forms				40	Other	DAY 1-4 THEN DAYS 9-12					1	33	1
MMRF_1216	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					43	1023	1
MMRF_1216	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.3	mg	mg	D1,8,15 AND 22 Q42DAYS	Other	IV SubQ	IV SubQ	Log Forms				2.3	Other	D1,8,15 AND 22 Q42DAYS					141	1023	1
MMRF_1216	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1024	1108	1
MMRF_1216	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		4	Q day	Q day					1024	1108	1
MMRF_1216	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1207	1345	1
MMRF_1216	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1207	1345	1
MMRF_1228	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms				3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1366	1
MMRF_1228	First line of therapy	First Line Therapy			Doxorubicin	Doxorubicin			Disease progression/Relapse	Disease progression/Relapse	70	mg	mg	Q3 WEEKS	Other	IV	IV	Log Forms				70	Other	Q3 WEEKS					1	1366	1
MMRF_1228	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		16	Q week	Q week					1218	1366	1
MMRF_1228	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					103	1366	1
MMRF_1228	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	300	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV	IV	Log Forms	Induction	Induction		300	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					916	1098	1
MMRF_1296	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	197	1
MMRF_1296	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	256	1
MMRF_1296	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					198	256	1
MMRF_1364	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	Q day	Q day	PO	PO	Log Forms				25	Q day	Q day					1	83	1
MMRF_1364	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown	Checked	40	Q week	Q week					1		1
MMRF_1364	First line of therapy	First Line Therapy	MOBILIZATION FOR TRANSPLANT	Other	Cyclophosphamide	Cyclophosphamide		1			4	G/M^2	Other	Q week	Q week	IV	IV	Log Forms	Other	MOBILIZATION FOR TRANSPLANT	Checked	4	Q week	Q week					172		1
MMRF_1364	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.8	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction	Checked	2.8	Q week	Q week					1		1
MMRF_1531	First line of therapy	First Line Therapy	Unknown	Unknown	Bortezomib	Bortezomib			DEATH	Other	1.5	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.5	QWK	QWK					1	520	1
MMRF_1531	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			DEATH	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1	520	1
MMRF_1531	First line of therapy	First Line Therapy	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			DEATH	Other	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		300	Q week	Q week					1	520	1
MMRF_1659	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.6	mg	mg	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV	IV	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					21	323	1
MMRF_1659	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	1772	1
MMRF_1659	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					7	589	1
MMRF_1659	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					505	506	1
MMRF_1659	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	41	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		41	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					331	1773	1
MMRF_1659	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Melphalan	Melphalan		0	Completed regimen	Completed regimen	200	mg	mg	QD (D1-3)	QD (D1-3)	IV	IV	Log Forms	Induction	Induction		200	QD (D1-3)	QD (D1-3)					679	679	1
MMRF_1691	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.3	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		3.3	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	78	1
MMRF_1691	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	147	1
MMRF_1691	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	487	1
MMRF_1691	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	300	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		300	Q day	Q day					600	600	1
MMRF_1691	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	25	Q day	Q day					118		1
MMRF_1803	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	3	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	99	1
MMRF_1803	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	182	1
MMRF_1803	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	600	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		600	Q day	Q day					1	182	1
MMRF_1810	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	994	1
MMRF_1810	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	8	1
MMRF_1810	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					23	999	1
MMRF_1810	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	191	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		191	Q day	Q day					159	160	1
MMRF_1810	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Elotuzumab	Elotuzumab		0	Completed regimen	Completed regimen	10	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		10	QWK	QWK					1090	1132	1
MMRF_1810	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan		0			200	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					1154	1155	1
MMRF_1810	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	D1, 2, 4, 5, 8, 9, 11, 12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1, 2, 4, 5, 8, 9, 11, 12					20	196	1
MMRF_1810	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	ONCE EVERY OTHER WEEK	Other	PO	PO	Log Forms	Induction	Induction		4	Other	ONCE EVERY OTHER WEEK					261	642	1
MMRF_1810	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		4	Q week	Q week					936	1055	1
MMRF_1810	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Lack of response	Lack of response	4	mg	mg	D1, D8, D15, D22	Other	PO	PO	Log Forms	Induction	Induction		4	Other	D1, D8, D15, D22					1090	1693	1
MMRF_1810	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Lack of response	Lack of response	2.6	mg	mg	D1, D15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	Other	D1, D15					1258	1693	1
MMRF_1810	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab		1			16	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction	Checked	16	Q week	Q week					1707		1
MMRF_1810	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			220	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction	Checked	220	Q week	Q week					1707		1
MMRF_1810	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		1			3	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	3	Q day	Q day					1707		1
MMRF_1831	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.8	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	80	1
MMRF_1831	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	80	1
MMRF_1831	First line of therapy	First Line Therapy	Induction	Induction	Liposomal doxorubicin	Liposomal doxorubicin			Adverse Event or co-morbidity	Adverse Event or co-morbidity	64	mg	mg	EVERY 3 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		64	Other	EVERY 3 WEEKS					2	80	1
MMRF_1831	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Lack of response	Lack of response	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					114	1738	1
MMRF_1831	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	Lack of response	Lack of response	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					204	1738	1
MMRF_1917	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	315	1
MMRF_1917	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	315	1
MMRF_1917	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	D1,2,8,9,15,16	Other	IV	IV	Log Forms	Induction	Induction		20	Other	D1,2,8,9,15,16					16	303	1
MMRF_1917	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					329	389	1
MMRF_1917	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	25	Q day	Q day					715		1
MMRF_1917	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	93	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		93	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					44	142	1
MMRF_2290	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		20	Q day	Q day					1	139	1
MMRF_2290	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DEATH	Other	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					14	139	1
MMRF_2461	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	504	1
MMRF_2461	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib			Patient decision	Patient decision	3	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		3	Q week	Q week					505	767	1
MMRF_2461	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Patient decision	Patient decision	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					505	767	1
MMRF_2461	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					505	767	1
MMRF_2461	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.7	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.7	Q week	Q week					1	491	1
MMRF_1254	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.4	mg	mg	D1, 8, 15, 22	Other	IV	IV	Log Forms				2.4	Other	D1, 8, 15, 22					1	267	1
MMRF_1254	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms				40	QD (D1-4)	QD (D1-4)					1	211	1
MMRF_1254	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					283	967	1
MMRF_1254	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		3	Q day	Q day					1386	1451	1
MMRF_1254	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide			Patient decision	Patient decision	2	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		2	Q day	Q day					1451	1719	1
MMRF_1348	First line of therapy	First Line Therapy			Bortezomib	Bortezomib		1			3.4	mg	mg	DAYS 1,8, 15 & 22	Other	IV SubQ	IV SubQ	Log Forms			Checked	3.4	Other	DAYS 1,8, 15 & 22					1		1
MMRF_1348	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms			Checked	40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1		1
MMRF_1371	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms				1.3	QWK	QWK					1	57	1
MMRF_1371	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		25	QWK	QWK					71	250	1
MMRF_1371	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1500	mg	mg	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		1500	Other	ONCE					264	264	1
MMRF_1371	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			CHANGED DOSE	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					404	819	1
MMRF_1371	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			CHANGE DOSE	Other	10	mg	mg	QD (D1-5)	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	QD (D1-5)					819	911	1
MMRF_1371	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-4)	QD (D1-4)					911	2290	1
MMRF_1371	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	IVB	IVB	Log Forms	Induction	Induction		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	264	1
MMRF_1371	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	20/27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction			QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2308	2469	1
MMRF_1371	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide		0	Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					2308	2469	1
MMRF_1371	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2337	2464	1
MMRF_1371	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	20/27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation			QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2308	2469	1
MMRF_1371	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide		0	Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)						2469	1
MMRF_1371	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2310	2469	1
MMRF_1371	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	PRE-TRANSPLANT	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	PRE-TRANSPLANT		100	Q day	Q day					2497	2498	1
MMRF_1377	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	QWK	QWK	PO	PO	Log Forms				500	QWK	QWK					1	143	1
MMRF_1377	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.5	mg	mg	QWK	QWK	SQ	Other	Log Forms				3.5	QWK	QWK					1	134	1
MMRF_1377	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	143	1
MMRF_1377	First line of therapy	First Line Therapy	AUTOLOGOUS BLOOD STEM CELL MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3000	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	AUTOLOGOUS BLOOD STEM CELL MOBILIZATION		3000	Other	ONCE					165	165	1
MMRF_1377	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			CHANGING DOSE	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					753	984	1
MMRF_1377	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			CHANGED DOSE	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					753	1026	1
MMRF_1377	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QOD DAYS 1-21	Other	PO	PO	Log Forms	Induction	Induction		15	Other	QOD DAYS 1-21					984	1257	1
MMRF_1377	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					1267	1799	1
MMRF_1377	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q2WK	Other	SUB-Q	Other	Log Forms	Maintenance	Maintenance		1.3	Other	Q2WK					1813	2061	1
MMRF_1703	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	164	1
MMRF_1703	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3.1	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3.1	Q week	Q week					1	164	1
MMRF_1703	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	563	1
MMRF_1703	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-14)	QD (D1-14)					164	1318	1
MMRF_1703	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	TAKE 10 TABLETS PER WEEK (40MG PER WK)	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	TAKE 10 TABLETS PER WEEK (40MG PER WK)					606	1318	1
MMRF_1703	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.7	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	Q week	Q week					164	185	1
MMRF_1703	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.1	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.1	Q week	Q week					185	598	1
MMRF_1703	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.7	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.7	Q week	Q week					612	773	1
MMRF_2166	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	TID	TID	PO	PO	Log Forms	Induction	Induction		4	TID	TID					1	12	1
MMRF_2166	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					17	28	1
MMRF_2324	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	98	1
MMRF_2324	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-21)	QD (D1-21)					1	126	1
MMRF_2324	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	126	1
MMRF_2324	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-7)	QD (D1-7)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-7)	QD (D1-7)					275		1
MMRF_2326	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	99	1
MMRF_2326	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					2	106	1
MMRF_2326	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					2	203	1
MMRF_2326	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-7)	QD (D1-7)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-7)	QD (D1-7)					281	1543	1
MMRF_2326	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		0	PT UNDERWENT SURGERY FOR RECONSTRUCTION OF MANDIBLE	Other	4	mg	mg	DAYS 1,8,15	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	DAYS 1,8,15					1549	1655	1
MMRF_2326	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	UNDERGOING RECONSTRUCTIVE SURGERY	Other	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					1549	1655	1
MMRF_2326	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		0	UNDERGOING RECONSTRUCTIVE SURGERY OF MANDIBLE	Other	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1549	1653	1
MMRF_2326	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QWK WEEKS 1-3.  WEEK 4 REST	Other	IV	IV	Log Forms	Unknown	Unknown		1.3	Other	QWK WEEKS 1-3.  WEEK 4 REST					1763	1872	1
MMRF_2326	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	DEATH	Other	4	mg	mg	QD (D1-21)	QD (D1-21)	FEEDING TUBE	Other	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1763	1933	1
MMRF_2326	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	DEATH	Other	40	mg	mg	QWK	QWK	FEEDING TUBE	Other	Log Forms	Unknown	Unknown		40	QWK	QWK					1763	1933	1
MMRF_1090	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.4	MG	Other	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV SubQ	IV SubQ	Log Forms				2.4	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	94	1
MMRF_1090	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	IV	IV	Log Forms				40	QWK	QWK					134	432	1
MMRF_1090	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	250	mg/m^2	mg/m^2	DAY 1 AND DAY 8 Q 35 DAYS	Other	IV	IV	Log Forms				250	Other	DAY 1 AND DAY 8 Q 35 DAYS					1	73	1
MMRF_1090	First line of therapy	First Line Therapy			Thalidomide	Thalidomide			Investigator decision for other reasons	Investigator decision for other reasons	100	MG	Other	Q day	Q day	PO	PO	Log Forms				100	Q day	Q day					1	127	1
MMRF_1090	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QWK	QWK					134	432	1
MMRF_1090	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bendamustine	Bendamustine			PATIENT DECEASED	Other	90	mg	mg	(D1& 2 Q 28 D)	Other	IV	IV	Log Forms	Maintenance	Maintenance		90	Other	(D1& 2 Q 28 D)					435	681	1
MMRF_1090	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	RITUXAN	Other			PATIENT DECEASED	Other	375	mg	mg	D1	Other	IV	IV	Log Forms	Maintenance	Maintenance		375	Other	D1					435	681	1
MMRF_1122	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.63	mg	mg	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV SubQ	IV SubQ	Log Forms				2.63	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	123	1
MMRF_1122	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	D1-14 Q 21 D	Other	PO	PO	Log Forms				25	Other	D1-14 Q 21 D					64	123	1
MMRF_1122	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	TID	TID	PO	PO	Log Forms	Maintenance	Maintenance		4	TID	TID					1	123	1
MMRF_1122	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			PATIENT TO RECEIVE TRANSPLANT	Other	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		25	Q day	Q day					176	229	1
MMRF_1122	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	NEW TREATMENT FOR DISEASE PROGRESSION	Other	Bortezomib	Bortezomib			PATIENT DIED	Other	2.67	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	NEW TREATMENT FOR DISEASE PROGRESSION		2.67	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					666	697	1
MMRF_1122	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	NEW TREATMENT FOR DISEASE PROGRESSION	Other	Dexamethasone	Dexamethasone			PATIENT DIED	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	NEW TREATMENT FOR DISEASE PROGRESSION		20	Q week	Q week					666	697	1
MMRF_1386	First line of therapy	First Line Therapy			Carfilzomib	Carfilzomib			PER PROTOCOL, 20 MG/M^2 ONLY FOR C1D1 AND C1D2	Other	20	mg/m^2	mg/m^2	QD (C1D1, C1D2)	Other	IV	IV	Log Forms				20	Other	QD (C1D1, C1D2)					1	2	1
MMRF_1386	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	45	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	176	1
MMRF_1386	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	176	1
MMRF_1386	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PROTOCOL PROCEDURES	Other	40	mg	mg	QD (D1, 8, 15, 22)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1, 8, 15, 22)					177	232	1
MMRF_1386	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			PER PROTOFCOL PROCEDURES	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					177	232	1
MMRF_1386	First line of therapy	First Line Therapy	Induction	Induction	CLARITHROMYCIN	Other			PROTOCOL PROCEDURES	Other	500	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		500	BID	BID					177	232	1
MMRF_1386	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					232		1
MMRF_1403	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			PER PROTOCOL, 20 MG/M^2 ONLY FOR C1D1 AND C1D2	Other	20	mg/m^2	mg/m^2	QD (C1D1, C1D2)	Other	IV	IV	Log Forms	Induction	Induction		20	Other	QD (C1D1, C1D2)					1	2	1
MMRF_1403	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	45	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	156	1
MMRF_1403	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	156	1
MMRF_1403	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			PROTOCOL PROCEDURES	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					177	226	1
MMRF_1403	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			PROTOCOL PROCEDURES	Other	40	mg	mg	QD (D1, 8, 15, 22)	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	QD (D1, 8, 15, 22)					177	227	1
MMRF_1403	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other			PROTOCOL PROCEDURES	Other	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					177	233	1
MMRF_1403	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					234	926	1
MMRF_1403	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TRANSPLANT PHASE (CONDITIONING)	Other	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	350	mg	mg	150MG QAM AND 200MG QPM ON DAYS 1-5	Other	PO	PO	Log Forms	Other	TRANSPLANT PHASE (CONDITIONING)		350	Other	150MG QAM AND 200MG QPM ON DAYS 1-5					940	944	1
MMRF_1403	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1518	2213	1
MMRF_1403	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TRANSPLANT PHASE (CONDITIONING)	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	DAYS 4 AND 5	Other	IV	IV	Log Forms	Other	TRANSPLANT PHASE (CONDITIONING)		200	Other	DAYS 4 AND 5					943	944	1
MMRF_1403	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	DAYS 1, 8, 15					1518	2213	1
MMRF_1403	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1045	1093	1
MMRF_1403	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	ORDERED THE CORRECT DOSAGE THE FOLLOWING CYCLE	Other	25	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		25	Other	EVERY OTHER DAY					1101	1121	1
MMRF_1403	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					1129	1184	1
MMRF_1403	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	ORDERED THE CORRECT DOSAGE THE FOLLOWING CYCLE	Other	15	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		15	Other	EVERY OTHER DAY					1192	1212	1
MMRF_1403	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1226	1275	1
MMRF_1403	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	ORDERED THE CORRECT DOSAGE FOR THE FOLLOWING CYCLE	Other	10	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	EVERY OTHER DAY					1290	1310	1
MMRF_1403	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					1318	1394	1
MMRF_1403	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		2.5	QD (D1-21)	QD (D1-21)					1402	1506	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Completed regimen	Completed regimen	16	mg/kg	mg/kg	C1-2 (D1,8,15,22), C3-6 (D1,15)	Other	IV	IV	Log Forms	Induction	Induction		16	Other	C1-2 (D1,8,15,22), C3-6 (D1,15)					2234	2283	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	4-20	mg	mg	12-20MG DAY OF, 4 MG DAY +1 AND +2	Other	PO	PO	Log Forms	Induction	Induction			Other	12-20MG DAY OF, 4 MG DAY +1 AND +2					2234	2283	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	D1, 8, 15	Other	IV	IV	Log Forms	Consolidation	Consolidation		1.3	Other	D1, 8, 15					2318	2388	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Daratumumab	Daratumumab		0	Completed regimen	Completed regimen	16	mg/kg	mg/kg	QD (D1, D15)	Other	IV	IV	Log Forms	Consolidation	Consolidation		16	Other	QD (D1, D15)					2290	2388	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	12	mg	mg	QD (D1, D15)	Other	PO OR IV	Other	Log Forms	Consolidation	Consolidation		12	Other	QD (D1, D15)					2290	2388	1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	D1, D8, D15	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	D1, D8, D15					2402		1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	MONTHLY	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	16	Other	MONTHLY					2409		1
MMRF_1403	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			12	mg	mg	D1, D15	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	12	Other	D1, D15					2402		1
MMRF_1458	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			PER PROTOCOL, 20 MG/M^2 ONLY FOR C1D1 AND C1D2	Other	20	mg/m^2	mg/m^2	QD (C1D1, C1D2)	Other	IV	IV	Log Forms	Induction	Induction		20	Other	QD (C1D1, C1D2)					1	2	1
MMRF_1458	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	45	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	128	1
MMRF_1458	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	135	1
MMRF_1458	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					233	540	1
MMRF_1458	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					233	641	1
MMRF_1458	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1342	1459	1
MMRF_1458	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					1342	2202	1
MMRF_1462	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			PER PROTOCOL, 20 MG/M^2 ONLY FOR C1D1 AND C1D2	Other	20	mg/m^2	mg/m^2	QD (C1D1, C1D2)	Other	IV	IV	Log Forms	Induction	Induction		20	Other	QD (C1D1, C1D2)					1	2	1
MMRF_1462	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			PROTOCOL PROCEDURES	Other	45	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	100	1
MMRF_1462	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PROTOCOL PROCEDURES	Other	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	107	1
MMRF_1462	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other			PROTOCOL PROCEDURES	Other	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					122	177	1
MMRF_1462	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			PROTOCOL PROCEDURES	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					122	170	1
MMRF_1462	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			PROTOCOL PROCEDURES	Other	40	mg	mg	QD (D1, D8, D15, D22)	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	QD (D1, D8, D15, D22)					122	171	1
MMRF_1462	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					178	627	1
MMRF_1462	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					646	822	1
MMRF_1462	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D4-5, D8-9, D11-12)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D4-5, D8-9, D11-12)					646	822	1
MMRF_1462	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	ACY-241	Other			Investigator decision for other reasons	Investigator decision for other reasons	180	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		180	QD (D1-21)	QD (D1-21)					890	910	1
MMRF_1462	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	DAYS 1, 8, 15, 22					890	912	1
MMRF_1462	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					900	912	1
MMRF_1462	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		1			46	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown	Checked	46	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					912		1
MMRF_1462	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown	Checked	20	Q day	Q day					912		1
MMRF_1462	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			4	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown	Checked	4	Q day	Q day					912		1
MMRF_1462	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	CONDITIONING	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING		100	Q day	Q day					1128	1129	1
MMRF_1493	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			THIS DOSE IS ONLY FOR C1D1 AND C1D2	Other	20	mg/m^2	mg/m^2	QD (C1D1, C1D2)	Other	IV	IV	Log Forms	Induction	Induction		20	Other	QD (C1D1, C1D2)					1	2	1
MMRF_1493	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	37	1
MMRF_1493	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Patient decision	Patient decision	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	37	1
MMRF_1493	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	500	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		500	Q week	Q week					50	162	1
MMRF_1493	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					50	162	1
MMRF_1493	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.6	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	Q week	Q week					50	162	1
MMRF_1493	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					163		1
MMRF_1608	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1, D2)	Other	IV	IV	Log Forms	Induction	Induction		20	Other	QD (D1, D2)					1	2	1
MMRF_1608	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	115	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		115	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					3	56	1
MMRF_1608	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	398	1
MMRF_1608	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	93	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		93	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					56	398	1
MMRF_1608	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		500	BID	BID					399	539	1
MMRF_1608	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					399	539	1
MMRF_1608	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					399	539	1
MMRF_1608	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					540		1
MMRF_1662	First line of therapy	First Line Therapy	Induction	Induction	CLARITHROMYCIN	Other			Investigator decision for other reasons	Investigator decision for other reasons	500	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		500	BID	BID					1	98	1
MMRF_1662	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	398	1
MMRF_1662	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	98	1
MMRF_1662	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					99	192	1
MMRF_1662	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					399		1
MMRF_1689	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.6	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		2.6	QWK	QWK					1	44	1
MMRF_1689	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	500	mg	mg	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV	IV	Log Forms	Induction	Induction		500	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	1	1
MMRF_1689	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		300	QWK	QWK					7	28	1
MMRF_1689	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	28	1
MMRF_1689	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.7	mg	mg	Q week	Q week	SC	Other	Log Forms	Maintenance	Maintenance		2.7	Q week	Q week					45	129	1
MMRF_1689	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		4	QWK	QWK					45	715	1
MMRF_1689	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					177	230	1
MMRF_1689	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		1			10	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction	Checked	10	Q week	Q week					1213		1
MMRF_1718	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			CHANGE OF DOSE AS PART OF REGIMEN	Other	20	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1718	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					3	183	1
MMRF_1718	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	183	1
MMRF_1718	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					205	288	1
MMRF_1718	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D8, D15, D22)	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	QD (D1, D8, D15, D22)					205	288	1
MMRF_1718	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					205	260	1
MMRF_1718	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other			Completed regimen	Completed regimen	250	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		250	BID	BID					261	288	1
MMRF_1718	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					289	410	1
MMRF_1718	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			PATIENT WENT TO TRANSPLANT	Other	500	mg	mg	QD (D1, D8)	Other	PO	PO	Log Forms	Induction	Induction		500	Other	QD (D1, D8)					418	449	1
MMRF_1718	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			PATIENT WENT TO TRANSPLANT	Other	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					418	449	1
MMRF_1718	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			PATIENT WENT TO TRANSPLANT	Other	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					418	449	1
MMRF_1733	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			CHANGE OF DOSE AS PART OF REGIMEN	Other	20	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1733	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	19	1
MMRF_1733	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					3	8	1
MMRF_1733	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other			Completed regimen	Completed regimen	250	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		250	BID	BID					37	274	1
MMRF_1733	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					37	119	1
MMRF_1733	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					37	274	1
MMRF_1733	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					120	336	1
MMRF_1733	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					337	420	1
MMRF_1733	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	45	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					15	15	1
MMRF_1733	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					274	302	1
MMRF_1733	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	12	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		12	QWK	QWK					302	337	1
MMRF_1775	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	20	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1775	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					3	28	1
MMRF_1775	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	84	1
MMRF_1775	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	45	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					29	56	1
MMRF_1775	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					57	168	1
MMRF_1775	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		12	Other	QD (D1-2, D8-9, D15-16, D22-23)					85	168	1
MMRF_1775	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	24	mg	mg	QD (D1, D8, D15, D22)	Other	PO	PO	Log Forms	Consolidation	Consolidation		24	Other	QD (D1, D8, D15, D22)					184	267	1
MMRF_1775	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					184	267	1
MMRF_1775	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					184	231	1
MMRF_1775	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					268		1
MMRF_1795	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			CHANGE OF DOSE AS PART OF REGIMEN	Other	20	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1795	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D22-23, D29-30)	Other	IV	IV	Log Forms	Induction	Induction		36	Other	QD (D1-2, D8-9, D22-23, D29-30)					9	390	1
MMRF_1795	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QD (D8-9, D22-23, D29-30)	Other	PO	PO	Log Forms	Induction	Induction		4	Other	QD (D8-9, D22-23, D29-30)					9	390	1
MMRF_1795	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	7	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		7	QD (D1-4)	QD (D1-4)					1	1	1
MMRF_1795	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	5	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-4)	QD (D1-4)					2	392	1
MMRF_1795	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	100	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	390	1
MMRF_1795	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Elotuzumab	Elotuzumab		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	689	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Induction	Induction		689	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1307	1335	1
MMRF_1795	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1307	1335	1
MMRF_1795	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Prednisone	Prednisone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	WITH ELOTUZUMAB	Other	PO	PO	Log Forms	Induction	Induction		20	Other	WITH ELOTUZUMAB					1307	1335	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	INCREASED DOSE	Other	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1342	1376	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1342	1350	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Prednisone	Prednisone		0	SWITCHED DOSING SCHEDULE	Other	20	mg	mg	D1,8,15	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1,8,15					1342	1600	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	START MAINTENANCE	Other	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1390	1433	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Prednisone	Prednisone		0	PATIENT PREFERENCE	Other	20	mg	mg	D1,15	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	D1,15					1614	2042	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	56	mg/m^2	mg/m^2	D1,15	Other	IV	IV	Log Forms	Maintenance	Maintenance		56	Other	D1,15					1446	2070	1
MMRF_1795	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	36	mg/m^2	mg/m^2	D1,15	Other	IV	IV	Log Forms	Maintenance	Maintenance		36	Other	D1,15					2084	2167	1
MMRF_1825	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1215	2053	1
MMRF_1825	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	CORRECT DOSE ORDERED	Other	25	mg	mg	EVERY OTHER DAY FROM D1-21	Other	PO	PO	Log Forms	Maintenance	Maintenance		25	Other	EVERY OTHER DAY FROM D1-21					2061	2088	1
MMRF_1825	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					2089		1
MMRF_1825	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Melphalan	Melphalan		0	Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	DAY -2 AND -1	Other	IV	IV	Log Forms	Consolidation	Consolidation		100	Other	DAY -2 AND -1					1114	1115	1
MMRF_1825	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	350	mg	mg	150MG QAM, 200MG QPM	Other	PO	PO	Log Forms	Induction	Induction		350	Other	150MG QAM, 200MG QPM					1111	1115	1
MMRF_1825	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			CHANGE OF DOSE AS PART OF REGIMEN	Other	20	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1825	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	45	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	196	1
MMRF_1825	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	196	1
MMRF_1825	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					197	287	1
MMRF_1825	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					197	257	1
MMRF_1825	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other			Completed regimen	Completed regimen	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					197	287	1
MMRF_1825	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1	927	1
MMRF_1825	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Elotuzumab	Elotuzumab			Patient decision	Patient decision	10	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Consolidation	Consolidation		10	QWK	QWK					889	1088	1
MMRF_1825	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Patient decision	Patient decision	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		25	Q day	Q day					889	1081	1
MMRF_1825	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Patient decision	Patient decision	4	mg	mg	7TABS 3-24 HOURS PRIOR D1,8,15,22 & IN C1&C2 & D1 & D1&D15 IN C3 AND BEYOND	Other	PO	PO	Log Forms	Consolidation	Consolidation		4	Other	7TABS 3-24 HOURS PRIOR D1,8,15,22 & IN C1&C2 & D1 & D1&D15 IN C3 AND BEYOND					889	1088	1
MMRF_1835	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			CHANGE OF DOSE AS PART OF REGIMEN	Other	20	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1835	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	204	1
MMRF_1835	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					9	282	1
MMRF_1835	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Investigator decision for other reasons	Investigator decision for other reasons	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		16	QWK	QWK					1984	2047	1
MMRF_1835	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1984	2004	1
MMRF_1835	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Induction	Induction		1.3	QWK	QWK					1984	1991	1
MMRF_1835	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	D1,15	Other	IV	IV	Log Forms	Induction	Induction	Checked	16	Other	D1,15					2054		1
MMRF_1835	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Induction	Induction		1	QWK	QWK					1997	2026	1
MMRF_1835	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		20	Other	ONCE					2033	2033	1
MMRF_1835	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Investigator decision for other reasons	Investigator decision for other reasons	27	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		27	Other	ONCE					2040	2040	1
MMRF_1835	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib		1			56	mg/m^2	mg/m^2	3/4 WEEKS	Other	IV	IV	Log Forms	Induction	Induction	Checked	56	Other	3/4 WEEKS					2047		1
MMRF_1835	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		12	Other	QD (D1-2, D8-9, D15-16, D22-23)					205	282	1
MMRF_1835	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					289	305	1
MMRF_1835	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					289	372	1
MMRF_1835	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	24	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		24	Q week	Q week					289	305	1
MMRF_1835	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					373	1934	1
MMRF_1855	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			CHANGE OF DOSE AS PART OF REGIMEN	Other	20	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1855	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	183	1
MMRF_1855	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	183	1
MMRF_1855	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					184	239	1
MMRF_1855	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	QD (D1-2, D8-9, D15-16, D22-23)					184	239	1
MMRF_1855	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other			Completed regimen	Completed regimen	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					184	239	1
MMRF_1855	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			PATIENT MOVING AWAY	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					240	882	1
MMRF_1935	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	611	1
MMRF_1935	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	611	1
MMRF_1935	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	611	1
MMRF_1935	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Elotuzumab	Elotuzumab			Completed regimen	Completed regimen	10	mg/kg	mg/kg	WEEKLY X 3 WEEKS ON/1 WEEK OFF	Other	IV	IV	Log Forms	Induction	Induction		10	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					632	1343	1
MMRF_1935	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					632	1630	1
MMRF_1935	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	8	mg	mg	WEEKLY X 3 WEEKS ON/1 WEEK OFF	Other	PO	PO	Log Forms	Consolidation	Consolidation		8	Other	WEEKLY X 3 WEEKS ON/1 WEEK OFF					632	1630	1
MMRF_1935	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Consolidation	Consolidation		1.3	Q week	Q week					804	1343	1
MMRF_1935	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					1378	1602	1
MMRF_1935	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	ATEZOLIZUMAB	Other			Disease progression/Relapse	Disease progression/Relapse	840	mg/dL	mg/dL	Q2WEEKS	Other	IV	IV	Log Forms	Unknown	Unknown		840	Other	Q2WEEKS					1378	1616	1
MMRF_1935	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1378	1630	1
MMRF_1935	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	JNJ-64407564	Other		0	Disease progression/Relapse	Disease progression/Relapse	3.38	MCG/KG	Other	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		3.38	QWK	QWK					1715	1812	1
MMRF_1935	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	681	mg	mg	QD (D1-3)	QD (D1-3)	IV	IV	Log Forms	Unknown	Unknown		681	QD (D1-3)	QD (D1-3)					1865	1867	1
MMRF_1935	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	FLUDARABINE	Other		0	Completed regimen	Completed regimen	68	mg	mg	QD (D1-3)	QD (D1-3)	IV	IV	Log Forms	Unknown	Unknown		68	QD (D1-3)	QD (D1-3)					1865	1867	1
MMRF_1935	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Melphalan	Melphalan		0	Completed regimen	Completed regimen	40	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Unknown	Unknown		40	Other	ONCE					1829	1829	1
MMRF_1935	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	EVERY 3 DAYS	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.3	Other	EVERY 3 DAYS					1829	1838	1
MMRF_1985	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	20	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		20	Q day	Q day					1	2	1
MMRF_1985	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					3	175	1
MMRF_1985	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	175	1
MMRF_1985	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					198	252	1
MMRF_1985	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					198	252	1
MMRF_1985	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other			Completed regimen	Completed regimen	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					198	252	1
MMRF_1985	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					253		1
MMRF_2072	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	15	1
MMRF_2072	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	D1-2, 8-9, 15-16, 22-23	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1-2, 8-9, 15-16, 22-23					1	37	1
MMRF_2072	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	56	mg/dL	mg/dL	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					16	36	1
MMRF_2072	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	45	mg/dL	mg/dL	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		45	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					57	140	1
MMRF_2072	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		12	Other	QD (D1-2, D8-9, D15-16, D22-23)					57	140	1
MMRF_2072	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	24	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		24	Q week	Q week					141	197	1
MMRF_2072	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					50	197	1
MMRF_2072	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other			Completed regimen	Completed regimen	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					50	197	1
MMRF_2072	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					198	1006	1
MMRF_2072	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction	Checked	16	Q week	Q week					1073		1
MMRF_2072	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					580	964	1
MMRF_2072	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	UNKNOWN	Other	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		3	QD (D1-21)	QD (D1-21)					1073	1117	1
MMRF_2072	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib		0	UNKNOWN	Other	3	mg	mg	D1,8,15	Other	PO	PO	Log Forms	Induction	Induction		3	Other	D1,8,15					1073	1117	1
MMRF_2072	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	2	QD (D1-21)	QD (D1-21)					1529		1
MMRF_2095	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QOW	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	QOW					1534	1646	1
MMRF_2095	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	12	mg	mg	ONCE	Other	PO	PO	Log Forms	Induction	Induction		12	Other	ONCE					1534	1534	1
MMRF_2095	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		16	QWK	QWK					1543	1856	1
MMRF_2095	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.2	mg	mg	D1, 4, 8, 11, 22, 25, 29, 32	Other	IV	IV	Log Forms	Induction	Induction		2.2	Other	D1, 4, 8, 11, 22, 25, 29, 32					1	519	1
MMRF_2095	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Disease progression/Relapse	Disease progression/Relapse	12	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		12	QD (D1-4)	QD (D1-4)					1	519	1
MMRF_2095	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	519	1
MMRF_2095	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	QID	QID	PO	PO	Log Forms	Induction	Induction		3	QID	QID					877	1079	1
MMRF_2095	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					877	1079	1
MMRF_2095	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Induction	Induction		16	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					877	1079	1
MMRF_2159	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	72	1
MMRF_2159	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1-2, 8-9, 15-16, 22-23	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1-2, 8-9, 15-16, 22-23					1	90	1
MMRF_2159	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/dL	mg/dL	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2159	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Patient decision	Patient decision	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					91	455	1
MMRF_2159	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					91	120	1
MMRF_2159	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other			Patient decision	Patient decision	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					91	455	1
MMRF_2159	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					121	455	1
MMRF_2159	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	MG/M2	Other	BID	BID	IV	IV	Log Forms	Other	CONDITIONING		100	BID	BID					1149	1150	1
MMRF_2159	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Patient decision	Patient decision	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					1311	1690	1
MMRF_2159	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					1800		1
MMRF_2237	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	D1,2	Other	IV	IV	Log Forms	Induction	Induction		20	Other	D1,2					1	2	1
MMRF_2237	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					120	208	1
MMRF_2237	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other		0	Completed regimen	Completed regimen	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					120	208	1
MMRF_2237	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					120	208	1
MMRF_2237	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	120	1
MMRF_2237	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	100	1
MMRF_2237	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					233		1
MMRF_2236	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib		1			56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction	Checked	56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1		1
MMRF_2236	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction	Checked	20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1		1
MMRF_2244	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	100	1
MMRF_2244	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	715	1
MMRF_2244	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					220	712	1
MMRF_2244	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	DOSE REDUCED	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					786	1818	1
MMRF_2244	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	D1,2	Other	IV	IV	Log Forms	Induction	Induction		20	Other	D1,2					1	2	1
MMRF_2244	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					120	212	1
MMRF_2244	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other		0	Completed regimen	Completed regimen	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					120	219	1
MMRF_2244	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					120	213	1
MMRF_2244	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	CLARITHROMYCIN	Other		0	IGA INCREASE	Other	500	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		500	BID	BID					786	1863	1
MMRF_2244	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	IGA INCREASE	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					786	1863	1
MMRF_2244	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	IGA INCREASE	Other	12	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		12	QWK	QWK					1818	1863	1
MMRF_2244	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					1895		1
MMRF_2244	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	CLARITHROMYCIN	Other		1			500	mg	mg	BID	BID	PO	PO	Log Forms	Unknown	Unknown	Checked	500	BID	BID					1895		1
MMRF_2244	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			12	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown	Checked	12	QWK	QWK					1895		1
MMRF_2281	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					262	864	1
MMRF_2281	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					880	1052	1
MMRF_2281	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	CLARITHROMYCIN	Other		0	Disease progression/Relapse	Disease progression/Relapse	500	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		500	BID	BID					880	1052	1
MMRF_2281	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					880	1052	1
MMRF_2281	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		16	QWK	QWK					1054	1129	1
MMRF_2281	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1054	1129	1
MMRF_2281	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	DOSE CHANGE	Other	20	mg	mg	ONCE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	ONCE					1054	1054	1
MMRF_2281	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	12	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		12	QWK	QWK					1060	1129	1
MMRF_2281	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	DOSE CHANGE	Other	57	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		57	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1144	1263	1
MMRF_2281	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	ASCT	Other	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1144	1382	1
MMRF_2281	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	SCHEDULE CHANGE	Other	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1144	1242	1
MMRF_2281	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	ASCT	Other	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1269	1382	1
MMRF_2281	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	ASCT	Other	20	mg	mg	D1,8,15	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1,8,15					1256	1382	1
MMRF_2281	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	CONDITIONING	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	DAY -2 AND -1	Other	IV	IV	Log Forms	Other	CONDITIONING		100	Other	DAY -2 AND -1					1399	1400	1
MMRF_2281	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	CONDITIONING	Other	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	350	mg	mg	D-5 TO -1 (150MG QAM AND 200MG QPM)	Other	PO	PO	Log Forms	Other	CONDITIONING		350	Other	D-5 TO -1 (150MG QAM AND 200MG QPM)					1396	1400	1
MMRF_2281								0										Log Forms													1
MMRF_2281	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1502	1605	1
MMRF_2281	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1613	1655	1
MMRF_2281	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QWK	QWK	SC	Other	Log Forms	Induction	Induction		1.3	QWK	QWK					1613	1655	1
MMRF_2281	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Induction	Induction	Bendamustine	Bendamustine		0	Disease progression/Relapse	Disease progression/Relapse	90	mg/m^2	mg/m^2	D1,8	Other	IV	IV	Log Forms	Induction	Induction		90	Other	D1,8					1613	1655	1
MMRF_2281	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	N/A	N/A	Other	N/A	Other	N/A	Other	Log Forms	Unknown	Unknown			Other	N/A					1689	1694	1
MMRF_2281	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	N/A	N/A	Other	N/A	Other	N/A	Other	Log Forms	Unknown	Unknown			Other	N/A					1689	1694	1
MMRF_2281	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	ETOPOSIDE	Other		0	Completed regimen	Completed regimen	N/A	N/A	Other	N/A	Other	N/A	Other	Log Forms	Unknown	Unknown			Other	N/A					1689	1694	1
MMRF_2281	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	CISTPLATIN	Other		0	Completed regimen	Completed regimen	N/A	N/A	Other	N/A	Other	N/A	Other	Log Forms	Unknown	Unknown			Other	N/A					1689	1694	1
MMRF_2281	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	N/A	N/A	Other	N/A	Other	N/A	Other	Log Forms	Unknown	Unknown			Other	N/A					1689	1694	1
MMRF_2281	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Doxorubicin	Doxorubicin		0	Completed regimen	Completed regimen	N/A	N/A	Other	N/A	Other	N/A	Other	Log Forms	Unknown	Unknown			Other	N/A					1689	1694	1
MMRF_2281	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	CAR-T CELL INFUSION	Other		0	Completed regimen	Completed regimen	N/A	N/A	Other	ONCE	Other	N/A	Other	Log Forms	Unknown	Unknown			Other	ONCE					1731	1731	1
MMRF_2281	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2281	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	162	1
MMRF_2281	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	156	1
MMRF_2281	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					178	254	1
MMRF_2281	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					178	254	1
MMRF_2281	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other		0	Completed regimen	Completed regimen	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					178	255	1
MMRF_2292	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	127	1
MMRF_2292	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	D1,8	Other	IV	IV	Log Forms	Induction	Induction		500	Other	D1,8					1	9	1
MMRF_2292	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	241	1
MMRF_2292	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Investigator decision for other reasons	Investigator decision for other reasons	800	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		800	QWK	QWK					857	865	1
MMRF_2292	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	3 OUT OF 4 WEEKS	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	3 OUT OF 4 WEEKS					429	836	1
MMRF_2292	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab			Investigator decision for other reasons	Investigator decision for other reasons	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		16	QWK	QWK					871	879	1
MMRF_2292	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	21.3	mg/m^2	mg/m^2	D1,15	Other	SC	Other	Log Forms	Induction	Induction		21.3	Other	D1,15					955	969	1
MMRF_2292	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide		0	Investigator decision for other reasons	Investigator decision for other reasons	500	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		500	QWK	QWK					127	241	1
MMRF_2292	First line of therapy	First Line Therapy	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	500	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		500	QWK	QWK					241	484	1
MMRF_2292	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		20	QWK	QWK					241	484	1
MMRF_2292	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Investigator decision for other reasons	Investigator decision for other reasons	800	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		800	QWK	QWK					886	886	1
MMRF_2292	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Investigator decision for other reasons	Investigator decision for other reasons	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		16	QWK	QWK					892	906	1
MMRF_2292	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Investigator decision for other reasons	Investigator decision for other reasons	16	mg/kg	mg/kg	D1,15	Other	IV	IV	Log Forms	Induction	Induction		16	Other	D1,15					913	983	1
MMRF_2292	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Investigator decision for other reasons	Investigator decision for other reasons	16	mg/kg	mg/kg	MONTHLY	Other	IV	IV	Log Forms	Maintenance	Maintenance		16	Other	MONTHLY					997	1019	1
MMRF_2292	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					1013		1
MMRF_2292	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Investigator decision for other reasons	Investigator decision for other reasons	16	mg/kg	mg/kg	D1,8,22	Other	IV	IV	Log Forms	Maintenance	Maintenance		16	Other	D1,8,22					1026	1081	1
MMRF_2292	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Investigator decision for other reasons	Investigator decision for other reasons	16	mg/kg	mg/kg	D1,15	Other	IV	IV	Log Forms	Maintenance	Maintenance		16	Other	D1,15					1095	1207	1
MMRF_2292	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	MONTHLY	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	16	Other	MONTHLY					1235		1
MMRF_2292	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide		0	Investigator decision for other reasons	Investigator decision for other reasons	500	mg	mg	D1,8	Other	IV	IV	Log Forms	Induction	Induction		500	Other	D1,8					30	127	1
MMRF_2325	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	D1,2	Other	IV	IV	Log Forms	Induction	Induction		20	Other	D1,2					1	2	1
MMRF_2325	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, 8-9, 15-16, 22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, 8-9, 15-16, 22-23)					1	212	1
MMRF_2325	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	212	1
MMRF_2325	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					234	393	1
MMRF_2325	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					234	394	1
MMRF_2325	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other		0	Completed regimen	Completed regimen	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					234	400	1
MMRF_2325	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					401		1
MMRF_2363	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2363	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/dL	mg/dL	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					7	127	1
MMRF_2363	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	127	1
MMRF_2363	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					619	829	1
MMRF_2363	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	500	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		500	Q week	Q week					231	364	1
MMRF_2363	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					231	364	1
MMRF_2363	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					231	364	1
MMRF_2363	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	DAY -2 AND -1	Other	IV	IV	Log Forms	Consolidation	Consolidation		100	Other	DAY -2 AND -1					384	385	1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Investigator decision for other reasons	Investigator decision for other reasons	16	mg/kg	mg/kg	QOW	Other	IV	IV	Log Forms	Induction	Induction		16	Other	QOW					883	1066	1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	SCHEDULE CHANGE	Other	47	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		47	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					883	961	1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	UNKNOWN	Other	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					891	1051	1
MMRF_2363	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					148	216	1
MMRF_2363	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					148	216	1
MMRF_2363	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					148	216	1
MMRF_2363	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	50	mg	mg	BID DAYS -5 TO -1	Other	PO	PO	Log Forms	Consolidation	Consolidation		50	Other	BID DAYS -5 TO -1					381	385	1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			1045	mg	mg	MONTHLY	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	1045	Other	MONTHLY					728		1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	DOSE CHANGE	Other	47	mg	mg	QOW	Other	IV	IV	Log Forms	Unknown	Unknown		47	Other	QOW					974	1267	1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	DOSE CHANGE	Other	45	mg/m^2	mg/m^2	QOW	Other	IV	IV	Log Forms	Unknown	Unknown		45	Other	QOW					1275	1351	1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	METHYLPREDNISOLONE	Other		1			20-100	mg	mg	QOW	Other	IV	IV	Log Forms	Unknown	Unknown	Checked		Other	QOW					1267		1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		1			56	mg/m^2	mg/m^2	QOW	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	56	Other	QOW					1393		1
MMRF_2363	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	3	QD (D1-21)	QD (D1-21)					1051		1
MMRF_2394	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2394	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	104	1
MMRF_2394	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					6	97	1
MMRF_2394	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			DOSE INCREASE	Other	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					582	582	1
MMRF_2394	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Melphalan	Melphalan			UNKNOWN	Other	20	mg	mg	MONTHLY	Other	IV	IV	Log Forms	Induction	Induction		20	Other	MONTHLY					582	722	1
MMRF_2394	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4-20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction			QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					582	839	1
MMRF_2394	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	NIVOLUMAB	Other		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	240	mg	mg	D1,15	Other	IV	IV	Log Forms	Induction	Induction		240	Other	D1,15					860	860	1
MMRF_2394	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					860	872	1
MMRF_2394	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					860	873	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	D1,8,15	Other	SC	Other	Log Forms	Maintenance	Maintenance		1	Other	D1,8,15					1266	1315	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	0.7	mg/m^2	mg/m^2	D1,8,15	Other	SC	Other	Log Forms	Maintenance	Maintenance		0.7	Other	D1,8,15					1364	1426	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	2-4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance			QD (D1-21)	QD (D1-21)					1224	1610	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	D1,8,15	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	D1,8,15					1259	1707	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	VENETOCLAX	Other		0	DOSE CHANGE	Other	100	mg	mg	QID	QID	PO	PO	Log Forms	Maintenance	Maintenance		100	QID	QID					1253	1497	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	VENETOCLAX	Other		0	Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	5 TIMES/DAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		100	Other	5 TIMES/DAY					1498	1707	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	DOSE INCREASED	Other	27	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Maintenance	Maintenance		27	Other	ONCE					1434	1434	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	DOSE INCREASED	Other	36	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Maintenance	Maintenance		36	Other	ONCE					1441	1441	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	UNKNOWN	Other	56	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Maintenance	Maintenance		56	Other	ONCE					1447	1447	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	DOSE INCREASED	Other	36	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Maintenance	Maintenance		36	Other	ONCE					1463	1463	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	56	mg/m^2	mg/m^2	D1,8,15	Other	IV	IV	Log Forms	Maintenance	Maintenance		56	Other	D1,8,15					1469	1707	1
MMRF_2394	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Induction	Induction	SEA-BCMA	Other		0	Disease progression/Relapse	Disease progression/Relapse	1600	mg	mg	D1,15	Other	IV	IV	Log Forms	Induction	Induction		1600	Other	D1,15					1728	1756	1
MMRF_2394	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Induction	Induction	SELINEXOR	Other		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	80	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		80	QWK	QWK					1777	1784	1
MMRF_2394	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	27	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Induction	Induction		27	QWK	QWK					1777	1784	1
MMRF_2394	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	12-16	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction			QWK	QWK					1777	1784	1
MMRF_2394	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Induction	Induction	Bendamustine	Bendamustine		1			90	mg/m^2	mg/m^2	D1,8	Other	IV	IV	Log Forms	Induction	Induction	Checked	90	Other	D1,8					1791		1
MMRF_2394	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	D1,8,15	Other	SC	Other	Log Forms	Induction	Induction	Checked	1.3	Other	D1,8,15					1791		1
MMRF_2394	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	D1,8,15	Other	PO	PO	Log Forms	Induction	Induction	Checked	20	Other	D1,8,15					1791		1
MMRF_2394	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					118	166	1
MMRF_2394	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					118	167	1
MMRF_2394	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other		0	Completed regimen	Completed regimen	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					118	173	1
MMRF_2394	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					174	425	1
MMRF_2394	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	ELOTUZUMAB	Other		0	Disease progression/Relapse	Disease progression/Relapse	720	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		720	QWK	QWK					454	559	1
MMRF_2394	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					454	559	1
MMRF_2394	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		20	QWK	QWK					454	559	1
MMRF_2394	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					587	839	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Daratumumab	Daratumumab		0	DOSING SCHEDULE CHANGE	Other	1175	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		1175	QWK	QWK					905	968	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	12-20	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction			QWK	QWK					905	1023	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	2.4	mg	mg	QOW	Other	SC	Other	Log Forms	Induction	Induction		2.4	Other	QOW					951	1015	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	1175	mg	mg	QOW	Other	IV	IV	Log Forms	Induction	Induction		1175	Other	QOW					975	1023	1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Consolidation	Consolidation	Melphalan	Melphalan		0	Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	QD	Other	IV	IV	Log Forms	Consolidation	Consolidation		100	Other	QD					1028	1029	1
MMRF_2394								0										Log Forms													1
MMRF_2394	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	D1,8,15	Other	SC	Other	Log Forms	Maintenance	Maintenance		1.3	Other	D1,8,15					1148	1259	1
MMRF_2399	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					212	372	1
MMRF_2399	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					212	373	1
MMRF_2399	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other		0	Completed regimen	Completed regimen	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					212	379	1
MMRF_2399	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					380	709	1
MMRF_2399	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					711	848	1
MMRF_2399	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					711	848	1
MMRF_2399	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Ixazomib	Ixazomib		0	Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		4	QWK	QWK					856	1289	1
MMRF_2399	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					856	1289	1
MMRF_2399	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					856	1289	1
MMRF_2399	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Melphalan	Melphalan		0	Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	DAY -2 AND -1	Other	IV	IV	Log Forms	Consolidation	Consolidation		100	Other	DAY -2 AND -1					1325	1326	1
MMRF_2399	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	350	mg	mg	DAY -5 TO -1 (150MG QAM AND 200MG QPM)	Other	PO	PO	Log Forms	Consolidation	Consolidation		350	Other	DAY -5 TO -1 (150MG QAM AND 200MG QPM)					1322	1326	1
MMRF_2399								0										Log Forms													1
MMRF_2399	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	25	QD (D1-21)	QD (D1-21)					1435		1
MMRF_2399	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/dL	mg/dL	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2399	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	184	1
MMRF_2399	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	192	1
MMRF_2453	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	500	mg	mg	QD (D1, D8)	Other	PO	PO	Log Forms	Induction	Induction		500	Other	QD (D1, D8)					1	273	1
MMRF_2453	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	301	1
MMRF_2453	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	301	1
MMRF_2453	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	DAY -2 AND DAY-1	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	DAY -2 AND DAY-1					310	312	1
MMRF_2453	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		1			4	mg	mg	QD D1, 8, 15 AND 28	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	4	Other	QD D1, 8, 15 AND 28					481		1
MMRF_2503	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	C1 D1-2	Other	IV	IV	Log Forms	Induction	Induction		20	Other	C1 D1-2					1	2	1
MMRF_2503	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	156	1
MMRF_2503	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16, D22-23)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D15-16, D22-23)					1	163	1
MMRF_2503	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	QD (D1-21)					261	868	1
MMRF_2503	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	CC-122 (PLEIOTROPIC PATHWAY MODIFIER ML-122)	Other		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	D1-5, 8-12, 15-19, AND 22-26	Other	PO	PO	Log Forms	Induction	Induction		4	Other	D1-5, 8-12, 15-19, AND 22-26					883	995	1
MMRF_2503	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					883	904	1
MMRF_2503	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					176	253	1
MMRF_2503	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	CC-122	Other		0	Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	D1-5, 8-12, 15-19, AND 22-26	Other	PO	PO	Log Forms	Induction	Induction		3	Other	D1-5, 8-12, 15-19, AND 22-26					1002	1506	1
MMRF_2503	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					911	911	1
MMRF_2503	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		10	QWK	QWK					918	1506	1
MMRF_2503	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					176	252	1
MMRF_2503	First line of therapy	First Line Therapy	Consolidation	Consolidation	CLARITHROMYCIN	Other		0	Completed regimen	Completed regimen	500	mg	mg	BID	BID	PO	PO	Log Forms	Consolidation	Consolidation		500	BID	BID					176	259	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	CONDITIONING	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	DAY -2 AND -1	Other	IV	IV	Log Forms	Other	CONDITIONING		100	Other	DAY -2 AND -1					1548	1549	1
MMRF_2503								0										Log Forms													1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	SCHEDULE CHANGE	Other	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		16	QWK	QWK					1646	1704	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Investigator decision for other reasons	Investigator decision for other reasons	27	mg/m^2	mg/m^2	D1,8,15	Other	IV	IV	Log Forms	Maintenance	Maintenance		27	Other	D1,8,15					1646	1653	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	UNKNOWN	Other	20	mg	mg	ONCE	Other	IV	IV	Log Forms	Maintenance	Maintenance		20	Other	ONCE					1646	1646	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	UNKNOWN	Other	12	mg	mg	ONCE	Other	IV	IV	Log Forms	Maintenance	Maintenance		12	Other	ONCE					1653	1653	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	56	mg/m^2	mg/m^2	D1,8,15	Other	IV	IV	Log Forms	Maintenance	Maintenance		56	Other	D1,8,15					1660	1732	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	SCHEDULE CHANGE	Other	16	mg/kg	mg/kg	D1,15	Other	IV	IV	Log Forms	Maintenance	Maintenance		16	Other	D1,15					1709	1744	1
MMRF_2503	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	MONTHLY	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	16	Other	MONTHLY					1772		1
MMRF_2522	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2522	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1,2,8,9,15,16,22,23)	Other	PO	PO	Log Forms	Induction	Induction	Checked	20	Other	QD (D1,2,8,9,15,16,22,23)					1		1
MMRF_2522	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					3	92	1
MMRF_2522	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	25	QD (D1-21)	QD (D1-21)					92		1
MMRF_2524	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib		1			56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction	Checked	56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					3		1
MMRF_2524	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1,2,8,9,15,16,22,23)	Other	PO	PO	Log Forms	Induction	Induction	Checked	20	Other	QD (D1,2,8,9,15,16,22,23)					1		1
MMRF_2524	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	2	1
MMRF_2599	First line of therapy	First Line Therapy	CAR/DEX TO PLATEAU FOLLOWD BY BIOXIN/REV/DEX TO PLATEAU FOLLOWED BY REV MAINTENANCE	Other	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	31	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	CAR/DEX TO PLATEAU FOLLOWD BY BIOXIN/REV/DEX TO PLATEAU FOLLOWED BY REV MAINTENANCE		31	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	85	1
MMRF_2599	First line of therapy	First Line Therapy	CAR/DEX TO PLATEAU FOLLOWD BY BIOXIN/REV/DEX TO PLATEAU FOLLOWED BY REV MAINTENANCE	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	1, 8, 15, 22	Other	PO	PO	Log Forms	Other	CAR/DEX TO PLATEAU FOLLOWD BY BIOXIN/REV/DEX TO PLATEAU FOLLOWED BY REV MAINTENANCE		20	Other	1, 8, 15, 22					1	100	1
MMRF_2599	First line of therapy	First Line Therapy	CAR/DEX TO PLATEAU FOLLOWD BY BIOXIN/REV/DEX TO PLATEAU FOLLOWED BY REV MAINTENANCE	Other	BIAXIN	Other			Disease progression/Relapse	Disease progression/Relapse	500	mg	mg	BID	BID	PO	PO	Log Forms	Other	CAR/DEX TO PLATEAU FOLLOWD BY BIOXIN/REV/DEX TO PLATEAU FOLLOWED BY REV MAINTENANCE		500	BID	BID					114	793	1
MMRF_2599	First line of therapy	First Line Therapy	CAR/DEX TO PLATEAU FOLLOWD BY BIOXIN/REV/DEX TO PLATEAU FOLLOWED BY REV MAINTENANCE	Other	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	CAR/DEX TO PLATEAU FOLLOWD BY BIOXIN/REV/DEX TO PLATEAU FOLLOWED BY REV MAINTENANCE		25	QD (D1-21)	QD (D1-21)					114	814	1
MMRF_2599	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	CELGENE CC-122 -PLEIOTROPIC PATHWAY	Other		1			4	mg	mg	Q D1-5, 8-12, 15-19, AND 22-26	Other	PO	PO	Log Forms	Induction	Induction	Checked	4	Other	Q D1-5, 8-12, 15-19, AND 22-26					828		1
MMRF_2599	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q D1 D8 D15 D22	Other	PO	PO	Log Forms	Induction	Induction	Checked	40	Other	Q D1 D8 D15 D22					828		1
MMRF_1120	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms				1.6	Q week	Q week					1	21	1
MMRF_1120	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.6	Q week	Q week					35	203	1
MMRF_1120	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAY OF AND DAY AFTER EACH DOSE OF VELCADE. DAY 1,2,8,9,15,16, 22, 23	Other	PO	PO	Log Forms				20	Other	DAY OF AND DAY AFTER EACH DOSE OF VELCADE. DAY 1,2,8,9,15,16, 22, 23					1	237	1
MMRF_1120	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	Q day	Q day	PO	PO	Log Forms				25	Q day	Q day					16	237	1
MMRF_1120	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					473		1
MMRF_1120	First line of therapy	First Line Therapy	CONDITIONING REGIMEN	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	DAILY ON DAYS -2 AND -1 FROM ASCT	Other	IV	IV	Log Forms	Other	CONDITIONING REGIMEN		100	Other	DAILY ON DAYS -2 AND -1 FROM ASCT					237	238	1
MMRF_1120	First line of therapy	First Line Therapy	CONDITIONING REGIMEN	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	DAILY ON DAYS -2 AND -1 FROM ASCT	Other	IV	IV	Log Forms	Other	CONDITIONING REGIMEN		100	Other	DAILY ON DAYS -2 AND -1 FROM ASCT					356	357	1
MMRF_1140	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	MG	Other	Q day	Q day	PO	PO	Log Forms				25	Q day	Q day					2	23	1
MMRF_1140	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	TAKEN DAY OF AND DAY AFTER EACH DOSE OF VELCADE. DAY 1, 2, 8, 9, 15, 16, 22	Other	PO	PO	Log Forms				20	Other	TAKEN DAY OF AND DAY AFTER EACH DOSE OF VELCADE. DAY 1, 2, 8, 9, 15, 16, 22					1	330	1
MMRF_1140	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				2.5	Q week	Q week					169	204	1
MMRF_1140	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					451	1955	1
MMRF_1140	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			LOCAL VELCADE REACTION, <GRADE 3 RXN	Other	1.6	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.6	Q week	Q week					1	8	1
MMRF_1140	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				3	Q week	Q week					15	162	1
MMRF_1140	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Investigator decision for other reasons	Investigator decision for other reasons	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		16	Q week	Q week					1988	2144	1
MMRF_1140	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1988	2144	1
MMRF_1140	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					1988	2002	1
MMRF_1140	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	ASCT CONDITIONING	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	ASCT CONDITIONING		200	Q day	Q day					2164	2165	1
MMRF_1167	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	ONCE	Other	PO	PO	Log Forms				40	Other	ONCE					1	2	1
MMRF_1167	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms				10	Q day	Q day					2	5	1
MMRF_1167	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms				10	Q day	Q day					9	10	1
MMRF_1167	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms				10	Q day	Q day					12	13	1
MMRF_1167	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms				1.3	Q week	Q week					12	22	1
MMRF_1167	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms				10	Q day	Q day					15	16	1
MMRF_1167	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q WEEK FOR THREE WEEKS THEN HOLD FOR TWO WEEKS	Other	PO	PO	Log Forms				10	Other	Q WEEK FOR THREE WEEKS THEN HOLD FOR TWO WEEKS					43	630	1
MMRF_1167	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.75	mg	mg	Q WEEK FOR THREE WEEKS THEN HOLD FOR TWO WEEKS	Other	IV SubQ	IV SubQ	Log Forms				2.75	Other	Q WEEK FOR THREE WEEKS THEN HOLD FOR TWO WEEKS					43	293	1
MMRF_1167	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.5	mg/m^2	mg/m^2	Q2WEEKS	Other	IV SubQ	IV SubQ	Log Forms				1.5	Other	Q2WEEKS					293	630	1
MMRF_1167	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					630	819	1
MMRF_1167	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					630	834	1
MMRF_1167	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			HIGH RISK COMPLICATIONS OF WARFARIN ON TERMINAL, SECOND MALIGNANCY	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					834	946	1
MMRF_1336	First line of therapy	First Line Therapy			Melphalan	Melphalan			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms				15	QD (D1-4)	QD (D1-4)					1	30	1
MMRF_1336	First line of therapy	First Line Therapy			Prednisone	Prednisone			Investigator decision for other reasons	Investigator decision for other reasons	100	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms				100	QD (D1-4)	QD (D1-4)					1	30	1
MMRF_1336	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	D1, 8, 15, 22	Other	IV SubQ	IV SubQ	Log Forms				1.3	Other	D1, 8, 15, 22					6	30	1
MMRF_1336	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	DAY 1, 8, 15 AND 22	Other	PO	PO	Log Forms				40	Other	DAY 1, 8, 15 AND 22					30	275	1
MMRF_1336	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	300	mg/m^2	mg/m^2	DAYS 1, 8, 15, AND 22	Other	PO	PO	Log Forms				300	Other	DAYS 1, 8, 15, AND 22					37	268	1
MMRF_1336	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					275	359	1
MMRF_1336	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	D1, 8, 15, 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1, 8, 15, 22					44	268	1
MMRF_1336	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	D1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Other	D1, 8, 15					275	359	1
MMRF_1336	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					289	360	1
MMRF_1336	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			PATIENT COULD NO LONGER AFFORD TREATMENT	Other	1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY OTHER WEEK					616	933	1
MMRF_1587	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.75	mg	mg	D1, D4, D8, D11	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.75	Other	D1, D4, D8, D11					1	167	1
MMRF_1587	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1-4 AND D8-11	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1-4 AND D8-11					1	167	1
MMRF_1587	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	D1, D8, D15	Other	IV	IV	Log Forms	Induction	Induction		300	Other	D1, D8, D15					1	167	1
MMRF_1587	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.5	mg/m^2	mg/m^2	D1, D8, D15, D22	Other	IV	IV	Log Forms	Maintenance	Maintenance		1.5	Other	D1, D8, D15, D22					190	234	1
MMRF_1587	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	D1, D2	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	D1, D2					190	234	1
MMRF_1587	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	600	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		600	Q week	Q week					234	298	1
MMRF_1587	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	D1-4, D8-11	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1-4, D8-11					234	298	1
MMRF_1587	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.8	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					238	298	1
MMRF_1587	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Lack of response	Lack of response	1.5	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.5	Q week	Q week					309	629	1
MMRF_1587	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Lack of response	Lack of response	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					309	550	1
MMRF_1587	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					309	550	1
MMRF_1857	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	450	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		450	Q week	Q week					1	114	1
MMRF_1857	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					2	114	1
MMRF_1857	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	114	1
MMRF_1857	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					377		1
MMRF_1857	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	PER EMR, FREQUENCY NOT KNOWN; PATIENT NOT SEEN AT OHSU	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2	Other	PER EMR, FREQUENCY NOT KNOWN; PATIENT NOT SEEN AT OHSU					124	219	1
MMRF_1857	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					124	206	1
MMRF_1857	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		15	Q day	Q day					124	206	1
MMRF_2297	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	24	1
MMRF_2297	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	26	1
MMRF_2297	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	D1-2, 4-5, 8-9, 11-12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1-2, 4-5, 8-9, 11-12					1	24	1
MMRF_2297	First line of therapy	First Line Therapy	CONDITIONING REGIMEN	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	DAYS -2 AND -1	Other	IV	IV	Log Forms	Other	CONDITIONING REGIMEN		100	Other	DAYS -2 AND -1					274	275	1
MMRF_2297	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	D1, 8, 15, 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Other	D1, 8, 15, 22					105	210	1
MMRF_2297	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					105	198	1
MMRF_2297	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	D1, D15	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	D1, D15					406	686	1
MMRF_2297	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					138	198	1
MMRF_2297	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	D1 AND D15	Other	IV	IV	Log Forms	Maintenance	Maintenance		2	Other	D1 AND D15					728	1234	1
MMRF_2297	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1248		1
MMRF_2302	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	264	1
MMRF_2302	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	264	1
MMRF_2302	First line of therapy	First Line Therapy	Unknown	Unknown	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	D1, 8, 15, 22	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.3	Other	D1, 8, 15, 22					283	325	1
MMRF_2302	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	D1, 8,15, 22	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	D1, 8,15, 22					283	325	1
MMRF_2302	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					283	325	1
MMRF_2302	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Patient decision	Patient decision	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					376	1056	1
MMRF_2352	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	139	1
MMRF_2352	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	600	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		600	QWK	QWK					1	139	1
MMRF_2352	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 2, 4, 5, 8, 9, 11, 12, 15, 16	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 2, 4, 5, 8, 9, 11, 12, 15, 16					3	139	1
MMRF_2352	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					307	882	1
MMRF_2352	First line of therapy	First Line Therapy	CONDITIONING REGIMEN	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	190	mg	mg	DAY -2 AND -1 TO ASCT	Other	IV	IV	Log Forms	Other	CONDITIONING REGIMEN		190	Other	DAY -2 AND -1 TO ASCT					149	150	1
MMRF_2352	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	D1-D28 OF A 28 DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Other	D1-D28 OF A 28 DAY CYCLE					883		1
MMRF_2464	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2464	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	56	1
MMRF_2464	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAYS 1-2, 4-5, 8-9, 11-12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1-2, 4-5, 8-9, 11-12					1	54	1
MMRF_2464	First line of therapy	First Line Therapy	CONDITIONING REGIMEN	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	DAY -2 AND -1	Other	IV	IV	Log Forms	Other	CONDITIONING REGIMEN		100	Other	DAY -2 AND -1					119	120	1
MMRF_2464	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					252	1129	1
MMRF_2464	First line of therapy	First Line Therapy	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1900	mg	mg	Q 3HRS X3	Other	IV	IV	Log Forms	Unknown	Unknown		1900	Other	Q 3HRS X3					95	96	1
MMRF_2464	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					210	241	1
MMRF_2464	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	D1, 2, 4, 5, 8, 9, 11 AND 12	Other	PO	PO	Log Forms	Consolidation	Consolidation		10	Other	D1, 2, 4, 5, 8, 9, 11 AND 12					210	242	1
MMRF_2464	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-14)	QD (D1-14)					210	244	1
MMRF_2464	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					1157		1
MMRF_2217	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	BCMA AB	Other	NCT03489525	0	Disease progression/Relapse	Disease progression/Relapse								Log Forms	Induction	Induction									1542	1619	1
MMRF_2217	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Induction	Induction	Ixazomib	Ixazomib	NCT02633059	0	Disease progression/Relapse	Disease progression/Relapse								Log Forms	Induction	Induction									1633	1667	1
MMRF_2217	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_2217	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	DAY 1 AND 8	Other	PO	PO	Log Forms	Induction	Induction		500	Other	DAY 1 AND 8					1	8	1
MMRF_2217	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1,8,15,22)	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	QD (D1,8,15,22)					1204	1487	1
MMRF_2217	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1-4, DAY 8 AND DAY 11	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1-4, DAY 8 AND DAY 11					1	11	1
MMRF_2217	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			DOSE INCREASED	Other	600	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		600	QWK	QWK					21	254	1
MMRF_2217	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					21	373	1
MMRF_2217	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	Q week	Q week					21	373	1
MMRF_2217	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	650	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		650	Q week	Q week					254	373	1
MMRF_2217	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	DAY 1 AND DAY 15	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	DAY 1 AND DAY 15					373	718	1
MMRF_2217	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	4 MG ON DAYS 1, 2, 15, 16 OF 28-DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	4 MG ON DAYS 1, 2, 15, 16 OF 28-DAY CYCLE					373	736	1
MMRF_2217	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	NIVOLUMAB	Other		0	Disease progression/Relapse	Disease progression/Relapse	240	mg	mg	C1D15, C2-6 D1, D15	Other	IV	IV	Log Forms	Induction	Induction		240	Other	C1D15, C2-6 D1, D15					997	1164	1
MMRF_2217	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Lack of response	Lack of response	16	mg/kg	mg/kg	C1 D1,15,22. C2 D1,16,22. C3-6 D1,15	Other	IV	IV	Log Forms	Induction	Induction		16	Other	C1 D1,15,22. C2 D1,16,22. C3-6 D1,15					1182	1203	1
MMRF_2217	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Lack of response	Lack of response	4	mg	mg	C1,C2 D2,3,9,10,16,17,23,24	Other	PO	PO	Log Forms	Induction	Induction		4	Other	C1,C2 D2,3,9,10,16,17,23,24					1182	1203	1
MMRF_2217	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Lack of response	Lack of response	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					1172	1200	1
MMRF_2217	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Lack of response	Lack of response	4	mg	mg	D 2 AND 3 EACH CYCLE	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	D 2 AND 3 EACH CYCLE					1172	1200	1
MMRF_2217	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	D1,2,8,9,15,16	Other	IV	IV	Log Forms	Unknown	Unknown		20	Other	D1,2,8,9,15,16					1204	1487	1
MMRF_2217	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1204	1487	1
MMRF_1629	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.8	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					350	1707	1
MMRF_1629	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					350	1707	1
MMRF_1629	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	SALVAGE	Checked	16	Q week	Q week					1721		1
MMRF_1629	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		2	QD (D1-21)	QD (D1-21)					1721	2085	1
MMRF_1629	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SALVAGE	Checked	40	Q week	Q week					1721		1
MMRF_1629	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			MOVED TO SCT	Other	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	189	1
MMRF_1629	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			MOVED TO SCT	Other	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	189	1
MMRF_1629	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			MOVED TO SCT	Other	50	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		50	Q week	Q week					1	189	1
MMRF_1380	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.6	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms				2.6	QWK	QWK					1	166	1
MMRF_1380	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	166	1
MMRF_1380	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms				20	QWK	QWK					1	386	1
MMRF_1380	First line of therapy	First Line Therapy	INTENSIFICATION OF  INDUCTION THERAPY	Other	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	950	mg	mg	Q week	Q week	IV	IV	Log Forms	Other	INTENSIFICATION OF  INDUCTION THERAPY		950	Q week	Q week					106	166	1
MMRF_1380	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					166	387	1
MMRF_1380	First line of therapy	First Line Therapy	Consolidation	Consolidation	Pomalidomide	Pomalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		4	QD (D1-21)	QD (D1-21)					178	1251	1
MMRF_1380	First line of therapy	First Line Therapy	Maintenance	Maintenance	Pomalidomide	Pomalidomide		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	2	QD (D1-21)	QD (D1-21)					1252		1
MMRF_1432	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			PATIENT DIED	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms				20	Q week	Q week					1	400	1
MMRF_1432	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.3	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms				2.3	QWK	QWK					1	48	1
MMRF_1432	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					1	337	1
MMRF_1432	First line of therapy	First Line Therapy	REPLACEMENT OF VELCADE	Other	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	1200	mg	mg	QMONTH	Other	IV	IV	Log Forms	Other	REPLACEMENT OF VELCADE		1200	Other	QMONTH					89	194	1
MMRF_1432	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Patient decision	Patient decision	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					337	393	1
MMRF_1432	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Melphalan	Melphalan			Patient decision	Patient decision	8	mg	mg	QD (D1-3)	QD (D1-3)	PO	PO	Log Forms	Unknown	Unknown		8	QD (D1-3)	QD (D1-3)					348	393	1
MMRF_1460	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TREATMENT DISCONTINUED DUE TO PROGRESSION OF DEMENTIA	Other	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	258	1
MMRF_1460	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	166	1
MMRF_1542	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Patient decision	Patient decision	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	128	1
MMRF_1542	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					5	43	1
MMRF_1542	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					5	101	1
MMRF_1542	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					262	437	1
MMRF_1542	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			DEATH	Other	1	GRAM	Other	Q EVERY 4 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		1	Other	Q EVERY 4 WEEKS					520	1137	1
MMRF_1542	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DEATH	Other	1.3	mg/m^2	mg/m^2	QEVERY 4 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QEVERY 4 WEEKS					155	1137	1
MMRF_1542	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			DEATH	Other	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					803	1137	1
MMRF_1646	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Patient decision	Patient decision	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	15	1
MMRF_1646	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	23	1
MMRF_1647	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	204	1
MMRF_1647	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	36	1
MMRF_1647	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					206	239	1
MMRF_1647	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Patient decision	Patient decision	2.3	mg	mg	QD (D1-14)	QD (D1-14)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.3	QD (D1-14)	QD (D1-14)					344	766	1
MMRF_1647	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-14)	QD (D1-14)					344	766	1
MMRF_1778	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	1	1
MMRF_1778	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.5	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.5	Q week	Q week					1	1	1
MMRF_2058	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DOSE REDUCED FOR MAINTENANCE	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	191	1
MMRF_2058	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PATIENT REACHED VGPR	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	191	1
MMRF_2058	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	INCREASE IN M-SPIKE	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					191	306	1
MMRF_2058	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Lack of response	Lack of response	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					307	370	1
MMRF_2058	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					371	703	1
MMRF_2058	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					704		1
MMRF_2079	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2079	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					1		1
MMRF_2079	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			RASH	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					2	26	1
MMRF_2079	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide		1			500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	500	Q week	Q week					65		1
MMRF_2143	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			HOSPITAL ADMISSION	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	1	1
MMRF_2143	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DEATH	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					42	841	1
MMRF_2143	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DISCONTINUED BY PHARMACIST	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					42	118	1
MMRF_2204	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	109	1
MMRF_2204	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Patient decision	Patient decision	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	147	1
MMRF_2204	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.6	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	Q week	Q week					232	359	1
MMRF_2204	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					375	394	1
MMRF_2204	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					235	394	1
MMRF_2362	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					36	527	1
MMRF_2362	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					631		1
MMRF_2362	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Investigator decision for other reasons	Investigator decision for other reasons	100	mg	mg	3 WEEKS ON, 1 WEEK OFF	Other	IV	IV	Log Forms	Maintenance	Maintenance		100	Other	3 WEEKS ON, 1 WEEK OFF					1585	1649	1
MMRF_2362	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib		1			100	mg	mg	EVERY 4 WEEKS	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	100	Other	EVERY 4 WEEKS					1677		1
MMRF_2362	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	246	1
MMRF_2362	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Patient decision	Patient decision	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					1	527	1
MMRF_2487	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QWEEK, 3 WEEKS ON, 1 WEEK OFF.	Other	SUBQ	Other	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	QWEEK, 3 WEEKS ON, 1 WEEK OFF.					1899		1
MMRF_2487	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	QWEEK, 3 WEEKS ON, 1 WEEK OFF.	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	QWEEK, 3 WEEKS ON, 1 WEEK OFF.					1899		1
MMRF_2487	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	RADIATION THERAPY	Other	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBQ	Other	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	52	1
MMRF_2487	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	RADIATION THERAPY	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	52	1
MMRF_2487	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	QD 1-2	Other	IV	IV	Log Forms	Consolidation	Consolidation		100	Other	QD 1-2					258	259	1
MMRF_2487	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	BONE MARROW TRANSPLANTATION	Other	2.7	mg	mg	Q week	Q week	SUBQ	Other	Log Forms	Induction	Induction		2.7	Q week	Q week					79	226	1
MMRF_2487	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	BONE MARROW TRANSPLANTATION	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					79	226	1
MMRF_2487	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Investigator decision for other reasons	Investigator decision for other reasons	2.1	mg	mg	EVERY 2 WEEKS	Other	SUBQ	Other	Log Forms	Maintenance	Maintenance		2.1	Other	EVERY 2 WEEKS					435	1268	1
MMRF_2487	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	EVERY 2 WEEKS	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	EVERY 2 WEEKS					898	1268	1
MMRF_2487	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Investigator decision for other reasons	Investigator decision for other reasons	3.0	mg	mg	Q week	Q week	SUBQ	Other	Log Forms	Maintenance	Maintenance		3	Q week	Q week					1283	1465	1
MMRF_2487	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1283	1465	1
MMRF_2581	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	83	1
MMRF_2581	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	83	1
MMRF_1504	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	700	mg	mg	EVERY WEEK FOR 8 WEEKS, THEN EVERY 2 WEEKS	Other	IV	IV	Log Forms	Unknown	Unknown		700	Other	EVERY WEEK FOR 8 WEEKS, THEN EVERY 2 WEEKS					2058	2314	1
MMRF_1504	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	D2-3, D8-9, D14-15, D21-22	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	D2-3, D8-9, D14-15, D21-22					2058	2424	1
MMRF_1504	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					34937	2346	1
MMRF_1504	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	84	1
MMRF_1504	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_1504	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					11	158	1
MMRF_1504	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.4	mg	mg	DAY 1 AND DAY 8 OF EACH CYCLE	Other	SUBQ	Other	Log Forms	Maintenance	Maintenance		2.4	Other	DAY 1 AND DAY 8 OF EACH CYCLE					84	152	1
MMRF_1504	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	DAYS 1, 8 AND 15	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 8 AND 15					84	309	1
MMRF_1504	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Patient decision	Patient decision	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					179	262	1
MMRF_1504	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Patient decision	Patient decision	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					309	675	1
MMRF_1504	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1082	1345	1
MMRF_1504	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1082	2424	1
MMRF_1504	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	DAY 1, 8 AND 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1, 8 AND 15					1345	2043	1
MMRF_1504	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab		0	Disease progression/Relapse	Disease progression/Relapse	800	mg	mg	WEEKLY FIRST 2 CYCLES, THEN EVERY 4 WK AFTER C3	Other	IV	IV	Log Forms	Unknown	Unknown		800	Other	WEEKLY FIRST 2 CYCLES, THEN EVERY 4 WK AFTER C3					2358	2380	1
MMRF_1504	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Completed regimen	Completed regimen	4	mg	mg	QD (1-21 OF 28 DAY CYCLE)	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD (1-21 OF 28 DAY CYCLE)					2353	2424	1
MMRF_1504	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2387	2415	1
MMRF_2055	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Induction	Induction		15	Other	EVERY OTHER DAY					1	283	1
MMRF_2055	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			HYPERGLYCEMIA	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	178	1
MMRF_2055	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	15	mg	mg	EVERY OTHER DAY; TAKE EVERY OTHER DAY FOR 21 DAYS EVERY 28 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		15	Other	EVERY OTHER DAY; TAKE EVERY OTHER DAY FOR 21 DAYS EVERY 28 DAY CYCLE					811	1177	1
MMRF_2055	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	1.3	mg/dL	mg/dL	DAY 1, 8, 15 AND 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1, 8, 15 AND 22					906	1655	1
MMRF_2055	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	28	mg	mg	DAY 1, 8, 15 AND 22	Other	PO	PO	Log Forms	Induction	Induction		28	Other	DAY 1, 8, 15 AND 22					906	1662	1
MMRF_2253	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	DAYS 1, 5 , 8 & 11	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	Other	DAYS 1, 5 , 8 & 11					1	157	1
MMRF_2253	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	157	1
MMRF_2253	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 8 AND 15	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8 AND 15					1	157	1
MMRF_2253	First line of therapy	First Line Therapy	STEM CELL TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	401	mg	mg	DAILY X 1, DAY (-2)	Other	IV	IV	Log Forms	Other	STEM CELL TRANSPLANT		401	Other	DAILY X 1, DAY (-2)					164	164	1
MMRF_2253	First line of therapy	First Line Therapy	STEM CALL TRANSPLANT	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	DAY (-2)	Other	IV	IV	Log Forms	Other	STEM CALL TRANSPLANT		12	Other	DAY (-2)					164	164	1
MMRF_2253	First line of therapy	First Line Therapy	STEM CELL TRANSPLANT	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	8	mg	mg	DAILY DAYS (-1, 0)	Other	IV	IV	Log Forms	Other	STEM CELL TRANSPLANT		8	Other	DAILY DAYS (-1, 0)					165	166	1
MMRF_2253	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					260	495	1
MMRF_2253	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.7	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	Q week	Q week					514	710	1
MMRF_2253	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					514	716	1
MMRF_2253	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			DEATH	Other	42	mg	mg	X1 ON DAY 1 TO 2	Other	IV	IV	Log Forms	Induction	Induction		42	Other	X1 ON DAY 1 TO 2					716	744	1
MMRF_2253	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			DEATH	Other	4	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		4	Q day	Q day					719	744	1
MMRF_1349	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	508	1
MMRF_1349	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	512	1
MMRF_1332	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	167	1
MMRF_1332	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	167	1
MMRF_1332	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	Q day	Q day	PO	PO	Log Forms				25	Q day	Q day					10	167	1
MMRF_1332	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					310		1
MMRF_1365	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DOSE CHANGE	Other	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	1	1
MMRF_1365	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DOSE PRESCRIBED CHANGED TRANSFER TO NEW PROVIDER	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	30	1
MMRF_1365	First line of therapy	First Line Therapy			Cyclophosphamide	Cyclophosphamide			DOSE CHANGED	Other	460	mg	mg	Q week	Q week	IV	IV	Log Forms				460	Q week	Q week					8	20	1
MMRF_1365	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DOSE CHANGE	Other	2.3	mg	mg	ONCE	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.3	Other	ONCE					8	8	1
MMRF_1365	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DOSE CHANGE	Other	2.45	mg	mg	ONCE	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.45	Other	ONCE					22	22	1
MMRF_1365	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DOSE CHANGE	Other	1	mg	mg	ONCE	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Other	ONCE					30	30	1
MMRF_1365	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1	QWK	QWK					60		1
MMRF_1365	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			DOSE CHANGED	Other	470	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		470	QWK	QWK					22	30	1
MMRF_1365	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide		1			300	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Induction	Induction	Checked	300	QWK	QWK					67		1
MMRF_1425	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QWK	QWK	PO	PO	Log Forms				40	QWK	QWK					1	22	1
MMRF_1425	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_1425	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.6	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	Q week	Q week					22	108	1
MMRF_1425	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					115	227	1
MMRF_1425	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			PERIPHERAL NEUROPATHY	Other	1.3	mg/m^2	mg/m^2	EVERY 2 WEEK	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY 2 WEEK					227	1107	1
MMRF_1425	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					22	227	1
MMRF_1425	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	EVERY 2 WEEKS	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	EVERY 2 WEEKS					237	1260	1
MMRF_1451	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			DEATH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	154	1
MMRF_1451	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	QWK	QWK	PO	PO	Log Forms				20	QWK	QWK					1	154	1
MMRF_1451	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DEATH	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					147	154	1
MMRF_1501	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	2.5	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.5	Q week	Q week					1	375	1
MMRF_1501	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		40	Q week	Q week					1	314	1
MMRF_1501	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Lack of response	Lack of response	4	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		4	Q day	Q day					375	504	1
MMRF_1501	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		10	QWK	QWK					84	224	1
MMRF_1501	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Lack of response	Lack of response	42	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		42	QWK	QWK					504	734	1
MMRF_1501	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					224	671	1
MMRF_1501	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	4	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		4	BID	BID					448	606	1
MMRF_1501	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	TAKE 1 TAB BY MOUTH EVERY 6 HOURS. 2 DAILY FOR 4 DAYS, THEN 1 DAILY X 4 DA	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	TAKE 1 TAB BY MOUTH EVERY 6 HOURS. 2 DAILY FOR 4 DAYS, THEN 1 DAILY X 4 DA					606	622	1
MMRF_1501	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Lack of response	Lack of response	4	mg	mg	TAKE 40 MG PER WEEK	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	TAKE 40 MG PER WEEK					622	874	1
MMRF_1525	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	D1, D8, D15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1, D8, D15					1	237	1
MMRF_1525	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	D1, 8, 15	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1, 8, 15					1	1568	1
MMRF_1525	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					27	208	1
MMRF_1525	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					208	273	1
MMRF_1525	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					889	1421	1
MMRF_1525	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-7)	QD (D1-7)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-7)	QD (D1-7)					1421	1568	1
MMRF_1525	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib			Lack of response	Lack of response	4	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		4	QWK	QWK					1421	1568	1
MMRF_1525	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	NEW THERAPY AFTER A LACK OF RESPOSE TO SECOND LINE THERAPY	Other	Carfilzomib	Carfilzomib		0	Lack of response	Lack of response	35.4	mg	mg	D1 - D2	Other	IV	IV	Log Forms	Other	NEW THERAPY AFTER A LACK OF RESPOSE TO SECOND LINE THERAPY		35.4	Other	D1 - D2					1589	1773	1
MMRF_1525	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	4	QD (D1-21)	QD (D1-21)					1840		1
MMRF_1519	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			CHANGE FROM ONE TIME DOSING TO WEEKLY DOSING AND TO WEIGHT BASED DOSE	Other	3.1	mg	mg	ONE TIME ORDER AUG 10 AND 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3.1	Other	ONE TIME ORDER AUG 10 AND 15					1	6	1
MMRF_1519	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	195	1
MMRF_1519	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					81	391	1
MMRF_1519	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					13	195	1
MMRF_1519	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	EVERY 2 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	EVERY 2 WEEKS					265	307	1
MMRF_1519	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			PATIENT DEATH	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					269	647	1
MMRF_1627	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	13	1
MMRF_1627	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	13	1
MMRF_1627	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					103	165	1
MMRF_1627	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					172	251	1
MMRF_1627	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					27	90	1
MMRF_1627	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					27	97	1
MMRF_1627	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					131	160	1
MMRF_1627	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		5	Q day	Q day					644	742	1
MMRF_1627	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					1325	1472	1
MMRF_1627	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			PATIENT DECEASED AFTER THIS LAST DATE OF TREATMENT	Other	1.3	mg/m^2	mg/m^2	ONCE VERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	ONCE VERY OTHER WEEK					1526	1568	1
MMRF_1633	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1633	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction	Checked	40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1639	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	105	1
MMRF_1639	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	105	1
MMRF_1639	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					140	575	1
MMRF_1639	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	1	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		1	Q day	Q day					520	679	1
MMRF_1639	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		5	Q day	Q day					210	521	1
MMRF_1639	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Lack of response	Lack of response	34.2	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		34.2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					657	679	1
MMRF_1639	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	ONCE	Other	IV	IV	Log Forms	Induction	Induction		4	Other	ONCE					657	657	1
MMRF_1645	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Other	EVERY OTHER WEEK					1	117	1
MMRF_1645	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	EVERY OTHER WEEK	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	EVERY OTHER WEEK					1	117	1
MMRF_1645	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	600	mg	mg	EVERY OTHER WEEK	Other	PO	PO	Log Forms	Induction	Induction		600	Other	EVERY OTHER WEEK					1	117	1
MMRF_1645	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			STEM CELL TRANSPLANT	Other	5	mg	mg	M-W-F FOR 3 WEEKS AND ONE WEEK OFF	Other	PO	PO	Log Forms	Consolidation	Consolidation		5	Other	M-W-F FOR 3 WEEKS AND ONE WEEK OFF					180	439	1
MMRF_1645	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					180	370	1
MMRF_1645	First line of therapy	First Line Therapy	SCT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	MG/M2	Other	Q day	Q day	IV	IV	Log Forms	Other	SCT		140	Q day	Q day					440	440	1
MMRF_1645	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	2.5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		2.5	Q day	Q day					943	1639	1
MMRF_1645	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			STEM CELL TRANSPLANT SURGEON WANTED TO INCREASE DOSE	Other	5	mg	mg	3 TIMES PER WEEK - MONDAY, WEDNESDAY, AND FRIDAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	3 TIMES PER WEEK - MONDAY, WEDNESDAY, AND FRIDAY					540	943	1
MMRF_1651	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.6	mg/m^2	mg/m^2	DAY 1, 8, 15, 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.6	Other	DAY 1, 8, 15, 22					1	120	1
MMRF_1651	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAY 8, 15, 22	Other	IV	IV	Log Forms	Induction	Induction		300	Other	DAY 8, 15, 22					8	120	1
MMRF_1651	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAY 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15, 22					1	120	1
MMRF_1651	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			PATIENT RESPONDING TO TREATMENT	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					120	358	1
MMRF_1651	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		20	QWK	QWK					120	633	1
MMRF_1651	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					358	379	1
MMRF_1650	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	32	1
MMRF_1650	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	36	1
MMRF_1650	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					106	316	1
MMRF_1650	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	BY MOUTH EVERY MON, WED, AND FRIDAY THEN ONE WEEK OFF.	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	BY MOUTH EVERY MON, WED, AND FRIDAY THEN ONE WEEK OFF.					316	486	1
MMRF_1650	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-14)	QD (D1-14)					486	659	1
MMRF_1650	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			HOSPICE	Other	2	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		2	Q day	Q day					652	997	1
MMRF_1650	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			HOSPICE	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					666	997	1
MMRF_1672	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.5	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.5	QWK	QWK					1	99	1
MMRF_1672	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	120	1
MMRF_1672	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	120	1
MMRF_1672	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.7	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.7	Q week	Q week					106	120	1
MMRF_1672	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DUE TO THROMBOCYTOPENIA	Other	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		25	Q day	Q day					154	536	1
MMRF_1672	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	10	Q day	Q day					536		1
MMRF_1693	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	166	1
MMRF_1693	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	166	1
MMRF_1693	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					145	166	1
MMRF_1693	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					532		1
MMRF_1693	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab		1			10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown	Checked	10	Q week	Q week					2182		1
MMRF_1780	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	182	1
MMRF_1780	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	259	1
MMRF_1780	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					182	259	1
MMRF_1780	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					259	287	1
MMRF_1780	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	3.26	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		3.26	Q week	Q week					559	615	1
MMRF_1780	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		5	Q day	Q day					287	629	1
MMRF_1780	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		15	Q day	Q day					552	629	1
MMRF_1780	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	41	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		41	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					629	644	1
MMRF_1780	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.42	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		3.42	Q week	Q week					673	680	1
MMRF_1780	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	700	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		700	Q week	Q week					673	687	1
MMRF_1897	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	26	1
MMRF_1897	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					25	61	1
MMRF_1922	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					2078		1
MMRF_1922	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	169	1
MMRF_1922	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	271	1
MMRF_1922	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					341	1323	1
MMRF_1922	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		1			1634	mg	mg	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Induction	Induction	Checked	1634	Other	EVERY OTHER WEEK					1482		1
MMRF_1922	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1482	1791	1
MMRF_1945	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1945	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction	Checked	40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1994	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			LACK OF RESPONSE AND HOSPICE	Other	1.96	mg	mg	QD (D1, D8, D15, D22)	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.96	Other	QD (D1, D8, D15, D22)					1	272	1
MMRF_1994	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			LACK OF RESPONSE AND HOSPICE	Other	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		4	Q week	Q week					1	249	1
MMRF_1994	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					148	207	1
MMRF_2160	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.72	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.72	Q week	Q week					1	11	1
MMRF_2160	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	79	1
MMRF_2160	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Patient decision	Patient decision	5	mg	mg	QD (D1-3)	QD (D1-3)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-3)	QD (D1-3)					60	71	1
MMRF_2478	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.81	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		2.81	QWK	QWK					6	167	1
MMRF_2478	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	167	1
MMRF_2478	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	550	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		550	Q week	Q week					1	601	1
MMRF_2478	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					174	855	1
MMRF_2478	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.81	mg	mg	Q week	Q week	IV	IV	Log Forms	Maintenance	Maintenance		2.81	Q week	Q week					174	319	1
MMRF_2478	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab			Patient decision	Patient decision	1324	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		1324	Q day	Q day					848	848	1
MMRF_2478	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	1	mg	mg	TUESDAYS, THURSDAY, AND SATURDAY DAYS 1 - 21	Other	PO	PO	Log Forms	Induction	Induction		1	Other	TUESDAYS, THURSDAY, AND SATURDAY DAYS 1 - 21					847	910	1
MMRF_2478	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	2	mg	mg	TUESDAYS, THURSDAY, AND SATURDAY DAYS 1 - 21	Other	PO	PO	Log Forms	Induction	Induction		2	Other	TUESDAYS, THURSDAY, AND SATURDAY DAYS 1 - 21					910	938	1
MMRF_2478	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	ELOTUZUMAB	Other		1			10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction	Checked	10	Q week	Q week					1035		1
MMRF_2478	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1035		1
MMRF_2505	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		15	Q week	Q week					2	22	1
MMRF_2505	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	443	1
MMRF_2505	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.6	mg	mg	EVERY 21 DAYS	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	Other	EVERY 21 DAYS					74	808	1
MMRF_2505	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	41	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		41	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					850	865	1
MMRF_2505	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					850	857	1
MMRF_2504	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.17	mg	mg	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.17	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					3	164	1
MMRF_2504	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		4	Q week	Q week					23	185	1
MMRF_2504	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DID NOT TOLERATE DUE TO PRURITUS OF THE SCALP	Other	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		15	Q day	Q day					1	80	1
MMRF_2504	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	516	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		516	Q week	Q week					54	68	1
MMRF_2504	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	525	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		525	QWK	QWK					102	118	1
MMRF_2523	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		2.5	QWK	QWK					1	297	1
MMRF_2523	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		40	Q week	Q week					1	661	1
MMRF_2523	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		5	Q day	Q day					24	641	1
MMRF_2589	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.65	mg	mg	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV	IV	Log Forms	Induction	Induction		2.65	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	131	1
MMRF_2589	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PREPARE FOR BLOODESS TRANSPLANT	Other	4	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		4	Q day	Q day					2	327	1
MMRF_2589	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			PREPARE FOR TRANSPLANT	Other	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					8	327	1
MMRF_2589	First line of therapy	First Line Therapy	HIGH DOSE CHEMOTHERAPY FOR BLOODLESS TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	HIGH DOSE CHEMOTHERAPY FOR BLOODLESS TRANSPLANT		140	Other	ONCE					374	374	1
MMRF_2589	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			PNEUMONIA	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					519	712	1
MMRF_2589	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			PATIENT DECEASED	Other	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					766	911	1
MMRF_1607	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.58	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		2.58	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	203	1
MMRF_1607	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction	Checked	15	QD (D1-14)	QD (D1-14)					1		1
MMRF_1607	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	113	1
MMRF_1607	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.2	mg	mg	DAYS 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	Other	DAYS 1, 8, 15					141	190	1
MMRF_1607	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PREPARING FOR STEM CELL TRANSPLANT	Other	8	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		8	Q week	Q week					113	190	1
MMRF_1605	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAYS 1, 8, 15					1	176	1
MMRF_1605	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	176	1
MMRF_1605	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	DAYS 1-4 AND DAYS 9-11	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1-4 AND DAYS 9-11					1	113	1
MMRF_1605	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					383	453	1
MMRF_1605	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	DAYS 1-14 FOLLOWED BY DAYS 15-27 REST	Other	PO	PO	Log Forms	Maintenance	Maintenance		25	Other	DAYS 1-14 FOLLOWED BY DAYS 15-27 REST					383	525	1
MMRF_1605	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAYS 1, 8, 15 FOLLOWED BY 14 DAYS REST	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	DAYS 1, 8, 15 FOLLOWED BY 14 DAYS REST					114	176	1
MMRF_1605	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib		1			20	mg/m^2	mg/m^2	DAYS 1, 8, 15 FOLLOWED BY 14 DAYS REST	Other	IV	IV	Log Forms	Consolidation	Consolidation	Checked	20	Other	DAYS 1, 8, 15 FOLLOWED BY 14 DAYS REST					523		1
MMRF_1605	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					383	494	1
MMRF_1605	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			25	mg	mg	25 MG PO DAILY X 21 DAY FOLLOWED BY 7 DAYS OFF	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	25	Other	25 MG PO DAILY X 21 DAY FOLLOWED BY 7 DAYS OFF					579		1
MMRF_1605	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		12	Q day	Q day					495	525	1
MMRF_1605	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					579		1
MMRF_1939	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Patient decision	Patient decision	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					1	295	1
MMRF_1939	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	WEEKLY X 3 WEEKS WHEN RECEIVING VELCADE	Other	PO	PO	Log Forms	Induction	Induction		40	Other	WEEKLY X 3 WEEKS WHEN RECEIVING VELCADE					1	295	1
MMRF_1939	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Patient decision	Patient decision	1.3	mg/m^2	mg/m^2	WEEKLY X 3 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	WEEKLY X 3 WEEKS					1	295	1
MMRF_2035	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2035	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction	Checked	40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2493	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					6	16	1
MMRF_2493	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	16	1
MMRF_2493	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	WEEKLY X 3 FOLLOWED BY 1 WEEK REST	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	WEEKLY X 3 FOLLOWED BY 1 WEEK REST					36	258	1
MMRF_2493	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					36		1
MMRF_2493	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib			Lack of response	Lack of response	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		4	Q week	Q week					482	573	1
MMRF_2493	First line of therapy	First Line Therapy	Maintenance	Maintenance	Daratumumab	Daratumumab		1			16	mg/m^2	mg/m^2	Q 4 WEEKS	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	16	Other	Q 4 WEEKS					587		1
MMRF_1470	First line of therapy	First Line Therapy			Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				25	QD (D1-21)	QD (D1-21)					5	59	1
MMRF_1470	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					60	199	1
MMRF_1470	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	27	1
MMRF_1470	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					200	611	1
MMRF_1470	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					185	213	1
MMRF_1470	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					291	607	1
MMRF_1820	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					22	29	1
MMRF_1820	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SQ	Other	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_1820	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D 1,2,4,5,8,9,11,12 Q 21 DAYS	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D 1,2,4,5,8,9,11,12 Q 21 DAYS					1	106	1
MMRF_1820	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					43	57	1
MMRF_1820	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					64	77	1
MMRF_1820	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					85	106	1
MMRF_1820	First line of therapy	First Line Therapy	STEM CELL MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	5160	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	STEM CELL MOBILIZATION		5160	Other	ONCE					138	138	1
MMRF_1820	First line of therapy	First Line Therapy	CONDITIONING REGIMEN FOR TRANSPLANT	Other	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	34.4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	CONDITIONING REGIMEN FOR TRANSPLANT		34.4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					164	179	1
MMRF_2115	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PATIENT DIED OF NON DISEASE RELATED CAUSES	Other	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	21	1
MMRF_2115	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PATIENT DIED OF NON DISEASE RELATED CAUSES	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	21	1
MMRF_2115	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			PATIENT DIED OF NON DISEASE RELATED CAUSES	Other	650	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		650	Q week	Q week					1	21	1
MMRF_2269	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	119	1
MMRF_2269	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	116	1
MMRF_2269	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1,2,4,5,8,9,11,12 Q 21 DAYS	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1,2,4,5,8,9,11,12 Q 21 DAYS					1	117	1
MMRF_2269	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	DAY 1-21 EVERY 28 DAYS	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	DAY 1-21 EVERY 28 DAYS					134	1355	1
MMRF_2026	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PATIENT'S NEUROPATHY- GRADE 2	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	147	1
MMRF_2026	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			PATIENT'S NEUROPATHY	Other	750	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		750	QWK	QWK					1	147	1
MMRF_2026	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	938	1
MMRF_2026	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					155	917	1
MMRF_2026	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Patient decision	Patient decision	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					918	938	1
MMRF_2436	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DOSE CHANGE TO 1.5 MG/M^2	Other	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	27	1
MMRF_2436	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					34	215	1
MMRF_2436	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			DOSE CHANGE FROM 500 TO 550 MG D1, D8, D15 AND D22	Other	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					27	54	1
MMRF_2436	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	215	1
MMRF_2436	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	550	mg	mg	D1, D8, D15, D22	Other	PO	PO	Log Forms	Induction	Induction		550	Other	D1, D8, D15, D22					54	215	1
MMRF_2436	First line of therapy	First Line Therapy	PT VERY FRAIL, TRAVEL DIFFICULTY, NEED TO HAVE HIM ON A REGIMEN THAT HE WOULD HAVE A RESTORED QOL	Other	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	PT VERY FRAIL, TRAVEL DIFFICULTY, NEED TO HAVE HIM ON A REGIMEN THAT HE WOULD HAVE A RESTORED QOL	Checked	5	QD (D1-21)	QD (D1-21)					259		1
MMRF_1486	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	D1, D8, D15, OFF DAY 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1, D8, D15, OFF DAY 22					1	316	1
MMRF_1486	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PATIENT DECEASED	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	437	1
MMRF_1486	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	600	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		600	Q week	Q week					113	316	1
MMRF_1486	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PATIENT DECEASED	Other	1.3	mg/m^2	mg/m^2	Q WEEK (D1, D8, D15, OFF DAY 22)	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	Q WEEK (D1, D8, D15, OFF DAY 22)					317	437	1
MMRF_1486	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			PATIENT DECEASED	Other	600	mg	mg	Q WEEK (D1, D8, D15, OFF DAY 22)	Other	IV	IV	Log Forms	Induction	Induction		600	Other	Q WEEK (D1, D8, D15, OFF DAY 22)					317	437	1
MMRF_1671	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.4	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.4	Q week	Q week					1	394	1
MMRF_1671	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	394	1
MMRF_1671	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	550	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		550	Q week	Q week					1	394	1
MMRF_1671	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		15	Q day	Q day					141	407	1
MMRF_1671	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.3	mg	mg	D1, D8. D15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.3	Other	D1, D8. D15					449	547	1
MMRF_1671	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	530	mg	mg	D1, D8, D15	Other	IV	IV	Log Forms	Induction	Induction		530	Other	D1, D8, D15					449	547	1
MMRF_1671	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					449	547	1
MMRF_1671	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		15	Q day	Q day					449	547	1
MMRF_1671	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					548	903	1
MMRF_1671	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			DOSE OF CARFILZOMIB INCREASED AT BEGINNING OF NEXT CYCLE	Other	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					877	903	1
MMRF_1671	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Consolidation	Consolidation		40	QWK	QWK					877	1227	1
MMRF_1671	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		2	Q day	Q day					904	1227	1
MMRF_1671	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			DOSE OF CARFILZOMIB INCREASED AT BEGINNING OF NEXT CYCLE	Other	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					904	1050	1
MMRF_1671	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			DOSE OF CARFILZOMIB INCREASED AT BEGINNING OF NEXT CYCLE	Other	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1072	1128	1
MMRF_1671	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			DOSE OF CARFILZOMIB INCREASED AT BEGINNING OF NEXT CYCLE	Other	30	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		30	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1051	1071	1
MMRF_1671	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	52	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		52	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1128	1227	1
MMRF_1671	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	300	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV	IV	Log Forms	Consolidation	Consolidation		300	Other	QD (D1, D8, D15)					1156	1227	1
MMRF_1671	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	56	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV	IV	Log Forms	Consolidation	Consolidation		56	Other	QD (D1, D8, D15)					1303	1507	1
MMRF_1671	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	100	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV	IV	Log Forms	Consolidation	Consolidation		100	Other	QD (D1, D8, D15)					1303	1507	1
MMRF_1671	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					1303	1507	1
MMRF_1671	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		2	QD (D1-21)	QD (D1-21)					1303	1507	1
MMRF_1671	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		16	Q week	Q week					1527	1835	1
MMRF_1671	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1527	1835	1
MMRF_1671	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		40	Q week	Q week					1527	1835	1
MMRF_1671	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	DAYS 1-21 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	DAYS 1-21 OF 28 DAY CYCLE					2161	2224	1
MMRF_1671	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					2161	2224	1
MMRF_1671	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	CLINICAL TRIAL	Other	CAR-T	Other	NCT03288493	0	Completed regimen	Completed regimen								Log Forms	Other	CLINICAL TRIAL									1977	1978	1
MMRF_1671	Seventh Line of Therapy (following 6th relapse)	Seventh Line of Therapy (following 6th relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab		0	Disease progression/Relapse	Disease progression/Relapse	700	mg	mg	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		700	QWK	QWK					2161	2224	1
MMRF_1671	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	Bortezomib	Bortezomib		0	Lack of response	Lack of response	2.4	mg	mg	ONCE EVERY 21 DAY CYCLE	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.4	Other	ONCE EVERY 21 DAY CYCLE					2252	2314	1
MMRF_1671	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Lack of response	Lack of response	40	mg	mg	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	QD (D1, D8, D15)					2252	2314	1
MMRF_1671	Eighth Line of Therapy (following 7th relapse)	Eighth Line of Therapy (following 7th relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		0	Lack of response	Lack of response	15	mg	mg	DAYS 1-14 OF 21 DAY CYCLE	Other	PO	PO	Log Forms	Unknown	Unknown		15	Other	DAYS 1-14 OF 21 DAY CYCLE					2266	2314	1
MMRF_1671	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Unknown	Unknown	SELINEXOR	Other		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	80	mg	mg	QD DAY 1 AND DAY 4	Other	PO	PO	Log Forms	Unknown	Unknown		80	Other	QD DAY 1 AND DAY 4					2320	2335	1
MMRF_1671	Ninth Line of Therapy (following 8th relapse)	Ninth Line of Therapy (following 8th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD DAY 1 AND DAY 4	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	QD DAY 1 AND DAY 4					2320	2335	1
MMRF_1671	Tenth Line of Therapy (following 9th relapse)	Tenth Line of Therapy (following 9th relapse)	Unknown	Unknown	Melphalan	Melphalan		1			0.25	mg/kg	mg/kg	DAY 1-4 OF 42 DAY CYCLE	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	0.25	Other	DAY 1-4 OF 42 DAY CYCLE					2351		1
MMRF_1671	Tenth Line of Therapy (following 9th relapse)	Tenth Line of Therapy (following 9th relapse)	Unknown	Unknown	Prednisone	Prednisone		1			60	mg/m^2	mg/m^2	D1-4 OF 42 DAY CYCLE	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	60	Other	D1-4 OF 42 DAY CYCLE					2351		1
MMRF_1720	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	38	1
MMRF_1720	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			GIVEN AS ONE TIME DOSE SINCE PATIENT DID NOT HAVE ORAL AVAILABLE	Other	8	mg	mg	IV ONE TIME ONLY	Other	IV	IV	Log Forms	Induction	Induction		8	Other	IV ONE TIME ONLY					1	1	1
MMRF_1720	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	8	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	38	1
MMRF_1912	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.8	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	127	1
MMRF_1912	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	610	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		610	Q week	Q week					1	127	1
MMRF_1912	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	127	1
MMRF_1912	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	60	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					211	341	1
MMRF_1912	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.7	mg	mg	D1, D8, D15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	Other	D1, D8, D15					128	204	1
MMRF_1912	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					128	204	1
MMRF_1912	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	630	mg	mg	D1, D8, D15	Other	IV	IV	Log Forms	Induction	Induction		630	Other	D1, D8, D15					128	204	1
MMRF_1912	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	640	mg	mg	D1, D8, D15	Other	IV	IV	Log Forms	Consolidation	Consolidation		640	Other	D1, D8, D15					211	341	1
MMRF_1912	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	D1, D8, D15	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	D1, D8, D15					211	341	1
MMRF_1505	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			3.6	mg/dL	mg/dL	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	3.6	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1		1
MMRF_1505	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1204	mg	mg	DAY 8 STARTING CYCLE 2 ONWARDS	Other	IV	IV	Log Forms	Induction	Induction		1204	Other	DAY 8 STARTING CYCLE 2 ONWARDS					36	127	1
MMRF_1505	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	15	1
MMRF_1782	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.4	mg	mg	WEEKLY X3 WEEKS/MONTH	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.4	Other	WEEKLY X3 WEEKS/MONTH					1	113	1
MMRF_1782	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	113	1
MMRF_1782	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	WEEKLY X3 WEEKS/MONTH WITH VELCADE	Other	PO	PO	Log Forms	Induction	Induction		40	Other	WEEKLY X3 WEEKS/MONTH WITH VELCADE					1	113	1
MMRF_1782	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		25	Q week	Q week					574	727	1
MMRF_1782	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					727	835	1
MMRF_1944	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.4	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		1.4	Q week	Q week					4	84	1
MMRF_1944	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		300	Q week	Q week					4	19	1
MMRF_1944	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	49	1
MMRF_1944	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	695	mg	mg	ONE DOSE	Other	IV	IV	Log Forms	Consolidation	Consolidation		695	Other	ONE DOSE					33	40	1
MMRF_1944	First line of therapy	First Line Therapy	DOSE REDUCED	Other	Dexamethasone	Dexamethasone			DEATH	Other	4	mg	mg	TID	TID	PO	PO	Log Forms	Other	DOSE REDUCED		4	TID	TID					67	84	1
MMRF_2203	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.5	Q week	Q week					1		1
MMRF_2203	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					1		1
MMRF_2203	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide		1			500	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	500	QWK	QWK					1		1
MMRF_1533	First line of therapy	First Line Therapy	Induction	Induction	METHYLPREDNISOLONE	Other		1			8	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Induction	Induction	Checked	8	Other	EVERY OTHER DAY					1		1
MMRF_1533	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3.7	mg	mg	Q week	Q week	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		3.7	Q week	Q week					1	398	1
MMRF_1533	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	EVERY 2 WEEKS	Other	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		3	Other	EVERY 2 WEEKS					399	567	1
MMRF_1533	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		1			4	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	4	Q day	Q day					581		1
MMRF_1580	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3.3	mg	mg	QWK	QWK	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		3.3	QWK	QWK					1	70	1
MMRF_1580	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	EVERY 48 HOURS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	EVERY 48 HOURS					1	8	1
MMRF_1580	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			3.3	mg	mg	Q week	Q week	SUBCUTANEOUS	Other	Log Forms	Maintenance	Maintenance	Checked	3.3	Q week	Q week					81		1
MMRF_2113	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					1	116	1
MMRF_2113	First line of therapy	First Line Therapy	Induction	Induction	METHYLPREDNISOLONE	Other		1			40	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Induction	Induction	Checked	40	Other	EVERY OTHER DAY					1		1
MMRF_2113	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			31	mg	mg	Q week	Q week	SUBCUTANEOUS	Other	Log Forms	Induction	Induction	Checked	31	Q week	Q week					123		1
MMRF_1499	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	25	1
MMRF_1499	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	28	mg	mg	D1, D15	Other	PO	PO	Log Forms	Induction	Induction		28	Other	D1, D15					1	363	1
MMRF_1499	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	IT IS TAKEN ON D8, D22 NON-ELOTUZUMAB TREATMENT DAYS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	IT IS TAKEN ON D8, D22 NON-ELOTUZUMAB TREATMENT DAYS					56	363	1
MMRF_1499	First line of therapy	First Line Therapy	Induction	Induction	Elotuzumab	Elotuzumab			Investigator decision for other reasons	Investigator decision for other reasons	10	mg/kg	mg/kg	IT IS TAKEN ON D1, D8, D15, D22	Other	IV	IV	Log Forms	Induction	Induction		10	Other	IT IS TAKEN ON D1, D8, D15, D22					1	507	1
MMRF_1499	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	IT IS TAKEN FROM D1 TO D21	Other	PO	PO	Log Forms	Induction	Induction		25	Other	IT IS TAKEN FROM D1 TO D21					85	624	1
MMRF_1499	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	Q2 DAYS FOR 21 DAYS.	Other	PO	PO	Log Forms	Induction	Induction		15	Other	Q2 DAYS FOR 21 DAYS.					624	1232	1
MMRF_1499	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	12	mg	mg	TAKE IT ON DAY 1 AND DAY 15	Other	PO	PO	Log Forms	Induction	Induction		12	Other	TAKE IT ON DAY 1 AND DAY 15					364	447	1
MMRF_1499	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	TAKE ON DAY 8 AND DAY 22 ON NON-ELOTUZUMAB DAYS.	Other	PO	PO	Log Forms	Induction	Induction		20	Other	TAKE ON DAY 8 AND DAY 22 ON NON-ELOTUZUMAB DAYS.					364	447	1
MMRF_1499	First line of therapy	First Line Therapy	Induction	Induction	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	20	mg/kg	mg/kg	DAILY FOR 1 DAY	Other	IV	IV	Log Forms	Induction	Induction		20	Other	DAILY FOR 1 DAY					516	1232	1
MMRF_1499	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	12	mg	mg	TAKE ON DAY 8, 15 AND 22.	Other	PO	PO	Log Forms	Induction	Induction		12	Other	TAKE ON DAY 8, 15 AND 22.					448	1232	1
MMRF_1499	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	DAY 1 OF EACH CYCLE	Other	IV	IV	Log Forms	Induction	Induction		16	Other	DAY 1 OF EACH CYCLE					1254	1308	1
MMRF_1499	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	DAILY FOR 21 DAYS EVERY CYCLE.	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAILY FOR 21 DAYS EVERY CYCLE.					1254	1308	1
MMRF_1499	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q1 WEEK FOR 4 WEEKS IN EACH CYCLE	Other	PO	PO	Log Forms	Induction	Induction		40	Other	Q1 WEEK FOR 4 WEEKS IN EACH CYCLE					1254	1308	1
MMRF_1499	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			DOSE CHANGE	Other	300	mg/m^2	mg/m^2	Q1 WEEK FOR 3 WEEKS.	Other	PO	PO	Log Forms	Induction	Induction		300	Other	Q1 WEEK FOR 3 WEEKS.					1309	1309	1
MMRF_1499	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib		1			1.5	mg/m^2	mg/m^2	1 DAY PER WEEK, EVERY 3 WEEKS ( ONE CYCLE)	Other	IV	IV	Log Forms	Induction	Induction	Checked	1.5	Other	1 DAY PER WEEK, EVERY 3 WEEKS ( ONE CYCLE)					1309		1
MMRF_1499	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q 1 WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	Q 1 WEEK FOR 4 WEEKS					1309	1336	1
MMRF_1499	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide		1			263.15	mg/m^2	mg/m^2	Q1 WEEK FOR 3 WEEKS	Other	PO	PO	Log Forms	Induction	Induction	Checked	263.15	Other	Q1 WEEK FOR 3 WEEKS					1393		1
MMRF_1499	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	Q 1 WEEK FOR 3 WEEKS	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	Q 1 WEEK FOR 3 WEEKS					1337		1
MMRF_1512	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	425	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		425	Q week	Q week					1	84	1
MMRF_1512	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Induction	Induction		1.5	QWK	QWK					1	84	1
MMRF_1512	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	22	1
MMRF_1512	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.2	mg	mg	THIS IS 4TH CYCLE, IT IS GIVEN ON D1, D8, D15, D22	Other	IV	IV	Log Forms	Induction	Induction		2.2	Other	THIS IS 4TH CYCLE, IT IS GIVEN ON D1, D8, D15, D22					85	158	1
MMRF_1512	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3680	mg	mg	AT 2500MG/M^2 FOR 1 DAY	Other	IV	IV	Log Forms	Induction	Induction		3680	Other	AT 2500MG/M^2 FOR 1 DAY					119	119	1
MMRF_1512	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	THIS IS 4TH CYCLE, IT IS TAKEN ONCE A WEEK FOR FOUR WEEKS.	Other	PO	PO	Log Forms	Induction	Induction		12	Other	THIS IS 4TH CYCLE, IT IS TAKEN ONCE A WEEK FOR FOUR WEEKS.					119	125	1
MMRF_1512	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	DAILY FOR 21 DAYS	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	DAILY FOR 21 DAYS					344	943	1
MMRF_1512	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	ON DAY 1 AND 7 FOR 1 WEEK.	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	ON DAY 1 AND 7 FOR 1 WEEK.					155	162	1
MMRF_1512	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	425	mg	mg	Q1 WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Maintenance	Maintenance		425	Other	Q1 WEEK FOR 4 WEEKS					1541	1988	1
MMRF_1512	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Patient decision	Patient decision	2.2	mg	mg	Q day	Q day	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.2	Q day	Q day					1546	1777	1
MMRF_1512	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	Q1 WEEK FOR 4 WEEKS EACH CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	Q1 WEEK FOR 4 WEEKS EACH CYCLE					1541		1
MMRF_1512	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	2.2	mg	mg	Q2WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.2	Other	Q2WEEKS					1874	1988	1
MMRF_1512	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			720	mg	mg	Q day	Q day	IV	IV	Log Forms	Maintenance	Maintenance	Checked	720	Q day	Q day					1989		1
MMRF_1512	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					1989		1
MMRF_1577	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide		1	Adverse Event or co-morbidity	Adverse Event or co-morbidity	200	mg	mg	DAYS 1,8 AND 15	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	200	Other	DAYS 1,8 AND 15					1998		1
MMRF_1577	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	300	mg	mg	DAYS 1,8 AND 15	Other	PO	PO	Log Forms	Maintenance	Maintenance		300	Other	DAYS 1,8 AND 15					1969	1998	1
MMRF_1577	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	3	mg	mg	TWICE A WEEK FOR 14 DAYS	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3	Other	TWICE A WEEK FOR 14 DAYS					1	128	1
MMRF_1577	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	700	mg	mg	ONCE A WEEK FOR 3 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		700	Other	ONCE A WEEK FOR 3 WEEKS					1	149	1
MMRF_1577	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	ONCE A WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	ONCE A WEEK FOR 4 WEEKS					1	233	1
MMRF_1577	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	DAILY FOR 14 DAYS	Other	PO	PO	Log Forms	Induction	Induction		25	Other	DAILY FOR 14 DAYS					86	233	1
MMRF_1577	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4640	mg	mg	DAILY FOR 1 DAY	Other	IV	IV	Log Forms	Induction	Induction		4640	Other	DAILY FOR 1 DAY					172	172	1
MMRF_1577	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	ONCE A WEEK FOR 14 DAYS	Other	IV	IV	Log Forms	Induction	Induction		1.5	Other	ONCE A WEEK FOR 14 DAYS					128	152	1
MMRF_1577	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	DAILY FOR 21 DAYS	Other	PO	PO	Log Forms	Consolidation	Consolidation		15	Other	DAILY FOR 21 DAYS					340	382	1
MMRF_1577	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	DAILY FOR 21 DAYS	Other	IV	IV	Log Forms	Consolidation	Consolidation		1.5	Other	DAILY FOR 21 DAYS					340	382	1
MMRF_1577	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q 1 WEEK FOR 3 WEEKS	Other	PO	PO	Log Forms	Consolidation	Consolidation		20	Other	Q 1 WEEK FOR 3 WEEKS					340	539	1
MMRF_1577	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	DAILY FOR 21 DAYS	Other	PO	PO	Log Forms	Maintenance	Maintenance		15	Other	DAILY FOR 21 DAYS					396	1061	1
MMRF_1577	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	16	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		16	Q day	Q day					535	562	1
MMRF_1577	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	8	mg	mg	Q 1 WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Maintenance	Maintenance		8	Other	Q 1 WEEK FOR 4 WEEKS					563	589	1
MMRF_1577	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	Q1 WEEK FOR 4 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	Q1 WEEK FOR 4 WEEKS					1081	1494	1
MMRF_1577	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	SELINEXOR (KPT-330)	Other			Investigator decision for other reasons	Investigator decision for other reasons	100	mg	mg	Q 1 WEEK FOR 5 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		100	Other	Q 1 WEEK FOR 5 WEEKS					1081	1227	1
MMRF_1577	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			POOR TOLERANCE	Other	40	mg	mg	Q 1 WEEK FOR 5 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	Q 1 WEEK FOR 5 WEEKS					1081	1473	1
MMRF_1577	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	SELINEXOR (KPT-330)	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	80	mg	mg	Q 1 WEEK FOR 5 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		80	Other	Q 1 WEEK FOR 5 WEEKS					1228	1332	1
MMRF_1577	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	SELINEXOR (KPT-330)	Other			Patient decision	Patient decision	60	mg	mg	Q 1 WEEK FOR 5 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		60	Other	Q 1 WEEK FOR 5 WEEKS					1333	1473	1
MMRF_1577	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q day	Q day	IV	IV	Log Forms	Induction	Induction	Checked	16	Q day	Q day					1572		1
MMRF_1577	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	4	QD (D1-21)	QD (D1-21)					1572		1
MMRF_1577	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	400	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Induction	Induction		400	Other	DAYS 1, 8, 15					1572	1998	1
MMRF_1577	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	20	Q day	Q day					1572		1
MMRF_1589	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	600	mg	mg	(AT 263.2MG/M2) TWICE A DAY  FOR 14 DAYS	Other	PO	PO	Log Forms	Induction	Induction		600	Other	(AT 263.2MG/M2) TWICE A DAY  FOR 14 DAYS					1	128	1
MMRF_1589	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.4	mg	mg	(AT 1.5MG/M2) DAILY FOR 1DAY FOR 14 DAYS	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3.4	Other	(AT 1.5MG/M2) DAILY FOR 1DAY FOR 14 DAYS					1	128	1
MMRF_1589	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	FOR 1 DAY	Other	PO	PO	Log Forms	Induction	Induction		40	Other	FOR 1 DAY					1	134	1
MMRF_1589	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2500	mg/m^2	mg/m^2	DAILY FOR 1 DAY	Other	IV	IV	Log Forms	Consolidation	Consolidation		2500	Other	DAILY FOR 1 DAY					162	162	1
MMRF_1589	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2500	mg/m^2	mg/m^2	DAILY FOR 1 DAY	Other	IV	IV	Log Forms	Consolidation	Consolidation		2500	Other	DAILY FOR 1 DAY					167	196	1
MMRF_1589	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	DAILY FOR 21 DAYS	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	DAILY FOR 21 DAYS					273	480	1
MMRF_1589	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	DAILY FOR 1 DAY	Other	PO	PO	Log Forms	Induction	Induction		12	Other	DAILY FOR 1 DAY					162	196	1
MMRF_1589	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	DAILY FOR 21 DAYS.	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	DAILY FOR 21 DAYS.					610	1211	1
MMRF_1715	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	525	mg	mg	Q 1 WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		525	Other	Q 1 WEEK FOR 4 WEEKS					1	126	1
MMRF_1715	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.3	mg	mg	DAILY FOR 1 DAY	Other	IV	IV	Log Forms	Induction	Induction		2.3	Other	DAILY FOR 1 DAY					64	64	1
MMRF_1715	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	12 MG PRIOR TO CHEMO,4MG FOR FOUR DOSES STARTING ON DAY 1 OF EACH CYCLE.	Other	PO	PO	Log Forms	Induction	Induction		40	Other	12 MG PRIOR TO CHEMO,4MG FOR FOUR DOSES STARTING ON DAY 1 OF EACH CYCLE.					1	126	1
MMRF_1715	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	DAILY FOR 1 DAY WEEKLY	Other	IV	IV	Log Forms	Induction	Induction		2.6	Other	DAILY FOR 1 DAY WEEKLY					15	43	1
MMRF_1715	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	DAILY FOR 1 DAY EVERY TWO WEEKS	Other	IV	IV	Log Forms	Induction	Induction		2.6	Other	DAILY FOR 1 DAY EVERY TWO WEEKS					50	63	1
MMRF_1867	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	Q 1 WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		300	Other	Q 1 WEEK FOR 4 WEEKS					1	91	1
MMRF_1867	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	ONCE A WEEK FOR THREE WEEKS	Other	IV	IV	Log Forms	Induction	Induction		1.5	Other	ONCE A WEEK FOR THREE WEEKS					1	71	1
MMRF_1867	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q 1 WEEK FOR FOUR WEEKS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	Q 1 WEEK FOR FOUR WEEKS					1	91	1
MMRF_1867	First line of therapy	First Line Therapy	PART OF BONE MARROW TRANSPLANT PROCEDURE.	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2500	mg/m^2	mg/m^2	FOR 1 DAY.	Other	IV	IV	Log Forms	Other	PART OF BONE MARROW TRANSPLANT PROCEDURE.		2500	Other	FOR 1 DAY.					92	92	1
MMRF_1867	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	DAILY FOR 21 DAYS.	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Other	DAILY FOR 21 DAYS.					233		1
MMRF_1867	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	DAILY FOR 1 DAY	Other	PO	PO	Log Forms	Induction	Induction		12	Other	DAILY FOR 1 DAY					92	93	1
MMRF_1867	First line of therapy	First Line Therapy	BOTEZOMIB PRE-TREATMENT FOR AUTOLOGOUS BONE MARROW TRANSPLANT	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	FOR 1 DAY	Other	IV	IV	Log Forms	Other	BOTEZOMIB PRE-TREATMENT FOR AUTOLOGOUS BONE MARROW TRANSPLANT		1.3	Other	FOR 1 DAY					121	124	1
MMRF_1873	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg	mg	ONCE A WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		300	Other	ONCE A WEEK FOR 4 WEEKS					1	127	1
MMRF_1873	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	ON DAYS 1, 8, AND 16.	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	ON DAYS 1, 8, AND 16.					1	127	1
MMRF_1873	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	ONCE A WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		20	Other	ONCE A WEEK FOR 4 WEEKS					1	127	1
MMRF_1910	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	ONCE A WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	ONCE A WEEK FOR 4 WEEKS					52	220	1
MMRF_1910	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.5	mg/m^2	mg/m^2	DAILY FOR 1 DAY	Other	IV	IV	Log Forms	Induction	Induction		1.5	Other	DAILY FOR 1 DAY					95	193	1
MMRF_1910	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	DAILY FOR 21 DAYS	Other	PO	PO	Log Forms	Induction	Induction		25	Other	DAILY FOR 21 DAYS					123	415	1
MMRF_1910	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2500	mg/m^2	mg/m^2	DAILY FOR 1 DAY	Other	IV	IV	Log Forms	Induction	Induction		2500	Other	DAILY FOR 1 DAY					220	220	1
MMRF_1910	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.5	mg/m^2	mg/m^2	Q 1 WEEK FOR 3 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		1.5	Other	Q 1 WEEK FOR 3 WEEKS					333	415	1
MMRF_1910	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	ONCE A WEEK	Other	PO	PO	Log Forms	Induction	Induction		40	Other	ONCE A WEEK					333	415	1
MMRF_1910	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.5	mg/m^2	mg/m^2	Q 1 WEEK FOR 3 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		1.5	Other	Q 1 WEEK FOR 3 WEEKS					417	487	1
MMRF_1910	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	DAILY FOR 21 DAYS.	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAILY FOR 21 DAYS.					417	487	1
MMRF_1910	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	KPT-330	Other			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	DAILY ON MONDAY AND WEDNESDAY FOR 7 DAYS.	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAILY ON MONDAY AND WEDNESDAY FOR 7 DAYS.					491	507	1
MMRF_1910	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	KPT-330	Other			Disease progression/Relapse	Disease progression/Relapse	60	mg	mg	DAILY ON TU AND THUR FOR 7 DAYS.	Other	PO	PO	Log Forms	Induction	Induction		60	Other	DAILY ON TU AND THUR FOR 7 DAYS.					512	533	1
MMRF_1910	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	20MG DAILY ON TU TH FOR 7 DAYS, 8MG EVERY 8 HOURS FOR 4 WEEKS.	Other	PO	PO	Log Forms	Induction	Induction		40	Other	20MG DAILY ON TU TH FOR 7 DAYS, 8MG EVERY 8 HOURS FOR 4 WEEKS.					512	514	1
MMRF_1910	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QID	QID	PO	PO	Log Forms	Induction	Induction		5	QID	QID					526	535	1
MMRF_1910	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	DAILY	Other	PO	PO	Log Forms	Induction	Induction		5	Other	DAILY					1	62	1
MMRF_1910	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	ORAL Q 1 WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		300	Other	ORAL Q 1 WEEK FOR 4 WEEKS					52	93	1
MMRF_1910	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	ONCE A WEEK FOR 4 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	ONCE A WEEK FOR 4 WEEKS					52	94	1
MMRF_1927	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	ONCE A WEEK	Other	IV	IV	Log Forms	Induction	Induction		1.5	Other	ONCE A WEEK					1	274	1
MMRF_1927	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	ONCE A WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		300	Other	ONCE A WEEK FOR 4 WEEKS					1	204	1
MMRF_1927	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	8	mg	mg	DAILY FOR 12 DAYS	Other	PO	PO	Log Forms	Induction	Induction		8	Other	DAILY FOR 12 DAYS					3	148	1
MMRF_1927	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	5200	mg	mg	ONCE FOR ONE DAY	Other	IV	IV	Log Forms	Induction	Induction		5200	Other	ONCE FOR ONE DAY					175	175	1
MMRF_1927	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q 1 WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	Q 1 WEEK FOR 4 WEEKS					175	204	1
MMRF_1927	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	DAILY FOR 21 DAYS.	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	DAILY FOR 21 DAYS.					389	472	1
MMRF_1927	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	DAILY FOR 21 DAYS.	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	DAILY FOR 21 DAYS.					473	788	1
MMRF_1927	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q1 WEEK FOR 4 WEEKS IN EACH CYCLE.	Other	IV	IV	Log Forms	Induction	Induction		16	Other	Q1 WEEK FOR 4 WEEKS IN EACH CYCLE.					1072	1121	1
MMRF_1927	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	DAILY FOR 14 DAYS.	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAILY FOR 14 DAYS.					1128	1260	1
MMRF_1927	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			DOSE CHANGE	Other	40	mg	mg	Q 1 WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	Q 1 WEEK FOR 4 WEEKS					1072	1525	1
MMRF_1927	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.9	mg	mg	DAILY M,F FOR 2 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.9	Other	DAILY M,F FOR 2 WEEKS					1128	1238	1
MMRF_1927	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			DOSE CHANGE	Other	40	mg	mg	DAILY FOR 2 DAYS	Other	IV	IV	Log Forms	Consolidation	Consolidation		40	Other	DAILY FOR 2 DAYS					1260	1261	1
MMRF_1927	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			DOSE CHANGE	Other	113	mg	mg	DAILY FOR 2 DAYS	Other	IV	IV	Log Forms	Consolidation	Consolidation		113	Other	DAILY FOR 2 DAYS					1271	1279	1
MMRF_1927	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib		1			27	mg/m^2	mg/m^2	DAILY FOR 2 DAYS	Other	IV	IV	Log Forms	Consolidation	Consolidation	Checked	27	Other	DAILY FOR 2 DAYS					1292		1
MMRF_1927	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-7)	QD (D1-7)	PO	PO	Log Forms	Induction	Induction	Checked	20	QD (D1-7)	QD (D1-7)					1525		1
MMRF_2265	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	276.2	mg/m^2	mg/m^2	Q 1 WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		276.2	Other	Q 1 WEEK FOR 4 WEEKS					1	124	1
MMRF_2265	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	DAILY FOR 1 DAY	Other	IV	IV	Log Forms	Induction	Induction		1.5	Other	DAILY FOR 1 DAY					1	124	1
MMRF_2265	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1TO 4, AND 17 TO 20.	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1TO 4, AND 17 TO 20.					1	124	1
MMRF_2265	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2500	mg/m^2	mg/m^2	FOR 1 DAY	Other	IV	IV	Log Forms	Consolidation	Consolidation		2500	Other	FOR 1 DAY					126	127	1
MMRF_2265	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	FOR 1 DAY	Other	PO	PO	Log Forms	Consolidation	Consolidation		12	Other	FOR 1 DAY					126	127	1
MMRF_2265	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	FOR 1 DAY	Other	IV	IV	Log Forms	Consolidation	Consolidation		1	Other	FOR 1 DAY					153	153	1
MMRF_2265	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	FOR DAY 1 AND DAY 3.	Other	IV	IV	Log Forms	Consolidation	Consolidation		1	Other	FOR DAY 1 AND DAY 3.					155	158	1
MMRF_2265	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			STARTING MAINTENANCE	Other	10	mg	mg	DAILY FOR 21 DAYS.	Other	PO	PO	Log Forms	Consolidation	Consolidation		10	Other	DAILY FOR 21 DAYS.					260	315	1
MMRF_2265	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	ONCE A WEEK FOR 4 WEEKS.	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	ONCE A WEEK FOR 4 WEEKS.					260	316	1
MMRF_2265	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	DAYS 1-21	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	DAYS 1-21					316	1548	1
MMRF_2563	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Induction	Induction		1.5	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	98	1
MMRF_2563	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q 1 WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	Q 1 WEEK FOR 4 WEEKS					1	299	1
MMRF_2563	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	Q1 WEEK FOR 4 WEEKS	Other	PO	PO	Log Forms	Induction	Induction		300	Other	Q1 WEEK FOR 4 WEEKS					1	113	1
MMRF_2563	First line of therapy	First Line Therapy	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2500	mg/m^2	mg/m^2	FOR 1 DAY.	Other	IV	IV	Log Forms	Consolidation	Consolidation		2500	Other	FOR 1 DAY.					134	135	1
MMRF_2563	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	10 MG PER DAY FOR 21 DAYS, THEN 7 DAYS OFF.	Other	PO	PO	Log Forms	Consolidation	Consolidation		10	Other	10 MG PER DAY FOR 21 DAYS, THEN 7 DAYS OFF.					238	293	1
MMRF_2563	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	FOR 1 DAY.	Other	IV	IV	Log Forms	Consolidation	Consolidation		1.3	Other	FOR 1 DAY.					167	171	1
MMRF_2563	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q1 WEEK FOR 4 WEEKS	Other	IV	IV	Log Forms	Consolidation	Consolidation		1.5	Other	Q1 WEEK FOR 4 WEEKS					240	300	1
MMRF_2563	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	DAILY FOR 21 DAYS.	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	DAILY FOR 21 DAYS.					342	707	1
MMRF_2563	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.5	mg/m^2	mg/m^2	Q 2 WEEKS FOR 2 DOSES.	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.5	Other	Q 2 WEEKS FOR 2 DOSES.					342	650	1
MMRF_2563	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	Q 2 WEEKS FOR 4 DOSES.	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	Q 2 WEEKS FOR 4 DOSES.					651		1
MMRF_2563	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	DAILY FOR 21 TRO 42 DAYS	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Other	DAILY FOR 21 TRO 42 DAYS					775		1
MMRF_1597	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	600	mg	mg	D1, 8, 15	Other	PO	PO	Log Forms	Induction	Induction		600	Other	D1, 8, 15					2	16	1
MMRF_1597	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			MAINTENANCE THERAPY STARTED	Other	40	mg	mg	DAY 1, 8, 15	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15					2	16	1
MMRF_1597	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3	mg	mg	DAY 1, D7, D14	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		3	Other	DAY 1, D7, D14					27	100	1
MMRF_1597	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	12	1
MMRF_1597	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	ONE DOSE	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	ONE DOSE					27	27	1
MMRF_1597	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	SINGLE DOSE	Other	PO	PO	Log Forms	Induction	Induction		40	Other	SINGLE DOSE					1	1	1
MMRF_1597	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	5100	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		5100	Q day	Q day					117	117	1
MMRF_1597	First line of therapy	First Line Therapy	Induction	Induction	BUSULPHAN	Other			Completed regimen	Completed regimen	225	mg	mg	DAY -5, -4, -3	Other	IV	IV	Log Forms	Induction	Induction		225	Other	DAY -5, -4, -3					147	149	1
MMRF_1597	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	280	mg	mg	SINGLE DOSE	Other	IV	IV	Log Forms	Induction	Induction		280	Other	SINGLE DOSE					150	150	1
MMRF_1597	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					251	501	1
MMRF_1597	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					502		1
MMRF_1610	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.4	mg	mg	DAY 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3.4	Other	DAY 1, 8, 15					1	15	1
MMRF_1610	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	700	mg	mg	DAY 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		700	Other	DAY 1, 8, 15, 22					1	22	1
MMRF_1610	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAY 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15, 22					1	22	1
MMRF_1610	First line of therapy	First Line Therapy	Induction	Induction	BUSULPHAN	Other			Completed regimen	Completed regimen	274.6	mg	mg	DAY -5, -4, -3	Other	IV	IV	Log Forms	Induction	Induction		274.6	Other	DAY -5, -4, -3					150	152	1
MMRF_1610	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	330.4	mg	mg	SINGLE DOSE	Other	IV	IV	Log Forms	Induction	Induction		330.4	Other	SINGLE DOSE					153	153	1
MMRF_1610	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					260		1
MMRF_1610	First line of therapy	First Line Therapy	ASCT CONDITIONING	Other	BUSULFAN	Other		0	Completed regimen	Completed regimen	274.6	mg	mg	QD (D1-3)	QD (D1-3)	IV	IV	Log Forms	Other	ASCT CONDITIONING		274.6	QD (D1-3)	QD (D1-3)					150	152	1
MMRF_1610	First line of therapy	First Line Therapy	ASCT CONDITIONING	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	330.4	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	ASCT CONDITIONING		330.4	Q day	Q day					153	153	1
MMRF_1614	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_1614	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			EXCELLANT RESPONSE SO DISCONTINUED	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	394	1
MMRF_1638	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DOSE TITRATED	Other	3.2	mg	mg	D1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3.2	Other	D1, 8, 15					1	15	1
MMRF_1638	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	D1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		500	Other	D1, 8, 15, 22					1	128	1
MMRF_1638	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1, 8, 15, 22					1	128	1
MMRF_1638	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.3	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3.3	QWK	QWK					29	135	1
MMRF_1638	First line of therapy	First Line Therapy	TRANSPLANT INDUCTION	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	440	MCG	Other	SINGLE DOSE	Other	IV	IV	Log Forms	Other	TRANSPLANT INDUCTION		440	Other	SINGLE DOSE					184	184	1
MMRF_1638	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					319	683	1
MMRF_1638	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					683	767	1
MMRF_1638	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					683	767	1
MMRF_1655	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Daratumumab	Daratumumab		1			922	mg	mg	QWK	QWK	IV	IV	Log Forms			Checked	922	QWK	QWK					1858	1908	1
MMRF_1655	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms			Checked	40	Q week	Q week					2002		1
MMRF_1655	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Cyclophosphamide	Cyclophosphamide		1			300	mg	mg	Q week	Q week	PO	PO	Log Forms			Checked	300	Q week	Q week					2171		1
MMRF_1655	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Daratumumab	Daratumumab		0			922	mg	mg	DAY1 DAY15	Other	IV	IV	Log Forms				922	Other	DAY1 DAY15					1915	2016	1
MMRF_1655	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	ONCE EVERY 4 WEEKS	Other	IV	IV	Log Forms			Checked	16	Other	ONCE EVERY 4 WEEKS					2030		1
MMRF_1655	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.5	Q week	Q week					1	162	1
MMRF_1655	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			TITRATED	Other	300	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	77	1
MMRF_1655	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	162	1
MMRF_1655	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		500	QWK	QWK					84	162	1
MMRF_1655	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	350	MCG	Other	ONE DOSE	Other	IV	IV	Log Forms	Induction	Induction		350	Other	ONE DOSE					225	225	1
MMRF_1655	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					318	1851	1
MMRF_1655	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms			Checked	25	QD (D1-21)	QD (D1-21)					1853		1
MMRF_1856	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.1	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3.1	Q week	Q week					1	138	1
MMRF_1856	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	138	1
MMRF_1856	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	138	1
MMRF_1856	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					253	335	1
MMRF_1856	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					253	335	1
MMRF_1856	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					340	735	1
MMRF_1856	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					736	2007	1
MMRF_1856	First line of therapy	First Line Therapy	ASCT CONDITIONING	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	400	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	ASCT CONDITIONING		400	Q day	Q day					187	187	1
MMRF_2170	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DOSE ADJUSTED FOR WEIGHT LOSS	Other	2.2	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	Q week	Q week					2	10	1
MMRF_2170	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	D1, 8, 15	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1, 8, 15					1	14	1
MMRF_2170	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			DRUG SENSITIVITY	Other	441	mg	mg	D1,8,15, 22	Other	PO	PO	Log Forms	Induction	Induction		441	Other	D1,8,15, 22					1	65	1
MMRF_2170	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.9	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.9	Q week	Q week					15	71	1
MMRF_2170	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	DAY 1, 8,15 & 22	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY 1, 8,15 & 22					15	429	1
MMRF_2170	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					72	107	1
MMRF_2170	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					86	429	1
MMRF_2170	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide		1			400	mg	mg	D1,D8,D15	Other	PO	PO	Log Forms	Induction	Induction	Checked	400	Other	D1,D8,D15					1291		1
MMRF_2170	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	D1,D2D8,D9,D15,D16,D22,D23	Other	PO	PO	Log Forms	Induction	Induction	Checked	20	Other	D1,D2D8,D9,D15,D16,D22,D23					1291		1
MMRF_2170	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		1			1008	mg	mg	C1-2 (D1,8,15,22) C3-6 (D1,15) C6+ (D1)	Other	IV	IV	Log Forms	Induction	Induction	Checked	1008	Other	C1-2 (D1,8,15,22) C3-6 (D1,15) C6+ (D1)					1291		1
MMRF_2279	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.8	mg	mg	D1, 8, 15, 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	2.8	Other	D1, 8, 15, 22					1		1
MMRF_2279	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	550	mg	mg	D1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		550	Other	D1, 8, 15, 22					1	101	1
MMRF_2279	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	D1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction	Checked	40	Other	D1, 8, 15, 22					1		1
MMRF_2279	First line of therapy	First Line Therapy	ASCT CONDITIONING	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	330	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	ASCT CONDITIONING		330	Q day	Q day					148	148	1
MMRF_2279	First line of therapy	First Line Therapy	ASCT CONDITIONING	Other	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	2.1	mg	mg	D1, D4	Other	IV	IV	Log Forms	Other	ASCT CONDITIONING		2.1	Other	D1, D4					151	154	1
MMRF_2279	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					260	1913	1
MMRF_2288	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.9	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.9	Q week	Q week					1	333	1
MMRF_2288	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	22	1
MMRF_2288	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	333	1
MMRF_2288	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	300	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					32	332	1
MMRF_2288	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	QD (D1-14)	QD (D1-14)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.5	QD (D1-14)	QD (D1-14)					416	466	1
MMRF_1676	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			STEM CELL MOBILIZATON AND COLLECTION	Other	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	112	1
MMRF_1676	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			STEM CELL MOBILIZATON AND COLLECTION	Other	550	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		550	Q week	Q week					1	112	1
MMRF_1676	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			STEM CELL MOBILIZATON AND COLLECTION	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	112	1
MMRF_1676	First line of therapy	First Line Therapy	STEM CELL MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4700	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL MOBILIZATION		4700	Q day	Q day					123	123	1
MMRF_1676	First line of therapy	First Line Therapy	ASCT CONDITIONING	Other	BUSULFAN	Other			Completed regimen	Completed regimen	3.2	mg/kg	mg/kg	Q day	Q day	IV	IV	Log Forms	Other	ASCT CONDITIONING		3.2	Q day	Q day					176	178	1
MMRF_1676	First line of therapy	First Line Therapy	ASCT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	ASCT CONDITIONING		140	Q day	Q day					179	179	1
MMRF_1676	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					140	175	1
MMRF_1676	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					140	175	1
MMRF_1676	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	550	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		550	Q week	Q week					140	175	1
MMRF_1676	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					271	326	1
MMRF_1676	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE INCREASE	Other	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					327	354	1
MMRF_1676	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					355	1426	1
MMRF_1676	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons		ALTERNATE BETWEEN 5 AND 10MG DAILY	Other	ALTERNATE BETWEEN 5 AND 10MG DAILY	Other	PO	PO	Log Forms	Maintenance	Maintenance			Other	ALTERNATE BETWEEN 5 AND 10MG DAILY					1426	1650	1
MMRF_1676	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					1650		1
MMRF_1725	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			STEM CELL MOBILIZATION AND COLLECTION	Other	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	112	1
MMRF_1725	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			STEM CELL MOBILIZATION AND COLLECTION	Other	575	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		575	Q week	Q week					1	112	1
MMRF_1725	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	56	1
MMRF_1725	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			STEM CELL MOBILIZATION AND COLLECTION	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					57	112	1
MMRF_1725	First line of therapy	First Line Therapy	STEM CELL MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4750	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL MOBILIZATION		4750	Q day	Q day					119	119	1
MMRF_1725	First line of therapy	First Line Therapy	ASCT CONDITIONING	Other	BUSULFAN	Other			Completed regimen	Completed regimen	3.2	mg/kg	mg/kg	Q day	Q day	IV	IV	Log Forms	Other	ASCT CONDITIONING		3.2	Q day	Q day					192	194	1
MMRF_1725	First line of therapy	First Line Therapy	ASCT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	ASCT CONDITIONING		140	Q day	Q day					195	195	1
MMRF_1725	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					148	196	1
MMRF_1725	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	575	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		575	Q week	Q week					148	196	1
MMRF_1725	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					148	196	1
MMRF_1725	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					271	452	1
MMRF_1725	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					513	627	1
MMRF_1725	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					638	932	1
MMRF_1725	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			ANTIBIOTICS PROPHYLAXIS DUE TO ROOT CANAL	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					452	504	1
MMRF_1725	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE REDUCE	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					932	1107	1
MMRF_1725	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1107	1380	1
MMRF_1725	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					1380	1828	1
MMRF_1725	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	COLONOSCOPY	Other	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					1836	1871	1
MMRF_1725	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					1880		1
MMRF_1725	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)							1
MMRF_1771	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	48	1
MMRF_1771	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	550	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		550	Q week	Q week					1	48	1
MMRF_1771	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	48	1
MMRF_1771	First line of therapy	First Line Therapy	STEM CELL MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4550	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL MOBILIZATION		4550	Q day	Q day					118	118	1
MMRF_1771	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	550	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		550	Q week	Q week					189	201	1
MMRF_1771	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					189	201	1
MMRF_1771	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			STEM CELL MOBILIZATION AND COLLECTION	Other	1.5	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					56	111	1
MMRF_1771	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			STEM CELL MOBILIZATION AND COLLECTION	Other	550	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		550	Q week	Q week					56	111	1
MMRF_1771	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			STEM CELL MOBILIZATION AND COLLECTION	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					56	111	1
MMRF_1771	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					133	160	1
MMRF_1771	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	550	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		550	Q week	Q week					133	160	1
MMRF_1771	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					133	160	1
MMRF_1771	First line of therapy	First Line Therapy	STEM CELL TRANSPLANT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		200	Q day	Q day					203	203	1
MMRF_1771	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					310	346	1
MMRF_1771	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE INCREASE	Other	5	mg	mg	MONDAY, WEDNESDAY AND FRIDAY (3 DAYS PER WEEK)	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	MONDAY, WEDNESDAY AND FRIDAY (3 DAYS PER WEEK)					364	426	1
MMRF_1771	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TREATMENT OF CEREBROSPINAL FLUID INVOLVEMENT	Other	CYTARABINE	Other			LOST TO FOLLOW-UP	Other	40	mg	mg	TWICE WEEKLY	Other	INTRATHECAL	Other	Log Forms	Other	TREATMENT OF CEREBROSPINAL FLUID INVOLVEMENT		40	Other	TWICE WEEKLY					491	507	1
MMRF_1771	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TREATMENT OF CEREBROSPINAL FLUID INVOLVEMENT	Other	METHOTREXATE	Other			LOST TO FOLLOW-UP	Other	12	mg	mg	TWICE WEEKLY	Other	INTRATHECAL	Other	Log Forms	Other	TREATMENT OF CEREBROSPINAL FLUID INVOLVEMENT		12	Other	TWICE WEEKLY					491	507	1
MMRF_1771	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TREATMENT OF CEREBROSPINAL FLUID INVOLVEMENT	Other	HYDROCORTISONE	Other			LOST TO FOLLOW-UP	Other	15	mg	mg	TWICE WEEKLY	Other	INTRATHECAL	Other	Log Forms	Other	TREATMENT OF CEREBROSPINAL FLUID INVOLVEMENT		15	Other	TWICE WEEKLY					491	507	1
MMRF_1771	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			ELEVATED LIVER FUNCTION TESTS. TREAT HELD DUE TO SUSPECTED VIRAL HEPATITIS	Other	5	mg	mg	MONDAY TO FRIDAY (5 DAYS PER WEEK)	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	MONDAY TO FRIDAY (5 DAYS PER WEEK)					427	455	1
MMRF_1777	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	97	1
MMRF_1777	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	525	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		525	Q week	Q week					1	405	1
MMRF_1777	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	29	1
MMRF_1777	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					30	92	1
MMRF_1777	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					112	405	1
MMRF_1777	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					163	405	1
MMRF_1777	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		0	Investigator decision for other reasons	Investigator decision for other reasons	2.5	mg/m^2	mg/m^2	ONCE EVERY 2 WEEKS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.5	Other	ONCE EVERY 2 WEEKS					441	2241	1
MMRF_1777	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			2.5	mg/m^2	mg/m^2	Q MONTH	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	2.5	Other	Q MONTH					2241		1
MMRF_1785	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		1			3	mg	mg	QD (D1, D8, AND D22 OF 28 DAY CYCLE)	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	3	Other	QD (D1, D8, AND D22 OF 28 DAY CYCLE)					1618		1
MMRF_1785	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RELAPSE	Other	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen		UNKNOWN	Other	UNKNOWN	Other	IV	IV	Log Forms	Other	RELAPSE			Other	UNKNOWN					796	1352	1
MMRF_1785	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21 OF 28)	Other	PO	PO	Log Forms	Induction	Induction		15	Other	QD (D1-21 OF 28)					796	1010	1
MMRF_1785	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					796	884	1
MMRF_1785	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					884	888	1
MMRF_1785	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	8	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		8	Q week	Q week					888	940	1
MMRF_1785	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					49	217	1
MMRF_1785	First line of therapy	First Line Therapy	STEM CELL MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4550	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL MOBILIZATION		4550	Q day	Q day					223	223	1
MMRF_1785	First line of therapy	First Line Therapy	STEM CELL TRANSPLANT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		200	Q day	Q day					258	258	1
MMRF_1785	First line of therapy	First Line Therapy	STEM CELL TRANSPLANT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		200	Q day	Q day					417	417	1
MMRF_1785	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	DAY 1 TO 21 OF A 28 DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	DAY 1 TO 21 OF A 28 DAY CYCLE					461	553	1
MMRF_1785	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			RECURRING COUGH	Other	10	mg	mg	DAY 1 TO 21 OF A 28 DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	DAY 1 TO 21 OF A 28 DAY CYCLE					639	687	1
MMRF_1785	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	11	1
MMRF_1785	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	550	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		550	Q week	Q week					1	11	1
MMRF_1785	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	11	1
MMRF_1785	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					49	217	1
MMRF_1785	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	550	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		550	Q week	Q week					49	217	1
MMRF_1785	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1010	1248	1
MMRF_1785	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RELAPSE	Other	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	RELAPSE		5	QD (D1-21)	QD (D1-21)					1248	1366	1
MMRF_1785	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	WEEKLY (3 WEEK ON 1 WEEK OFF)	Other	PO	PO	Log Forms	Maintenance	Maintenance		4	Other	WEEKLY (3 WEEK ON 1 WEEK OFF)					1366	1618	1
MMRF_1792	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			STEM CELL MOBILIZATION AND COLLECTION	Other	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	113	1
MMRF_1792	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			STEM CELL MOBILIZATION AND COLLECTION	Other	550	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		550	Q week	Q week					1	113	1
MMRF_1792	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	57	1
MMRF_1792	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			STEM CELL MOBILIZATION AND COLLECTION	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					58	113	1
MMRF_1792	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Q week	Q week					163	197	1
MMRF_1792	First line of therapy	First Line Therapy	STEM CELL MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4600	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL MOBILIZATION		4600	Q day	Q day					118	118	1
MMRF_1792	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					149	162	1
MMRF_1792	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	550	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		550	Q week	Q week					149	197	1
MMRF_1792	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					149	197	1
MMRF_1792	First line of therapy	First Line Therapy	STEM CELL TRANSPLANT CONDITIONING	Other	BUSULFAN	Other			Completed regimen	Completed regimen	3.2	mg/kg	mg/kg	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		3.2	Q day	Q day					203	205	1
MMRF_1792	First line of therapy	First Line Therapy	STEM CELL TRANSPLANT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		140	Q day	Q day					206	206	1
MMRF_1792	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					301	482	1
MMRF_1792	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					484	1131	1
MMRF_1792	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Patient decision	Patient decision	2.91	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.91	Q week	Q week					1154	1181	1
MMRF_1792	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.91	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.91	Q week	Q week					1189	1229	1
MMRF_1792	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.91	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.91	Q week	Q week					1252	1279	1
MMRF_1792	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1154	1228	1
MMRF_1792	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					1154	1228	1
MMRF_1792	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	4 DAYS ON 4 DAYS OFF	Other	PO	PO	Log Forms	Induction	Induction		40	Other	4 DAYS ON 4 DAYS OFF					1143	1153	1
MMRF_1792	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.91	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.91	Q week	Q week					1229	1244	1
MMRF_1792	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1229	1274	1
MMRF_1792	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	Other	PO	PO	Log Forms	Induction	Induction		4	Other	QD (D1-21)					1229	1274	1
MMRF_1792	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	RELAPSE	Other	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	QWEEK (WEEK 1 TO 8), Q2WEEK (WEEK 9 TO 24), Q4WEEK (WEEK 25+)	Other	IV	IV	Log Forms	Other	RELAPSE		16	Other	QWEEK (WEEK 1 TO 8), Q2WEEK (WEEK 9 TO 24), Q4WEEK (WEEK 25+)					1276	1465	1
MMRF_1792	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	RELAPSE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	RELAPSE		40	QWK	QWK					1276	1437	1
MMRF_1792	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	RELAPSE	Other	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	RELAPSE		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1309	1465	1
MMRF_1792	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	RELAPSE	Other	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	RELAPSE		4	QD (D1-21)	QD (D1-21)					1406	1465	1
MMRF_1792	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	RELAPSE	Other	Carfilzomib	Carfilzomib			LOWER DOSE FOR FIRST AND 2ND INFUSION OF CARFILZOMIB	Other	20	mg/m^2	mg/m^2	DAY 1 AND 2 OF FIRST CYCLE	Other	IV	IV	Log Forms	Other	RELAPSE		20	Other	DAY 1 AND 2 OF FIRST CYCLE					1302	1303	1
MMRF_1792	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	RELAPSE	Other	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	708	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	RELAPSE		708	QD (D1-4)	QD (D1-4)					1497	1500	1
MMRF_1792	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	RELAPSE	Other	Doxorubicin	Doxorubicin			Disease progression/Relapse	Disease progression/Relapse	17.7	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	RELAPSE		17.7	QD (D1-4)	QD (D1-4)					1497	1500	1
MMRF_1792	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	RELAPSE	Other	CISPLATIN	Other			Disease progression/Relapse	Disease progression/Relapse	17.7	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	RELAPSE		17.7	QD (D1-4)	QD (D1-4)					1497	1500	1
MMRF_1792	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	RELAPSE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	RELAPSE		40	QD (D1-4)	QD (D1-4)					1497	1500	1
MMRF_1792	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	RELAPSE	Other	ETOPOSIDE	Other			Disease progression/Relapse	Disease progression/Relapse	70.8	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Other	RELAPSE		70.8	QD (D1-4)	QD (D1-4)					1497	1500	1
MMRF_1792	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	RELAPSE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	DAY 1,2,3,4,8,15, AND 22	Other	PO	PO	Log Forms	Other	RELAPSE		40	Other	DAY 1,2,3,4,8,15, AND 22					1437	1465	1
MMRF_1805	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			STEM CELL MOBILIZATION AND COLLECTION	Other	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	168	1
MMRF_1805	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			STEM CELL MOBILIZATION AND COLLECTION	Other	525	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		525	Q week	Q week					1	175	1
MMRF_1805	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			STEM CELL MOBILIZATION AND COLLECTION	Other	1.5	mg/m^2	mg/m^2	QD (D1, D8, D15, D22) OF 35 DAY CYCLE	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Other	QD (D1, D8, D15, D22) OF 35 DAY CYCLE					190	259	1
MMRF_1805	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			DOSE INCREASE	Other	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					190	224	1
MMRF_1805	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			STEM CELL MOBILIZATION AND COLLECTION	Other	550	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		550	Q week	Q week					225	259	1
MMRF_1805	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			AUTOLOGOUS STEM CELL TRANSPLANT	Other	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					281	313	1
MMRF_1805	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			AUTOLOGOUS STEM CELL TRANSPLANT	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					281	313	1
MMRF_1805	First line of therapy	First Line Therapy	CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANT		200	Q day	Q day					314	314	1
MMRF_1805	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					415	467	1
MMRF_1805	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	EVERY OTHER DAY					467	498	1
MMRF_1805	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	EVERY OTHER DAY					532	589	1
MMRF_1805	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	3 TIMES PER WEEK	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	3 TIMES PER WEEK					701	889	1
MMRF_1805	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	EVERY OTHER DAY					889	973	1
MMRF_1805	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					973	1631	1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Ixazomib	Ixazomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1, D8, AND D15 OF 28)	Other	PO	PO	Log Forms				4	Other	QD (D1, D8, AND D15 OF 28)					1941	2053	1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Cyclophosphamide	Cyclophosphamide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	550	mg	mg	Q week	Q week	PO	PO	Log Forms				550	Q week	Q week					1948	2419	1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1948	2419	1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1716	1850	1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Ixazomib	Ixazomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1, D8, AND D15 OF 28)	Other	PO	PO	Log Forms				4	Other	QD (D1, D8, AND D15 OF 28)					1716	1850	1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Cyclophosphamide	Cyclophosphamide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	550	mg	mg	Q week	Q week	PO	PO	Log Forms				550	Q week	Q week					1716	1850	1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Ixazomib	Ixazomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1, D8, D15 OF 28)	Other	PO	PO	Log Forms				4	Other	QD (D1, D8, D15 OF 28)					1694	1716	1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Cyclophosphamide	Cyclophosphamide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	550	mg	mg	Q week	Q week	PO	PO	Log Forms				550	Q week	Q week					1694	1716	1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1694	1716	1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Ixazomib	Ixazomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1, D8, D15 OF 28D CYCLE)	Other	PO	PO	Log Forms				4	Other	QD (D1, D8, D15 OF 28D CYCLE)					2060	2086	1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Cyclophosphamide	Cyclophosphamide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	550	mg	mg	Q week	Q week	PO	PO	Log Forms				550	Q week	Q week					2060	2086	1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					2060	2086	1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Ixazomib	Ixazomib		1			4	mg	mg	QD (D1, D8, D15 OF 28D CYCLE)	Other	PO	PO	Log Forms			Checked	4	Other	QD (D1, D8, D15 OF 28D CYCLE)					2130		1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Cyclophosphamide	Cyclophosphamide		1			550	mg	mg	Q week	Q week	PO	PO	Log Forms			Checked	550	Q week	Q week					2130		1
MMRF_1805	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms			Checked	40	Q week	Q week					2130		1
MMRF_1846	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					2044	2247	1
MMRF_1846	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			STEM CELL MOBILIZATION AND COLLECTION	Other	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	116	1
MMRF_1846	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	600	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		600	Q week	Q week					1	28	1
MMRF_1846	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			STEM CELL MOBILIZATION AND COLLECTION	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	116	1
MMRF_1846	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			STEM CELL MOBILIZATION AND COLLECTION	Other	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					28	116	1
MMRF_1846	First line of therapy	First Line Therapy	STEM CELL MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4950	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL MOBILIZATION		4950	Q day	Q day					119	119	1
MMRF_1846	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					145	186	1
MMRF_1846	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					145	186	1
MMRF_1846	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					145	168	1
MMRF_1846	First line of therapy	First Line Therapy	ASCT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	ASCT CONDITIONING		200	Q day	Q day					190	190	1
MMRF_1846	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					317	561	1
MMRF_1846	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					575	833	1
MMRF_1846	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	EVERY OTHER DAY					834	885	1
MMRF_1846	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					885	1093	1
MMRF_1846	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					1097	2010	1
MMRF_1846	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RELAPSE	Other	Ixazomib	Ixazomib		1			4	mg	mg	QD (D1, D8, AND D15)	Other	PO	PO	Log Forms	Other	RELAPSE	Checked	4	Other	QD (D1, D8, AND D15)					2263		1
MMRF_1846	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RELAPSE	Other	Cyclophosphamide	Cyclophosphamide		1			600	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	RELAPSE	Checked	600	Q week	Q week					2263		1
MMRF_1846	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RELAPSE	Other	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	RELAPSE	Checked	40	Q week	Q week					2263		1
MMRF_1845	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	56	1
MMRF_1845	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	475	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		475	Q week	Q week					1	56	1
MMRF_1845	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	56	1
MMRF_1845	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					171	198	1
MMRF_1845	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					145	198	1
MMRF_1845	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					145	170	1
MMRF_1845	First line of therapy	First Line Therapy	STEM CELL TRANSPLANT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		200	Q day	Q day					200	200	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1147	1278	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD 1-21 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		25	Other	QD 1-21 OF 28 DAY CYCLE					1147	1278	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1147	1166	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1167	1278	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	STEM CELL TRANSPLANT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		200	Q day	Q day					1297	1297	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	39-42	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation			QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1399	1490	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide		1			25	mg	mg	DAYS 1 TO 21 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Consolidation	Consolidation	Checked	25	Other	DAYS 1 TO 21 OF 28 DAY CYCLE					1399		1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation	Checked	20	Q week	Q week					1399		1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-2, D15-16)	Other	IV	IV	Log Forms	Maintenance	Maintenance		40	Other	QD (D1-2, D15-16)					1513	1541	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21 OF 28)	Other	PO	PO	Log Forms	Maintenance	Maintenance		25	Other	QD (D1-21 OF 28)					1513	1542	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1513	1554	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	39-43	mg	mg	QD (D1-2, D15-16)	Other	IV	IV	Log Forms	Maintenance	Maintenance			Other	QD (D1-2, D15-16)					1541	1554	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	42-43	mg	mg	QD (D1-2, D15-16)	Other	IV	IV	Log Forms	Maintenance	Maintenance			Other	QD (D1-2, D15-16)					1613	1744	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-21 OF 28)	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (D1-21 OF 28)					1613	1653	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1613	1884	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	43	mg	mg	QD (D1-2, 15-16)	Other	IV	IV	Log Forms	Maintenance	Maintenance		43	Other	QD (D1-2, 15-16)					1762	1884	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	20	mg	mg	QD (D1-21 OF 28)	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (D1-21 OF 28)					1653	1884	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					1884	1945	1
MMRF_1845	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	Q day	Q day					1959		1
MMRF_1928	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Daratumumab	Daratumumab		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg/kg	mg/kg	Q MONTH	Other	IV	IV	Log Forms				16	Other	Q MONTH					1330	1944	1
MMRF_1928	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q week	Q week	PO	PO	Log Forms				10	Q week	Q week					1386	1944	1
MMRF_1928	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Daratumumab	Daratumumab		0	Investigator decision for other reasons	Investigator decision for other reasons	16	mg/kg	mg/kg	Q MONTH	Other	IV	IV	Log Forms				16	Other	Q MONTH					1974	2113	1
MMRF_1928	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms			Checked	4	QD (D1-21)	QD (D1-21)					1974		1
MMRF_1928	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	119	1
MMRF_1928	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					1	119	1
MMRF_1928	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	119	1
MMRF_1928	First line of therapy	First Line Therapy	STEM CELL MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	5150	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL MOBILIZATION		5150	Q day	Q day					123	123	1
MMRF_1928	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			ADMITTED FOR ASCT	Other	600	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		600	Q week	Q week					138	169	1
MMRF_1928	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			ADMITTED FOR ASCT	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					138	169	1
MMRF_1928	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			ADMITTED FOR ASCT	Other	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					148	169	1
MMRF_1928	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					170	170	1
MMRF_1928	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					276	1140	1
MMRF_1928	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms				4	QD (D1-21)	QD (D1-21)					1162	1944	1
MMRF_1928	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1162	1300	1
MMRF_1928	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)			Daratumumab	Daratumumab		0	Completed regimen	Completed regimen	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms				16	Q week	Q week					1162	1330	1
MMRF_1928	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RELAPSE	Other	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	RELAPSE		20	Q week	Q week					1301	1386	1
MMRF_1960	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D8, D15, D22) OF 35 DAY CYCLE	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1, D8, D15, D22) OF 35 DAY CYCLE					1	315	1
MMRF_1960	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Investigator decision for other reasons	Investigator decision for other reasons	14	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					1	35	1
MMRF_1960	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	95	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		95	QD (D1-4)	QD (D1-4)					1	315	1
MMRF_1960	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	10	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					36	315	1
MMRF_1960	First line of therapy	First Line Therapy	SUSPECTED AMYLOID INVOLVEMENT	Other	Lenalidomide	Lenalidomide			PALLIATIVE	Other	5	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Other	SUSPECTED AMYLOID INVOLVEMENT		5	Other	EVERY OTHER DAY					525	565	1
MMRF_1960	First line of therapy	First Line Therapy	SUSPECTED AMYLOID INVOLVEMENT	Other	Dexamethasone	Dexamethasone			PALLIATIVE	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	SUSPECTED AMYLOID INVOLVEMENT		20	Q week	Q week					525	565	1
MMRF_2174	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		20	Q day	Q day					1	4	1
MMRF_2174	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	1, 8, 15, 22 OF A 35 DAY CYCLE	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	1, 8, 15, 22 OF A 35 DAY CYCLE					6	250	1
MMRF_2174	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			CONCERNS ON NONCOMPLIANCE AND LACK OF RESPONSE	Other	4	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-4)	QD (D1-4)					6	145	1
MMRF_2174	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			CONCERNS ON NONCOMPLIANCE AND LACK OF RESPONSE	Other	120	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		120	QD (D1-4)	QD (D1-4)					6	145	1
MMRF_2174	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	400	mg	mg	1, 8, 15, 22 OF 35 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		400	Other	1, 8, 15, 22 OF 35 DAY CYCLE					146	250	1
MMRF_2174	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	1, 8, 15, 22 OF A 35 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	1, 8, 15, 22 OF A 35 DAY CYCLE					146	201	1
MMRF_2174	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	1, 8, 15, 22 OF A 35 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		10	Other	1, 8, 15, 22 OF A 35 DAY CYCLE					202	250	1
MMRF_2251	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					8	99	1
MMRF_2251	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			DOSE INCREASE	Other	400	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		400	Q week	Q week					8	21	1
MMRF_2251	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-4, D9-12, D17-20)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D9-12, D17-20)					8	99	1
MMRF_2251	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	500	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		500	Q week	Q week					22	99	1
MMRF_2251	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		40	Q day	Q day					1	4	1
MMRF_2428	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			START CLINICAL TRIAL	Other	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					15	28	1
MMRF_2428	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			START CLINICAL TRIAL	Other	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	28	1
MMRF_2428	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	147	1
MMRF_2428	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16). FIRST CYCLE ONLY 20MG/M^2 FOR D1-2.	Other	IV	IV	Log Forms	Induction	Induction		36	Other	QD (D1-2, D8-9, D15-16). FIRST CYCLE ONLY 20MG/M^2 FOR D1-2.					29	147	1
MMRF_2428	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	DAYS 1 TO 21 OF A 28 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		25	Other	DAYS 1 TO 21 OF A 28 DAY CYCLE					29	147	1
MMRF_2428	First line of therapy	First Line Therapy	ASCT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	ASCT CONDITIONING		200	Q day	Q day					261	261	1
MMRF_2428	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	DAY 1,2,8,9,15 AND 16 OF A 28 DAY CYCLE	Other	IV	IV	Log Forms	Induction	Induction		36	Other	DAY 1,2,8,9,15 AND 16 OF A 28 DAY CYCLE					197	224	1
MMRF_2428	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	DAYS 1 TO 21 OF A 28 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		25	Other	DAYS 1 TO 21 OF A 28 DAY CYCLE					197	224	1
MMRF_2428	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					197	224	1
MMRF_2428	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	4 DAYS ON THEN 4 DAYS OFF	Other	PO	PO	Log Forms	Induction	Induction		40	Other	4 DAYS ON THEN 4 DAYS OFF					176	191	1
MMRF_2428	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	8	1
MMRF_2428	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16) OF A 28 DAY CYCLE	Other	IV	IV	Log Forms	Consolidation	Consolidation		36	Other	QD (D1-2, D8-9, D15-16) OF A 28 DAY CYCLE					351	357	1
MMRF_2428	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			DOSE INCREASE	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					351	378	1
MMRF_2428	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					351	385	1
MMRF_2428	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16) OF A 28 DAY CYCLE	Other	IV	IV	Log Forms	Consolidation	Consolidation		36	Other	QD (D1-2, D8-9, D15-16) OF A 28 DAY CYCLE					365	385	1
MMRF_2428	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					407	434	1
MMRF_2428	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	QD (D1-2, D15-16)	Other	IV	IV	Log Forms	Maintenance	Maintenance		36	Other	QD (D1-2, D15-16)					435	715	1
MMRF_2428	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		20	Q week	Q week					407	434	1
MMRF_2428	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					435	715	1
MMRF_2428	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					407	434	1
MMRF_2428	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					435	715	1
MMRF_2428	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					379	385	1
MMRF_2428	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					715	1135	1
MMRF_2428	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	DOSE INCREASE	Other	10	mg	mg	EVERY OTHER DAY, 21 DAYS OF 28	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	EVERY OTHER DAY, 21 DAYS OF 28					1268		1
MMRF_2428	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21 OF 28)	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	QD (D1-21 OF 28)						1730	1
MMRF_1555	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	Q D1 & D8 Q21DAYS	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	Q D1 & D8 Q21DAYS					1	79	1
MMRF_1555	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					1	47	1
MMRF_1555	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	D1 AND D8	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1 AND D8					1	79	1
MMRF_1555	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					47	79	1
MMRF_1555	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					130	230	1
MMRF_1555	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					130	230	1
MMRF_1555	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					130	230	1
MMRF_1555	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD D1-21	Other	PO	PO	Log Forms	Induction	Induction		2	Other	QD D1-21					248	340	1
MMRF_1555	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	20	mg/m^2	mg/m^2	TWICE WEEKLY	Other	IV	IV	Log Forms	Induction	Induction		20	Other	TWICE WEEKLY					248	340	1
MMRF_1555	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	TWICE WEEKLY BEFORE CARFILZOMIB	Other	IV	IV	Log Forms	Induction	Induction		4	Other	TWICE WEEKLY BEFORE CARFILZOMIB					248	340	1
MMRF_1564	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	193	1
MMRF_1564	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	72	1
MMRF_1564	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		12	Q week	Q week					72	137	1
MMRF_1564	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	THREE TIMES A WEEK	Other	PO	PO	Log Forms	Induction	Induction		4	Other	THREE TIMES A WEEK					137	193	1
MMRF_1564	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	0900 EVERY OTHER DAY, DAYS 1-21 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Induction	Induction		4	Other	0900 EVERY OTHER DAY, DAYS 1-21 OF 28 DAY CYCLE					193	216	1
MMRF_1564	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	2	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		2	Q week	Q week					216	528	1
MMRF_1564	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	1	mg	mg	TAKE 1 MG FOR 2 DAYS THEN 1 DAY OFF, REPEAT CYCLE	Other	PO	PO	Log Forms	Induction	Induction		1	Other	TAKE 1 MG FOR 2 DAYS THEN 1 DAY OFF, REPEAT CYCLE					528	603	1
MMRF_1564	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	.5	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		0.5	Q day	Q day					603	884	1
MMRF_1564	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					193	1215	1
MMRF_1564	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	1	mg	mg	QD EVERY SATURDAY AND SUNDAY	Other	PO	PO	Log Forms	Induction	Induction		1	Other	QD EVERY SATURDAY AND SUNDAY					884	1215	1
MMRF_1564	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Lack of response	Lack of response	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		5	QD (D1-21)	QD (D1-21)					1215	1290	1
MMRF_1564	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Lack of response	Lack of response	2.75	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		2.75	Q week	Q week					1215	1290	1
MMRF_1564	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Lack of response	Lack of response	8	mg	mg	8MG PRIOR TO BORTEZOMIB  INFUSION AND 1MG Q DAY FOR ADRENAL SUPPORT	Other	PO	PO	Log Forms	Unknown	Unknown		8	Other	8MG PRIOR TO BORTEZOMIB  INFUSION AND 1MG Q DAY FOR ADRENAL SUPPORT					1215	1290	1
MMRF_1564	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1640	mg	mg	WEEKLY INFUSIONS FOR 8 WEEKS, THEN EVERY TWO WEEKS FOR 16 WEEKS, FOLLOWED B	Other	IV	IV	Log Forms	Induction	Induction		1640	Other	WEEKLY INFUSIONS FOR 8 WEEKS, THEN EVERY TWO WEEKS FOR 16 WEEKS, FOLLOWED B					1304	1355	1
MMRF_1564	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	8	mg	mg	PRIOR TO DARA INFUSION AND 4MG X2 DAYS FOLLOWING EACH DARATUMUMAB INFUSION	Other	IV ON DARA DOSING DAYS PO X2 DAYS FOLLOWING	Other	Log Forms	Induction	Induction		8	Other	PRIOR TO DARA INFUSION AND 4MG X2 DAYS FOLLOWING EACH DARATUMUMAB INFUSION					1304	1355	1
MMRF_1564	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Completed regimen	Completed regimen	1640	mg	mg	EVERY 2 WEEKS	Other	IV	IV	Log Forms	Unknown	Unknown		1640	Other	EVERY 2 WEEKS					1397	1493	1
MMRF_1564	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	2	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Unknown	Unknown		2	Other	EVERY OTHER DAY					1397	1493	1
MMRF_1569	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	1202	1
MMRF_1569	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	429	1
MMRF_1569	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		8	Q week	Q week					616	1104	1
MMRF_1569	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	DAYS 1,8,15	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAYS 1,8,15					1222	1361	1
MMRF_1569	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1,8,15	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1,8,15					1222	1361	1
MMRF_1569	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1222	1361	1
MMRF_1569	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	DURVALUMAB	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1500	mg	mg	ONCE EVERY 4 WEEKS	Other	IV	IV	Log Forms	Unknown	Unknown		1500	Other	ONCE EVERY 4 WEEKS					1407	1557	1
MMRF_1569	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	DAYS 1-21 OF CYCLE	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	DAYS 1-21 OF CYCLE					1407	1557	1
MMRF_1569	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	DAYS 1, 8, 15, 22 OF CYCLE	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	DAYS 1, 8, 15, 22 OF CYCLE					1407	1557	1
MMRF_1569	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Q week	Q week					1556		1
MMRF_1569	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.5	Q week	Q week					1556	1674	1
MMRF_1569	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1556		1
MMRF_1574	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	32	1
MMRF_1574	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TRANSPLANT	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	221	1
MMRF_1574	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			TRANSPLANT	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					32	221	1
MMRF_1574	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	455	mg	mg	ONCE	Other	IV	IV	Log Forms	Induction	Induction		455	Other	ONCE					246	246	1
MMRF_1574	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					569	723	1
MMRF_1574	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Induction	Induction		10	Other	EVERY OTHER DAY					569	1577	1
MMRF_1593	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	TWICE A WEEK	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	TWICE A WEEK					1	73	1
MMRF_1593	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	TWICE A WEEK, PRIOR TO VELCADE DOSE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	TWICE A WEEK, PRIOR TO VELCADE DOSE					1	73	1
MMRF_1593	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			DOSE CHANGE	Other	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IVB	IVB	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					105	133	1
MMRF_1593	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			TRANSPLANT	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					105	189	1
MMRF_1593	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			TRANSPLANT	Other	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IVB	IVB	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					133	189	1
MMRF_1593	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			TRANSPLANT	Other	8	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IVB	IVB	Log Forms	Induction	Induction		8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					133	217	1
MMRF_1593	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					216	216	1
MMRF_1593	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE CHANGE	Other	10	mg	mg	2 WEEKS ON, 1 WEEK OFF	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	2 WEEKS ON, 1 WEEK OFF					343	492	1
MMRF_1593	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE CHANGE SECONDARY TO DIARRHEA AT DAILY DOSING LEVEL S/P 28 DAYS	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					312	343	1
MMRF_1593	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE CHANGE	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					492	606	1
MMRF_1593	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					606		1
MMRF_1618	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide		1			50	mg	mg	DAYS 1,8, AND 15	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	50	Other	DAYS 1,8, AND 15					2252		1
MMRF_1618	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	DAYS 1, 8, AND 15	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	20	Other	DAYS 1, 8, AND 15					2252		1
MMRF_1618	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TRANSPLANT	Other	AUTO-HSCT	Other		0	Completed regimen	Completed regimen				ONCE	Other	TRANSPLATNT	Other	Log Forms	Other	TRANSPLANT			Other	ONCE					1681	1681	1
MMRF_1618	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Disease progression/Relapse	Disease progression/Relapse						IV	IV	Log Forms	Maintenance	Maintenance									1753	2198	1
MMRF_1618	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1753	2198	1
MMRF_1618	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse						PO	PO	Log Forms	Maintenance	Maintenance									1753	2564	1
MMRF_1618	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	CB-839HCL	Other		0	INSURANCE	Other	600	mg	mg	BID	BID	PO	PO	Log Forms	Maintenance	Maintenance		600	BID	BID					2226	2252	1
MMRF_1618	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	INSURANCE	Other	56	mg/m^2	mg/m^2	DAYS 1, 8, AND 15	Other	IV	IV	Log Forms	Maintenance	Maintenance		56	Other	DAYS 1, 8, AND 15					2226	2252	1
MMRF_1618	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	INSURANCE	Other	40	mg	mg	DAYS 1, 8, 15, AND 22	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	DAYS 1, 8, 15, AND 22					2226	2252	1
MMRF_1618	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		1			70	mg/m^2	mg/m^2	DAYS 1, 8, AND 15	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	70	Other	DAYS 1, 8, AND 15					2252		1
MMRF_1618	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TRANSPLANT	Other	2.44	mg	mg	TWICE A WEEK, MONDAYS AND THURSDAYS	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.44	Other	TWICE A WEEK, MONDAYS AND THURSDAYS					1	86	1
MMRF_1618	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			TRANSPLANT	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	86	1
MMRF_1618	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TRANSPLANT	Other	4	mg	mg	TWICE WEEKLY, MONDAYS AND THURSDAYS	Other	PO	PO	Log Forms	Induction	Induction		4	Other	TWICE WEEKLY, MONDAYS AND THURSDAYS					1	86	1
MMRF_1618	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DECREASE OF DOSE DUE TO NEUTROPENIA (NOT DEEMED GRADE 3)	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					338	1479	1
MMRF_1618	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1479	1630	1
MMRF_1618	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab			Completed regimen	Completed regimen	16	mg/kg	mg/kg	EVERY 2 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		16	Other	EVERY 2 WEEKS					1479	1630	1
MMRF_1618	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		40	Q week	Q week					1479	1630	1
MMRF_1618	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TRANSPLANT	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	325	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	TRANSPLANT		325	Other	ONCE					1679	1679	1
MMRF_1717	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			TRANSPLANT	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	104	1
MMRF_1717	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TRANSPLANT	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	104	1
MMRF_1717	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					160	162	1
MMRF_1717	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	REVLIMID RESTARTED 25-MAR-2015 TIW X 1 WEEK, THEN QOD X 1 WEEK, THEN DAILY.	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	REVLIMID RESTARTED 25-MAR-2015 TIW X 1 WEEK, THEN QOD X 1 WEEK, THEN DAILY.					334	391	1
MMRF_1717	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DOSE MODIFICATION	Other	5	mg	mg	TIW X 1 WEEK, THEN QOD X 1 WEEK, THEN DAILY	Other	PO	PO	Log Forms	Induction	Induction		5	Other	TIW X 1 WEEK, THEN QOD X 1 WEEK, THEN DAILY					419	454	1
MMRF_1717	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		5	Q day	Q day					454	1464	1
MMRF_1717	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	DEATH	Other	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		2	QD (D1-21)	QD (D1-21)					1499	2086	1
MMRF_1717	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	DEATH	Other	20	mg	mg	DAYS 1, 8, AND 15 OF 28 DAY CYCLES	Other	PO OR IV DEPENDING ON CHEMO DAYS	Other	Log Forms	Induction	Induction		20	Other	DAYS 1, 8, AND 15 OF 28 DAY CYCLES					1499	2086	1
MMRF_1717	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib		0	DEATH	Other	20	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		20	Q week	Q week					1499	2086	1
MMRF_1726	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	119	1
MMRF_1726	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					99	176	1
MMRF_1726	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					176	564	1
MMRF_1726	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					135	564	1
MMRF_1726	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Other	DAYS 1, 8, 15					566	635	1
MMRF_1726	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					564	635	1
MMRF_1726	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					564	635	1
MMRF_1726	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	DAYS 1,8,15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Other	DAYS 1,8,15					664	678	1
MMRF_1726	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					664	678	1
MMRF_1726	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg/dL	mg/dL	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					664	693	1
MMRF_1726	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.75	mg	mg	Q week	Q week	SUBQ	Other	Log Forms	Induction	Induction		2.75	Q week	Q week					1	99	1
MMRF_1763								0										Log Forms													1
MMRF_1763								0										Log Forms													1
MMRF_1763								0										Log Forms													1
MMRF_1763	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.32	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV	IV	Log Forms	Unknown	Unknown		1.32	Other	DAYS 1, 8, 15					769	937	1
MMRF_1763	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					769	937	1
MMRF_1763	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					769	937	1
MMRF_1763	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			ALLOGENIC SCT 1/17/2017	Other	25	mg	mg	DAYS 1-21	Other	PO	PO	Log Forms	Unknown	Unknown		25	Other	DAYS 1-21					939	1072	1
MMRF_1763	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			ALLOGENIC SCT 1/17/2017	Other	12	mg	mg	WEEKLY	Other	PO	PO	Log Forms	Unknown	Unknown		12	Other	WEEKLY					939	1072	1
MMRF_1763	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib			DOSE INCREASE DUE TO A STUDY PROTOCOL	Other	3	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Maintenance	Maintenance		3	Other	DAYS 1, 8, 15					1192	1275	1
MMRF_1763	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib			Investigator decision for other reasons	Investigator decision for other reasons	7	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Maintenance	Maintenance		7	Other	DAYS 1, 8, 15					1276	1400	1
MMRF_1763	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		1			2.3	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	2.3	Other	DAYS 1, 8, 15					1405		1
MMRF_1763	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Prednisone	Prednisone		1			20	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q day	Q day					1496		1
MMRF_1763	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			TRANSPLANT	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1	133	1
MMRF_1763	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			HIGH COPAY	Other	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		25	Q day	Q day					2	38	1
MMRF_1763	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			DOSE CHANGE	Other	21	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		21	Q day	Q day					1	2	1
MMRF_1763	First line of therapy	First Line Therapy	Unknown	Unknown	Bortezomib	Bortezomib			TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					54	106	1
MMRF_1763	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					131	131	1
MMRF_1763	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	Q 2WKS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	Q 2WKS					194	764	1
MMRF_1847	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	DAY 1,4,8&11	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY 1,4,8&11					1	44	1
MMRF_1847	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	DAYS 1,4,8 &11	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAYS 1,4,8 &11					1	44	1
MMRF_1847	First line of therapy	First Line Therapy	IN ADDITTION	Other	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	IN ADDITTION		15	QD (D1-21)	QD (D1-21)					20	44	1
MMRF_1847	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	DAY 1,8	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1,8					44	128	1
MMRF_1847	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TRANSPLANT	Other	20	mg	mg	DAY 1,8	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY 1,8					44	128	1
MMRF_1847	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			TRANSPLANT	Other	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					44	128	1
MMRF_1847	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			FOR PT. CONVENIENCE	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					380	672	1
MMRF_1847	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			FOR PT. CONVENIENCE	Other	1.3	mg/m^2	mg/m^2	QD D1 AND D15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD D1 AND D15					380	672	1
MMRF_1847	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	QD D1 AND D15	Other	PO	PO	Log Forms	Induction	Induction		12	Other	QD D1 AND D15					380	455	1
MMRF_1847	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			FOR PT. CONVENIENCE	Other	8	mg	mg	TAKE ON DAYS 1 AND 15	Other	PO	PO	Log Forms	Induction	Induction		8	Other	TAKE ON DAYS 1 AND 15					455	672	1
MMRF_1847	First line of therapy	First Line Therapy	Maintenance	Maintenance	Ixazomib	Ixazomib		1			4	mg	mg	DAYS 1,8,15 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	4	Other	DAYS 1,8,15 OF 28 DAY CYCLE					692		1
MMRF_1847	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			8	mg	mg	DAYS 1,8,15 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	8	Other	DAYS 1,8,15 OF 28 DAY CYCLE					692		1
MMRF_1847	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					692		1
MMRF_1888	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					1	29	1
MMRF_1888	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	29	1
MMRF_1888	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	DAY 1,8&15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1,8&15					29	85	1
MMRF_1888	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			TRANSPLANT	Other	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					29	85	1
MMRF_1888	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TRANSPLANT	Other	20	mg	mg	BIW ( MONDAY AND THURSDAY)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	BIW ( MONDAY AND THURSDAY)					29	85	1
MMRF_1888	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	DAYS 1-21	Other	PO	PO	Log Forms	Induction	Induction	Checked	10	Other	DAYS 1-21					388		1
MMRF_1915	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DECREASED DOES D/T PREPHERAL NEUROPATHY	Other	1.3	mg/m^2	mg/m^2	BIW	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	BIW					1	53	1
MMRF_1915	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TRANSPLANT	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	82	1
MMRF_1915	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TRANSPLANT	Other	1	mg/m^2	mg/m^2	BIW	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Other	BIW					53	82	1
MMRF_1915	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			TRANSPLANT	Other	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					25	82	1
MMRF_1915	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	360	mg	mg	ONCE W AUTO-HSCT	Other	IV	IV	Log Forms	Induction	Induction		360	Other	ONCE W AUTO-HSCT					113	113	1
MMRF_1915	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					358	365	1
MMRF_1915	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	TIW X 1 WEEK, THEN EVERY OTHER DAY X1 WEEK THEN DAILY	Other	PO	PO	Log Forms	Induction	Induction		10	Other	TIW X 1 WEEK, THEN EVERY OTHER DAY X1 WEEK THEN DAILY					358	850	1
MMRF_2041	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TRANSPLANT	Other	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	29	1
MMRF_2041	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	29	1
MMRF_2041	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			TRANSPLANT	Other	400	mg	mg	ON D1 AND 8 EVERY 21DAYS	Other	PO	PO	Log Forms	Induction	Induction		400	Other	ON D1 AND 8 EVERY 21DAYS					1	29	1
MMRF_2041	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD DAYS 1-21 EACH 28 DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	QD DAYS 1-21 EACH 28 DAY CYCLE					199	497	1
MMRF_2041	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	5	QD (D1-21)	QD (D1-21)					497		1
MMRF_2064	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_2064	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TRANSPLANT	Other	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	102	1
MMRF_2064	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Patient decision	Patient decision	20	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		20	Q week	Q week					1221	1338	1
MMRF_2064	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		20	Q week	Q week					1221	1338	1
MMRF_2064	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1341		1
MMRF_2064	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		12	Q week	Q week					1341	1430	1
MMRF_2064	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			8	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	8	Q week	Q week					1430		1
MMRF_2409	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TRANSPLANT	Other	1.3	mg/m^2	mg/m^2	BIW	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	BIW					1	135	1
MMRF_2409	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			STEM CELL TRANSPLANT	Other	20	mg	mg	PRE MED	Other	PO	PO	Log Forms	Induction	Induction		20	Other	PRE MED					1	135	1
MMRF_2409	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			AUTO-HSCT	Other	410	mg/dL	mg/dL	ONCE	Other	IV	IV	Log Forms	Induction	Induction		410	Other	ONCE					176	176	1
MMRF_2409	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	10	Q day	Q day					345		1
MMRF_2585	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	8	1
MMRF_2585	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TRANSPLANT AUTO HSCT	Other	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	413	1
MMRF_2585	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			CHANGED DOSE FREQUENCY	Other	15	mg	mg	TIW	Other	PO	PO	Log Forms	Induction	Induction		15	Other	TIW					19	44	1
MMRF_2585	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			CHANGED DRUG FREQUENCY	Other	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		15	Q day	Q day					45	59	1
MMRF_2585	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			TRANSPLANT AUTO HSCT	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					59	413	1
MMRF_2585	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	10	QD (D1-21)	QD (D1-21)					635		1
MMRF_2585	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		1			8	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Consolidation	Consolidation	Checked	8	Other	DAYS 1, 8, 15					635		1
MMRF_1750	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3	Q week	Q week					1	51	1
MMRF_1750	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	50	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		50	Q week	Q week					1	79	1
MMRF_1750	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		4	Q week	Q week					1	79	1
MMRF_1750	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	Q week	Q week					51	79	1
MMRF_1750	First line of therapy	First Line Therapy	CONDITIONING REGIMEN	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING REGIMEN		200	Other	ONCE					126	126	1
MMRF_1750	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					212	316	1
MMRF_1750	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					317	961	1
MMRF_1750	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					962		1
MMRF_2019	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	115	1
MMRF_2019	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	140	1
MMRF_2019	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					251	303	1
MMRF_2019	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	DAYS 1&15 Q 28 DAYS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	DAYS 1&15 Q 28 DAYS					399	771	1
MMRF_2377	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2377	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAYS 1, 2, 4, 5, 8,9,11, AND 12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1, 2, 4, 5, 8,9,11, AND 12					1	53	1
MMRF_2377	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	53	1
MMRF_2377	First line of therapy	First Line Therapy	MOBILIZATION FOR TRANSPLANT	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3000	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	MOBILIZATION FOR TRANSPLANT		3000	Other	ONCE					85	85	1
MMRF_2377	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					113	207	1
MMRF_2377	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-14)	QD (D1-14)					113	207	1
MMRF_2377	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					113	207	1
MMRF_2377	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	Q day	Q day					211		1
MMRF_2380	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	170	1
MMRF_2380	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	DAY OF AND VELCADE AND DAY AFTER VELCADE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY OF AND VELCADE AND DAY AFTER VELCADE					4	177	1
MMRF_2380	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		1.5	Q week	Q week					547	631	1
MMRF_2380	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-14)	QD (D1-14)					547	631	1
MMRF_2380	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					547	631	1
MMRF_2380	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	CONDITIONING REGIMEN FOR SCT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING REGIMEN FOR SCT		200	Other	ONCE					659	659	1
MMRF_2402	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	414	1
MMRF_2402	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	414	1
MMRF_2402	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			20	mg	mg	QD DAYS 1-21/28	Other	PO	PO	Log Forms	Induction	Induction	Checked	20	Other	QD DAYS 1-21/28					414		1
MMRF_2402	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib		1			4	mg	mg	DAYS 1, 8, 15 / 28	Other	PO	PO	Log Forms	Induction	Induction	Checked	4	Other	DAYS 1, 8, 15 / 28					414		1
MMRF_2402	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction	Checked	40	QWK	QWK					414		1
MMRF_1930	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	59	1
MMRF_1930	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1, D2, D4, D5, D8, D9, D11, D12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1, D2, D4, D5, D8, D9, D11, D12					1	59	1
MMRF_1930	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	59	1
MMRF_1930	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					224	273	1
MMRF_1930	First line of therapy	First Line Therapy	MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3000	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION		3000	Q day	Q day					87	87	1
MMRF_1930	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					113	113	1
MMRF_1930	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					224	256	1
MMRF_1930	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-14)	QD (D1-14)					224	259	1
MMRF_1930	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					274		1
MMRF_2167	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	3.07	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		3.07	QWK	QWK					1	185	1
MMRF_2167	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		40	Q day	Q day					1	4	1
MMRF_2167	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		10	QWK	QWK					10	194	1
MMRF_2167	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					201	299	1
MMRF_2167	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					201	299	1
MMRF_2167	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Induction	Induction		200	Q day	Q day					333	333	1
MMRF_2167	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		20	Q week	Q week					460	839	1
MMRF_2167	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		5	Q day	Q day					454	531	1
MMRF_2167	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	ELOTUZUMAB	Other			Disease progression/Relapse	Disease progression/Relapse	1202	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		1202	Q week	Q week					460	517	1
MMRF_2167	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		2	QD (D1-21)	QD (D1-21)					517	833	1
MMRF_2167	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1886.4	mg	mg	QWK C1-2, C3-6 D 1&15, THEN D1 EVERY CYCLE (1 CYCLE=28 DAYS)	Other	IV	IV	Log Forms	Induction	Induction		1886.4	Other	QWK C1-2, C3-6 D 1&15, THEN D1 EVERY CYCLE (1 CYCLE=28 DAYS)					524	622	1
MMRF_2167	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	66	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		66	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					636	824	1
MMRF_2167	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	660	mg/dL	mg/dL	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		660	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					678	823	1
MMRF_2167	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Induction	Induction	PEMBROLIZUMAB (KEYTRUDA)	Other			SUBJECT ON HOSPICE 1-5-17 AND EXPIRED SAME DAY	Other	200	mg	mg	ONCE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	ONCE					825	825	1
MMRF_2167	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					201	307	1
MMRF_1456	First line of therapy	First Line Therapy			Bortezomib	Bortezomib			Patient decision	Patient decision	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV SubQ	IV SubQ	Log Forms				1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	43	1
MMRF_1456	First line of therapy	First Line Therapy			Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	Q week	Q week	PO	PO	Log Forms				40	Q week	Q week					1	43	1
MMRF_1456	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			Patient decision	Patient decision	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		15	Q day	Q day					22	43	1
MMRF_1535	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	154	1
MMRF_1535	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	154	1
MMRF_1535	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	MONDAY, WEDNESDAY, FRIDAY	Other	PO	PO	Log Forms	Maintenance	Maintenance		5	Other	MONDAY, WEDNESDAY, FRIDAY					366	394	1
MMRF_2112	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			PATIENT DECEASED	Other	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	201	1
MMRF_2112	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PATIENT DECEASED	Other	2.3	mg	mg	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					5	201	1
MMRF_2112	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	4	mg	mg	TID	TID	PO	PO	Log Forms	Induction	Induction		4	TID	TID					1	201	1
MMRF_2151	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	13	1
MMRF_2151	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-14)	QD (D1-14)					9	13	1
MMRF_2151	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	13	1
MMRF_2379	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	83	1
MMRF_1882	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.3	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3.3	QWK	QWK					1	86	1
MMRF_1882	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					30	562	1
MMRF_1882	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	450	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		450	QWK	QWK					37	268	1
MMRF_1882	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.5	mg	mg	Q week	Q week	SUBCUTANEOUSLY	Other	Log Forms	Consolidation	Consolidation		3.5	Q week	Q week					93	121	1
MMRF_1882	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.3	mg	mg	Q week	Q week	SUBCUTANEOUSLY	Other	Log Forms	Maintenance	Maintenance		3.3	Q week	Q week					134	268	1
MMRF_1882	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Patient decision	Patient decision	3.6	mg	mg	Q week	Q week	SUBQ	Other	Log Forms	Maintenance	Maintenance		3.6	Q week	Q week					280	562	1
MMRF_2015	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.8	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.8	QWK	QWK					33	138	1
MMRF_2015	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	50	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		50	QD (D1-14)	QD (D1-14)					8	23	1
MMRF_2015	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	533	1
MMRF_2187	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_2187	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	11	1
MMRF_2187	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	ONCE	Other	PO	PO	Log Forms	Induction	Induction		10	Other	ONCE					1	11	1
MMRF_2386	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.17	mg	mg	Q week	Q week	SUB-Q	Other	Log Forms	Induction	Induction		3.17	Q week	Q week					1	210	1
MMRF_2386	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	600	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		600	Q week	Q week					1	179	1
MMRF_2386	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	179	1
MMRF_2386	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.9	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.9	Q week	Q week					197	316	1
MMRF_2386	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					197	316	1
MMRF_2386	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					197	316	1
MMRF_2386	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Lack of response	Lack of response	60	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					341	867	1
MMRF_2386	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					341		1
MMRF_2386	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					341	454	1
MMRF_2386	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	4	QD (D1-21)	QD (D1-21)					467		1
MMRF_2386	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			1600	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown	Checked	1600	Q week	Q week					867		1
MMRF_2078	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.8	mg	mg	QWK	QWK	SUB Q	Other	Log Forms	Induction	Induction	Checked	1.8	QWK	QWK					1		1
MMRF_1644	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.1	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	2.1	Q week	Q week					1		1
MMRF_2118	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	705	1
MMRF_2118	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q day	Q day	FIRST IV AND THEN PO	Other	Log Forms	Induction	Induction	Checked	40	Q day	Q day					1		1
MMRF_2118	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	667	mg	mg	Q week	Q week	IV	IV	Log Forms	Maintenance	Maintenance		667	Q week	Q week					624	1016	1
MMRF_2118	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					624	1044	1
MMRF_2118	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			1110	mg/kg	mg/kg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Maintenance	Maintenance	Checked	1110	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1056		1
MMRF_2118	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		1			2.4	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Maintenance	Maintenance	Checked	2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1056		1
MMRF_2118	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	METHOTREXATE	Other			Completed regimen	Completed regimen	12	mg	mg	Q week	Q week	INTRATHECAL	Other	Log Forms	Consolidation	Consolidation		12	Q week	Q week					1037	1058	1
MMRF_2138	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	2.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	119	1
MMRF_2138	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q day	Q day	FIRST IV THEN PO	Other	Log Forms	Induction	Induction	Checked	40	Q day	Q day					1		1
MMRF_2138	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	34	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance		34	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					165	567	1
MMRF_2138	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Elotuzumab	Elotuzumab		1			667	mg	mg	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown	Checked	667	QWK	QWK					609		1
MMRF_2138	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					609		1
MMRF_1706	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	105	1
MMRF_1706	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	105	1
MMRF_1706	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	700	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		700	Q week	Q week					1	105	1
MMRF_1706	First line of therapy	First Line Therapy	STEM CELL MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	5650	mg	mg	ONCE (SINGLE TREATMENT)	Other	IV	IV	Log Forms	Other	STEM CELL MOBILIZATION		5650	Other	ONCE (SINGLE TREATMENT)					116	116	1
MMRF_1706	First line of therapy	First Line Therapy	STEM CELL TRANSPLANT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	310	mg	mg	ONCE (SINGLE TREATMENT)	Other	IV	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		310	Other	ONCE (SINGLE TREATMENT)					163	163	1
MMRF_1706	First line of therapy	First Line Therapy	STEM CELL TRANSPLANT CONDITIONING	Other	BUSULFAN	Other			Completed regimen	Completed regimen	280	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		280	Q day	Q day					160	162	1
MMRF_1706	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					265	455	1
MMRF_1881	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	171	1
MMRF_1881	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	171	1
MMRF_1881	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	171	1
MMRF_1881	First line of therapy	First Line Therapy	STEM CELL MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	4400	mg	mg	ONCE (SINGLE ADMINISTRATION)	Other	IV	IV	Log Forms	Other	STEM CELL MOBILIZATION		4400	Other	ONCE (SINGLE ADMINISTRATION)					196	196	1
MMRF_1881	First line of therapy	First Line Therapy	STEM CELL TRANSPLANT CONDITIONING	Other	BUSULFAN	Other			Completed regimen	Completed regimen	216	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		216	Q day	Q day					249	251	1
MMRF_1881	First line of therapy	First Line Therapy	STEM CELL TRANSPLANT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	250	mg	mg	ONCE (SINGLE ADMINISTRATION)	Other	IV	IV	Log Forms	Other	STEM CELL TRANSPLANT CONDITIONING		250	Other	ONCE (SINGLE ADMINISTRATION)					252	252	1
MMRF_1881	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			PER MCRN-001 PROTOCOL (MAINTENANCE REV DOSE TO BE INCREASED TO 15 MG)	Other	10	mg	mg	QDAY (D1-28 OF 28 DAY CYCLE)	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	QDAY (D1-28 OF 28 DAY CYCLE)					358	446	1
MMRF_1881	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	Q DAY (D1-28 OF 28 DAY CYCLE)	Other	PO	PO	Log Forms	Maintenance	Maintenance		15	Other	Q DAY (D1-28 OF 28 DAY CYCLE)					448	751	1
MMRF_1972	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	88	1
MMRF_1972	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	88	1
MMRF_1972	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	88	1
MMRF_1972	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	DAY 1, 7, 15 OF 28 DAY CYCLE (3WEEKS ON, 1 WEEK REST)	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Other	DAY 1, 7, 15 OF 28 DAY CYCLE (3WEEKS ON, 1 WEEK REST)					95	368	1
MMRF_1972	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	DAY 1, 7, 15 OF 28 DAY CYCLE (3WEEKS ON, 1 WEEK REST)	Other	PO	PO	Log Forms	Induction	Induction		300	Other	DAY 1, 7, 15 OF 28 DAY CYCLE (3WEEKS ON, 1 WEEK REST)					95	368	1
MMRF_1972	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAY 1, 7, 15 OF 28 DAY CYCLE (3WEEKS ON, 1 WEEK REST)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY 1, 7, 15 OF 28 DAY CYCLE (3WEEKS ON, 1 WEEK REST)					95	368	1
MMRF_1972	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			PHYSICIAN INCREASED DOSE TO 15 MG	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1054	1183	1
MMRF_1972	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RELAPSED DISEASE	Other	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	D1, D8, D15, D22 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Other	RELAPSED DISEASE		20	Other	D1, D8, D15, D22 OF 28 DAY CYCLE					1054	1915	1
MMRF_1972	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1184	1235	1
MMRF_1972	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	REALPSED DISEASE TREATMENT	Other	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	REALPSED DISEASE TREATMENT		10	QD (D1-21)	QD (D1-21)					1236	1915	1
MMRF_1972	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	RELAPSED DISEASE TREATMENT	Other	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Other	RELAPSED DISEASE TREATMENT	Checked	16	Q week	Q week					1933		1
MMRF_1972	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	RELAPSED DISEASE TREATMENT	Other	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Other	RELAPSED DISEASE TREATMENT	Checked	1.3	Q week	Q week					1933		1
MMRF_1972	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	RELAPSED DISEASE TREATMENT	Other	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	RELAPSED DISEASE TREATMENT	Checked	40	Q week	Q week					1933		1
MMRF_2007	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RELAPSED DISEASE TREATMENT	Other	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Other	RELAPSED DISEASE TREATMENT	Checked	40	Q week	Q week					1704		1
MMRF_2007	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RELAPSED DISEASE TREATMENT	Other	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	D1-15	Other	IV	IV	Log Forms	Other	RELAPSED DISEASE TREATMENT	Checked	16	Other	D1-15					1704		1
MMRF_2007	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	101	1
MMRF_2007	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	101	1
MMRF_2007	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	101	1
MMRF_2007	First line of therapy	First Line Therapy	STEM CELL MOBILIZATION	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2500	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	STEM CELL MOBILIZATION		2500	Other	ONCE					112	112	1
MMRF_2007	First line of therapy	First Line Therapy	MELPHALAN CONDITIONING FOR ASCT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	210	mg	mg	QDAY FOR 2 DAYS	Other	IV	IV	Log Forms	Other	MELPHALAN CONDITIONING FOR ASCT		210	Other	QDAY FOR 2 DAYS					151	152	1
MMRF_2007	First line of therapy	First Line Therapy	CONSOLIDATION AND MAINTENANCE	Other	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QDAY (D1-28 OF 28 DAY CYCLE)	Other	PO	PO	Log Forms	Other	CONSOLIDATION AND MAINTENANCE		10	Other	QDAY (D1-28 OF 28 DAY CYCLE)					436	1005	1
MMRF_1829	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			I DIDN'T SEE THE REASON FOR DISCONTINUED DOCUMENTED. THE NURSE AND MD ARE NO LONGER HERE.	Other	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	167	1
MMRF_1829	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					104	245	1
MMRF_1829	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.6	mg	mg	D1, D4, D8	Other	IV	IV	Log Forms	Consolidation	Consolidation		2.6	Other	D1, D4, D8					94	104	1
MMRF_1829	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	D1, D4, D8	Other	IV	IV	Log Forms	Consolidation	Consolidation		10	Other	D1, D4, D8					94	167	1
MMRF_1829	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			UTI	Other	5	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Consolidation	Consolidation		5	QD (D1-14)	QD (D1-14)					49	248	1
MMRF_1829	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					160	216	1
MMRF_1829	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Consolidation	Consolidation		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					104	167	1
MMRF_1829	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	2.5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		2.5	QD (D1-21)	QD (D1-21)					230	455	1
MMRF_1829	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					938	939	1
MMRF_1977	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction	Checked	2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_1977	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			15	mg	mg	Q 48 HOURS X 14 DAYS	Other	PO	PO	Log Forms	Induction	Induction	Checked	15	Other	Q 48 HOURS X 14 DAYS					1		1
MMRF_1977	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					1		1
MMRF_2012	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1	325	1
MMRF_2012	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			NOT SURE WHY STUDY MD CHANGED THE DECREASED THE DOSE	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	39	1
MMRF_2012	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			8	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	8	Q week	Q week					39		1
MMRF_2106	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	225	1
MMRF_2106	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	225	1
MMRF_2106	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	D1-5, 8-9, 11-12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1-5, 8-9, 11-12					1	225	1
MMRF_2106	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	20	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					271	272	1
MMRF_2106	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	ETOPOSIDE	Other			Completed regimen	Completed regimen	68	mg	mg	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		68	Q day	Q day					272	277	1
MMRF_2106	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	ONE DOSE	Other	IV	IV	Log Forms	Induction	Induction		1	Other	ONE DOSE					276	276	1
MMRF_2106	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	30	mg/m^2	mg/m^2	ONE DOSE	Other	IV	IV	Log Forms	Induction	Induction		30	Other	ONE DOSE					276	276	1
MMRF_2106	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	2	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		2	Q day	Q day					271	337	1
MMRF_2106	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	475	mg	mg	ONE DOSE	Other	PO	PO	Log Forms	Induction	Induction		475	Other	ONE DOSE					337	337	1
MMRF_2106	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	ONE DOSE	Other	PO	PO	Log Forms	Induction	Induction		20	Other	ONE DOSE					337	337	1
MMRF_2106	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	ONE DOSE	Other	IV	IV	Log Forms	Induction	Induction		20	Other	ONE DOSE					337	337	1
MMRF_2125	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	294	1
MMRF_2125	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	442	1
MMRF_2125	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DOSE ADJUSTMENT	Other	20	mg	mg	D1, 2, 4, 5, 8-9 AND 11-12	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1, 2, 4, 5, 8-9 AND 11-12					1	116	1
MMRF_2125	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	D1, D2, D4, D5, D8, D9, D11, D12	Other	PO	PO	Log Forms	Consolidation	Consolidation		10	Other	D1, D2, D4, D5, D8, D9, D11, D12					116	294	1
MMRF_2125	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Elotuzumab	Elotuzumab			ELOTUZUMAB WAS APPROVED BY THE FDA.	Other	10	mg/kg	mg/kg	D1, D8, D15, D22	Other	IV	IV	Log Forms	Induction	Induction		10	Other	D1, D8, D15, D22					455	512	1
MMRF_2125	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					455	512	1
MMRF_2125	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	28	mg	mg	3-24 HOURS PRIOR TO ELO ON D1, D8, D15, D22	Other	PO	PO	Log Forms	Induction	Induction		28	Other	3-24 HOURS PRIOR TO ELO ON D1, D8, D15, D22					455	512	1
MMRF_2125	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	8	mg	mg	45-90 MINUTES PRIOR TO ELO INFUSION ON D1, D8, D15, D22	Other	IV	IV	Log Forms	Induction	Induction		8	Other	45-90 MINUTES PRIOR TO ELO INFUSION ON D1, D8, D15, D22					455	512	1
MMRF_2125	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Elotuzumab	Elotuzumab			CHANGED DUE TO STABLE PROTEINS	Other	10	mg/kg	mg/kg	EVERY TWO WEEKS	Other	IV	IV	Log Forms	Consolidation	Consolidation		10	Other	EVERY TWO WEEKS					518	609	1
MMRF_2125	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			STABLE PROTEINS	Other	8	mg	mg	EVERY TWO WEEKS	Other	IV	IV	Log Forms	Consolidation	Consolidation		8	Other	EVERY TWO WEEKS					518	609	1
MMRF_2125	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib		1			20	mg/m^2	mg/m^2	EVERY TWO WEEKS	Other	IV	IV	Log Forms	Consolidation	Consolidation	Checked	20	Other	EVERY TWO WEEKS					609		1
MMRF_2125	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		1			10	mg	mg	EVERY TWO WEEKS	Other	IV	IV	Log Forms	Consolidation	Consolidation	Checked	10	Other	EVERY TWO WEEKS					609		1
MMRF_2256	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	D1, D4, D7, D10	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	D1, D4, D7, D10					1	309	1
MMRF_2256	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	D1, D4, D7, D10	Other	PO	PO	Log Forms	Induction	Induction		10	Other	D1, D4, D7, D10					1	196	1
MMRF_2259	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DEATH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_2259	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DEATH	Other	25	mg	mg	EVERY DAY X 14 DAYS	Other	PO	PO	Log Forms	Induction	Induction		25	Other	EVERY DAY X 14 DAYS					1	123	1
MMRF_2259	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	D1, D2, D4, D5, D8, D9	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1, D2, D4, D5, D8, D9					1	123	1
MMRF_2525	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	148	1
MMRF_2525	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					1	505	1
MMRF_1753	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DEATH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	101	1
MMRF_1753	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			DEATH	Other	300	mg/m^2	mg/m^2	QWK	QWK	PO	PO	Log Forms	Induction	Induction		300	QWK	QWK					1	101	1
MMRF_1753	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	101	1
MMRF_1786	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	109	1
MMRF_1786	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		300	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	120	1
MMRF_1786	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					8	120	1
MMRF_1786	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	DAILY 1-21 (28 DAY CYCLE)	Other	PO	PO	Log Forms	Maintenance	Maintenance		15	Other	DAILY 1-21 (28 DAY CYCLE)					207	360	1
MMRF_1786	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					360	1290	1
MMRF_1786	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	28	mg	mg	DAY 1	Other	PO	PO	Log Forms	Maintenance	Maintenance		28	Other	DAY 1					1444	1549	1
MMRF_1786	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	DAYS 1, 2	Other	IV	IV	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 2					1444	1543	1
MMRF_1786	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			8	mg	mg	DAY 1	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	8	Other	DAY 1					1444		1
MMRF_1786	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab		1			10	mg/kg	mg/kg	DAY 1	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	10	Other	DAY 1					1444		1
MMRF_1786	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	25	QD (D1-21)	QD (D1-21)					1444		1
MMRF_1793	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	42	1
MMRF_1793	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	42	1
MMRF_1793	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	105	1
MMRF_1793	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					64	105	1
MMRF_1793	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					64	105	1
MMRF_1793	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	QD (D1-21)	QD (D1-21)					196		1
MMRF_1816	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	96	1
MMRF_1816	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	450	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		450	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	100	1
MMRF_1816	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	100	1
MMRF_1816	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg	mg	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					140	140	1
MMRF_1816	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	20	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Maintenance	Maintenance		20	Q day	Q day					232	233	1
MMRF_1816	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					239	352	1
MMRF_1816	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					359	1235	1
MMRF_1816	First line of therapy	First Line Therapy	Maintenance	Maintenance	Pomalidomide	Pomalidomide		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	2	QD (D1-21)	QD (D1-21)					232		1
MMRF_1816	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Maintenance	Maintenance		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					232	562	1
MMRF_1816	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					576	1235	1
MMRF_1842	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_1842	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	106	1
MMRF_1842	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	400	mg	mg	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		400	Other	ONCE					159	159	1
MMRF_1842	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					227	689	1
MMRF_1842	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			M-SPIKE AND FLC CONTINUE TO RISE	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					732	897	1
MMRF_1842	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Unknown	Unknown		20	Other	DAYS 1, 8, 15, 22					732	1289	1
MMRF_1842	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab			M-SPIKE AND FLC CONTINUE TO RISE	Other	10	mg/kg	mg/kg	DAYS 1, 15	Other	IV	IV	Log Forms	Maintenance	Maintenance		10	Other	DAYS 1, 15					732	884	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab			Investigator decision for other reasons	Investigator decision for other reasons	16	mg/m^2	mg/m^2	DAYS 1, 8, 15, 22	Other	IV	IV	Log Forms	Maintenance	Maintenance		16	Other	DAYS 1, 8, 15, 22					898	1122	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-21)	QD (D1-21)					898	1072	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1094	1142	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	42	mg	mg	DAYS 1, 2	Other	IV	IV	Log Forms	Maintenance	Maintenance		42	Other	DAYS 1, 2					1157	1158	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	60	mg	mg	DAYS 8, 9, 15, 16	Other	IV	IV	Log Forms	Maintenance	Maintenance		60	Other	DAYS 8, 9, 15, 16					1157	1290	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	VENETOCLAX	Other			PATIENT DID NOT TAKE C1D1 CORRECTLY	Other	200	mg	mg	DAYS 1-7	Other	PO	PO	Log Forms	Maintenance	Maintenance		200	Other	DAYS 1-7					1157	1163	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	VENETOCLAX	Other			PATIENT DID NOT TAKE C1D1 CORRECTLY	Other	400	mg	mg	DAYS 8-14	Other	PO	PO	Log Forms	Maintenance	Maintenance		400	Other	DAYS 8-14					1164	1170	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	VENETOCLAX	Other			PATIENT DID NOT TAKE C1D1 CORRECTLY	Other	800	mg	mg	DAYS 15-21	Other	PO	PO	Log Forms	Maintenance	Maintenance		800	Other	DAYS 15-21					1171	1177	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	VENETOCLAX	Other			Investigator decision for other reasons	Investigator decision for other reasons	800	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		800	QD (D1-21)	QD (D1-21)					1191	1211	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	VENETOCLAX	Other			Investigator decision for other reasons	Investigator decision for other reasons	700	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		700	QD (D1-21)	QD (D1-21)					1219	1267	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	VENETOCLAX	Other			Investigator decision for other reasons	Investigator decision for other reasons	200	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		200	QD (D1-21)	QD (D1-21)					1275	1295	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 2, 3, 4	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	DAYS 1, 2, 3, 4					1297	1300	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	43	mg	mg	DAY 1, 2	Other	IV	IV	Log Forms	Maintenance	Maintenance		43	Other	DAY 1, 2					1297	1298	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	CISPLATIN	Other			Completed regimen	Completed regimen	22	mg	mg	DAYS 1, 2, 3, 4	Other	IV	IV	Log Forms	Maintenance	Maintenance		22	Other	DAYS 1, 2, 3, 4					1297	1327	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	ETOPOSIDE	Other			Completed regimen	Completed regimen	64	mg	mg	DAYS 1, 2, 3, 4	Other	IV	IV	Log Forms	Maintenance	Maintenance		64	Other	DAYS 1, 2, 3, 4					1297	1327	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	860	mg	mg	DAYS 1, 2, 3, 4	Other	IV	IV	Log Forms	Maintenance	Maintenance		860	Other	DAYS 1, 2, 3, 4					1297	1300	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	16	mg	mg	DAYS 1, 2, 3, 4	Other	IV	IV	Log Forms	Maintenance	Maintenance		16	Other	DAYS 1, 2, 3, 4					1297	1300	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	120	mg	mg	DAYS 1, 8, 15, 22	Other	IV	IV	Log Forms	Maintenance	Maintenance		120	Other	DAYS 1, 8, 15, 22					1325	1375	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Panobinostat	Panobinostat			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	DAYS 1, 3, 5, 15, 17, 18	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	DAYS 1, 3, 5, 15, 17, 18					1325	1372	1
MMRF_1842	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	DAYS 1, 8, 15, 22					1325	1522	1
MMRF_1842	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1409	2253	1
MMRF_1842	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	500	mg	mg	DAYS 1, 8, 15, 22	Other	IV	IV	Log Forms	Maintenance	Maintenance		500	Other	DAYS 1, 8, 15, 22					1409	1522	1
MMRF_1842	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_1858	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	25	1
MMRF_1858	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		500	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	25	1
MMRF_1858	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	25	1
MMRF_1858	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					76	327	1
MMRF_1858	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					76	153	1
MMRF_1858	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		12	Q week	Q week					153	327	1
MMRF_1858	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					744	1033	1
MMRF_1858	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		12	Q week	Q week					744	909	1
MMRF_1858	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		8	Q week	Q week					910	1033	1
MMRF_1858	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 8, 15, 22					1037	1278	1
MMRF_1858	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			DEATH	Other	20	mg/m^2	mg/m^2	DAY 1	Other	IV	IV	Log Forms	Maintenance	Maintenance		20	Other	DAY 1					1037	1278	1
MMRF_1858	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			DEATH	Other	56	mg/m^2	mg/m^2	DAYS 8, 15	Other	IV	IV	Log Forms	Maintenance	Maintenance		56	Other	DAYS 8, 15					1037	1278	1
MMRF_1858	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide			DEATH	Other	300	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV	IV	Log Forms	Maintenance	Maintenance		300	Other	DAYS 1, 8, 15					1037	1278	1
MMRF_1886	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_1886	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	43	1
MMRF_1886	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		500	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	43	1
MMRF_1886	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					99	143	1
MMRF_1886	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	300	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		300	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					43	99	1
MMRF_1886	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		200	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					99	143	1
MMRF_1886	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					43	143	1
MMRF_1886	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	DAYS 1  AND DAY15	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1	Other	DAYS 1  AND DAY15					155	477	1
MMRF_1886	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	DAYS 1 AND DAY 15	Other	PO	PO	Log Forms	Maintenance	Maintenance		12	Other	DAYS 1 AND DAY 15					155	477	1
MMRF_1886	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	.8	mg/m^2	mg/m^2	DAYS 1 AND 15	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		0.8	Other	DAYS 1 AND 15					547	561	1
MMRF_1886	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Elotuzumab	Elotuzumab			Completed regimen	Completed regimen	10	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		10	Q week	Q week					1514	1563	1
MMRF_1886	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		20	Q week	Q week					1514	1535	1
MMRF_1886	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	30	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		30	Q week	Q week					1542	1563	1
MMRF_1886	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					1514		1
MMRF_1886	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					1570		1
MMRF_1886	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Elotuzumab	Elotuzumab		1			10	mg/kg	mg/kg	QD (D1, D15)	Other	IV	IV	Log Forms	Induction	Induction	Checked	10	Other	QD (D1, D15)					1570		1
MMRF_2074	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_2074	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	100	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		100	QD (D1-21)	QD (D1-21)					1	50	1
MMRF_2074	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Completed regimen	Completed regimen	50	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		50	QD (D1-21)	QD (D1-21)					57	127	1
MMRF_2074	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		12	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					85	116	1
MMRF_2074	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					85	116	1
MMRF_2074	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					169	169	1
MMRF_2074	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1	mg/m^2	mg/m^2	DAYS 1 AND 15	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1	Other	DAYS 1 AND 15					302	1198	1
MMRF_2074	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			AMGEN-20160275 TRIAL; C2+ CYCLES ARE DIFFERENT	Other	20	mg	mg	DAYS 1, 2	Other	IV	IV	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 2					1268	1269	1
MMRF_2074	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			AMGEN-20160275 TRIAL; C2+ CYCLES ARE DIFFERENT	Other	20	mg/m^2	mg/m^2	DAYS 1, 2	Other	IV	IV	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 2					1268	1269	1
MMRF_2074	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1296		1
MMRF_2074	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		1			56	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Maintenance	Maintenance	Checked	56	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1296		1
MMRF_2074	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			40	mg	mg	DAYS 22, 23	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	40	Other	DAYS 22, 23					1296		1
MMRF_2074	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	67	1
MMRF_2093	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	57	1
MMRF_2093	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	43	1
MMRF_2093	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		300	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	127	1
MMRF_2093	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					57	123	1
MMRF_2093	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		300	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					57	127	1
MMRF_2093	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					177	177	1
MMRF_2093	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					253	531	1
MMRF_2093	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	DAYS 1, 8, 15, 22 (MISSED C2 D8, 15, 22)	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 8, 15, 22 (MISSED C2 D8, 15, 22)					827	1158	1
MMRF_2093	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	20	mg/m^2	mg/m^2	DAYS 1, 2	Other	IV	IV	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1, 2					827	829	1
MMRF_2093	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	27	mg/m^2	mg/m^2	DAYS 8, 9, 15, 16 (MISSED C2 D8, 9, 15, 16)	Other	IV	IV	Log Forms	Maintenance	Maintenance		27	Other	DAYS 8, 9, 15, 16 (MISSED C2 D8, 9, 15, 16)					827	843	1
MMRF_2093	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	DAYS 1, 8, 15 (MISSED C2 D8, 15)	Other	IV	IV	Log Forms	Maintenance	Maintenance		300	Other	DAYS 1, 8, 15 (MISSED C2 D8, 15)					827	1158	1
MMRF_2093	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	27	mg/m^2	mg/m^2	DAYS 1, 2, 8, 9, 15, 16	Other	IV	IV	Log Forms	Maintenance	Maintenance		27	Other	DAYS 1, 2, 8, 9, 15, 16					855	1158	1
MMRF_2093	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	DAY 1	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	16	Other	DAY 1					1172		1
MMRF_2093	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	2	QD (D1-21)	QD (D1-21)					1172		1
MMRF_2093	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	DAY 1	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	20	Other	DAY 1					1172		1
MMRF_2266	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	DAY 1, DAY 7, DAY 14	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1, DAY 7, DAY 14					1	68	1
MMRF_2266	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	300	mg/m^2	mg/m^2	DAY 1, DAY 7, DAY 14	Other	IV	IV	Log Forms	Induction	Induction		300	Other	DAY 1, DAY 7, DAY 14					1	68	1
MMRF_2266	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	DAY 1, DAY 7, DAY 14	Other	IV	IV	Log Forms	Induction	Induction		40	Other	DAY 1, DAY 7, DAY 14					1	68	1
MMRF_2266	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1	mg/m^2	mg/m^2	DAYS 1 AND 15 EVERY 28 DAYS	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Other	DAYS 1 AND 15 EVERY 28 DAYS					68	369	1
MMRF_2266	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	8	mg	mg	DAYS 1 AND 15 OF EVERY 28 DAYS	Other	IV	IV	Log Forms	Induction	Induction		8	Other	DAYS 1 AND 15 OF EVERY 28 DAYS					68	369	1
MMRF_2306	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	DAY 1, 7, 14	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Other	DAY 1, 7, 14					1	14	1
MMRF_2306	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAY 1, 7, 14	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 7, 14					1	14	1
MMRF_2306	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	DAY 1, 7, 14	Other	IV	IV	Log Forms	Induction	Induction		500	Other	DAY 1, 7, 14					1	14	1
MMRF_2306	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.5	mg/m^2	mg/m^2	DAY 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Other	DAY 1, 8, 15					21	98	1
MMRF_2306	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	DAY 1, 8, 15	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAY 1, 8, 15					21	119	1
MMRF_2306	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	DAY 1, 8, 15	Other	IV	IV	Log Forms	Induction	Induction		500	Other	DAY 1, 8, 15					21	168	1
MMRF_2306	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAY 1, 8, 15	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAY 1, 8, 15					126	168	1
MMRF_2306	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1	mg	mg	DAY 1, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Other	DAY 1, 15					126	245	1
MMRF_2306	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	DAY 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Other	DAY 1, 8, 15					105	168	1
MMRF_2306	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8, 15, 22					266	287	1
MMRF_2306	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	DAYS 1 AND 2	Other	IV	IV	Log Forms	Induction	Induction		20	Other	DAYS 1 AND 2					266	267	1
MMRF_2306	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	DAYS 8, 9, 15, AND 16	Other	IV	IV	Log Forms	Induction	Induction		27	Other	DAYS 8, 9, 15, AND 16					273	281	1
MMRF_2306	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV	IV	Log Forms	Induction	Induction		500	Other	DAYS 1, 8, 15					266	364	1
MMRF_2306	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					294	365	1
MMRF_2306	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	12	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		12	Other	DAYS 1, 8, 15, 22					294	371	1
MMRF_2306	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE ON DAY -2	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE ON DAY -2					425	425	1
MMRF_2306	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	27	mg/m^2	mg/m^2	Q 2 WEEKS	Other	IV	IV	Log Forms	Maintenance	Maintenance		27	Other	Q 2 WEEKS					502	961	1
MMRF_2306	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	8	mg	mg	DAYS 1, 15	Other	IV	IV	Log Forms	Maintenance	Maintenance		8	Other	DAYS 1, 15					516	852	1
MMRF_2306	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	DAYS 1, 15	Other	IV	IV	Log Forms	Maintenance	Maintenance		4	Other	DAYS 1, 15					866	961	1
MMRF_2306	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		1			27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1006		1
MMRF_2306	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	25	QD (D1-21)	QD (D1-21)					1006		1
MMRF_2306	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	DAYS 1, 8, 15					1006		1
MMRF_2486	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	800	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		800	Other	DAYS 1, 8, 15, 22					1	176	1
MMRF_2486	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	DAYS 1, 8, 15, 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAYS 1, 8, 15, 22					1	176	1
MMRF_2486	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8, 15, 22					1	176	1
MMRF_2486	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	DAYS 1, 8, 15, 22					288	337	1
MMRF_2486	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	DAY 1 (PATIENT MISSED DAY 2)	Other	IV	IV	Log Forms	Maintenance	Maintenance		20	Other	DAY 1 (PATIENT MISSED DAY 2)					288	288	1
MMRF_2486	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	DAYS 8, 9, 15, 16	Other	IV	IV	Log Forms	Maintenance	Maintenance		27	Other	DAYS 8, 9, 15, 16					295	303	1
MMRF_2486	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					288	552	1
MMRF_2486	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					316	331	1
MMRF_2486	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE ON DAY -2	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE ON DAY -2					217	217	1
MMRF_2486	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	DAYS 1 (MISSED DAY 15)	Other	IV	IV	Log Forms	Maintenance	Maintenance		56	Other	DAYS 1 (MISSED DAY 15)					344	344	1
MMRF_2486	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8, 15, 22					383	553	1
MMRF_2486	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg/m^2	mg/m^2	DAYS 1-2,8-9,15-16	Other	IV	IV	Log Forms	Induction	Induction		27	Other	DAYS 1-2,8-9,15-16					383	547	1
MMRF_2486	First line of therapy	First Line Therapy	Consolidation	Consolidation	Carfilzomib	Carfilzomib		1			27	mg/m^2	mg/m^2	DAYS 1, 15	Other	IV	IV	Log Forms	Consolidation	Consolidation	Checked	27	Other	DAYS 1, 15					560		1
MMRF_2486	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-21)	QD (D1-21)					560	629	1
MMRF_2486	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					714		1
MMRF_2497	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DECREASED TO 10MG FOR CYCLE 1 FOR CREATENINE CLEARENCE < 60	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	22	1
MMRF_2497	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	D1, D8, D15, D22	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1, D8, D15, D22					1	1043	1
MMRF_2497	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					30	223	1
MMRF_2497	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					240	490	1
MMRF_2497	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	10	QD (D1-21)	QD (D1-21)					511		1
MMRF_2497	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			10	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction	Checked	10	Other	DAYS 1, 8, 15, 22					1050		1
MMRF_2501	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	D1, D8, D15, D22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1, D8, D15, D22					1	113	1
MMRF_2501	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	D1, D8, D15, D22	Other	PO	PO	Log Forms	Induction	Induction		300	Other	D1, D8, D15, D22					1	113	1
MMRF_2501	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1, D8, D15, D22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1, D8, D15, D22					1	113	1
MMRF_2501	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	IV OVER 20 MINUTES	Other	IV	IV	Log Forms	Induction	Induction		200	Other	IV OVER 20 MINUTES					170	170	1
MMRF_2501	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					276	984	1
MMRF_2501	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg/kg	mg/kg	DAYS 1, 8, 15 (CYCLE 1: DAY 1 ONLY)	Other	IV	IV	Log Forms	Maintenance	Maintenance		16	Other	DAYS 1, 8, 15 (CYCLE 1: DAY 1 ONLY)					1012	1121	1
MMRF_2501	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	DAYS 1, 8, 15 (CYCLE 1: DAY 1 ONLY)	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	DAYS 1, 8, 15 (CYCLE 1: DAY 1 ONLY)					1012	1121	1
MMRF_2501	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	DAYS 1, 8, 15 (CYCLE 2+)	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	DAYS 1, 8, 15 (CYCLE 2+)					1029	1121	1
MMRF_2501	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	DAYS 1, 8, 15 (CYCLE 1: DAY 1 ONLY)	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Other	DAYS 1, 8, 15 (CYCLE 1: DAY 1 ONLY)					1205		1
MMRF_2501	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	DAYS 1, 8, 15 (CYCLE 1: DAY 1 ONLY)	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown	Checked	1.3	Other	DAYS 1, 8, 15 (CYCLE 1: DAY 1 ONLY)					1205		1
MMRF_2501	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			12	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	12	Other	DAYS 1, 8, 15					1205		1
MMRF_2557	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.01	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.01	Other	DAYS 1, 8, 15					5	117	1
MMRF_2557	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	DAYS 1, 8, AND 15	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1, 8, AND 15					1	264	1
MMRF_2557	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	300	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV	IV	Log Forms	Induction	Induction		300	Other	DAYS 1, 8, 15					131	222	1
MMRF_2557	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Other	DAYS 1, 8, 15					131	222	1
MMRF_2557	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Patient decision	Patient decision	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					232	257	1
MMRF_2557	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	OVER 3 MINUTES FOR 1 DAY	Other	IV	IV	Log Forms	Induction	Induction		10	Other	OVER 3 MINUTES FOR 1 DAY					131	222	1
MMRF_2557	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg/m^2	mg/m^2	DAYS 1, 8, 15	Other	IV	IV	Log Forms	Induction	Induction		20	Other	DAYS 1, 8, 15					251	264	1
MMRF_2087	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			MEDICATION IS ON HOLD DUE TO PATIENT'S NAUSEA	Other	10	mg	mg	3 WEEKS ON 1 WEEK OFF	Other	PO	PO	Log Forms	Induction	Induction		10	Other	3 WEEKS ON 1 WEEK OFF					1	26	1
MMRF_2087	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			INCREASED DOSAGE	Other	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1	165	1
MMRF_2087	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			MEDICATION HOLD/CHEMO INDUCED NEUTROPENIA	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					58	86	1
MMRF_2087	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			REDUCED DOSE/ 5 MG EVERY OTHER DAY	Other	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		5	Q day	Q day					103	130	1
MMRF_2087	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			HELD BY PHYSICIAN FOR PT DEVELOPING SHINGLES; PLAN RESTART AFTER RECOVERY	Other	5	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Induction	Induction		5	Other	EVERY OTHER DAY					131	198	1
MMRF_2087	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			HELD BY PHYSICIAN FOR PT DEVELOPING SHINGLES; PLAN RESTART AFTER RECOVERY	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					166	198	1
MMRF_2087	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			HELD BY PHYSICIAN FOR PT DEVELOPING SHINGLES; PLAN RESTART AFTER RECOVERY	Other	2.34	mg	mg	QD (1, 4, 8, 15)	Other	SUBQ	Other	Log Forms	Induction	Induction		2.34	Other	QD (1, 4, 8, 15)					165	198	1
MMRF_2087	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			COVERING DOCTOR HELD MEDICATION	Other	5	mg	mg	EVERY OTHER DAY	Other	PO	PO	Log Forms	Induction	Induction		5	Other	EVERY OTHER DAY					208	229	1
MMRF_2087	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	2.2	mg	mg	Q week	Q week	SUBQ	Other	Log Forms	Induction	Induction		2.2	Q week	Q week					208	249	1
MMRF_2087	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			DOCTOR COVERING: REDUCED DOSE TO 20 MG QWK	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					208	229	1
MMRF_2087	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			BEGAN HOSPICE CARE STRICT PALLIATIVE CARE ONLY WITHOUT CHEMOTHERAPY	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					230	261	1
MMRF_2087	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			COVERING DOCTOR INCREASED DOSAGE TO 45 MG	Other	35	mg	mg	DAY 1, DAY 2 OF EVERY WEEK, 3 WEEKS ON, 1 WEEK OFF	Other	IV	IV	Log Forms	Induction	Induction		35	Other	DAY 1, DAY 2 OF EVERY WEEK, 3 WEEKS ON, 1 WEEK OFF					249	256	1
MMRF_2087	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			BEGAN HOSPICE CARE STRICT PALLIATIVE CARE ONLY WITHOUT CHEMOTHERAPY	Other	45	mg	mg	DAY 1, DAY 2 OF EVERY WEEK, 3 WEEKS ON, 1 WEEK OFF	Other	IV	IV	Log Forms	Induction	Induction		45	Other	DAY 1, DAY 2 OF EVERY WEEK, 3 WEEKS ON, 1 WEEK OFF					256	261	1
MMRF_2141	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			HOLD VELCADE: EVAL FOR AUTOLOGOUS TRANSPLANT	Other	2.67	mg	mg	Q week	Q week	SUBQ	Other	Log Forms	Induction	Induction		2.67	Q week	Q week					3	175	1
MMRF_2141	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DECREASE DOSE TO 20 MG TO MINIMIZE SIDE EFFECTS	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	175	1
MMRF_2141	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					176		1
MMRF_2141	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			25	mg	mg	DAILY FOR 14 DAYS WITH 7 DAY REST PERIOD	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	25	Other	DAILY FOR 14 DAYS WITH 7 DAY REST PERIOD					1837		1
MMRF_2141	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib		1			2.7	mg	mg	Q week	Q week	SC	Other	Log Forms	Maintenance	Maintenance	Checked	2.7	Q week	Q week					1837		1
MMRF_2141	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					1837	1864	1
MMRF_2141	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					1865		1
MMRF_2149	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Patient decision	Patient decision	2.27	mg	mg	Q week	Q week	SUBQ	Other	Log Forms	Induction	Induction		2.27	Q week	Q week					1	163	1
MMRF_2149	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	163	1
MMRF_2153	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	Q week	Q week	SUBQ	Other	Log Forms	Induction	Induction		2	Q week	Q week					3	382	1
MMRF_2153	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1	382	1
MMRF_2153	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			PATIENT LOST TO FOLLOW-UP AFTER THIS CYCLE, MOVED TO DIFFERENT CITY	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					393	584	1
MMRF_2191	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Lack of response	Lack of response	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1891	1939	1
MMRF_2191	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Maintenance	Maintenance	SELINEXOR	Other		1			80	mg	mg	TWICE WEEKLY	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	80	Other	TWICE WEEKLY					1968		1
MMRF_2191	Sixth Line Therapy (following 5th relapse)	Sixth Line Therapy (following 5th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	TWICE WEEKLY WITH SELINEXOR	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Other	TWICE WEEKLY WITH SELINEXOR					1968		1
MMRF_2191	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	3	mg	mg	QWK	QWK	SUBQ	Other	Log Forms	Induction	Induction		3	QWK	QWK					1	135	1
MMRF_2191	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	379	1
MMRF_2191	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.6	mg	mg	Q week	Q week	SUBQ	Other	Log Forms	Maintenance	Maintenance		2.6	Q week	Q week					141	268	1
MMRF_2191	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.6	mg	mg	Q week	Q week	SUBQ	Other	Log Forms	Maintenance	Maintenance		2.6	Q week	Q week					287	352	1
MMRF_2191	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	96	mg	mg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		96	QWK	QWK					581	689	1
MMRF_2191	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					568	694	1
MMRF_2191	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	8	mg/kg	mg/kg	D1-2 Q28D	Other	IV	IV	Log Forms	Maintenance	Maintenance		8	Other	D1-2 Q28D					868	1211	1
MMRF_2191	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-21)	QD (D1-21)					868	1291	1
MMRF_2191	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAY 2, Q28D CYCLE	Other	IV	IV	Log Forms	Maintenance	Maintenance		20	Other	DAY 2, Q28D CYCLE					869	1291	1
MMRF_2191	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	MELFLUFEN (OP-103)	Other	NCT03151811	0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q4W	Other	IV	IV	Log Forms	Maintenance	Maintenance		40	Other	Q4W					1353	1780	1
MMRF_2191	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone	NCT03151811	0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					1353	1780	1
MMRF_2191	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1200	mg	mg	Q week	Q week	IV	IV	Log Forms	Maintenance	Maintenance		1200	Q week	Q week					1856	1877	1
MMRF_2191	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	28	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		28	Q week	Q week					1855	1876	1
MMRF_2191	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		0	Lack of response	Lack of response	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		4	QD (D1-21)	QD (D1-21)					1856	1939	1
MMRF_2228	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.5	mg	mg	Q week	Q week	SUBQ	Other	Log Forms	Induction	Induction		3.5	Q week	Q week					1	406	1
MMRF_2228	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	392	1
MMRF_2301	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.9	mg	mg	Q week	Q week	SUBQ	Other	Log Forms	Induction	Induction		2.9	Q week	Q week					1	157	1
MMRF_2301	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	WITH BORTEZOMIB	Other	PO	PO	Log Forms	Induction	Induction		20	Other	WITH BORTEZOMIB					1	157	1
MMRF_2301	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-21)	QD (D1-21)					1122	1284	1
MMRF_2301	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					1122	1284	1
MMRF_1766	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	155	1
MMRF_1766	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	155	1
MMRF_1766	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	22	1
MMRF_1766	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					22	155	1
MMRF_1766	First line of therapy	First Line Therapy	PRIMING CHEMOTHERAPY	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	8440	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	PRIMING CHEMOTHERAPY		8440	Other	ONCE					185	185	1
MMRF_1766	First line of therapy	First Line Therapy	PREP REGIMEN	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	410	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	PREP REGIMEN		410	Other	ONCE					217	217	1
MMRF_1766	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	Q2W	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	Q2W					339	989	1
MMRF_1766	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	SELINEXOR	Other		1			60	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	60	Q week	Q week					1066		1
MMRF_1766	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1066		1
MMRF_1766	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					1066		1
MMRF_1824	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	42	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		42	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	163	1
MMRF_1824	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Induction	Induction		300	Other	QD (D1, D8, D15)					1	162	1
MMRF_1824	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	162	1
MMRF_1824	First line of therapy	First Line Therapy	PREP REGIMEN	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	255	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	PREP REGIMEN		255	Other	ONCE					220	220	1
MMRF_1824	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					325	430	1
MMRF_1824	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Q day	Q day					430		1
MMRF_1879	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PATIENT INABLE TO COMPLY WITH TREATMENT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1, D8, D15)					1	225	1
MMRF_1879	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			PATIENT INABLE TO COMPLY WITH TREATMENT	Other	300	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Induction	Induction		300	Other	QD (D1, D8, D15)					1	225	1
MMRF_1879	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PATIENT INABLE TO COMPLY WITH TREATMENT	Other	40	mg	mg	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D15)					1	225	1
MMRF_2006	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1, D8, D15)					7	102	1
MMRF_2006	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	700	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		700	Q week	Q week					1	102	1
MMRF_2006	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	102	1
MMRF_2006	First line of therapy	First Line Therapy	PRIMING CHEMOTHERAPY	Other	PLERIXAFOR	Other			Completed regimen	Completed regimen	27	mg	mg	ONCE	Other	IV SubQ	IV SubQ	Log Forms	Other	PRIMING CHEMOTHERAPY		27	Other	ONCE					121	121	1
MMRF_2006	First line of therapy	First Line Therapy	PRIMING CHEMOTHERAPY	Other	PLERIXAFOR	Other			Completed regimen	Completed regimen	24	mg	mg	Q day	Q day	IV SubQ	IV SubQ	Log Forms	Other	PRIMING CHEMOTHERAPY		24	Q day	Q day					122	123	1
MMRF_2006	First line of therapy	First Line Therapy	PRIMING CHEMOTHERAPY	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	440	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	PRIMING CHEMOTHERAPY		440	Other	ONCE					127	127	1
MMRF_2006	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	EVERY OTHER WEEK					232		1
MMRF_2047	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	56	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		56	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1	162	1
MMRF_2047	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Induction	Induction		300	Other	QD (D1, D8, D15)					1	162	1
MMRF_2047	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D8, D15, D22)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D15, D22)					1	162	1
MMRF_2047	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					185	185	1
MMRF_2047	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	EVERY OTHER WEEK					288		1
MMRF_2116	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_2116	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	300	mg/m^2	mg/m^2	D1, D8, D15	Other	PO	PO	Log Forms	Induction	Induction		300	Other	D1, D8, D15					1	99	1
MMRF_2116	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	D1, D8, D15, D21	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1, D8, D15, D21					1	99	1
MMRF_2116	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			WENT TO TRANSPLANT	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					107	190	1
MMRF_2116	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			WENT TO TRANSPLANT	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					107	190	1
MMRF_2116	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	420	mg	mg	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		420	Other	ONCE					226	226	1
MMRF_2116	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Patient decision	Patient decision	10	mg/dL	mg/dL	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					303	487	1
MMRF_2116	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					631	639	1
MMRF_2116	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	EVERY OTHER WEEK					729		1
MMRF_2201	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1, D8, D15)					1	8	1
MMRF_2201	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	300	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Induction	Induction		300	Other	QD (D1, D8, D15)					1	8	1
MMRF_2201	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D8, D15)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1, D8, D15)					1	8	1
MMRF_2232	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	57	1
MMRF_2232	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	MG/ML	Other	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	50	1
MMRF_2232	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D2, D4, D5, D8, D9, D11, D12)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1	53	1
MMRF_2232	First line of therapy	First Line Therapy	PRIMING CHEMOTHERAPY	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3000	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	PRIMING CHEMOTHERAPY		3000	Other	ONCE					80	80	1
MMRF_2232	First line of therapy	First Line Therapy	PREP REGIMEN	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	PREP REGIMEN		200	Other	ONCE					99	99	1
MMRF_2232	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Consolidation	Consolidation		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					176	207	1
MMRF_2232	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-14)	QD (D1-14)					176	207	1
MMRF_2232	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1, D2, D4, D5, D8, D9, D11, D12)	Other	PO	PO	Log Forms	Consolidation	Consolidation		10	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					176	207	1
MMRF_2232	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			PER PROTOCOL DOSE INCREASED	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					227	310	1
MMRF_2232	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					311	380	1
MMRF_2232	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					381		1
MMRF_2425	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	225	1
MMRF_2425	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		300	Q week	Q week					1	225	1
MMRF_2425	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	225	1
MMRF_2425	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					232	232	1
MMRF_2425	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			INCREASED DOSE	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					344	521	1
MMRF_2425	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			PT WAS ON LEANALIDOMIDE MAINTENANCE UP TO HOSPITAL ADMIT ON 5/22	Other	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					521	812	1
MMRF_2440	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	84	1
MMRF_2440	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D2, D4, D5, D8, D9, D11, D12)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1	84	1
MMRF_2440	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	84	1
MMRF_2440	First line of therapy	First Line Therapy	PRIMING CHEMOTHERAPY	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3000	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	PRIMING CHEMOTHERAPY		3000	Other	ONCE					88	88	1
MMRF_2440	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					113	113	1
MMRF_2440	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					210	253	1
MMRF_2440	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					210	253	1
MMRF_2440	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-14)	QD (D1-14)					210	253	1
MMRF_2440	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			INCREASED DOSE	Other	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					259	349	1
MMRF_2440	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					350	462	1
MMRF_2440	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					463		1
MMRF_2485	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance	Checked	1.3	Other	EVERY OTHER WEEK					434		1
MMRF_2485	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			WENT TO TRANSPLANT	Other	1.5	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.5	Q week	Q week					1	238	1
MMRF_2485	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			WENT TO TRANSPLANT	Other	300	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		300	Q week	Q week					1	238	1
MMRF_2485	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			WENT TO TRANSPLANT	Other	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		40	Q week	Q week					1	238	1
MMRF_2485	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	CONDITIONING		200	Other	ONCE					291	291	1
MMRF_2566	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			STOPPED FOR STEM CELL COLLECTION	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2566	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			STOPPED FOR STEM CELL COLLECTION	Other	20	mg	mg	QD (D1, D2, D4, D5, D8, D9, D11, D12)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1	74	1
MMRF_2566	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			STOPPED FOR STEM CELL COLLECTION	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	57	1
MMRF_2566	First line of therapy	First Line Therapy	PRIMING CHEMOTHERAPY	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	3000	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	PRIMING CHEMOTHERAPY		3000	Other	ONCE					74	74	1
MMRF_2566	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					123	221	1
MMRF_2566	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1, D2, D4, D5, D8, D9, D11, D12)	Other	PO	PO	Log Forms	Induction	Induction		10	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					123	221	1
MMRF_2566	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					123	221	1
MMRF_2566	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					241		1
MMRF_2590	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	8	1
MMRF_2590	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TOLERATED WELL, INCREASED DOSE	Other	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					50	60	1
MMRF_2590	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Patient decision	Patient decision	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					71	113	1
MMRF_2590	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Patient decision	Patient decision	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					71	113	1
MMRF_2590	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Patient decision	Patient decision	60	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		60	Q week	Q week					113	120	1
MMRF_2590	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	62.5	mg	mg	Q week	Q week	INTRAMUSCULAR	Other	Log Forms	Induction	Induction		62.5	Q week	Q week					113	127	1
MMRF_2590	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					113	127	1
MMRF_2590	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					192	199	1
MMRF_2590	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Lack of response	Lack of response	62.5	mg	mg	Q week	Q week	INTRAMUSCULAR	Other	Log Forms	Induction	Induction		62.5	Q week	Q week					192	253	1
MMRF_2590	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1	Q week	Q week					199		1
MMRF_2590	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	8	1
MMRF_2590	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	8	1
MMRF_2622	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			STEM CELL COLLECTION	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2622	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1, D2, D4, D5, D8, D9, D11, D12)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1, D2, D4, D5, D8, D9, D11, D12)					1	205	1
MMRF_2622	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	197	1
MMRF_2622	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE CHANGED	Other	10	mg/dL	mg/dL	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					205	288	1
MMRF_2622	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		15	Q day	Q day					288	316	1
MMRF_2622	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance	Checked	10	Q day	Q day					337		1
MMRF_2147	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	21	1
MMRF_2147	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	78	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		78	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					29	274	1
MMRF_2147	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					29	280	1
MMRF_2147	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1, D8, D15, D22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1, D8, D15, D22					29	281	1
MMRF_2147	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	DAILY 3 WEEKS OUT OF 4	Other	PO	PO	Log Forms	Induction	Induction		15	Other	DAILY 3 WEEKS OUT OF 4					309	392	1
MMRF_2147	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q WEEK D1, D8 D15, D22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	Q WEEK D1, D8 D15, D22					1	22	1
MMRF_2147	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	45	mg	mg	D1 AND D2	Other	IV	IV	Log Forms	Induction	Induction		45	Other	D1 AND D2					1	2	1
MMRF_2147	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg	mg	D 8, D9, D15, D16	Other	IV	IV	Log Forms	Induction	Induction		36	Other	D 8, D9, D15, D16					12	16	1
MMRF_2419	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	3.3	mg	mg	WEEKLY D1,D8,D15,D21,D28	Other	IV	IV	Log Forms	Induction	Induction		3.3	Other	WEEKLY D1,D8,D15,D21,D28					1	162	1
MMRF_2419	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PBSCT	Other	40	mg	mg	WEEKLY D1, D8,D15,D21,D28	Other	PO	PO	Log Forms	Induction	Induction		40	Other	WEEKLY D1, D8,D15,D21,D28					1	274	1
MMRF_2419	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			PBSCT	Other	600	mg	mg	WEEKLY D1, D8, D15, D21, D28	Other	PO	PO	Log Forms	Induction	Induction		600	Other	WEEKLY D1, D8, D15, D21, D28					1	274	1
MMRF_2419	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			PBSCT	Other	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					162	274	1
MMRF_2419	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			PBSCT	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					162	274	1
MMRF_2419	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			PBSCT	Other	43.6	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		43.6	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					162	274	1
MMRF_2419	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	QD (D1-21)	QD (D1-21)					519		1
MMRF_2438	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.93	mg	mg	D1, D8, D15, AND D22	Other	SUBCUTANEOUSLY	Other	Log Forms	Induction	Induction		2.93	Other	D1, D8, D15, AND D22					1	106	1
MMRF_2438	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	D1,D8, D15, AND D22	Other	PO	PO	Log Forms	Induction	Induction		500	Other	D1,D8, D15, AND D22					1	106	1
MMRF_2438	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.5	MG/ML	Other	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.5	Q week	Q week					288	457	1
MMRF_2438	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	52	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		52	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					458	606	1
MMRF_2438	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					458	465	1
MMRF_2438	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					458	606	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					656	671	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					684	694	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Unknown	Unknown		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					684	694	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	CISPLATIN	Other			Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		10	QD (D1-4)	QD (D1-4)					684	694	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	400	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		400	QD (D1-4)	QD (D1-4)					684	694	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	ETOPOSIDE	Other			Completed regimen	Completed regimen	40	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					684	694	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		10	QD (D1-4)	QD (D1-4)					684	694	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1300	mg	mg	QWEEK (W1-8) Q2WEEKS (W9-24)	Other	IV	IV	Log Forms	Induction	Induction		1300	Other	QWEEK (W1-8) Q2WEEKS (W9-24)					739	866	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-28)	Other	PO	PO	Log Forms	Induction	Induction		4	Other	QD (D1-28)					739	866	1
MMRF_2438	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QAM (D2, D3, FOLLOWING DARA INFUSION)	Other	PO	PO	Log Forms	Induction	Induction		4	Other	QAM (D2, D3, FOLLOWING DARA INFUSION)					739	866	1
MMRF_2438	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	300	mg	mg	QD (D1, D8, D15; EVERY 28 DAY CYCLE)	Other	PO	PO	Log Forms	Unknown	Unknown		300	Other	QD (D1, D8, D15; EVERY 28 DAY CYCLE)					929	1066	1
MMRF_2438	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					929	1066	1
MMRF_2438	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					929	1219	1
MMRF_2517	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	EVERY 7 DAYS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	EVERY 7 DAYS					1	120	1
MMRF_2517	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.2	mg	mg	Q D1, D8, D15, AND D22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3.2	Other	Q D1, D8, D15, AND D22					1	106	1
MMRF_2517	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	120	1
MMRF_2517	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					260	673	1
MMRF_2573	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					1	268	1
MMRF_2573	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QD DAY 2, DAY 9, AND DAY16	Other	PO	PO	Log Forms	Induction	Induction		4	Other	QD DAY 2, DAY 9, AND DAY16					2	268	1
MMRF_2573	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	40	mg	mg	QD DAY 1 AND DAY 2	Other	IV	IV	Log Forms	Induction	Induction		40	Other	QD DAY 1 AND DAY 2					1	2	1
MMRF_2573	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	27	mg	mg	QD DAY 8 , DAY 9, DAY 15, AND DAY 16	Other	IV	IV	Log Forms	Induction	Induction		27	Other	QD DAY 8 , DAY 9, DAY 15, AND DAY 16					8	268	1
MMRF_2573	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	268	1
MMRF_2573	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Patient decision	Patient decision	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					284	979	1
MMRF_2573	First line of therapy	First Line Therapy	Unknown	Unknown	Daratumumab	Daratumumab		1			1300	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown	Checked	1300	Q week	Q week					981		1
MMRF_2573	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone		1			8	mg	mg	Q WEEK (D2, D3; WITH DARA BEING INFUSED ON D1)	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	8	Other	Q WEEK (D2, D3; WITH DARA BEING INFUSED ON D1)					982		1
MMRF_2597	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD DAYS 1,8,15,AND 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD DAYS 1,8,15,AND 22					1	106	1
MMRF_2597	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.85	mg	mg	QD DAYS 1,8,15, AND 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.85	Other	QD DAYS 1,8,15, AND 22					1	106	1
MMRF_2597	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	600	mg	mg	QD DAYS 1,8, 15, AND 22	Other	PO	PO	Log Forms	Induction	Induction		600	Other	QD DAYS 1,8, 15, AND 22					1	106	1
MMRF_2597	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		40	Q day	Q day					261	288	1
MMRF_2597	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					261	288	1
MMRF_2597	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		10	Q day	Q day					290	988	1
MMRF_2608	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	105	1
MMRF_2608	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			DOES REDUCED	Other	500	mg	mg	QD D1, D4, D8, D11	Other	PO	PO	Log Forms	Induction	Induction		500	Other	QD D1, D4, D8, D11					4	105	1
MMRF_2608	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1-4, D9-13, D17-21)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D9-13, D17-21)					1	33	1
MMRF_2608	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					44	326	1
MMRF_2608	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			CONCERNS WORSENING HEART FAILURE	Other	400	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		400	Q week	Q week					168	326	1
MMRF_2608	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	15	QD (D1-21)	QD (D1-21)					986		1
MMRF_2608	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	8	mg	mg	D1, D8, D15	Other	PO	PO	Log Forms	Unknown	Unknown		8	Other	D1, D8, D15					986	1064	1
MMRF_2608																		Log Forms													1
MMRF_2223	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	158	1
MMRF_2223	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	22	1
MMRF_2223	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					22	176	1
MMRF_2223	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib		0	BORTEZOMIB CONTINUED, BUT DOSAGE WAS HANGED	Other	1.3	mg/m^2	mg/m^2	DAY 1 AND DAY 15	Other	IV	IV	Log Forms	Maintenance	Maintenance		1.3	Other	DAY 1 AND DAY 15					447	603	1
MMRF_2223	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	Q2W	Other	PO	PO	Log Forms	Induction	Induction	Checked	20	Other	Q2W					1757		1
MMRF_2223	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					43	176	1
MMRF_2223	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					176	237	1
MMRF_2223	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1-21)	QD (D1-21)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1-21)	QD (D1-21)					433	629	1
MMRF_2223	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	REDUCING DOSAGE	Other	1.3	mg/m^2	mg/m^2	DAY 1 AND DAY 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAY 1 AND DAY 15					629	1757	1
MMRF_2223	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	DAY 1 AND DAY 15	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	Other	DAY 1 AND DAY 15					1757		1
MMRF_2223	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	INCREASING DOSAGE	Other	4	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-14)	QD (D1-14)					433	1462	1
MMRF_2223	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	10	mg	mg	Q2W	Other	PO	PO	Log Forms	Induction	Induction		10	Other	Q2W					1462	1757	1
MMRF_2568	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Completed regimen	Completed regimen	1200	mg	mg	QD (D1-14)	QD (D1-14)	IV	IV	Log Forms	Induction	Induction		1200	QD (D1-14)	QD (D1-14)					1481	1634	1
MMRF_2568	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	2.5	mg	mg	QD (D1-14)	QD (D1-14)	IV	IV	Log Forms	Induction	Induction		2.5	QD (D1-14)	QD (D1-14)					1481	1634	1
MMRF_2568	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	757	1
MMRF_2568	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	757	1
MMRF_2568	First line of therapy	First Line Therapy	Unknown	Unknown	Melphalan	Melphalan			Completed regimen	Completed regimen	270	mg	mg	ONCE	Other	IVB	IVB	Log Forms	Unknown	Unknown		270	Other	ONCE					169	169	1
MMRF_1833	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.85	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.85	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					8	162	1
MMRF_1833	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	43	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Consolidation	Consolidation		43	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					176	360	1
MMRF_1833	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-7)	QD (D1-7)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-7)	QD (D1-7)					1	44	1
MMRF_1833	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Pomalidomide	Pomalidomide		1			4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	4	QD (D1-21)	QD (D1-21)					1009		1
MMRF_1833	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	QWK	QWK					8		1
MMRF_2196	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.08	mg	mg	D1, D8, D15, D22	Other	IV	IV	Log Forms	Induction	Induction		3.08	Other	D1, D8, D15, D22					1	134	1
MMRF_2196	First line of therapy	First Line Therapy	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	50	mg	mg	DAY 1, 8, 15, 22	Other	PO	PO	Log Forms	Unknown	Unknown		50	Other	DAY 1, 8, 15, 22					1	126	1
MMRF_2196	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1	126	1
MMRF_2196	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					406	1050	1
MMRF_2196	First line of therapy	First Line Therapy	CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	PO	PO	Log Forms	Other	CONDITIONING		200	Q day	Q day					196	198	1
MMRF_2196	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD FOR 21 DAYS	Other	PO	PO	Log Forms	Unknown	Unknown		4	Other	QD FOR 21 DAYS					1073	1121	1
MMRF_2196	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1500	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		1500	Q week	Q week					1086	1319	1
MMRF_2196	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	3	mg	mg	QD FOR 21 DAYS	Other	PO	PO	Log Forms	Unknown	Unknown		3	Other	QD FOR 21 DAYS					1122	1263	1
MMRF_2196	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	PATIENT PASSED	Other	40	mg	mg	PRN	Other	IV	IV	Log Forms	Unknown	Unknown		40	Other	PRN					1086	1412	1
MMRF_2196	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		40	Q week	Q week					1086	1383	1
MMRF_2196	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		2	QD (D1-21)	QD (D1-21)					1243	1270	1
MMRF_2196	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Pomalidomide	Pomalidomide		0	Investigator decision for other reasons	Investigator decision for other reasons	1	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		1	QD (D1-21)	QD (D1-21)					1278	1399	1
MMRF_2196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			DOSE CHANGE	Other	36.6	mg	mg	Q day	Q day	IV	IV	Log Forms	Maintenance	Maintenance		36.6	Q day	Q day					1347	1361	1
MMRF_2196	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib		0	Investigator decision for other reasons	Investigator decision for other reasons	53.46	mg	mg	Q day	Q day	IV	IV	Log Forms	Maintenance	Maintenance		53.46	Q day	Q day					1361	1383	1
MMRF_2054	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	DAYS # 1,8,15,+ 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAYS # 1,8,15,+ 22					1	227	1
MMRF_2054	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	750	mg/m^2	mg/m^2	Q DAY #1 ONLY	Other	IVB	IVB	Log Forms	Induction	Induction		750	Other	Q DAY #1 ONLY					1	85	1
MMRF_2054	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1,8,15 + 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1,8,15 + 22					1	576	1
MMRF_2054	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					85	227	1
MMRF_2054	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			CHANGE TO 15MG DOSE	Other	20	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-21)	QD (D1-21)					934	1059	1
MMRF_2054	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib			CHANGE DOSE TO 2.3	Other	3	mg	mg	Q D1, D8, D15	Other	PO	PO	Log Forms	Maintenance	Maintenance		3	Other	Q D1, D8, D15					934	1059	1
MMRF_2054	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.3	mg	mg	Q D1, D8, D15 OF 28 DAY CYCLE	Other	PO	PO	Log Forms	Maintenance	Maintenance		2.3	Other	Q D1, D8, D15 OF 28 DAY CYCLE					1059	1800	1
MMRF_2054	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					1059		1
MMRF_2054	First line of therapy	First Line Therapy	Unknown	Unknown	Melphalan	Melphalan			MEPHALAN AND STEM CELL REINFUSION	Other	380	mg	mg	ONCE	Other	IV	IV	Log Forms	Unknown	Unknown		380	Other	ONCE					288	288	1
MMRF_2054	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	40	mg	mg	D 1, 2, 8 & 15	Other	IV	IV	Log Forms	Unknown	Unknown		40	Other	D 1, 2, 8 & 15					401	576	1
MMRF_2054	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	REFRACTORY DISEASE	Other	Pomalidomide	Pomalidomide			Completed regimen	Completed regimen	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	REFRACTORY DISEASE		4	QD (D1-21)	QD (D1-21)					401	576	1
MMRF_2054	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Ixazomib	Ixazomib			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	Q D1, D8, D15	Other	PO	PO	Log Forms	Other	SALVAGE		4	Other	Q D1, D8, D15					730	933	1
MMRF_2054	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	4	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	SALVAGE		4	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					730	1291	1
MMRF_2054	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SALVAGE	Other	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SALVAGE		25	QD (D1-21)	QD (D1-21)					730	933	1
MMRF_2054	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Ixazomib	Ixazomib		1			2.3	mg	mg	Q1,15	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	2.3	Other	Q1,15					1800		1
MMRF_2062	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PATIENT FAILED TO COME FOR APPOINTMENTS	Other	2.9	mg	mg	DAYS # 1,8,15, + 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.9	Other	DAYS # 1,8,15, + 22					1	472	1
MMRF_2062	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PATIENT DID NOT KEEP APPOINTMENTS	Other	40	mg	mg	DAYS 1,8,15, AND 22	Other	IV	IV	Log Forms	Induction	Induction		40	Other	DAYS 1,8,15, AND 22					1	472	1
MMRF_2171	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.5	mg/m^2	mg/m^2	QWK	QWK	SUBQ	Other	Log Forms	Induction	Induction		1.5	QWK	QWK					1	120	1
MMRF_2171	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	750	mg/m^2	mg/m^2	DAY 1 OF EACH CYCLE	Other	IV	IV	Log Forms	Induction	Induction		750	Other	DAY 1 OF EACH CYCLE					1	95	1
MMRF_2171	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	95	1
MMRF_2171	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			5	mg	mg	DAILY FOR 21 DAYS, THEN NONE FOR 1 WEEK	Other	PO	PO	Log Forms	Maintenance	Maintenance	Checked	5	Other	DAILY FOR 21 DAYS, THEN NONE FOR 1 WEEK					287		1
MMRF_2181	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBQ	Other	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	304	1
MMRF_2181	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	304	1
MMRF_2181	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	500	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		500	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					42	155	1
MMRF_2181	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	5	QD (D1-21)	QD (D1-21)					318		1
MMRF_2222	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	1665	mg	mg	ONE TIME	Other	IV	IV	Log Forms	Induction	Induction		1665	Other	ONE TIME					1	1	1
MMRF_2222	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV	IV	Log Forms	Induction	Induction		4	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	106	1
MMRF_2222	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3.33	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	SUBCU	Other	Log Forms	Induction	Induction		3.33	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	106	1
MMRF_2222	First line of therapy	First Line Therapy	Unknown	Unknown	Melphalan	Melphalan			Completed regimen	Completed regimen	400	mg	mg	ONE TIME	Other	IV	IV	Log Forms	Unknown	Unknown		400	Other	ONE TIME					153	153	1
MMRF_2222	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					258	915	1
MMRF_2222	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					915	1666	1
MMRF_2222	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					1666	1724	1
MMRF_2222	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance	Checked	20	Q week	Q week					1688		1
MMRF_2222	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		1			1800	mg	mg	EVERY OTHER WEEK	Other	IV	IV	Log Forms	Maintenance	Maintenance	Checked	1800	Other	EVERY OTHER WEEK					1689	1878	1
MMRF_2222	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance	Checked	15	QD (D1-21)	QD (D1-21)					1766		1
MMRF_2222	First line of therapy	First Line Therapy	PRE BONE MARROW TRANSPLANT	Other	CARMUSTINE	Other		0	Completed regimen	Completed regimen	500	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	PRE BONE MARROW TRANSPLANT		500	Other	ONCE					1958	1958	1
MMRF_2222	First line of therapy	First Line Therapy	PRE-BONE MARROW TRANSPLANT	Other	Melphalan	Melphalan		0	Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Other	PRE-BONE MARROW TRANSPLANT		200	Other	ONCE					1960	1960	1
MMRF_2222	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1800	mg	mg	EVERY 4 WEEKS	Other	IV	IV	Log Forms	Maintenance	Maintenance		1800	Other	EVERY 4 WEEKS					1878	1906	1
MMRF_2286	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	3	mg	mg	DAYS 1, 8, 15, 22	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3	Other	DAYS 1, 8, 15, 22					1	110	1
MMRF_2286	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1507	mg	mg	DAYS 1, 8, 15, 22	Other	IV	IV	Log Forms	Induction	Induction		1507	Other	DAYS 1, 8, 15, 22					1	110	1
MMRF_2286	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	DAYS 1, 8, 15, 22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1, 8, 15, 22					1	110	1
MMRF_2286	First line of therapy	First Line Therapy	PRIOR TO STEM CELL TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	PRIOR TO STEM CELL TRANSPLANT		200	Q day	Q day					342	342	1
MMRF_2286	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			UNKNOWN, OCCURRED DURING HOSPITAL STAY	Other	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					473	920	1
MMRF_2286	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DEATH	Other	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		5	Q day	Q day					985	1069	1
MMRF_2507	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			CARE TRANSFERRED TO ANOTHER FACILITY	Other	2.2	mg	mg	EVERY 3RD DAY	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	Other	EVERY 3RD DAY					1	162	1
MMRF_2507	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			MOVED TREATMENT TO ANOTHER FACILITY	Other	40	mg	mg	EVERY THIRD DAY	Other	IV	IV	Log Forms	Induction	Induction		40	Other	EVERY THIRD DAY					1	162	1
MMRF_2507	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			PT BEING FOLLOWED AT ANOTHER FACILITY	Other	1257	mg	mg	EVERY 3 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		1257	Other	EVERY 3 WEEKS					28	162	1
MMRF_2507	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					171	324	1
MMRF_2507	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					171		1
MMRF_2507	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.2	mg/kg	mg/kg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					328		1
MMRF_2126	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	36	1
MMRF_2126	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	249	1
MMRF_2126	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	36	1
MMRF_2126	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.8	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					92	117	1
MMRF_2126	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					134	246	1
MMRF_2126	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q WEEK 3 WEEKS ON 1 WEEK OFF	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	Q WEEK 3 WEEKS ON 1 WEEK OFF					330	543	1
MMRF_2126	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					330	551	1
MMRF_2339	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			CHANGE IN DOSE	Other	2.2	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	Q week	Q week					1	50	1
MMRF_2339	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	162	1
MMRF_2339	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	162	1
MMRF_2339	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	2.3	mg	mg	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.3	Q week	Q week					57	162	1
MMRF_2114	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TX D'CED BECAUSE PT IS GOING FOR STEM CELL HARVEST ON 1/13 -1/14/15	Other	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	134	1
MMRF_2114	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TX D'CED BECAUSE PT IS GOING FOR STEM CELL HARVEST ON 1/13 -1/14/15	Other	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	134	1
MMRF_2114	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DOSE REDUCED DUE TO NEUTROPENIA	Other	25	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-14)	QD (D1-14)					1	36	1
MMRF_2114	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			CYTOXAN WAS REPLACED WITH REVLIMID WHILE WAITING TO SCHEDULE FOR TRANSPLANT	Other	300	mg/m^2	mg/m^2	WEEKLY 3/4 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		300	Other	WEEKLY 3/4 WEEKS					109	134	1
MMRF_2114	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	ONCE	Other	IV	IV	Log Forms	Consolidation	Consolidation		200	Other	ONCE					236	236	1
MMRF_2114	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			TX DCED IN PREP FOR POSSIBLE TRANSPLANT	Other	15	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-14)	QD (D1-14)					37	85	1
MMRF_2114	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			TREATMENT WAS INTERRUPTED DUE TO RIGHT BREAST MASTITIS.	Other	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					169	177	1
MMRF_2114	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			TX WAS HELD BECAUSE PT GOING FOR ASCTX ON 4/7/15	Other	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					189	218	1
MMRF_2114	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			TREATMENT WAS INTERRUPTED DUE TO RIGHT BREAST MASTITIS & DUE TO CYTOPENIAS	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					169	179	1
MMRF_2114	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TREATMENT WAS INTERRUPTED DUE TO RIGHT BREAST MASTITIS.	Other	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					169	177	1
MMRF_2114	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			D'CED DUE TO WORSENING OF NEUROPATHY	Other	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QWK	QWK					351	383	1
MMRF_2114	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			MS MD DECIDED TO DOSE REDUCED DUE TO DIARRHEA & INCREASE IN NEUROPATHY	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					351	635	1
MMRF_2114	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			DOSE REDUCED WITH THE NEW REGIMEN	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		40	QWK	QWK					351	383	1
MMRF_2114	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TX WAS HELD BECAUSE PT GOING FOR ASCTX ON 4/7/15	Other	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					189	211	1
MMRF_2114	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			TX WAS HELD BECAUSE PT GOING FOR ASCTX ON 4/7/15	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					204	224	1
MMRF_2114	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			DOSE INCREASED DUE TO ADDITION OF MORE MEDS	Other	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		20	QWK	QWK					393	1041	1
MMRF_2114	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			DOSE INCREASED TO ACCOMODATE PATIENTS TRAVEL PLANS	Other	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					393	475	1
MMRF_2114	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			MD CHANGED REGIMEN TO 2 CONSECUTIVE DAYS EOW	Other	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					481	796	1
MMRF_2114	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			STOPPED DUE TO CHRONIC DIARRHEA	Other	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					642	725	1
MMRF_2114	First line of therapy	First Line Therapy	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	2 CONSECUTIVE DAYS EOW FOR A 28 DAY CYCLE	Other	IV	IV	Log Forms	Maintenance	Maintenance		27	Other	2 CONSECUTIVE DAYS EOW FOR A 28 DAY CYCLE					817	887	1
MMRF_2114	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			CHANGED DUE TO URI & RIGHT BREST MASTITIS	Other	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					908	1222	1
MMRF_2114	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab			AFTER THIS DOSE, PT WILL BE SWITCHING OVER TO EOW	Other	10	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		10	QWK	QWK					1054	1111	1
MMRF_2114	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			CHANGED DUE TO URI & RIGHT BREST MASTITIS	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		40	QWK	QWK					1054	1222	1
MMRF_2114	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DOSE REDUCED DUE TO DIARRHEA	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					1062	1082	1
MMRF_2114	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					1083	1266	1
MMRF_2114	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab			CHANGED DUE TO URI & RIGHT BREST MASTITIS	Other	10	mg/kg	mg/kg	EOW	Other	IV	IV	Log Forms	Maintenance	Maintenance		10	Other	EOW					1111	1222	1
MMRF_2114	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab			Disease progression/Relapse	Disease progression/Relapse	10	mg/kg	mg/kg	EOW	Other	IV	IV	Log Forms	Maintenance	Maintenance		10	Other	EOW					1237	1266	1
MMRF_2114	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Maintenance	Maintenance		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1237	1266	1
MMRF_2114	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	WEEKLY FOR 3 OUT OF 4 WEEKS	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	WEEKLY FOR 3 OUT OF 4 WEEKS					1237	1266	1
MMRF_2114	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab			Completed regimen	Completed regimen	16	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		16	QWK	QWK					1279	1328	1
MMRF_2114	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			PATIENT TRANSFERRED HER CARE TO AN OUTSIDE INSTITUTION	Other	20	mg	mg	ONLY DAY AFTER TX	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	ONLY DAY AFTER TX					1280	1461	1
MMRF_2114	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Daratumumab	Daratumumab			PATIENT TRANSFERRED HER CARE TO AN OUTSIDE INSTITUTION	Other	16	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Maintenance	Maintenance		16	QWK	QWK					1335	1461	1
MMRF_2114	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Elotuzumab	Elotuzumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg/kg	mg/kg	QOW	Other	IV	IV	Log Forms	Maintenance	Maintenance		10	Other	QOW					1125	1210	1
MMRF_2150	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			TX WAS HELD IN THE ANTICIPATION OF STEM CELL HARVEST	Other	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					1	212	1
MMRF_2150	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			TX WAS HELD IN THE ANTICIPATION OF STEM CELL HARVEST	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1	212	1
MMRF_2150	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			TX WAS HELD IN THE ANTICIPATION OF STEM CELL HARVEST	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					120	212	1
MMRF_2150	First line of therapy	First Line Therapy	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			PROGRESSIVE INCREASE IN IGA	Other	300	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		300	QWK	QWK					225	267	1
MMRF_2150	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			PROGRESSIVE DECREASE IN MONOCLONAL PROTEIN, THEREFORE, TX REG WAS CHANGED.	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					288	470	1
MMRF_2150	First line of therapy	First Line Therapy	Unknown	Unknown	Bortezomib	Bortezomib			PROGRESSIVE INCREASE IN IGA	Other	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.3	QWK	QWK					225	267	1
MMRF_2150	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			PROGRESSIVE INCREASE IN IGA	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					225	267	1
MMRF_2150	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PROGRESSIVE DECREASE IN MONOCLONAL PROTEIN, THEREFORE, TX REG WAS CHANGED.	Other	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QWK	QWK					288	470	1
MMRF_2150	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			PROGRESSIVE DECREASE IN MONOCLONAL PROTEIN, THEREFORE, TX REG WAS CHANGED.	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					288	470	1
MMRF_2150	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			SWITCHED FROM 1ST LINE TO 2ND LINE THERAPY	Other	1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	EVERY OTHER WEEK					491	1129	1
MMRF_2150	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					491	1135	1
MMRF_2150	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			POD CONFIRMED BY INCREASE IN MONOCLONAL PROTEIN + PROGRESSIVE ANEMIA	Other	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Maintenance	Maintenance		40	QWK	QWK					491	1135	1
MMRF_2150	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			SWITCHED LINES OF THERAPY, DUE TO POD	Other	2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		2	QD (D1-21)	QD (D1-21)					1143	1219	1
MMRF_2150	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab			Completed regimen	Completed regimen	16	mg/kg	mg/kg	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		16	QWK	QWK					1226	1282	1
MMRF_2150	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	EVERY OTHER WEEK FOR 16 WEEKS	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	16	Other	EVERY OTHER WEEK FOR 16 WEEKS					1289		1
MMRF_2150	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		40	QWK	QWK					1143	1213	1
MMRF_2150	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	EVERY OTHER WEEK	Other	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.3	Other	EVERY OTHER WEEK					1143	1213	1
MMRF_2150	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		1			2	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	2	QD (D1-21)	QD (D1-21)					1227		1
MMRF_2150	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			40	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown	Checked	40	QWK	QWK					1226		1
MMRF_1642	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	8	1
MMRF_1642	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					1	8	1
MMRF_1661	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Investigator decision for other reasons	Investigator decision for other reasons	14	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					18	36	1
MMRF_1661	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.5	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	250	1
MMRF_1661	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1200	mg	mg	QD (D1-21)	QD (D1-21)	IV	IV	Log Forms	Induction	Induction		1200	QD (D1-21)	QD (D1-21)					86	250	1
MMRF_1661	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					18	250	1
MMRF_1682	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	295	1
MMRF_1682	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Disease progression/Relapse	Disease progression/Relapse	14	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					1	295	1
MMRF_1682	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		100	QD (D1-14)	QD (D1-14)					1	295	1
MMRF_1682	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	2.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					338	447	1
MMRF_1682	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					338	447	1
MMRF_1682	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Maintenance	Maintenance		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					338	447	1
MMRF_1682	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-4)	QD (D1-4)					448	577	1
MMRF_1682	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					448	577	1
MMRF_1682	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					448	577	1
MMRF_1682	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					578	617	1
MMRF_1682	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Maintenance	Maintenance		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					578	617	1
MMRF_1682	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Doxorubicin	Doxorubicin			Investigator decision for other reasons	Investigator decision for other reasons	36	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Maintenance	Maintenance		36	Q day	Q day					612	612	1
MMRF_1682	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	30	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Maintenance	Maintenance		30	Q day	Q day					578	580	1
MMRF_1705	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	610	1
MMRF_1705	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	14	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					1	610	1
MMRF_1705	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	100	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	610	1
MMRF_1862	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	198	1
MMRF_1862	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					1	198	1
MMRF_1862	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					728	1059	1
MMRF_1862	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-4)	QD (D1-4)					728	1059	1
MMRF_1862	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib		1			2	mg	mg	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)	IV	IV	Log Forms	Consolidation	Consolidation	Checked	2	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)					1913		1
MMRF_1862	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone		1			20	mg	mg	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)	PO	PO	Log Forms	Consolidation	Consolidation	Checked	20	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)					1913		1
MMRF_1969	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	279	1
MMRF_1969	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		40	Q day	Q day					1	279	1
MMRF_1969	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					538	600	1
MMRF_1969	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		5	Q day	Q day					538	600	1
MMRF_1969	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					538	600	1
MMRF_1969	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			DEATH	Other	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					600	945	1
MMRF_1969	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-4)	QD (D1-4)					628	945	1
MMRF_2024	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Carfilzomib	Carfilzomib		0	TASPE	Other	2	mg	mg	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)	IV	IV	Log Forms	Consolidation	Consolidation		2	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)					1654	1773	1
MMRF_2024	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone	20	0	TASPE	Other	20	mg	mg	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1, D4, D8, D11, D28, D35, D38)	QD (D1, D4, D8, D11, D28, D35, D38)					1654	1773	1
MMRF_2024	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		10	QD (D1-21)	QD (D1-21)					374	420	1
MMRF_2024	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Lack of response	Lack of response	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					452	732	1
MMRF_2024	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		5	QD (D1-21)	QD (D1-21)					1313	1481	1
MMRF_2024	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	200	1
MMRF_2024	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	10	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					1	200	1
MMRF_2024	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			DOSE CHANGED	Other	15	mg	mg	QD (D1-3)	QD (D1-3)	PO	PO	Log Forms	Consolidation	Consolidation		15	QD (D1-3)	QD (D1-3)					88	95	1
MMRF_2024	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	5	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		5	Q day	Q day					96	200	1
MMRF_2024	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Consolidation	Consolidation		1.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					374	420	1
MMRF_2024	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation		40	Q day	Q day					374	420	1
MMRF_2039	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	197	1
MMRF_2039	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	IV	IV	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	197	1
MMRF_2039	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		100	BID	BID					154	280	1
MMRF_2039	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	5	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		5	QD (D1-21)	QD (D1-21)					386	473	1
MMRF_2039	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					312	473	1
MMRF_2039	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Maintenance	Maintenance		40	QD (D1-4)	QD (D1-4)					312	475	1
MMRF_2515	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	12	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		12	QD (D1-4)	QD (D1-4)					1	441	1
MMRF_2515	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone		0	Completed regimen	Completed regimen	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					1	469	1
MMRF_2515	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	1.8	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.8	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					33	469	1
MMRF_2543	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	161	1
MMRF_2543	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1900	mg	mg	QD (D1-21)	QD (D1-21)	IV	IV	Log Forms	Induction	Induction		1900	QD (D1-21)	QD (D1-21)					1	161	1
MMRF_2543	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	161	1
MMRF_2543	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Consolidation	Consolidation		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					800	1100	1
MMRF_2543	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					800	1100	1
MMRF_2543	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab		1	DEATH	Other	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction	Checked	16	Q week	Q week					1113	1400	1
MMRF_2543	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib		1	DEATH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1113	1400	1
MMRF_2543	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1	DEATH	Other	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1113	1400	1
MMRF_2586	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.3	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.3	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	707	1
MMRF_2586	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Disease progression/Relapse	Disease progression/Relapse	16	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	707	1
MMRF_2586	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	707	1
MMRF_1908	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.99	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.99	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_1908	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			PARESTHESIA	Other	100	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		100	Q day	Q day					1	179	1
MMRF_1908	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	123	1
MMRF_1908	First line of therapy	First Line Therapy	Maintenance	Maintenance	Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	100	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		100	Q day	Q day					387	718	1
MMRF_1908	First line of therapy	First Line Therapy	CONDITIONING REGIMEN FOR AUTOLOGOUS TRANSPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING REGIMEN FOR AUTOLOGOUS TRANSPLANT		200	Q day	Q day					187	188	1
MMRF_1908	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bendamustine	Bendamustine		0	Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					983	1734	1
MMRF_1908	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib		0	Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					983	2057	1
MMRF_1908	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					983	2057	1
MMRF_2013	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	165	1
MMRF_2013	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD DAYS 1-21	Other	PO	PO	Log Forms	Induction	Induction	Checked	25	Other	QD DAYS 1-21					1		1
MMRF_2013	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	QD DAYS 1,2,3,4,9,10,11,12	Other	PO	PO	Log Forms	Induction	Induction	Checked	40	Other	QD DAYS 1,2,3,4,9,10,11,12					1		1
MMRF_2013	First line of therapy	First Line Therapy	BMT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	BMT CONDITIONING		100	Q day	Q day					224	225	1
MMRF_2185	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SC	Other	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	165	1
MMRF_2185	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Completed regimen	Completed regimen	100	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		100	Q day	Q day					1	183	1
MMRF_2185	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD DAYS 1 TO 11	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD DAYS 1 TO 11					1	165	1
MMRF_2185	First line of therapy	First Line Therapy	BMT CONDITIONING	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	BMT CONDITIONING		100	Q day	Q day					219	220	1
MMRF_2185	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					533	718	1
MMRF_2185	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	36	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					774	861	1
MMRF_2185	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					774	861	1
MMRF_2185	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					774	861	1
MMRF_2185	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab			Lack of response	Lack of response	1200	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		1200	Q week	Q week					949	1002	1
MMRF_2185	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.35	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		2.35	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					949	1002	1
MMRF_2185	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-14)	QD (D1-14)					949	1002	1
MMRF_2185	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1200	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		1200	Q week	Q week					897	946	1
MMRF_1790	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.88	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1.88	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	113	1
MMRF_1790	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					1	123	1
MMRF_1790	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Investigator decision for other reasons	Investigator decision for other reasons	90	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		90	QD (D1-4)	QD (D1-4)					1	123	1
MMRF_1790	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.88	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUS	Other	Log Forms	Unknown	Unknown		1.88	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					359	554	1
MMRF_1790	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Unknown	Unknown		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					359	554	1
MMRF_1790	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bendamustine	Bendamustine			Adverse Event or co-morbidity	Adverse Event or co-morbidity	100	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		100	QD (D1-4)	QD (D1-4)					359	547	1
MMRF_1790	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Lack of response	Lack of response	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					614	660	1
MMRF_1790	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Unknown	Unknown		20	QWK	QWK					614	663	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	400	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		400	QD (D1-4)	QD (D1-4)					677	739	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	ETOPOSIDE	Other			Lack of response	Lack of response	40	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					677	739	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	CISPLATIN	Other			Lack of response	Lack of response	20	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1-4)	QD (D1-4)					677	739	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					677	740	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					780	813	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					828	897	1
MMRF_1790	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					780	897	1
MMRF_1790	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Lack of response	Lack of response	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					926	962	1
MMRF_1790	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					926	962	1
MMRF_2225	First line of therapy	First Line Therapy	HIGH DOSE CHEMOTHERAPY GIVEN FOR BMT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	160	mg	mg	D1,D2	Other	IV	IV	Log Forms	Other	HIGH DOSE CHEMOTHERAPY GIVEN FOR BMT		160	Other	D1,D2					180	181	1
MMRF_2225	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Consolidation	Consolidation		40	Q week	Q week					353	527	1
MMRF_2225	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					353	527	1
MMRF_2225	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					552	555	1
MMRF_2225	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	ETOPOSIDE	Other			Lack of response	Lack of response	60	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		60	QD (D1-4)	QD (D1-4)					552	555	1
MMRF_2225	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	CISPLATIN	Other			Lack of response	Lack of response	10	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		10	QD (D1-4)	QD (D1-4)					552	555	1
MMRF_2225	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	630	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		630	QD (D1-4)	QD (D1-4)					552	555	1
MMRF_2225	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	20	mg/m^2	mg/m^2	D1-D2	Other	IV	IV	Log Forms	Unknown	Unknown		20	Other	D1-D2					591	592	1
MMRF_2225	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		40	Q week	Q week					591	635	1
MMRF_2225	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					591	639	1
MMRF_2225	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib			Lack of response	Lack of response	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Unknown	Unknown		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					598	635	1
MMRF_2225	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			CHANGED DOSE	Other	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					648	675	1
MMRF_2225	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	3	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		3	QD (D1-21)	QD (D1-21)					684	765	1
MMRF_2225	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	50	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		50	QD (D1-21)	QD (D1-21)					648	765	1
MMRF_2225	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	D1-D4 EVERY WEEK	Other	PO	PO	Log Forms	Unknown	Unknown		40	Other	D1-D4 EVERY WEEK					648	765	1
MMRF_2225	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	CLARITHOMYCIN	Other			Disease progression/Relapse	Disease progression/Relapse	500	mg	mg	BID	BID	PO	PO	Log Forms	Unknown	Unknown		500	BID	BID					648	765	1
MMRF_2225	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	168	1
MMRF_2225	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.11	mg	mg	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		2.11	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					2	165	1
MMRF_2225	First line of therapy	First Line Therapy	Induction	Induction	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	32	mg	mg	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV	IV	Log Forms	Induction	Induction		32	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					2	165	1
MMRF_2225	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUS	Other	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					239	270	1
MMRF_2225	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Consolidation	Consolidation		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					239	270	1
MMRF_2307	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.26	mg	mg	D1,D2,D3,D4	Other	SUBCUTANEOUS	Other	Log Forms	Induction	Induction	Checked	2.26	Other	D1,D2,D3,D4					1		1
MMRF_2307	First line of therapy	First Line Therapy	Induction	Induction	Doxorubicin	Doxorubicin		1			34	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction	Checked	34	QD (D1-4)	QD (D1-4)					1		1
MMRF_2307	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone		1			40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction	Checked	40	QD (D1-4)	QD (D1-4)					1		1
MMRF_2465	First line of therapy	First Line Therapy	Induction	Induction	Doxorubicin	Doxorubicin			Completed regimen	Completed regimen	26	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		26	QD (D1-4)	QD (D1-4)					4	138	1
MMRF_2465	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	-4/-3/-2/-1	Other	IV	IV	Log Forms	Induction	Induction		40	Other	-4/-3/-2/-1					1	145	1
MMRF_2465	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		200	Q day	Q day					177	178	1
MMRF_2465	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.92	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.92	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					4	145	1
MMRF_2465	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		0	Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	D1	Other	IV	IV	Log Forms	Unknown	Unknown		20	Other	D1					1660	1660	1
MMRF_2465	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Carfilzomib	Carfilzomib		1			56	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV	IV	Log Forms	Unknown	Unknown	Checked	56	Other	QD (D1, D8, D15)					1667		1
MMRF_2465	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1, D8, D15, D22)	Other	PO	PO	Log Forms	Unknown	Unknown	Checked	40	Other	QD (D1, D8, D15, D22)					1660		1
MMRF_2465	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					1660		1
MMRF_2556	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SC	Other	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	180	1
MMRF_2556	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD 1-4 / 9-12	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD 1-4 / 9-12					1	181	1
MMRF_2556	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	190	1
MMRF_2556	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	180	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		180	Q day	Q day					207	208	1
MMRF_2556	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Consolidation	Consolidation		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					310	348	1
MMRF_2556	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					310	358	1
MMRF_2556	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-D4) (D9-D12)	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	QD (D1-D4) (D9-D12)					310	349	1
MMRF_2556	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					408	1767	1
MMRF_2556	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			DOSE REDUCTION	Other	20	mg	mg	D1D4, D9-D12	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	D1D4, D9-D12					408	447	1
MMRF_2556	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	D1-D4/D9-D12	Other	PO	PO	Log Forms	Maintenance	Maintenance		10	Other	D1-D4/D9-D12					466	1750	1
MMRF_2567	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	105	1
MMRF_2567	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	189	1
MMRF_2567	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1-4 / D9-12	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1-4 / D9-12					1	180	1
MMRF_2567	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					106	179	1
MMRF_2567	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	210	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		210	Q day	Q day					211	212	1
MMRF_2567	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	.7	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SC	Other	Log Forms	Consolidation	Consolidation		0.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					295	343	1
MMRF_2567	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1-4/D9-12	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	D1-4/D9-12					295	344	1
MMRF_2567	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					295	352	1
MMRF_2567	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			COLON CANCER	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					407	443	1
MMRF_2567	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			COLON CANCER	Other	20	mg	mg	QD D1-4/D9-12	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	QD D1-4/D9-12					407	438	1
MMRF_1727	First line of therapy	First Line Therapy	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	36	mg/m^2	mg/m^2	DAYS: 1,2,8.9,22,23,29,30	Other	IV	IV	Log Forms	Induction	Induction		36	Other	DAYS: 1,2,8.9,22,23,29,30					1	372	1
MMRF_1727	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	PATIEND DIED	Other	4	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-14)	QD (D1-14)					2190	2256	1
MMRF_1727	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Bortezomib	Bortezomib		0	PATIEND DIED	Other	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					2190	2256	1
MMRF_1727	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	PATIEND DIED	Other	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					2190	2256	1
MMRF_1727	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	9	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	344	1
MMRF_1727	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	60	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	344	1
MMRF_1727	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	4	mg	mg	DAYS: 8,9,22,23,29,30	Other	PO	PO	Log Forms	Induction	Induction		4	Other	DAYS: 8,9,22,23,29,30					9	29	1
MMRF_1727	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					831	1924	1
MMRF_1727	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					831	1924	1
MMRF_1727	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					831	1924	1
MMRF_1727	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	MELFLUFLEN	Other		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q4W	Other	IV	IV	Log Forms	Induction	Induction		40	Other	Q4W					1970	2092	1
MMRF_1727	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1970	2092	1
MMRF_1916	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	9	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	346	1
MMRF_1916	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	370	1
MMRF_1916	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	60	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	D1: IV AND D2-4: PO	Other	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	345	1
MMRF_1916	First line of therapy	First Line Therapy	Induction	Induction	Daratumumab	Daratumumab			Completed regimen	Completed regimen	16	mg/kg	mg/kg	DAYS, 1, 8,15,22	Other	IV	IV	Log Forms	Induction	Induction		16	Other	DAYS, 1, 8,15,22					1	363	1
MMRF_1916	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1266	1598	1
MMRF_1916	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		4	Q week	Q week					1266	1598	1
MMRF_1916	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1266	1598	1
MMRF_1971	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	364	1
MMRF_1971	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAYS 1,2,4,5,8,9,15,16	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1,2,4,5,8,9,15,16					1	357	1
MMRF_1971	First line of therapy	First Line Therapy	Induction	Induction	Daratumumab	Daratumumab			Completed regimen	Completed regimen	16	mg/kg	mg/kg	DAYS: 1,8,15,22	Other	IV	IV	Log Forms	Induction	Induction		16	Other	DAYS: 1,8,15,22					1	357	1
MMRF_1971	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					865	1239	1
MMRF_1971	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					865	1239	1
MMRF_1971	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		4	QWK	QWK					865	1239	1
MMRF_1971	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	FILANESIB	Other			Investigator decision for other reasons	Investigator decision for other reasons	1.4	mg/m^2	mg/m^2	DAYS 1,2,15,16 EACH 28	Other	IV	IV	Log Forms	Induction	Induction		1.4	Other	DAYS 1,2,15,16 EACH 28					1246	1391	1
MMRF_1971	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Investigator decision for other reasons	Investigator decision for other reasons	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1246	1391	1
MMRF_1971	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1246	1391	1
MMRF_2017	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	188	1
MMRF_2017	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	DAYS 1,2,4,5,8,9,11,12	Other	IV	IV	Log Forms	Induction	Induction		20	Other	DAYS 1,2,4,5,8,9,11,12					1	188	1
MMRF_2017	First line of therapy	First Line Therapy	Induction	Induction	DARATUMUMAB	Other			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		16	Q week	Q week					1	188	1
MMRF_2017	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					258	366	1
MMRF_2017	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					258	366	1
MMRF_2017	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			DEATH	Other	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					372	410	1
MMRF_2017	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					366	400	1
MMRF_2068	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	397	1
MMRF_2068	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAYS: 1,2,4,5,8,9,11,12,15,16 (21 DAYS EACH CYCLE)	Other	DAYS 1,8,15 IV  ..... REST DAYS  PO	Other	Log Forms	Induction	Induction		20	Other	DAYS: 1,2,4,5,8,9,11,12,15,16 (21 DAYS EACH CYCLE)					1	397	1
MMRF_2068	First line of therapy	First Line Therapy	Induction	Induction	Daratumumab	Daratumumab			Completed regimen	Completed regimen	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		16	Q week	Q week					1	391	1
MMRF_2089	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	DAYS 1,4,8,11,22,25,29,32	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	DAYS 1,4,8,11,22,25,29,32					1	274	1
MMRF_2089	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Disease progression/Relapse	Disease progression/Relapse	9	mg/m^2	mg/m^2	DAYS 1,2,3,4	Other	PO	PO	Log Forms	Induction	Induction		9	Other	DAYS 1,2,3,4					1	253	1
MMRF_2089	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	60	mg/m^2	mg/m^2	DAYS 1,2,3,4	Other	PO	PO	Log Forms	Induction	Induction		60	Other	DAYS 1,2,3,4					1	253	1
MMRF_2089	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			EXITUS	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					295	449	1
MMRF_2089	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			EXITUS	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					295	449	1
MMRF_2102	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD(1-21)	Other	PO	PO	Log Forms	Induction	Induction		10	Other	QD(1-21)					711	1166	1
MMRF_2102	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD(D1,D8,D15)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD(D1,D8,D15)					711	1166	1
MMRF_2102	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	36	mg/m^2	mg/m^2	QD(D1,D2,D8,D9,D15,D16)	Other	IV	IV	Log Forms	Induction	Induction		36	Other	QD(D1,D2,D8,D9,D15,D16)					717	1166	1
MMRF_2102	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	FILANESIB	Other			Disease progression/Relapse	Disease progression/Relapse	1.4	mg/m^2	mg/m^2	DAYS 1,2,15,16 EACH 28	Other	IV	IV	Log Forms	Induction	Induction		1.4	Other	DAYS 1,2,15,16 EACH 28					1173	1389	1
MMRF_2102	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1173	1389	1
MMRF_2102	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1173	1389	1
MMRF_2102	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	DARATUMUMAB	Other		1			896	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction	Checked	896	Q week	Q week					1394		1
MMRF_2102	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction	Checked	20	Q week	Q week					1394		1
MMRF_2102	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.2	mg/m^2	mg/m^2	DAYS 1,4,8,11,22,25,29,32	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.2	Other	DAYS 1,4,8,11,22,25,29,32					1	379	1
MMRF_2102	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	9	mg/m^2	mg/m^2	DAYS 1,2,3,4	Other	PO	PO	Log Forms	Induction	Induction		9	Other	DAYS 1,2,3,4					1	379	1
MMRF_2102	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	60	mg/m^2	mg/m^2	DAYS 1,2,3,4	Other	PO	PO	Log Forms	Induction	Induction		60	Other	DAYS 1,2,3,4					1	379	1
MMRF_2142	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	274	1
MMRF_2142	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	14	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					1	274	1
MMRF_2142	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	100	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	274	1
MMRF_2335	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DEATH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	264	1
MMRF_2335	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			DEATH	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	264	1
MMRF_2335	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	40	mg	mg	QD (1-4) QD (9-12)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (1-4) QD (9-12)					1	264	1
MMRF_2468	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	189	1
MMRF_2468	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	189	1
MMRF_2468	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-D4) Y (D9-12)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1-D4) Y (D9-12)					1	189	1
MMRF_2468	First line of therapy	First Line Therapy	BONE MARROW TRASPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	DAYS -2, AND -1 RESPECT AT BONE MARROW TRASPLANT	Other	IV	IV	Log Forms	Other	BONE MARROW TRASPLANT		200	Other	DAYS -2, AND -1 RESPECT AT BONE MARROW TRASPLANT					220	221	1
MMRF_2468	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	1.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					351	404	1
MMRF_2468	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					351	404	1
MMRF_2468	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	40	mg	mg	(QD (D1-D4) Y (D9-12))	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	(QD (D1-D4) Y (D9-12))					351	404	1
MMRF_2468	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					418	1082	1
MMRF_2468	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Completed regimen	Completed regimen	20	mg	mg	(QD (D1-D4) Y (D9-12))	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	(QD (D1-D4) Y (D9-12))					418	1082	1
MMRF_1654	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DEATH	Other	2.21	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.21	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	81	1
MMRF_1654	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			DEATH	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	50	1
MMRF_1678	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			DEATH	Other	100	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		100	BID	BID					1	231	1
MMRF_1678	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	100	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		100	BID	BID					1	212	1
MMRF_1678	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	100	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		100	BID	BID					1	212	1
MMRF_1738	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	71	1
MMRF_1738	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1	71	1
MMRF_1738	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	50	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		50	Q day	Q day					93	526	1
MMRF_1738	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide			DEATH	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					554	689	1
MMRF_1738	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Unknown	Unknown		20	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					554	689	1
MMRF_2224	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.63	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SC	Other	Log Forms	Induction	Induction		2.63	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	400	1
MMRF_2224	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					1	45	1
MMRF_2224	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	401	1
MMRF_2224	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					477	1222	1
MMRF_2224	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (1-4, 9-12)	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	QD (1-4, 9-12)					477	1222	1
MMRF_2368	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_2368	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Disease progression/Relapse	Disease progression/Relapse	13.32	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		13.32	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_2368	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	88.8	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		88.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	106	1
MMRF_2050	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	EVERY 42 DAYS	Other	IV	IV	Log Forms	Induction	Induction	Checked	1.3	Other	EVERY 42 DAYS					1		1
MMRF_2050	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan		1			9	mg/m^2	mg/m^2	EVERY 42 DAYS	Other	PO	PO	Log Forms	Induction	Induction	Checked	9	Other	EVERY 42 DAYS					1		1
MMRF_2050	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone		1			60	mg/m^2	mg/m^2	EVERY042 DAYS	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	60	Other	EVERY042 DAYS					1		1
MMRF_2197	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.4	mg	mg	FOUR DAYS PER MONTH	Other	SUBCUTANEOUS	Other	Log Forms	Induction	Induction	Checked	2.4	Other	FOUR DAYS PER MONTH					1		1
MMRF_2197	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan		1			16	mg	mg	FOUR TIMES PER MONTH	Other	PO	PO	Log Forms	Induction	Induction	Checked	16	Other	FOUR TIMES PER MONTH					1		1
MMRF_2197	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone		1			110	mg	mg	FOUR DAYS PER MONTH	Other	PO	PO	Log Forms	Induction	Induction	Checked	110	Other	FOUR DAYS PER MONTH					1		1
MMRF_2200	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.6	mg	mg	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	147	1
MMRF_2200	First line of therapy	First Line Therapy	Induction	Induction	Doxorubicin	Doxorubicin			Disease progression/Relapse	Disease progression/Relapse	79.6	mg	mg	ONCE A MONTH	Other	IV	IV	Log Forms	Induction	Induction		79.6	Other	ONCE A MONTH					20	147	1
MMRF_2200	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					1	147	1
MMRF_2200	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Thalidomide	Thalidomide			COMPLETE RESPONSE, PATIENT IS ADMITTED FOR AUTOLOGOUS STEM CELL TCPH	Other	200	mg	mg	ONCE A DAY	Other	PO	PO	Log Forms	Induction	Induction		200	Other	ONCE A DAY					147	208	1
MMRF_2200	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			COMPLETE RESPONSE, PATIENT IS ADMITTED FOR AUTOLOGOUS STEM CELL TCPH	Other	50	mg	mg	ONCE A DAY	Other	PO	PO	Log Forms	Induction	Induction		50	Other	ONCE A DAY					147	208	1
MMRF_2200	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			COMPLETE RESPONSE, PATIENT IS ADMITTED FOR AUTOLOGOUS STEM CELL TCPH	Other	40	mg	mg	ONCE A DAY, ONLY THE FIRST 4DAYS OF EACH CICLE	Other	PO	PO	Log Forms	Induction	Induction		40	Other	ONCE A DAY, ONLY THE FIRST 4DAYS OF EACH CICLE					147	208	1
MMRF_2200	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	260	mg	mg	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		260	Q day	Q day					209	940	1
MMRF_2273	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	266	1
MMRF_2273	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		500	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	266	1
MMRF_2273	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					1	266	1
MMRF_2273	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab		1			16	mg/kg	mg/kg	ONCE A WEEK	Other	IV	IV	Log Forms	Induction	Induction	Checked	16	Other	ONCE A WEEK					1075		1
MMRF_2273	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction	Checked	25	Q day	Q day					1076		1
MMRF_2273	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	ONCE A WEEK	Other	PO	PO	Log Forms	Induction	Induction	Checked	20	Other	ONCE A WEEK					1075		1
MMRF_2336	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	132	1
MMRF_2336	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Completed regimen	Completed regimen	100	mg	mg	100MG A DAY FOR 21DAYS. TOTAL 2100MG	Other	PO	PO	Log Forms	Induction	Induction		100	Other	100MG A DAY FOR 21DAYS. TOTAL 2100MG					1	122	1
MMRF_2336	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					1	125	1
MMRF_2336	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					670		1
MMRF_2336	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	EVERY WEEK	Other	PO	PO	Log Forms	Induction	Induction	Checked	40	Other	EVERY WEEK					670		1
MMRF_2336	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib		1			27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					729		1
MMRF_2365	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.87	mg	mg	D1,D8	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.87	Other	D1,D8					1		1
MMRF_2365	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone		1			80	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction	Checked	80	QD (D1-4)	QD (D1-4)					1		1
MMRF_2365	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan		1			12	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction	Checked	12	QD (D1-14)	QD (D1-14)					1		1
MMRF_2519	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	156	1
MMRF_2519	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Completed regimen	Completed regimen	100	mg	mg	ONCE A DAY	Other	PO	PO	Log Forms	Induction	Induction		100	Other	ONCE A DAY					1	876	1
MMRF_2519	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	ONCE A DAY ON DAY 1,2,3,4.	Other	PO	PO	Log Forms	Induction	Induction		40	Other	ONCE A DAY ON DAY 1,2,3,4.					1	148	1
MMRF_2578	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	81	1
MMRF_2578	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	100	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	81	1
MMRF_2578	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	D1, D8, D15, D21	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1, D8, D15, D21					126	760	1
MMRF_2578	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					126	760	1
MMRF_2578	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.28	mg	mg	ONCE A DAY, DAYS 1,4,8,11,22,25,29,32	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.28	Other	ONCE A DAY, DAYS 1,4,8,11,22,25,29,32					1	109	1
MMRF_2602	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2602	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction	Checked	40	QD (D1-4)	QD (D1-4)					1		1
MMRF_2606	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.98	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.98	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	200	1
MMRF_2606	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	460	mg	mg	ONCE A DAY ON DAYS 1, 8, 15 AND 22	Other	IV	IV	Log Forms	Induction	Induction		460	Other	ONCE A DAY ON DAYS 1, 8, 15 AND 22					1	211	1
MMRF_2606	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	209	1
MMRF_2606	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	310	mg	mg	QD (D1-7)	QD (D1-7)	IV	IV	Log Forms	Consolidation	Consolidation		310	QD (D1-7)	QD (D1-7)					220	227	1
MMRF_2606	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib		1			27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction	Checked	27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					625		1
MMRF_2606	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					592		1
MMRF_2606	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					592		1
MMRF_1923	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	162	1
MMRF_1923	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1-2, D8-9	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1-2, D8-9					1	152	1
MMRF_1923	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Completed regimen	Completed regimen	10	mg	mg	D1-21	Other	PO	PO	Log Forms	Induction	Induction		10	Other	D1-21					1	152	1
MMRF_1923	First line of therapy	First Line Therapy	Induction	Induction	Daratumumab	Daratumumab			Completed regimen	Completed regimen	16	mg/kg	mg/kg	D1, D8, D15	Other	IV	IV	Log Forms	Induction	Induction		16	Other	D1, D8, D15					1	152	1
MMRF_1923	First line of therapy	First Line Therapy	Consolidation	Consolidation	Melphalan	Melphalan			Completed regimen	Completed regimen	360	mg	mg	Q day	Q day	IV	IV	Log Forms	Consolidation	Consolidation		360	Q day	Q day					171	171	1
MMRF_1923	First line of therapy	First Line Therapy	Maintenance	Maintenance	IXAZOMIB VS PLACEBO	Other		0	Completed regimen	Completed regimen	2.3	mg	mg	DAYS 1, 8, 15	Other	PO	PO	Log Forms	Maintenance	Maintenance		2.3	Other	DAYS 1, 8, 15					318	990	1
MMRF_1716	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DEATH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	76	1
MMRF_1716	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			DEATH	Other	60	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	76	1
MMRF_1716	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			DEATH	Other	9	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	76	1
MMRF_1931	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD(D1,D4,D8,D11,D22,D25,D29,D32	Other	SC	Other	Log Forms	Induction	Induction		1.3	Other	QD(D1,D4,D8,D11,D22,D25,D29,D32					1	310	1
MMRF_1931	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	9	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	310	1
MMRF_1931	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	60	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	310	1
MMRF_1931	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					796	1768	1
MMRF_1931	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					796	936	1
MMRF_1931	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					936	1768	1
MMRF_1931	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib	KYCYDEX	0	Patient decision	Patient decision	56	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV	IV	Log Forms	Induction	Induction		56	Other	QD (D1, D8, D15)					1895	2084	1
MMRF_1931	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide	KYCYDEX	0	Patient decision	Patient decision	300	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV	IV	Log Forms	Induction	Induction		300	Other	QD (D1, D8, D15)					2261	2266	1
MMRF_1931	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone	KYCYDEX	0	Patient decision	Patient decision	10	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1895	2084	1
MMRF_2194	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Vincristine	Vincristine			Lack of response	Lack of response	.4	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		0.4	QD (D1-4)	QD (D1-4)					592	648	1
MMRF_2194	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Lack of response	Lack of response	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					670	787	1
MMRF_2194	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					670	787	1
MMRF_2194	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	QD (D 1-4, D9-12)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D 1-4, D9-12)					670	787	1
MMRF_2194	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	16	mg/kg	mg/kg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		16	Q week	Q week					850	1061	1
MMRF_2194	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	ADRIAMYCIN	Other			Lack of response	Lack of response	9	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					592	648	1
MMRF_2194	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					592	648	1
MMRF_2194	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	50	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		50	Q day	Q day					542	591	1
MMRF_2194	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	289	1
MMRF_2194	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	9	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	289	1
MMRF_2194	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	60	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	289	1
MMRF_2194	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					449	591	1
MMRF_2194	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		40	Q week	Q week					449	591	1
MMRF_2245	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	Q week	Q week	SUBCUTANEOUS	Other	Log Forms	Induction	Induction	Checked	1.3	Q week	Q week					1		1
MMRF_2245	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan		1			9	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction	Checked	9	QD (D1-4)	QD (D1-4)					1		1
MMRF_2245	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone		1			60	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction	Checked	60	QD (D1-4)	QD (D1-4)					1		1
MMRF_2257	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	103	1
MMRF_2257	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1	103	1
MMRF_2257	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1.3	Q week	Q week					1154	1293	1
MMRF_2257	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	400	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		400	Q week	Q week					1154	1293	1
MMRF_2257	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1154	1293	1
MMRF_2526	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	260	1
MMRF_2526	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	8	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		8	QD (D1-4)	QD (D1-4)					1	260	1
MMRF_2526	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	90	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		90	QD (D1-4)	QD (D1-4)					1	260	1
MMRF_1913	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	369	1
MMRF_1913	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	9	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	369	1
MMRF_1913	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	60	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	369	1
MMRF_1913	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	15	mg	mg	ALTERNATE DAYS	Other	PO	PO	Log Forms	Induction	Induction		15	Other	ALTERNATE DAYS					651	676	1
MMRF_1913	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		15	Q day	Q day					677	733	1
MMRF_1913	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4, 9-12)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, 9-12)					651	662	1
MMRF_1913	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		4	Q week	Q week					684	704	1
MMRF_1913	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Prednisone	Prednisone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	50	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		50	Q week	Q week					705	733	1
MMRF_1913	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					677	683	1
MMRF_1913	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	70	mg/m^2	mg/m^2	QD (D1, D8, D15)	Other	IV	IV	Log Forms	Induction	Induction		70	Other	QD (D1, D8, D15)					804	936	1
MMRF_1913	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					804	936	1
MMRF_1913	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1800	mg	mg	C1-2: D1, 8, 15, 22; C3-6: D1, 15; FROM C7: D1.	Other	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1800	Other	C1-2: D1, 8, 15, 22; C3-6: D1, 15; FROM C7: D1.					1104	1265	1
MMRF_1978	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	18	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		18	QD (D1-4)	QD (D1-4)					1	263	1
MMRF_1978	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	120	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		120	QD (D1-4)	QD (D1-4)					1	263	1
MMRF_1978	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.5	mg	mg	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV	IV	Log Forms	Induction	Induction		2.5	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	281	1
MMRF_1978	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	15	QD (D1-21)	QD (D1-21)					646		1
MMRF_1978	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown	Checked	40	Q week	Q week					646		1
MMRF_1989	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Maintenance	Maintenance		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					333	1205	1
MMRF_1989	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					333	1205	1
MMRF_1989	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D9-12)	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	QD (D1-4, D9-12)					333	1205	1
MMRF_1989	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.7	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.7	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	190	1
MMRF_1989	First line of therapy	First Line Therapy	CONDITIONING TREATMENT PRETRASPLANT	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	100	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING TREATMENT PRETRASPLANT		100	Q day	Q day					232	233	1
MMRF_1989	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	200	1
MMRF_1989	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D9-12)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D9-12)					1	191	1
MMRF_2049	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					1	157	1
MMRF_2049	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	147	1
MMRF_2049	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D 1-4, D9-12)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D 1-4, D9-12)					1	147	1
MMRF_2049	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib		0	DOSE CHANGE	Other	1.0	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1	QWK	QWK					1730	1759	1
MMRF_2049	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide		0	Completed regimen	Completed regimen	300	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		300	QWK	QWK					1730	1946	1
MMRF_2049	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Prednisone	Prednisone		0	Completed regimen	Completed regimen	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		15	Q day	Q day					1730	1946	1
MMRF_2049	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib		0	DOSE CHANGE	Other	1.3	mg/m^2	mg/m^2	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		1.3	QWK	QWK					1760	1790	1
MMRF_2049	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Bortezomib	Bortezomib		0	Completed regimen	Completed regimen	1.0	mg/m^2	mg/m^2	QWK	QWK	IV	IV	Log Forms	Unknown	Unknown		1	QWK	QWK					1836	1946	1
MMRF_2049	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Cyclophosphamide	Cyclophosphamide		1			650	mg/m^2	mg/m^2			IV	IV	Log Forms	Consolidation	Consolidation	Checked	650							1947		1
MMRF_2049	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Consolidation	Consolidation	Prednisone	Prednisone		1			7.5	mg	mg	Q day	Q day	PO	PO	Log Forms	Consolidation	Consolidation	Checked	7.5	Q day	Q day					1947		1
MMRF_2384	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction	Checked	1.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2384	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					1		1
MMRF_2384	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1-4, D9-12)	Other	PO	PO	Log Forms	Induction	Induction	Checked	40	Other	QD (D1-4, D9-12)					1		1
MMRF_2385	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	77	1
MMRF_2385	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1600	mg	mg	MONTHLY	Other	IV	IV	Log Forms	Induction	Induction		1600	Other	MONTHLY					1	77	1
MMRF_2385	First line of therapy	First Line Therapy	Induction	Induction	METHYLPREDNISOLONE	Other			Completed regimen	Completed regimen	125	mg	mg	MONTHLY	Other	IV	IV	Log Forms	Induction	Induction		125	Other	MONTHLY					1	77	1
MMRF_2385	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RESCUE	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.8	mg	mg	QWK	QWK	IV SubQ	IV SubQ	Log Forms	Other	RESCUE		2.8	QWK	QWK					619	701	1
MMRF_2385	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	DEATH	Other	20	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		20	Q week	Q week					1137	1816	1
MMRF_2385	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Bortezomib	Bortezomib		0	DEATH	Other	2.8	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV SubQ	IV SubQ	Log Forms	Unknown	Unknown		2.8	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1137	1816	1
MMRF_2385	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RESCUE	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1080	mg	mg	MONTHLY	Other	IV	IV	Log Forms	Other	RESCUE		1080	Other	MONTHLY					619	701	1
MMRF_2385	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	RESCUE	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	RESCUE		40	QWK	QWK					619	701	1
MMRF_2385	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		25	QD (D1-21)	QD (D1-21)					738	1027	1
MMRF_2385	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		40	Q week	Q week					738	1027	1
MMRF_2385	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Daratumumab	Daratumumab		0	DEATH	Other	1550	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		1550	Q week	Q week					1137	1816	1
MMRF_2413	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	1200	mg	mg	Q week	Q week	IV	IV	Log Forms	Unknown	Unknown		1200	Q week	Q week					851	935	1
MMRF_2413	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Unknown	Unknown		15	Q day	Q day					857	913	1
MMRF_2413	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Lenalidomide	Lenalidomide		0	DEATH	Other	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		15	QD (D1-21)	QD (D1-21)					935	1442	1
MMRF_2413	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	DEATH	Other	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown		20	Q week	Q week					935	1442	1
MMRF_2413	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	2.9	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		2.9	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	11	1
MMRF_2413	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	4	1
MMRF_2413	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	125	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		125	QD (D1-14)	QD (D1-14)					1	4	1
MMRF_2413	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1200	mg	mg	EACH 4 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		1200	Other	EACH 4 WEEKS					48	400	1
MMRF_2413	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		15	Q day	Q day					48	400	1
MMRF_2580	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.1	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction	Checked	2.1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2580	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan		1			14	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction	Checked	14	QD (D1-4)	QD (D1-4)					1		1
MMRF_2580	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone		1			96	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction	Checked	96	QD (D1-4)	QD (D1-4)					1		1
MMRF_1861	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	D1, D4, D8, D11, D22, D25, D29, D32 (CYCLE 1) AND Q WEEK STARTING CYCLE 2	Other	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1.3	Other	D1, D4, D8, D11, D22, D25, D29, D32 (CYCLE 1) AND Q WEEK STARTING CYCLE 2					1	123	1
MMRF_1861	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		12	QD (D1-4)	QD (D1-4)					1	77	1
MMRF_1861	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	90	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		90	QD (D1-4)	QD (D1-4)					1	252	1
MMRF_1861	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1	mg/m^2	mg/m^2	Q week	Q week	SUBCUTANEOS	Other	Log Forms	Induction	Induction		1	Q week	Q week					130	270	1
MMRF_1861	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	10	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					102	252	1
MMRF_1861	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1040	1067	1
MMRF_1861	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1040	1067	1
MMRF_1861	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					1068	1305	1
MMRF_1861	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1068	1305	1
MMRF_1861	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Ixazomib	Ixazomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		4	Q week	Q week					1237	1255	1
MMRF_1933	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1	29	1
MMRF_1933	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			BY MISSUNDERSTANDING OF THE PROPER ADMINISTRATION	Other	2	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		2	Q day	Q day					1	38	1
MMRF_1933	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	120	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		120	QD (D1-4)	QD (D1-4)					1	242	1
MMRF_1933	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q week	Q week	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1.3	Q week	Q week					39	95	1
MMRF_1933	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	SUBCUTANEOS	Other	Log Forms	Induction	Induction		1.3	Q week	Q week					109	260	1
MMRF_1933	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	16	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					39	126	1
MMRF_1933	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	12	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		12	QD (D1-4)	QD (D1-4)					151	242	1
MMRF_1933	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Melphalan	Melphalan		1			12	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction	Checked	12	QD (D1-4)	QD (D1-4)					944		1
MMRF_1933	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Prednisone	Prednisone		1			120	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction	Checked	120	QD (D1-4)	QD (D1-4)					944		1
MMRF_1995	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			WE DECIDED ONLY ONE CYCLE OF VELCADE+DEXA AND THEN ANOTHER TREATMENT	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	22	1
MMRF_1995	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			WE DECIDED ONLY ONE CYCLE OF VELCADE+DEXA AND THEN ANOTHER TREATMENT	Other	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					1	22	1
MMRF_1995	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			CHANGE OF FRECUENCY	Other	1.3	mg/m^2	mg/m^2	DAY 1,4,8,11,22,25,29,32 (CYCLES OF 42 DAYS)	Other	IV	IV	Log Forms	Induction	Induction		1.3	Other	DAY 1,4,8,11,22,25,29,32 (CYCLES OF 42 DAYS)					41	75	1
MMRF_1995	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			CHANGE OF DOSE	Other	18	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		18	QD (D1-4)	QD (D1-4)					41	145	1
MMRF_1995	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	120	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		120	QD (D1-4)	QD (D1-4)					41	275	1
MMRF_1995	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			CHANGE OF DOSE	Other	1.3	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		1.3	Q week	Q week					76	208	1
MMRF_1995	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	14	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					146	275	1
MMRF_1995	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	.7	mg/m^2	mg/m^2	Q week	Q week	IV	IV	Log Forms	Induction	Induction		0.7	Q week	Q week					209	293	1
MMRF_1995	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Investigator decision for other reasons	Investigator decision for other reasons	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					460	980	1
MMRF_1995	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					460	1159	1
MMRF_1995	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					981	1147	1
MMRF_1995	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1184	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		1184	Q week	Q week					1198	1218	1
MMRF_1995	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBQ	Other	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1198	1218	1
MMRF_1995	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		40	Q week	Q week					1198	1218	1
MMRF_1995	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			DAYS 1,2 DIFFERENT DOSE	Other	37	mg	mg	Q day	Q day	IV	IV	Log Forms	Induction	Induction		37	Q day	Q day					1232	1233	1
MMRF_1995	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	128	mg	mg	DAYS 1,8,15	Other	IV	IV	Log Forms	Induction	Induction		128	Other	DAYS 1,8,15					1234	1362	1
MMRF_1995	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	550	mg	mg	DAYS1,8,15	Other	IV	IV	Log Forms	Induction	Induction		550	Other	DAYS1,8,15					1232	1362	1
MMRF_1995	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					1232	1363	1
MMRF_1995	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1367	1461	1
MMRF_1995	Fifth Line Therapy (following 4th relapse)	Fifth Line Therapy (following 4th relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1367	1461	1
MMRF_2008	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			DOSIS REDUCED DUE TO RENAL INSUFICENCE	Other	9	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					34	61	1
MMRF_2008	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			DOSIS REDUCED DUE TO ADVERSE EVENT	Other	60	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					34	61	1
MMRF_2008	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			INCREASE OF DOSE	Other	12	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		12	QD (D1-4)	QD (D1-4)					62	208	1
MMRF_2008	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	90	mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Induction	Induction		90	QD (D1-14)	QD (D1-14)					62	426	1
MMRF_2008	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			INCREASE OF DOSE DUE TO CREATININE IS BETTER	Other	14	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					209	236	1
MMRF_2008	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	18	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		18	QD (D1-4)	QD (D1-4)					237	426	1
MMRF_2008	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					427	568	1
MMRF_2008	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Lack of response	Lack of response	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					427	925	1
MMRF_2008	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					569	1063	1
MMRF_2008	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	30	mg	mg	2 DAYS PER WEEK	Other	PO	PO	Log Forms	Induction	Induction		30	Other	2 DAYS PER WEEK					926	1065	1
MMRF_2008	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1101	1210	1
MMRF_2008	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					1101	1210	1
MMRF_2008	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1600	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		1600	Q week	Q week					1263	1324	1
MMRF_2008	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		20	Q week	Q week					1263	1324	1
MMRF_2008	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			DECEASED PATIENT	Other	70	mg/m^2	mg/m^2	DAY 1,8,15	Other	IV	IV	Log Forms	Induction	Induction		70	Other	DAY 1,8,15					1325	1380	1
MMRF_2008	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			DECEASED PATIENT	Other	650	mg	mg	DAYS 1,8,15	Other	IV	IV	Log Forms	Induction	Induction		650	Other	DAYS 1,8,15					1325	1380	1
MMRF_2008	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			DECEASED PATIENT	Other	40	mg	mg	DAYS 1,8,15,22	Other	PO	PO	Log Forms	Induction	Induction		40	Other	DAYS 1,8,15,22					1325	1380	1
MMRF_2008	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					6	426	1
MMRF_2008	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	1-4 AND 9-12 DAYS	Other	PO	PO	Log Forms	Induction	Induction		20	Other	1-4 AND 9-12 DAYS					1	12	1
MMRF_2011	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	D1, D8, D22 AND D29	Other	SC	Other	Log Forms	Induction	Induction		1.3	Other	D1, D8, D22 AND D29					1	42	1
MMRF_2011	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1348	1737	1
MMRF_2011	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1348	1737	1
MMRF_2011	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1768	1816	1
MMRF_2011	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					1768	1816	1
MMRF_2011	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Pomalidomide	Pomalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		4	QD (D1-21)	QD (D1-21)					1838	1885	1
MMRF_2011	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					1838	1885	1
MMRF_2011	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			ADVERSE EVENT + DISEASE PROGRESION	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	SC	Other	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					281	302	1
MMRF_2011	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					316	399	1
MMRF_2011	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	EVERY 48 HOURS D1-D21	Other	PO	PO	Log Forms	Induction	Induction		15	Other	EVERY 48 HOURS D1-D21					400	429	1
MMRF_2011	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	D1-2, D8-9, D15-16, D22-23	Other	PO	PO	Log Forms	Induction	Induction		20	Other	D1-2, D8-9, D15-16, D22-23					316	429	1
MMRF_2011	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	EVERY 48 HOURS D1-D21	Other	PO	PO	Log Forms	Induction	Induction		15	Other	EVERY 48 HOURS D1-D21					444	464	1
MMRF_2011	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-2, D8-9, D14-15, D21-22)	Other	PO	PO	Log Forms	Induction	Induction		20	Other	QD (D1-2, D8-9, D14-15, D21-22)					444	466	1
MMRF_2011	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Completed regimen	Completed regimen	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					661	688	1
MMRF_2011	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					661	1207	1
MMRF_2011	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	120	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		120	QWK	QWK					689	1193	1
MMRF_2011	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-4)	QD (D1-4)					1	98	1
MMRF_2011	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		40	Q day	Q day					1	4	1
MMRF_2011	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q week	Q week	SC	Other	Log Forms	Induction	Induction		1.3	Q week	Q week					43	98	1
MMRF_2011	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	D1, D4, D8, D11, D22, D25, D29, D32	Other	SC	Other	Log Forms	Induction	Induction		1.3	Other	D1, D4, D8, D11, D22, D25, D29, D32					113	133	1
MMRF_2011	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					113	315	1
MMRF_2011	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	60	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					5	98	1
MMRF_2011	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	60	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					113	315	1
MMRF_2011	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	SC	Other	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					137	227	1
MMRF_2011	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	SC	Other	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					239	259	1
MMRF_2011	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	SC	Other	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					267	280	1
MMRF_2085	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	DAY 1,4,8,11,22,25,29,32 (CYCLES OF 42 DAYS)	Other	SC	Other	Log Forms	Induction	Induction		1.3	Other	DAY 1,4,8,11,22,25,29,32 (CYCLES OF 42 DAYS)					1	9	1
MMRF_2085	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					1	4	1
MMRF_2085	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	120	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		120	QD (D1-4)	QD (D1-4)					1	4	1
MMRF_2085	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1000	mg	mg	ONLY 1 DAY	Other	IV	IV	Log Forms	Induction	Induction		1000	Other	ONLY 1 DAY					96	96	1
MMRF_2085	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					96	99	1
MMRF_2085	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					122	141	1
MMRF_2085	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					122	141	1
MMRF_2085	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					418	435	1
MMRF_2085	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Melphalan	Melphalan			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-4)	QD (D1-4)					234	417	1
MMRF_2085	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	120	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		120	QD (D1-4)	QD (D1-4)					234	417	1
MMRF_2229	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					533	1002	1
MMRF_2229	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1	mg/m^2	mg/m^2	DAY 1 AND 8 OF CYCLES OF 28 DAYS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1	Other	DAY 1 AND 8 OF CYCLES OF 28 DAYS					967	1002	1
MMRF_2229	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Daratumumab	Daratumumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1056	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		1056	Q week	Q week					1248	1342	1
MMRF_2229	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1248	1347	1
MMRF_2229	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		40	Q week	Q week					1248	1347	1
MMRF_2229	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					1	239	1
MMRF_2229	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	250	mg	mg	DAYS 2,9,16	Other	PO	PO	Log Forms	Induction	Induction		250	Other	DAYS 2,9,16					1	28	1
MMRF_2229	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	100	mg	mg	3 TIMES PER WEEK (MONDAY, WEDNESDAY AND FRIDAY)	Other	PO	PO	Log Forms	Induction	Induction		100	Other	3 TIMES PER WEEK (MONDAY, WEDNESDAY AND FRIDAY)					1	250	1
MMRF_2229	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	1000	mg	mg	DAY 1 OF EACH CYCLE	Other	IV	IV	Log Forms	Induction	Induction		1000	Other	DAY 1 OF EACH CYCLE					29	225	1
MMRF_2229	First line of therapy	First Line Therapy	Maintenance	Maintenance	Bortezomib	Bortezomib			TOXICITY	Other	1.3	mg/m^2	mg/m^2	DAY 1 AND 8 OF CYCLES OF 28 DAYS	Other	IV SubQ	IV SubQ	Log Forms	Maintenance	Maintenance		1.3	Other	DAY 1 AND 8 OF CYCLES OF 28 DAYS					337	966	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					939	941	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Daratumumab	Daratumumab			Disease progression/Relapse	Disease progression/Relapse	1100	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		1100	Q week	Q week					945	970	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	2.3	mg	mg	D1, D7	Other	SC	Other	Log Forms	Induction	Induction		2.3	Other	D1, D7					945	970	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		40	Q week	Q week					945	970	1
MMRF_2328	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D 1-4, D8-11	Other	PO	PO	Log Forms	Maintenance	Maintenance		40	Other	D 1-4, D8-11					813	823	1
MMRF_2328	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					690	774	1
MMRF_2328	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		20	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					690	774	1
MMRF_2328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	36	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		36	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					824	858	1
MMRF_2328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	Q week	Q week	IV+PO	Other	Log Forms	Induction	Induction		40	Q week	Q week					824	879	1
MMRF_2328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Disease progression/Relapse	Disease progression/Relapse	545	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		545	Q week	Q week					824	879	1
MMRF_2328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	66	mg	mg	QID	QID	IV	IV	Log Forms	Induction	Induction		66	QID	QID					866	867	1
MMRF_2328	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	PO	PO	Log Forms	Maintenance	Maintenance		40	Q day	Q day					880	883	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Daratumumab	Daratumumab			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1176	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		1176	Q week	Q week					908	919	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					908	919	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	IV	IV	Log Forms	Induction	Induction		40	Q week	Q week					908	919	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	Pomalidomide	Pomalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	4	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		4	Q day	Q day					939	941	1
MMRF_2328	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Induction	Induction	CLARITROMICINE	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		500	BID	BID					939	941	1
MMRF_2328	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	D1, D4, D8, D11, D21, D24, D28, D31	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	D1, D4, D8, D11, D21, D24, D28, D31					5	35	1
MMRF_2328	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			INTERRUPTED DUE TO MOBILIZATION PREVIOUS TPH	Other	1000	mg	mg	D1, D21	Other	IV	IV	Log Forms	Induction	Induction		1000	Other	D1, D21					5	272	1
MMRF_2328	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	D1-4, D25-28	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1-4, D25-28					1	28	1
MMRF_2328	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	D1, D4, D8, D11, D21, D24, D28, D31	Other	SUBCUTANEOS	Other	Log Forms	Induction	Induction		1	Other	D1, D4, D8, D11, D21, D24, D28, D31					53	56	1
MMRF_2328	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	.7	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	SUBCUTANEOS	Other	Log Forms	Induction	Induction		0.7	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					137	165	1
MMRF_2328	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	D1, D4, D8, D11, D21, D24, D28, D31	Other	SUBCUTANEOS	Other	Log Forms	Induction	Induction		1	Other	D1, D4, D8, D11, D21, D24, D28, D31					63	77	1
MMRF_2328	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	SUBCUTANEOS	Other	Log Forms	Induction	Induction		1	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					179	207	1
MMRF_2328	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			INTERRUPTED DUE TO MOBILIZATION PREVIOUS TPH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	SUBCUTANEOS	Other	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					221	272	1
MMRF_2328	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	D25-28	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D25-28					74	161	1
MMRF_2328	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	D1-4, D25-28	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1-4, D25-28					179	357	1
MMRF_2328	First line of therapy	First Line Therapy	MOBILIZATION OF PERIPHERAL BLOOD HEMATOPOIETIC PROGENITORS	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2870	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION OF PERIPHERAL BLOOD HEMATOPOIETIC PROGENITORS		2870	Q day	Q day					273	273	1
MMRF_2328	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					312	354	1
MMRF_2328	First line of therapy	First Line Therapy	IN ORDER TO OBTAIN A BETTER RESPONSE PREVIOUS TO TPH, THERE WAS NO RELAPSE/PROGRESSION	Other	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	IN ORDER TO OBTAIN A BETTER RESPONSE PREVIOUS TO TPH, THERE WAS NO RELAPSE/PROGRESSION		25	QD (D1-21)	QD (D1-21)					426	572	1
MMRF_2328	First line of therapy	First Line Therapy	IN ODER TO OBTAIN A BETTER RESPONSE PREVIOUS TO TPH, THERE WAS NO RELAPSE/PROGRESSION	Other	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	D1-4, D9-12, D17-20	Other	PO	PO	Log Forms	Other	IN ODER TO OBTAIN A BETTER RESPONSE PREVIOUS TO TPH, THERE WAS NO RELAPSE/PROGRESSION		40	Other	D1-4, D9-12, D17-20					426	572	1
MMRF_2328	First line of therapy	First Line Therapy	MOBILIZATION OF PERIPHERAL BLOOD HEMATOPOIETIC PROGENITORS	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	2870	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	MOBILIZATION OF PERIPHERAL BLOOD HEMATOPOIETIC PROGENITORS		2870	Q day	Q day					385	385	1
MMRF_2401	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOS	Other	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	99	1
MMRF_2401	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Investigator decision for other reasons	Investigator decision for other reasons	50	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		50	Q day	Q day					1	14	1
MMRF_2401	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	DAY 1-4, DAY 8-11	Other	IV AND PO	Other	Log Forms	Induction	Induction		40	Other	DAY 1-4, DAY 8-11					1	98	1
MMRF_2401	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Bortezomib	Bortezomib			EVOLUTION TO PLASMA CELL LEUKEMIA	Other	1.3	mg/m^2	mg/m^2	QD (D1, 5, 8, 12,22, 26, 29, 33)	Other	SUBCUTANEOS	Other	Log Forms	Induction	Induction		1.3	Other	QD (D1, 5, 8, 12,22, 26, 29, 33)					123	249	1
MMRF_2401	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			EVOLUTION TO PLASMA CELL LEUKEMIA	Other	1000	mg/m^2	mg/m^2	QD (D1, D22)	Other	IV	IV	Log Forms	Induction	Induction		1000	Other	QD (D1, D22)					123	249	1
MMRF_2401	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			EVOLUTION TO PLASMA CELL LEUKEMIA	Other	40	mg	mg	QD (D1-4, D22-25)	Other	IV + PO	Other	Log Forms	Induction	Induction		40	Other	QD (D1-4, D22-25)					123	249	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	CLARITHROMYCIN	Other			Disease progression/Relapse	Disease progression/Relapse	500	mg	mg	12 HOURS	Other	PO	PO	Log Forms	Unknown	Unknown		500	Other	12 HOURS					251	270	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	CISPLATINE	Other			Disease progression/Relapse	Disease progression/Relapse	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		10	QD (D1-4)	QD (D1-4)					251	270	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	ETOPOSIDE (VP16)	Other			Disease progression/Relapse	Disease progression/Relapse	40	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					251	270	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Doxorubicin	Doxorubicin			Disease progression/Relapse	Disease progression/Relapse	10	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		10	QD (D1-4)	QD (D1-4)					251	270	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Melphalan	Melphalan			Disease progression/Relapse	Disease progression/Relapse	16	mg	mg	QD (D1-4)	QD (D1-4)	IV	IV	Log Forms	Unknown	Unknown		16	QD (D1-4)	QD (D1-4)					251	270	1
MMRF_2401	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Maintenance	Maintenance		20	QD (D1-4)	QD (D1-4)					295	298	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					251	270	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	Q week	Q week	SUBCUTANEOS	Other	Log Forms	Maintenance	Maintenance		1	Q week	Q week					305	364	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		10	QD (D1-21)	QD (D1-21)					305	350	1
MMRF_2401	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Disease progression/Relapse	Disease progression/Relapse	100	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		100	Q day	Q day					15	115	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	CONDITIONING FOR AUTO-TRASPLANT	Other	Melphalan	Melphalan			Disease progression/Relapse	Disease progression/Relapse	167	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING FOR AUTO-TRASPLANT		167	Q day	Q day					271	272	1
MMRF_2401	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	EVERY 2 DAYS /WEEK	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	EVERY 2 DAYS /WEEK					305	364	1
MMRF_2427	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	235	1
MMRF_2427	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	1-4 AND 9-12 DAYS	Other	PO	PO	Log Forms	Induction	Induction		40	Other	1-4 AND 9-12 DAYS					1	306	1
MMRF_2427	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	100	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		100	Q day	Q day					1	246	1
MMRF_2427	First line of therapy	First Line Therapy	Induction	Induction	CLARITROMICINA	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	BID	BID	PO	PO	Log Forms	Induction	Induction		500	BID	BID					180	250	1
MMRF_2427	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					246	250	1
MMRF_2427	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					344	370	1
MMRF_2427	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					344	398	1
MMRF_2427	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		15	QD (D1-21)	QD (D1-21)					371	398	1
MMRF_2427	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	DAY1-21	Other	PO	PO	Log Forms	Induction	Induction		10	Other	DAY1-21					446	554	1
MMRF_2427	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4, D9-13, D17-21)	QD (D1-4, D9-13, D17-21)					446	554	1
MMRF_2435	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Investigator decision for other reasons	Investigator decision for other reasons	1.3	mg/m^2	mg/m^2	D 1, 4, 8, 11, 22, 25, 29, 32	Other	SUBCUTANEOS	Other	Log Forms	Induction	Induction		1.3	Other	D 1, 4, 8, 11, 22, 25, 29, 32					1	32	1
MMRF_2435	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	14	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					1	102	1
MMRF_2435	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	105	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		105	QD (D1-4)	QD (D1-4)					1	221	1
MMRF_2435	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	Q week	Q week	SUBCUTANEOS	Other	Log Forms	Induction	Induction		1.3	Q week	Q week					43	218	1
MMRF_2435	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	12	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		12	QD (D1-4)	QD (D1-4)					127	130	1
MMRF_2435	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	12	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		12	Q day	Q day					218	221	1
MMRF_2435	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Maintenance	Maintenance		20	Q week	Q week					260	705	1
MMRF_2488	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			EXTRACTION PROGENITORS FOR AUTO-TPH	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOS	Other	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	90	1
MMRF_2488	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			EXTRACTION PROGENITORS FOR AUTO-TPH	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					1	90	1
MMRF_2488	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			EXTRACTION PROGENITORS FOR AUTO-TPH	Other	40	mg	mg	D1-4, D9-12	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1-4, D9-12					1	90	1
MMRF_2488	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOS	Other	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					105	188	1
MMRF_2488	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					105	188	1
MMRF_2488	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1-4, D8-11	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D1-4, D8-11					105	188	1
MMRF_2488	First line of therapy	First Line Therapy	CONDITIONING FOR AUTO-TPH	Other	BUSULFAN	Other			Completed regimen	Completed regimen	3.2	mg/kg	mg/kg	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING FOR AUTO-TPH		3.2	Q day	Q day					243	245	1
MMRF_2488	First line of therapy	First Line Therapy	CONDITIONING FOR AUTO-TPH	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	140	mg/m^2	mg/m^2	Q day	Q day	IV	IV	Log Forms	Other	CONDITIONING FOR AUTO-TPH		140	Q day	Q day					246	246	1
MMRF_2488	First line of therapy	First Line Therapy	Consolidation	Consolidation	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOS	Other	Log Forms	Consolidation	Consolidation		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					346	402	1
MMRF_2488	First line of therapy	First Line Therapy	Consolidation	Consolidation	Lenalidomide	Lenalidomide			Completed regimen	Completed regimen	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Consolidation	Consolidation		25	QD (D1-21)	QD (D1-21)					346	402	1
MMRF_2488	First line of therapy	First Line Therapy	Consolidation	Consolidation	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D1-4, D8-11	Other	PO	PO	Log Forms	Consolidation	Consolidation		40	Other	D1-4, D8-11					346	402	1
MMRF_2488	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					430	609	1
MMRF_2488	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	DAYS 1-4 AND 9-12	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	DAYS 1-4 AND 9-12					430	609	1
MMRF_2488	First line of therapy	First Line Therapy	Maintenance	Maintenance	Lenalidomide	Lenalidomide		0	Disease progression/Relapse	Disease progression/Relapse	15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Maintenance	Maintenance		15	QD (D1-21)	QD (D1-21)					700	1520	1
MMRF_2488	First line of therapy	First Line Therapy	Maintenance	Maintenance	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	D1-4, 8-11	Other	PO	PO	Log Forms	Maintenance	Maintenance		20	Other	D1-4, 8-11					700	1520	1
MMRF_2488	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib	GEM-KYCYDEX	1			56	mg/m^2	mg/m^2	D1, 8, 15 EVERY 28 DAYS	Other	IV	IV	Log Forms	Induction	Induction	Checked	56	Other	D1, 8, 15 EVERY 28 DAYS					1585		1
MMRF_2488	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide	GEM-KYCYDEX	1			300	mg/m^2	mg/m^2	D1, 8, 15 EVERY 28 DAYS	Other	IV	IV	Log Forms	Induction	Induction	Checked	300	Other	D1, 8, 15 EVERY 28 DAYS					1585		1
MMRF_2488	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone	GEM-KYCYDEX	1			20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Induction	Induction	Checked	20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1585		1
MMRF_2490	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			DOSE CHANGED	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	53	1
MMRF_2490	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	20	mg	mg	DAYS 1-4 AND 8-11	Other	PO	PO	Log Forms	Induction	Induction		20	Other	DAYS 1-4 AND 8-11					1	53	1
MMRF_2490	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Disease progression/Relapse	Disease progression/Relapse	1	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Q week	Q week					54	82	1
MMRF_2490	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Disease progression/Relapse	Disease progression/Relapse	8	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		8	QD (D1-4)	QD (D1-4)					54	82	1
MMRF_2490	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Disease progression/Relapse	Disease progression/Relapse	60	mg/m^2	mg/m^2	Q week	Q week	PO	PO	Log Forms	Induction	Induction		60	Q week	Q week					54	82	1
MMRF_2490	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Disease progression/Relapse	Disease progression/Relapse	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		10	QD (D1-21)	QD (D1-21)					91	146	1
MMRF_2490	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		20	Q week	Q week					91	146	1
MMRF_2490	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					161	343	1
MMRF_2490	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1000	mg	mg	DAY 1 OF EACH CYCLE	Other	IV	IV	Log Forms	Induction	Induction		1000	Other	DAY 1 OF EACH CYCLE					161	343	1
MMRF_2490	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	CLARITROMICINA	Other			Adverse Event or co-morbidity	Adverse Event or co-morbidity	500	mg	mg	BID DURING 21 DAYS	Other	PO	PO	Log Forms	Induction	Induction		500	Other	BID DURING 21 DAYS					161	343	1
MMRF_2490	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	50	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		50	Q day	Q day					161	223	1
MMRF_2518	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	42	1
MMRF_2518	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Patient decision	Patient decision	16	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	171	1
MMRF_2518	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Patient decision	Patient decision	105	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		105	QD (D1-4)	QD (D1-4)					1	171	1
MMRF_2518	First line of therapy	First Line Therapy	Induction	Induction	Daratumumab	Daratumumab			Completed regimen	Completed regimen	1168	mg	mg	QWK	QWK	IV	IV	Log Forms	Induction	Induction		1168	QWK	QWK					1	42	1
MMRF_2518	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Q week	Q week					43	125	1
MMRF_2518	First line of therapy	First Line Therapy	Induction	Induction	Daratumumab	Daratumumab			Patient decision	Patient decision	16	mg/kg	mg/kg	QD (D1-21)	QD (D1-21)	IV	IV	Log Forms	Induction	Induction		16	QD (D1-21)	QD (D1-21)					43	188	1
MMRF_2518	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Patient decision	Patient decision	1	mg/m^2	mg/m^2	Q week	Q week	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1	Q week	Q week					126	237	1
MMRF_2293	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2293	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		200	Q day	Q day					1	399	1
MMRF_2293	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1-4, D 9-13)	Other	PO	PO	Log Forms	Induction	Induction	Checked	40	Other	QD (D1-4, D 9-13)					1		1
MMRF_2300	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			EXITUS	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	66	1
MMRF_2300	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	14	1
MMRF_2300	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			EXITUS	Other	100	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					24	66	1
MMRF_2300	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			EXITUS	Other	1000	mg	mg	Q 3WK	Other	IV	IV	Log Forms	Induction	Induction		1000	Other	Q 3WK					42	66	1
MMRF_2313	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	340	1
MMRF_2313	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD (D1-4, D 9-13)	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD (D1-4, D 9-13)					1	340	1
MMRF_2313	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		200	Q day	Q day					8	358	1
MMRF_2313	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TREATMENT AT RELAPSE WHILE WAITING FOR A DEFINITIVE REGIMEN	Other	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Other	TREATMENT AT RELAPSE WHILE WAITING FOR A DEFINITIVE REGIMEN		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					749	759	1
MMRF_2313	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TREATMENT AT RELAPSE WHILE WAITING FOR A DEFINITIVE REGIMEN	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	500	mg	mg	SINGLE DOSE	Other	IV	IV	Log Forms	Other	TREATMENT AT RELAPSE WHILE WAITING FOR A DEFINITIVE REGIMEN		500	Other	SINGLE DOSE					743	743	1
MMRF_2313	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TREATMENT AT RELAPSE WHILE WAITING FOR A DEFINITIVE REGIMEN	Other	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	Q day	Q day	IV	IV	Log Forms	Other	TREATMENT AT RELAPSE WHILE WAITING FOR A DEFINITIVE REGIMEN		40	Q day	Q day					743	746	1
MMRF_2313	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TREATMENT AT RELAPSE	Other	Carfilzomib	Carfilzomib			Disease progression/Relapse	Disease progression/Relapse	60	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	TREATMENT AT RELAPSE		60	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					773	1282	1
MMRF_2313	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TREATMENT AT RELAPSE	Other	Lenalidomide	Lenalidomide		1	Disease progression/Relapse	Disease progression/Relapse	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	TREATMENT AT RELAPSE	Checked	25	QD (D1-21)	QD (D1-21)					773	1610	1
MMRF_2313	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TREATMENT AT RELAPSE	Other	Dexamethasone	Dexamethasone			Disease progression/Relapse	Disease progression/Relapse	40	mg	mg	D1, D8, CD15, D22	Other	PO	PO	Log Forms	Other	TREATMENT AT RELAPSE		40	Other	D1, D8, CD15, D22					773	1282	1
MMRF_2313	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	TREATMENT AT RELAPSE	Other	Daratumumab	Daratumumab		1	Disease progression/Relapse	Disease progression/Relapse	1878	mg	mg	QWK	QWK	IV	IV	Log Forms	Other	TREATMENT AT RELAPSE	Checked	1878	QWK	QWK					1295	1610	1
MMRF_2313	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	TREATMENT AT RELAPSE	Other	Dexamethasone	Dexamethasone		1	Disease progression/Relapse	Disease progression/Relapse	20	mg	mg	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	PO	PO	Log Forms	Other	TREATMENT AT RELAPSE	Checked	20	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					1295	1610	1
MMRF_2313	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide		0	Disease progression/Relapse	Disease progression/Relapse	1000	mg	mg	EVERY TWO WEEKS	Other	IV	IV	Log Forms	Unknown	Unknown		1000	Other	EVERY TWO WEEKS					1610	1893	1
MMRF_2313	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Pomalidomide	Pomalidomide		0	Disease progression/Relapse	Disease progression/Relapse	4	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		4	QD (D1-21)	QD (D1-21)					1624	1933	1
MMRF_2313	Fourth Line Therapy (following 3rd relapse)	Fourth Line Therapy (following 3rd relapse)	Unknown	Unknown	Dexamethasone	Dexamethasone		0	Disease progression/Relapse	Disease progression/Relapse		mg	mg	QD (D1-14)	QD (D1-14)	PO	PO	Log Forms	Unknown	Unknown			QD (D1-14)	QD (D1-14)					1624	1933	1
MMRF_2314	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			EXITUS	Other	50	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		50	Q day	Q day					5	90	1
MMRF_2314	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			EXITUS	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					2	90	1
MMRF_2314	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			EXITUS	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV	IV	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	90	1
MMRF_2327	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Lack of response	Lack of response	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D22, D25, D29, D32)	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	Other	QD (D1, D4, D8, D11, D22, D25, D29, D32)					1	204	1
MMRF_2327	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Lack of response	Lack of response	16	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					2	204	1
MMRF_2327	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Lack of response	Lack of response	100	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					2	204	1
MMRF_2327	First line of therapy	First Line Therapy	Unknown	Unknown	Cyclophosphamide	Cyclophosphamide			Investigator decision for other reasons	Investigator decision for other reasons	1000	mg	mg	Q day	Q day	IV	IV	Log Forms	Unknown	Unknown		1000	Q day	Q day					225	225	1
MMRF_2327	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		25	QD (D1-21)	QD (D1-21)					263	1108	1
MMRF_2327	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		40	QD (D1-4)	QD (D1-4)					263	1108	1
MMRF_2327	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide			Lack of response	Lack of response	10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown		10	QD (D1-21)	QD (D1-21)					1140	1196	1
MMRF_2327	First line of therapy	First Line Therapy	Unknown	Unknown	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Unknown	Unknown	Checked	20	Q week	Q week					1140	1507	1
MMRF_2327	First line of therapy	First Line Therapy	Unknown	Unknown	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Unknown	Unknown	Checked	25	QD (D1-21)	QD (D1-21)					1196	1507	1
MMRF_2364	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			EXITUS	Other	2.6	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.6	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	156	1
MMRF_2364	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			EXITUS	Other	40	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	PO	PO	Log Forms	Induction	Induction		40	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	156	1
MMRF_2364	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			EXITUS	Other	200	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		200	Q day	Q day					1	156	1
MMRF_2452	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib		1			2.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction	Checked	2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1		1
MMRF_2452	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	200	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		200	Q day	Q day					1	294	1
MMRF_2452	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	QD (D1-4, D9-13)	Other	PO	PO	Log Forms	Induction	Induction	Checked	40	Other	QD (D1-4, D9-13)					1		1
MMRF_2535	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					3	200	1
MMRF_2535	First line of therapy	First Line Therapy	Induction	Induction	Thalidomide	Thalidomide			Completed regimen	Completed regimen	200	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		200	Q day	Q day					17	200	1
MMRF_2535	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	D 1-4, D 5-9 Q 28D	Other	PO	PO	Log Forms	Induction	Induction		40	Other	D 1-4, D 5-9 Q 28D					1	200	1
MMRF_2535	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE THERAPY AFTER FIRST RELAPSE	Other	Vincristine	Vincristine			Completed regimen	Completed regimen	2	mg	mg	Q10WEEK	Other	IV	IV	Log Forms	Other	SECOND LINE THERAPY AFTER FIRST RELAPSE		2	Other	Q10WEEK					342	358	1
MMRF_2535	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE THERAPY AFTER FIRST RELAPSE	Other	CARMUSTINE	Other			Completed regimen	Completed regimen	37	mg	mg	Q10 SEMANAS	Other	IV	IV	Log Forms	Other	SECOND LINE THERAPY AFTER FIRST RELAPSE		37	Other	Q10 SEMANAS					342	358	1
MMRF_2535	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE THERAPY AFTER FIRST RELAPSE	Other	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	749	mg	mg	Q10WEEK	Other	IV	IV	Log Forms	Other	SECOND LINE THERAPY AFTER FIRST RELAPSE		749	Other	Q10WEEK					342	358	1
MMRF_2535	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE THERAPY AFTER FIRST RELAPSE	Other	Melphalan	Melphalan			Completed regimen	Completed regimen	20	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SECOND LINE THERAPY AFTER FIRST RELAPSE		20	QD (D1-4)	QD (D1-4)					341	358	1
MMRF_2535	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE THERAPY AFTER FIRST RELAPSE	Other	Prednisone	Prednisone			Completed regimen	Completed regimen	75	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Other	SECOND LINE THERAPY AFTER FIRST RELAPSE		75	QD (D1-4)	QD (D1-4)					341	358	1
MMRF_2535	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	200	mg/m^2	mg/m^2	SINGLE DOSE	Other	IV	IV	Log Forms	Induction	Induction		200	Other	SINGLE DOSE					212	212	1
MMRF_2572	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.3	mg	mg	QD (D1, D4, D8, D11, D22, D25, D29, D32)	Other	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.3	Other	QD (D1, D4, D8, D11, D22, D25, D29, D32)					1	376	1
MMRF_2572	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	16	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	376	1
MMRF_2572	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	100	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	376	1
MMRF_2572	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE AFTER FIRST PROGRESSION	Other	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	750	mg	mg	EVERY 2 MONTHS	Other	IV	IV	Log Forms	Other	SECOND LINE AFTER FIRST PROGRESSION		750	Other	EVERY 2 MONTHS					813	876	1
MMRF_2572	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE AFTER FIRST PROGRESSSION	Other	Bortezomib	Bortezomib			Lack of response	Lack of response	2	mg	mg	DAYS 1 AND 8	Other	IV SubQ	IV SubQ	Log Forms	Other	SECOND LINE AFTER FIRST PROGRESSSION		2	Other	DAYS 1 AND 8					652	729	1
MMRF_2572	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	SECOND LINE AFTER FIRST PROGRESSION	Other	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	50	mg	mg	Q day	Q day	PO	PO	Log Forms	Other	SECOND LINE AFTER FIRST PROGRESSION		50	Q day	Q day					652	715	1
MMRF_2572	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SECOND LINE AFTER FIRST PROGRESSION	Other	Lenalidomide	Lenalidomide		1			10	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	SECOND LINE AFTER FIRST PROGRESSION	Checked	10	QD (D1-21)	QD (D1-21)					887		1
MMRF_2572	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	SECOND LINE AFTER FIRST PROGRESSION	Other	Dexamethasone	Dexamethasone		1			16	mg	mg	QWK	QWK	PO	PO	Log Forms	Other	SECOND LINE AFTER FIRST PROGRESSION	Checked	16	QWK	QWK					887		1
MMRF_2601	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.47	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.47	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	366	1
MMRF_2601	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	16	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	341	1
MMRF_2601	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	100	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					1	341	1
MMRF_2601	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TREATMENE AT FIRST RELAPSE	Other	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	TREATMENE AT FIRST RELAPSE	Checked	25	QD (D1-21)	QD (D1-21)					575		1
MMRF_2601	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	TREATMENE AT FIRST RELAPSE	Other	Dexamethasone	Dexamethasone		1			40	mg	mg	D1, D8, D15, D22	Other	PO	PO	Log Forms	Other	TREATMENE AT FIRST RELAPSE	Checked	40	Other	D1, D8, D15, D22					575		1
MMRF_2613	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.3	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		2.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	326	1
MMRF_2613	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			DEATH	Other	14	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		14	QD (D1-4)	QD (D1-4)					4	621	1
MMRF_2613	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	100	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		100	QD (D1-4)	QD (D1-4)					4	326	1
MMRF_2613	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Lack of response	Lack of response	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					344	534	1
MMRF_2613	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		40	QD (D1-4)	QD (D1-4)					344	348	1
MMRF_2613	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	TREATMENE AT SECOND RELAPSE	Other	Cyclophosphamide	Cyclophosphamide			Lack of response	Lack of response	1000	mg	mg	D1 EVERY 28 DAYS	Other	IV	IV	Log Forms	Other	TREATMENE AT SECOND RELAPSE		1000	Other	D1 EVERY 28 DAYS					536	575	1
MMRF_2613	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	TREATMENT AT RELAPSE	Other	Carfilzomib	Carfilzomib			DEATH	Other	44	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Other	TREATMENT AT RELAPSE		44	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					582	621	1
MMRF_2613	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	TREATMENT AT RELAPSE	Other	Lenalidomide	Lenalidomide			DEATH	Other	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Other	TREATMENT AT RELAPSE		25	QD (D1-21)	QD (D1-21)					582	621	1
MMRF_2613	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	TREATMENT AT RELAPSE	Other	Dexamethasone	Dexamethasone			DEATH	Other	20	mg	mg	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	PO	PO	Log Forms	Other	TREATMENT AT RELAPSE		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					582	621	1
MMRF_2016	First line of therapy	First Line Therapy	Unknown	Unknown	Bortezomib	Bortezomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	SC	Other	Log Forms	Unknown	Unknown		1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	107	1
MMRF_2016	First line of therapy	First Line Therapy	Unknown	Unknown	Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	9	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		9	QD (D1-4)	QD (D1-4)					1	107	1
MMRF_2016	First line of therapy	First Line Therapy	Unknown	Unknown	Prednisone	Prednisone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	120	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Unknown	Unknown		120	QD (D1-4)	QD (D1-4)					1	107	1
MMRF_2016	First line of therapy	First Line Therapy	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					124	1520	1
MMRF_2016	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	10	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		10	Q day	Q day					124	1520	1
MMRF_2268	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	85	1
MMRF_2268	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	60	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	405	1
MMRF_2268	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	9	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	405	1
MMRF_2268	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D8, D22, D29)	QD (D1, D8, D22, D29)					92	405	1
MMRF_2268	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	27	mg/m^2	mg/m^2	DAYS 1,2, 8,9, 15,16	Other	IV	IV	Log Forms	Induction	Induction		27	Other	DAYS 1,2, 8,9, 15,16					907	1184	1
MMRF_2268	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		25	Q day	Q day					907	1548	1
MMRF_2268	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	20	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		20	QWK	QWK					907	1548	1
MMRF_2305	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	131	1
MMRF_2305	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	900	mg/m^2	mg/m^2	EVERY THREE WEEKS	Other	IV	IV	Log Forms	Induction	Induction		900	Other	EVERY THREE WEEKS					1	131	1
MMRF_2305	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Lack of response	Lack of response	15	mg	mg	Q day	Q day	PO	PO	Log Forms	Induction	Induction		15	Q day	Q day					1	131	1
MMRF_2305	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Adverse Event or co-morbidity	Adverse Event or co-morbidity	27	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		27	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					873	889	1
MMRF_2305	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	25	QD (D1-21)	QD (D1-21)					862		1
MMRF_2305	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	40	Q week	Q week					862		1
MMRF_2421	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	98	1
MMRF_2421	First line of therapy	First Line Therapy	Induction	Induction	Dexamethasone	Dexamethasone			Completed regimen	Completed regimen	40	mg	mg	QD1,2,4,5,8,9,11,12	Other	PO	PO	Log Forms	Induction	Induction		40	Other	QD1,2,4,5,8,9,11,12					1	98	1
MMRF_2421	First line of therapy	First Line Therapy	Induction	Induction	Cyclophosphamide	Cyclophosphamide			Completed regimen	Completed regimen	900	mg/m^2	mg/m^2	EVERY 3 WEEKS	Other	IV	IV	Log Forms	Induction	Induction		900	Other	EVERY 3 WEEKS					1	98	1
MMRF_2444	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			PAIENT DIED 23.05.15 AT 00:05H	Other	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	75	1
MMRF_2444	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Adverse Event or co-morbidity	Adverse Event or co-morbidity	9	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		9	QD (D1-4)	QD (D1-4)					1	75	1
MMRF_2444	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	60	mg/m^2	mg/m^2	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		60	QD (D1-4)	QD (D1-4)					1	75	1
MMRF_2558	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Patient decision	Patient decision	1.3	mg/m^2	mg/m^2	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)	IV SubQ	IV SubQ	Log Forms	Induction	Induction		1.3	QD (D1, D4, D8, D11, D28, D31, D35, D38)	QD (D1, D4, D8, D11, D28, D31, D35, D38)					1	113	1
MMRF_2558	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Patient decision	Patient decision	9	mg/m^2	mg/m^2	D1,D9	Other	PO	PO	Log Forms	Induction	Induction		9	Other	D1,D9					1	113	1
MMRF_2558	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Patient decision	Patient decision	60	mg/m^2	mg/m^2	D1, D9	Other	PO	PO	Log Forms	Induction	Induction		60	Other	D1, D9					1	113	1
MMRF_2195	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Investigator decision for other reasons	Investigator decision for other reasons	40	mg	mg	QWK	QWK	PO	PO	Log Forms	Induction	Induction		40	QWK	QWK					1294	1362	1
MMRF_2195	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	PALLIATIVE CARE	Other	Cyclophosphamide	Cyclophosphamide		0	INSUFFICIENT RESPONSE	Other	750	mg	mg	MONTHLY	Other	IV	IV	Log Forms	Other	PALLIATIVE CARE		750	Other	MONTHLY					1362	1490	1
MMRF_2195	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	2.4	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		2.4	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	405	1
MMRF_2195	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	16	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	380	1
MMRF_2195	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	75	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		75	QD (D1-4)	QD (D1-4)					1	380	1
MMRF_2195	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide			Adverse Event or co-morbidity	Adverse Event or co-morbidity	25	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction		25	QD (D1-21)	QD (D1-21)					741	1149	1
MMRF_2195	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone			Adverse Event or co-morbidity	Adverse Event or co-morbidity	40	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction		40	Q week	Q week					741	784	1
MMRF_2195	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Carfilzomib	Carfilzomib			Investigator decision for other reasons	Investigator decision for other reasons	20	mg/m^2	mg/m^2	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)	IV	IV	Log Forms	Induction	Induction		20	QD (D1-2, D8-9, D15-16)	QD (D1-2, D8-9, D15-16)					1294	1362	1
MMRF_2195	Third Line Therapy (following 2nd relapse)	Third Line Therapy (following 2nd relapse)	Induction	Induction	Daratumumab	Daratumumab		0	Adverse Event or co-morbidity	Adverse Event or co-morbidity	1000	mg	mg	WEEKLY FIRST 2 CYCLES. BIWEEKLY AFTERWARDS	Other	IV	IV	Log Forms	Induction	Induction		1000	Other	WEEKLY FIRST 2 CYCLES. BIWEEKLY AFTERWARDS					1552	1678	1
MMRF_2317	First line of therapy	First Line Therapy	Induction	Induction	Bortezomib	Bortezomib			Completed regimen	Completed regimen	1.8	mg	mg	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)	SUBCUTANEOUS	Other	Log Forms	Induction	Induction		1.8	QD (D1, D4, D8, D11)	QD (D1, D4, D8, D11)					1	338	1
MMRF_2317	First line of therapy	First Line Therapy	Induction	Induction	Melphalan	Melphalan			Completed regimen	Completed regimen	16	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		16	QD (D1-4)	QD (D1-4)					1	288	1
MMRF_2317	First line of therapy	First Line Therapy	Induction	Induction	Prednisone	Prednisone			Completed regimen	Completed regimen	75	mg	mg	QD (D1-4)	QD (D1-4)	PO	PO	Log Forms	Induction	Induction		75	QD (D1-4)	QD (D1-4)					1	319	1
MMRF_2317	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Lenalidomide	Lenalidomide		1			15	mg	mg	QD (D1-21)	QD (D1-21)	PO	PO	Log Forms	Induction	Induction	Checked	15	QD (D1-21)	QD (D1-21)					610		1
MMRF_2317	Second Line Therapy (after first relapse)	Second Line Therapy (after first relapse)	Induction	Induction	Dexamethasone	Dexamethasone		1			20	mg	mg	Q week	Q week	PO	PO	Log Forms	Induction	Induction	Checked	20	Q week	Q week					610		1
MMRF_2426	First line of therapy				Dexamethasone				Adverse Event or co-morbidity			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Fatigue			1	64	1
MMRF_2426	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	125	1
MMRF_2426	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	125	1
MMRF_2426	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					64	125	1
MMRF_2426	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					125	135	1
MMRF_2426	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		344	Oth	prior to stem cell infusion					169	169	1
MMRF_2426	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					262	443	1
MMRF_2426	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					262	443	1
MMRF_2426	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					262	443	1
MMRF_2426	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Maintenance			10	Oth	Days 1-21 per cycle					443	583	1
MMRF_2583	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	116	1
MMRF_2583	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	116	1
MMRF_2583	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	116	1
MMRF_2583	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					116	128	1
MMRF_2583	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		292	Oth	prior to stem cell infusion					157	157	1
MMRF_2583	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					267	414	1
MMRF_2583	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					267	414	1
MMRF_2583	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					267	414	1
MMRF_2583	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Maintenance			10	Oth	Days 1-21 per cycle					414	526	1
MMRF_2584	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	118	1
MMRF_2584	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	118	1
MMRF_2584	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	118	1
MMRF_2584	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					118	129	1
MMRF_2584	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		284	Oth	prior to stem cell infusion					153	153	1
MMRF_2584	First line of therapy				Dexamethasone				Adverse Event or co-morbidity			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Respiratory tox			267	267	1
MMRF_2584	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					267	422	1
MMRF_2584	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					267	422	1
MMRF_2584	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					267	422	1
MMRF_2584	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Maintenance			10	Oth	Days 1-21 per cycle					422	534	1
MMRF_2604	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	133	1
MMRF_2604	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	133	1
MMRF_2604	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	133	1
MMRF_2604	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					133	143	1
MMRF_2604	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		390	Oth	prior to stem cell infusion					203	203	1
MMRF_2604	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					311	437	1
MMRF_2604	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					311	437	1
MMRF_2604	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					311	437	1
MMRF_2604	First line of therapy				Carfilzomib							mg/m^2				IV			Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					437		1
MMRF_2604	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					437		1
MMRF_2609	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	114	1
MMRF_2609	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	114	1
MMRF_2609	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	114	1
MMRF_2609	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					114	125	1
MMRF_2609	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					169	407	1
MMRF_2609	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					169	407	1
MMRF_2609	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					169	407	1
MMRF_2609	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					407		1
MMRF_2624	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	114	1
MMRF_2624	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	114	1
MMRF_2624	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	114	1
MMRF_2624	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					114	125	1
MMRF_2624	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					161	161	1
MMRF_2624	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					274	405	1
MMRF_2624	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					274	405	1
MMRF_2624	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					274	405	1
MMRF_2624	First line of therapy				Carfilzomib							mg/m^2				IV			Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					405		1
MMRF_2624	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					405		1
MMRF_2626	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2626	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	130	1
MMRF_2626	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2626	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	142	1
MMRF_2626	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					218		1
MMRF_2626	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					218		1
MMRF_2626	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					218		1
MMRF_2628	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	114	1
MMRF_2628	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	114	1
MMRF_2628	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	114	1
MMRF_2628	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					114	127	1
MMRF_2628	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		390	Oth	prior to stem cell infusion					157	157	1
MMRF_2628	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					253		1
MMRF_2628	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					253		1
MMRF_2628	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					253		1
MMRF_2630	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	139	1
MMRF_2630	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	139	1
MMRF_2630	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	139	1
MMRF_2630	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					139	151	1
MMRF_2630	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		380	Oth	prior to stem cell infusion					198	198	1
MMRF_2630	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					296	429	1
MMRF_2630	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					296	429	1
MMRF_2630	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					296	429	1
MMRF_2630	First line of therapy				Carfilzomib							mg/m^2				IV			Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					429		1
MMRF_2630	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					429		1
MMRF_2631	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	121	1
MMRF_2631	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	121	1
MMRF_2631	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	121	1
MMRF_2631	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					121	132	1
MMRF_2631	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		390	Oth	prior to stem cell infusion					157	157	1
MMRF_2631	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					274	393	1
MMRF_2631	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					274	393	1
MMRF_2631	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					274	393	1
MMRF_2631	First line of therapy				Carfilzomib							mg/m^2				IV			Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					393		1
MMRF_2631	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					393		1
MMRF_2634	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2634	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	117	1
MMRF_2634	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2634	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	129	1
MMRF_2634	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		386	Oth	prior to stem cell infusion					170	170	1
MMRF_2634	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					263	382	1
MMRF_2634	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					263	382	1
MMRF_2634	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					263	382	1
MMRF_2634	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					382		1
MMRF_2635	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2635	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	123	1
MMRF_2635	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2635	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	134	1
MMRF_2635	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		366	Oth	prior to stem cell infusion					163	163	1
MMRF_2635	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					275	385	1
MMRF_2635	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					275	385	1
MMRF_2635	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					275	385	1
MMRF_2635	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					385		1
MMRF_2636	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	113	1
MMRF_2636	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	113	1
MMRF_2636	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2636	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					113	125	1
MMRF_2636	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					158	158	1
MMRF_2636	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					259	371	1
MMRF_2636	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					259	371	1
MMRF_2636	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					259	371	1
MMRF_2637	First line of therapy				Carfilzomib				Adverse Event or co-morbidity			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Hepatic tox			1	30	1
MMRF_2637	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		Hepatic tox			1	30	1
MMRF_2637	First line of therapy				Dexamethasone				Adverse Event or co-morbidity			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Hepatic tox			1	30	1
MMRF_2637	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			15	Oth	Days 1-21 per cycle		Hepatic tox			30	71	1
MMRF_2637	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			20	Oth	Days 1-2, 8-9, 15-16 per cycle					30	144	1
MMRF_2637	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			4	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					30	144	1
MMRF_2637	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			10	Oth	Days 1-21 per cycle		Hepatic tox			71	106	1
MMRF_2637	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			5	Oth	Days 1-21 per cycle					106	144	1
MMRF_2637	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					144	154	1
MMRF_2637	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		334	Oth	prior to stem cell infusion					185	185	1
MMRF_2637	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					281	393	1
MMRF_2637	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			5	Oth	Days 1-21 per cycle					281	393	1
MMRF_2637	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			4	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					281	393	1
MMRF_2638	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	120	1
MMRF_2638	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	120	1
MMRF_2638	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	120	1
MMRF_2638	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					120	132	1
MMRF_2638	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		300	Oth	prior to stem cell infusion					163	163	1
MMRF_2638	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					260	386	1
MMRF_2638	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					260	386	1
MMRF_2638	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					260	386	1
MMRF_2638	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					386		1
MMRF_2639	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	146	1
MMRF_2639	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	146	1
MMRF_2639	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	146	1
MMRF_2639	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					146	155	1
MMRF_2639	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					203	441	1
MMRF_2639	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					203	441	1
MMRF_2639	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					203	441	1
MMRF_2640	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	157	1
MMRF_2640	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	157	1
MMRF_2640	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	157	1
MMRF_2640	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					157	170	1
MMRF_2640	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		370	Oth	prior to stem cell infusion					201	201	1
MMRF_2640	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					302	421	1
MMRF_2640	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					302	421	1
MMRF_2640	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					302	421	1
MMRF_2640	First line of therapy				Carfilzomib							mg/m^2				IV			Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					421		1
MMRF_2640	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					421		1
MMRF_2641	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	128	1
MMRF_2641	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	128	1
MMRF_2641	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	128	1
MMRF_2641	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					128	140	1
MMRF_2641	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					232	428	1
MMRF_2641	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					232	428	1
MMRF_2641	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					232	428	1
MMRF_2642	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2642	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	122	1
MMRF_2642	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2642	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	171	1
MMRF_2642	First line of therapy				Carfilzomib				Adverse Event or co-morbidity			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle		asthenia			196	315	1
MMRF_2642	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					196	427	1
MMRF_2642	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					196	427	1
MMRF_2642	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			27	Oth	Days 1-2, 8-9, 15-16 per cycle					315	427	1
MMRF_2643	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2643	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	117	1
MMRF_2643	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2643	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	128	1
MMRF_2643	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		380	Oth	prior to stem cell infusion					156	156	1
MMRF_2643	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					253	365	1
MMRF_2643	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					253	365	1
MMRF_2643	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					253	365	1
MMRF_2647	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	138	1
MMRF_2647	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	138	1
MMRF_2647	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	138	1
MMRF_2647	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					138	150	1
MMRF_2647	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		370	Oth	prior to stem cell infusion					198	198	1
MMRF_2647	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					309	421	1
MMRF_2647	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					309	421	1
MMRF_2647	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					309	421	1
MMRF_2644	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2644	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	130	1
MMRF_2644	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2644	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	140	1
MMRF_2644	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		350	Oth	prior to stem cell infusion					162	162	1
MMRF_2644	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					260	384	1
MMRF_2644	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					260	384	1
MMRF_2644	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					260	384	1
MMRF_2644	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					384		1
MMRF_2646	First line of therapy				Dexamethasone				Adverse Event or co-morbidity			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Hyperglicemia			1	42	1
MMRF_2646	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	127	1
MMRF_2646	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	127	1
MMRF_2646	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			15	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					42	127	1
MMRF_2646	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					127	138	1
MMRF_2646	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					154		1
MMRF_2646	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					154		1
MMRF_2646	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					154		1
MMRF_2646	First line of therapy				Dexamethasone				Adverse Event or co-morbidity			mg				PO			Consolidation			15	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Investigations and metabolism disorders			154	154	1
MMRF_2648	First line of therapy				Carfilzomib				Adverse Event or co-morbidity			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		GGT increased			1	50	1
MMRF_2648	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		GGT increased			1	78	1
MMRF_2648	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	144	1
MMRF_2648	First line of therapy				Carfilzomib				Adverse Event or co-morbidity			mg/m^2				IV			Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle		GGT increased			50	78	1
MMRF_2648	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			20	Oth	Days 1-2, 8-9, 15-16 per cycle					78	144	1
MMRF_2648	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			15	Oth	Days 1-21 per cycle					78	144	1
MMRF_2648	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					144	155	1
MMRF_2648	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			20	Oth	Days 1-2, 8-9, 15-16 per cycle					183	423	1
MMRF_2648	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			15	Oth	Days 1-21 per cycle					183	423	1
MMRF_2648	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					183	423	1
MMRF_2648	First line of therapy				Carfilzomib							mg/m^2				IV			Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					423		1
MMRF_2648	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					423		1
MMRF_2650	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	149	1
MMRF_2650	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	149	1
MMRF_2650	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	149	1
MMRF_2650	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					149	163	1
MMRF_2650	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		340	Oth	prior to stem cell infusion					188	188	1
MMRF_2651	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2651	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	123	1
MMRF_2651	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2651	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	136	1
MMRF_2651	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		368	Oth	prior to stem cell infusion					169	169	1
MMRF_2651	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					267	414	1
MMRF_2651	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					267	414	1
MMRF_2651	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					267	414	1
MMRF_2651	First line of therapy				Carfilzomib							mg/m^2				IV			Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					414		1
MMRF_2651	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					414		1
MMRF_2652	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2652	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	117	1
MMRF_2652	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2652	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	150	1
MMRF_2652	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					157	415	1
MMRF_2652	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					157	415	1
MMRF_2652	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					157	415	1
MMRF_2652	First line of therapy				Carfilzomib							mg/m^2				IV			Maintenance		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					415		1
MMRF_2652	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					415		1
MMRF_2653	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2653	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	130	1
MMRF_2653	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2653	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	141	1
MMRF_2653	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					183	456	1
MMRF_2653	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					183	456	1
MMRF_2653	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					183	456	1
MMRF_2654	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	116	1
MMRF_2654	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	116	1
MMRF_2654	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	116	1
MMRF_2654	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					116	126	1
MMRF_2654	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					175	175	1
MMRF_2655	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	150	1
MMRF_2655	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	150	1
MMRF_2655	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	150	1
MMRF_2655	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					150	162	1
MMRF_2655	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		315	Oth	prior to stem cell infusion					183	183	1
MMRF_2655	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					300	447	1
MMRF_2655	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					300	447	1
MMRF_2655	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					300	447	1
MMRF_2659	First line of therapy				Carfilzomib							mg/m^2				IV			Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2659	First line of therapy				Lenalidomide							mg				PO			Induction		Checked	25	Oth	Days 1-21 per cycle					1		1
MMRF_2659	First line of therapy				Dexamethasone							mg				PO			Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2660	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2660	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	123	1
MMRF_2660	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2660	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					30		1
MMRF_2660	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					30		1
MMRF_2660	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					30		1
MMRF_2660	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	134	1
MMRF_2660	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					162	162	1
MMRF_2664	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	138	1
MMRF_2664	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	138	1
MMRF_2664	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	138	1
MMRF_2664	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					138	152	1
MMRF_2664	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		360	Oth	prior to stem cell infusion					183	183	1
MMRF_2664	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					276		1
MMRF_2664	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					276		1
MMRF_2664	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					276		1
MMRF_2665	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	115	1
MMRF_2665	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	115	1
MMRF_2665	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	115	1
MMRF_2665	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					115	126	1
MMRF_2665	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					168	168	1
MMRF_2665	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					223	344	1
MMRF_2665	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					223	344	1
MMRF_2665	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					223	344	1
MMRF_2665	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					344		1
MMRF_2667	First line of therapy				Dexamethasone				Adverse Event or co-morbidity			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Costitutional Symptoms (Insomnia - Medical History			1	1	1
MMRF_2667	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2667	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	122	1
MMRF_2667	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2667	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	131	1
MMRF_2667	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					162	162	1
MMRF_2667	First line of therapy				Dexamethasone				Adverse Event or co-morbidity			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Gastrintestinal tox			247	275	1
MMRF_2667	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					247	366	1
MMRF_2667	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					247	366	1
MMRF_2667	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					275	366	1
MMRF_2667	First line of therapy				Lenalidomide							mg				PO			Maintenance		Checked	10	Oth	Days 1-21 per cycle					366		1
MMRF_2666	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2666	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	117	1
MMRF_2666	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2666	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	128	1
MMRF_2666	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		388	Oth	prior to stem cell infusion					156	156	1
MMRF_2669	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		Rash maculo-papular			1	62	1
MMRF_2669	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	128	1
MMRF_2669	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	128	1
MMRF_2669	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			15	Oth	Days 1-21 per cycle					62	128	1
MMRF_2669	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					128	140	1
MMRF_2669	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					230	342	1
MMRF_2669	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					230	342	1
MMRF_2669	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					230	342	1
MMRF_2670	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2670	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	124	1
MMRF_2670	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2670	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	134	1
MMRF_2670	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					169	386	1
MMRF_2670	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					169	386	1
MMRF_2670	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					169	386	1
MMRF_2671	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	160	1
MMRF_2671	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	160	1
MMRF_2671	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	160	1
MMRF_2671	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					160	173	1
MMRF_2671	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					197	197	1
MMRF_2671	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					310	436	1
MMRF_2671	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					310	436	1
MMRF_2671	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					310	436	1
MMRF_2675	First line of therapy				Carfilzomib							mg/m^2				IV			Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2675	First line of therapy				Dexamethasone							mg				PO			Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2675	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		Atrial fibrillation			1	29	1
MMRF_2675	First line of therapy				Lenalidomide							mg				PO			Induction		Checked	15	Oth	Days 1-21 per cycle					29		1
MMRF_2676	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2676	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	131	1
MMRF_2676	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2676	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	142	1
MMRF_2676	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		360	Oth	prior to stem cell infusion					178	178	1
MMRF_2676	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					269	451	1
MMRF_2676	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					269	451	1
MMRF_2676	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					269	451	1
MMRF_2677	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		Creatinine increase			1	34	1
MMRF_2677	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2677	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2677	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			10	Oth	Days 1-21 per cycle					34	123	1
MMRF_2677	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	135	1
MMRF_2677	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					170	447	1
MMRF_2677	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			10	Oth	Days 1-21 per cycle					170	447	1
MMRF_2677	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					170	447	1
MMRF_2678	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2678	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	117	1
MMRF_2678	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2678	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	127	1
MMRF_2678	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		292	Oth	prior to stem cell infusion					151	151	1
MMRF_2678	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					262	381	1
MMRF_2678	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					262	381	1
MMRF_2678	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					262	381	1
MMRF_2679	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	116	1
MMRF_2679	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	116	1
MMRF_2679	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	116	1
MMRF_2679	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					116	127	1
MMRF_2679	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		350	Oth	prior to stem cell infusion					149	149	1
MMRF_2679	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					246	372	1
MMRF_2679	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					246	372	1
MMRF_2679	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					246	372	1
MMRF_2680	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	144	1
MMRF_2680	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	144	1
MMRF_2680	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	144	1
MMRF_2680	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					144	154	1
MMRF_2680	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					184	429	1
MMRF_2680	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					184	429	1
MMRF_2680	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					184	429	1
MMRF_2681	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	121	1
MMRF_2681	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	121	1
MMRF_2681	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	121	1
MMRF_2681	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					121	133	1
MMRF_2681	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					160	160	1
MMRF_2681	First line of therapy				Dexamethasone				Adverse Event or co-morbidity			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Gastrintestinal tox			253	288	1
MMRF_2681	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					253	377	1
MMRF_2681	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					253	377	1
MMRF_2681	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					288	377	1
MMRF_2682	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	139	1
MMRF_2682	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	139	1
MMRF_2682	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	139	1
MMRF_2682	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					139	152	1
MMRF_2682	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		372	Oth	prior to stem cell infusion					196	196	1
MMRF_2682	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					295	427	1
MMRF_2682	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					295	427	1
MMRF_2682	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					295	427	1
MMRF_2683	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2683	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	130	1
MMRF_2683	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2683	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	142	1
MMRF_2683	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					222	222	1
MMRF_2685	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	145	1
MMRF_2685	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	145	1
MMRF_2685	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	145	1
MMRF_2685	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					145	157	1
MMRF_2685	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					268		1
MMRF_2685	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					268		1
MMRF_2685	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					268		1
MMRF_2688	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2688	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	123	1
MMRF_2688	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2688	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	137	1
MMRF_2688	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		340	Oth	prior to stem cell infusion					155	155	1
MMRF_2690	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2690	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	117	1
MMRF_2690	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2690	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	128	1
MMRF_2690	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					183	411	1
MMRF_2690	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					183	411	1
MMRF_2690	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					183	411	1
MMRF_2689	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	141	1
MMRF_2689	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	141	1
MMRF_2689	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	141	1
MMRF_2689	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					141	152	1
MMRF_2689	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					170	403	1
MMRF_2689	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					170	403	1
MMRF_2689	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					170	403	1
MMRF_2691	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	113	1
MMRF_2691	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	113	1
MMRF_2691	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2691	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					113	124	1
MMRF_2691	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		350	Oth	prior to stem cell infusion					152	152	1
MMRF_2691	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					251		1
MMRF_2691	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					251		1
MMRF_2691	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					251		1
MMRF_2692	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		Creatinine increase			1	29	1
MMRF_2692	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	125	1
MMRF_2692	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	125	1
MMRF_2692	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			10	Oth	Days 1-21 per cycle					29	125	1
MMRF_2692	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					125	136	1
MMRF_2694	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	125	1
MMRF_2694	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	125	1
MMRF_2694	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	125	1
MMRF_2694	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					125	136	1
MMRF_2694	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		350	Oth	prior to stem cell infusion					171	171	1
MMRF_2694	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					263	410	1
MMRF_2694	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					263	410	1
MMRF_2694	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					263	410	1
MMRF_2695	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	145	1
MMRF_2695	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	145	1
MMRF_2695	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	145	1
MMRF_2695	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					145	156	1
MMRF_2695	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					191	191	1
MMRF_2695	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					268	450	1
MMRF_2695	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					268	450	1
MMRF_2695	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					268	450	1
MMRF_2696	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	111	1
MMRF_2696	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	111	1
MMRF_2696	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	111	1
MMRF_2696	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					111	133	1
MMRF_2696	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					162	162	1
MMRF_2696	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					274	386	1
MMRF_2696	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Consolidation			300	Oth	Days 1, 8, 15 per cycle					274	386	1
MMRF_2696	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					274	386	1
MMRF_2697	First line of therapy				Carfilzomib				Adverse Event or co-morbidity			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Hepatic tox			1	71	1
MMRF_2697	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		Hepatic tox			1	71	1
MMRF_2697	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2697	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle					71	183	1
MMRF_2697	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			15	Oth	Days 1-21 per cycle					71	183	1
MMRF_2698	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	121	1
MMRF_2698	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	121	1
MMRF_2698	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	121	1
MMRF_2698	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					121	131	1
MMRF_2698	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					196	420	1
MMRF_2698	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					196	420	1
MMRF_2698	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					196	420	1
MMRF_2702	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2702	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	124	1
MMRF_2702	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2702	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	135	1
MMRF_2702	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					183	428	1
MMRF_2702	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					183	428	1
MMRF_2702	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					183	428	1
MMRF_2699	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	135	1
MMRF_2699	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	135	1
MMRF_2699	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	135	1
MMRF_2699	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					135	146	1
MMRF_2699	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					181	456	1
MMRF_2699	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					181	456	1
MMRF_2699	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					181	456	1
MMRF_2700	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	150	1
MMRF_2700	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	150	1
MMRF_2700	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	150	1
MMRF_2700	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					150	162	1
MMRF_2700	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					191	428	1
MMRF_2700	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					191	428	1
MMRF_2700	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					191	428	1
MMRF_2701	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	153	1
MMRF_2701	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	153	1
MMRF_2701	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	153	1
MMRF_2701	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					153	165	1
MMRF_2701	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		140	Oth	prior to stem cell infusion					195	195	1
MMRF_2703	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	165	1
MMRF_2703	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	165	1
MMRF_2703	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	165	1
MMRF_2703	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					165	178	1
MMRF_2703	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					206		1
MMRF_2703	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					206		1
MMRF_2703	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					206		1
MMRF_2704	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2704	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	123	1
MMRF_2704	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2704	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	137	1
MMRF_2704	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					155	295	1
MMRF_2704	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					155	295	1
MMRF_2704	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					155	295	1
MMRF_2705	First line of therapy				Carfilzomib				Adverse Event or co-morbidity			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Hepatic tox			1	37	1
MMRF_2705	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		Hepatic tox			1	37	1
MMRF_2705	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2705	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle					37	124	1
MMRF_2705	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			15	Oth	Days 1-21 per cycle					37	124	1
MMRF_2705	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	164	1
MMRF_2705	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					194	194	1
MMRF_2706	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	116	1
MMRF_2706	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	116	1
MMRF_2706	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	116	1
MMRF_2706	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					116	128	1
MMRF_2706	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					156	156	1
MMRF_2707	First line of therapy				Carfilzomib							mg/m^2				IV			Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2707	First line of therapy				Lenalidomide							mg				PO			Induction		Checked	25	Oth	Days 1-21 per cycle					1		1
MMRF_2707	First line of therapy				Dexamethasone							mg				PO			Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2708	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2708	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	131	1
MMRF_2708	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2708	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	142	1
MMRF_2709	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	120	1
MMRF_2709	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	120	1
MMRF_2709	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	120	1
MMRF_2709	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					120	132	1
MMRF_2709	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		300	Oth	prior to stem cell infusion					166	166	1
MMRF_2716	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	118	1
MMRF_2716	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	118	1
MMRF_2716	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	118	1
MMRF_2716	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					118	128	1
MMRF_2716	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		328	Oth	prior to stem cell infusion					162	162	1
MMRF_2716	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					260		1
MMRF_2716	First line of therapy				Cyclophosphamide							mg/m^2				PO			Consolidation		Checked	300	Oth	Days 1, 8, 15 per cycle					260		1
MMRF_2716	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					260		1
MMRF_2711	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	137	1
MMRF_2711	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	137	1
MMRF_2711	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	137	1
MMRF_2711	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					137	151	1
MMRF_2711	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		332	Oth	prior to stem cell infusion					200	200	1
MMRF_2715	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2715	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	124	1
MMRF_2715	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2715	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	135	1
MMRF_2715	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					159	159	1
MMRF_2717	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2717	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	117	1
MMRF_2717	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2717	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	131	1
MMRF_2717	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					158		1
MMRF_2717	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					158		1
MMRF_2717	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					158		1
MMRF_2714	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	139	1
MMRF_2714	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	139	1
MMRF_2714	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	139	1
MMRF_2714	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					139	150	1
MMRF_2714	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		388.4	Oth	prior to stem cell infusion					177	177	1
MMRF_2714	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					274		1
MMRF_2714	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					274		1
MMRF_2714	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					274		1
MMRF_2718	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	109	1
MMRF_2718	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	109	1
MMRF_2718	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	109	1
MMRF_2718	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					109	119	1
MMRF_2718	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					148	260	1
MMRF_2718	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					148	260	1
MMRF_2718	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					148	260	1
MMRF_2719	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	152	1
MMRF_2719	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	152	1
MMRF_2719	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	152	1
MMRF_2719	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					152	205	1
MMRF_2719	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		380	Oth	prior to stem cell infusion					231	231	1
MMRF_2720	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	115	1
MMRF_2720	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	115	1
MMRF_2720	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	115	1
MMRF_2720	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					115	129	1
MMRF_2721	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	125	1
MMRF_2721	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	125	1
MMRF_2721	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	125	1
MMRF_2721	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					125	135	1
MMRF_2727	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	145	1
MMRF_2727	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	145	1
MMRF_2727	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	145	1
MMRF_2727	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					145	156	1
MMRF_2722	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2722	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	130	1
MMRF_2722	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2722	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	141	1
MMRF_2723	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	125	1
MMRF_2723	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	125	1
MMRF_2723	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	125	1
MMRF_2723	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					125	134	1
MMRF_2723	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		404	Oth	prior to stem cell infusion					158	158	1
MMRF_2728	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	118	1
MMRF_2728	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	118	1
MMRF_2728	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	118	1
MMRF_2728	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					118	129	1
MMRF_2728	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Consolidation			36	Oth	Days 1-2, 8-9, 15-16 per cycle					154	266	1
MMRF_2728	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Consolidation			25	Oth	Days 1-21 per cycle					154	266	1
MMRF_2728	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Consolidation			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					154	266	1
MMRF_2729	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	115	1
MMRF_2729	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	115	1
MMRF_2729	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	115	1
MMRF_2729	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					115	126	1
MMRF_2729	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					154	154	1
MMRF_2730	First line of therapy				Carfilzomib							mg/m^2				IV			Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2730	First line of therapy				Lenalidomide							mg				PO			Induction		Checked	25	Oth	Days 1-21 per cycle					1		1
MMRF_2730	First line of therapy				Dexamethasone							mg				PO			Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2731	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	120	1
MMRF_2731	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	120	1
MMRF_2731	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	120	1
MMRF_2731	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					120	129	1
MMRF_2731	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		408	Oth	prior to stem cell infusion					165	165	1
MMRF_2732	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2732	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	131	1
MMRF_2732	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2732	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	142	1
MMRF_2732	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		394	Oth	prior to stem cell infusion					184	184	1
MMRF_2733	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	160	1
MMRF_2733	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	160	1
MMRF_2733	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	160	1
MMRF_2733	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					160	171	1
MMRF_2733	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		360	Oth	prior to stem cell infusion					223	223	1
MMRF_2734	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	113	1
MMRF_2734	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	113	1
MMRF_2734	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2734	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					113	125	1
MMRF_2734	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		350	Oth	prior to stem cell infusion					154	154	1
MMRF_2736	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	120	1
MMRF_2736	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	120	1
MMRF_2736	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	120	1
MMRF_2736	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					120	131	1
MMRF_2736	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		310	Oth	prior to stem cell infusion					150	150	1
MMRF_2737	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	116	1
MMRF_2737	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	116	1
MMRF_2737	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	116	1
MMRF_2737	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					116	125	1
MMRF_2737	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		320	Oth	prior to stem cell infusion					160	160	1
MMRF_2738	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2738	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	124	1
MMRF_2738	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2738	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	137	1
MMRF_2738	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					172		1
MMRF_2738	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					172		1
MMRF_2738	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					172		1
MMRF_2739	First line of therapy				Carfilzomib							mg/m^2				IV			Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2739	First line of therapy				Cyclophosphamide							mg/m^2				PO			Induction		Checked	300	Oth	Days 1, 8, 15 per cycle					1		1
MMRF_2739	First line of therapy				Dexamethasone							mg				PO			Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2742	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	121	1
MMRF_2742	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	121	1
MMRF_2742	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	121	1
MMRF_2742	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					121	134	1
MMRF_2740	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2740	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	122	1
MMRF_2740	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2740	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	133	1
MMRF_2740	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					162		1
MMRF_2740	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					162		1
MMRF_2740	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					162		1
MMRF_2743	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		Rash maculo-papular			1	29	1
MMRF_2743	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2743	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2743	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			15	Oth	Days 1-21 per cycle					29	122	1
MMRF_2743	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	132	1
MMRF_2743	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		330	Oth	prior to stem cell infusion					164	164	1
MMRF_2745	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	119	1
MMRF_2745	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	119	1
MMRF_2745	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	119	1
MMRF_2745	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					119	133	1
MMRF_2745	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					162		1
MMRF_2745	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					162		1
MMRF_2745	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					162		1
MMRF_2746	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	136	1
MMRF_2746	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	136	1
MMRF_2746	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	136	1
MMRF_2746	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					136	146	1
MMRF_2746	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					171	171	1
MMRF_2749	First line of therapy				Carfilzomib				Adverse Event or co-morbidity			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Hepatic tox			1	32	1
MMRF_2749	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		Hepatic tox			1	88	1
MMRF_2749	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2749	First line of therapy				Carfilzomib				Adverse Event or co-morbidity			mg/m^2				IV			Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle		Hepatic tox			32	88	1
MMRF_2749	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			20	Oth	Days 1-2, 8-9, 15-16 per cycle					88	124	1
MMRF_2749	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			15	Oth	Days 1-21 per cycle					88	124	1
MMRF_2749	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	136	1
MMRF_2749	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	20	Oth	Days 1-2, 8-9, 15-16 per cycle					190		1
MMRF_2749	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	15	Oth	Days 1-21 per cycle					190		1
MMRF_2749	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					190		1
MMRF_2750	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2750	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	123	1
MMRF_2750	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2750	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	133	1
MMRF_2750	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					183		1
MMRF_2750	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					183		1
MMRF_2750	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					183		1
MMRF_2751	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	128	1
MMRF_2751	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	128	1
MMRF_2751	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	128	1
MMRF_2751	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					128	142	1
MMRF_2752	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	140	1
MMRF_2752	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	140	1
MMRF_2752	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	140	1
MMRF_2752	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					140	151	1
MMRF_2754	First line of therapy				Carfilzomib							mg/m^2				IV			Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2754	First line of therapy				Lenalidomide							mg				PO			Induction		Checked	25	Oth	Days 1-21 per cycle					1		1
MMRF_2754	First line of therapy				Dexamethasone							mg				PO			Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2753	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	136	1
MMRF_2753	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	136	1
MMRF_2753	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	136	1
MMRF_2753	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					136	148	1
MMRF_2753	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					174	174	1
MMRF_2755	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2755	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	117	1
MMRF_2755	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2755	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	128	1
MMRF_2755	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		370	Oth	prior to stem cell infusion					152	152	1
MMRF_2756	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	143	1
MMRF_2756	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	143	1
MMRF_2756	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	143	1
MMRF_2756	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					143	154	1
MMRF_2757	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2757	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	131	1
MMRF_2757	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2757	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	142	1
MMRF_2757	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					191		1
MMRF_2757	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					191		1
MMRF_2757	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					191		1
MMRF_2758	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	135	1
MMRF_2758	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	135	1
MMRF_2758	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	135	1
MMRF_2758	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					135	146	1
MMRF_2758	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					197	197	1
MMRF_2760	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2760	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	117	1
MMRF_2760	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2760	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	129	1
MMRF_2760	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		286	Oth	prior to stem cell infusion					161	161	1
MMRF_2761	First line of therapy				Carfilzomib							mg/m^2				IV			Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2761	First line of therapy				Lenalidomide							mg				PO			Induction		Checked	25	Oth	Days 1-21 per cycle					1		1
MMRF_2761	First line of therapy				Dexamethasone							mg				PO			Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2762	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	126	1
MMRF_2762	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	126	1
MMRF_2762	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	126	1
MMRF_2762	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					126	135	1
MMRF_2762	First line of therapy				Carfilzomib							mg/m^2				IV			Consolidation		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					155		1
MMRF_2762	First line of therapy				Lenalidomide							mg				PO			Consolidation		Checked	25	Oth	Days 1-21 per cycle					155		1
MMRF_2762	First line of therapy				Dexamethasone							mg				PO			Consolidation		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					155		1
MMRF_2763	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	127	1
MMRF_2763	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	127	1
MMRF_2763	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	127	1
MMRF_2763	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					127	137	1
MMRF_2763	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		300	Oth	prior to stem cell infusion					160	160	1
MMRF_2764	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2764	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	130	1
MMRF_2764	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2764	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	150	1
MMRF_2764	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					214	214	1
MMRF_2765	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	138	1
MMRF_2765	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	138	1
MMRF_2765	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	138	1
MMRF_2765	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					138	149	1
MMRF_2767	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	143	1
MMRF_2767	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	143	1
MMRF_2767	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	143	1
MMRF_2767	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					143	155	1
MMRF_2767	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		280	Oth	prior to stem cell infusion					179	179	1
MMRF_2768	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		Erythroderma			1	94	1
MMRF_2768	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	154	1
MMRF_2768	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	154	1
MMRF_2768	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			15	Oth	Days 1-21 per cycle					94	154	1
MMRF_2768	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					154	165	1
MMRF_2769	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2769	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	122	1
MMRF_2769	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2769	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	133	1
MMRF_2769	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					156	156	1
MMRF_2770	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2770	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	123	1
MMRF_2770	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2770	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	133	1
MMRF_2770	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					160	160	1
MMRF_2772	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	147	1
MMRF_2772	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	147	1
MMRF_2772	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	147	1
MMRF_2772	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					147	158	1
MMRF_2774	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2774	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	122	1
MMRF_2774	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2774	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	134	1
MMRF_2774	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		303	Oth	prior to stem cell infusion					174	174	1
MMRF_2775	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	132	1
MMRF_2775	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	132	1
MMRF_2775	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	132	1
MMRF_2775	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					132	178	1
MMRF_2775	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		300	Oth	prior to stem cell infusion					198	198	1
MMRF_2776	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	133	1
MMRF_2776	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	133	1
MMRF_2776	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	133	1
MMRF_2776	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					133	145	1
MMRF_2776	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		180	Oth	prior to stem cell infusion					203	203	1
MMRF_2778	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	113	1
MMRF_2778	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	113	1
MMRF_2778	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2778	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					113	124	1
MMRF_2778	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		335	Oth	prior to stem cell infusion					151	151	1
MMRF_2779	First line of therapy				Carfilzomib				Adverse Event or co-morbidity			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Rash maculo-papular			1	44	1
MMRF_2779	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		Rash maculo-papular			1	44	1
MMRF_2779	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	133	1
MMRF_2779	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			20	Oth	Days 1-2, 8-9, 15-16 per cycle					44	133	1
MMRF_2779	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			15	Oth	Days 1-21 per cycle					44	133	1
MMRF_2779	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					133	143	1
MMRF_2781	First line of therapy				Carfilzomib							mg/m^2				IV			Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2781	First line of therapy				Cyclophosphamide							mg/m^2				PO			Induction		Checked	300	Oth	Days 1, 8, 15 per cycle					1		1
MMRF_2781	First line of therapy				Dexamethasone							mg				PO			Induction		Checked	10	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2781	First line of therapy				Dexamethasone				Adverse Event or co-morbidity			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Hyperglycemia			1	1	1
MMRF_2782	First line of therapy				Dexamethasone				Adverse Event or co-morbidity			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle		Hyperglycemia			1	92	1
MMRF_2782	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	127	1
MMRF_2782	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	127	1
MMRF_2782	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			15	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					92	127	1
MMRF_2782	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					127	139	1
MMRF_2782	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		358	Oth	prior to stem cell infusion					213	213	1
MMRF_2787	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2787	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	123	1
MMRF_2787	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2787	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	132	1
MMRF_2788	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	138	1
MMRF_2788	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	138	1
MMRF_2788	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	138	1
MMRF_2788	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					138	148	1
MMRF_2788	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					198	198	1
MMRF_2789	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	117	1
MMRF_2789	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	117	1
MMRF_2789	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	117	1
MMRF_2789	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					117	128	1
MMRF_2792	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	134	1
MMRF_2792	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	134	1
MMRF_2792	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	134	1
MMRF_2792	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					134	148	1
MMRF_2793	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	137	1
MMRF_2793	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	137	1
MMRF_2793	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	137	1
MMRF_2793	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					137	148	1
MMRF_2793	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		300	Oth	prior to stem cell infusion					179	179	1
MMRF_2794	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2794	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	131	1
MMRF_2794	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2794	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	143	1
MMRF_2795	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	119	1
MMRF_2795	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	119	1
MMRF_2795	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	119	1
MMRF_2795	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					119	130	1
MMRF_2795	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		346	Oth	prior to stem cell infusion					162	162	1
MMRF_2801	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	127	1
MMRF_2801	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	127	1
MMRF_2801	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	127	1
MMRF_2801	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					127	165	1
MMRF_2801	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		294	Oth	prior to stem cell infusion					203	203	1
MMRF_2796	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	121	1
MMRF_2796	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	121	1
MMRF_2796	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	121	1
MMRF_2796	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					121	132	1
MMRF_2796	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		330	Oth	prior to stem cell infusion					159	159	1
MMRF_2799	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	128	1
MMRF_2799	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	128	1
MMRF_2799	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	128	1
MMRF_2799	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					128	138	1
MMRF_2805	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	118	1
MMRF_2805	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	118	1
MMRF_2805	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	118	1
MMRF_2805	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					118	128	1
MMRF_2805	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					163	163	1
MMRF_2807	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2807	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	124	1
MMRF_2807	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2807	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	137	1
MMRF_2807	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					194	194	1
MMRF_2808	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2808	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	131	1
MMRF_2808	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2808	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	177	1
MMRF_2809	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	127	1
MMRF_2809	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	127	1
MMRF_2809	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	127	1
MMRF_2809	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					127	138	1
MMRF_2809	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		370	Oth	prior to stem cell infusion					223	223	1
MMRF_2810	First line of therapy				Carfilzomib				Adverse Event or co-morbidity			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		ischemic heart disease			1	29	1
MMRF_2810	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	130	1
MMRF_2810	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2810	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle					29	130	1
MMRF_2810	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	140	1
MMRF_2810	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					175	175	1
MMRF_2813	First line of therapy				Carfilzomib				Adverse Event or co-morbidity			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Infusion-related reaction (acute episode of intens			1	30	1
MMRF_2813	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	116	1
MMRF_2813	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	116	1
MMRF_2813	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle					30	116	1
MMRF_2813	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					116	128	1
MMRF_2814	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	128	1
MMRF_2814	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	128	1
MMRF_2814	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	128	1
MMRF_2814	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					128	140	1
MMRF_2814	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					198	198	1
MMRF_2815	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	141	1
MMRF_2815	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	141	1
MMRF_2815	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	141	1
MMRF_2815	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					141	150	1
MMRF_2816	First line of therapy				Cyclophosphamide				Adverse Event or co-morbidity			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle		Hematological tox			1	65	1
MMRF_2816	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	130	1
MMRF_2816	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	130	1
MMRF_2816	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			200	Oth	Days 1, 8, 15 per cycle					65	130	1
MMRF_2816	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					130	141	1
MMRF_2816	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		366	Oth	prior to stem cell infusion					169	169	1
MMRF_2817	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	118	1
MMRF_2817	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	118	1
MMRF_2817	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	118	1
MMRF_2817	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					118	160	1
MMRF_2818	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	140	1
MMRF_2818	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	140	1
MMRF_2818	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	140	1
MMRF_2818	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					140	152	1
MMRF_2819	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	127	1
MMRF_2819	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	127	1
MMRF_2819	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	127	1
MMRF_2819	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					127	139	1
MMRF_2819	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		271.6000061	Oth	prior to stem cell infusion					245	245	1
MMRF_2820	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	129	1
MMRF_2820	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	129	1
MMRF_2820	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	129	1
MMRF_2820	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					129	139	1
MMRF_2820	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		330	Oth	prior to stem cell infusion					175	175	1
MMRF_2821	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2821	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	124	1
MMRF_2821	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2821	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	135	1
MMRF_2822	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	123	1
MMRF_2822	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	123	1
MMRF_2822	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	123	1
MMRF_2822	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					123	134	1
MMRF_2822	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		280	Oth	prior to stem cell infusion					173	173	1
MMRF_2823	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	183	1
MMRF_2823	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	183	1
MMRF_2823	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	183	1
MMRF_2823	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		340	Oth	prior to stem cell infusion					223	223	1
MMRF_2826	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	119	1
MMRF_2826	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	119	1
MMRF_2826	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	119	1
MMRF_2826	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					119	130	1
MMRF_2827	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	133	1
MMRF_2827	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			15	Oth	Days 1-21 per cycle					1	133	1
MMRF_2827	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	133	1
MMRF_2827	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					133	143	1
MMRF_2827	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		360	Oth	prior to stem cell infusion					189	189	1
MMRF_2828	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	145	1
MMRF_2828	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	145	1
MMRF_2828	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	145	1
MMRF_2828	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					145	157	1
MMRF_2829	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	144	1
MMRF_2829	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	144	1
MMRF_2829	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	144	1
MMRF_2829	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					144	155	1
MMRF_2830	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		Rash maculo-papular			1	58	1
MMRF_2830	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	113	1
MMRF_2830	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2830	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			15	Oth	Days 1-21 per cycle					58	113	1
MMRF_2830	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					113	124	1
MMRF_2831	First line of therapy				Carfilzomib				Adverse Event or co-morbidity			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle		Cardiac ischemia			1	85	1
MMRF_2831	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	166	1
MMRF_2831	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	166	1
MMRF_2831	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			27	Oth	Days 1-2, 8-9, 15-16 per cycle					85	166	1
MMRF_2831	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					166	177	1
MMRF_2831	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		374	Oth	prior to stem cell infusion					203	203	1
MMRF_2832	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	124	1
MMRF_2832	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	124	1
MMRF_2832	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	124	1
MMRF_2832	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					124	134	1
MMRF_2832	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		360	Oth	prior to stem cell infusion					173	173	1
MMRF_2833	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	113	1
MMRF_2833	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	113	1
MMRF_2833	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	113	1
MMRF_2834	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	126	1
MMRF_2834	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	126	1
MMRF_2834	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	126	1
MMRF_2834	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					126	140	1
MMRF_2835	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	136	1
MMRF_2835	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	136	1
MMRF_2835	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	136	1
MMRF_2835	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					136	147	1
MMRF_2835	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		400	Oth	prior to stem cell infusion					167	167	1
MMRF_2836	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	126	1
MMRF_2836	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	126	1
MMRF_2836	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	126	1
MMRF_2836	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					126	135	1
MMRF_2836	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		340	Oth	prior to stem cell infusion					161	161	1
MMRF_2838	First line of therapy				Lenalidomide				Adverse Event or co-morbidity			mg				PO			Induction			25	Oth	Days 1-21 per cycle		Rash maculo-papular			1	65	1
MMRF_2838	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	145	1
MMRF_2838	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	145	1
MMRF_2838	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			15	Oth	Days 1-21 per cycle					65	145	1
MMRF_2838	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					145	159	1
MMRF_2839	First line of therapy				Carfilzomib							mg/m^2				IV			Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2839	First line of therapy				Cyclophosphamide							mg/m^2				PO			Induction		Checked	300	Oth	Days 1, 8, 15 per cycle					1		1
MMRF_2839	First line of therapy				Dexamethasone							mg				PO			Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2840	First line of therapy				Carfilzomib							mg/m^2				IV			Induction		Checked	36	Oth	Days 1-2, 8-9, 15-16 per cycle					1		1
MMRF_2840	First line of therapy				Cyclophosphamide							mg/m^2				PO			Induction		Checked	300	Oth	Days 1, 8, 15 per cycle					1		1
MMRF_2840	First line of therapy				Dexamethasone							mg				PO			Induction		Checked	20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1		1
MMRF_2843	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	177	1
MMRF_2843	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	177	1
MMRF_2843	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	177	1
MMRF_2843	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					177	190	1
MMRF_2846	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	121	1
MMRF_2846	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	121	1
MMRF_2846	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	121	1
MMRF_2846	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					121	131	1
MMRF_2846	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					199	199	1
MMRF_2847	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	131	1
MMRF_2847	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	131	1
MMRF_2847	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	131	1
MMRF_2847	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					131	144	1
MMRF_2848	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	154	1
MMRF_2848	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	154	1
MMRF_2848	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	154	1
MMRF_2848	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					154	166	1
MMRF_2848	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		340	Oth	prior to stem cell infusion					198	198	1
MMRF_2851	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	122	1
MMRF_2851	First line of therapy				Cyclophosphamide				Completed regimen			mg/m^2				PO			Induction			300	Oth	Days 1, 8, 15 per cycle					1	122	1
MMRF_2851	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	122	1
MMRF_2851	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					122	133	1
MMRF_2851	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		360	Oth	prior to stem cell infusion					189	189	1
MMRF_2853	First line of therapy				Carfilzomib				Completed regimen			mg/m^2				IV			Induction			36	Oth	Days 1-2, 8-9, 15-16 per cycle					1	129	1
MMRF_2853	First line of therapy				Lenalidomide				Completed regimen			mg				PO			Induction			25	Oth	Days 1-21 per cycle					1	129	1
MMRF_2853	First line of therapy				Dexamethasone				Completed regimen			mg				PO			Induction			20	Oth	Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle					1	129	1
MMRF_2853	First line of therapy				Cyclophosphamide				Completed regimen			g/m^2				IV			Other	Mobilization - CD34+ cells generation for stem cell collection		2	Oth	9-14 days, dependent on CD34+ cell generation					129	139	1
MMRF_2853	First line of therapy				Melphalan				Completed regimen			mg/m^2				IV			Other	In preparation for stem cell infusion		200	Oth	prior to stem cell infusion					170	170	1
